<SEC-DOCUMENT>0001062822-22-000005.txt : 20220310
<SEC-HEADER>0001062822-22-000005.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310172314
ACCESSION NUMBER:		0001062822-22-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		22730164

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lxrx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22,d:c8e1d29868b149c9aff5685ac938a1e8--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:lxrx="http://www.lexpharma.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV80LTEtMS0xLTE2MTE4_ebf5169f-3693-4e77-bf00-03e2d07165dc">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV81LTEtMS0xLTE2MTE4_c4d7bb25-3863-4fb0-913f-a73320c246f6">2019</ix:nonNumeric><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV82LTEtMS0xLTE2MTE4_0779aa08-be54-4d8c-aa71-73cb45699458">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV83LTEtMS0xLTE2MTE4_43589f59-91e1-4a89-8045-e32dad083422">false</ix:nonNumeric><ix:nonNumeric contextRef="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMzNjA_fd6c9083-ac60-4aa0-af6d-eabe40774af9">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzMzI_73bd8c0d-44ee-40f0-9385-b10f02c7cfec">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="iddcd02aeb6f54c27b62d323917d83e97_D20171201-20171231" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5MTU_7b0c5791-d8c3-4747-83ec-263e9d8b54d5">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NDQ_e22aa56a-ed2a-4ea4-b4d9-85a943d8c4ac">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i0bdba477612f406591bdc6aaf6c502bf_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQzMjM_2603f12e-430e-4fbf-beee-195251baa8fe">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b830e55112e413294d94a95da2c31d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iaea6bf5e65b144809174989bbe6607b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i75536cf4a4174691b204bb1a118bb561_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de7ae68674e4d58a012b15b9e1f640d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a484df8d34a48168ddc67636fee53d7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc0d4d9dd1147749e2496817aad0133_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf0e7cc645e4f69a6ece2184dc576cb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5229e5ba37471fb75d1796184d22b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d73276a9f54188a234d30a5c7db573_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61ea8ca87054ca299e35899d20f0821_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f0c660c256a4099bc5d00a590fa3ae2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51590a994bf24c4ca00c39f49378fafb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i479d65c47ea34ef3a9d80c56a9fa552a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib658c65a014d4e83b3f212fa1f301a87_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id62e4b39721d47a18227ec951181b233_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a8eb0c931e47bb8781df60680b3b5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66152bef9ef94ee28758450b0c7d3bf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f855dd7993f49eeb1b627eb46715eef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0ad57c0c334f0386685e094334b434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb78b879b1247648386171510533efd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92be0a5177c4f85879df29eafff809c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729d06e13a06473b9ca5a295173d860e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80201290325143af97f2fb030d3e10d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a188a482da64a818cb53605d5b01571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lxrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8522830166f449a58c9cec1c88e894b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">naics:ZZ541713</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18d8e20549d44f094d78c20f57067a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7da2f3e97c46d389e37d815311f301_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37cf340c919946f4bfab989e262c817c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c48b80d6d71414d86074d2c8dec0efa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc58a9208454195ae83b844c05fd101_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1b6c22beee4da5b9a413b0fd5a000c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091b4225a0724082a4b25d2b383f9518_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53afd739da224f3588c2279414d4f677_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2adb638834b14d05ad8e434cc4531023_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30138e6503c4ffda82b615c312c176c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib964838f757842dc89d306cdb12966ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ede039b32984c72893e8e8c75c2b9fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id380ecc83b6e49a789334d406e5727f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4dd544ad16c4850b2b176d752df0a1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29f411a667c4474b294d320f9ebcb4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251665a0c7944e8d9bb8853d049ed549_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535698f3d692460b81cba7884c86e4e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1397c77d1b6f4185845e1699cd219089_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9e7435336a44558427742a97851cad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30aff4dded0c44ae865d00df32ebe612_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eced0a8b11146888768ff4b14b2f375_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4455ddb6c214da7961fd95cd24842c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic47c902d195d41518cadfff77db8830a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99f027008024261ace720d15f140e6b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815538a41da140838b0cb583686e2574_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b5aed98e3345b39cf920b0e50e105d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e10dc122274204badbada626c6296e_I20010712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2001-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5170da333de84c9ab9e1c854f5a3f263_I20100730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b1d627868546fca39177189a903e94_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cb62af37d048978f015209a192adc4_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74800149cb834920a98e1fed9979820d_I20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89421ae837f48509b4bf1206d468d61_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcd02aeb6f54c27b62d323917d83e97_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1154d94c6995462ba768d2bd7b39e722_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie941169ab2164798abaed9016c336c29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7478be4ff58a46a4936f451a7f97265d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdba477612f406591bdc6aaf6c502bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89e3823a40a049809c8d559277e562bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00be06ddbff74be8bbf65ceefcef5599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721b502840b14174be6cc3a22bfa99fd_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c3e38005194277b23efa2e68887d55_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.926%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV84NQ_94372846-055c-461d-aa03-b4d6b65bfcf6">10-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.762%"><tr><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8xLTAtMS0xLTE2MTE4_3c48b631-a678-4d5c-82a9-40c9e29ed2b3">&#9745;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Fiscal Year Ended </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8zLTItMS0xLTE2MTE4_93a6d69b-b8e3-4601-81d8-d4ec418e2ddd"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8zLTItMS0xLTE2MTE4_5cb4ca1f-f3b9-4479-a6cc-877ff91c4523">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.305%"><tr><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZWQxNzRjYmVkM2ZlNGJlOTg2YmUzMzQyNDUxOTA0M2UvdGFibGVyYW5nZTplZDE3NGNiZWQzZmU0YmU5ODZiZTMzNDI0NTE5MDQzZV8wLTAtMS0xLTE2MTE4_ed9e51bf-a961-4ad4-97dd-6f12a9d3e5df">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Transition Period from _____________ to _____________</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xMjE_f282deed-09f3-43d7-858e-c02c280e5506">000-30111</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDMz_c75c0cba-4485-4c14-8d24-396ce803bf00">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.446%"><tr><td style="width:0.1%"></td><td style="width:2.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6YmI0MmQ5OGY2ZGNjNDIzOWFlMjJiNjQ3NTljMTM1OWIvdGFibGVyYW5nZTpiYjQyZDk4ZjZkY2M0MjM5YWUyMmI2NDc1OWMxMzU5Yl8wLTEtMS0xLTE2MTE4_e5dfa78a-9c80-4414-8884-c54b5c888a7a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6YmI0MmQ5OGY2ZGNjNDIzOWFlMjJiNjQ3NTljMTM1OWIvdGFibGVyYW5nZTpiYjQyZDk4ZjZkY2M0MjM5YWUyMmI2NDc1OWMxMzU5Yl8wLTMtMS0xLTE2MTE4_2a60d4c7-18a0-4bde-9caf-5328a74127ab">76-0474169</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.118%"><tr><td style="width:1.0%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTEtMS0xLTE2MTE4_b9d5143b-10ba-4d1f-9de4-fe71d47238e5">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTUtMS0xLTE2MTE4_ed127fac-6bc3-4fd6-85dd-cbb704ae3042">(281)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTYtMS0xLTE2MTE4_4a140651-2d73-4ab1-89b4-e305f20ba505">863-3000</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTEtMS0xLTE2MTE4_72674c32-62e1-498f-89fb-22c306fd6dd6">The Woodlands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTItMS0xLTE2MTE4_2d39b862-8220-420b-971c-fd26dd836976">Texas</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTMtMS0xLTE2MTE4_31353da9-c7ad-4d58-bb18-69c77ac2610c">77381</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices and Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.491%"><tr><td style="width:1.0%"></td><td style="width:3.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange on which Registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTEtMS0xLTE2MTE4_4990094b-a2b3-4a5f-aa2b-0973be16dfd3">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTItMS0xLTE2MTE4_ed1b6b43-1730-4fcb-89a4-c65907bd10f8">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTMtMS0xLTE2MTE4_41d73fec-3c42-4229-bdd7-5b0c4241d00a">Nasdaq Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;None</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act of 1933.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV80Nzg_70487d40-5895-480b-a8cd-0f715e25a8b1">No</ix:nonNumeric> &#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV82NDU_fa0780a8-d46c-433b-b069-3f7c946c1c58">No</ix:nonNumeric> &#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV85OTY_7de9a5f6-0360-4970-9fc3-a3a06bc092da">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xMjk5_ee4b1e0e-f892-4611-8d93-d9c094e4cdf1">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.&#160;&#160;(check one):&#160;&#160;Large accelerated filer &#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzE0_ce8b2443-5b2e-4f2c-b57c-84e6b0dba20d">Accelerated filer</ix:nonNumeric>&#160;&#160;&#9744;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer &#9745;&#160;&#160;&#160;Smaller reporting company <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzcy_772405b4-6ba2-4516-8f65-72d02cd3abeb">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzk5_857cd120-d4c2-41d3-b4df-276ff7e0a8a6">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDM0_c2bebc9d-2dce-49c8-a3d1-ca059f6c9f68">&#9745;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;Yes <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8yNTUw_2ab21ea1-e09f-4f2b-9399-c54dcc514fc2">&#9744;</ix:nonNumeric> No&#160;&#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant&#8217;s most recently completed second quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i7b830e55112e413294d94a95da2c31d6_I20210630" decimals="-3" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8yNzM4_10b0d66d-5b0d-415e-b76e-6ad04f00d1d5">309.4</ix:nonFraction> million, based on the closing price of the common stock on the Nasdaq Global Select Market on June&#160;30, 2021 of $4.59 per share.&#160;&#160;For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.&#160;&#160;As of March 8, 2022, 149,593,551 shares of common stock were outstanding.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDM1_f4efd8c8-51bd-417f-b7f1-f3459892180d" escape="true">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2022 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this annual report on Form 10-K.</ix:nonNumeric></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.926%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_13">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_49">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_49">18</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_52">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_55">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_55">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_58">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_58">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_61">35</a></span></div></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_67">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_70">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_67">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_73">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_76">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_79">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_82">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_82">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_85">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_85">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_91">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_91">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_1810">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_1810">48</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_97">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_97">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_100">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_100">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_103">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_103">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_106">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_106">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_109">Principal Account</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_109">ant</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_109"> Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_109">48</a></span></div></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_115">Exhibit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_115"> and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_115">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_118">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_118">51</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_121">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_121">52</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this annual report on Form 10-K, &#8220;Lexicon Pharmaceuticals,&#8221; &#8220;Lexicon,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Lexicon Pharmaceuticals, Inc. and its subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward-Looking Statements</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report on Form 10-K contains forward-looking statements.&#160;&#160;These statements relate to future events or our future financial performance.&#160;&#160;We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Item 1A.&#160;&#160;Risk Factors,&#8221; that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this annual report on Form 10-K to conform these statements to actual results, unless required by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.  We have reported positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively.  We are now preparing a resubmission of our application for regulatory approval to market sotagliflozin in the United States for heart failure after voluntarily withdrawing our initial application to correct a technical issue with the initial submission.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reported positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively.  The U.S. Food and Drug Administration, or FDA, issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States.  At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our application and the hearing process is ongoing.  Sotagliflozin has been approved in the European Union for use as an adjunct to insulin therapy in the treatment of type 1 diabetes, but has not yet been commercially launched.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported results from two Phase 1 clinical trials of LX9211 and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.  LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160; LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals was incorporated in Delaware in July 1995, commenced operations in September 1995 and was listed on The Nasdaq Global Select Market in April 2000.  Our corporate headquarters are located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381, and our telephone number is (281) 863-3000.  &#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are made available free of charge on our corporate website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as soon as reasonably practicable after the filing of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those reports with the Securities and Exchange Commission, or the SEC.&#160;&#160;Information found on our website should not be considered part of this annual report on Form 10-K.  Alternatively, you may access these reports on the SEC&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug Development Programs</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:  sotagliflozin, which we are developing as a treatment for heart failure and type 1 diabetes, and LX9211, which we are developing as a treatment for neuropathic pain.  We have also advanced a number of additional compounds into various stages of clinical and preclinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sotagliflozin</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of heart failure and type 1 diabetes. Our scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type&#160;1, or SGLT1, and sodium-glucose cotransporter type&#160;2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we granted Sanofi-Aventis Deutschland GmbH an exclusive, worldwide (excluding Japan), royalty-bearing right to develop, manufacture and commercialize sotagliflozin.  In September 2019, we and Sanofi agreed to terminate our collaboration, pursuant to which we regained and hold exclusive development and commercialization rights to sotagliflozin.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Heart Failure.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have completed two Phase 3 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on long-term outcomes related to composite primary endpoints of total cardiovascular death, hospitalizations for heart failure and urgent visits for heart failure.  Both clinical trials were initiated by Sanofi and transitioned to us in connection with the termination of our collaboration, following which both clinical trials were closed out early beginning in March 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our SCORED Phase 3 clinical trial enrolled 10,584 patients with type 2 diabetes, chronic kidney disease with an estimated glomerular filtration rate, or eGFR, of 25 to 60 ml per minute per</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of body surface area and risks for cardiovascular disease in a randomized, double-blind, placebo-controlled study of sotagliflozin added to standard of care over a median treatment period of 16 months.  Patients were initiated on a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 200mg once daily dose of sotagliflozin, which was increased at the discretion of the investigator to 400mg if unacceptable side effects did not occur.  The primary efficacy endpoint under evaluation in the study was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.  Data from the study showed that treatment with sotagliflozin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo, meeting the study&#8217;s primary efficacy endpoint.  A total of 930 primary endpoint events occurred in the study, with 400 events in the sotagliflozin-treated group and 530 events in the placebo group.  There were 5.6 primary endpoint events per 100 patient-years in the sotagliflozin-treated group as compared to 7.5 events per 100 patient-years in the placebo group (HR=0.74; 95% CI=0.63 to 0.88; p&lt;0.001).  There were 2.2 events of cardiovascular death per 100 patient-years in the sotagliflozin-treated group as compared to 2.4 events per 100 patient-years in the placebo group (HR=0.90; 95% CI=0.73 to 1.12; p=0.35).  The data showed an average reduction in hemoglobin A1c, or A1C, of 0.56% in the sotagliflozin-treated group as compared to a reduction of 0.25% in the placebo group in patients with severe chronic kidney disease, defined as having an eGFR of less than 30 ml per minute per 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of body surface area (p&lt;0.001).  In patients with moderate chronic kidney disease, defined as having an eGFR of greater than or equal to 30 ml per minute per 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of body surface area, the data showed an average reduction in A1C of 0.60% in the sotagliflozin-treated group as compared to a reduction of 0.17% in the placebo group (p&lt;0.001).  Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 2.1% (n=112) of the patients in the sotagliflozin-treated group and in 1.8% (n=94) of the patients in the placebo group.  Based on investigator reported events, the most common adverse events of special interest included urinary tract infections (11.5% on sotagliflozin versus 11.1% on placebo), diarrhea (8.5% on  sotagliflozin versus 6.0% on placebo), volume depletion (5.3% on sotagliflozin versus 4.0% on placebo), bone fractures (2.1% on sotagliflozin versus 2.2% on placebo), and genital mycotic infections (2.4% on sotagliflozin versus 0.9% on placebo).  Among other adverse events of interest, diabetic ketoacidosis (0.6% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin-treated group and severe hypoglycemia (1.0% on sotagliflozin vs. 1.0% on placebo) was similar between treatment groups.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SCORED clinical trial was originally designed with co-primary endpoints, assessed in time-to-event analyses, of the first occurrence of a major adverse cardiovascular, or MACE, event, defined as death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke, and the first occurrence of death from cardiovascular causes or hospitalization from heart failure, as determined by independent adjudication.  The co-primary endpoints were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study group assignments and without information from an interim analysis.  In a time-to-event analysis, applying the original co-primary endpoints based on investigator reported events, the results for both the first occurrence of a MACE event (HR=0.84; 95% CI=0.72 to 0.99; p=0.035) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR=0.78; 95% CI=0.66 to 0.91; p=0.001) were consistent with those of the modified primary endpoint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our SOLOIST Phase 3 clinical trial enrolled 1,222 patients with type 2 diabetes who had recently been hospitalized with worsening heart failure in a randomized, double-blind, placebo-controlled study of sotagliflozin initiated either before or within three days of hospital discharge over a median treatment period of nine months.  Patients were initiated on a 200mg once daily dose of sotagliflozin, which was increased at the discretion of the investigator to 400mg if unacceptable side effects did not occur.  The primary efficacy endpoint under evaluation in the study was the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo, with dosing initiated either before or within three days of hospital discharge.  The first dose of sotagliflozin or placebo was administered prior to hospital discharge in 48.8% of patients and a median of two days following discharge in 51.2% of patients, with the benefits of sotagliflozin being consistent between those prespecified patient subgroups.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data from the study showed that treatment with sotagliflozin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo, meeting the study&#8217;s primary efficacy endpoint.  A total of 600 primary endpoint events occurred in the study, with 245 events in the sotagliflozin-treated group and 355 events in the placebo group.  There were 51.0 primary endpoint events per 100 patient-years in the sotagliflozin-treated group as compared to 76.3 events per 100 patient-years in the placebo group (HR=0.67; 95% CI=0.52 to 0.85; p&lt;0.001).  There were 10.6 events of cardiovascular death per 100 patient-years in the sotagliflozin-treated group as compared to 12.5 events per 100 patient-years in the placebo group (HR=0.84; 95% CI=0.58 to 1.22; p=0.36).  Effects on the primary endpoint were consistent among patients suffering from heart failure with reduced ejection fraction, or HFrEF, and heart failure with preserved ejection fraction, or HFpEF.  Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 3.0% (n=18) of the patients in the sotagliflozin-treated group and in 2.8% (n=17) of the patients in the placebo group.  The most common adverse events of special interest included hypotension (6.0% on sotagliflozin versus 4.6% on placebo), urinary tract infections (4.8% on sotagliflozin versus 5.1% on placebo), acute kidney injury (4.1% on sotagliflozin versus 4.4% on placebo), and diarrhea (6.1% on sotagliflozin versus 3.4% on placebo).  Among other adverse events of interest, genital mycotic infections (0.8% on sotagliflozin vs. 0.2% on placebo) were infrequent, severe hypoglycemia (1.5% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin-treated group and diabetic ketoacidosis (0.3% on sotagliflozin vs. 0.7% on placebo) was similar between treatment groups.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SOLOIST clinical trial was originally designed with a primary endpoint of the first occurrence of death from cardiovascular causes or hospitalization from heart failure, as determined by independent adjudication.  The primary endpoint were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study group assignments and without information from an interim analysis.  Applying the original primary endpoint based on investigator reported events, the results for the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR=0.71; 95% CI=0.57 to 0.89; p=0.003) were consistent with those of the modified primary endpoint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Results from both the SCORED and SOLOIST clinical trials were published in the New England Journal of Medicine in November 2020.  In December 2021, we submitted an application for regulatory approval to market sotagliflozin in the United States for heart failure.  In February 2022, we voluntarily withdrew the application to correct a technical issue we identified in the initial submission and are now preparing a resubmission of the application.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Type 1 Diabetes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA issued a complete response letter in March 2019 regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter in November 2019 and March 2020.  In November 2020, we requested an opportunity for an administrative hearing on whether there are grounds for denying approval of our application.  In response to such request, the FDA issued a public Notice of Opportunity for Hearing in March 2021 and the hearing process is ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2019, sotagliflozin was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 27 kg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, who could not achieve adequate glycemic control despite optimal insulin therapy.  We have not commercially launched sotagliflozin for the treatment of type 1 diabetes in the European Union or any other region.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed three Phase 3 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 1 diabetes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pivotal inTandem1 Phase 3 clinical trial enrolled 793 patients with type 1 diabetes in the United States and Canada in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing an event of severe hypoglycemia or diabetic ketoacidosis, or DKA, change in meal-time, or bolus, insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.43% for the 200mg dose (p&lt;0.001) and 0.48% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.07% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Benefits in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo, with statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm and in the percentage of patients achieving A1C levels of less than 7% without any severe hypoglycemia or DKA events and weight loss observed in the 200mg dose arm and statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 80.6%, 81.7% and 79.8%, respectively; the incidences of serious adverse events were 7.5%, 10.3% and 11.1%, respectively; and the incidences of discontinuation due to adverse events were 4.1%, 4.9% and 6.5%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 26 (9.7%), 17 (6.5%) and 17 (6.5%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 1 (0.4%), 9 (3.4%) and 11 (4.2%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our pivotal inTandem2 Phase 3 clinical trial enrolled 782 patients with type 1 diabetes in Europe and Israel in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  As with inTandem1, the primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemia or DKA event, change in bolus insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.39% for the 200mg dose (p&lt;0.001) and 0.37% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.02% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Statistically significant improvements in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 61.2%, 68.2% and 68.8%, respectively; the incidences of serious adverse events were 6.6%, 10.0% and 8.0%, respectively; and the incidences of discontinuation due to adverse events were 3.5%, 3.8% and 6.8%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 13 (5.0%), 13 (5.0%) and 6 (2.3%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 0 (0.0%), 6 (2.3%) and 9 (3.4%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additionally reported pooled continuous glucose monitoring, or CGM, data from the inTandem1 and inTandem2 clinical trials.  The percentage of time during the initial 24-week treatment period spent inside the target range for CGM glucose (70-180 mg/dL) increased from 52.2% to 57.8% in patients treated with 200mg of sotagliflozin and from 50.7% to 64.1% in patients treated with 400mg of sotagliflozin, with no relevant change observed in patients receiving placebo.  The differences from placebo were clinically significant for both the 200mg and 400mg dose groups (p=0.026 and p&lt;0.001, respectively).  The increase in time spent in range by both sotagliflozin dose groups was a result of significantly reduced time </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spent above 180 mg/dL, while the time spent below 70 mg/dL was not increased.  These results translate into an additional 1.41 hours and 3.02 hours that a patient would spend within the 70-180 mg/dL target range in a 24-hour period, for the 200mg and 400mg dose groups respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inTandem3 Phase 3 clinical trial enrolled 1,405 patients with type 1 diabetes in the United States and Europe in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a 24-week treatment period.  Insulin therapy was not optimized in patients and eligibility criteria included any background insulin therapy.  The primary efficacy endpoint under evaluation in the trial was the proportion of patients achieving A1C levels of less than 7% at 24 weeks without experiencing a severe hypoglycemic or DKA event, with secondary endpoints including the change from baseline in A1C, body weight, systolic blood pressure and bolus insulin use.  Data from the study showed statistically significant superiority of sotagliflozin (28.6%) compared to placebo (15.2%) in the proportion of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemic or DKA event (p&lt;0.001), meeting the study&#8217;s primary endpoint.  Patients treated with sotagliflozin also experienced statistically significant improvements in all secondary efficacy endpoints compared to placebo.  The incidences of treatment-emergent adverse events in the placebo and 400mg dose arms were 52.5% and 55.1%, respectively; the incidences of serious adverse events were 3.3% and 6.9%, respectively; and the incidences of discontinuation due to adverse events were 2.3% and 6.3%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the 24-week treatment period was 17 (2.4%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the 24-week treatment period was 4 (0.6%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  Results from the inTandem3 trial were published in the New England Journal of Medicine in September 2017.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">LX9211</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain.  Our scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models.  LX9211 and another development candidate were discovered by scientists working within our drug discovery alliance with Bristol-Myers Squibb from which we hold exclusive development and commercialization rights.  Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.  LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed two Phase 1 clinical trials evaluating the safety, tolerability and pharmacokinetics of LX9211.  The first trial enrolled 11 dose cohorts of healthy volunteers in a randomized, double-blind, placebo-controlled, ascending single dose study of daily doses of LX9211.  The second trial enrolled five dose cohorts of healthy volunteers in a randomized, double-blind, placebo-controlled, ascending multiple dose study of daily doses of LX9211, followed by a maintenance dose for 14 days.  In both trials, LX9211 demonstrated a safety, tolerability and pharmacokinetics profile identifying the maximum tolerated dose and supportive of once-daily dosing, while exhibiting dose proportional pharmacokinetics.  The most common adverse events were headache and dizziness, and there were no drug-related serious adverse events.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are conducting a Phase 2 clinical trial, RELIEF-DPN-1, evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic pain, or DPN.  The trial is expected to enroll approximately 300 patients experiencing DPN in a randomized, double-blind, placebo-controlled study evaluating three treatment groups receiving an initial loading dose of 100mg or 200mg of LX9211 or placebo, followed by once daily doses of 10mg or 20mg of LX9211 or placebo, respectively.  The effects of LX9211 will be assessed over an 11-week evaluation period.  The primary efficacy endpoint under evaluation is the reduction in an average daily pain score at 6 weeks, with secondary endpoints including the proportion of patients with 30% or greater and 50% or greater reduction in pain intensity at 6 weeks and the proportion of patients discontinuing treatment due to lack of efficacy.  Certain patient-reported outcome measures will also be assessed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a second Phase 2 clinical trial, RELIEF-PHN-1, evaluating the safety and tolerability of LX9211 and its effects on post-herpetic neuralgia, or PHN.  The trial is expected to enroll approximately 74 patients experiencing PHN in a randomized, double-blind, placebo-controlled study evaluating two treatment groups receiving an initial loading dose of 200mg of LX9211 or placebo, followed by once daily doses of 20mg of LX9211 or placebo, respectively.  The effects of LX9211 will be assessed over an 11-week evaluation period.  The primary efficacy endpoint under evaluation is the reduction in an average daily pain score at 6 weeks, with secondary endpoints including the proportion of patients with 30% or greater and 50% or greater reduction in pain intensity at 6 weeks and the proportion of patients discontinuing treatment due to lack of efficacy.  Certain patient-reported outcome measures will also be assessed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Drug Discovery and Development Programs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Strategic Alliances</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.  We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established a drug discovery alliance with Bristol-Myers Squibb Company in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.&#160;&#160;Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006.&#160;&#160;We initiated the alliance with a number of neuroscience drug discovery programs at various stages of development and used our gene knockout technologies to identify additional drug targets with promise in the neuroscience field.&#160;&#160;For those targets that were selected for the alliance, we and Bristol-Myers Squibb worked together, on an exclusive basis, to identify, characterize and carry out the preclinical development of small molecule drugs.  Bristol-Myers Squibb has the first option to assume full responsibility for clinical development and commercialization of any drugs resulting from the alliance which enter clinical trials, other than LX9211 and additional compounds acting through AAK1, for which we hold exclusive development and commercialization rights under the alliance.  We received $86&#160;million in upfront payments and research funding under the agreement during the target discovery portion of the alliance, which expired in October 2009. &#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76&#160;million for each drug developed by Bristol-Myers Squibb under the alliance.&#160;&#160;We will also earn royalties on sales of drugs commercialized by Bristol-Myers Squibb under the alliance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 and another development compound acting through AAK1 were discovered by scientists working within our alliance with Bristol-Myers Squibb.  We have agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication and up to $16 million in clinical and regulatory milestones for each of the second and third indications, if applicable.  We have also agreed to pay single digit royalties on worldwide net sales and up to $40 million in commercial milestones.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established a drug discovery alliance with Genentech, Inc. in December 2002 to discover novel therapeutic proteins and antibody targets.&#160;&#160;We and Genentech expanded the alliance in November 2005 for the advanced research, development and commercialization of new biotherapeutic drugs.&#160;&#160;Under the original alliance agreement, we used our target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech&#8217;s internal drug discovery research.&#160;&#160;In the expanded alliance, we conducted additional, advanced research on a broad subset of those proteins and targets.&#160;&#160;We have exclusive rights to develop and commercialize biotherapeutic drugs for two of these targets, while Genentech has exclusive rights to develop and commercialize biotherapeutic drugs for the other targets.&#160;&#160;We retain certain other rights to discoveries made in the alliance, including non-exclusive rights, along with Genentech, for the development and commercialization of small molecule drugs addressing the targets included in the alliance.  We received $58&#160;million in upfront payments, research funding and research milestone payments under the agreement during the research collaboration term, which expired in November 2008.&#160;&#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the extent of our efforts in the alliance, up to $25&#160;million for each drug target for which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech develops a biotherapeutic drug under the alliance.&#160;&#160;We will also earn royalties on sales of biotherapeutic drugs commercialized by Genentech under the alliance.&#160;&#160;Genentech is entitled to receive milestone payments and royalties on sales of biotherapeutic drugs which we develop or commercialize under the alliance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established collaborations with a number of pharmaceutical and biotechnology companies, research institutes and academic institutions under which we have received fees in exchange for generating knockout mice for genes requested by the collaborator, providing phenotypic data with respect to such knockout mice or otherwise granting access to some of our technologies and discoveries.&#160;&#160;In some cases, we remain eligible to receive milestone or royalty payments on the sale of mice and phenotypic data or on products that our collaborators discover or develop using our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities or resources for production and distribution of sotagliflozin, LX9211 or our other drug candidates.  Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations, or CMOs, who, on our behalf, manufacture&#160;supplies of sotagliflozin, LX9211 and our other drug candidates, and will continue to do so for the foreseeable future.  We have selected well-established and reputable global CMOs for our active pharmaceutical ingredient, or API, and drug product manufacturing that have good regulatory standing, large manufacturing capacities, and multiple manufacturing sites within their business footprint.  We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our CMOs.  Our quality department audits these suppliers on a periodic basis.  We work closely with our third-party manufacturers to ensure compliance with current good manufacturing practices, or cGMP, and other stringent regulatory requirements enforced by the FDA and foreign regulatory agencies in other territories, as applicable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials that are used to manufacture our API are sourced from multiple third-party suppliers in Asia and Europe.  Third-party API contract manufacturers in Asia and Europe stock sufficient quantities of these materials to ensure they can manufacture adequate API quantities per our requirements for clinical purposes.  We store API at third-party facilities in North America, and provide appropriate amounts to third-party drug product contract manufacturers in North America who then manufacture, package and label our specified quantities of finished goods for sotagliflozin and our other drug candidates.  Our third-party contract manufacturers also need to obtain materials such as excipients, components and reagents to manufacture our API and finished drug products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our supply chain, we have established safety stock amounts for both our API and drug products, and store those in multiple locations.  The quantities that we store are based on our business needs and take into account scenarios for demand, production lead times, potential supply interruptions and shelf life for our API and drug products.  In parallel, for business continuity reasons, we will evaluate the need to establish an additional or backup supplier for our API and drug product, as necessary.  </span></div><div><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.&#160;&#160;We face significant competition in each of the aspects of our business from other pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and governmental agencies that are pursuing research or development activities similar to ours.  Many of our competitors have substantially greater research, development and commercialization capabilities and financial, scientific, marketing and human resources than we do.&#160;&#160;As a result, our competitors may succeed in developing products earlier than we do, obtaining approvals from the FDA or other regulatory agencies for those products more rapidly than we do, developing products that are more effective than those we develop or commercializing products more effectively and profitably than we do.&#160;&#160;Similarly, our collaborators face similar competition from other competitors who may succeed in developing products more quickly, developing products that are more effective than those developed by our collaborators or commercialize products more effectively and profitably than our collaborators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition for our drug candidates includes both marketed products and drug candidates that are being developed by others, including pharmaceutical products that are currently in a more advanced stage of clinical development or commercialization than are our own drug candidates.&#160;&#160;These competitive marketed products and drug candidates include compounds that employ different mechanisms of action in addressing diseases and conditions for which we are developing our own drug candidates and, in some cases such as sotagliflozin, that employ the same or similar mechanisms of action.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to successfully compete with these potentially competitive drug candidates and other competitive products currently on the market will depend on, among other things:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy, safety and reliability of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to complete preclinical and clinical development and obtain regulatory approvals for our drug candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and scope of regulatory approvals of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to obtain product acceptance by physicians and other health care providers and secure coverage and adequate reimbursement for product use in approved indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to manufacture and sell commercial quantities of our products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protection of our intellectual property; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for sotagliflozin for the treatment of heart failure would include selective SGLT2 inhibitors which have gained or may gain regulatory approval for the treatment of heart failure.  Such selective SGLT2 inhibitors include dapagliflozin and empagliflozin, currently marketed for the treatment of heart failure by AstraZeneca and through an alliance between Boehringer Ingelheim and Eli Lilly, respectively.  We expect that such competition would also include, to some extent, other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan, currently marketed for the treatment of heart failure by Novartis, and vericiguat, currently marketed for the treatment of heart failure by Merck, or which may gain regulatory approval for the treatment of heart failure, such as omecamtiv mecarbil, currently being developed for the treatment of heart failure by Cytokinetics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for sotagliflozin in the treatment of type 1 diabetes would include established insulin therapies, as well as selective SGLT2 inhibitors currently being prescribed off-label.  Such selective SGLT2 inhibitors include dapagliflozin, empagliflozin and canagliflozin, currently marketed for the treatment of type 2 diabetes by AstraZeneca, through an alliance between Boehringer Ingelheim and Eli Lilly, and by Janssen (a subsidiary of Johnson &amp; Johnson), respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for LX9211 for the treatment of DPN would include duloxetine and pregabalin, which are currently marketed for the treatment of DPN by Eli Lilly and Pfizer, respectively, and are also available as generics.  We expect that our principal competition for LX9211 for the treatment of PHN would include gabapentin and pregabalin, both of which are currently marketed for the treatment of PHN by Pfizer and also available as generics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and sale of pharmaceutical products are subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.&#160;&#160;In the United States, new drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the FDC Act.&#160;&#160;The FDA and comparable governmental authorities regulate, among other things, research and development activities and the testing, manufacture, quality control, safety, efficacy, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, export and import of pharmaceutical products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard process required by the FDA before a drug candidate may be marketed in the United States generally includes the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical laboratory and animal tests performed under current good laboratory practices, or cGLP;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of an IND, which must become effective before human clinical trials may commence;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for its intended use;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of a New Drug Application, or NDA, for approval of commercial marketing and sale, or of an NDA supplement, or sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and current good clinical practices, or cGCP;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approval of the NDA or sNDA.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process for the testing and approval of drug candidates requires substantial time, effort and financial resources.&#160;&#160;Preclinical development of a drug candidate can take from one to several years to complete, with no guarantee that an IND based on those studies will become effective to even permit clinical testing to begin.&#160;&#160;Before commencing the first clinical trial of a drug candidate in the United States, we must submit an IND to the FDA.&#160;&#160;The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial.&#160;&#160;In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial may begin.&#160;&#160;Submission of an IND may not result in FDA authorization to commence a clinical trial.  A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, and the FDA must grant permission for each clinical trial to start and continue.&#160;&#160;Further, an independent institutional review board for each medical center proposing to participate in the clinical trial must review and approve the plan for any clinical trial before it commences at that center.&#160;&#160;Regulatory authorities or an institutional review board or we may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 clinical trials are conducted in a limited number of healthy human volunteers or, in some cases, patients, to evaluate the safety, dosage tolerance, absorption, metabolism, distribution and excretion of the drug candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials are conducted in groups of patients afflicted with a specified disease or condition to obtain preliminary data regarding efficacy as well as to further evaluate safety and optimize dosing of the drug candidate.  Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials are conducted in larger patient populations at multiple clinical trial sites to obtain statistically significant evidence of the efficacy of the drug candidate for its intended use and to further test for safety in an expanded patient population.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may require, or companies may pursue, additional clinical trials after a product is approved.&#160;&#160;These so-called Phase&#160;4 studies may be made a condition to be satisfied after a drug receives approval.  Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up and to including withdrawal of NDA approval.  The results of Phase 4 studies can confirm the effectiveness of a drug candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of clinical trials, FDA approval of an NDA must be obtained before a new drug may be marketed in the United States.&#160;&#160;The submission of an NDA requires payment of a substantial user fee to the FDA.  An NDA must contain, among other things, information on chemistry, manufacturing controls and potency and purity, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability and clinical data.&#160;&#160;There can be no assurance that the FDA will accept an NDA for filing and, even if accepted for filing, that approval will be granted.&#160;&#160;The FDA may convene an advisory committee to provide clinical insight on NDA review questions.  Although the FDA is not required to follow the recommendations of an advisory committee, the agency typically does so.  Among other things, the FDA reviews an NDA to determine whether a product is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.&#160;&#160;The FDA may deny approval of an NDA by way of a complete response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial.&#160;&#160;Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.&#160;&#160;An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy or otherwise that could restrict the commercial applications of a product or impose costly procedures in connection with the commercialization or use of the product.  Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market.&#160;&#160;In addition, the FDA may require testing and surveillance programs to monitor the effect of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA approval for each product, each drug manufacturing establishment must be inspected and approved by the FDA.&#160;&#160;All manufacturing establishments are subject to inspections by the FDA and by other federal, state and local agencies and must comply with current Good Manufacturing Practices requirements.&#160;&#160;Non-compliance with these requirements can result in, among other things, total or partial suspension of production, failure of the government to grant approval for marketing and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes many years, with the actual time required varying substantially based on, among other things, the nature, novelty and complexity of the drug candidate and of the disease or condition.&#160;&#160;Government regulation may delay or prevent marketing of drug candidates or new diseases for a considerable period of time and impose costly procedures upon our activities.  The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all.  Success in earlier-stage clinical trials does not ensure success in later-stage clinical trials.&#160;&#160;Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results.  Furthermore, data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.  Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages.  Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA approves a product, a manufacturer must provide certain updated safety and efficacy information.&#160;&#160;Product changes as well as certain changes in a manufacturing process or facility would necessitate additional FDA review and approval.&#160;&#160;Other post-approval changes may also necessitate further FDA review and approval.&#160;&#160;Additionally, a manufacturer must meet other requirements including those related to adverse event reporting and record keeping.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug.  Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency.&#160;&#160;Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which the FDA has approved the drug and are otherwise consistent with the FDA-approved label for the drug.&#160;&#160;Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.  Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA.  Such off-label uses are common across medical specialties.  Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances.  The FDA does not regulate the behavior of physicians in their choice of treatments.  The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use.  Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various United States federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various United States federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDC Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Orphan Drug Act is intended to incentivize the development of products for rare diseases or conditions that affect fewer than 200,000 people in the United States.  If a drug is being developed for a rare disease or condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug&#8221; for the same orphan indication.  If the FDA has previously approved another same drug for the same indication, the sponsor of the subsequent drug would be required to provide a plausible hypotheses of clinical superiority over the previously approved drug to obtain an orphan designation.  Upon FDA receipt of orphan drug designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses, the ability to apply for annual grant funding and waiver of PDUFA application fee.  In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of market exclusivity for the approved orphan-designated indication.  Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication.  Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.  Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.  For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs.  Priority review is designed to give drugs that treat serious conditions and offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months of NDA filing as compared to a standard review time of 10 months from NDA filing.  Certain other types of drug applications are also eligible for priority review.  Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track-designated drug and expedite review of the application for a drug designated for priority review.  Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint.  As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.  In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.  Drugs designated as breakthrough therapies are also eligible for accelerated approval.  The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional programs intended to expedite the development of drug products were included in the 21st Century Cures Act, or the Cures Act.  The Cures Act includes various provisions to accelerate the development and delivery of new treatments, such as those intended to expand the types of evidence manufacturers may bring to the FDA to support drug approval, to encourage patient-centered drug development, to liberalize the communication of healthcare economic information to payers, and to create greater transparency with regard to manufacturer expanded access programs.  Central to the Cures Act are provisions that enhance and accelerate the FDA&#8217;s processes for reviewing and approving new drugs and supplements to approved NDAs, including provisions that:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to establish a program to evaluate the potential use of real world evidence to help support the approval of a new indication for an approved drug and to help support or satisfy post-approval study requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the FDA may rely upon qualified data summaries to support the approval of a supplemental application with respect to a qualified indication for an already approved drug;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to issue guidance for purposes of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to establish a process for the qualification of drug development tools for use in supporting or obtaining FDA approval for or investigational use of a drug.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cures Act amends Section 114 of the Food and Drug Administration Modernization Act of 1997 to help clarify and facilitate the dissemination of healthcare economic information, including by broadening the definition of healthcare economic information, expressly extending the dissemination of healthcare economic information to payors, and clarifying that healthcare economic information must only relate to an FDA-approved indication rather than directly relate to the indication.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the United States</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to the regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the United States.  Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic areas, such as the European Union, before we may market products in those countries or areas.  The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European Union regulatory systems, a company may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the European Medicines Agency, or EMA, whose Committee for Medicinal Products for Human Use reviews the application and issues an opinion on it.  The opinion is considered by the European Commission which is responsible for deciding applications.  If the application is approved, the European Commission grants a single marketing authorization that is valid for all European Union member states as well as Iceland, Liechtenstein and Norway, or the EEA.  The national authorization procedures, the decentralized and mutual recognition procedures, as well as national applications, are available for products for which the centralized procedure is not compulsory.  The mutual recognition procedure provides for the European Union member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State, or RMS.  The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state.  Under this procedure the applicant can select the member state that will act as the RMS.  In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States or CMS.  Within 90 days of receiving the application and assessment report, each CMS must decide whether to recognize the RMS assessment.  If a member state does not agree with the assessment and the disputed points cannot be resolved, the matter is eventually referred to the European Commission, whose decision is binding on all member states.  If the application is successful, national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted for a limited number of medicinal products for human use referenced in European Union law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if the risk-benefit balance of the product is positive, it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, unmet medical needs will be fulfilled and the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.  Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, orphan designation is available for products in development which are either intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union, or intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the community and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.  Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product.  The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Regulation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business.  If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.  The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent.  Additionally, we are subject to state law equivalents of each of the above federal laws, which may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information.  Other countries also have, or are developing, laws governing the collection, use and transmission of personal information.  In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services, or CMS, annually certain payments and other transfers of value provided to physicians and certain advanced non-physician health care practitioners and teaching hospitals made in the previous calendar year, as well as ownership and investment interests held by physicians and their immediate family members.  In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.  These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.  In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those marketed products which are covered in the United States by the Medicaid program, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers.  We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply.  These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear.  Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of pharmaceutical products, restrict or regulate post-approval activities, and affect the ability to profitably sell pharmaceutical products that obtain marketing approval.  The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of drug candidates.  Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ACA has had a significant impact on the health care industry in the United States.  The ACA was designed to expand coverage for the uninsured while at the same time contain overall healthcare costs.  With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. Additionally, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019, or the CREATES Act, aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a risk evaluation and mitigation strategies, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REMS, program for certain products, to deny generic product developers access to samples of brand products.  Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products.  To remedy this concern, the CREATES Act established a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221;  Whether and how generic product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on future competition are unknown.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, the 2021 Consolidated Appropriations Act incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#8217;s average sales price to the Department of Health and Human Services, or DHHS, beginning on January 1, 2022, subject to enforcement via civil money penalties.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA and we expect there will be additional challenges and amendments to the ACA in the future.  Members of the United States Congress have indicated that they may continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the ACA.  For example, the Tax Cuts and Jobs Act, among other things, removed penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, commonly referred to as the &#8220;individual mandate.&#8221;  It is unclear how this and other efforts to repeal and replace the ACA will impact the implementation of the ACA, the pharmaceutical industry more generally, and our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.  DHHS has solicited feedback on some of various measures intended to lower drug prices and reduce the out of pocket costs of drugs and implemented others under its existing authority.  Congress and the executive branch have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs, making this area subject to ongoing uncertainty.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.  In December 2020, the United States Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental and Worker Safety Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the foregoing, our business is subject to regulation under various state and federal environmental and worker safety laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, the Comprehensive Environmental Response, Compensation and Liability Act and the Toxic Substances Control Act, each as amended from time to time.&#160;&#160;These and other laws and their implementing regulations govern our manufacture, use, storage, handling, transport and disposal of various biological, chemical, radioactive and other hazardous substances used in our operations and the wastes generated by those activities.  We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these substances.  We may face liability for any injury or contamination that results from our use or the use by third parties of those substances, and such liability may exceed our insurance coverage and our total assets.  Historically, our environmental and worker safety compliance costs have not had a material adverse effect on our results of operations, but there can be no assurance that such costs will not be material in the future or that such future compliance will not have a material adverse effect on our business and operational results.  The trend in environmental and occupational health and safety laws and regulations is to typically place more restrictions and limitations on activities that may adversely affect the environment or expose workers to injury.  If existing regulatory requirements or enforcement policies change or new regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or enforcement initiatives are developed and implemented in the future, we may be required to make significant, unanticipated capital and operating expenditures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can protect our proprietary rights from unauthorized use by third parties only to the extent that those rights are covered by valid and enforceable patents or are effectively maintained as trade secrets.  Accordingly, patents and other proprietary rights are an essential element of our business.&#160;&#160;We own or exclusively license patents and patent applications throughout the world that claim our products and drug candidates, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim sotagliflozin, crystalline forms of sotagliflozin, pharmaceutical compositions comprising sotagliflozin, and methods of its manufacture and use; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim LX9211, pharmaceutical compositions comprising LX9211, and methods of its use.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.  We have filed patent applications and hold issued patents covering each of our drug candidates.  None of our United States patents that claim one of our drug candidates has a normal expiration date earlier than 2028.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees, consultants and advisors are required to execute a proprietary information agreement upon the commencement of employment or consultation. In general, the agreement provides that all inventions conceived by the employee or consultant, and all confidential information developed or made known to the individual during the term of the agreement, shall be our exclusive property and shall be kept confidential, with disclosure to third parties allowed only in specified circumstances. We cannot assure you, however, that these agreements will provide useful protection of our proprietary information in the event of unauthorized use or disclosure of such information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent and intellectual property rights are subject to certain rights and uncertainties.  See &#8220;Risks Related to Our Intellectual Property&#8221; under &#8220;Item 1A.&#160;Risk Factors.&#8221;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and their ages and positions are listed below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:27.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Position with the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Medical Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth B. Kassler-Taub, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Regulatory and Quality Assurance</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Innovation and Chemical Sciences</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy E. McDermott</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Human Resources</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kiernan A. Seth, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and Accounting</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lonnel Coats</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our chief executive officer and a director since July 2014.  Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining our company, most recently as chief executive officer from 2010 to 2014.  Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson &amp; Johnson, where he held a variety of management and sales positions.  Mr. Coats serves as a director of Blueprint Medicines Corporation and holds a B.S. from Oakland University.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey L. Wade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our president and chief financial officer since October 2021, having previously served in a series of finance, corporate development, administrative and legal leadership positions since joining our company in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1999.&#160;&#160;Before joining Lexicon, Mr.&#160;Wade was a partner with the law firm of Andrews&#160;&amp; Kurth&#160;L.L.P., where he represented companies in the biotechnology, information technology and energy industries in venture capital financings, public offerings and private placements, mergers and acquisitions, collaborations and licensing, and other corporate matters.&#160;&#160;Mr.&#160;Wade is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston.&#160;&#160;He received his B.A. and J.D. from the University of Texas.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Brian T. Crum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president and general counsel since October 2021 and previously served in a series of legal leadership positions since joining our company in 2001.  Mr. Crum was previously a corporate securities attorney with the law firms of Brobeck, Phleger &amp; Harrison LLP and Andrews &amp; Kurth L.L.P., where he represented companies in the energy and information technology industries.  Mr. Crum received his B.B.A. and J.D. from the University of Texas.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Craig B. Granowitz, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president and chief medical officer since August 2021.  Dr. Granowitz previously served as chief medical officer of Amarin Corporation plc since 2016.  Prior to joining Amarin, Dr. Granowitz served as senior vice president and head of global medical affairs, global human health of Merck &amp; Co., Inc. and in a variety of medical and commercial management positions for Schering-Plough Corporation. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Kenneth B. Kassler-Taub, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president, regulatory affairs and quality assurance since October 2021 and previously served as vice president, clinical operations and in other senior capacities since joining our company in 2014.  Dr. Kassler-Taub previously served in various senior clinical and medical leadership positions at Becton Dickinson and Company, where he worked for 12 years, most recently as vice president, corporate clinical development.  Prior to joining Becton Dickinson, Dr. Kassler-Taub spent 14 years with Bristol-Myers Squibb Company Pharmaceutical Research Institute, where he held a variety of clinical and drug safety positions.  Dr. Kassler-Taub received his B.A. from Amherst College and M.D. from the Boston University School of Medicine.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alan J. Main, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. has been our executive vice president of innovation and chemical sciences since September 2020 and previously served in a series of manufacturing and scientific leadership positions since joining our company in 2001.&#160;&#160;Dr.&#160;Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until our acquisition of Coelacanth in 2001.&#160;&#160;Dr.&#160;Main was formerly senior vice president, U.S.&#160;Research at Novartis Pharmaceuticals Corporation, where he worked for 20&#160;years before joining Coelacanth.&#160;&#160;Dr.&#160;Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wendy E. McDermott</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president, human resources since January 2022.  Ms. McDermott previously served as chief people officer of Rafael Pharmaceuticals, Inc. since 2019, vice president, human resources of Sanofi from 2017 to 2019 and in a variety of human resources positions with Sanofi, Schering-Plough Corporation and other companies in the tobacco, media and talent and event management industries.  Ms. McDermott received her B.A. from State University of New York at Plattsburgh.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kiernan A. Seth, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president and chief commercial officer since October 2021 and previously served in a series of commercial and medical leadership positions since joining our company in 2014.  Dr. Seth previously served as executive director and head of the oncology business unit with Eisai, Inc. and in a series of marketing roles with Bristol-Myers Squibb Company, Pfizer Inc. and Schering Plough Corporation.  Dr. Seth received his B.S. from Norfolk State University, his M.B.A. from St. Joseph&#8217;s University and his Ph.D. from Meharry Medical College.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristen L. Alexander</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president of finance and accounting and principal accounting officer since September 2021 and previously served as controller since joining our company in 2017.  Ms. Alexander previously served as controller of Johnson Specialty Tools, LLC and in a variety of finance and accounting management positions for Trican Well Services, L.P., Nabors Industries Ltd. and Ernst &amp; Young, LLP.  Ms. Alexander is a certified public accountant and received her B.B.A. from the University of Oklahoma.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Shareholders</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have valuable relationships with Invus, L.P. and its affiliates, which we collectively refer to as Invus.  Invus currently owns approximately 50.7% of the outstanding shares of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2022, we employed 87 persons, of whom 14 hold M.D. or Ph.D. degrees and another 24 hold other advanced degrees.&#160;&#160;All of our employees are located in the United States.  None of our employees are represented by a labor union and we believe that our relationship with our employees is good.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our company culture is supported by our five core values: innovation, transparency, ownership, respect and integrity.  We value a diverse workforce and proudly reflect a company culture developed with a variety of ethnic backgrounds, nationalities, races, religions, military service, sexual preferences and abilities.  We are committed to promoting and maintaining an inclusive, high-performing environment where all team members embrace and leverage each other&#8217;s talents and backgrounds and nourish innovative thinking in order to achieve their full potential and contribute to our success.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our most valued resource is the collective talent and time that our employees dedicate to support and advance our mission.  Accordingly, we offer our employees a comprehensive compensation and benefits package that is competitive within the industry and make investing in the growth and development of our employees an important priority.  Employee development is advanced through talent management, promotions, mentoring, stretch assignments, internships, formal training, speaker series, conferences, continuing education and educational reimbursement.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, respectively, we incurred expenses of $55.0&#160;million, $153.6&#160;million and $91.9&#160;million in company-sponsored as well as collaborative research and development activities, including $4.3&#160;million, $6.4&#160;million and $7.1&#160;million of stock-based compensation expense in 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.&#160;&#160;The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the material risks to our business, operations and the investment in our common stock. This summary does not include all of the risks we face and you should carefully review and consider the full discussion of our risk factors below, together with the other information in this annual report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Business and Industry</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on our ability to obtain positive results from our ongoing Phase 2 clinical trials of LX9211 in diabetic neuropathic pain and post-herpetic neuralgia.  If we fail to successfully complete and obtain positive results from such clinical trials, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Environmental and Product Liability</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Common Stock</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are preparing a resubmission of our application for regulatory approval to market sotagliflozin in the United States for heart failure after voluntarily withdrawing our initial application to correct a technical issue with the submission.  </span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot offer any assurances that the FDA will accept our resubmission or grant marketing approval for sotagliflozin in heart failure, on acceptable timelines or at all. Furthermore, regulatory approval in the United States for sotagliflozin in heart failure, even if obtained, may limit the type of patients in which sotagliflozin may be used or otherwise require specific warning or labeling language, any of which may reduce the commercial potential of sotagliflozin in heart failure. Even if approved, our existing capital resources and commercial infrastructure are insufficient to commercially launch sotagliflozin for heart failure and we may not be successful in obtaining such resources, building such infrastructure or otherwise effectively commercializing sotagliflozin for heart failure. Should we fail to obtain regulatory approval in the United States, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved, we expect that a significant portion of our total revenues will be attributable to sales of sotagliflozin for heart failure in the United States, but we cannot be certain that sotagliflozin will be commercially successful. If approved, our future sales of sotagliflozin will depend on numerous factors, including:</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients suffering from heart failure;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from dapagliflozin, empagliflozin and, to some extent, other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety profile of sotagliflozin, including whether previously unknown side effects or increased incidence or severity of known side effects as compared to those seen during development are identified with the commercial use of sotagliflozin;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our commercial strategy for marketing sotagliflozin and our execution of that strategy, including our pricing strategy and the effectiveness of our efforts to obtain and maintain adequate third-party reimbursement;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance of sotagliflozin by patients, the medical community and third-party payers; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of sotagliflozin and to maintain and successfully monitor commercial manufacturing arrangements for sotagliflozin with third-party manufacturers to ensure they meet our standards and those of the FDA, which extensively regulates and monitors pharmaceutical manufacturing facilities.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that sotagliflozin, if approved, will have a competitive commercial profile, our current estimates of the revenues that sotagliflozin could generate in future periods may change based upon the above factors, and could prove to be incorrect. If our revenues, market share or other indicators of market acceptance of sotagliflozin fail to meet the expectations of investors or public market analysts, the market price of our common stock could decline. In addition, if one or more of the factors above negatively affects sotagliflozin sales, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend heavily on our ability to obtain positive results from our ongoing Phase 2 clinical trials of LX9211 in diabetic neuropathic pain and post-herpetic neuralgia.  If we fail to successfully complete and obtain positive results from such clinical trials, our business will suffer and our stock price will likely decline.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.  We cannot offer any assurances or predict with any certainty that such Phase 2 clinical trials will be successfully completed, that positive clinical data will be obtained from such clinical trials or that such clinical trials will demonstrate a competitive commercial profile for LX9211, in any such case on the expected timelines.  Should we fail to obtain positive results from such clinical trials, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain regulatory approvals for the commercial sale of any products that we or our collaborators may develop, we or our collaborators are required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of our drug candidates.&#160;&#160;We or our collaborators may not be able to obtain authority from the FDA, or other equivalent foreign regulatory agencies, to initiate or complete any clinical trials.&#160;&#160;In addition, we have limited internal resources for making regulatory filings and interacting with regulatory authorities.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and the results from nonclinical testing of a drug candidate that is under development may not be predictive of results that will be obtained in human clinical trials.&#160;&#160;In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger-scale, advanced stage clinical trials.&#160;&#160;A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving positive results in earlier trials. Negative or inconclusive results from a nonclinical study or a clinical trial could cause us, our collaborators or the FDA or other equivalent foreign regulatory agencies to terminate a nonclinical study or clinical trial or require that we or our collaborators repeat or modify it.&#160;&#160;Furthermore, we, one of our collaborators or a regulatory agency with jurisdiction over the trials may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks or for other reasons.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any nonclinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.&#160;&#160;Nonclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval.  The FDA or institutional review boards at the medical institutions and healthcare facilities where we or our collaborators sponsor clinical trials may suspend any trial indefinitely if they find deficiencies in the conduct of these trials.&#160;&#160;Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practices.&#160;&#160;The FDA and these institutional review boards have authority to oversee our and our collaborators&#8217; clinical trials, and the FDA may require large numbers of subjects or patients.&#160;&#160;In addition, we or our collaborators must manufacture, or contract for the manufacture of, the drug candidates that we use in our clinical trials under the FDA&#8217;s current Good Manufacturing Practices.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of completion of clinical trials is dependent, in part, upon the rate of enrollment of patients.&#160;&#160;Patient accrual is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the nature of the study, the existence of competitive clinical trials and the availability of alternative treatments.&#160;&#160;Delays in planned patient enrollment may result in increased costs and prolonged clinical development, which in turn could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or potential products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may not be able to successfully complete any clinical trial of a drug candidate within any specified time period.&#160;&#160;In some cases, we or our collaborators may not be able to complete the trial at all. Moreover, clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials may not show our drug candidates to be both safe and effective.&#160;&#160;Thus, the FDA and other regulatory authorities may not approve any drug candidates that we develop for any indication or may limit the approved indications or impose other conditions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.&#160;&#160;Failure to obtain regulatory approval for any drug candidate would prevent us from commercializing that drug candidate.&#160;&#160;The process of obtaining regulatory approvals is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved.&#160;&#160;Before a new drug application can be filed with the FDA, the drug candidate must undergo extensive clinical trials, which can take many years and may require substantial expenditures.&#160;&#160;Any clinical trial may fail to produce results satisfactory to the FDA.&#160;&#160;For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results.&#160;&#160;Furthermore, prior to approving a new drug, the FDA typically requires that the efficacy of the drug be demonstrated in two double-blind, controlled studies.  The regulatory process also requires nonclinical testing, and data obtained from nonclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.&#160;&#160;In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review.&#160;&#160;Changes in regulatory approval policy, regulations or statutes or the process for regulatory review during the development or approval periods of our drug candidates may cause delays in the approval or rejection of an application.  Even if the FDA or a comparable authority in another country approves a drug candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials.&#160;&#160;These agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or our collaborators&#8217; ability to commercialize any products that we or they may develop will be highly dependent upon the extent to which such products gain market acceptance among physicians, patients, health care payers, such as commercial health insurers, Medicare and Medicaid, and the medical community.&#160;&#160;If such products do not achieve an adequate level of acceptance, we may not generate adequate product revenues and we may not become profitable.&#160;&#160;The degree of market acceptance of such products will depend upon a number of factors, including:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness, or perceived effectiveness, of our products in comparison to competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of any significant side effects, as well as their severity in comparison to any competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages or disadvantages in relation to alternative treatments;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">current and future indications for which our products may be approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products for sale at competitive prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party coverage or reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to reestablish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully commercialize any product that we or our collaborators may develop, we or they must establish or maintain an effective commercialization infrastructure supporting such product, including sales force, marketing organization and distribution capabilities.  We no longer maintained a commercialization infrastructure following our sale of XERMELO (telotristat ethyl) and related assets to TerSera and will need to reestablish such capabilities in order to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize any future products, including sotagliflozin for heart failure.  Factors that may hinder efforts to effectively reestablish, manage and maintain such infrastructure for products that we or our collaborators may develop include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to recruit, retain and effectively manage adequate numbers of effective sales and marketing personnel;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to maintain relationships with third-party logistics providers, pharmacies, third-party manufacturers and other third parties instrumental in the commercial manufacture and distribution of such products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to establish or implement internal controls and procedures required in connection with sales of such products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of sales personnel to obtain access to or convince adequate numbers of physicians to prescribe such products; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential lack of complementary products to be offered by sales personnel, which may put us or our collaborators at a competitive disadvantage relative to companies with more extensive product lines.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators are unable to sustain our or their sales force, marketing infrastructure and distribution capability for such products, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators will need to expend significant time and resources to train our sales forces to be credible, persuasive and compliant in discussing such products with the physicians treating the patients indicated under the label.  We or our collaborators will also need to continue to train our sales forces to ensure that a consistent and appropriate message about such products is being delivered to potential customers.  If we or our collaborators are unable to effectively train our sales forces and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of such products and their proper administration, our and their ability to successfully commercialize such products could be diminished, which could have a material adverse effect on our financial condition, stock price and operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize any products that we or our collaborators may develop is highly dependent on the extent to which coverage and reimbursement for such products are available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers, including managed care organizations and group purchasing organizations.&#160;&#160;Many patients are not capable of paying themselves for the products that we or our collaborators may develop, and rely on third-party payers to pay for, or subsidize, their medical needs.&#160;&#160;If third-party payers do not provide coverage or reimbursement for such products, our revenues and prospects for profitability will suffer.&#160;&#160;In addition, even if third-party payers provide some coverage or reimbursement for such products, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans often varies based on the type of contract or plan purchased.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, particularly the countries in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.&#160;&#160;In these countries, price negotiations with governmental authorities can take six to 12&#160;months or longer after the receipt of regulatory marketing approval for a product.&#160;&#160;To obtain reimbursement and/or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost effectiveness of our drug candidates or products to other available therapies.&#160;&#160;The conduct of such a clinical trial could be expensive and result in delays in the commercialization of our drug candidates.&#160;&#160;Third-party payers are challenging the prices charged for medical products and services, and many third-party payers limit reimbursement for newly approved health care products.&#160;&#160;In particular, third-party payers may limit the indications for which they will reimburse patients who use any products that we or our collaborators may develop.&#160;&#160;Cost-control initiatives could decrease prices we or our collaborators might establish for products that may be developed, which would result in lower product revenues to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates have been manufactured in relatively small quantities for nonclinical and clinical trials.&#160;&#160;If any of these drug candidates, including sotagliflozin, are approved by the FDA or other regulatory agencies for commercial sale, we or our collaborators will need to manufacture them in larger quantities.  We may not be able to successfully increase the manufacturing capacity, whether in collaboration with third-party manufacturers or on our own, for any approved product in a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timely or economic manner, or at all.&#160;&#160;Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.&#160;&#160;If we or our collaborators are unable to successfully increase the manufacturing capacity for any such product, the regulatory approval or commercial launch of that product may be delayed or there may be a shortage in supply.&#160;&#160;Pharmaceutical products typically require precise, high-quality manufacturing.&#160;&#160;The failure to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive and rigorous ongoing domestic and foreign government regulation of, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of any products which receive regulatory approvals from the FDA or foreign regulatory authorities.&#160;&#160;The failure to comply with these requirements or the identification of safety problems during commercial marketing could lead to the need for product marketing restrictions, product withdrawal or recall or other voluntary or regulatory action, which could delay further marketing until the product is brought into compliance.&#160;&#160;The failure to comply with these requirements may also subject us or our collaborators to stringent penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, without limitation:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which constrains our marketing practices, educational programs, pricing policies, relationships with healthcare providers or other entities, and other business activities, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and federal government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported price may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and potentially limit our ability to offer certain marketplace discounts); and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and federal expenditure tracking and reporting laws, which generally require certain types of expenditures in the United States to be tracked and reported.  For example, the Physician Payments Sunshine Act, among other things, imposes reporting requirements on certain manufacturers to annually report to CMS information related to payments </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other transfers of value to physicians and certain advanced non-physician health care practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.  Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain marketing practices, including off-label promotion, may also violate certain federal and state health regulatory fraud and abuse laws as well as false claims laws, including the civil False Claims Act.  Suits filed under the civil False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement.  The filing of&#160;qui tam&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to defend a civil False Claims Act action.  When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our operations, the exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to sell our products or operate our business and also adversely affect our financial results.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may be expected to prescribe our products and from whom we may obtain patient health information are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business.  International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within Europe and between European countries and the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign countries, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of pharmaceutical products, restrict or regulate post-approval activities, and affect the ability to profitably sell pharmaceutical products that obtain marketing approval.  The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of drug candidates.  If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability.  Moreover, complying with any new legislation or regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the United States and some foreign countries is toward reform and cost containment in the health care industry.&#160;&#160;The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals that may have the effect of reducing the prices that we are able to charge for products we or our collaborators may develop.  Healthcare reform measures which may be adopted in the future in the United States and foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions may result in more rigorous coverage criteria and significant downward pressure on the prices drug manufacturers may charge.  As a result, our revenues and prospects for profitability could be significantly harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the United States, third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. They may use tiered reimbursement and may adversely affect demand for products we or our collaborators may develop by placing them in an expensive tier.  They may also refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals.  As a result, significant uncertainty exists as to whether and how much third-party payers will reimburse for newly approved drugs, which in turn will put pressure on the pricing of drugs.  Further, we do not have experience in ensuring approval by applicable third-party payers outside of the United States for coverage and reimbursement of pharmaceutical products.  We also anticipate pricing pressures in connection with the sale of products we or our collaborators may develop due to the increasing influence of health maintenance organizations and additional legislative proposals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are highly diversified and are characterized by rapid technological change.&#160;&#160;We and our collaborators face, and will continue to face, intense competition from biotechnology and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research and development activities similar to ours.&#160;&#160;In addition, significant delays in the development of our drug candidates could allow our competitors to bring products to market before us, which would impair our or our collaborators&#8217; ability to commercialize our drug candidates.&#160;&#160;Any products that we or our collaborators develop will compete in highly competitive markets.&#160;&#160;Further, our competitors may be more effective at using their technologies to develop commercial products.&#160;&#160;Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and marketing capabilities.&#160;&#160;As a result, our competitors may be able to more easily develop products that would render any products that we or our collaborators develop obsolete and noncompetitive.&#160;&#160;For example, dapagliflozin and empagliflozin are currently being marketed by AstraZeneca and through an alliance between Boehringer Ingelheim and Eli Lilly, respectively, for the treatment of heart failure and certain other indications.  Each of those products act through SGLT2, one of the targets of sotagliflozin. We expect that our principal competition for sotagliflozin for the treatment of heart failure would include such selective SGLT2 inhibitors which have already received or may gain regulatory approval for the treatment of heart failure, as well as other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan, currently marketed for the treatment of heart failure by Novartis, and vericiguat, currently marketed for the treatment of heart failure by Merck, or which may gain regulatory approval for the treatment of heart failure, such as omecamtiv mecarbil, currently being developed for the treatment of heart failure by Cytokinetics.  In addition, there may be drug candidates of which we are not aware at an earlier stage of development that may compete with our drug candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been disrupted and could be materially adversely affected by the COVID-19 pandemic. In response to the ongoing pandemic and resulting state and local restrictions, we implemented work-from-home policies for all employees except certain key essential members involved in business-critical activities. The effects of our work-from-home policies may negatively impact productivity, disrupt our business and delay our ongoing research and development efforts, the magnitude of which will depend, in part, on the length and severity of the pandemic and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure to COVID-19) may be hindered, which would adversely impact our clinical trial operations. For example, due to the impact of the COVID-19 pandemic, we delayed initiation of our Phase 2 clinical trials of LX9211 and enrollment in such trials have been negatively affected by the pandemic. In addition, the pandemic could cause significant disruption in the operations of third party manufacturers and research and development organizations upon whom we rely and, as a result, could severely impact our business operations. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has also resulted in disruption of global financial markets and supply chains. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity, and effectively manage the clinical and commercial supply of our products. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Capital Requirements and Financial Results</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs.&#160;&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $86.7&#160;million in cash, cash equivalents and investments.&#160;&#160;We anticipate that our existing capital resources and the cash and revenues we expect to derive from collaborations and other sources will enable us to fund our currently planned operations for at least the next 12 months from the date of this report.  However, we caution you that we may generate less cash and revenues or incur expenses more rapidly than we currently anticipate.  Our currently planned operations for the next twelve months include the continued nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates and preparations for the commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although difficult to accurately predict, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amount of our future capital requirements will be substantial and will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of our clinical trials of sotagliflozin, LX9211 and our other drug candidates and our ability to obtain necessary regulatory approvals based on such clinical trials, including for sotagliflozin for the treatment of heart failure;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing new collaborations and licenses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of our research, development and commercialization expenditures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing programs and products, and of technological and market developments; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet future capital requirements, we will need to raise additional funds to continue our currently planned operations.&#160;&#160;Our ability to raise additional capital is dependent on a number of factors, including the market demand for our securities, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.  If we raise additional capital by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preferences over our common stock.  We cannot be certain that additional financing, whether debt or equity, will be available in amounts or on terms acceptable to us, if at all.&#160;&#160;We may be unable to raise sufficient additional capital on reasonable terms, and if so, we will be forced to delay, reduce or eliminate our clinical development programs or commercialization efforts or obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred aggregate net losses since our inception, including an aggregate net loss of $16.2 million for the three years </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2021.&#160;&#160;As o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f December&#160;31, 2021, we had an accumulated deficit of $1.5&#160;billion.&#160;&#160;Because of the numerous risks and uncertainties associated with successfully developing and commercializing drug products, we are unable to predict the extent of any future losses or whether or when we will become profitable, if at all.&#160;&#160;The size of our net losses will depend, in part, on the rate of decline or growth in our revenues and on the amount of our expenses.  We expect to continue to incur significant expenses over the next several years as we expect to make significant investments in the continued nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates, and in the commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived a substantial portion of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any products developed or commercialized under the collaborations.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to spend significant amounts to fund our planned nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates and our planned commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved.  As a result, we will need to generate substantial additional revenues to achieve profitability in future periods.&#160;&#160;Even if we do achieve profitability in future periods, we may not be able to sustain or increase such profitability on a quarterly or annual basis.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have fluctuated in the past and are likely to fluctuate in the future.  A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our ongoing nonclinical and clinical development efforts and our ability to obtain regulatory approval of our drug candidates as a result of such efforts, including for sotagliflozin for the treatment of heart failure;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of expenses incurred with respect to our nonclinical and clinical development and commercialization efforts;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing new collaborations and technology licenses and the timing and financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and willingness of our collaborators to commercialize pharmaceutical products that would result in milestone payments and royalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products and technologies; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general and industry-specific economic conditions, which may affect our and our collaborators&#8217; research and development expenditures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of these and other factors, including the risks and uncertainties described in this section, our operating results have fluctuated in the past and are likely to do so in the future.&#160;&#160;Due to the likelihood of fluctuations in our revenues and expenses, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have derived a substantial majority of our revenues to date from collaborative arrangements with other pharmaceutical and biotechnology companies for the research, development and commercialization of our drug candidates and other research and development collaborations and technology licenses.  Future revenues from our existing and future collaborations depend upon the achievement of milestones and payment of royalties we earn from any future products developed under those arrangements.&#160;&#160;If our relationship terminates with any collaborator, as occurred with our collaboration with Sanofi, our reputation in the business and scientific community may suffer and revenues will be negatively impacted to the extent such losses are not offset by additional collaborations or strategic alliances.&#160;&#160;If milestones are not achieved or our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborators are unable to successfully develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by those arrangements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited or no control over the resources that any third party may devote to the development and commercialization of products under our collaborations.&#160;&#160;Any of our present or future collaborators may not perform their obligations as expected.&#160;Our collaborators may breach or terminate their agreements with us or otherwise fail to conduct research, development or commercialization activities successfully or in a timely manner.&#160;&#160;Further, our collaborators may elect not to develop pharmaceutical products arising out of our arrangements or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products.&#160;&#160;If any of these events occurs, we may not receive revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pursue opportunities in specific disease and therapeutic modality fields that could result in conflicts with our collaborators, if any of our collaborators takes the position that our internal activities overlap with those activities that are exclusive to our collaboration.&#160;&#160;Moreover, disagreements could arise with our collaborators over rights to our intellectual property or our rights to share in any of the future revenues of compounds or therapeutic approaches developed by our collaborators.&#160;&#160;Any conflict with or among our collaborators could result in the termination of our collaborative agreements, delay collaborative research or development activities, impair our ability to renew or obtain future collaborative agreements or lead to costly and time consuming litigation.&#160;&#160;Conflicts with our collaborators could also have a negative impact on our relationship with existing collaborators, materially impairing our business and revenues.&#160;&#160;Some of our collaborators are also potential competitors or may become competitors in the future.&#160;&#160;Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors or terminate their agreements with us prematurely.&#160;&#160;Any of these events could harm our product development efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on clinical research organizations and other third-party contractors to carry out many of our drug development activities, including the performance of nonclinical laboratory and animal tests under the FDA&#8217;s current Good Laboratory Practices regulations and the conduct of clinical trials of our drug candidates in accordance with protocols we establish.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, our drug development activities may be delayed, suspended or terminated.&#160;&#160;Such a failure by these third parties could significantly impair our ability to develop and commercialize the affected drug candidates.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We lack the capability to manufacture materials for nonclinical studies and clinical trials and commercial supplies for any products which gain regulatory approval. Our reliance on third parties to manufacture our drug candidates may harm or delay our research, development and commercialization efforts.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have the manufacturing capabilities or experience necessary to produce materials for nonclinical studies or clinical trials or commercial supplies for any products which gain regulatory approval and intend in the future to continue to rely on collaborators and third-party contractors to produce such materials.&#160;&#160;We will rely on selected manufacturers to deliver materials on a timely basis and to comply with applicable regulatory requirements, including the current Good Manufacturing Practices of the FDA, which relate to manufacturing and quality control activities.&#160;&#160;These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development and commercialization timelines and applicable regulatory requirements.&#160;&#160;In addition, there are a limited number of manufacturers that operate under the FDA&#8217;s current Good Manufacturing Practices and that are capable of producing such materials, and we may experience difficulty finding manufacturers with adequate capacity for our needs.&#160;&#160;If we are unable to contract for the production of sufficient quantity and quality of materials on acceptable terms, our product development or commercialization efforts may be delayed.&#160;&#160;Moreover, noncompliance with the FDA&#8217;s current Good Manufacturing Practices can result in, among other things, fines, injunctions, civil and criminal penalties, product recalls or seizures, suspension of production, failure to obtain marketing approval and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our products and technologies.&#160;&#160;The patent positions of biotechnology and pharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions.&#160;&#160;We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our products and technologies are covered by valid and enforceable patents or other intellectual property rights, or are effectively maintained as trade secrets or otherwise protected from disclosure by non-disclosure agreements.&#160;&#160;We will continue to apply for patents covering our products and technologies as, where and when we deem appropriate.  However, pending patent applications do not provide protection against competitors because they are not enforceable until they issue as patents.&#160;&#160;Further, the disclosures contained in our current and future patent applications may not be sufficient to meet statutory requirements for patentability and our applications may fail to result in issued patents.&#160;&#160;Once issued, patents still may not provide commercially meaningful protection.&#160;&#160;Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from developing competing products and technologies.&#160;&#160;Furthermore, others may independently develop similar or alternative products or technologies or design around our patents.&#160;&#160;If anyone infringes upon our or our collaborators&#8217; patent rights, enforcing these rights may be difficult, costly and time-consuming and, as a result, it may not be cost-effective or otherwise expedient to pursue litigation to enforce those patent rights.  Further, as we customarily assess whether to apply for new patents based on our ongoing research and development activities, this assessment and the filing for additional patent protection may require significant expenditures and therefore may not be commercially practicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and other intellectual property rights may be challenged by third parties and may be invalidated, cancelled or held unenforceable under U.S. or foreign laws, or they may be infringed or misappropriated by third parties.  As a result, we may be involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United States and elsewhere.  The costs of defending our patents or enforcing our other intellectual property rights, such as trademarks and trade secrets, in post-issuance administrative proceedings and litigation may be substantial and the outcome can be uncertain.  An adverse outcome may allow third parties to use our intellectual property without a license and negatively impact our business.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our products and drug candidates.&#160;&#160;&#160;If any such patents are issued to other entities, we may be unable to obtain patent protection for the same or similar discoveries that we make relating to our products and drug candidates.&#160;&#160;Moreover, we may be blocked from using our drug targets or drug candidates or developing or commercializing our products and other drug candidates, or may be required to obtain a license from a third party that may not be available on reasonable terms, if at all.&#160;&#160;Further, others may discover uses for our products and technology other than those covered in or claimed by our issued or pending patents, such as other uses for our drug targets and drug candidates, and these other uses may be separately patentable.&#160;&#160;Even if we have a patent claim on a particular technology or product, the holder of a patent covering the use of a similar technology or product could exclude us from selling a product that is based on the same use of that product.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions.&#160;&#160;Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, if the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements).&#160;&#160;In addition, many countries limit the enforceability of patents against government agencies or government contractors.&#160;&#160;In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.&#160;&#160;Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives.&#160;&#160;Such compulsory licenses could be extended to include some of our products and drug candidates, which could limit our potential revenue opportunities.  Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement and misappropriation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on trade secret protection for some of our confidential and proprietary information.&#160;&#160;We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection.&#160;&#160;While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">meaningfully protect our trade secrets.&#160;&#160;In addition, our competitors may independently develop or duplicate substantially equivalent proprietary information or may otherwise gain access to or misappropriate our trade secrets.  For example, publicly available information, such as information in issued patents, published patent applications and scientific literature, can be used by third parties to independently develop technology and we cannot provide assurance that any such independently developed technology will not be equivalent or superior to our proprietary technology.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on registered trademarks to protect our investment in our brand and goodwill.  However, competitors may challenge the validity of those trademarks and other brand names in which we have invested or may invest. Such challenges can be expensive and may adversely affect our ability to maintain the goodwill gained in connection with a particular trademark. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and those of our collaborators, as well as our nonclinical and clinical development efforts, may give rise to claims that they infringe or misappropriate the patents or other intellectual property rights of others.&#160;&#160;We are aware that other companies and institutions are developing products acting through the same drug targets through which some of our drug candidates currently in clinical development act, have conducted research on many of the same targets that we have identified and have filed patent applications potentially covering drug targets that we have identified and certain therapeutic products addressing such targets.&#160;&#160;In some cases, patents have issued, and may issue in the future, from these applications.&#160;&#160;In addition, many companies and institutions have well-established patent portfolios directed to common techniques, methods and means of developing, producing and manufacturing pharmaceutical products.&#160;&#160;These or other companies or institutions could bring legal actions against us or our collaborators for damages or to stop us or our collaborators from engaging in certain nonclinical or clinical development activities or from manufacturing and marketing therapeutic products that allegedly infringe their patent rights.&#160;&#160;If any of these actions are successful, in addition to our potential liability for damages, these entities may require us or our collaborators to obtain a license in order to continue engaging in the infringing activities or to manufacture or market the infringing therapeutic products or may force us to terminate such activities or manufacturing and marketing efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may deem it advisable to pursue litigation or other dispute resolution proceedings against others to enforce our patents and intellectual property rights and may be the subject of litigation brought by third parties to enforce their patent and intellectual property rights.&#160;&#160;In addition, we may become involved in litigation or other dispute resolution proceedings based on intellectual property indemnification undertakings that we have given to certain of our collaborators.&#160;&#160;Patent and other intellectual property litigation is expensive and requires substantial amounts of management attention.&#160;&#160;The eventual outcome of any such litigation or dispute resolution proceedings is uncertain and involves substantial risks.  If we are sued for infringement or misappropriation and lose, we could be required to pay substantial damages and/or be enjoined from using or selling the allegedly infringing or misappropriation products or technology. The results or costs of any such litigation or dispute resolution proceedings may have an adverse effect on our business, operating results and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there will continue to be significant litigation in our industry regarding patent and other intellectual property rights.&#160;&#160;We have expended and many of our competitors have expended and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation.&#160;&#160;If we become involved in future intellectual property litigation, it could consume a substantial portion of our resources and could negatively affect our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners.  We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information and personal data.  The secure maintenance of this information is critical to our business and reputation.  We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access and unintentional breaches.  These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage).  Cyber threats may be generic, or they may be custom-crafted against our information systems.  Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or information security breaches due to operator error, malfeasance or other system disruptions.  It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents, particularly for cyber incidents such as advanced persistent threats.  These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our intellectual property and expose sensitive business information.  A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others.  Cyber-attacks and information security breaches could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.  Our network security and data recovery measures and those of our vendors may not be able to detect or prevent every attempted breach and may not permit us to respond effectively to every breach.  These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.  Reputational harm resulting from a significant cyber incident may cause unquantifiable damage to our established goodwill. Moreover, as cyber incidents continue to evolve, we will likely be required to expend additional resources to enhance our security posture and cybersecurity defenses or to investigate and remediate any vulnerability to or consequences of cyber incidents. Our insurance coverage may not be sufficient to prevent or recover from cyberattacks, including coverage of applicable resulting losses arising from the incident.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, each foreign jurisdiction and U.S. state in which we operate may have laws governing how we must respond to a cyber incident that results in the unauthorized access, disclosure, or loss of personal information.  Additionally, new laws and regulations governing data privacy and unauthorized disclosure of confidential information, including recent California legislation providing for a private right of action, pose increasingly complex compliance challenges and could potentially elevate our costs over time.  As legislation continues to develop and cyber incidents continue to evolve, we will likely be required to expend significant resources to continue to modify or enhance our protective measures to comply with such legislation and to detect, investigate and remediate vulnerabilities to cyber incidents.  Any failure by us to comply with such laws and regulations could result in reputational harm, loss of goodwill, penalties, liabilities and/or mandated changes in our business practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and independent contractors were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.&#160;&#160;We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.&#160;&#160;Litigation or other dispute resolution proceedings may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation or other dispute resolution proceedings could result in substantial costs and divert management&#8217;s attention.&#160;&#160;If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel.&#160;&#160;A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain drug candidates, which could severely harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience growth in the number of our employees and in the scope of our operations.  This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth.  To effectively manage our potential growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies.  We may need to increase our medical, clinical, commercial and other personnel, and recruiting and retaining qualified individuals is difficult.  If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified personnel when advisable, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as medical and clinical staff, the loss of whose services might adversely impact the achievement of our objectives.&#160;&#160;Retaining and, where advisable, recruiting qualified commercial, medical and clinical personnel will be critical to commercially launching sotagliflozin for heart failure, if approved, and advancing our nonclinical and clinical development programs for sotagliflozin, LX9211 and our other drug candidates.&#160;&#160;Competition is intense for experienced commercial, medical and clinical personnel, and we may be unable to retain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products.&#160;&#160;Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are located in The Woodlands, Texas and Basking Ridge, New Jersey, and therefore our facilities are vulnerable to damage from hurricanes.  We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events and any insurance we may maintain may not be adequate to cover our losses.  If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development processes have historically involved the controlled use of hazardous substances, including chemicals and radioactive and biological materials, and our operations have produced hazardous waste products.&#160;&#160;See &#8220;Part I, Item 1. Business &#8211; Government Regulation &#8211; Environmental Matters&#8221; for more discussion on these and other environmental matters.  Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, these hazardous materials used by these parties.&#160;&#160;Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product that we or our collaborators develop or commercialize, or any product that is made with the use or incorporation of any of our technologies, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale.&#160;&#160;Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop.  These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products.  We have obtained limited product liability insurance coverage for our clinical trials.  However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer.  Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.  On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects.  In addition, the pharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation.  A successful product liability claim or series of claims brought against us could harm our reputation and business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invus, L.P. and its affiliates, which we collectively refer to as Invus, currently own approximately 50.7% of the outstanding shares of our common stock and are thereby able to control the election and removal of our directors and determine our corporate and management policies, including potential mergers or acquisitions, asset sales, the amendment of our articles of incorporation or bylaws and other significant corporate transactions.  This concentration of ownership may delay or deter possible changes in control of our company, which may reduce the value of an investment in our common stock.  The interests of Invus and its affiliates may not be aligned with the interests of other holders of our common stock.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invus has additional rights under its stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its stockholders&#8217; agreement, Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates, rounded up to the nearest whole number of directors.  Invus has designated three of the nine current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.  Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors, and no Invus-designated directors currently serve on the audit committee of our board of directors.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation also grants holders of 20% or more of our issued and outstanding common stock customary preemptive rights and consent rights prior to us taking any of the following actions: (1) creating or issuing any new class or series of shares of capital stock (or securities convertible into or exercisable for shares of capital stock) having rights, preferences or privileges senior to or on parity with the common stock, (2) subject to certain exceptions, repurchasing, retiring, redeeming or otherwise acquiring any equity securities (or securities convertible into or exchangeable for equity securities) or any subsidiary and (3) adopting, or proposing to adopt, or maintaining any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless such stockholder is exempt from such plan or agreement.  Invus currently has such preemptive and consent rights as a result of its ownership position in our issued and outstanding common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these rights provide Invus with substantial influence over significant corporate matters and Invus&#8217; interest in those matters may not be aligned with the interests of other holders of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price may be extremely volatile.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results or delays in our or our collaborators&#8217; clinical trials;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of FDA approval or non-approval, or delays in the FDA review process, of our or our collaborators&#8217; drug candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to sotagliflozin, LX9211 and our other drug candidates;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of new products by our competitors;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with our collaborators, including conflicts, litigation or the termination or modification of our agreements;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of an in-licensed drug candidate or strategic acquisition;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, including intellectual property infringement and misappropriation, and product liability lawsuits, involving us;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to achieve operating results projected by securities analysts;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in earnings estimates or recommendations by securities analysts;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the satisfaction of outstanding debt obligations or entry into new financing arrangements;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology or pharmaceutical industry;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">departures of key personnel or board members;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or international regulatory actions;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party coverage and reimbursement policies;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposition of any of our drug programs or other technologies; and</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors, including general market, economic and political conditions and other factors unrelated to our operating performance or the operatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance of our competitors.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may materially adversely affect the market price of our common stock.  In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies.  For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks.  Likewise, the broader financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks.  These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock.  Excessive volatility may continue for an extended period of time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted.&#160;&#160;A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial number of shares of our common stock is reserved for issuance upon the exercise of stock options and vesting of restricted stock units.  If we or our stockholders issue or sell substantial amounts of our common stock (including shares issued upon the exercise of stock options or vesting of restricted stock units) in the public market, or if the market perceives that such sales may occur, the market price of our common stock could fall and it may become more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.&#160;&#160;In addition, any such issuance or sale of our common stock will dilute the ownership interests of existing stockholders and may cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.&#160;&#160;If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline.&#160;&#160;If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas.  The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc., leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our facilities are well-maintained, in good operating condition and acceptable for our current operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_67"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#8220;LXRX.&#8221;  As of March&#160;8, 2022, there were approximately 298 holders of record of our common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the performance of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period beginning December&#160;31, 2016 and ending December&#160;31, 2021. The graph assumes that the value of the investment in our common stock and each index was $100 at December&#160;31, 2016, and that all dividends were reinvested.  The stock performance shown on the graph below represents historical performance and is not necessarily indicative of future stock price performance.</span></div><div><img src="lxrx-20211231_g1.jpg" alt="lxrx-20211231_g1.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing stock price performance comparisons shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this annual report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate such comparisons by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[Reserved]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis should be read with our financial statements and notes included elsewhere in this annual report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.  We have reported positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively.  We are now preparing a resubmission of our application for regulatory approval to market sotagliflozin in the United States for heart failure after voluntarily withdrawing our initial application to correct a technical issue with the initial submission.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reported positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively.  The FDA issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States.  At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our application and the hearing process is ongoing.  Sotagliflozin has been approved in the European Union for use as an adjunct to insulin therapy in the treatment of type 1 diabetes, but has not yet been commercially launched.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported results from two Phase 1 clinical trials of LX9211 and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.  LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160; LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.  To date, we have generated a substantial portion of our revenues from a limited number of sources.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; and general and industry-specific economic conditions which may affect research, development and commercialization expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of December&#160;31, 2021, we had an accumulated deficit of $1.5 billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants.&#160;&#160;Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.&#160;&#160;We expect to continue to incur significant research and development costs in connection with the continuing research and development of our drug candidates.  As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements included in this Annual Report on Form 10-K have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), which require that we make numerous estimates and assumptions. Actual results could differ from those estimates and assumptions, thus impacting our reported results of operations and financial position. The critical accounting policies and estimates described in this section are those that are most important to the depiction of our financial condition and results of operations and the application of which requires our most subjective judgments in making estimates about the effect of matters that are inherently uncertain. We describe our significant accounting policies more fully in Note 2, "Summary of Significant Accounting Policies," to the Consolidated Financial Statements included in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  We recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below. Our estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  Our net product revenues reflected our best estimates of the amounts of consideration to which we were entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to our customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  Our customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  We expected that our customers would earn prompt payment discounts.  As a result, we deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates included mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts were based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates was based on statutory discount rates and expected utilization.  Our estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual rebates varied from estimates, we adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to us the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  Our estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual funding varied from estimates, we adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to may receive co-payment assistance.  We accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation.  We apply this five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer to the customer.  At contract inception, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  We develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we evaluate whether development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within our control or the control of our licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, we re-evaluate the probability of achievement of the development milestones and any related constraint, and if necessary, adjust our estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to our intellectual property is determined distinct from other performance obligations identified in the agreement, we recognize revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and we recognize revenue at the later of (i) when the related sales occur </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may receive payments from our licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until we perform our obligations under these agreements.  Amounts are recorded as accounts receivable when our right to consideration is unconditional.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred for research and development activities solely sponsored by us as well as collaborative research and development activities.&#160;&#160;These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are presently devoting most of our resources to the research and development of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sotagliflozin, an orally-delivered small molecule drug candidate that we are developing as a treatment for heart failure and type&#160;1 diabetes; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LX9211, an orally-delivered small molecule drug candidate that we are developing as a treatment for neuropathic pain.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The drug development process takes many years to complete.&#160;&#160;The cost and length of time varies due to many factors including the type, complexity and intended use of the drug candidate.&#160;&#160;We estimate that drug development activities are typically completed over the following periods:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Completion Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 clinical trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2 clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 clinical trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-4 years</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to remain substantial in the future as we continue to fund our nonclinical and clinical development efforts and advance new drug candidates into clinical development.&#160;&#160;Due to the variability in the length of time necessary for drug development, the uncertainties related to the cost of these activities and ultimate ability to obtain regulatory approval for commercialization, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record significant accrued liabilities related to unbilled expenses for products or services that we have received from service providers, specifically related to ongoing nonclinical studies and clinical trials.&#160;&#160;These costs primarily relate to clinical study management, monitoring, laboratory and analysis costs, drug supplies, toxicology studies and investigator grants.&#160;&#160;We may have multiple drugs in concurrent nonclinical studies and clinical trials at clinical sites throughout the world.&#160;&#160;In order to ensure that we have adequately provided for ongoing nonclinical and clinical development costs during the period in which we incur such costs, we maintain accruals to cover these expenses.&#160;&#160;Substantial portions of our nonclinical studies and clinical trials are performed by third party laboratories, medical centers, contract research organizations and other vendors.  For nonclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the vendors and clinical site visits.  Our estimates depend on the timeliness and accuracy of the data provided by our vendors regarding the status of each program and total program spending.  We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&#160;&#160;Although we use consistent milestones or subject or patient enrollment to drive expense recognition, the assessment of these costs is a subjective process that requires judgment.&#160;&#160;Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract. In accruing the relevant costs, we estimated the time period over which services were to be performed and the level of effort required to complete or wind down each study.  Upon completion and settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our research and development costs by type or category, rather than by project.&#160;&#160;Significant categories of costs include personnel, facilities and equipment costs and third-party and other services.&#160;&#160;In addition, a significant portion of our research and development expenses is not tracked by project as it benefits multiple projects. Consequently, fully-loaded research and development cost summaries by project are not available.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-lived assets include property, plant and equipment, right-of-use assets for leases and goodwill.  We regularly review long-lived assets for impairment.  The recoverability of long-lived assets, other than goodwill, is measured by comparing the assets carrying amount to the expected undiscounted future cash flows that the asset is expected to generate.  Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any.  We use internal cash flow estimates, quoted market prices when available and independent appraisals as appropriate to determine fair value.  We derive the required cash flow estimates from our historical experience and our internal business plans and apply an appropriate discount rate.  In 2020, we recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs. There were no significant impairments of long-lived assets in 2021 or 2019. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which was comprised primarily of in-process research and development, or IPR&amp;D, projects acquired in business combinations which had not reached technological feasibility, is reviewed annually for impairment and whenever events or changes in circumstances indicated that the carrying amount may not have been recoverable.  In 2019, we terminated certain research and development activities related to a program for the treatment of irritable bowel syndrome and as a result, recognized $28.6 million of impairment to indefinite-lived intangible assets.  There were no impairments to indefinite-lived intangible assets in 2021 or 2020. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;We have determined that the reporting unit is the single operating segment disclosed in our current financial statements.&#160;&#160;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;We determined that the market capitalization approach is the most appropriate method of measuring fair value of the reporting unit.&#160;&#160;Under this approach, fair value is calculated as the average closing price of our common stock for the 30 days preceding the date that the annual impairment test is performed, multiplied by the number of outstanding shares on that date.&#160;&#160;A control premium, which is representative of premiums paid in the marketplace to acquire a controlling interest in a company, is then added to the market capitalization to determine the fair value of the reporting unit.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if we encounter events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2021, 2020 and 2019.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of new accounting standards on our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations &#8211; Comparison of Years Ended December&#160;31, 2021, 2020 and 2019 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read with &#8220;Results of Operations&#8221; and our financial statements and notes included in our annual report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2021 and 2020 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net product revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Net product revenue recognized from XERMELO sales were $23.4 million in 2020 prior to the sale of XERMELO and related assets to TerSera on September 8, 2020. Product revenues were recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalties and other revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues from royalties and other revenue decreased to $0.3 million in 2021 from $0.6 million in 2020.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, two companies, AC Biosciences Ltd. and Taconic Farms, Inc. represented 76% and 24% of revenues, respectively. In 2020, two specialty pharmacies, Biologics, Inc. and Diplomat Pharmacy, represented 65% and 22% of revenues, respectively.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $1.9 million in 2020 prior to the sale of XERMELO in September 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar (decrease) increase </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage (decrease) increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs and stock-based compensation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2021 and 2020 </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services decreased 71% in 2021 to $34.9 million, primarily due to decreases in external clinical development costs relating to sotagliflozin subsequent to the wind down of the activities beginning in March 2020. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs decreased 41% in 2021 to $10.8 million, primarily due to lower headcount as a result of the reduction in force of our personnel in September 2020. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock-based compensation expense decreased 33% in 2021 to $4.3 million, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Facilities and equipment costs decreased to $1.5 million in 2021 from $2.5 million in 2020, primarily due to lower depreciation expense subsequent to the sale of our facilities in December 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs decreased to $3.5 million in 2021 from $5.1 million in 2020, primarily due to lower insurance and software license expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support the commercialization of XERMELO and our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2021 and 2020  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs decreased 57% in 2021 to $10.8 million, primarily due to lower headcount as a result of the reduction in force of our personnel in September 2020.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees increased 18% in 2021 to $10.8 million, primarily as a result of higher legal expenses, partially offset by lower marketing expenses. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense decreased 9% in 2021 to $6.3 million, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs decreased to $1.4 million in 2021 from $1.7 million in 2020, primarily due to lower property taxes and depreciation expense subsequent to the sale of our facilities in December 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs decreased to $3.1 million in 2021 from $4.6 million in 2020, primarily due to decreases in travel expenses due to the COVID-19 pandemic and lower software license expenses.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Losses</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss of $1.6&#160;million in the year ended December&#160;31, 2020 was recognized as a result of writing down the assets related to our campus in The Woodlands, Texas to the estimated selling price.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on the sale of XERMELO</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A gain of $132.6&#160;million in the year ended December&#160;31, 2020 was recognized in connection with the sale of XERMELO and related assets to TerSera.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Interest and Other Income, Net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Interest expense decreased to $0.8 million in 2021 from $14.5 million in 2020, primarily due to the $150 million payoff of the BioPharma term loan in September 2020 and the $75.8 million exchange of convertible notes in September and October 2020.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Interest and other income, net was $0.1 million and $2.8 million in the years ended December&#160;31, 2021 and 2020, respectively.&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss&#160;per Common Share </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $87.8 million, or a loss of $0.60 per share, in 2021 as compared to a net loss of $58.6 million, or $0.53 per share in 2020.&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements.&#160;&#160;We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, we had $86.7 million in cash, cash equivalents and short-term investments. &#160;As of December&#160;31, 2020, we had $152.3 million in cash, cash equivalents and short-term investments.&#160;&#160;We used cash of $87.0 million in our operations in 2021. This consisted primarily of the net loss for the year of $87.8&#160;million, and a net decrease in operating liabilities net of assets of $10.2&#160;million, partially offset by non-cash charges of $10.9&#160;million primarily related to stock-based compensation expense.  Investing activities provided cash of $2.1&#160;million in 2021, primarily due to net maturities of investments of $3.3&#160;million partially offset by $1.2&#160;million of asset purchases.  Financing activities provided cash of $22.7&#160;million, primarily as a result of $37.1&#160;million net proceeds from the sales of common stock during January, August and September of 2021 under our Open Market Agreement with Jefferies LLC which was partially offset by $11.7&#160;million used to pay off the matured convertible notes and $2.7&#160;million used to repurchase common stock.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other commitments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> April 2019, sotagliflozin was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, who could not achieve adequate glycemic control despite optimal insulin therapy. Upon the achievement of certain European regulatory pricing approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. In September 2020, we initiated a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain. As a result of the commencement of the Phase 2 trial, we were required to make a royalty payment to Bristol-Myers Squibb of $2.5 million, which was paid in October 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2020, our subsidiary, Lex-Gen Woodlands, L.P., sold our facilities in The Woodlands, Texas for $11.9 million.  Concurrent with such sale, we entered into a leaseback agreement with respect to 38,000 square feet of such facilities for a period of up to six months, with monthly gross rent payments of $101,000, which ended on June 15, 2021. In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas and in June 2021, we relocated our corporate offices. The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc., leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to prepare for the commercialization of sotagliflozin, if approved; successfully complete our nonclinical and clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development efforts with respect to sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our currently planned operations for at least the next 12 months from the date of this report.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock. If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase.&#160;&#160;We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk.&#160;&#160;We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $86.7 million in cash and cash equivalents and short-term investments as of&#160;December&#160;31, 2021.  We believe that t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 7. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required by this Item are incorporated under Item 15 in Part IV of this report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2021 to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021.&#160;&#160;In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013 Framework)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on such assessment using those criteria, management concluded that, as of December&#160;31, 2021, our internal control over financial reporting was effective.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzMw_7a3b32dc-264c-440e-be2a-caf470510ce2">Ernst &amp; Young LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzNA_5e4f2ee9-275f-44af-a6fe-4df49c9aa62d">Houston, Texas</ix:nonNumeric>, PCAOB ID: <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzNQ_82331d81-8983-4f87-a6ed-8107ccf0ac72">42</ix:nonNumeric>, has audited the financial statements included in this Annual Report and has issued a report on the effectiveness of our internal control over financial reporting.  The report of Ernst &amp; Young LLP is included below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to our evaluation described above, there were no significant changes in internal controls or other factors during the fiscal quarter ended December&#160;31, 2021 that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_88"></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Lexicon Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework (the COSO criteria). In our opinion, Lexicon Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated March 10, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Houston, Texas</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;10, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_1810"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_94"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from (a) the information appearing under the captions &#8220;Election of Directors,&#8221; &#8220;Stock Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the SEC pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2021 and (b)&#160;the information appearing under Item&#160;1 in Part&#160;I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2021. Notwithstanding the foregoing, in accordance with the instructions to Item 407(e)(5) of Regulation S-K, the information contained in our proxy statement under the sub-heading &#8220;Compensation Committee Report&#8221; shall not be deemed to be filed as part of or incorporated by reference into this annual report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Stock Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Transactions with Related Persons&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item as to the fees we pay our principal accountant is hereby incorporated by reference from the information appearing under the caption &#8220;Ratification and Approval of Independent Auditors&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_115"></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibit and Financial Statement Schedules</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Documents filed as a part of this report:</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Consolidated Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"><tr><td style="width:1.0%"></td><td style="width:88.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_127">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: 42)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_127">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_127">-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_127">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_130">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_130">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_130">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_133">Consolidated Statements of Comprehensive Income (Loss</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_133">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_133">-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_133">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_136">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_136">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_136">-5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_139">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_139">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_139">-6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_142">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_142">-7</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other financial statement schedules are omitted because they are not applicable or not required, or because the required information is included in the financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:11.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh31-secondamendedandrest.htm">Second Amended and Restated Certificate of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh32secondamendedandresta.htm">Second Amended and Restated Bylaws </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated April 26, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w1.htm">Securities Purchase Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000118/exh10_1.htm">Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated October 7, 2009, to Securities Purchase Agreement, dated June&#160;17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w3.htm">Registration Rights Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w4.htm">Stockholders&#8217; Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012310024973/h70210exv10w1.htm">Supplement to Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000005/exhibit101.htm">Supplement No. 2 to Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312520321518/d87169dex101.htm">Supplement No. 3 to the Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated December 16, 2020, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated December 16, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh48descriptionofcommonst.htm">Description of Common Stock</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh101coatsofferletteramen.htm">Offer Letter</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 1, 2014, with Lonnel Coats, as amended (filed as Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Employment Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated January 1, 1999, with Jeffrey L. Wade (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh103offerlettergranowitz.htm">Offer Letter</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 27, 2021, with Craig B. Granowitz, M.D., Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012901504054/h92253ex10-1.txt">Employment Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 12, 2001, with Alan J. Main, Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2001 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Form of Indemnification Agreement with Officers and Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:11.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh101proposedsummaryofnon.htm">Summary of Non-Employee</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh101proposedsummaryofnon.htm"> Director Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001062822/000106282220000025/exh1012017equityincent.htm">2017 Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 23, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh101-2017nonxemployeedir.htm">2017 Non-Employee Directors&#8217; Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1062822/000106282218000008/exh1011officerstockoptiona.htm">Form of Stock Option Agreement with Officers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Equity Incentive Plan (filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2017 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh1010formofrestrictedsto.htm">Form of Restricted Stock Unit Agreement with Officers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Equity Incentive Plan</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh102non-employeedirector.htm">Form of Notice of Stock Option Grant to Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh103non-employeedirector.htm">Form of Notice of Restricted Stock Unit Grant to Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh102bmsagreement.htm">Collaboration and License Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh103bmsagreeementamendme.htm">First Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated May 30, 2006, to Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000081/secondamendmenttocollabora.htm">Second Amendment,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> dated November 2, 2016, to Collaboration and License Agreement, dated December 17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated November 2, 2016 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012906002238/h33572exv10w22.txt">Second Amended and Restated Collaboration and License Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.22 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000109/exh10_1.htm">Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 8, 2009, to Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A dated June 8, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000005/subleaseagreementlexicon-r.htm">Sublease Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated February 8, 2021, with Repsol Oil &amp; Gas USA, LLC (filed as Exhibit 10.1 to the  Company&#8217;s Current Report on Form 8-K dated February 8, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh211subsidiaries.htm">Subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh231ernstyoungconsent2021.htm">Consent of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_121">Power of Attorney</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (contained in signature page).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 200</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been requested for portions of this exhibit (indicated by &#8220;[**]&#8221;).&#160;&#160;The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic8e1d29868b149c9aff5685ac938a1e8_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form 10-K Summary</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LONNEL COATS</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JEFFREY L. WADE</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lonnel Coats and Jeffrey L. Wade, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ LONNEL COATS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ JEFFREY L. WADE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ KRISTEN L. ALEXANDER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vice President, Finance and Accounting<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ RAYMOND DEBBANE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ PHILIPPE J. AMOUYAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Philippe J. Amouyal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ SAMUEL L. BARKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ ROBERT J. LEFKOWITZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Robert J. Lefkowitz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ ALAN S. NIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Alan S. Nies, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ FRANK P. PALANTONI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Frank P. Palantoni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ CHRISTOPHER J. SOBECKI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ JUDITH L. SWAIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Judith L. Swain, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_127"></div><div style="margin-bottom:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 10, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued research and development expenses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 2 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial in accordance with agreements established with contract research organizations ("CROs"), clinical trial sites and other third parties. Estimates are determined by reviewing contracts, vendor agreements, purchase orders, change orders and trial budgets, as well as through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing management&#8217;s accounting for accrued third-party clinical trial research and development expenses is especially challenging because of the judgment applied by management to determine the progress or stage of completion of the activities under the Company&#8217;s research and development agreements and the cost and extent of work performed during the reporting period for services not yet billed by contracted third-party vendors.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s accounting for accrued research and development expenses process, including controls over management&#8217;s review of clinical trial activity progress in comparison to budgets and invoices received from third parties. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures included, among others, testing the accuracy and completeness of the underlying inputs used in management&#8217;s analysis to determine costs incurred. We compared expenses incurred to budgeted amounts per executed vendor contracts and to expenses incurred in prior periods and obtained an understanding of the reasons for changes. We inspected the terms and conditions of vendor contracts, change orders and trial budgets, and clerically tested the cost models to track progress against trial budgets. We evaluated estimated services incurred by third parties by understanding the terms and timeline of significant projects, evaluating management&#8217;s estimate of work performed and costs incurred by meeting with members of the Company&#8217;s clinical operations team, and obtaining external confirmation of key terms and conditions and other key inputs to the accrual calculation, such as total approved trial budgets and amounts invoiced, and number and timing of patients enrolled in clinical studies. Further, we inspected invoices received from third parties during the year as well as after the balance sheet date and performed a lookback analysis to evaluate the completeness of accrued research and development expenses.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ernst &amp; Young LLP  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2002.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Houston, Texas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;10, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_130"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzQtMS0xLTEtMTYxMTg_a32cf862-1615-4d86-bc43-83487e8a1ed4">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzQtMy0xLTEtMTYxMTg_8090d0c7-09e4-460c-989a-01279ea19ad6">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzUtMS0xLTEtMTYxMTg_6c8b49cf-f5e9-48be-9dae-d3524f8037e6">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzUtMy0xLTEtMTYxMTg_9e39871b-e967-4346-a7f0-672612796944">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzYtMS0xLTEtMTYxMTg_066521cf-d617-4e25-a1a9-0e2cda547a2f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzYtMy0xLTEtMTYxMTg_5c7d3921-c6ed-4083-b3a0-b5d574a45642">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzktMS0xLTEtMTYxMTg_6cb5ef48-312c-4c3b-9872-bc827c7f5e3d">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzktMy0xLTEtMTYxMTg_65346aa8-a732-431c-b130-d06c4c19329c">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEwLTEtMS0xLTE2MTE4_724c77df-a1d5-4b90-8d7b-31a019825eeb">88,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEwLTMtMS0xLTE2MTE4_ac517166-29b7-4a1c-af13-3b4cd7400b20">157,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MWQyN2Q5ZmYzYzI0NGJiODllYjc2Yzg0NDU3OGE2OTJfODA_c7326471-0286-4951-8a05-cd85dc204bd9">4,853</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MWQyN2Q5ZmYzYzI0NGJiODllYjc2Yzg0NDU3OGE2OTJfODc_63edb102-8f62-46a6-afef-5677b2ee9103">5,815</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTEtMS0xLTE2MTE4_08ae1e6a-bc9a-491e-8d04-bbc8c030c04f">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTMtMS0xLTE2MTE4_62c26a8c-ff5b-4b67-b6f4-19f2bcd8ca4d">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEyLTEtMS0xLTE2MTE4_d79de4ad-f08a-4d32-bdcc-434e2e20e030">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEyLTMtMS0xLTE2MTE4_1fb884f9-df89-4b34-b99e-32f35a0939d3">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE0LTEtMS0xLTE2MTE4_f67bf9c2-5401-45e3-a7ea-fe7972ab0847">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE0LTMtMS0xLTE2MTE4_f1713956-84b0-489f-be25-b53f9e735198">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE1LTEtMS0xLTE2MTE4_cac6dafe-ab04-48fb-b66a-c7b635439372">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE1LTMtMS0xLTE2MTE4_788cb786-8545-48fc-9d28-df7511477e52">203,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE4LTEtMS0xLTE2MTE4_3dcb98f3-4c59-489e-95c2-bedeb6bd64f7">9,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE4LTMtMS0xLTE2MTE4_05f4a957-d766-4748-b240-906be1b28fa6">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE5LTEtMS0xLTE2MTE4_a00e4a2b-3d73-4151-81b0-8d0cb90020e6">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE5LTMtMS0xLTE2MTE4_1067377d-fdf1-4ef2-bd30-6490c17f5059">29,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of deferred issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIxLTEtMS0xLTE2MTE4_b146774f-87af-4a60-8805-e35da58605db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIxLTMtMS0xLTE2MTE4_cb4aec7e-5b87-47ef-b367-aa808cb35140">11,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIyLTEtMS0xLTE2MTE4_653a76c4-ab09-4729-8f70-ff4b39282afc">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIyLTMtMS0xLTE2MTE4_08376849-e527-4b3f-85b2-9e6f8e050222">46,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI2LTEtMS0xLTE2MTE4_53299aff-22e7-4cbc-92fa-2d18598282ce">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI2LTMtMS0xLTE2MTE4_98ac44ed-69d2-4e7c-a7af-223211df55f8">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI3LTEtMS0xLTE2MTE4_8097eea7-ad10-472c-b3ae-886fded5b1ea">23,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI3LTMtMS0xLTE2MTE4_fb8d55af-f85c-4b6e-a08c-c6c73e630ed6">47,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI4LTEtMS0xLTE2MTE4_c777da7b-56b9-40cb-a728-cc3f853df04d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI4LTMtMS0xLTE2MTE4_539447e0-d957-44cd-b052-0ee0570a6915"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMjE_27a3df4e-46ea-4765-82d5-556cedad6649"><ix:nonFraction unitRef="usdPerShare" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMjE_d09f2a5e-2ea4-4e33-9aff-2d7a52215d56">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMzU_19f59020-6791-4216-ba96-02092301636a"><ix:nonFraction unitRef="shares" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMzU_e9ba9393-452c-4c4a-a25a-10e21f1005b8">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_175b4f5d-3735-4d2a-ad8a-4524bdc8f213"><ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_1bbea409-08c8-416e-84aa-b896ded19a28"><ix:nonFraction unitRef="shares" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_33642187-31b3-4187-a81a-94ffeab07adb"><ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_f27446c2-620f-48c3-816e-69dfc693e638">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTEtMS0xLTE2MTE4_a2636386-4414-4085-812c-b0507e72498e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTMtMS0xLTE2MTE4_7f8d52b3-849f-4df7-a768-3b0f3c155437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMTg_843019bf-35bb-4315-b9e3-0ad7be3e8819"><ix:nonFraction unitRef="usdPerShare" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMTg_fdb92310-fcb9-452a-9cd2-faad951542cf">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMzI_0eee4f56-cfea-484a-ba1d-209453cf3417"><ix:nonFraction unitRef="shares" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMzI_5390eb96-6f9c-4f3d-a57b-3cdd489cf775">225,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfNTQ_60ec1097-15bc-44d0-8633-85e2bbb97363">150,082</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfNjE_2235ea24-7a2b-4951-8f27-8f6789cae5a9">142,289</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTEtMS0xLTE2MTE4_7be58699-8f1c-47d8-a325-f70f9abca8dc">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTMtMS0xLTE2MTE4_21d76471-9386-4b60-9f83-e6f2359972af">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMyLTEtMS0xLTE2MTE4_b1ce75e5-ba06-43f7-a96d-e6090d3471cd">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMyLTMtMS0xLTE2MTE4_c625f818-da94-4767-b049-cc9f910a7fad">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMzLTEtMS0xLTE2MTE4_8ee9b042-fc4d-48a5-a06c-239c198c9f14">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMzLTMtMS0xLTE2MTE4_2589975f-3f1d-4948-8a4f-ae6d7e339a4c">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM0LTEtMS0xLTE2MTE4_e79a91a6-0781-453b-bc48-5562e8ea493f">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM0LTMtMS0xLTE2MTE4_8b58f7f4-fc33-47a0-9e34-6771541c852b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTAtMS0xLTE2MTE4L3RleHRyZWdpb246OWE3NzI5ZmU4ZmI5NGY0OTliZDBkNTg2Zjk0YjQ5NGRfMjk_6255b217-ddd1-454e-b65d-ca000646710c">1,165</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTAtMS0xLTE2MTE4L3RleHRyZWdpb246OWE3NzI5ZmU4ZmI5NGY0OTliZDBkNTg2Zjk0YjQ5NGRfMzY_22edb5c6-a508-4d0e-84fb-8d3704ac720a">793</ix:nonFraction> shares, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTEtMS0xLTE2MTE4_0a8a748b-bd66-432b-9861-14cd3ab7bb61">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTMtMS0xLTE2MTE4_290b0518-950f-4b34-a8f7-1814b5c03b10">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM2LTEtMS0xLTE2MTE4_ae8fcc70-8acb-4ea5-9b5e-cb940c95f5ff">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM2LTMtMS0xLTE2MTE4_0f0b90ce-85cc-45bc-94a7-68c78916d6e8">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM3LTEtMS0xLTE2MTE4_19c985d8-cd9e-4fa0-8f78-64bf8137aa35">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM3LTMtMS0xLTE2MTE4_93b15685-f960-40b9-8503-4d42920bb242">203,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtMS0xLTEtMTYxMTg_d64c42ae-3380-4570-b481-2f185a6640ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtMy0xLTEtMTYxMTg_a1d36636-d434-418a-acd1-8a48e752218a">23,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtNS0xLTEtMTYxMTg_83e40488-685e-4434-8021-d6d3b19578a5">32,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtMS0xLTEtMTYxMTg_d1ee7816-ba6c-4c39-9d96-9e8e3986d972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtMy0xLTEtMTYxMTg_26c1d913-bc09-498e-b77e-3927696d1d9a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtNS0xLTEtMTYxMTg_5cae452e-6982-48c8-9b2f-621d362b6f26">289,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtMS0xLTEtMTYxMTg_2fd0a09e-4cf4-4c0e-878d-d189d287346f">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtMy0xLTEtMTYxMTg_dab32b21-1e7a-4a6a-ab0c-4b43a1b460d5">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtNS0xLTEtMTYxMTg_a30ee23f-19ef-40f7-8985-85d77cbed276">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtMS0xLTEtMTYxMTg_b2e0cacf-db41-4818-981f-be9b98e84c22">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtMy0xLTEtMTYxMTg_aba6bad9-c601-4cab-a166-5d84f2d8f1ee">23,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtNS0xLTEtMTYxMTg_e117dd25-4900-4677-b894-94664d874e27">322,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtMS0xLTEtMTYxMTg_6dc5cada-a7c9-4139-abf8-0d7805ab9013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtMy0xLTEtMTYxMTg_417c2b9c-649b-4a80-b3b2-9e15412aeb93">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtNS0xLTEtMTYxMTg_a1529872-cfd0-4251-8185-b94b93145d24">3,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF82OA_3f908dfe-7fb1-4a53-a2c0-a00c21b7dbdc">4,284</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF83Mg_2cd3d22f-e018-496f-ad04-2c9277c3bc2a">6,376</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF83OQ_cebaf36d-a065-46e8-aec1-1dfc0ae7b11a">7,096</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMS0xLTEtMTYxMTg_e923ac4e-e2bb-487e-ac1b-060c5173f548">55,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMy0xLTEtMTYxMTg_a9eed46d-5352-4ef7-9cf4-f139146ede51">153,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktNS0xLTEtMTYxMTg_ded5fcfa-b112-41b7-ad9e-f7918f1dbdc7">91,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfNzk_6d4f6485-6afd-4397-9a21-659f7e22b98c">6,293</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfODM_aba6d462-0735-46ae-984c-bc9865c87270">6,898</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfOTA_17ba4546-c5c4-48d4-af18-1e4d9477156e">7,122</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTEtMS0xLTE2MTE4_24d36ce6-ee0b-42f1-b27c-44cf4705bfc5">32,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTMtMS0xLTE2MTE4_aeb6cc77-63ac-4311-8d72-54446b2bb7a3">47,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTUtMS0xLTE2MTE4_171ef795-16d2-4a77-acf5-455ef7d7cebf">56,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTEtMS0xLTE2MTE4_a989633b-8232-422b-8a31-e87cd19caa81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTMtMS0xLTE2MTE4_4089f9be-10ee-43ee-9d05-0e304e7882e8">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTUtMS0xLTE2MTE4_4c826ca8-04a5-4495-a16b-8460344ac807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTEtMS0xLTE2MTE4_2011393e-e2ff-43cb-a68c-9ff3c8342512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTMtMS0xLTE2MTE4_9488abe7-cad7-4489-9a43-6d6475b47670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTUtMS0xLTE2MTE4_b6f78d13-fad2-4ad5-a738-c17196f2c075">28,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTEtMS0xLTE2MTE4_2da6a766-8637-4545-8dbe-bc57602fce7d">87,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTMtMS0xLTE2MTE4_54a3a7a3-71e0-4fb2-9f01-b2e2201e1839">204,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTUtMS0xLTE2MTE4_63441f79-df49-4259-b2f9-8080acd4c9e0">180,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTEtMS0xLTE2MTE4_271430eb-cb86-4f31-a9ac-cc981da8cfe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTMtMS0xLTE2MTE4_7d4513fc-a900-4fd8-941a-d151ea82bf0d">132,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTUtMS0xLTE2MTE4_c52826fa-fa11-4e18-9bee-936e9ab9eeb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTEtMS0xLTE2MTE4_38c2af13-155b-4cc5-ab43-c555baf7fac8">87,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTMtMS0xLTE2MTE4_511873c1-b668-46c1-9912-d6d1bf98f576">47,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTUtMS0xLTE2MTE4_fbfffa43-f218-4520-aaf7-8bba18e6f790">141,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTEtMS0xLTE2MTE4_13c59c50-c9fb-43ed-93f7-cdd3807b2e63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTMtMS0xLTE2MTE4_4e7dca1f-d925-4070-97cb-e8ccfaa0c383">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTUtMS0xLTE2MTE4_5987cb2b-3413-444d-a24b-a32e7a4fe1ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTEtMS0xLTE2MTE4_dc54a5ed-553b-471d-8e72-5978b45c0e64">802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTMtMS0xLTE2MTE4_bc20d21d-f65f-41c1-82fd-a37becf7db2c">14,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTUtMS0xLTE2MTE4_b3982542-6e3a-449d-8b00-ab47b66e61d0">20,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTEtMS0xLTE2MTE4_cad78e47-0de3-43d2-91a7-55d4c685ff29">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTMtMS0xLTE2MTE4_d1e5d5d6-4e25-4287-ac27-ebf79813714d">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTUtMS0xLTE2MTE4_ab18fa68-f8ff-4520-a9c9-f6875ab53052">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTEtMS0xLTE2MTE4_e3870f03-c798-4b0f-a51f-92dafb672e82">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTMtMS0xLTE2MTE4_8a33e541-a898-43b1-bc99-7316dda26f3d">58,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTUtMS0xLTE2MTE4_d024420f-3d65-4f07-b624-6261af632333">124,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTEtMS0xLTE2MTE4_c48293d5-7b17-4634-b19f-33babb5f4ade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTMtMS0xLTE2MTE4_b7e74afc-2955-4aa5-8423-6ef53d857b20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTUtMS0xLTE2MTE4_8f5135e7-2983-475b-907b-6925f17becbc">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTEtMS0xLTE2MTE4_7a4efce4-0e68-45cf-882f-2e3741e650e3">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTMtMS0xLTE2MTE4_80440268-86e1-4297-bedc-87db9176b12a">58,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTUtMS0xLTE2MTE4_9dfa7baa-259b-46de-9a4f-1625686afc70">130,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic </span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTEtMS0xLTE2MTE4_7f4c84b3-49f8-4111-9c14-d33a4eb4146f">0.60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTMtMS0xLTE2MTE4_ac5fcade-4eb5-414c-8e1b-28fbe90aeb30">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTUtMS0xLTE2MTE4_192fb07d-6d13-4706-9f62-48d734b40d61">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTEtMS0xLTE2MTE4_6e3385a4-c74d-443c-994d-848ae298e23e">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTMtMS0xLTE2MTE4_39366a6f-072e-4c17-8cef-5ffda06cd629">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTUtMS0xLTE2MTE4_b7adfa0e-5cae-49bd-9eef-df10401bdd41">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTEtMS0xLTE2MTE4_b18a26e4-e3fb-4456-9b54-2cfde3c0cd56">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTMtMS0xLTE2MTE4_518dc7f1-a659-4321-8bc1-f9c678768c47">110,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTUtMS0xLTE2MTE4_f8946366-cfc0-48f9-a59e-e019dc646107">106,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTEtMS0xLTE2MTE4_74e8602d-d11b-464e-9043-97973b05d1e0">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTMtMS0xLTE2MTE4_7c394243-cb59-403a-9fe3-c616daa10f48">110,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTUtMS0xLTE2MTE4_684c5752-d6c9-471e-b399-f33f4502d5a6">116,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTEtMS0xLTE2MTE4_60294a62-0f74-4b9e-8b58-86a55215b320">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTMtMS0xLTE2MTE4_9b5d071f-a4a9-42f7-8fac-8edbc7646693">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTUtMS0xLTE2MTE4_0975b854-f66b-489b-be7b-f4462ede542d">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTEtMS0xLTE2MTE4_42f13e7c-96b6-40bd-810d-43cc8eb0128f">87,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTMtMS0xLTE2MTE4_50eda140-0601-430c-b743-0332a7481107">58,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTUtMS0xLTE2MTE4_395748fd-d1ef-41f1-9a0e-d9ff7a51c5cb">130,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:32.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2de7ae68674e4d58a012b15b9e1f640d_I20181231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTEtMS0xLTE2MTE4_5190f21e-cfc2-47e1-970a-7213db643b7b">106,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de7ae68674e4d58a012b15b9e1f640d_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTMtMS0xLTE2MTE4_294f5c2a-66c1-4963-b36d-e1e9cd0d3959">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a484df8d34a48168ddc67636fee53d7_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTUtMS0xLTE2MTE4_ca1b499a-ce78-4885-955c-5e34b859c41b">1,447,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbc0d4d9dd1147749e2496817aad0133_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTctMS0xLTE2MTE4_4e8155d2-06e8-4446-bc16-55294c90146a">1,471,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf0e7cc645e4f69a6ece2184dc576cb_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTktMS0xLTE2MTE4_3bf637c2-79e4-4938-9ca2-47d9fb407416">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5229e5ba37471fb75d1796184d22b2_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTExLTEtMS0xNjExOA_9a85ce6d-36dd-417e-9eff-51fca414b727">2,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTEzLTEtMS0xNjExOA_b8167093-2f08-42e3-b179-cbfc38317a0c">26,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTMtMS0xLTE2MTE4_b6e6c682-a693-4cf8-b046-55b637c9059a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTUtMS0xLTE2MTE4_1fa5456c-2498-4d9c-b048-5e7d8746bd2e">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTctMS0xLTE2MTE4_dbbecec6-7f1c-43e9-b3c2-0dc3db0b93cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTktMS0xLTE2MTE4_bfb9a268-fbdb-4e00-b4ab-5ddb87aeb0a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTExLTEtMS0xNjExOA_3bd1ffae-5c1b-409c-baf8-d69d80aa7013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTEzLTEtMS0xNjExOA_20ef6301-d888-42e7-9398-d9afee710ef3">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTEtMS0xLTE2MTE4_f31a8cb5-a892-4c68-8cdb-d9a019a513cd">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTMtMS0xLTE2MTE4_9437973f-7e90-4a14-bb1e-97fa33b94599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTUtMS0xLTE2MTE4_954c449d-8e98-4c30-9c14-2c81029ef9ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTctMS0xLTE2MTE4_9b91fa2b-dc21-453b-957e-7e1c9884702a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTktMS0xLTE2MTE4_7457d3fe-b197-4c08-9041-00459560180c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTExLTEtMS0xNjExOA_92cd55b6-3325-4b77-bda5-a14e13247a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTEzLTEtMS0xNjExOA_eb9c1b23-71d8-4f70-a99c-b5cc0d3b63c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTMtMS0xLTE2MTE4_830b32ec-19fd-42f2-80be-c73031e525c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTUtMS0xLTE2MTE4_3d59314b-53c8-4d72-9680-83ca391434d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTctMS0xLTE2MTE4_a643407e-341e-4ab5-aba0-8a9f1ed33a8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTktMS0xLTE2MTE4_4320c036-7083-4f80-9c2a-541916042177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTExLTEtMS0xNjExOA_e2f6a7c0-f6d9-4faf-b9e3-50d887044cc0">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTEzLTEtMS0xNjExOA_54d6714c-5e23-46af-8491-591a0669565d">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTMtMS0xLTE2MTE4_67f182f3-6b44-4bf3-aa08-483daa929584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTUtMS0xLTE2MTE4_dabd8478-47d4-4024-883d-048f28ea09c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTctMS0xLTE2MTE4_ae6b98ec-c16d-4442-a97f-03da76e51716">130,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTktMS0xLTE2MTE4_1006c872-1cae-4a2b-bd9f-b0d32816e0b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTExLTEtMS0xNjExOA_d23b779c-4291-4412-8c38-b9c924d25213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTEzLTEtMS0xNjExOA_a55de9d9-0eef-4781-80e0-840eb44b5a45">130,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTMtMS0xLTE2MTE4_2faf0068-8030-49c4-bd81-e479fcd20de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTUtMS0xLTE2MTE4_d6802c14-6c35-42a3-8963-49cd5f1a1662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTctMS0xLTE2MTE4_ff85284e-0f5f-4196-a81a-3fe95f5e290c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTktMS0xLTE2MTE4_ce4da4d9-3e0f-46e9-b673-3d42c39e3116">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTExLTEtMS0xNjExOA_d9e2c30d-a35d-4b26-bacf-66be966de339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTEzLTEtMS0xNjExOA_a4cf3aa2-64d2-41aa-913c-05b8ed7b5c5a">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66d73276a9f54188a234d30a5c7db573_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTEtMS0xLTE2MTE4_446b390e-8ecf-4564-ba17-2e1e850520b0">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d73276a9f54188a234d30a5c7db573_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTMtMS0xLTE2MTE4_0a5a012a-f1ea-40a1-b3f1-db42a67bc7b8">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61ea8ca87054ca299e35899d20f0821_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTUtMS0xLTE2MTE4_f0c510a8-7512-44e5-ac3f-1bca34d2620c">1,462,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f0c660c256a4099bc5d00a590fa3ae2_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTctMS0xLTE2MTE4_4f6db1a9-b245-420c-a35b-c94e430f9203">1,341,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51590a994bf24c4ca00c39f49378fafb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTktMS0xLTE2MTE4_a00a423e-9956-4fe3-a61c-19e88b3215d0">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i479d65c47ea34ef3a9d80c56a9fa552a_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTExLTEtMS0xNjExOA_b453a294-c6ac-413a-8b30-f7f7bd15a952">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTEzLTEtMS0xNjExOA_1646448d-3747-4780-9fab-f7c82acfd706">117,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTMtMS0xLTE2MTE4_4d4c5a7d-d7cd-4f03-84cf-aae21c2a4dbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTUtMS0xLTE2MTE4_d432e8e1-4a12-4431-88b4-89691d267873">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTctMS0xLTE2MTE4_5cafdeaf-025b-4c83-bba9-07065dd15fd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTktMS0xLTE2MTE4_9cf66b21-68b0-4fbc-9029-d2ee90d1d522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTExLTEtMS0xNjExOA_9a7bda48-0acb-4b69-abf5-d0be01405738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTEzLTEtMS0xNjExOA_ebc876ee-cae6-4a1b-9dab-f1ddfebd2fae">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTEtMS0xLTE2MTE4_6ea4ba8d-6d32-4c06-99a9-10b737f5c4ac">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTMtMS0xLTE2MTE4_6bf10d08-7afe-4d9f-92a9-7da71ffbdcd2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTUtMS0xLTE2MTE4_b83c9dd3-425f-4a81-ac3a-2facf797c95d">6,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTctMS0xLTE2MTE4_66685a54-2bb1-4518-9791-1b396f912f38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTktMS0xLTE2MTE4_c6276273-8deb-40af-86a1-9f4cdb50bfdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTExLTEtMS0xNjExOA_33436e2d-731b-4d05-8d67-45129d4b0d44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTEzLTEtMS0xNjExOA_f6f3a1e2-dcca-4d5f-8f29-3d90efbea6ae">6,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon private placement, net of issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTEtMS0xLTE2MTE4_b1874e78-099c-4cc6-a5f6-bae6ea29f93e">20,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTMtMS0xLTE2MTE4_9f121973-2e19-47bb-8dd2-1261ef8fb446">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTUtMS0xLTE2MTE4_ecbf3ff2-a298-47f2-9e05-27bf4b45f702">62,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTctMS0xLTE2MTE4_e78ad863-d120-4309-a463-9034328813b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTktMS0xLTE2MTE4_3efaa7fe-129f-4e18-85db-24b098e3977c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTExLTEtMS0xNjExOA_5aaf5ea5-1143-47cb-b5a5-46c9237d82be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTEzLTEtMS0xNjExOA_fa19190a-eda0-4e98-a09a-0f032ab2c8a7">63,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in settlement of convertible notes, net of issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTEtMS0xLTE2MTE4_0505c133-4893-4736-958c-4e4d6a11f05a">10,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTMtMS0xLTE2MTE4_70921dd0-c013-4943-93a4-d1daf720454e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTUtMS0xLTE2MTE4_dfef7f71-d9a0-465d-adeb-673905c57f40">15,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTctMS0xLTE2MTE4_31bcd661-5582-4c46-b278-76b48cd33a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTktMS0xLTE2MTE4_8d221337-9948-4aff-b460-a25301caf2ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTExLTEtMS0xNjExOA_c5c1faa8-3524-4e1e-8eea-16cf50cc09e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTEzLTEtMS0xNjExOA_58ad855f-1aa4-4a50-a888-5565a7b14307">15,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTEtMS0xLTE2MTE4_16300af9-f86a-4884-ac7f-5f8f3a3df8ae">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTMtMS0xLTE2MTE4_6fc5fe99-a6cb-456e-bd13-cc603d31e326">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTUtMS0xLTE2MTE4_da45919d-1483-4c61-b551-e9a3bd45b49e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTctMS0xLTE2MTE4_030e92cf-1089-46cf-8850-9f34d6a6ad74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTktMS0xLTE2MTE4_b354a6dd-3e2f-4902-8dc8-673925474d12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTExLTEtMS0xNjExOA_95df793a-6b34-441c-8a8f-e105b6b60780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTEzLTEtMS0xNjExOA_d8202520-e662-47d2-b10f-302cc6219ca9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTMtMS0xLTE2MTE4_cd26d683-deac-4fe0-b326-a6459a149e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTUtMS0xLTE2MTE4_a1b8a2e3-0ac0-447b-bec5-877e9f002f47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTctMS0xLTE2MTE4_b36334d8-fc8c-40e4-9242-d1e0c2cedbc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTktMS0xLTE2MTE4_0ea023d2-4ce0-48bb-a4cf-b5364056a840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTExLTEtMS0xNjExOA_25a21c0f-8291-46f9-984c-b4fc1abbd753">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTEzLTEtMS0xNjExOA_e0e08fcd-d43c-46a3-b4c3-38b083f7dd8a">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTMtMS0xLTE2MTE4_208fba54-e4bd-43af-8de3-a55f32f78dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTUtMS0xLTE2MTE4_115c5018-80be-4c7f-9554-f6b93f154bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTctMS0xLTE2MTE4_5cecafac-16c8-4ae4-9e43-d123bf758572">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTktMS0xLTE2MTE4_88790731-80b2-4829-9846-c3b76857aa93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTExLTEtMS0xNjExOA_2e8fadf1-3cc7-4b27-877c-daf0ce037dd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTEzLTEtMS0xNjExOA_e8f0f911-4d97-4841-87e1-228789b8ff6a">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTMtMS0xLTE2MTE4_742fbdf2-1d2f-4eb8-b7e3-4abfc62586ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTUtMS0xLTE2MTE4_af2af1a7-f0fe-4aa0-a49f-6ff32120f4f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTctMS0xLTE2MTE4_ecdc65c0-1cbf-4a21-9e47-96cb262dd7e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTktMS0xLTE2MTE4_92c9e6f1-6348-49c3-9707-67127e77a189">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTExLTEtMS0xNjExOA_edad7746-727c-4310-a01f-14420f8b5165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTEzLTEtMS0xNjExOA_829643ba-a686-4e3a-8b61-bf4964ba35e9">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTEtMS0xLTE2MTE4_256bcf24-6774-4d7e-917e-7f02a18490d4">142,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTMtMS0xLTE2MTE4_6a83616d-3b05-4e9f-aafb-c46a371ca80a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a8eb0c931e47bb8781df60680b3b5e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTUtMS0xLTE2MTE4_a25b9aef-e66d-489f-95a5-350e8a14a702">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66152bef9ef94ee28758450b0c7d3bf1_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTctMS0xLTE2MTE4_536b34ce-9321-49cf-b889-4f24e1d61d36">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f855dd7993f49eeb1b627eb46715eef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTktMS0xLTE2MTE4_2f096e11-720e-4f7d-b5cd-6a4662145699">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d0ad57c0c334f0386685e094334b434_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTExLTEtMS0xNjExOA_78801ac4-bf0e-4b8b-8ebb-a324e59e0818">4,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTEzLTEtMS0xNjExOA_dfaa84ce-81fa-402d-9fd4-b3762a087669">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTMtMS0xLTE5MDUw_8d7b1c55-bbde-46bd-a29e-b68842833c23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTUtMS0xLTE5MDUw_c74830fb-c28a-48d2-8244-bb9efaf01bab">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTctMS0xLTE5MDUw_a86abbb3-9c18-4572-9a62-6cde1de61d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTktMS0xLTE5MDUw_d0cd42f0-be17-45d3-9d59-425a1e4b93b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTExLTEtMS0xOTA1MA_4c670775-5b34-4db1-9cd6-6e6a26965e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTEzLTEtMS0xOTA1MA_6ddc4a60-126f-4c49-a667-a24845278271">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTEtMS0xLTE5MDU3_d606e76c-0b35-483c-8cc5-6d460ae30e04">6,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTMtMS0xLTE5MDU3_40e2addb-3fad-46f8-9b3a-b42cddc4e8ad">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTUtMS0xLTE5MDU3_57eb6c7d-f989-47c0-ae0c-2c7bc9331548">35,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTctMS0xLTE5MDU3_dd6bc366-0129-4726-9e85-d9b4f6bcf72e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTktMS0xLTE5MDU3_88b548aa-1901-47bf-bc82-72c808ffb587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTExLTEtMS0xOTA1Nw_59b4659f-7917-49f5-8399-c0379449d93c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTEzLTEtMS0xOTA1Nw_06d0bbc7-f979-4c52-acc6-467aa9c9313d">35,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTEtMS0xLTE5MDY0_2e08d2db-ff89-4c48-a366-1cfa0f1d3207">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTMtMS0xLTE5MDY0_e094670f-27e2-41b9-8a8f-73f781efcd19">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTUtMS0xLTE5MDY0_b78d3935-3896-4f62-8a78-f865252f327f">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTctMS0xLTE5MDY0_e4aaa1f7-86c0-45d3-ba4d-853a6f683962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTktMS0xLTE5MDY0_9b5d918c-0c9a-438f-b6ea-077f4af357e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTExLTEtMS0xOTA2NA_c1d8d95b-5a30-4e50-baf0-4499fd929b81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTEzLTEtMS0xOTA2NA_14e09df1-0486-4d25-a862-42a1eb4453d1">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTMtMS0xLTE5MDcz_47cede46-2746-4e8c-bdfd-eff191a10cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTUtMS0xLTE5MDcz_3b346a25-4f2f-4de6-99f7-2f5784a80fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTctMS0xLTE5MDcz_e3cffe5a-4db6-44ba-a7b5-1c7f06394028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTktMS0xLTE5MDcz_60328f4f-9f45-4fc7-bac4-7124777920e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTExLTEtMS0xOTA3Mw_949ef857-1ac6-463f-911a-6d54446e8b06">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTEzLTEtMS0xOTA3Mw_3009ae82-5547-477c-abbc-1b7275db9bf7">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTMtMS0xLTE5MDgw_95d77d86-ae77-4320-8b58-090fb0860051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTUtMS0xLTE5MDgw_02289914-c881-47ec-b847-1587e20701dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTctMS0xLTE5MDgw_636e50ec-86d5-4a65-901f-88d3ce74c8ff">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTktMS0xLTE5MDgw_28c1357f-efca-4972-b5e4-60adf08df158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTExLTEtMS0xOTA4MA_e0c7af6d-d681-4bf2-a35c-560822ca9b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTEzLTEtMS0xOTA4MA_4cdc0687-ac1a-4866-ab29-69b72372d0a5">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTMtMS0xLTE5MDg4_006f932b-9041-4cd7-bf4d-7879bd23872b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTUtMS0xLTE5MDg4_ac8aacf2-4c3b-4e8b-8b27-c007acafa1fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTctMS0xLTE5MDg4_e4caf7c0-d1a5-47bf-a568-138bc7030b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTktMS0xLTE5MDg4_18894acf-fe39-422e-8283-03f778b1fa3c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTExLTEtMS0xOTA4OA_7c08799b-8409-49c6-99b2-7257a3316d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTEzLTEtMS0xOTA4OA_e521094a-ef3f-430d-a56f-f765bbab9d1d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTEtMS0xLTE5MDk1_b01c043d-aa01-477b-b5f9-ab9d1dbeff2e">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTMtMS0xLTE5MDk1_45a46b44-933d-4ac5-8df6-086c05fcd782">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92be0a5177c4f85879df29eafff809c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTUtMS0xLTE5MDk1_d47c53f5-2325-4028-b0f1-ae242d7857ca">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i729d06e13a06473b9ca5a295173d860e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTctMS0xLTE5MDk1_e2be38eb-37a3-46a0-89f1-65033a8d4508">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80201290325143af97f2fb030d3e10d4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTktMS0xLTE5MDk1_0890c248-8044-4363-9d2f-c95f9e6485a3">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a188a482da64a818cb53605d5b01571_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTExLTEtMS0xOTA5NQ_d64b870c-a161-48f8-9c49-88bc929e0ab0">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTEzLTEtMS0xOTA5NQ_72ff0faa-f258-4e33-aa49-183da6b50be7">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMS0xLTEtMTkxMzQ_90752ca5-21c5-4b1a-a9bc-b76973e9e9d6">87,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMS0xLTEtMTYxMTg_4bb9fa18-ffcf-4213-8c95-4175d9a7cc93">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMy0xLTEtMTYxMTg_30985afe-805a-467c-8a6d-11a1135e5eb8">130,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMS0xLTEtMTkxMzQ_0a52d1ab-8505-4da5-b5ec-7e6207f82aac">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMS0xLTEtMTYxMTg_7b82165c-8a1a-4b34-b955-fdaafb766d3f">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMy0xLTEtMTYxMTg_3aeb11cc-c078-40b5-a378-e42d89b5163e">3,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMS0xLTEtMTkxMzQ_a69d4516-8c46-4a52-bec7-be9f70a6b6c3">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMS0xLTEtMTYxMTg_686ccac9-82cc-4a41-ab1a-d1c227270e24">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMy0xLTEtMTYxMTg_88489802-1829-4609-9251-35fbb3eaacc4">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMS0xLTEtMTkxMzQ_ab22dc64-6321-4802-840b-7e5abb2a2c32">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMS0xLTEtMTYxMTg_019f1ea1-c825-4a56-a5e8-9f5a97395fa4">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMy0xLTEtMTYxMTg_6d7801be-38aa-404d-a6a6-0b731c59cd14">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMS0xLTEtMTkxNDc_beffba23-098c-4b0d-b278-ace863a7e034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMS0xLTEtMTYxMTg_87f00bd1-0ec4-472d-b740-bdeacaa3335a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMy0xLTEtMTYxMTg_989ba7bf-be68-4232-b9e9-e588ae2c590f">6,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMS0xLTEtMTkxNDc_172d1586-8827-45ea-a623-1bd2f5b148fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMS0xLTEtMTYxMTg_0b6f46e4-7ebc-4200-83b1-eb3d159d07e8">132,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMy0xLTEtMTYxMTg_d1148e41-c509-451f-b53c-5dee01624a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on building</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTEtMS0xLTE5MTQ3_2f81fa75-7582-4c6b-893a-f06e6168d901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTEtMS0xLTE2MTE4_55434dcc-7b8d-4d91-8b3b-1fe3c33b96f1">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTMtMS0xLTE2MTE4_30bd1e42-b0f7-42c3-b3f3-3d39bb614198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTEtMS0xLTE5MTQ3_1d86e222-7be1-447b-9be9-43616f5918ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTEtMS0xLTE2MTE4_03f8f882-d86e-4419-9aad-d43dde8ef661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTMtMS0xLTE2MTE4_b416e082-ac00-4c68-b0da-41d09280bd6f">28,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTEtMS0xLTE5MTQ3_64b3b158-f734-4ac4-aa73-208f0faaff4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTEtMS0xLTE2MTE4_1acd4ff7-fbae-4ac5-901d-6b0162d1e93a">1,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTMtMS0xLTE2MTE4_d1401819-8bb8-489b-b9c7-68479aa577a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTEtMS0xLTE5MTQ3_b16e2958-b2e6-490d-98a5-e48820fe155c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTEtMS0xLTE2MTE4_4127c397-fe67-4455-9758-2f8b6998ff24">707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTMtMS0xLTE2MTE4_7f09026b-1238-4f24-9da5-b303fa3a61c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTEtMS0xLTE5MTQ3_9a1c8bf0-f64b-4549-b8d3-df90df91e9db">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTEtMS0xLTE2MTE4_204b6abb-a8cf-4153-bfcf-ecffe80ed2f7">53,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTMtMS0xLTE2MTE4_2b26518d-94a2-4ffa-bd16-04083908c9ad">50,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTEtMS0xLTE5MTQ3_bc933a7b-1b8e-422a-af7e-296e517c5089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTEtMS0xLTE2MTE4_415db859-40df-47ee-bd00-e9b0eb7e88fb">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTMtMS0xLTE2MTE4_5a7612cc-3232-40fe-92ee-14f02a0370c8">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTEtMS0xLTE5MTQ3_c3665552-1eae-4865-97dc-9ef843c2f037">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTEtMS0xLTE2MTE4_116e251b-d3ed-40d7-bcee-c863c88c9dec">1,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTMtMS0xLTE2MTE4_6329c70a-a9a9-4374-88ab-6161857180ac">2,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTEtMS0xLTE5MTQ3_1b78e278-d1b8-490e-a432-b0c88853ccf8">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTEtMS0xLTE2MTE4_04c8d130-8453-4a3d-aeeb-fb109f52fcb0">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTMtMS0xLTE2MTE4_eeadcc07-1df4-416a-811f-e6ba8cbee766">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTEtMS0xLTE5MTQ3_3c862721-ab78-4e91-b3fc-0613c228ff80">14,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTEtMS0xLTE2MTE4_ef6d472d-0f02-4edc-bd38-c344ff5f0a96">20,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTMtMS0xLTE2MTE4_9a31f6cb-37ec-4669-8bf2-c5c6020459bf">20,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in deferred revenue&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTEtMS0xLTE5MTQ3_a1aa4f16-b55e-456b-99b2-67a3c947ad92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTEtMS0xLTE2MTE4_d0e12c13-dee1-44b3-8897-ed8f31724d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTMtMS0xLTE2MTE4_30165b23-e163-43ef-980a-05ae4e3b45a6">25,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTEtMS0xLTE5MTU0_bfd7c646-dc81-4590-941d-83db9e0a5fb6">87,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTEtMS0xLTE2MTE4_91c2028d-ede5-40bd-be5b-172b49db2a3b">142,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTMtMS0xLTE2MTE4_e7a163d8-dd59-4eda-86e0-adc99604fb02">113,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTEtMS0xLTE5MTU0_57b9bf6e-32f7-4719-ab16-91035d82b9fd">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTEtMS0xLTE2MTE4_4ff9beb9-bdbc-47a2-8dca-a0404f5a66d9">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTMtMS0xLTE2MTE4_a05d13e4-416c-4405-bef7-b3e85a05f5fa">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from XERMELO sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTEtMS0xLTE5MTU0_5e5759bc-e30c-4594-986b-667c5ac5bebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTEtMS0xLTE2MTE4_c03cb9df-7410-4542-85df-e15d22de7e4f">160,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTMtMS0xLTE2MTE4_42f9062d-5596-4309-b64b-1d1674b6f43d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTEtMS0xLTE5MTU0_699a57cd-d139-465c-bd59-a5537ff84ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTEtMS0xLTE2MTE4_1e77fde9-833e-4aea-949f-cbbdf0366890">11,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTMtMS0xLTE2MTE4_8d18992a-1721-4d97-bb17-02552bd19e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTEtMS0xLTE5MTU0_34bb79cd-7dd5-459c-90db-514a614e0ea7">34,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTEtMS0xLTE2MTE4_6c121c07-d091-4ab5-9437-9314ac088e86">58,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTMtMS0xLTE2MTE4_a12a8234-7962-496d-b0af-47e8e3b48aa5">322,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTEtMS0xLTE5MTU0_2e5c2564-a133-4313-86bf-47d864f579dd">37,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTEtMS0xLTE2MTE4_e71aa107-b861-4fb2-bc05-d4933cd1ebcc">268,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTMtMS0xLTE2MTE4_9746bc48-e3a4-4c33-99ee-32559248a3c3">166,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTEtMS0xLTE5MTU0_e300aa4b-d29b-4bbc-8a83-2cde2465f85b">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTEtMS0xLTE2MTE4_8d96bf37-cf50-4284-b98e-51faffc99eec">380,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTMtMS0xLTE2MTE4_f95f266d-2a19-4fd0-b943-b7347c8aab82">155,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTEtMS0xLTE5MTYx_27aea6de-3e9a-41a2-bae0-042cd9881ff2">37,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTEtMS0xLTE2MTE4_bb022cd4-1942-4a1e-a499-d1bb3682b54f">69,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTMtMS0xLTE2MTE4_e26991b8-6a1d-4c5e-9fa4-bd87d9971afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTEtMS0xLTE5MTYx_072aa611-564a-4174-bcca-1e44cb046cf9">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTEtMS0xLTE2MTE4_669ad34f-00e7-4cc6-9ebf-2c34df74a445">1,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTMtMS0xLTE2MTE4_403988f1-4a02-4918-97e2-e2aca9678d38">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTEtMS0xLTE5MTYx_8a6134be-a5e7-42e9-bfa5-b4b079b6c4e4">11,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTEtMS0xLTE2MTE4_41ddae49-2487-4f8a-b3f3-864db885c2a8">216,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTMtMS0xLTE2MTE4_7856f7a3-878b-4390-9f82-20307502aa47">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTEtMS0xLTE5MTYx_d4a684c4-9ff8-42ef-a18d-ea64f3e37fd4">22,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTEtMS0xLTE2MTE4_79d18aa6-6ce8-4361-a15d-83a3e34e18bd">147,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTMtMS0xLTE2MTE4_2c5e82d1-0c98-47c1-87e0-d49a13fe830d">2,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTEtMS0xLTE5MTYx_e6219749-e23f-4f99-a8b4-c93c42518b0c">62,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTEtMS0xLTE2MTE4_c74f558f-7980-4fc7-a010-4b7eb1642980">90,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTMtMS0xLTE2MTE4_74292659-2abb-4130-bebb-6fb4af8c54ac">44,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTEtMS0xLTE5MTYx_5e60b9db-53c4-4bab-9379-1cb529efc9ee">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTEtMS0xLTE2MTE4_af6305e4-0020-477e-b762-ea3c02e64467">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTMtMS0xLTE2MTE4_3ae823a0-0a8c-428c-8200-962f6c7e5178">80,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTEtMS0xLTE5MTYx_4d0e2653-a429-4eea-a64f-8380f9c5a095">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTEtMS0xLTE2MTE4_c2442a0d-9e41-4a16-85b6-f86ae978285e">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTMtMS0xLTE2MTE4_0705c732-f94e-410a-97a8-43ae3c7dcc74">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTEtMS0xLTE5MTY4_d16b8446-97e0-4a63-9959-11091a519e3c">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTEtMS0xLTE2MTE4_3de75c50-be02-49d1-8a0e-0891bd2d93b2">17,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTMtMS0xLTE2MTE4_f65b3577-c0ee-41d2-a175-a6e804f1b3f1">19,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE5MTg1_a688761e-8fae-49b6-bf32-0a6c2770d0e5">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTMtMS0xLTE5MTky_d3d685a1-d31c-46b9-b7d5-59c68958be1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTUtMS0xLTE5MTk1_95e41980-4831-43b0-9c54-5dd99d658e5a">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by TerSera from the XERMELO sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE5MTc1_0f47a5b2-b052-43e8-aac2-6eeb7f3d7674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE2MTE4_fecb7d0e-33d2-4364-916a-47901875f0d7">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTMtMS0xLTE2MTE4_5f1ec211-d24c-4216-8583-ba07b5bfa00c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in satisfaction of convertible debt exchanges</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTEtMS0xLTE5MTc1_f91adc96-6cf1-45e6-8b53-049870553aaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTEtMS0xLTE2MTE4_d0eecfc4-1d07-4f52-917a-ef71a18cbafd">15,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTMtMS0xLTE2MTE4_f8bc977d-f480-4692-86d9-a0348b4c09eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2021 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDUvZnJhZzowYWJjNDc0YmE3MTA0Zjg1YTRlM2ZkZjU1NjgyMzVhMy90ZXh0cmVnaW9uOjBhYmM0NzRiYTcxMDRmODVhNGUzZmRmNTU2ODIzNWEzXzE4ODA_faa8c833-2376-419c-afb8-b3a06bf6d94b" continuedAt="i22480f65913b4f759f00a3e7a7b006c8" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="i22480f65913b4f759f00a3e7a7b006c8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, the success of its ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk3_924b7e55-3f47-433b-b670-32ec509333c8" continuedAt="i762b878ceab347d79758ab857bbd0bc0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i762b878ceab347d79758ab857bbd0bc0" continuedAt="i3e70097be299456f9db6b00f5df41ec5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDg1_90b61e70-aeb4-46d2-9a70-2cecbdb53611" continuedAt="i109330d89e9d4a3e90e7cce033877491" escape="true">Basis of Presentation:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="i109330d89e9d4a3e90e7cce033877491"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.</ix:continuation>    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDc0_e41766cc-d8c1-46e8-af85-0a6ee3a6ae00" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDMy_2250c08e-0828-469d-9f21-a5cd29d48777" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2021, short-term investments consist of U.S. treasury bills and corporate debt securities. As of December&#160;31, 2020, short-term investments consist of corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTE5_b7769331-aea7-453d-835f-60e23c3f6a18" continuedAt="i6e891442200d43eca56a8783a659b4ad" escape="true">Accounts Receivable:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e891442200d43eca56a8783a659b4ad">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</ix:continuation>&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTEy_2ec7a70a-abd1-4afe-aeea-81b6026d5a88" continuedAt="i138a5aecfaec41bd8c255a9c24fa14ff" escape="true">Concentration of Credit Risk:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i138a5aecfaec41bd8c255a9c24fa14ff"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</ix:continuation>&#160; In 2021, customers in Switzerland and the United States represented <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE0MjQ_12d9b9fe-4f39-42d0-bbb0-5d8c766f44a4">76</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODEwOTE_c95e7792-c9fb-41c2-b603-7e856c16bdae">24</ix:nonFraction>% of revenue, respectively.&#160;In 2020, customers in the United States represented <ix:nonFraction unitRef="number" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5MDg_8b37f8e7-6804-4479-aa04-90b52f9c6bbd">98</ix:nonFraction>% of revenue.  In 2019, customers in Germany and the United States represented <ix:nonFraction unitRef="number" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5ODY_f8d0ddc0-96f1-467f-9931-ddfcf2cf334c">89</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5OTM_0fd17b2a-dd4a-47fd-9ab9-4394466e1f92">10</ix:nonFraction>% of revenues, respectively. &#160;&#160;At December&#160;31, 2021, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDY2_4853eee4-95ca-497a-a46c-885988d06808" continuedAt="iaa116cb30ec5475087f9d31a239f157b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in <ix:nonFraction unitRef="segment" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzMyNzQ_c30d1b5e-7be7-473a-945c-b71a2779c842">one</ix:nonFraction> business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3e70097be299456f9db6b00f5df41ec5" continuedAt="i4a14e6417c5d4cd5a0e648c8858a08d3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa116cb30ec5475087f9d31a239f157b">for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.</ix:continuation>  In 2021, AC Bioscience Ltd. represented <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:LXRXBiologicscustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODEyOTE_f541d0a7-4bd0-462e-8088-2a60d7ac49ea">76</ix:nonFraction>% of revenues and Taconic Farms, Inc. represented <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:LXRXDiplomatcustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1MTk_821d5e16-8282-4a62-9e0c-c237e1afb839">24</ix:nonFraction>% of revenues, respectively.  In 2020, two specialty pharmacies, Biologics, Inc. and Diplomat Pharmacy, represented <ix:nonFraction unitRef="number" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="INF" name="lxrx:LXRXBiologicscustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM4ODY_68464451-9ac5-4d86-8b76-ce529cb8682d">65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="INF" name="lxrx:LXRXDiplomatcustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM4OTM_1823dd47-0dbb-4aa5-b168-ed885ad5c38c">22</ix:nonFraction>% of revenues, respectively.  In 2019, Sanofi represented <ix:nonFraction unitRef="number" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="lxrx:EntityWideRevenueSanofiPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM5NDY_2b1810f5-7734-4157-9aa5-272fdae115e3">89</ix:nonFraction>% of revenues and no individual XERMELO customer represented more than 10% of revenues.  </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDIw_9cc71fd0-86e5-4957-9412-cdfc9f5e29e4" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0">three</span> to <ix:nonNumeric contextRef="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwODE_7bfb2d09-6fc7-497e-a508-738598501276">40</ix:nonNumeric> years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:52.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzMtMi0xLTEtMTYxMTg_1f7f51be-53d5-4907-9984-ba346b8d0c54">3,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzMtNC0xLTEtMTYxMTg_fbd404ac-3837-4c0d-9613-78931dd9793f">21,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzQtMi0xLTEtMTYxMTg_7007bcb6-4e87-4e2a-bb5a-08d7362155e8">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzQtNC0xLTEtMTYxMTg_1864a2ed-4930-42e0-a1a8-7fe9cc5a9626">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzUtMi0xLTEtMTYxMTg_df27b334-2838-4e46-9f10-37148c99e981">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzUtNC0xLTEtMTYxMTg_3c3e2e83-eb26-4397-89ac-ce3f14b438e6">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzYtMi0xLTEtMTYxMTg_2ff1551a-1006-4ef4-bd60-8366ad0a6ffc">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzYtNC0xLTEtMTYxMTg_8aca2fab-4bd8-4208-9b14-288eae81af3f">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzctMi0xLTEtMTYxMTg_832bdd4c-2755-4cad-9afa-182e67de2705">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzctNC0xLTEtMTYxMTg_f1badf60-8d37-4141-9e45-76939b41e33a">29,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk1_21d2d1f6-ad11-47c0-99a8-185871489639" continuedAt="i1afba900878b4758bdaa24b2d4cd4d8a" escape="true">Impairment of Long-Lived Assets:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1afba900878b4758bdaa24b2d4cd4d8a">&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1MzY_4089f9be-10ee-43ee-9d05-0e304e7882e8">1.6</ix:nonFraction> million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were <ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzYzNzE_1c9d9718-56fa-41f5-8e24-a41d0d96cecc"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzYzNzE_ce299a56-b4b3-4975-ab71-d7d529bd0ccb">no</ix:nonFraction></ix:nonFraction> impairments of long-lived assets, including finite-lived intangible assets, in 2021 or 2019.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDg5_3690ee93-3e83-4549-ad98-96ec95476d2e" escape="true">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than the Company&#8217;s carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  In 2019, Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 14) and Lexicon&#8217;s resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1NjI_5d1b9d49-c110-4de4-83da-2b6086de00bb">28.6</ix:nonFraction>&#160;million to IPR&amp;D in 2019.  The impairment reduced the remaining book value to zero. There was no impairment of indefinite lived intangible assets in 2020 or 2021.</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDQ2_9f486704-8c59-4a18-8dcb-8faabfb76178" continuedAt="ia8aba215f1984a13a699c626264bb141" escape="true">Goodwill Impairment:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8aba215f1984a13a699c626264bb141">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</ix:continuation>&#160;&#160;There was no impairment of goodwill in 2021, 2020 or 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4a14e6417c5d4cd5a0e648c8858a08d3" continuedAt="iab433948de0547d68e6b607079df6099"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk4_0bfc5a5b-9dc9-4c1d-a65c-1ac79ecf147c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iab433948de0547d68e6b607079df6099" continuedAt="i96669c207da84169844d79e0d01555ef"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTI1_5b787ebf-9a56-43c7-8cef-eb1df71ae521" continuedAt="i10c570a44a7c498ab8c6099f4bbd5293" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10c570a44a7c498ab8c6099f4bbd5293"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of <ix:nonNumeric contextRef="ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzE3MjYz_8c4368b8-12dc-401a-a655-3eccc9248955">14</ix:nonNumeric> years.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDUx_016cd7f7-f636-4e73-8141-b46571e176c6" continuedAt="if4ee6a2829644103a2a96e7d909776a9" escape="true">Research and Development Expenses:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if4ee6a2829644103a2a96e7d909776a9"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDQw_8747d048-2214-46aa-a7b0-18f9868a1b8a" continuedAt="id90c67633db44fabb42922a3b63da441" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2021, stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzE5OTYx_6fbb9411-ff75-4a86-bd55-d7beef6fd55f">15.9</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIwMDM0_ca46a72a-f429-45bc-adb2-9f9dc5e0a2f1">1.2</ix:nonNumeric>&#160;years.</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96669c207da84169844d79e0d01555ef"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id90c67633db44fabb42922a3b63da441" continuedAt="i1f50bbe773fa407e87c5f7e77645b737">&#160;</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1f50bbe773fa407e87c5f7e77645b737">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2021, 2020 and 2019, respectively:</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTIy_ae22c612-be83-4da2-92a7-8514cec97e13" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItMS0xLTEtMTYxMTg_d002498f-312d-4805-bea0-2d02d033a988">104</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItMy0xLTEtMTYxMTg_622ed979-e5a1-487a-9d18-bc556a5f7ca3">0.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItNS0xLTEtMTYxMTg_366b7f95-77af-4ef4-a8ae-6ef66f349144">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItNy0xLTEtMTYxMTg_13a896a5-a5cd-4786-9ac2-59cefbcb0a84">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtMS0xLTEtMTYxMTg_b498d6b2-c852-48ea-a34d-d58080642803">90</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtMy0xLTEtMTYxMTg_73e564a3-bda7-44ed-930c-b9cb90230574">1.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtNS0xLTEtMTYxMTg_85c7c283-474e-4f7b-aa74-7d23238e0c8b">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtNy0xLTEtMTYxMTg_5add94f9-f1ce-4d70-a648-062a51bdfa42">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtMS0xLTEtMTYxMTg_55e4bc64-7e49-478c-863f-5cfbcb8c8df8">98</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtMy0xLTEtMTYxMTg_5bf079cf-f495-4c5e-a655-382e7b996145">1.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtNS0xLTEtMTYxMTg_da74c889-2997-4488-8818-381e2f0b99bd">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtNy0xLTEtMTYxMTg_b225308c-a860-4373-a6e2-719e667e08d9">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtMS0xLTEtMTYxMTg_c7eaf0ba-24ef-43e1-9d69-54783d50faf1">85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtMy0xLTEtMTYxMTg_27999356-7462-4a8e-985b-a31d1ce5c490">1.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtNS0xLTEtMTYxMTg_17dd5837-e6b9-43cb-9d4c-dfff3aa1d9e1">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtNy0xLTEtMTYxMTg_3e7a30db-52b4-41b0-b21e-7843c58c5395">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtMS0xLTEtMTYxMTg_e4b458a9-3599-43d9-8b45-8ba37505f6e6">88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtMy0xLTEtMTYxMTg_e4820464-c0cc-4583-bce6-69059f92b132">2.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtNS0xLTEtMTYxMTg_72fff5ca-6b3a-4f63-9fe4-0ee60cd1e0b4">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtNy0xLTEtMTYxMTg_6dfd4d7c-0785-411c-835f-df336a91369c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktMS0xLTEtMTYxMTg_910d4cbc-fa7a-4642-96d4-74b56298f710">77</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktMy0xLTEtMTYxMTg_8d63f383-a324-47f2-8f45-dee859ffd31c">2.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktNS0xLTEtMTYxMTg_0d6b35aa-bb1c-4185-9460-0cb62ddba6d0">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktNy0xLTEtMTYxMTg_887cbf2f-b2b5-4a60-aac5-5428a4d58300">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTAw_991c3d6e-1357-4635-870c-1eb7084bae93" continuedAt="i3711a26290334a6392e298929219166c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2021, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2021 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2021 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIzMzU4_2b45bd4c-b776-4015-9cc0-bd0c483ce5f1">326.6</ix:nonFraction>&#160;million at December&#160;31, 2021. </span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3711a26290334a6392e298929219166c">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDMw_8ac7faee-7f74-4f64-9513-5709e5ec2bd7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></ix:nonNumeric></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTEvZnJhZzo5ODJjZDAyYTc3MjU0NGI5YjE2Mjg5NDY1OTM1YTJkOS90ZXh0cmVnaW9uOjk4MmNkMDJhNzcyNTQ0YjliMTYyODk0NjU5MzVhMmQ5XzE2OTk_6ba4deb4-b156-48c8-a3e4-87261666d5a4" continuedAt="if624e09e952b4d16b7328ea322d42e03" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="if624e09e952b4d16b7328ea322d42e03" continuedAt="ib20cbf95cd344ae0bfa8f782b1cf4ee4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib20cbf95cd344ae0bfa8f782b1cf4ee4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and adoption of this ASU did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU during the first quarter of 2020 did not have a material impact on the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="lxrx:SaleOfNonFinancialAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzIxMTA_d15d7962-e6bd-45cd-9fc3-0f77ad54e853" continuedAt="ia123fcf3cc9249cea05f76c086e5b986" escape="true">Asset Sale</ix:nonNumeric></span></div><ix:continuation id="ia123fcf3cc9249cea05f76c086e5b986"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO product and related assets (the &#8220;XERMELO sale&#8221;) to TerSera pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The final consideration paid by TerSera was $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-5" name="lxrx:FinalConsiderationIncludingAmountsReleasedToSettle" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzMxNQ_b11d5a39-3230-450a-a164-fbc29c15da8a">160.0</ix:nonFraction> million and the net gain recognized in connection with the XERMELO sale was $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzM4Ng_b3e203a0-2c80-4d51-b33d-060265510b4a">132.6</ix:nonFraction>&#160;million.  The gain is reflected on the consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzYxNw_f6ed83e4-7efe-47e8-ae19-7840207ccb5a">65.0</ix:nonFraction> million for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made. Such adjustment would be included in Gain on sale of XERMELO in the consolidated statement of comprehensive income (loss).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#8217;s operations.  For the years ended December&#160;31, 2020 and 2019, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#8217;s XERMELO operations is $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE2MzQ_0aac2823-1795-4a1a-81a2-9c7d6dee7ddd">12.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE2Mzg_9a852a2b-b929-4168-950d-955f85661231">15.4</ix:nonFraction> million, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company incurred and recognized severance charges of approximate $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE4NzQ_eeba343b-470d-4733-9b72-514c22c658a0">5.5</ix:nonFraction> million. Of this charge, $<ix:nonFraction unitRef="usd" contextRef="i8522830166f449a58c9cec1c88e894b9_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE4OTQ_410d8267-19b3-48b6-aa34-9d34f57b1d24">2.5</ix:nonFraction> million was recorded in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="ib18d8e20549d44f094d78c20f57067a7_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE5NTA_8ee2b335-75bd-434c-9295-9a1c7714a4ab">3.0</ix:nonFraction> million was recorded in selling, general and administrative expense in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzI0Mg_de44f83d-838c-408a-8ecc-27d609a35714" continuedAt="if43f70f8c79c445598aa7f04e7956010" escape="true">Cash, Cash Equivalents and Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if43f70f8c79c445598aa7f04e7956010" continuedAt="i4ffd7bf37dc54260af141d63de115bf2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at December&#160;31, 2021 and 2020 are as follows:</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzIzMQ_714ebad6-2eb0-4df4-8204-d9a55e35454b" continuedAt="ib494b263a0d642889bcade6cf94e2081" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:42.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtMS0xLTEtMTYxMTg_6c28b53c-ddba-4bf8-ab79-e8d418b44874">64,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtMy0xLTEtMTYxMTg_eebfe6b1-a3d6-4383-84c3-d33948b33fd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtNS0xLTEtMTYxMTg_0bd72ed4-d508-4126-84b0-e2590312b146">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtNy0xLTEtMTYxMTg_8a01d532-2036-4117-964f-cf24724bdcf5">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cf340c919946f4bfab989e262c817c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtMS0xLTEtMTYxMTg_0770650a-a800-4885-9b11-c7254f7bae5b">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cf340c919946f4bfab989e262c817c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtMy0xLTEtMTYxMTg_3f14b805-8602-4bc6-8980-a765993722d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37cf340c919946f4bfab989e262c817c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtNS0xLTEtMTYxMTg_5d2766c7-495d-4fcc-afa1-a03bbe2dfce0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cf340c919946f4bfab989e262c817c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtNy0xLTEtMTYxMTg_e45273d2-308a-4231-b7a1-6d50dc88a297">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtMS0xLTEtMTYxMTg_b5627f62-c3ca-4cde-bf96-b8bdee11d329">15,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtMy0xLTEtMTYxMTg_5dc8227f-6958-4bd1-9bb0-5370b1897431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtNS0xLTEtMTYxMTg_672301de-4b51-4834-8838-b02a7fda6772">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtNy0xLTEtMTYxMTg_3a019901-2757-4f0b-ba2b-cd585fb7a663">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctMS0xLTEtMTYxMTg_ca538e5a-d1c6-4c6a-ae89-ab79300c35e1">22,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctMy0xLTEtMTYxMTg_61d0b736-16d3-4f7e-b742-ce3408985cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctNS0xLTEtMTYxMTg_c67b5bde-e485-48bf-9999-e965cfc7e3f3">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctNy0xLTEtMTYxMTg_3d695fa4-c87a-434b-a11c-a3c0b870c349">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtMS0xLTEtMTYxMTg_3bac7243-ca7a-403e-90e0-f3d6982d7d26">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtMy0xLTEtMTYxMTg_4a85a3e1-2112-499d-a034-11f4320cb81c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtNS0xLTEtMTYxMTg_502cfed8-2b02-4d20-beee-2f021da2eef0">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtNy0xLTEtMTYxMTg_08a4b6a3-d4ed-4b1e-a73c-db53b9787df4">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><ix:continuation id="ib494b263a0d642889bcade6cf94e2081"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:42.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtMS0xLTEtMTYxMTg_0355752b-8fca-41d3-b6cb-bc951620f222">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtMy0xLTEtMTYxMTg_2cfeb944-ae80-4837-bdc2-6b2f4410d5bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtNS0xLTEtMTYxMTg_be7c5471-5fef-42b0-9a3b-7888c3341ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtNy0xLTEtMTYxMTg_b591e072-fcd8-46c3-86a4-ff5d36b7722c">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1b6c22beee4da5b9a413b0fd5a000c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzUtNy0xLTEtMTYxMTg_8d2d38af-56e9-4614-937e-b4919667fcb2">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctMS0xLTEtMTYxMTg_3f11a997-d76c-4b0c-ab97-402421cf7a2d">26,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctMy0xLTEtMTYxMTg_f1b0d1b4-6356-45a8-a234-27605b2ce5ce">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctNS0xLTEtMTYxMTg_52560623-710a-4aea-8c03-abe9322dbb7c">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctNy0xLTEtMTYxMTg_c73904b6-4af6-4179-b338-7a74ac6eb22d">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53afd739da224f3588c2279414d4f677_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtMS0xLTEtMTYxMTg_a8dd3168-7129-4cb0-932e-aa5193c6e473">152,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53afd739da224f3588c2279414d4f677_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtMy0xLTEtMTYxMTg_2ef15eb1-c49c-42f9-880a-e7f108939e81">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53afd739da224f3588c2279414d4f677_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtNS0xLTEtMTYxMTg_f3d7360e-6854-4bc7-b2c9-3a1b6bf2a542">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53afd739da224f3588c2279414d4f677_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtNy0xLTEtMTYxMTg_c35271d1-674f-4752-8e11-b780f284e6f4">152,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ffd7bf37dc54260af141d63de115bf2">There were <ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzE2Mw_0d5b4802-548c-417b-a948-3a40dd17e956">no</ix:nonFraction> realized gains or losses for the years ended December&#160;31, 2021, 2020, and 2019.</ix:continuation>  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_160"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90ZXh0cmVnaW9uOmVmZWNjYTA4ZTE4YzQwMmQ5NmRjMDEwNTNmYzJmYjk3XzE1NzE_04f28c46-3fc5-42c2-a761-9797df7b354e" continuedAt="i7430d094cb564814a50d9ea3eb162d4e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i7430d094cb564814a50d9ea3eb162d4e" continuedAt="iec57461f4c7a4a0195af109af3d2b1e9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; significant unobservable inputs </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec57461f4c7a4a0195af109af3d2b1e9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90ZXh0cmVnaW9uOmVmZWNjYTA4ZTE4YzQwMmQ5NmRjMDEwNTNmYzJmYjk3XzE1NzA_bde55dfa-12cf-4f92-a73b-b98e44789367" continuedAt="i50a0485639f747c5bf956d31a8da4f0c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtMS0xLTEtMTYxMTg_5533248c-ad43-4e15-b5c3-d697d88d9ba9">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30138e6503c4ffda82b615c312c176c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtMy0xLTEtMTYxMTg_1152e110-64d4-4476-84e0-985b7f64f116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib964838f757842dc89d306cdb12966ee_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtNS0xLTEtMTYxMTg_f34aa5ca-2462-4090-a049-6ec5d3465081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtNy0xLTEtMTYxMTg_7781a67e-3b92-45e0-aad7-43067d65839f">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtMS0xLTEtMTYxMTg_e8ffd4c8-2edb-4178-b1da-03e0b9324181">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30138e6503c4ffda82b615c312c176c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtMy0xLTEtMTYxMTg_89d0884c-e3d6-467f-be16-e87e2140c96b">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib964838f757842dc89d306cdb12966ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtNS0xLTEtMTYxMTg_bbbb5524-b56a-437a-a138-c1848dff37e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtNy0xLTEtMTYxMTg_fb3ea934-f934-4e2f-8182-7364683eb049">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctMS0xLTEtMTYxMTg_8dbe360e-2120-4bf5-89e6-4f86b2892619">71,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30138e6503c4ffda82b615c312c176c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctMy0xLTEtMTYxMTg_f1ab9e78-78c8-42b9-9c56-5a90c4d3d69b">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib964838f757842dc89d306cdb12966ee_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctNS0xLTEtMTYxMTg_d803f396-24f1-42e3-b1a4-924b17d6fed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctNy0xLTEtMTYxMTg_ab7a2c56-bc8a-41c7-8ac1-adbee8b08c69">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:center"><ix:continuation id="i50a0485639f747c5bf956d31a8da4f0c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtMS0xLTEtMTYxMTg_1f307942-2f90-45a8-b0f3-18e9f5343076">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtMy0xLTEtMTYxMTg_9101a038-8b95-40b5-8183-84c0137cf744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtNS0xLTEtMTYxMTg_5613f448-4a4f-4972-9c8e-0720e4b19f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtNy0xLTEtMTYxMTg_08a9ce7f-08cb-444f-b1f0-0d21a8841fa1">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtMS0xLTEtMTYxMTg_8e8df265-6fa1-4f3e-8a0c-9f7e53ad276b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtMy0xLTEtMTYxMTg_120c080d-36ce-4cdf-afd3-b155faf4d161">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtNS0xLTEtMTYxMTg_9e4f73ce-aaf2-4f31-9d56-f9e9082f021a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtNy0xLTEtMTYxMTg_1f53db77-2761-4397-83cf-ac68f67263b2">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctMS0xLTEtMTYxMTg_f1657d8b-571a-47e7-a1bb-3c56aa49d851">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctMy0xLTEtMTYxMTg_b789d0ef-5d17-43ac-b82a-ef7eb86d1b22">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctNS0xLTEtMTYxMTg_09530ec6-34fa-4773-b265-14b13a66d86c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctNy0xLTEtMTYxMTg_d27ac6f2-026c-452c-be73-0a84748c034a">152,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2021 or 2020. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_163"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzUwNg_ae81d0cc-8f46-4cb1-a5e6-130aaa7b8c98" continuedAt="i4e62393ee0934631abbca0c1e4358b90" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i4e62393ee0934631abbca0c1e4358b90"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at December&#160;31, 2021 and 2020 are as follows:</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzQ5NQ_8628f96b-f7df-4c22-aeb4-5ac6ea0c84f6" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic29f411a667c4474b294d320f9ebcb4f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjpiYjRmY2MwZDg0MDg0ZTRkYmRhM2QyYWVjZjJiMzE3OF80_38158472-4933-4169-8634-70878d7b9f06">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i251665a0c7944e8d9bb8853d049ed549_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjpiYjRmY2MwZDg0MDg0ZTRkYmRhM2QyYWVjZjJiMzE3OF83_5759aaa8-e5ec-4f1f-95ee-2471efa8c0a1">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535698f3d692460b81cba7884c86e4e2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtNS0xLTEtMTYxMTg_c9c18cfb-964c-4e87-97d8-4649ae6415d9">3,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1397c77d1b6f4185845e1699cd219089_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtNy0xLTEtMTYxMTg_a6cccb54-4885-4949-9d4a-297bc989b4af">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c9e7435336a44558427742a97851cad_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo2YzM3M2I5ZGU1M2M0N2YzYjI4MTkxNjFkNDg3MTM3Ml80_9285a313-7717-42e6-b918-4e7af3f60562">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i30aff4dded0c44ae865d00df32ebe612_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo2YzM3M2I5ZGU1M2M0N2YzYjI4MTkxNjFkNDg3MTM3Ml83_8143f694-2a39-4cd0-b2ef-c680f93dccd2">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eced0a8b11146888768ff4b14b2f375_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtNS0xLTEtMTYxMTg_a22ee8d5-3242-495e-b9d2-b38042f0fbb8">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4455ddb6c214da7961fd95cd24842c2_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtNy0xLTEtMTYxMTg_ddf5019a-f29a-42f4-b0f5-9e9c0bdbe931">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic47c902d195d41518cadfff77db8830a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo1ZjAxZmZmZjc4MTY0OTk1YmY1Y2QzN2I3Y2Y1MTk5NF80_3c74bc33-20f0-4dc6-bb68-25f919f4e341">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ib99f027008024261ace720d15f140e6b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo1ZjAxZmZmZjc4MTY0OTk1YmY1Y2QzN2I3Y2Y1MTk5NF83_766ad0a2-9add-40a7-aa3e-af40a93f97ee">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815538a41da140838b0cb583686e2574_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtNS0xLTEtMTYxMTg_aba35a33-de5e-434d-935b-5bb0016b7ba5">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b5aed98e3345b39cf920b0e50e105d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtNy0xLTEtMTYxMTg_84c03a81-e4d7-4490-8521-de7f64132123">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzktNS0xLTEtMTYxMTg_ebb86b0b-7439-4be1-89f9-405915f2d3c6">6,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzktNy0xLTEtMTYxMTg_8298c6fc-076e-4aaf-8479-943c30f64847">6,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzEwLTUtMS0xLTE2MTE4_b3c4ef20-6454-42fc-8c89-8438b427060b">4,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzEwLTctMS0xLTE2MTE4_dd3be792-e5e2-44e6-a6fb-1f7f95be88e8">5,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzExLTUtMS0xLTE2MTE4_4127cf54-3c9a-444b-afd8-c4fd32b58c97">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzExLTctMS0xLTE2MTE4_6d1aa359-753d-4bbf-9a5b-783d79602ec5">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, the Company&#8217;s subsidiary, Lex-Gen Woodlands, L.P., sold its facilities in The Woodlands, Texas for $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIwNg_b0e93510-4a4d-4baa-9ad5-098f8508b41e">11.9</ix:nonFraction> million. The land had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="6" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzI0Mw_b8d12613-0dc8-4ea3-adea-1c692e137b37">2.7</ix:nonFraction> million and buildings and related assets sold had a net carrying value of $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="6" name="us-gaap:InventoryBuildingsAndImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzMxMg_8ed30196-d4c8-41df-a8b8-71864d0920e4">7.9</ix:nonFraction> million.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the sale, the Company entered into a leaseback agreement with the purchaser with respect to a portion of such facilities for a period of up to six months.  In connection with the sale, the Company recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTYyODE_66ab80c1-0172-49f8-9300-dd716284e644">1.6</ix:nonFraction>&#160;million to reduce the carrying value of the assets to its estimated fair value, less estimated selling costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2021, the Company retired $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="6" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTY3NzM_d5c597b9-d79e-403c-9bd8-3d5dff6958db">1.3</ix:nonFraction>&#160;million of computers and software and furniture and fixtures, which had been fully depreciated. During the year ended December 31, 2021, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTY4NDQ_45dd8502-121b-453c-a096-2d162d7b7a14">1.2</ix:nonFraction>&#160;million of assets comprised of leasehold improvements, computers and software and furniture. The leasehold improvements are being amortized over the lease term.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwODg_037d2a69-7100-4b80-bc9e-3414d1bc72cd" continuedAt="ib0951d329cef412fa667a3a5ab5e3d5a" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ib0951d329cef412fa667a3a5ab5e3d5a" continuedAt="i78d77ac4eeb94108a428e9e21f99f477"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted on March 27, 2020 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws. For the year ended December 31, 2020, the impact of the CARES Act was immaterial to the Company&#8217;s tax provision. Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2021 and 2020 are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwNzg_91643caa-29f4-446d-a589-983d815455c4" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzQtMS0xLTEtMTYxMTg_039eded5-9d10-4da5-b5e3-face5790eaea">229,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzQtMy0xLTEtMTYxMTg_d8d784d9-3fe9-4f8f-8325-c249d6f9d583">201,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzUtMS0xLTEtMTYxMTg_79f7f048-e04e-496c-a0d6-60ee9f4a0664">29,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzUtMy0xLTEtMTYxMTg_52379834-8090-4cc8-977e-78460c82e633">29,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzYtMS0xLTEtMTYxMTg_ba37f443-c5e7-4052-add1-f7558060aec1">24,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzYtMy0xLTEtMTYxMTg_e2e8649b-81c6-4fd8-ba29-55924e4abb09">24,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzctMS0xLTEtMTYxMTg_151ddf7c-efcf-4d01-b62a-78178eeb8f10">36,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzctMy0xLTEtMTYxMTg_b3983c9a-9f61-4fec-9bda-c3be06cfa157">47,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzgtMS0xLTEtMTYxMTg_adac7299-5b53-4ed1-bc5d-9947fbf13782">5,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzgtMy0xLTEtMTYxMTg_43e072b6-db5c-4f6b-8464-f4664467b5bc">5,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:DeferredTaxAssetsSection163j_LXRX" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEwLTEtMS0xLTE2MTE4_2fae5dd4-0664-49ff-a143-e712258aa983">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:DeferredTaxAssetsSection163j_LXRX" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEwLTMtMS0xLTE2MTE4_f2710c4c-127f-44f6-a447-f8b7d74c75f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzExLTEtMS0xLTE2MTE4_ea3892b7-53e1-4acd-8494-56c292b07621">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzExLTMtMS0xLTE2MTE4_84f810c9-ce02-48c5-bf0a-48694eca9b0a">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEyLTEtMS0xLTE2MTE4_14aac96c-d19c-456c-b870-b455e3af6b6e">326,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEyLTMtMS0xLTE2MTE4_89dd4c9f-4448-4444-8518-ce7c83e5f307">309,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE1LTEtMS0xLTE2MTE4_af00acb8-ab5f-4e73-9d78-cb0f011b5351">412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE1LTMtMS0xLTE2MTE4_a1a041a4-a17f-4b81-bd92-6385e8a64b7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE2LTEtMS0xLTE2MTE4_19c10c53-0015-4a14-9aeb-3e4e28436c56">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE2LTMtMS0xLTE2MTE4_980972f9-4dff-495a-9eed-8bfbebfcde09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE3LTEtMS0xLTE2MTE4_d658a1c7-20c5-43e8-8953-2dbb91f7676d">326,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE3LTMtMS0xLTE2MTE4_615d176c-4a58-4824-91c6-2bafd89cb345">309,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE4LTEtMS0xLTE2MTE4_28cfd9f6-6205-416d-b089-2850b279c76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE4LTMtMS0xLTE2MTE4_1b9bbc37-1812-485d-9699-41d9d3aadec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i78d77ac4eeb94108a428e9e21f99f477"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwNzk_8f7aa163-c26b-4cb4-855d-b41774a31f46" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2021, 2020 and 2019 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:51.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjoyN2JhZjdlNjE3ODI0NGJjODg1MWQxYzhmN2VhNWMyNF80NQ_b7ca6868-328d-4999-a614-5d844dc3a983">21</ix:nonFraction>%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMS0xLTEtMTYxMTg_d183d9f5-ae42-4982-a93b-75dc1566f1f2">18,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMy0xLTEtMTYxMTg_f7801f1d-cb8e-4f27-9583-ff021566c374">12,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtNS0xLTEtMTYxMTg_6c43c228-346b-434a-80e9-522f1e850239">26,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtMS0xLTEtMTYxMTg_42daeed8-e20c-4b99-a652-c193af26c656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtMy0xLTEtMTYxMTg_55297f35-5a38-4abc-b07d-c3f741281074">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtNS0xLTEtMTYxMTg_3b9ac82b-887b-41fa-801e-fc887aea76d0">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtMS0xLTEtMTYxMTg_0fda4f4d-4bda-42e5-871d-6bd33d2a625e">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtMy0xLTEtMTYxMTg_8f96af07-db43-4efa-94b3-f40f6c49e51d">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtNS0xLTEtMTYxMTg_b3987044-0792-4e85-92b6-ea892a8a0eee">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="lxrx:WriteOffOfTaxCredits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzExLTEtMS0xLTE2MTE4_e8f38f32-f8fa-462b-a7a8-de74805ef48d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:WriteOffOfTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzExLTMtMS0xLTE2MTE4_e49e3e89-9298-4aa2-a45c-4cc6b0170771">31,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTEtMS0xLTE2MTE4_dbffe84c-41f0-45c0-a873-4ea4e83e007a">17,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTMtMS0xLTE2MTE4_1136546f-ec31-4734-af9d-1fbd60993da9">20,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTUtMS0xLTE2MTE4_562c340b-6cd0-49bc-b9a6-8e08ea2cf27f">35,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTEtMS0xLTE2MTE4_2de37996-828d-4b29-89c7-580ed57ec199">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTMtMS0xLTE2MTE4_c985a38e-5986-4251-b6b6-583c6f737662">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTUtMS0xLTE2MTE4_9ca0eb9a-faae-40d5-805a-02647ea130ed">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTEtMS0xLTE2MTE4_cc66284b-21a1-46ee-b48e-edac6207d738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTMtMS0xLTE2MTE4_2829dabb-4e80-4a33-9a22-05cc6904ea9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTUtMS0xLTE2MTE4_f30eb1c6-eb68-4e17-8895-3f75b91e6b84">6,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019 and nondeductible expenses for the years ended December&#160;31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#8220;ownership change.&#8221; An &#8220;ownership change&#8221; is generally defined as any change in ownership of more than 50% of a corporation&#8217;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2021, Lexicon had both federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI4ODY_e0c34323-aa58-4f94-a0c3-a0417e7f204a">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI4OTM_73fd6457-a759-4b25-9b1b-3bdeb7731ef2">86.9</ix:nonFraction> million, respectively.&#160;&#160;In 2021, federal NOLs increased by $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-5" name="lxrx:A2020FederalNOLIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI5NDc_1b0f3aee-59e5-471d-9acd-01b32527ffbe">132.7</ix:nonFraction> million related to a current year NOL. The Company had $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzIxOTkwMjMyNjIyMjk_74bd011e-3d0f-40db-8d04-040fc08611d6">342.0</ix:nonFraction> million of U.S. federal NOL carryforwards as of December 31, 2021, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2021, the valuation allowance increased $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzM3Nzc_3be33780-386e-4ba8-9c00-6902a37417bf">17.2</ix:nonFraction> million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021 and 2020, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwMDc_1daed868-f5f3-4b9b-88cd-f98771d95c92"><ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwMDc_dfd5edc2-b014-435a-a4e3-9c1d04229bf7">no</ix:nonFraction></ix:nonFraction> accruals for interest or penalties related to income tax matters.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzEzMTI_0348dffd-f304-4edd-86ea-153251e3c192" continuedAt="i6c5ecfe2aac74058abb52fb218767c45" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="i6c5ecfe2aac74058abb52fb218767c45" continuedAt="i06ce052475544b53a2b95e7360d7a552"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="ic1e10dc122274204badbada626c6296e_I20010712" decimals="-5" name="lxrx:CoelacanthGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzQ2NQ_e02ee4d4-2ca3-4e91-8fe6-804da54b449a">25.8</ix:nonFraction> million, which represents the excess of the $<ix:nonFraction unitRef="usd" contextRef="ic1e10dc122274204badbada626c6296e_I20010712" decimals="-5" name="lxrx:CoelacanthPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzUwNA_4743ac1a-300e-4250-9518-bf89228be944">36.0</ix:nonFraction> million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i06ce052475544b53a2b95e7360d7a552"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="i5170da333de84c9ab9e1c854f5a3f263_I20100730" decimals="-5" name="lxrx:SymphonyIconGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzc5Mg_c1bc86a9-0fad-4364-9d8f-e1612ae470c9">18.7</ix:nonFraction> million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzcwODE_df049125-f995-46a8-8927-2a0671770e56" continuedAt="ic1bdd740bd51472f8ee13f74c380b48e" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="ic1bdd740bd51472f8ee13f74c380b48e" continuedAt="i14c65f76365d425c9fbbf73df928dd24"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzk4_927c27ba-b2f4-4d8e-8b69-8af8df3b1c93">87.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzEzOA_8ef23d71-0249-49e7-952e-53d0f3e0442d">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzIxOTkwMjMyNjU3MTM_8ef23d71-0249-49e7-952e-53d0f3e0442d">5.25</ix:nonFraction>%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzUzMQ_d0ec37cb-301c-4f55-88af-85b3d3ac5988">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at <ix:nonFraction unitRef="number" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="INF" name="lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzYxNA_36ff23bb-827f-4f36-a111-c45c6239aa21">85</ix:nonFraction>% of the principal amount of the Convertible Notes.  In 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="0" name="lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5NA_60357527-55b0-49c7-a236-375bd3991b39">10,368,956</ix:nonFraction> shares of the Company&#8217;s common stock and paid $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:ConvertibleDebtExchangeTotalCashConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzc0Mw_16b52776-69d8-49cd-9e39-3bb8987ec105">50.0</ix:nonFraction> million in cash, which included $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:A2020ConvertibleDebtExchangeAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzc3MA_9a325423-9252-4abf-941a-b1b8b38bf2c0">1.3</ix:nonFraction> million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:ConvertibleDebtExchange" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzk5Ng_69459633-8caf-4683-b302-e5a20ea42697">9.6</ix:nonFraction> million was recorded and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.  As of December&#160;31, 2020, the carrying value of the remaining Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzExOTQ_fefc9540-3397-46f4-8a14-9c26b623d883">11.6</ix:nonFraction> million. In December 2021, the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzIxOTkwMjMyNjI4MjM_fefc9540-3397-46f4-8a14-9c26b623d883">11.6</ix:nonFraction>&#160;million was repaid in cash.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Convertible Notes, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130" decimals="-5" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMxMTg_f2bc040f-d727-4c15-9cf4-22663be5c58b">3.4</ix:nonFraction> million of debt issuance costs.  The debt issuance costs were amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMzNjA_fd6c9083-ac60-4aa0-af6d-eabe40774af9">seven</span>-year term of the Convertible Notes.  There are no debt issuance costs as of December 31, 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with <ix:nonFraction unitRef="usd" contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831" decimals="INF" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQyMDg_19001bca-aee0-4a90-8f18-980afb58d03a">no</ix:nonFraction> recognition of gain or loss on the transaction.  The loan agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="-5" name="lxrx:MortgageDebtInstrument_Revere_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQyOTQ_176f013c-52be-4253-b473-97844501c745">12.9</ix:nonFraction>&#160;million mortgage on the Property and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzMzI_73bd8c0d-44ee-40f0-9385-b10f02c7cfec">two</span>-year term with a <ix:nonNumeric contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzNTI_476ec688-ef00-4bb2-a978-bcade737d69f">10</ix:nonNumeric>-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0ODE_10b6e18d-a501-45bd-a6ef-b19b10de4223"><ix:nonFraction unitRef="number" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0ODE_eb7473d0-c9c3-4db5-96a4-b93304fb528f">5.5</ix:nonFraction></ix:nonFraction>% and (b) <ix:nonFraction unitRef="number" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0OTE_0c2e1c95-e1ea-4ed5-99d6-cbea90421ec2"><ix:nonFraction unitRef="number" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0OTE_48684574-62c3-492d-8670-663c1a5521ba">7.5</ix:nonFraction></ix:nonFraction>% and provided for a balloon payment of $<ix:nonFraction unitRef="usd" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="-5" name="lxrx:MortgageDebtBalloonPayment_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ1MzI_395476ac-626e-42c2-af9c-9979cedfc870"><ix:nonFraction unitRef="usd" contextRef="i74800149cb834920a98e1fed9979820d_I20180830" decimals="-5" name="lxrx:MortgageDebtBalloonPayment_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ1MzI_8cd61fce-ef7b-4ce3-bcb7-765692968589">10.3</ix:nonFraction></ix:nonFraction>&#160;million, which was paid in full in August 2020.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LP under which $<ix:nonFraction unitRef="usd" contextRef="ia89421ae837f48509b4bf1206d468d61_I20171218" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ4ODI_c65566de-a213-401e-95fb-39786aca5c53">150</ix:nonFraction> million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at <ix:nonFraction unitRef="number" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzUwMjY_72f5b0b0-47f8-4ecb-bb31-dfff68760e57">9</ix:nonFraction>% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO Sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. </span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14c65f76365d425c9fbbf73df928dd24">In connection with the BioPharma Term Loan, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia89421ae837f48509b4bf1206d468d61_I20171218" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY2NjQ_372bafff-21b7-4c32-8717-338202a7044a">4.1</ix:nonFraction> million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5MTU_7b0c5791-d8c3-4747-83ec-263e9d8b54d5">five</span>-year term of the BioPharma Term Loan.  There are no debt issuance costs as of December 31, 2021.</ix:continuation>   </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_175"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzQ4NzM_cd61fe52-c476-4b6e-a113-96774abb6854" continuedAt="i4cf947c2cc224df1a0a1b410e0b4e965" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4cf947c2cc224df1a0a1b410e0b4e965"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include leases of office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.  As of December&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5MzI_3bf1b265-bddb-4ac7-a7b8-f563cfa3c39d">2.3</ix:nonFraction> million, which is included in other assets in the consolidated balance sheet. Current and non-current liabilities relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5NTE_702c3b3f-4e92-4638-839a-b6c8fa72bc86">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5NjY_76bc52b7-e4ef-48bd-a6c4-601851509707">1.2</ix:nonFraction> million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2021:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzQ4NTc_8ecf463d-03e5-4eca-8ade-5ae054203d5e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzItMS0xLTEtMTYxMTg_7f2cf2be-9c66-4bb3-9085-ef9a4454e631">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzMtMS0xLTEtMTYxMTg_7470dc06-0873-425d-8abf-dc54bbc80416">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzQtMS0xLTEtMTYxMTg_3860d2e6-b730-4e33-8f5c-b980548b451e">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzUtMS0xLTEtMTYxMTg_961ed188-7a8b-49bc-8940-ad1e3d1281b0">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzYtMS0xLTEtMTYxMTg_ea60de7f-a451-4464-9f59-f3a14144c443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzctMS0xLTEtMTYxMTg_cd1b01f5-4c54-4631-9c4b-3927560eddd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzgtMS0xLTEtMTYxMTg_7e5627cc-a1a6-460c-9c63-073f78829104">2,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="lxrx:InterestOnLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzktMS0xLTEtMTYxMTg_be572f06-eaa6-45f4-952c-d00a2e92648f">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:PresentValueOfFutureLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzEwLTEtMS0xLTE2MTE4_8243d757-2221-46aa-b34d-d7ee3d90cb28">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzExLTEtMS0xLTE2MTE4_a8955f3e-31c6-4ec7-8f16-edb1aa901b1f">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzEyLTEtMS0xLTE2MTE4_0359bc86-a644-4278-8a29-e9f085b5c8bb">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Arrangements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NDQ_e22aa56a-ed2a-4ea4-b4d9-85a943d8c4ac">six</span> or <ix:nonNumeric contextRef="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NTA_4b3707de-d7ee-41f1-8fb5-014b35718f19">12</ix:nonNumeric> months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_178"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUxMTE_37efda2c-af91-4a22-b7ed-0b3bef50392b" continuedAt="i45249d9f02cc440ea8a330a94afa341f" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="i45249d9f02cc440ea8a330a94afa341f" continuedAt="ibbd8d9a7945b4776b7f9e29301589d10"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of <ix:nonFraction unitRef="number" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzY2OA_7179aae1-3c71-4c92-807a-2ccedd3121d7">100</ix:nonFraction>% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of <ix:nonNumeric contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzg2Mw_dc9564a6-56c3-4cc0-821c-aa1a889f2b73">four years</ix:nonNumeric>; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of <ix:nonNumeric contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwMDI_7a151c3a-62a7-4270-b4a9-de4b7161a1de">ten years</ix:nonNumeric> from the date of grant.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzExODY_11b09fae-7ab3-43e3-951d-4800670d5958">30,000,000</ix:nonFraction> shares at December&#160;31, 2021.&#160;&#160;As of December&#160;31, 2021, options to purchase </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibbd8d9a7945b4776b7f9e29301589d10" continuedAt="i7ce1942e3fdf47a28d0bfed68b93b5ba"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:OptionsOutstandingEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0MDc_8779f269-e2e3-404b-970a-2ad315ae042d">7,958,179</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0MjE_65b04ac4-eb5b-4ccf-a33a-03a01a34e287">1,822,043</ix:nonFraction> restricted stock units were outstanding, <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:StockOptionsExercisedEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0NjU_56817524-0120-4391-8a9e-93a81982be49">2,285,702</ix:nonFraction> shares had been issued upon the exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE1Mjc_361594c8-ee57-4e3c-a01a-03c2f0a5c643">4,314,948</ix:nonFraction> shares had been issued pursuant to restricted stock units and <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE1OTI_45aae404-5f14-43ba-8919-b6caad4e37cf">113,940</ix:nonFraction> shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:Totalvalueofsharesbynonemployeeinayear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzIxMjQ_40acda60-791d-411e-bb3a-fe79977c0da0">500,000</ix:nonFraction> during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of <ix:nonNumeric contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI0NzY_d08804a7-c71b-403f-90e5-36abf48e80b7">ten years</ix:nonNumeric> from the date of grant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI2NTI_e7f752af-ae22-4277-9660-83d04f78b16a">1,200,000</ix:nonFraction> shares.&#160;&#160;As of December&#160;31, 2021, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3MDA_5b08c130-8b98-4986-9b50-5878d6e76769">408,864</ix:nonFraction> shares were outstanding, <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-3" name="lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3Mjg_b0f2ca8f-af37-471d-bee0-3c9a62cd8d34">none</ix:nonFraction> had been issued upon the exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3ODM_0f095ee3-8265-4d2b-b62b-c18a9d9fa233">32,192</ix:nonFraction> restricted stock units were outstanding and <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI4MzA_db3f7285-18ce-49fd-9e06-05bf94971bdb">216,040</ix:nonFraction> shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#8217; Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUxMDE_560589b3-05bf-4401-a4cd-d972123c66b2" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMi0xLTEtMTYxMTg_b483e976-6db9-47a3-b283-69fbd4008c5b">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItNC0xLTEtMTYxMTg_76d7cb3e-9507-46be-b482-89c0aed50f4a">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItNi0xLTEtMTYxMTg_32f367c5-1730-47f0-9941-6e02d18ed6f6">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItOC0xLTEtMTYxMTg_f34cb41d-a8e1-4b30-ae3f-422d05614b18">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMTAtMS0xLTE2MTE4_dfe54926-d3d5-4587-ab71-54a8b76375f2">6,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMTItMS0xLTE2MTE4_d137d19b-15cd-4acc-a150-180b11d5ae0e">10.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMi0xLTEtMTYxMTg_6a27f2dc-736f-4aae-a6ea-76f68edf87ae">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtNC0xLTEtMTYxMTg_39a976db-3c2f-497a-af13-d6fe701dab7d">6.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtNi0xLTEtMTYxMTg_114afb42-b4c6-4cad-bcc2-4329891eb21a">3,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtOC0xLTEtMTYxMTg_3085831c-aa5a-4202-bdec-4583bdaf2c23">3.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMTAtMS0xLTE2MTE4_22d31dc7-2b1d-4bd9-bf20-06d445599439">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMTItMS0xLTE2MTE4_73247290-b7d1-4a9c-9157-92a3204e40c1">5.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMi0xLTEtMTYxMTg_7f1a2281-62e3-4629-ac48-b1d8b664ef0f">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtNC0xLTEtMTYxMTg_3ae6aa90-82f4-4add-987f-66e0c8424370">4.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtNi0xLTEtMTYxMTg_003f8ee7-ddd7-4592-bb28-cf030941b48b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtOC0xLTEtMTYxMTg_9b499bad-1910-4e5d-a027-99a6bc75cb84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMTAtMS0xLTE2MTE4_27c6360d-f9cb-4aaa-a9af-0212c2cd509f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMTItMS0xLTE2MTE4_c1a3800f-c278-48d3-8313-e6d0594ca33f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMi0xLTEtMTYxMTg_6b0ef146-22aa-4ea4-b6a5-8ae344445ae0">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtNC0xLTEtMTYxMTg_033f8fbb-ceb7-4193-a424-a698a8e859ae">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtNi0xLTEtMTYxMTg_45024855-0d83-41dc-98c1-738a22438960">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtOC0xLTEtMTYxMTg_961c432e-929a-46e7-9f27-e92d01ec8468">12.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMTAtMS0xLTE2MTE4_f7b3ae8e-ea1a-4514-b43c-9bf823b7c397">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMTItMS0xLTE2MTE4_a97d89ce-311f-421d-bbb5-da8790334dbb">9.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMi0xLTEtMTYxMTg_741fee69-44ef-4ea7-b0d5-2f9d76263afb">1,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtNC0xLTEtMTYxMTg_c40d5c55-eb0d-4211-8d12-34e7938571b1">8.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtNi0xLTEtMTYxMTg_07a45c33-249c-4907-a8ba-7855575b9733">2,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtOC0xLTEtMTYxMTg_f4e3cd92-5949-43c6-b307-9dc5f6f96d37">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMTAtMS0xLTE2MTE4_25b34d28-8972-42fd-ad36-d3f583103fe3">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMTItMS0xLTE2MTE4_5e1d7369-0d56-4f06-97dd-11f1798b7b66">10.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMi0xLTEtMTYxMTg_cb396750-9a43-4363-bde5-d8532143996c">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctNC0xLTEtMTYxMTg_8887fa06-29f2-435f-a607-d6ae3888ec71">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctNi0xLTEtMTYxMTg_853368e2-fc4a-42cc-9926-2c61ed234401">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctOC0xLTEtMTYxMTg_9e9a8119-615b-417e-9dc5-817f17fc492d">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMTAtMS0xLTE2MTE4_85a8f282-9372-418b-bc25-0483b369e571">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMTItMS0xLTE2MTE4_0b373670-7416-42de-a9d4-56e9c2759d7c">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMi0xLTEtMTYxMTg_c3af105c-a33a-49c3-97f8-c8c057cd9636">5,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtNC0xLTEtMTYxMTg_fcaf30ff-5b27-4f4f-8045-2ce56a036735">7.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtNi0xLTEtMTYxMTg_8ce33c6e-8557-4cb6-8e39-1cd0687c32f3">4,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtOC0xLTEtMTYxMTg_6410e952-47fa-4540-9c87-79987baa4d62">9.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMTAtMS0xLTE2MTE4_244049ac-33ec-49c4-8779-f47cba626693">4,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie941169ab2164798abaed9016c336c29_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMTItMS0xLTE2MTE4_abcf5734-b19f-4e30-9d65-312554f25ba2">10.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMxOTQ_204054eb-e6a0-4f03-8e29-a22787e9d7ef">4.85</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMxOTg_35c94a9e-981a-4e5e-89b3-c81c2667842a">2.35</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMyMDU_cb5c1395-08b8-4130-94fc-48d213c9dd8a">3.18</ix:nonFraction>, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMzMDY_9f129f4b-d716-4908-b9ef-df72a4db0e42">0.6</ix:nonFraction> million.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM0MDg_5fd8d6f3-66fc-4f60-b2a8-0edd8a1f97c4">6.7</ix:nonNumeric> and <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM0MTU_88344008-9931-4279-a5c3-750947642f54">5.3</ix:nonNumeric> years, respectively, as of December&#160;31, 2021.&#160;&#160;At December&#160;31, 2021, the aggregate intrinsic value of the outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM1MjQ_9afca810-d273-4601-8f2b-5b4bf6cabc36">1.8</ix:nonFraction> million.  At December&#160;31, 2021, the intrinsic value of exercisable stock options was $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM1ODk_8292c509-ac39-47cb-b87b-96ead311615f">0.7</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQzMjM_2603f12e-430e-4fbf-beee-195251baa8fe">three</span> annual installments.  The total fair value of shares vested in 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MDc_6c75ab25-d68e-41e3-bab8-4cb2c2b274a3">8.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MTE_da7918b2-19d2-405c-904a-5c1d7f83ff3e">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MTg_0d8f7b37-d218-4ff6-946a-7ad248908e75">2.9</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its non-employee directors <ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3NzU_cbbd1912-b8bd-412c-8345-8224231f2b7f">32,192</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3ODA_aee04487-0bb3-40a6-9d5b-6dbf3f96a402">85,104</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3ODg_4541fd5d-1cd1-4906-8b65-f0d875be3dc6">27,728</ix:nonFraction> restricted stock units, respectively. The restricted stock granted in 2021, 2020 and 2019 had weighted average grant date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5MjY_516e5070-79c4-49b9-94d7-349ebea86fb9">5.04</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5MzE_38c90c90-fc10-4f8a-aae0-6900c9faf804">1.86</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5NDA_f4706135-365b-43e8-af5b-5f15ba3bc75f">5.67</ix:nonFraction> per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ce1942e3fdf47a28d0bfed68b93b5ba"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2021:</span><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUwOTc_b9679a9a-a2d6-492b-96d6-9460bd2e3e27" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89e3823a40a049809c8d559277e562bd_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzItMi0xLTEtMTYxMTg_ede633bb-9b19-45ee-843f-4fda1315f45e">2,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89e3823a40a049809c8d559277e562bd_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzItNC0xLTEtMTYxMTg_78166cd0-78e6-49dd-939d-65be8e4d64fa">4.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzMtMi0xLTEtMTYxMTg_89458ba2-2fcc-4c6b-86e3-62b185b21a69">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzMtNC0xLTEtMTYxMTg_3a4890c1-d044-474b-80f3-306ff09ad226">8.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzQtMi0xLTEtMTYxMTg_7048eca2-1c4d-4ecd-bbe2-c091c306490a">1,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzQtNC0xLTEtMTYxMTg_bc4fb6ac-1fd9-4091-a6b4-e01d512d3724">5.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzUtMi0xLTEtMTYxMTg_534484e6-7fa1-4817-b4c8-0e04fc018c92">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzUtNC0xLTEtMTYxMTg_38cddeb4-1c65-4fe8-ab60-997a3f47624a">5.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00be06ddbff74be8bbf65ceefcef5599_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzYtMi0xLTEtMTYxMTg_b8f04fcf-66e0-4231-b8b7-ede0ddd77b41">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00be06ddbff74be8bbf65ceefcef5599_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzYtNC0xLTEtMTYxMTg_8a18fced-530e-4cd5-95f3-419dd81bdebc">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, an aggregate of <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ2Mzk_f8360baf-74b0-43e9-b221-ab39fa6d1af9">10,221,278</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and <ix:nonFraction unitRef="shares" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ3ODk_ca08b55e-ab20-4143-85f1-e236fdb19b8c">14,048,092</ix:nonFraction> additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzY0NA_3d2d2fc8-5af2-4677-98d3-b7b4e3654b6f" continuedAt="i7c00f696fe3345368efe8c716dfb864c" escape="true">Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="i7c00f696fe3345368efe8c716dfb864c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ2Ng_88cf4af6-3de5-4598-a1c3-fae83e943d7a">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ3MA_a5ab5bfa-a916-4121-9399-c784a1e31047">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ3Nw_b66ea91b-4ea3-4070-8f75-9fab1674e036">1.2</ix:nonFraction> million in the years ended December&#160;31, 2021, 2020 and 2019, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="lxrx:DefinedContributionPlanRequisiteServicePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzYyOA_20a48ff5-0cff-40d8-920b-1a7f1bd20a97">four years</ix:nonNumeric>  of service.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NzE4_5fa9bf77-1061-4cc2-879e-463d8435e832" continuedAt="i37339a75a1264411988d1720ad291cb2" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i37339a75a1264411988d1720ad291cb2" continuedAt="i070e7c59ec1d4d5483cf335c4bcad860"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231" decimals="-5" name="lxrx:IpsenTotalPaymentsToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4MDA_4d4ad066-9099-49fa-9d8e-073dd9518131">47.2</ix:nonFraction> million through September 30, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized under the Agreement was $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="lxrx:IpsenRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc3MzY_a14a6477-106c-4cb6-a198-b58541b13a5b">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-5" name="lxrx:IpsenRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc3NDA_1281ec1c-59e1-44bd-a761-8be4a0b71e03">4.9</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively.  Revenue for each of the years ended December&#160;31, 2020 and 2019 included $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="lxrx:IpsenRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc4NTg_a14a6477-106c-4cb6-a198-b58541b13a5b">0.3</ix:nonFraction> million of royalties from Ipsen. Revenue for the year ended December&#160;31, 2019 included $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-5" name="lxrx:Ipsenproductsales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc5NDM_982ed8ef-bb86-4a11-b026-a67cb02ea142">1.3</ix:nonFraction> million from sales of bulk tablets of XERMELO to Ipsen. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i070e7c59ec1d4d5483cf335c4bcad860" continuedAt="ida746b20963d40f3929fdd78e8a2aae9"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development and commercialization of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#8220;Termination Agreement&#8221;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:SettlementPaymentFromTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzg5NDA_481efb46-1ebc-4afc-83ee-4840be377aa4">208</ix:nonFraction>&#160;million in September 2019, $<ix:nonFraction unitRef="usd" contextRef="i721b502840b14174be6cc3a22bfa99fd_D20200301-20200331" decimals="-3" name="lxrx:SettlementPaymentFromTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0NDA_c1426be0-e544-4e84-8019-1136835ef446">12.1</ix:nonFraction>&#160;million in March 2020 and $<ix:nonFraction unitRef="usd" contextRef="i13c3e38005194277b23efa2e68887d55_D20200901-20200930" decimals="-3" name="lxrx:SettlementPaymentFromTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0NjA_1e86ac40-100b-4f25-ab70-474c48df62de">2.7</ix:nonFraction>&#160;million in September 2020.  An arbitration panel issued a judgment in Sanofi&#8217;s favor in November 2021 with respect to a dispute regarding amounts withheld by Sanofi from its March and September 2020 payments offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable under the terms of the Termination Agreement.  Such judgment obligates Lexicon to reimburse Sanofi for its attorneys&#8217; fees and costs relating to the arbitration proceedings, which could require a payment up to $<ix:nonFraction unitRef="usd" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0OTg_fea1dc6e-9f51-48e3-bffa-ad8c76de3024">2.1</ix:nonFraction>&#160;million. Neither party will owe any additional payments pursuant to the Sanofi Agreement or Termination Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes and heart failure.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida746b20963d40f3929fdd78e8a2aae9">Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130" decimals="-6" name="lxrx:SanofiUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTAyNzk_3158ab5c-038d-4309-b140-57d820fe92cf">300</ix:nonFraction> million in December 2015. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130" decimals="-5" name="lxrx:SanofiRevenueAllocatedtoLicenseDeliverable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4NzYx_18f8127f-e1a9-4515-b71d-4fa7d8e981d4">126.8</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130" decimals="-6" name="lxrx:SanofiUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4Nzcx_3158ab5c-038d-4309-b140-57d820fe92cf">300</ix:nonFraction> million upfront payment for the license in 2015.  The Company was recognizing the $<ix:nonFraction unitRef="usd" contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130" decimals="-5" name="lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4ODQ4_700f3fdc-515f-4b5c-a8db-30191590d17b">113.8</ix:nonFraction> million allocated to the development services performance obligation and the $<ix:nonFraction unitRef="usd" contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130" decimals="-5" name="lxrx:SanofiRevenueAllocatedtoFundingDeliverable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4OTIw_e944bb7d-f0de-4b82-a7f4-8b8c5d5e2f62">59.4</ix:nonFraction> million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:SanofiDeferredRevenueFromTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5MjMy_0465d7fb-2501-4c2b-98b9-a394549bdccc">23.5</ix:nonFraction>&#160;million allocated to its performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="lxrx:SanofiTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NDA1_b70a40a8-f381-48d5-9a36-b4b8e5bd2038">260</ix:nonFraction>&#160;million, representing the full expected cash consideration from the Termination Agreement.  Subsequent to the Termination Agreement, the Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $<ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-5" name="lxrx:SanofiRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NjU5_dc42da68-9694-4a3a-8eda-8afcaf491cb1">286</ix:nonFraction> million for the year ended December&#160;31, 2019.</ix:continuation> &#160;</span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_187"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzgwMA_f5556f70-c4b9-499b-84e4-b6448e9c046c" continuedAt="if5f56ff92bd84fdf9e5626c35e9e7060" escape="true">Earnings (Loss) Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if5f56ff92bd84fdf9e5626c35e9e7060" continuedAt="i9953857a1e7941fa94b919840daba838"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzgwMQ_73a10321-67bb-4928-bbc7-98ee4ae342ea" continuedAt="i7fd540cd45e64a2087daa7f5aa6ab372" escape="true">The following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of the numerators and the denominators of the basic and diluted per share calculations.</ix:nonNumeric></ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9953857a1e7941fa94b919840daba838"><div><ix:continuation id="i7fd540cd45e64a2087daa7f5aa6ab372"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:40.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtMS0xLTEtMTYxMTg_3b719981-679e-433e-91e3-fef46501489e">87,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtMy0xLTEtMTYxMTg_e419777a-52f1-4ad4-8210-c467c517f371">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtNS0xLTEtMTYxMTg_9f429e2a-d622-4783-b7a8-744369c8c484">130,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtMS0xLTEtMTYxMTg_a339cc07-ead1-4ed6-9255-7fa89ad81257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtMy0xLTEtMTYxMTg_ec1004f8-47eb-4565-ba1a-b476bbef98df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtNS0xLTEtMTYxMTg_00b5b8d2-fe32-4389-ac30-e5bac878f640">5,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtMS0xLTEtMTYxMTg_e9f12f55-8006-4b60-82f7-a42a164a621f">87,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtMy0xLTEtMTYxMTg_768ae625-8337-4076-b460-52ca807ea93c">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtNS0xLTEtMTYxMTg_4445952b-c042-4c77-9ef1-d71fc2a82d81">135,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtMS0xLTEtMTYxMTg_e1456cec-2bbd-40b4-b1fb-a223edae93a8">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtMy0xLTEtMTYxMTg_281dc9ef-fa50-46ff-9a2d-07656d61d12b">110,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtNS0xLTEtMTYxMTg_1c5635b1-69e2-4896-9efb-9d3c96f84661">106,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTEtMS0xLTE2MTE4_f0c15bef-08b5-4465-8650-8ca9e9a24d42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTMtMS0xLTE2MTE4_0c5c9fb3-63b4-4d26-a65f-d88b02994462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTUtMS0xLTE2MTE4_38e17e8f-454e-49d3-b280-ff80e368989f">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTEtMS0xLTE2MTE4_f5630a80-9af1-44af-8902-d1b56b3f9f68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTMtMS0xLTE2MTE4_cd1f3dbf-653f-4683-89a3-543d9b3c2704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTUtMS0xLTE2MTE4_1fac5bc8-e8c8-4595-8e1d-5fc79f750814">10,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTEtMS0xLTE2MTE4_ecf1ce4c-46ae-4ce6-9138-3e12d80e9d20">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTMtMS0xLTE2MTE4_620bd16c-2971-4d6d-bfc0-f6fd3139c690">110,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTUtMS0xLTE2MTE4_95834ab0-0697-4b37-9481-c55c70a11a11">116,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTEtMS0xLTE2MTE4_7dd88241-3123-4211-ac52-e6a8ab420494">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTMtMS0xLTE2MTE4_2a661bb3-f260-4014-8029-744f5232075a">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTUtMS0xLTE2MTE4_abd78fcb-0898-4177-a653-f7efa72ac867">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTEtMS0xLTE2MTE4_96de08fa-bcd4-4a6b-bae4-93c614887464">0.60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTMtMS0xLTE2MTE4_6c47956b-14a9-4c1d-b223-7bec6bc30ac2">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTUtMS0xLTE2MTE4_44e46027-cfb1-4991-8bcd-988012f80e7b">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was <ix:nonFraction unitRef="shares" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU1MQ_5aaf644a-809f-4159-8af0-42fdedb36a7d">10,221,278</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU1NQ_3e85bfb8-3764-4368-b6a7-8b79df505216">11,113,054</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU2Mg_2d1739ee-5fe6-4fc6-9e05-49c2e1ed3117">8,206,390</ix:nonFraction>, respectively, for the years ended December&#160;31, 2021, 2020 and 2019.  Prior to the extinguishment of the Convertible Notes, for periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ic8e1d29868b149c9aff5685ac938a1e8_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" name="lxrx:OtherCapitalAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzE0NTU_d9de948d-830a-445c-88ed-8100b054c095" continuedAt="i95cc6e805791423cb6f5b8c84898ac71" escape="true">Other Capital Agreements</ix:nonNumeric></span></div><ix:continuation id="i95cc6e805791423cb6f5b8c84898ac71"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In December 2020, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzgy_7dc778f5-c344-4adb-90c6-a825fb8ddc06">20,312,500</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEyNg_58a09fe3-182b-4227-a0f0-403c8a431d96">3.200</ix:nonFraction> per share in a registered direct offering pursuant to an existing shelf registration statement.  Sale of the shares resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231" decimals="-3" name="lxrx:ProceedsFromDecember2020CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzI3Mw_98fa2cf0-d13b-4064-a090-def666d0da81">63.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:CommissionsFromDecember2020CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzMzNQ_4576d787-29c3-4e9d-be64-c8bfeb9a2102">1.8</ix:nonFraction>&#160;million and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-5" name="lxrx:OfferingExpensesFromDecember20CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzM2Mw_62413e5b-71c0-4673-860c-e359a0ff0e13">0.2</ix:nonFraction>&#160;million.  The investors in the offering were Artal International S.C.A., an affiliate of of Invus, L.P., the Company&#8217;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P.  All of the net proceeds of the registered direct offering are reflected as issuance of common stock in the accompanying financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="INF" name="lxrx:ATMOfferingTotal" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzk2MQ_1ec7e2f8-b876-4e3a-b93d-af2802a43f35">50,000,000</ix:nonFraction> from time to time through Jefferies acting as its sales agent.  In November 2020, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="0" name="lxrx:SharesSoldInNov2020ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEwNTk_053a5457-af0a-4381-8c2e-65e97d29c848">3,709,233</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231" decimals="3" name="lxrx:SharePriceInNovember20ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzExMDM_46d05d7c-f5b3-4b7d-a0da-0ef1672e333d">1.992</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231" decimals="-3" name="lxrx:ProceedsFromNov2020ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzExNzg_dfcbe724-c14b-4394-b848-924aea2e3d1f">7.0</ix:nonFraction>&#160;million.  In January 2021, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="0" name="lxrx:SharesSoldInJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEzMzA_b1c1a426-2114-4312-b07e-664796c1b800">2,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="shares" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="3" name="lxrx:SharePriceInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEzNzQ_7fc88788-3d3f-4d91-958a-f4ab91213631">8.463</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="-5" name="lxrx:ProceedsFromJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzE0NDk_0bd3be89-e233-4f30-9ad0-d214e0725a35">16.4</ix:nonFraction>&#160;million. In August and September 2021, Lexicon sold an aggregate of <ix:nonFraction unitRef="usd" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="0" name="lxrx:SharesSoldInSeptember2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNDg_feb11e62-3335-4123-95c0-4ffa63e42959">4,176,953</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="3" name="lxrx:SharePriceInSeptember2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNTc_8269ed15-87e7-4dc9-994b-2a20112482e7">4.732</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231" decimals="-5" name="lxrx:ProceedsFromSeptember2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNzM_129fda45-18c3-480c-85c5-82d084d8e890">19.1</ix:nonFraction>&#160;million. The net proceeds from each of these sales are reflected as issuances of common stock in the accompanying financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>exh48descriptionofcommonst.htm
<DESCRIPTION>EX-4.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ife673950fdae467989d3ee40a9f4716e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Authorized Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are authorized to issue up to 225 million shares of common stock, par value $0.001 per share.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary description of our common stock is based on the provisions of our second amended and restated certificate of incorporation, second amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law. This information may not be complete in all respects and is qualified entirely by reference to the provisions of our second amended and restated certificate of incorporation, second amended and restated bylaws and the Delaware General Corporation Law. For more detailed information about the rights of our common stock, you should refer to our second amended and restated certificate of incorporation, second amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law.</font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Rights</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders and do not have cumulative voting rights. Accordingly, holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election. </font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Rights</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution or winding up of Lexicon, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preemptive and Consent Rights</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation grants holders of 20% or more of our issued and outstanding common stock (a) customary preemptive rights related to the issuance of certain of our securities and (b) consent rights prior us taking any of the following actions&#58; (i) creating or issuing any new class or series of shares of capital stock (or securities convertible into or exercisable for shares of capital stock) having rights, preferences or privileges senior to or on parity with the common stock, (ii) subject to certain exceptions, repurchasing, retiring, redeeming or otherwise acquiring any of our equity securities (or securities convertible into or exchangeable for equity securities) or any subsidiary and (iii) adopting, or proposing to adopt, or maintaining any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless such stockholder is exempt from such plan or agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fully Paid and Non-assessable</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding shares of our common stock are fully paid and non-assessable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrangements with Invus</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2007, we entered into a securities purchase agreement with Invus, L.P., under which Invus, L.P. made an initial investment in our common stock in August 2007.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Concurrently with the execution of the securities purchase agreement, we entered into a stockholders&#8217; agreement with Invus, L.P. under which Invus, L.P. and its affiliates (collectively, &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Invus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) have the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus, rounded up to the nearest whole number of directors. Invus has designated three of the nine current members of our board of directors. While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion. To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary actions in accordance with our obligations under the stockholders&#8217; agreement to (a) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (b) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions. Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors. No Invus-designated directors currently serve on the audit committee of our board of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the stockholders&#8217; agreement relating to Invus&#8217; rights to designate members of our board of directors and its audit, compensation and corporate governance committees will terminate if the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%. Invus also has the right to terminate these provisions at any time in its discretion.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Concurrently with the execution of the securities purchase agreement, we also entered into a registration rights agreement with Invus, L.P., pursuant to which Invus has certain demand and piggyback registration rights with respect to shares of our common stock held by them. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preemptive and Consent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Invus holds preemptive and consent rights under the provisions of our second amended and restated certificate of incorporation based on their current ownership interest in our common stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Provisions of Delaware Law and Our Charter Documents</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delaware Takeover Statute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, the statute prohibits a publicly-held Delaware corporation such as Lexicon from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. For purposes of Section 203, a business combination includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or within three years prior, did own) 15% or more of our voting stock.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our second amended and restated certificate of incorporation requires that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent in writing. Additionally, our second amended and restated certificate of incorporation&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">does not provide for the use of cumulative voting in the election of directors&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">provides for a board of directors, classified into three classes of directors&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">provides that the authorized number of directors may be changed only by resolution of our board of directors&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">provides for the authority of our board of directors to issue up to five million shares of &#8220;blank check&#8221; preferred stock and to determine the price, powers, preferences and rights of these shares, without stockholder approval.</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second amended and restated bylaws provide that candidates for director may be nominated only by our board of directors or by a stockholder who gives written notice to us not less than 120 days nor more than 150 days in advance of the first anniversary of the date of our proxy statement relating to the previous year&#8217;s annual meeting of stockholders. The authorized number of directors is fixed in accordance with our second amended and restated certificate of incorporation. Our board of directors currently consists of nine members, divided into three classes. As a result, a portion of the board of directors will be elected each year. The board of directors may appoint new directors to fill vacancies or newly created directorships. Our second amended and restated bylaws also limit who may call a special meeting of stockholders.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware law and these charter provisions may have the effect of deterring hostile takeovers or delaying changes in control of our management, which could depress the market price of our common stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is Computershare Inc. </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>exh103offerlettergranowitz.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i542fab73567c4e2dbab25e9c9f3f6c80_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.3</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;Lexicon Pharmaceuticals, Inc. Letterhead&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">July 26, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Craig Granowitz, M.D., Ph.D. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;Address&#93; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dear Craig&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon Pharmaceuticals, Inc. is pleased to offer you the position of Senior Vice President and Chief Medical Officer. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms under which we are offering you this position are outlined below&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Start Date </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hope that you will begin employment on Monday, August 2, 2021. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Salary </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">You will receive a salary at the rate of $38,333.33 per month ($460,000 per year), paid in accordance with our standard payroll policies. We currently pay employees on the 15th and last day of each month. You will be eligible for a salary review in the first quarter of 2022 based on your start date with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Bonus Arrangements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">You will be eligible for an annual bonus, with a bonus target (i.e. the amount payable if all objectives are achieved) of 40% of your annual base salary, with an opportunity to earn a greater bonus for over-achievement. The actual amount of your bonus will be determined by the compensation committee of the board of directors, based upon achievement of corporate objectives established at the beginning of each year. As is the case with all Lexicon officers, decisions regarding the payment of bonuses are subject to the discretion of the compensation committee of the board of directors. For 2021, your bonus will be prorated based on your start date with the Company. Bonuses for 2021 are expected to be determined and paid in the first quarter of 2022. You must be employed on the date an annual bonus is paid in order to earn that bonus.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock Options </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">You will receive an option under our Equity Incentive Plan (the ''Plan&#34;) giving you the right to purchase 250,000 shares of common stock at an exercise price equal to the fair market value of the common stock, as defined in the Plan, on the date the option is granted (which will be on or as soon as administratively practicable following the date your employment with the Company commences). The option will vest and become exercisable according to the following schedule&#58; (a) twenty-five percent (25%) of the total after twelve months of continuous employment and (b) one forty-eighth (1148th) of the total after each subsequent month of employment thereafter. The option will have a ten-year term. and will be subject to the terms and conditions of the Plan and our standard form of stock option agreement for company officers ( which includes acceleration of vesting in the event of a change in control, as defined in that agreement), which you will receive after the option is granted.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Benefits                      </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms of the applicable plans, you will be eligible to participate in the employee benefits plans we make available to our employees generally, which currently include health, dental, vision, life and disability insurance, as well as a 40l(k) retirement plan. We currently make matching contributions under our 40l(k) plan in an amount equal to 100% of an employee's contributions up to four percent of eligible compensation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Severance </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event your employment is terminated without &#34;cause&#34; by the company, you will be eligible to receive (subject to your satisfaction of the release requirement described below), and the company shall be obligated to pay, salary continuation payments (pursuant to the company's normal payroll procedures) in an amount equal to your then</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current base salary for a period of six months following such termination (the &#34;Severance Payments&#34;). Notwithstanding the foregoing, in the event your employment is terminated without &#34;cause&#34; by the company in connection with a &#34;change in control,&#34; the term of your salary continuation payments will be extended for an additional six months to a total of one year following termination. For purposes of the foregoing,</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">termination for &#34;cause&#34; shall mean termination of employment directly resulting from (a) intentional misconduct causing a material violation by the company of any state or federal laws, (b) a theft of corporate funds or corporate assets or in a material act of fraud upon the company, (c) an act of personal dishonesty that was intended to result in personal enrichment at the expense of the company or (d) conviction of a felony&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a &#34;change in control&#34; of 1110 company shall be deemed to have occurred if any of the following shall have taken place&#58; (a) any &#34;person&#34; (as such term is used in Sections 13(d) and 14(d)(2)of the Securities Exchange Act of 1934 (the &#34;Exchange Act&#34;)) is or becomes the &#34;beneficial owner&#34; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the company representing 50% or more of the combined voting power of the company's then-outstanding voting securities&#59; (b) the approval by the stockholders of the company of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the company immediately prior to such reorganization, merger, or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company's then outstanding securities in substantially the same proportion as their ownership of the company's outstanding voting securities prior to such reorganization, merger or consolidation&#59; or ( c) a liquidation or dissolution of the company or the sale of all or substantially all of the company's assets. For the avoidance of doubt, Invus, LP being a majority owner or dropping below majority ownership does not by itself constitute a &#34;change in control&#59;&#34; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if you are a &#34;specified employee&#34; within the meaning of Treasury Regulation Section l.409A-l(i) as of the date of your &#34;separation from service&#34; (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#34;Code''), and any payment or benefit pursuant to this &#34;Severance&#34; section constitutes a &#34;deferral of compensation&#34; within the meaning of Treasury Regulation Section 1. 409A-l (b ), you will not be entitled to such payment or benefit until the earlier of ( a) the date which is six months after your separation from service for any reason other than death, or (b) the date of your death. The provisions of this sub-paragraph shall only apply if, and to the extent, required to avoid the imputation of any tax, penalty or interest pursuant to Section 409 A of the Code. Any amounts otherwise payable to you upon or in the six-month period following your separation from service that are not so paid by reason of this paragraph shall be paid (without interest) as soon as practicable (and in all events within twenty (20) days) after the date that is six months after your separation from service (or, if earlier, as soon as practicable, and in all events within 30 days, after the date of your death). Each payment under this &#34;Severance&#34; section shall be treated as one of a series of separate payments for purposes of Section 409 A of the Code. It is intended that any amounts payable under this letter and our or your exercise of authority or discretion hereunder shall comply with and avoid the imputation of any tax, penalty or interest under Section 409A of the Code. 111.is letter shall be construed and interpreted consistent with that intent.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Severance Payments will be paid in substantially equal installments paid over the six-month period following the date on which your employment terminates (the &#34;Termination Date&#34;) or, in the event that your employment terminates in connection with a change of control, over the twelve-month period following the Termination Date. On the company's first regularly scheduled pay date. that is on or after the date that is sixty (60) days after the Termination Date (the &#34;First Payment Date&#34;), the company shall pay to you, without interest, a number of such installments equal to the number of such installments that would have been paid during the period beginning on the Termination Date and ending on the First Payment Date had the installments been paid on the company's regularly scheduled pay dates on or following the Termination Date, and each of the remaining installments shall be paid on the company's regularly scheduled pay dates during the remainder of such six-month or twelve-month period, as applicable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to receive the Severance Payments (and any portion thereof), you will be required to execute, on or before the expiration date specified therein, and not revoke within any time provided by the company to do so, a release of all claims in a form acceptable to the Company (the &#34;Release&#34;), which Release shall release the company and its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">affiliates, and the foregoing entities' respective shareholders, members, partners, officers, managers, directors, predecessors, successors, fiduciaries, employees, representatives, agents and benefit plans (and fiduciaries of such plans) from any and all claims, including any and all causes of action arising out of your employment, engagement, or affiliation with the company and any of its affiliates or the termination of such employment, engagement or affiliation, but excluding all claims to severance payments you may have. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the payment obligations of the company, if any, under the preceding paragraph of this letter, this letter does not create any term of employment, and both you and the company will be free to terminate your employment at any time for any reason.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Proprietary Information Agreement </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consider the protection of our confidential information and proprietary rights to be very important. As a result, our offer of employment is conditioned upon your signing our standard form of Employee Proprietary Information Agreement. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If you have any questions regarding this offer, please contact Mary McKinney, Executive Director, Human Resources. If you have any questions regarding our employee benefit plans, please contact Saturday Siekman, Senior Director, Compensation and Benefits. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that this offer represents an excellent opportunity for you and us, and that you have the capabilities to add significantly to our efforts. If you find this offer to be acceptable, please indicate your acceptance by signing and returning a copy of this letter within 48 hours of receiving your verbal offer.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sincerely,</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lonnel Coats</font></div><div style="text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Craig Granowitz, M.D., Ph.D.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>exh1010formofrestrictedsto.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5bf274e770e746d6a66dedae37635424_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.10</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(Officer Restricted Stock Unit)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">THIS RESTRICTED STOCK UNIT AGREEMENT (this &#8220;Agreement&#8221;), effective as of _________ (the &#8220;Grant Date&#8221;), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ___________ (&#8220;Employee&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To carry out the purposes of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;) and the determination of the compensation committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s board of directors (the &#8220;Board&#8221;) to grant Employee a Restricted Stock Unit Award (as defined in the Plan) under the Plan, subject to the terms and conditions of this Agreement, of shares of the Company&#8217;s Common Stock, par value $0.001 per share (&#8220;Stock&#8221;), in order to provide Employee with incentives to exert maximum efforts for the Company&#8217;s success by providing Employee the opportunity to benefit from increases in the value of the Stock, and in consideration of the mutual agreements and other matters set forth herein and in the Plan, the Company and Employee hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:27.75pt;text-decoration:underline">Grant of Restricted Stock Unit Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  The Company hereby grants to Employee a Restricted Stock Unit Award, on the terms and conditions set forth in this Agreement and in the Plan, consisting of the right to receive an aggregate of ________ shares of Stock (the &#8220;Shares&#8221;).  </font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:27.75pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  (a) Subject to the terms and conditions set forth in this Agreement and the Plan, the right of Employee to receive the Shares shall vest with respect to one third of the total number of Shares on February 28 of each of the three years following the year of grant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> that, if not already vested in accordance with the foregoing, the right of Employee to receive the Shares shall become vested upon (i) a termination of Employee&#8217;s Continuous Service (as defined in the Plan) by the Company without Cause (as defined below) or by Employee for Good Reason (as defined below) that occurs after the occurrence of a Change in Control (as defined below) or (ii) the termination of Employee&#8217;s Continuous Service as a result of Employee&#8217;s death or Disability (as defined in the Plan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">            (b)        For purposes of the foregoing&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;A &#8220;Change in Control&#8221; shall be deemed to have occurred if any of the following shall have taken place&#58; (A) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) other than Invus, L.P. and its affiliates (collectively, &#8220;Invus&#8221;) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (B) Invus becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (C) the consummation of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the reorganized, merged or consolidated Company&#8217;s then-outstanding securities entitled to vote generally in the election of directors in substantially the same proportions as their ownership of the Company&#8217;s outstanding voting securities prior to such reorganization, merger or consolidation&#59; (D) a liquidation or dissolution of the Company or the sale of all or substantially all of the Company&#8217;s assets&#59; or (E) following the election or removal of directors, a majority of the Board consists of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">individuals who were not members of the Board two years before such election or removal, unless the election of each director who is not a director at the beginning of such two-year period has been approved in advance by directors representing at least a majority of the directors then in office who were directors at the beginning of the two-year period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that notwithstanding the foregoing, neither the execution by the Company of the Securities Purchase Agreement and Stockholders&#8217; Agreement with Invus, L.P., each dated June 15, 2007 (as amended, supplemented or otherwise modified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Invus Transaction Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), nor the consummation of the transactions contemplated in the Invus Transaction Agreements, including, without limitation, the acquisition by Invus of the Initial Shares and the Rights Shares (as defined in the Invus Transaction Agreements), the election of any representatives of Invus to the board of directors of the Company, or the acquisition by Invus of additional shares of Stock, as permitted or contemplated under the Invus Transaction Agreements, will constitute a &#8220;Change in Control.&#8221;  The Compensation Committee, in its discretion, may deem any other corporate event affecting the Company to be a &#8220;Change in Control&#8221; hereunder.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;&#8220;Cause&#8221; means a termination of Employee&#8217;s employment directly resulting from (A) Employee having engaged in intentional misconduct causing a material violation by the Company of any state or federal laws, (B) Employee having engaged in a theft of Company funds or Company assets or in a material act of fraud upon the Company, (C) an act of personal dishonesty taken by Employee that was intended to result in personal enrichment of Employee at the expense of the Company, (D) Employee&#8217;s final conviction (or the entry of any plea other than not guilty) in a court of competent jurisdiction of a felony, or (E) a breach by Employee of any contractual or fiduciary obligation to the Company, if such breach results in a material injury to the Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;&#8220;Good Reason&#8221; means the occurrence of any of the following events without Employee&#8217;s express written consent&#58; (A) a material diminution in Employee&#8217;s base salary, (B) a material diminution in Employee&#8217;s authority, duties, or responsibilities, or (C) any other action or inaction that constitutes a material breach by the Company of any contractual obligation to Employee.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Forfeiture upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Simultaneously with termination of Employee&#8217;s Continuous Service for any reason other than as a result of Employee&#8217;s death or Disability (as defined in the Plan) prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, Employee shall automatically forfeit all rights to receive the Shares, unless and except to the extent otherwise agreed by the Company, in its sole discretion.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Issuance of Shares upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Subject to the provisions of Sections 3 and 6 of this Agreement, upon vesting of the Shares in accordance with Section 2 of this Agreement, the Company shall (a) provide Employee with prompt notice of such vesting event and (b) issue the Shares to Employee for no additional consideration.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Employee&#8217;s rights under this Agreement, including with respect to any Shares as to which the interest of Employee has not vested in accordance with Section 2 of this Agreement, may not be transferred by Employee otherwise than by will or the laws of descent and distribution or pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.   Employee shall be liable for any and all federal, state or local taxes, including withholding taxes, arising out of the grant or vesting of Shares hereunder.  Unless Employee elects otherwise as provided below, Employee shall satisfy such withholding tax obligation by forfeiting to the Company that number of Shares having a Fair Market Value (as defined in the Plan) equal to the Company&#8217;s withholding obligation relating to such grant or vesting of Shares hereunder.  Employee may alternatively elect to satisfy such withholding tax obligation by making a cash payment to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Company equal to the Company&#8217;s minimum withholding obligation, in which case Employee shall (a) provide the Company with written notice of such election and (b) pay to the Company in immediately available funds an amount equal to the Company&#8217;s minimum withholding obligation, in each case by no later than the date giving rise to such withholding tax obligation.  No Shares shall be issued to Employee unless and until Employee shall have paid or otherwise satisfied the withholding tax obligations with respect thereto.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Dividend Equivalents&#59; Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  If the Board declares any dividends with respect to the Stock prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, dividend equivalents shall be credited to Employee in respect of the Shares and shall be converted into additional shares of Stock covered by this Agreement and such additional shares shall be subject to all of the terms and conditions of the underlying Shares.  Employee shall have no voting rights with respect to the Restricted Stock Unit Award or the Shares subject thereto until such time as the Shares are issued to Employee pursuant to Section 4 of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Nothing in this Agreement or the Plan shall confer upon Employee any right to continue in the employ of the Company or shall interfere with or restrict in any way the right of the Company, which is hereby expressly reserved, to terminate Employee&#8217;s employment at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">2017 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  The Plan, a copy of which is available for inspection by Employee at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Agreement.  This Agreement is subject to, and the Company and Employee agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Agreement and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Agreement, and the determinations of the administrator of the Plan shall be final and binding on Employee and the Company.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under Employee. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  This Agreement and all actions taken hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and Employee has executed this Agreement effective for all purposes as of the Grant Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon Pharmaceuticals, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                               </font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">            Lonnel Coats</font></div><div style="text-align:justify;text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">___________________________________________</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>exh211subsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i334bcadd8e6643048a9523507eb6ea8a_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiaries of Lexicon Pharmaceuticals, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The subsidiary of Lexicon Pharmaceuticals, Inc. set forth below does business under the name stated.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:53.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">State of Incorporation or Formation</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals (New Jersey), Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exh231ernstyoungconsent2021.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d42500e7a014144a6746047c2a95deb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Registration Statements (Form S-8 Nos. 333-41532, 333-168678, 333-183020, 333-210145, 333-217873, 333-234569, and 333-240169) pertaining to the 2017 Equity Incentive Plan and to the 2017 Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Registration Statement (Form S-3 No. 333-234568) of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;10, 2022, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended December&#160;31, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Houston, Texas</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;10, 2022 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d66af13b0d24f359eaccf1c61d9c09e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:3.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;10, 2022 </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2c62f2b1ebdf4b52b552b0fccf28a160_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:3.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;10, 2022 </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">r</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iadbedd7ecde54dc197a5e9006e5cdbac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:6.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon's Annual Report on Form 10-K for the year ended December 31, 2021, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 10th day of March, 2022.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lxrx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lexpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetParentheticals" roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals">
        <link:definition>1002003 - Statement - Balance Sheet Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofComprehensiveLossParentheticalsParentheticals" roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals">
        <link:definition>1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.lexpharma.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleassetDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCostofSalesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1">
        <link:definition>2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2">
        <link:definition>2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements">
        <link:definition>2115103 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsTables" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables">
        <link:definition>2316302 - Disclosure - Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>2417411 - Disclosure - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2118104 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails">
        <link:definition>2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2121105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2322304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2423413 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2">
        <link:definition>2424414 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lexpharma.com/role/PropertyandEquipment">
        <link:definition>2125106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables">
        <link:definition>2326305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails">
        <link:definition>2427415 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lexpharma.com/role/IncomeTaxes">
        <link:definition>2128107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lexpharma.com/role/IncomeTaxesTables">
        <link:definition>2329306 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1">
        <link:definition>2430416 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2">
        <link:definition>2431417 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3">
        <link:definition>2432418 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.lexpharma.com/role/Goodwill">
        <link:definition>2133108 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.lexpharma.com/role/GoodwillTables">
        <link:definition>2334307 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.lexpharma.com/role/GoodwillDetails">
        <link:definition>2435419 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2136109 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables">
        <link:definition>2337308 - Disclosure - Debt Obligations Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsNarrativeDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails">
        <link:definition>2438420 - Disclosure - Debt Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails1" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1">
        <link:definition>2439421 - Disclosure - Debt Obligations (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2140110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>2341309 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails2" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2">
        <link:definition>2443423 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards">
        <link:definition>2144111 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables">
        <link:definition>2345310 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsNarrativeDetails" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails">
        <link:definition>2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails2" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2">
        <link:definition>2447425 - Disclosure - Equity Incentive Awards (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails3" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3">
        <link:definition>2448426 - Disclosure - Equity Incentive Awards (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails4" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4">
        <link:definition>2449427 - Disclosure - Equity Incentive Awards (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlan" roleURI="http://www.lexpharma.com/role/BenefitPlan">
        <link:definition>2150112 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanTables" roleURI="http://www.lexpharma.com/role/BenefitPlanTables">
        <link:definition>2351311 - Disclosure - Benefit Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanDetails" roleURI="http://www.lexpharma.com/role/BenefitPlanDetails">
        <link:definition>2452428 - Disclosure - Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2153113 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2454429 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.lexpharma.com/role/EarningsPerShare">
        <link:definition>2155114 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.lexpharma.com/role/EarningsPerShareTables">
        <link:definition>2356312 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails">
        <link:definition>2457430 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2158115 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2359313 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails">
        <link:definition>2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSale" roleURI="http://www.lexpharma.com/role/AssetSale">
        <link:definition>2161116 - Disclosure - Asset Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleTables" roleURI="http://www.lexpharma.com/role/AssetSaleTables">
        <link:definition>2362314 - Disclosure - Asset Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleDetails" roleURI="http://www.lexpharma.com/role/AssetSaleDetails">
        <link:definition>2463432 - Disclosure - Asset Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>2164117 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>2465433 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_OfferingExpensesFromDecember20CommonStockOffering" abstract="false" name="OfferingExpensesFromDecember20CommonStockOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" abstract="false" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" abstract="false" name="SanofiCommercializationCostsFundedbyLexiconMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_OrganizationAndOperationsAbstract" abstract="true" name="OrganizationAndOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_A2020FederalNOLIncrease" abstract="false" name="A2020FederalNOLIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DefinedContributionPlanRequisiteServicePeriod" abstract="false" name="DefinedContributionPlanRequisiteServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_CommissionsFromDecember2020CommonStockOffering" abstract="false" name="CommissionsFromDecember2020CommonStockOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtInstrumentRepurchasePercentage" abstract="false" name="DebtInstrumentRepurchasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" abstract="false" name="RestrictedStockUnitsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalUpfrontPayments" abstract="false" name="IpsenTotalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SaleOfNonFinancialAssetsTextBlock" abstract="false" name="SaleOfNonFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_PresentValueOfFutureLeasePayments" abstract="false" name="PresentValueOfFutureLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SymphonyIconGoodwill" abstract="false" name="SymphonyIconGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_IpsenTotalPaymentsToDate" abstract="false" name="IpsenTotalPaymentsToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsSection163j_LXRX" abstract="false" name="DeferredTaxAssetsSection163j_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LXRXBiologicscustomerconcentration" abstract="false" name="LXRXBiologicscustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" abstract="false" name="DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInSeptember2021ATMOffering" abstract="false" name="SharesSoldInSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" abstract="false" name="TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" abstract="false" name="SanofiRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BenefitPlanAbstract" abstract="true" name="BenefitPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_BalanceSheetParentheticalsAbstract" abstract="true" name="BalanceSheetParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangeAccruedInterest" abstract="false" name="A2020ConvertibleDebtExchangeAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="SanofiRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_EntityWideRevenueSanofiPercentage" abstract="false" name="EntityWideRevenueSanofiPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiTerminationAgreement" abstract="false" name="SanofiTerminationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RDSeveranceCostsMember" abstract="true" name="RDSeveranceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_EquityIncentiveAwardsAbstract" abstract="true" name="EquityIncentiveAwardsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiDevelopmentMilestones" abstract="false" name="SanofiDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalCashConsideration" abstract="false" name="ConvertibleDebtExchangeTotalCashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" abstract="false" name="StockOptionExercisePriceAsPercentOfValueOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_ProceedsFromDecember2020CommonStockOffering" abstract="false" name="ProceedsFromDecember2020CommonStockOffering" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" abstract="false" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ProceedsFromSeptember2021ATMOffering" abstract="false" name="ProceedsFromSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvertibleDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoFundingDeliverable" abstract="false" name="SanofiRevenueAllocatedtoFundingDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CommitmentsAndContingenciesAbstract" abstract="true" name="CommitmentsAndContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_GoodwillAbstract" abstract="true" name="GoodwillAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" abstract="false" name="DeferredCompensationArrangementWithIndividualPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_SharePriceInSeptember2021ATMOffering" abstract="false" name="SharePriceInSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OptionsOutstandingEquityIncentivePlan" abstract="false" name="OptionsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" abstract="false" name="FinalConsiderationIncludingAmountsReleasedToSettle" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CoelacanthGoodwill" abstract="false" name="CoelacanthGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiOutcomesStudyMilestone" abstract="false" name="SanofiOutcomesStudyMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiDeferredRevenueFromTermination" abstract="false" name="SanofiDeferredRevenueFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" abstract="false" name="A2020ConvertibleDebtExchangeSharePaymentTotal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" abstract="false" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" abstract="false" name="A2020ConvertibleDebtExchangePercentageOfPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_LXRXDiplomatcustomerconcentration" abstract="false" name="LXRXDiplomatcustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_WriteOffOfTaxCredits" abstract="false" name="WriteOffOfTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DecreaseInNOLs" abstract="false" name="DecreaseInNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Totalvalueofsharesbynonemployeeinayear" abstract="false" name="Totalvalueofsharesbynonemployeeinayear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RDTaxCreditDecrease" abstract="false" name="RDTaxCreditDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRegulatoryMilestones" abstract="false" name="SanofiRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Ipsenproductsales" abstract="false" name="Ipsenproductsales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiUpfrontPayment" abstract="false" name="SanofiUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_CoelacanthPurchasePrice" abstract="false" name="CoelacanthPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LexiconBorrowingRate" abstract="false" name="LexiconBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_InterestOnLeasePayments" abstract="false" name="InterestOnLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedEquityIncentivePlan" abstract="false" name="StockOptionsExercisedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_PropertyAndEquipmentAbstract" abstract="true" name="PropertyAndEquipmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiSalesMilestonePayments" abstract="false" name="SanofiSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>lxrx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2824127f-8c1f-4fc6-afee-9bfd4db0db46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2824127f-8c1f-4fc6-afee-9bfd4db0db46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_195afe9c-1ae2-4c5b-bf3d-f8e2c782a920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:to="loc_us-gaap_ShortTermInvestments_195afe9c-1ae2-4c5b-bf3d-f8e2c782a920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3fe2533b-9157-4b0e-afa9-9a700bc6c180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3fe2533b-9157-4b0e-afa9-9a700bc6c180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_aadae7f5-d055-4ea0-8b15-500a87f3455f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:to="loc_us-gaap_InventoryNet_aadae7f5-d055-4ea0-8b15-500a87f3455f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d266070a-8f7f-4672-b1e1-476e74627015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cefed14-f149-4726-b2f1-23552bded0c6" xlink:to="loc_us-gaap_OtherAssetsCurrent_d266070a-8f7f-4672-b1e1-476e74627015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_58cd61a6-b10e-4361-b3dd-2cf7ba1dc243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f9cc4147-c91d-433e-891d-ea9e446e5bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58cd61a6-b10e-4361-b3dd-2cf7ba1dc243" xlink:to="loc_us-gaap_AccountsPayableCurrent_f9cc4147-c91d-433e-891d-ea9e446e5bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_54c01264-68b9-4b68-82b2-1938506836b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58cd61a6-b10e-4361-b3dd-2cf7ba1dc243" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_54c01264-68b9-4b68-82b2-1938506836b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_89cec0c9-f21a-434c-a3b1-d20d10e9f01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58cd61a6-b10e-4361-b3dd-2cf7ba1dc243" xlink:to="loc_us-gaap_LongTermDebtCurrent_89cec0c9-f21a-434c-a3b1-d20d10e9f01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_666a3e2e-bb52-4e27-ba67-779845194916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ebab62c-f7aa-46e0-98d5-2a8a45457798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_666a3e2e-bb52-4e27-ba67-779845194916" xlink:to="loc_us-gaap_StockholdersEquity_6ebab62c-f7aa-46e0-98d5-2a8a45457798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79f7c9af-30db-4223-8e74-b50aa7ed2db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_666a3e2e-bb52-4e27-ba67-779845194916" xlink:to="loc_us-gaap_Liabilities_79f7c9af-30db-4223-8e74-b50aa7ed2db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7396928a-25ec-4cfc-843f-356122c88aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_PreferredStockValue_7396928a-25ec-4cfc-843f-356122c88aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bfc3990c-4ab7-45b7-94e3-606a7300dfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_CommonStockValue_bfc3990c-4ab7-45b7-94e3-606a7300dfc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d081ccb-94f6-46c0-a5a7-97c4dd3937fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d081ccb-94f6-46c0-a5a7-97c4dd3937fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2af81af6-757e-4c5d-bffc-de8c312b5165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2af81af6-757e-4c5d-bffc-de8c312b5165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70fd8aa4-510e-4d55-9e34-e6c6e6bc641a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70fd8aa4-510e-4d55-9e34-e6c6e6bc641a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b20f25f8-fb07-41a5-adac-61f05373f439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_38779068-04b8-417f-9171-0cdd5be5d4dc" xlink:to="loc_us-gaap_TreasuryStockValue_b20f25f8-fb07-41a5-adac-61f05373f439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1d946aea-6636-49c7-b1c0-6f133a0c6a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:to="loc_us-gaap_AssetsCurrent_1d946aea-6636-49c7-b1c0-6f133a0c6a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bb6a853b-017f-4d0a-a2b2-31ba9174738b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bb6a853b-017f-4d0a-a2b2-31ba9174738b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f50943f3-aee9-46a0-9bcc-df5357b1693a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:to="loc_us-gaap_Goodwill_f50943f3-aee9-46a0-9bcc-df5357b1693a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_2e478c15-172e-4e5a-81fc-a22f95c85093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_2e478c15-172e-4e5a-81fc-a22f95c85093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c6da672f-9be5-4d9f-a096-5528e3ea5c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aaf048fd-6892-4d3e-b5b4-02302dd5f1c1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c6da672f-9be5-4d9f-a096-5528e3ea5c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bd7373b2-1605-4175-bf01-60c0cc9f4117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b60b649c-eae9-40fb-b59f-7f9ec07c07db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bd7373b2-1605-4175-bf01-60c0cc9f4117" xlink:to="loc_us-gaap_LiabilitiesCurrent_b60b649c-eae9-40fb-b59f-7f9ec07c07db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_08bb3aa7-8582-4f49-992b-c4caba5ec36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bd7373b2-1605-4175-bf01-60c0cc9f4117" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_08bb3aa7-8582-4f49-992b-c4caba5ec36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c6b51204-098a-46d3-ad65-21b716ed8a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bd7373b2-1605-4175-bf01-60c0cc9f4117" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c6b51204-098a-46d3-ad65-21b716ed8a35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2034794c-2107-44a1-9f38-ff3017bad26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ba3ea539-8a06-4cee-aee5-9faaee37cdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2034794c-2107-44a1-9f38-ff3017bad26f" xlink:to="loc_us-gaap_Revenues_ba3ea539-8a06-4cee-aee5-9faaee37cdb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_144fcbac-24ff-4ee8-83aa-670b4d104c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2034794c-2107-44a1-9f38-ff3017bad26f" xlink:to="loc_us-gaap_OperatingExpenses_144fcbac-24ff-4ee8-83aa-670b4d104c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_32c09465-4e93-4c96-917d-0b1855fe2768" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2034794c-2107-44a1-9f38-ff3017bad26f" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_32c09465-4e93-4c96-917d-0b1855fe2768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39930f40-d3da-4249-856e-e317e4240af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1647d248-7802-4692-8638-0e6f348b9d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39930f40-d3da-4249-856e-e317e4240af1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1647d248-7802-4692-8638-0e6f348b9d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_71e96df7-2177-49ea-9c29-afaf829d35cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39930f40-d3da-4249-856e-e317e4240af1" xlink:to="loc_us-gaap_InterestExpense_71e96df7-2177-49ea-9c29-afaf829d35cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_88e252cf-41c9-40e5-bd02-f96feb40d332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39930f40-d3da-4249-856e-e317e4240af1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_88e252cf-41c9-40e5-bd02-f96feb40d332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67c31592-5581-4b18-8017-c4f39957dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39930f40-d3da-4249-856e-e317e4240af1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67c31592-5581-4b18-8017-c4f39957dfa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d1572b5d-8490-4976-b51c-e3126fb4617e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a5a4200-b7d8-4210-bac8-fc7c3653dbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d1572b5d-8490-4976-b51c-e3126fb4617e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a5a4200-b7d8-4210-bac8-fc7c3653dbf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a5cb9d08-02d8-430c-ba36-7e744a0b40db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d1572b5d-8490-4976-b51c-e3126fb4617e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a5cb9d08-02d8-430c-ba36-7e744a0b40db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b52d03-2479-4bda-a4aa-0dde63c25546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b52d03-2479-4bda-a4aa-0dde63c25546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_854031ea-01ab-47a9-ad18-bf06fe5519c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_854031ea-01ab-47a9-ad18-bf06fe5519c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c192acc6-3c9a-4d93-a0be-5e3be4910e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c192acc6-3c9a-4d93-a0be-5e3be4910e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4156ec23-3910-49d8-9dab-8ef15e6a3103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4156ec23-3910-49d8-9dab-8ef15e6a3103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5eac8c54-0c53-48f4-8f7c-75b1f4b7e372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9c40aa42-308f-440c-a623-19f45ea0a076" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5eac8c54-0c53-48f4-8f7c-75b1f4b7e372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_64fdfa5f-7a6c-4f3e-82b7-3b843c057215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c29ad1a-088e-4db0-9088-971566645a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_64fdfa5f-7a6c-4f3e-82b7-3b843c057215" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c29ad1a-088e-4db0-9088-971566645a60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6e8bec3-bdf9-4c8e-a4dc-32403da1324c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_64fdfa5f-7a6c-4f3e-82b7-3b843c057215" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6e8bec3-bdf9-4c8e-a4dc-32403da1324c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_682e042a-b3b6-4036-93ba-3bdad0992231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_64fdfa5f-7a6c-4f3e-82b7-3b843c057215" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_682e042a-b3b6-4036-93ba-3bdad0992231" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29dc178f-d6b8-4c02-8c9b-eb50c0c4960e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2039dfc5-e657-4306-8ebd-a6e8553979c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29dc178f-d6b8-4c02-8c9b-eb50c0c4960e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2039dfc5-e657-4306-8ebd-a6e8553979c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8b393dd0-336e-4aef-859b-a6010037c7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29dc178f-d6b8-4c02-8c9b-eb50c0c4960e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8b393dd0-336e-4aef-859b-a6010037c7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3a71fa40-07a4-4a21-a566-53c2f718eeee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29dc178f-d6b8-4c02-8c9b-eb50c0c4960e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3a71fa40-07a4-4a21-a566-53c2f718eeee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fa8c4c8f-6843-4fa9-97cd-84b1fcf87e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29dc178f-d6b8-4c02-8c9b-eb50c0c4960e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fa8c4c8f-6843-4fa9-97cd-84b1fcf87e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86260225-2153-46f9-8121-6c01feeeb976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86260225-2153-46f9-8121-6c01feeeb976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_673d63ec-0547-4152-b153-f2301b6c0009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_673d63ec-0547-4152-b153-f2301b6c0009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_38219d39-3f80-4db6-8ff5-060a47792eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_38219d39-3f80-4db6-8ff5-060a47792eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f8eeb20b-6e86-4fe6-8ddf-5ebefbcf01a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f8eeb20b-6e86-4fe6-8ddf-5ebefbcf01a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2446bae-c960-4ad5-b771-b9dfc5697af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cfd649f-9c24-4818-a9f6-2d4dc11c8339" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2446bae-c960-4ad5-b771-b9dfc5697af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b120d3e6-74be-43e7-b5de-a87861b4919f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_ProfitLoss_b120d3e6-74be-43e7-b5de-a87861b4919f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fff36711-9508-4719-8802-de56ec32eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fff36711-9508-4719-8802-de56ec32eeb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b6d7a634-3ff7-496c-ba38-b6d78f349487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_ShareBasedCompensation_b6d7a634-3ff7-496c-ba38-b6d78f349487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_e3c99234-6a36-4eaa-80e6-45dacafae9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_e3c99234-6a36-4eaa-80e6-45dacafae9ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bdbf8a7b-40d8-429c-80f5-9ef5bfeae7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bdbf8a7b-40d8-429c-80f5-9ef5bfeae7df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c8670e16-c6c0-40a8-9322-1ec0a6a69b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c8670e16-c6c0-40a8-9322-1ec0a6a69b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f71c4796-c580-4f17-b045-5c76540afa19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f71c4796-c580-4f17-b045-5c76540afa19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_565add9a-1fb3-4bb9-997d-9bb125c8f706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_565add9a-1fb3-4bb9-997d-9bb125c8f706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e1955d14-5279-46f8-bb3f-3a33792668be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e1955d14-5279-46f8-bb3f-3a33792668be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c0ada1fc-30ff-4f37-bec5-549542255b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c0ada1fc-30ff-4f37-bec5-549542255b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a9757ac3-876d-4c4a-b462-55e9152f0f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef424e9c-ea5b-4212-afd4-6799d40fb724" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a9757ac3-876d-4c4a-b462-55e9152f0f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff366c3f-5fa7-45bf-a3dc-06b228086327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fe5567f-20a9-4a70-91af-8f5e9d383719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff366c3f-5fa7-45bf-a3dc-06b228086327" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fe5567f-20a9-4a70-91af-8f5e9d383719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46c5b493-f57f-4e05-b378-6caf09709c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff366c3f-5fa7-45bf-a3dc-06b228086327" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46c5b493-f57f-4e05-b378-6caf09709c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f097ec7-c492-4c91-998b-a50993d67da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff366c3f-5fa7-45bf-a3dc-06b228086327" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f097ec7-c492-4c91-998b-a50993d67da9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_6126ed3e-596e-4ebd-9429-8288ab63fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7b61c593-8528-4a65-8996-7ca5271660d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_6126ed3e-596e-4ebd-9429-8288ab63fa5e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7b61c593-8528-4a65-8996-7ca5271660d3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>lxrx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended" id="i224a1750da9a49a1b3fa226458744ad1_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_caa49b23-aff5-4384-bc78-c43680ecc938" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_caa49b23-aff5-4384-bc78-c43680ecc938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b2219fdf-8d57-4256-9213-e7a25189d012" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_CurrentFiscalYearEndDate_b2219fdf-8d57-4256-9213-e7a25189d012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a4aa30fe-e06e-4574-a99c-573c9fc15cdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorName_a4aa30fe-e06e-4574-a99c-573c9fc15cdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e79e7153-6993-4598-9ec7-1b1e22b36f16" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorLocation_e79e7153-6993-4598-9ec7-1b1e22b36f16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a98d759d-fd52-4c23-b5eb-7fb97e7bff6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorFirmId_a98d759d-fd52-4c23-b5eb-7fb97e7bff6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:to="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_68567d41-d1cc-43ae-9e7b-6a4770346d4a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:to="loc_srt_RestatementDomain_68567d41-d1cc-43ae-9e7b-6a4770346d4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f0c39131-9a66-4035-9140-b916db9ab22b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:to="loc_srt_RestatementDomain_f0c39131-9a66-4035-9140-b916db9ab22b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i2900b103aaa84958b430bcef00ac26e0_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30ad54ef-b2ba-4c6c-baf3-d113022803c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30ad54ef-b2ba-4c6c-baf3-d113022803c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3bcd5dd8-7897-45f5-be5a-d9b8a2f53150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_ShortTermInvestments_3bcd5dd8-7897-45f5-be5a-d9b8a2f53150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_550b9be9-ac22-4a16-aef9-d57565266494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_550b9be9-ac22-4a16-aef9-d57565266494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b587f12b-4e73-446b-8f2a-cb1c83335da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_InventoryNet_b587f12b-4e73-446b-8f2a-cb1c83335da7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cd8d642-6050-43e3-8c24-b9a12b6ea473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cd8d642-6050-43e3-8c24-b9a12b6ea473" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f11e4df2-d9c4-4412-a36f-b30f76eafa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_AssetsCurrent_f11e4df2-d9c4-4412-a36f-b30f76eafa51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4b776f48-355e-4172-bab2-881429669cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4b776f48-355e-4172-bab2-881429669cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_450a0a5b-d182-4d60-892a-00a3f5d21419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Goodwill_450a0a5b-d182-4d60-892a-00a3f5d21419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_9bfa4852-15f1-45f8-9297-0d256497c522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_9bfa4852-15f1-45f8-9297-0d256497c522" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa8b8862-b0c0-45fa-bb55-88de470adfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fa8b8862-b0c0-45fa-bb55-88de470adfdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3ed91df5-2653-4520-a5d9-c0388d3afd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Assets_3ed91df5-2653-4520-a5d9-c0388d3afd8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c12c6e33-747e-4d54-9256-592d0f47e62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_AccountsPayableCurrent_c12c6e33-747e-4d54-9256-592d0f47e62b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cdf77113-649b-41f0-b4bb-395a0372c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cdf77113-649b-41f0-b4bb-395a0372c2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8335d969-2db5-44c4-a24a-d0e8d6050c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_LongTermDebtCurrent_8335d969-2db5-44c4-a24a-d0e8d6050c11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4dfe61a-85f4-4c77-adab-5294dc2330a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4dfe61a-85f4-4c77-adab-5294dc2330a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3a6faddc-395a-4cc7-a064-d5f355acd323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3a6faddc-395a-4cc7-a064-d5f355acd323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_599111ae-8c66-4a57-8704-cabe05b9e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_599111ae-8c66-4a57-8704-cabe05b9e4e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f9ef11b-4729-4ad0-babc-6bcc1dbeab39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Liabilities_5f9ef11b-4729-4ad0-babc-6bcc1dbeab39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ec94245b-0e85-42f2-a731-6ee53e377027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ec94245b-0e85-42f2-a731-6ee53e377027" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7d84276d-cfcc-4f0f-8ed8-5416db2885a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_PreferredStockValue_7d84276d-cfcc-4f0f-8ed8-5416db2885a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5315be5c-9653-43b1-82cd-093aec55369f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_CommonStockValue_5315be5c-9653-43b1-82cd-093aec55369f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1db442e-1779-4448-8a8e-f55c68e27491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1db442e-1779-4448-8a8e-f55c68e27491" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dc03911-e1ad-443c-bfe8-a5dea596afb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dc03911-e1ad-443c-bfe8-a5dea596afb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cfd0e05-3c23-4d31-9355-da38110f5599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cfd0e05-3c23-4d31-9355-da38110f5599" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1c1ff4ba-6e1c-4b3d-8d32-8818a864c4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_TreasuryStockValue_1c1ff4ba-6e1c-4b3d-8d32-8818a864c4a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05ebaad7-cf37-4b68-96b5-360b3fb6c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_StockholdersEquity_05ebaad7-cf37-4b68-96b5-360b3fb6c347" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5515044-88f6-4139-9f93-b72b68e4f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5515044-88f6-4139-9f93-b72b68e4f3aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b4e1f90-c42a-4032-af71-df6512d2282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b4e1f90-c42a-4032-af71-df6512d2282f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e455cf4b-1c44-40e7-b4ad-cf4a453c8397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e455cf4b-1c44-40e7-b4ad-cf4a453c8397" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c55801bb-3796-4f92-83f4-c43ff02fa76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c55801bb-3796-4f92-83f4-c43ff02fa76c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8fe0ede0-e461-4215-ac39-6895b495cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8fe0ede0-e461-4215-ac39-6895b495cfbb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8860fd0e-2f05-4a2a-bf56-c2eb36a97866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8860fd0e-2f05-4a2a-bf56-c2eb36a97866" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5cae64c4-9700-4265-b516-3ce5ab36ad2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5cae64c4-9700-4265-b516-3ce5ab36ad2f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:to="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b87b1950-eaea-4ffc-a532-3ff7420e9994_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b87b1950-eaea-4ffc-a532-3ff7420e9994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_338c07a9-9bd2-4887-a1d6-0406462f7be8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:to="loc_srt_ScenarioUnspecifiedDomain_338c07a9-9bd2-4887-a1d6-0406462f7be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f04ff962-9976-46c4-9ef9-08528cf0ead2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:to="loc_us-gaap_ClassOfStockDomain_f04ff962-9976-46c4-9ef9-08528cf0ead2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d6f90a7-4dcc-4455-8a01-9b47b05d7aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:to="loc_us-gaap_ClassOfStockDomain_9d6f90a7-4dcc-4455-8a01-9b47b05d7aac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20211231.xsd#BalanceSheetParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended" id="i39026933443b4aa6823e2ed065edfa96_BalanceSheetParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5f5bf32-842d-4aee-b1dc-17ef3529bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5f5bf32-842d-4aee-b1dc-17ef3529bd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c82bff4b-81d0-4864-b6c8-37c2122ff5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c82bff4b-81d0-4864-b6c8-37c2122ff5bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_766f0b64-ae85-4f65-ad4e-e60da7e69e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_766f0b64-ae85-4f65-ad4e-e60da7e69e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_db12858d-bb1e-4abb-96b6-b77cbcd623ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesIssued_db12858d-bb1e-4abb-96b6-b77cbcd623ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9fa908a0-a350-4c1d-93ca-e55d26ac2dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9fa908a0-a350-4c1d-93ca-e55d26ac2dff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_da2ae359-b0ba-49b0-aa7b-a06cfe002ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_da2ae359-b0ba-49b0-aa7b-a06cfe002ef6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_364d2242-64f5-472d-9e0d-89536361fba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_364d2242-64f5-472d-9e0d-89536361fba7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_191b30ce-eb68-4b73-9d45-132a1d96c789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockSharesIssued_191b30ce-eb68-4b73-9d45-132a1d96c789" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_aa90863c-4481-40de-8481-3a80f0fb332a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_TreasuryStockShares_aa90863c-4481-40de-8481-3a80f0fb332a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dffaf25f-8977-4dc9-9902-e4d5ca9425c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:to="loc_us-gaap_EquityComponentDomain_dffaf25f-8977-4dc9-9902-e4d5ca9425c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:to="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_229f50a4-e769-41dd-b858-e8040618d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:to="loc_us-gaap_CommonStockMember_229f50a4-e769-41dd-b858-e8040618d01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_41504111-f221-4b57-bd79-4edbc0744480_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:to="loc_srt_ScenarioUnspecifiedDomain_41504111-f221-4b57-bd79-4edbc0744480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03c7b25e-3560-4898-a8d6-29684d0155d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03c7b25e-3560-4898-a8d6-29684d0155d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68803d4b-a51e-46f7-afc5-e771fe301984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:to="loc_us-gaap_ClassOfStockDomain_68803d4b-a51e-46f7-afc5-e771fe301984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a640b596-0fd0-4d18-8c41-2f0964585cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:to="loc_us-gaap_ClassOfStockDomain_a640b596-0fd0-4d18-8c41-2f0964585cc8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="ie03e94d8c4e545c1b4255d08ededeb0b_ConsolidatedStatementsofComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_765f3816-e70c-46ba-af52-d5ff29b976aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_765f3816-e70c-46ba-af52-d5ff29b976aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a588acc5-4dd5-443b-87f3-345bb0afdf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a588acc5-4dd5-443b-87f3-345bb0afdf5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_3a961e9c-680b-4779-99ff-2432e7147d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_3a961e9c-680b-4779-99ff-2432e7147d1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_71d92225-3aef-4b4e-8ee8-597330ba385b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_Revenues_71d92225-3aef-4b4e-8ee8-597330ba385b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_175f36f8-85de-484d-855d-cff17ef8a860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_175f36f8-85de-484d-855d-cff17ef8a860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0995f3c2-5b00-4d37-bfb5-e546ec550be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0995f3c2-5b00-4d37-bfb5-e546ec550be7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c69c1242-4879-495b-b302-058f32cd8b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c69c1242-4879-495b-b302-058f32cd8b5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e37def-f541-4f5c-a8ef-5b6a5de51b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e37def-f541-4f5c-a8ef-5b6a5de51b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e59f6ac5-8897-4fb2-9cda-319493a0a988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e59f6ac5-8897-4fb2-9cda-319493a0a988" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f487fb8d-1276-49b7-95aa-612e37e38523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_OperatingExpenses_f487fb8d-1276-49b7-95aa-612e37e38523" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_ade44b47-8574-4c8f-abe0-f768cbe5a6ea" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_ade44b47-8574-4c8f-abe0-f768cbe5a6ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e757a76e-8067-4129-b84c-63d316c6f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_e757a76e-8067-4129-b84c-63d316c6f2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9ffdab65-3191-4c3e-9c54-77c112996d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9ffdab65-3191-4c3e-9c54-77c112996d0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_37d908bc-fd18-48ac-901f-4a6d8c8add0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_InterestExpense_37d908bc-fd18-48ac-901f-4a6d8c8add0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5404c4da-f842-4a57-955d-35bfad65d138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5404c4da-f842-4a57-955d-35bfad65d138" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52f521d6-9d54-4770-8fe7-ae45bb99a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52f521d6-9d54-4770-8fe7-ae45bb99a09c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7d1d1131-3601-4061-9d39-0b92e1cff725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7d1d1131-3601-4061-9d39-0b92e1cff725" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47f7e4c2-6972-4c44-bb7e-ff72455eeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_NetIncomeLoss_47f7e4c2-6972-4c44-bb7e-ff72455eeaeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2bf6864b-c7b7-4870-adeb-f749ad5847ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2bf6864b-c7b7-4870-adeb-f749ad5847ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_52ff9513-6ed7-4122-ac54-47e6f24b932d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_52ff9513-6ed7-4122-ac54-47e6f24b932d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3bfb991-21d5-4277-ab92-cd1a84311f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3bfb991-21d5-4277-ab92-cd1a84311f43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_339253ee-f8f4-4de1-8bef-bbb18e046e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_339253ee-f8f4-4de1-8bef-bbb18e046e4d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8d257cd-5b78-4a0c-aad4-f9b5e659fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8d257cd-5b78-4a0c-aad4-f9b5e659fd07" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_ce677c3e-4c00-49dd-a23e-8f74086e532e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_ce677c3e-4c00-49dd-a23e-8f74086e532e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:to="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_329624b7-1b9e-48ca-ba69-4536eb35ce1b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_329624b7-1b9e-48ca-ba69-4536eb35ce1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_50067e02-3ec6-4017-9a83-587719010b2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_50067e02-3ec6-4017-9a83-587719010b2c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20211231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended" id="ia191f9870f554aa1b9b492b5f9e0e815_StatementsofComprehensiveLossParentheticalsParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_3a830d04-0dd5-441a-862a-4491b3e472e4" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_3a830d04-0dd5-441a-862a-4491b3e472e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_4502b0ce-0e30-4408-a024-574d266cbc49" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_4502b0ce-0e30-4408-a024-574d266cbc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:to="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:to="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_02c26d22-002f-4205-868e-831583869d3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_02c26d22-002f-4205-868e-831583869d3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6d7d65aa-dfc9-4a0c-8744-b52d9208c2e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6d7d65aa-dfc9-4a0c-8744-b52d9208c2e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i9875241bc19a4ae7a9a76dc7a70920dd_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_035d255f-a589-4dd7-86df-1ac6ed051e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_035d255f-a589-4dd7-86df-1ac6ed051e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8aa941c7-8502-4b27-8883-3e3bf5165f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockholdersEquity_8aa941c7-8502-4b27-8883-3e3bf5165f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07c604e6-879a-49f4-9f35-d32b060621f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07c604e6-879a-49f4-9f35-d32b060621f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20a878a0-58a5-496b-8942-d450b39f954d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20a878a0-58a5-496b-8942-d450b39f954d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca9883ab-f530-41e5-b8ca-7f7d54b5cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca9883ab-f530-41e5-b8ca-7f7d54b5cecb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a7e72fff-6a31-44d9-a602-86273ea944d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a7e72fff-6a31-44d9-a602-86273ea944d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_88cddc43-bc1d-4f6b-8420-6c9228d7711f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_88cddc43-bc1d-4f6b-8420-6c9228d7711f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e438a44-0843-4d3a-baaf-2d561529d81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e438a44-0843-4d3a-baaf-2d561529d81b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_39a74a00-1d59-4159-aa1e-194da8390076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_39a74a00-1d59-4159-aa1e-194da8390076" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_54740bfa-f561-42ed-8533-b74b5240a566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_54740bfa-f561-42ed-8533-b74b5240a566" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b2d8aa8-da93-48d9-857d-77cbea204ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_NetIncomeLoss_2b2d8aa8-da93-48d9-857d-77cbea204ed2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4f2dfdbe-79af-4932-9af1-38d5711a7510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4f2dfdbe-79af-4932-9af1-38d5711a7510" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fa9d66f2-7684-4f5d-a39f-db75db5e960b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_136ce4c5-b71e-4ee9-b0a7-f9c068989ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_d4468030-889c-4dce-91b2-b41c182c5897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_d4468030-889c-4dce-91b2-b41c182c5897" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_fbea0609-90dc-4318-b53e-5785655586cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_fbea0609-90dc-4318-b53e-5785655586cf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b7f95c4-bbf2-483d-803d-edbccb59f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b7f95c4-bbf2-483d-803d-edbccb59f9b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_bf4f216e-0fa1-4c8b-92aa-432639067bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_bf4f216e-0fa1-4c8b-92aa-432639067bf2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8e8bd27e-c58c-4ec2-8ae9-8649328941d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8e8bd27e-c58c-4ec2-8ae9-8649328941d3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_2e3e3fe8-9232-439c-8721-4c371a94a628" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_2e3e3fe8-9232-439c-8721-4c371a94a628" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a744a4e7-fefc-49f0-88b7-11fe2df54fae" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a744a4e7-fefc-49f0-88b7-11fe2df54fae" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_692fc6ed-e9e2-440a-a5a3-9f3fad4388ac" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_692fc6ed-e9e2-440a-a5a3-9f3fad4388ac" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_ec217246-5a1e-467f-afe4-c289043a9471" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_ec217246-5a1e-467f-afe4-c289043a9471" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_50cd0297-fa72-4c32-a6dc-96f1e202fdfb" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_50cd0297-fa72-4c32-a6dc-96f1e202fdfb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_c9932404-0c94-4da1-951e-bbe71297ba9b" xlink:href="lxrx-20211231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_c9932404-0c94-4da1-951e-bbe71297ba9b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_6ae7553a-fc50-4f8f-aa2a-7b7014c3a79a" xlink:href="lxrx-20211231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_6ae7553a-fc50-4f8f-aa2a-7b7014c3a79a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_e1db2322-fb4c-4404-a401-b984e2ca52c9" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ATMOfferingTotal_e1db2322-fb4c-4404-a401-b984e2ca52c9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_410b3d40-5b4f-49a0-8b13-7b0ef0de6a02" xlink:href="lxrx-20211231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_410b3d40-5b4f-49a0-8b13-7b0ef0de6a02" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_065df43b-6b7e-4095-81dc-086a3f109780" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_065df43b-6b7e-4095-81dc-086a3f109780" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8edf17ed-5038-41c7-825a-e44d0a313042_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:to="loc_us-gaap_EquityComponentDomain_8edf17ed-5038-41c7-825a-e44d0a313042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:to="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed6df58f-ade0-484f-9a8a-842aad53108f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_CommonStockMember_ed6df58f-ade0-484f-9a8a-842aad53108f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e20afdcc-58c8-4bbe-8029-33ea01dd6614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e20afdcc-58c8-4bbe-8029-33ea01dd6614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c0d15218-3fd7-4a45-a315-8f61f1a7e03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_RetainedEarningsMember_c0d15218-3fd7-4a45-a315-8f61f1a7e03b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d943b09-418e-49a3-afff-bc783746f69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d943b09-418e-49a3-afff-bc783746f69c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_31b37f4e-981a-4f96-a041-8379b4970490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_TreasuryStockMember_31b37f4e-981a-4f96-a041-8379b4970490" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="ie1d55f1bf71a455ebdf70fe9a9e66402_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ef872db-109b-44a7-9e21-6d5b0259403a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_ProfitLoss_2ef872db-109b-44a7-9e21-6d5b0259403a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98e91e06-8d64-4b95-88ed-bff3601def87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98e91e06-8d64-4b95-88ed-bff3601def87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a30c2317-cf73-4f3e-9f84-8d388fbfdb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_ShareBasedCompensation_a30c2317-cf73-4f3e-9f84-8d388fbfdb61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_6043bb29-723d-48e7-abfd-ce042143d365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_6043bb29-723d-48e7-abfd-ce042143d365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a56694e4-5c55-4ce9-ae49-1e8b36bd2b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a56694e4-5c55-4ce9-ae49-1e8b36bd2b5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0d82279c-e5e0-4e97-8d8f-45dd4c84dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0d82279c-e5e0-4e97-8d8f-45dd4c84dbb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3024b6eb-a712-466b-99fb-a0d5e270d410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3024b6eb-a712-466b-99fb-a0d5e270d410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56aba8a6-280f-4005-ab40-712ab6339f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56aba8a6-280f-4005-ab40-712ab6339f2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82d7c452-9cfd-4923-92ac-90bca8e17b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82d7c452-9cfd-4923-92ac-90bca8e17b00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_132e3190-b7f5-4bce-aac6-80f516ed4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_132e3190-b7f5-4bce-aac6-80f516ed4a90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e4d85684-02ce-49db-810d-74b85e541590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e4d85684-02ce-49db-810d-74b85e541590" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82cf8169-2f56-4003-9962-709405aeb5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82cf8169-2f56-4003-9962-709405aeb5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad926764-b572-43d1-9b05-364a214e9192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad926764-b572-43d1-9b05-364a214e9192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8e459f70-c993-4471-bf26-26dd4e8752ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8e459f70-c993-4471-bf26-26dd4e8752ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bba7c471-3c96-4027-8d6e-33b8932edab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bba7c471-3c96-4027-8d6e-33b8932edab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_017a49c5-7155-418c-98d4-37406632d7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_017a49c5-7155-418c-98d4-37406632d7ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c64ae282-bd4e-47d0-96b7-4821d5e97e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c64ae282-bd4e-47d0-96b7-4821d5e97e90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b08e85-e37a-4382-aaed-31e3e656decf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b08e85-e37a-4382-aaed-31e3e656decf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a51f3ced-5379-49ee-bf66-953397a080ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a51f3ced-5379-49ee-bf66-953397a080ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_147be746-ff37-4b02-9a5e-cd6b2d489839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_147be746-ff37-4b02-9a5e-cd6b2d489839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f4ce75b8-8814-4970-99ba-a676c7fa55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f4ce75b8-8814-4970-99ba-a676c7fa55e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1a6f721d-a35c-46ad-90e3-0b944793344e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1a6f721d-a35c-46ad-90e3-0b944793344e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63f713b8-3bcb-40a6-8386-f6128734d2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63f713b8-3bcb-40a6-8386-f6128734d2b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76a333a0-b4d5-4dd9-ad82-b266466d7617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76a333a0-b4d5-4dd9-ad82-b266466d7617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6827f682-4409-49cf-890a-847e277d9250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6827f682-4409-49cf-890a-847e277d9250" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_931e27cb-c516-4095-905d-dea6fe229fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b34a902e-84f8-4f05-b28e-758ba951fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:to="loc_us-gaap_InterestPaidNet_b34a902e-84f8-4f05-b28e-758ba951fa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bc0c9afe-0cf5-4e0b-b924-f421e2b78ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bc0c9afe-0cf5-4e0b-b924-f421e2b78ef7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ef8350ad-e247-435b-a4f6-a02f453ecd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ef8350ad-e247-435b-a4f6-a02f453ecd29" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_51039df2-577d-4ed7-b18a-a991cb957995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_51039df2-577d-4ed7-b18a-a991cb957995" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_316ff804-69d1-40c2-aa44-4d26b8d67f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_316ff804-69d1-40c2-aa44-4d26b8d67f64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_36bccf9d-d8f9-4ebf-9011-6d5b2ca4d4f9" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_36bccf9d-d8f9-4ebf-9011-6d5b2ca4d4f9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_fd5319ee-9b40-447b-8314-ed5a9e986f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_fd5319ee-9b40-447b-8314-ed5a9e986f4d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de4f68c7-2fa8-491c-a5f2-9fd9430b1949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de4f68c7-2fa8-491c-a5f2-9fd9430b1949" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7e6d3d8f-2df1-4c00-a08b-0d771facd107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_AssetImpairmentCharges_7e6d3d8f-2df1-4c00-a08b-0d771facd107" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3ea060af-179b-44d4-8eb2-c95dd10b46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3ea060af-179b-44d4-8eb2-c95dd10b46e6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_61b8cdcf-a575-4261-bfd4-0c02dff512ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_61b8cdcf-a575-4261-bfd4-0c02dff512ad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3d848b51-5029-483d-a726-3984261c9676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_SeveranceCosts1_3d848b51-5029-483d-a726-3984261c9676" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bab3b95c-3509-4769-bb47-c36dec43fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bab3b95c-3509-4769-bb47-c36dec43fe5d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3310cc92-b502-4b14-8cdd-6bc1758fe5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3310cc92-b502-4b14-8cdd-6bc1758fe5d9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:to="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f056931d-1ea9-4276-89d4-3dafabf7191c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f056931d-1ea9-4276-89d4-3dafabf7191c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d684994e-2b3e-4cb8-8672-3b9e83961c58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d684994e-2b3e-4cb8-8672-3b9e83961c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_a7eaed69-3590-46e4-b54d-55269e75725a" xlink:href="lxrx-20211231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:to="loc_lxrx_RDSeveranceCostsMember_a7eaed69-3590-46e4-b54d-55269e75725a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended" id="i48367ffebce34ea09ed762db9176d06a_SummaryofSignificantAccountingPoliciesIntangibleassetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_bb68482b-2569-4991-a2dd-142e712c831d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_bb68482b-2569-4991-a2dd-142e712c831d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_b81e1e91-3a0d-4a76-9073-d9e55b01362a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_b81e1e91-3a0d-4a76-9073-d9e55b01362a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_933e5957-40bc-41af-990f-669e9b573044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_933e5957-40bc-41af-990f-669e9b573044" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69926265-042f-4e19-bdcf-802cddac3e80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69926265-042f-4e19-bdcf-802cddac3e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e692aef-4775-4a29-8c50-de6e1540d424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e692aef-4775-4a29-8c50-de6e1540d424" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="ifec7c8309f6b41bfae380cc59bd6e661_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1449bfe-786a-4932-9eda-8817b7438b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1449bfe-786a-4932-9eda-8817b7438b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_c1757008-d0b9-4273-85d1-b67692af8479" xlink:href="lxrx-20211231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_c1757008-d0b9-4273-85d1-b67692af8479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_c9919840-6d26-4a0f-8063-d76eba29ed02" xlink:href="lxrx-20211231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_c9919840-6d26-4a0f-8063-d76eba29ed02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_557ed2dd-1097-4fdd-8e0e-d6be2a044d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_557ed2dd-1097-4fdd-8e0e-d6be2a044d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a35f5111-d6bf-4ed0-bca0-0992e08206f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a35f5111-d6bf-4ed0-bca0-0992e08206f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_322bfc2f-88b5-4a81-8e4a-35eb319152bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_322bfc2f-88b5-4a81-8e4a-35eb319152bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:to="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39823091-54ee-4e4d-ad9a-13860b9925a9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:to="loc_srt_RangeMember_39823091-54ee-4e4d-ad9a-13860b9925a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:to="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ce3f2bbf-5a5d-43b5-9fbc-e90be8838c02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:to="loc_srt_MinimumMember_ce3f2bbf-5a5d-43b5-9fbc-e90be8838c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_233f4f8d-4c9e-440f-b67b-c3195af474e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:to="loc_srt_MaximumMember_233f4f8d-4c9e-440f-b67b-c3195af474e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended" id="i3fad0b52ac764b708b8ca9eb21bb36d3_SummaryofSignificantAccountingPoliciesCostofSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_041c7f14-a108-477b-bccf-13968bec427f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_041c7f14-a108-477b-bccf-13968bec427f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6256d2d-0893-47c2-8a75-5d1a20b92f0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6256d2d-0893-47c2-8a75-5d1a20b92f0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d80a60f2-4711-43d2-9587-b62c41791f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d80a60f2-4711-43d2-9587-b62c41791f19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended" id="i6050cb301cd6476e8951cf05bd17f8db_SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_50478ec2-c9d7-42f3-9b32-6183848f93ae" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_50478ec2-c9d7-42f3-9b32-6183848f93ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_a9bb3d50-9ccd-45e7-986f-e56bb2432c02" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_a9bb3d50-9ccd-45e7-986f-e56bb2432c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_c474bf55-6272-43e6-9384-57b4714fbd63" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_c474bf55-6272-43e6-9384-57b4714fbd63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_0acbf815-1962-4a01-aae0-5e36073613d2" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_0acbf815-1962-4a01-aae0-5e36073613d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_89802a53-6063-4ff1-ad82-9e5e926e3f04" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_89802a53-6063-4ff1-ad82-9e5e926e3f04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_5994130f-fc98-4d75-9692-3ce466248a5b" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_5994130f-fc98-4d75-9692-3ce466248a5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_0135fa43-b724-4316-afdf-371f338d381d" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_0135fa43-b724-4316-afdf-371f338d381d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d738522a-da1d-459f-963f-3a2e013a968b" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d738522a-da1d-459f-963f-3a2e013a968b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa444d24-c170-4269-b44d-1aced012210f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa444d24-c170-4269-b44d-1aced012210f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:to="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88ddf5bd-90fe-4100-87ca-544c6e07be5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88ddf5bd-90fe-4100-87ca-544c6e07be5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6724c576-0d9b-4ff1-8da7-9ad39ac8f604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:to="loc_us-gaap_StockOptionMember_6724c576-0d9b-4ff1-8da7-9ad39ac8f604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b61e513-ebc7-4a2b-8677-98e805cc6b71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b61e513-ebc7-4a2b-8677-98e805cc6b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6354f0a5-7132-47bf-a2bd-b92c95b6d2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6354f0a5-7132-47bf-a2bd-b92c95b6d2ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" id="i08eac0a8bbc34ed2862c79d8c0466bee_RecentAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e28b7db0-fb18-44a9-9ed6-c4774eb4f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e28b7db0-fb18-44a9-9ed6-c4774eb4f09b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3c1c6c6d-0a8a-41ac-972c-c00499fed8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3c1c6c6d-0a8a-41ac-972c-c00499fed8b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="ie9623fbb58eb40448ac4220dbdc1ffaf_CashandCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_0f63d2ba-0a76-4f0f-aa0a-6c9b54dbd262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_0f63d2ba-0a76-4f0f-aa0a-6c9b54dbd262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2ce59521-d398-4ef9-9704-c60035f907d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2ce59521-d398-4ef9-9704-c60035f907d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dc1a4b91-5c20-4228-9b66-307660872ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dc1a4b91-5c20-4228-9b66-307660872ca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_645399b1-cdce-49ce-a234-58c0f3347e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_645399b1-cdce-49ce-a234-58c0f3347e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_b8fd90ac-5b91-4678-8a31-26ee5b1d6253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_b8fd90ac-5b91-4678-8a31-26ee5b1d6253" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:to="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f9de2f20-beeb-4124-a4b0-d44eb508017c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f9de2f20-beeb-4124-a4b0-d44eb508017c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_21426f79-8cff-40ee-9d96-c5c4e02fa8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_CashMember_21426f79-8cff-40ee-9d96-c5c4e02fa8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_caa55123-131d-4cd0-b4b8-56157e7a4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_caa55123-131d-4cd0-b4b8-56157e7a4cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d15fee10-9cd7-4a50-b9a7-b21288ce1e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d15fee10-9cd7-4a50-b9a7-b21288ce1e8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_80d8a23e-3644-45d2-9333-cc3b8900eebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_InvestmentsMember_80d8a23e-3644-45d2-9333-cc3b8900eebf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i2559fbd3b84b46de82fb03f07b08cdbe_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb8b9930-fa99-4dde-9a10-8c0e96e7d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb8b9930-fa99-4dde-9a10-8c0e96e7d6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_5d744b63-429e-4b1d-b75c-5dc776f20316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_AvailableForSaleSecurities_5d744b63-429e-4b1d-b75c-5dc776f20316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_d893c9ae-3879-42a7-8994-0e5067309363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_d893c9ae-3879-42a7-8994-0e5067309363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d209b0da-5aca-4e1a-96ba-a7858d91cd44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d209b0da-5aca-4e1a-96ba-a7858d91cd44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d0a7f1ca-ffd9-4f9e-864c-6c4f0a2dbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d0a7f1ca-ffd9-4f9e-864c-6c4f0a2dbb15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_914a7370-21b0-4673-968f-491ea259dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_914a7370-21b0-4673-968f-491ea259dba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7167daae-48b3-4a72-bb89-7ef3ac8404ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7167daae-48b3-4a72-bb89-7ef3ac8404ef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="iab92f25c8950442687ffce8d4b446f73_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_48c861a8-bb98-4973-aedf-fabffdb68638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_48c861a8-bb98-4973-aedf-fabffdb68638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d914b-26f6-4509-84aa-f11bf91a829f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d914b-26f6-4509-84aa-f11bf91a829f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d1e25c2b-96ed-456e-b285-c4ffd425ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d1e25c2b-96ed-456e-b285-c4ffd425ea49" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ibef0b32e867b43728b59a0d297d97fd4_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1986dde4-b0e0-4bbf-82ef-77aac380d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1986dde4-b0e0-4bbf-82ef-77aac380d13b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_22fecd9a-e777-4ba2-a1d3-6ab84f3dfcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_22fecd9a-e777-4ba2-a1d3-6ab84f3dfcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5999a5c-3392-4284-bf47-fd1b3b8672da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5999a5c-3392-4284-bf47-fd1b3b8672da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a283ed6-5995-4160-b1e1-3054c9b35e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a283ed6-5995-4160-b1e1-3054c9b35e8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_96ddb2e0-0159-4eae-b279-069316b39ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_96ddb2e0-0159-4eae-b279-069316b39ad6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_8d034c38-9c2b-4f95-be7d-54a79e79ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_Land_8d034c38-9c2b-4f95-be7d-54a79e79ebda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements_b97aaf08-4ec1-4406-b982-cb641cc21198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_InventoryBuildingsAndImprovements_b97aaf08-4ec1-4406-b982-cb641cc21198" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1a947a0a-1b69-42b8-9cb7-c3a41609c92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_AssetImpairmentCharges_1a947a0a-1b69-42b8-9cb7-c3a41609c92d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_70177cbc-f411-45e3-94fd-e22638fb7e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_70177cbc-f411-45e3-94fd-e22638fb7e90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_3359a48d-3d03-42b0-aacb-4d9727a4119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_3359a48d-3d03-42b0-aacb-4d9727a4119e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5537058-d838-41da-8763-d7b3f3ea436b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5537058-d838-41da-8763-d7b3f3ea436b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b70d7b03-7786-4f25-b7ae-3723f80d974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_ComputerEquipmentMember_b70d7b03-7786-4f25-b7ae-3723f80d974f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9235079b-0950-41a5-8a95-26038f8d153c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9235079b-0950-41a5-8a95-26038f8d153c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c101fe42-3734-41a8-99a4-1de439f600bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_EquipmentMember_c101fe42-3734-41a8-99a4-1de439f600bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8e55f27e-f49c-40f9-b277-9de884c95ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8e55f27e-f49c-40f9-b277-9de884c95ec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c74e457c-4384-4d4a-8259-d5cb097557d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c74e457c-4384-4d4a-8259-d5cb097557d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_744c6a58-29b3-4126-8ab4-4918efaa8af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_LandMember_744c6a58-29b3-4126-8ab4-4918efaa8af7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:to="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2f19845-c31b-4a11-b4d8-c36b8b62cc86_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:to="loc_srt_RangeMember_f2f19845-c31b-4a11-b4d8-c36b8b62cc86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:to="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_339d5dec-ed95-4625-8a92-95047966beea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:to="loc_srt_MinimumMember_339d5dec-ed95-4625-8a92-95047966beea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_502fc1df-c820-4e27-afb3-c73c112f8f10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:to="loc_srt_MaximumMember_502fc1df-c820-4e27-afb3-c73c112f8f10" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended" id="ie7707697f23445afbc49635b83530465_IncomeTaxesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6daeeebb-be20-46fb-a6a4-407e4f6711df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6daeeebb-be20-46fb-a6a4-407e4f6711df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d40c1117-fb45-482d-abd7-15a1566d69e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d40c1117-fb45-482d-abd7-15a1566d69e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_59f2747e-5842-4834-b102-0fe2392756bd" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_59f2747e-5842-4834-b102-0fe2392756bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa6373f2-636b-4381-b6a8-99d8769751d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa6373f2-636b-4381-b6a8-99d8769751d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1649fe1c-98e8-4464-9ac3-c667b8d71a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1649fe1c-98e8-4464-9ac3-c667b8d71a38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1002da13-c991-4b7f-989b-db95573214ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1002da13-c991-4b7f-989b-db95573214ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2e659190-26e3-45b1-8d53-3d32c2196a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2e659190-26e3-45b1-8d53-3d32c2196a7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_b0a915a5-109b-4f77-93e7-09544c9a6465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_b0a915a5-109b-4f77-93e7-09544c9a6465" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b7f8f8fe-221e-452f-a534-7330d98a54cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b7f8f8fe-221e-452f-a534-7330d98a54cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32cc57d2-98aa-4da9-8f86-d239512b702f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32cc57d2-98aa-4da9-8f86-d239512b702f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ade17fc5-6f43-42a8-8718-cd44026c8248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_ade17fc5-6f43-42a8-8718-cd44026c8248" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4fb8210c-a2ef-4829-b0aa-c37075e575b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4fb8210c-a2ef-4829-b0aa-c37075e575b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease_9da5fe5d-1a53-49f3-9e8c-cb997dc32c37" xlink:href="lxrx-20211231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_A2020FederalNOLIncrease_9da5fe5d-1a53-49f3-9e8c-cb997dc32c37" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs_45fa925a-b811-46fb-b259-891d93ff4f44" xlink:href="lxrx-20211231.xsd#lxrx_DecreaseInNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DecreaseInNOLs_45fa925a-b811-46fb-b259-891d93ff4f44" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease_18e529e0-2a17-418d-86e3-e4c20263205c" xlink:href="lxrx-20211231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_RDTaxCreditDecrease_18e529e0-2a17-418d-86e3-e4c20263205c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_8662fedd-0c2a-41c8-88d1-77ef23314490" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_8662fedd-0c2a-41c8-88d1-77ef23314490" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_61e6c4b8-d7d6-477e-a9f1-b75de139031f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_61e6c4b8-d7d6-477e-a9f1-b75de139031f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cab11ba3-7f44-4a0f-885b-a1b0cf23a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cab11ba3-7f44-4a0f-885b-a1b0cf23a7fd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_6ee7bb9e-155a-4151-808f-5f0503717efd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_6ee7bb9e-155a-4151-808f-5f0503717efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3a647b71-6395-46a4-aa98-4156365bad48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3a647b71-6395-46a4-aa98-4156365bad48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" id="ibffcee9f3ca74883a2831a2939f1e37d_IncomeTaxesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_c6f93116-d0cb-42ad-a867-b72f49a96532" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_c6f93116-d0cb-42ad-a867-b72f49a96532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ff9091e-2644-46cd-8dff-02fc404c4396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ff9091e-2644-46cd-8dff-02fc404c4396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_330e279c-feb2-45e0-82ff-948516f6b269_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_330e279c-feb2-45e0-82ff-948516f6b269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c44f15f8-103e-49ea-a974-c402c067173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c44f15f8-103e-49ea-a974-c402c067173c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#DebtObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended" id="ie55c800151e74f84865ab55d8db9ae8f_DebtObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_d3b01e61-8dfc-46a2-aa45-fc0941c4e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_d3b01e61-8dfc-46a2-aa45-fc0941c4e27e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_aedaceba-1fa7-4831-831f-b475fd315b30" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_aedaceba-1fa7-4831-831f-b475fd315b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bebd66d5-f474-4a5b-be09-e244c1b0079b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bebd66d5-f474-4a5b-be09-e244c1b0079b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_28d0fd0d-2ca0-4348-9973-e32bcc739347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_28d0fd0d-2ca0-4348-9973-e32bcc739347" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_91a7ec99-702c-4ad3-9c6d-c41c89313f42" xlink:href="lxrx-20211231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_91a7ec99-702c-4ad3-9c6d-c41c89313f42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_658a1508-2444-49e4-9d2e-80af67e283d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_658a1508-2444-49e4-9d2e-80af67e283d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_29a41e71-f6dd-49b9-b0f3-801344a670b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentTerm_29a41e71-f6dd-49b9-b0f3-801344a670b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a2bf6bcf-e032-4ea4-8826-c4842bda12d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a2bf6bcf-e032-4ea4-8826-c4842bda12d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_24672da6-635a-4103-887b-31a2fd705ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentFairValue_24672da6-635a-4103-887b-31a2fd705ef9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d396cd66-a382-41f8-a133-0fca83ca47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d396cd66-a382-41f8-a133-0fca83ca47b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b826646-dcb3-4e40-9214-a9fdb0b09580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b826646-dcb3-4e40-9214-a9fdb0b09580" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99c558c3-83b5-42a2-97b9-be3072cad92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99c558c3-83b5-42a2-97b9-be3072cad92f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_e3ea6386-c5d7-474a-b151-00c19d50dbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_e3ea6386-c5d7-474a-b151-00c19d50dbed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5c2ecd5f-87bd-4cc2-a360-cb997c9c192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5c2ecd5f-87bd-4cc2-a360-cb997c9c192c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_57009c7c-df38-4486-a197-40bebe15f478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_57009c7c-df38-4486-a197-40bebe15f478" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_57a7b80b-cda6-4dab-8323-b1c2dc044380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_ConvertibleDebt_57a7b80b-cda6-4dab-8323-b1c2dc044380" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_2328ed2f-9197-4da0-b074-884d7687c306" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_2328ed2f-9197-4da0-b074-884d7687c306" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_66583cca-896d-4745-8642-2bf983d2d05f" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_66583cca-896d-4745-8642-2bf983d2d05f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_fbf86389-8562-4586-802d-e4af4e4c8f0e" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_fbf86389-8562-4586-802d-e4af4e4c8f0e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f2da0430-f793-4a36-8e50-c786db2f1257" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f2da0430-f793-4a36-8e50-c786db2f1257" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_d975ebab-0519-4416-9e67-cb9fd2bcbec3" xlink:href="lxrx-20211231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_d975ebab-0519-4416-9e67-cb9fd2bcbec3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_15478960-47af-4f75-8a38-5f6b0db83cb1" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtExchange_15478960-47af-4f75-8a38-5f6b0db83cb1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_263afc15-a500-4a8a-8e66-80051af82a21" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_263afc15-a500-4a8a-8e66-80051af82a21" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_d0858472-cc5d-4449-bce6-fd5b14546f0d" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_d0858472-cc5d-4449-bce6-fd5b14546f0d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_6734650a-f910-456e-9fa2-fafc1df991e6" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_6734650a-f910-456e-9fa2-fafc1df991e6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_2a6b63f1-22a2-4277-bd62-7c4d287f65c1" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_2a6b63f1-22a2-4277-bd62-7c4d287f65c1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91663526-9e21-44a9-bfaf-dc126d6c5f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91663526-9e21-44a9-bfaf-dc126d6c5f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:to="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_056b5f90-4766-4c38-bb40-8e42c6a9b705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_056b5f90-4766-4c38-bb40-8e42c6a9b705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09f5e285-8557-44fd-a8c1-490347e2c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09f5e285-8557-44fd-a8c1-490347e2c486" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="iefc0dd8aef6a4cb5b90d4e2586288360_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_c27320b4-2412-4dce-93c4-195faa33c790" xlink:href="lxrx-20211231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_c27320b4-2412-4dce-93c4-195faa33c790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate_2f1a54af-6b45-4d91-9ddd-b95d1557ca6f" xlink:href="lxrx-20211231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_LexiconBorrowingRate_2f1a54af-6b45-4d91-9ddd-b95d1557ca6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_a0ad7267-e132-4429-883e-c0056473faef" xlink:href="lxrx-20211231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_a0ad7267-e132-4429-883e-c0056473faef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:to="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0097bd68-f66a-41d4-beb0-ef35571844dd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:to="loc_srt_RangeMember_0097bd68-f66a-41d4-beb0-ef35571844dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:to="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4f92678-a173-45db-9087-45d56d7f73fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:to="loc_srt_MinimumMember_d4f92678-a173-45db-9087-45d56d7f73fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_57c3deed-ffbb-4b73-9d97-33bc8dd1b889" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:to="loc_srt_MaximumMember_57c3deed-ffbb-4b73-9d97-33bc8dd1b889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_badee1a2-30f9-40e7-a51f-2af4f65b2fb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:to="loc_us-gaap_ReceivableTypeDomain_badee1a2-30f9-40e7-a51f-2af4f65b2fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:to="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e2099935-d22f-491e-96df-7e2ccca42f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:to="loc_us-gaap_AccountsReceivableMember_e2099935-d22f-491e-96df-7e2ccca42f10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended" id="id234e31c5fcc4e69a874dbbc834806b7_EquityIncentiveAwardsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_681ad277-56ed-4272-940c-9d17c2416a73" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_681ad277-56ed-4272-940c-9d17c2416a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8060796a-5cc2-4377-a4a0-870e00f4fdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8060796a-5cc2-4377-a4a0-870e00f4fdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcb96322-d08a-4561-903b-f2ead412b28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcb96322-d08a-4561-903b-f2ead412b28e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_bd07d084-1aa3-4f91-a853-1b34dd6cf0dd" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_bd07d084-1aa3-4f91-a853-1b34dd6cf0dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_82aa20d7-8c1c-49bd-b60f-afc03ed472d7" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_82aa20d7-8c1c-49bd-b60f-afc03ed472d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_c5f65eb3-1cda-446a-9179-0aac9929cbc2" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_c5f65eb3-1cda-446a-9179-0aac9929cbc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_345b3d95-5464-4bd1-9f13-0faa3bcac850" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_345b3d95-5464-4bd1-9f13-0faa3bcac850" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_d3e972d1-e663-4008-82e0-07a4add69582" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_d3e972d1-e663-4008-82e0-07a4add69582" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6e2f9581-ffae-44a9-9fa2-cc83927e8625" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6e2f9581-ffae-44a9-9fa2-cc83927e8625" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_8d1484e5-20fc-4174-87fb-5bdf5a6c0271" xlink:href="lxrx-20211231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_8d1484e5-20fc-4174-87fb-5bdf5a6c0271" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_5be1aa1a-9e1d-453b-b6ee-d8f32638e9aa" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_5be1aa1a-9e1d-453b-b6ee-d8f32638e9aa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_25688c61-6833-49f3-9bb5-ef56731c9e73" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_25688c61-6833-49f3-9bb5-ef56731c9e73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_2527e0d2-6e94-446a-9204-6882cf0d5d50" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_2527e0d2-6e94-446a-9204-6882cf0d5d50" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_78762a81-b956-4bc1-803c-b4a9fe7d55bf" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_78762a81-b956-4bc1-803c-b4a9fe7d55bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7c7391b-1e85-4cd9-b75d-95bbc20655ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7c7391b-1e85-4cd9-b75d-95bbc20655ce" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_021f24b6-323b-4e0e-8b94-d8ae8bf0491f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_021f24b6-323b-4e0e-8b94-d8ae8bf0491f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8b91c33f-4bd0-43f4-91e5-b437c2d7a015" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8b91c33f-4bd0-43f4-91e5-b437c2d7a015" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:to="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc08e04-166c-4056-829f-9334a35391a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc08e04-166c-4056-829f-9334a35391a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_968959cd-b8ff-4851-85cb-1040e6b35363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_968959cd-b8ff-4851-85cb-1040e6b35363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_73ff6a72-5ea5-4c7d-b60f-68e1a4f15b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:to="loc_us-gaap_RestrictedStockMember_73ff6a72-5ea5-4c7d-b60f-68e1a4f15b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:to="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b6e15b1-2ad3-4306-81cb-c521c6d54f28_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:to="loc_srt_RangeMember_9b6e15b1-2ad3-4306-81cb-c521c6d54f28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:to="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a25d51d-82f6-4d31-9027-7ba9d7befb69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:to="loc_srt_MinimumMember_6a25d51d-82f6-4d31-9027-7ba9d7befb69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2037dd0-4e4e-4aec-8e1a-c1e88c8a583a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:to="loc_srt_MaximumMember_e2037dd0-4e4e-4aec-8e1a-c1e88c8a583a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended" id="i791bbaebb2154f0d93bb28a5729762ac_EquityIncentiveAwardsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a842b6b-f4bb-43b0-b25d-df2fad0ca555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a842b6b-f4bb-43b0-b25d-df2fad0ca555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a689b73-2105-4326-8041-9cbca2f71dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a689b73-2105-4326-8041-9cbca2f71dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6545ac94-7d31-4274-8af1-f89706019aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6545ac94-7d31-4274-8af1-f89706019aec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0ab31f4-2152-4d5a-b786-918bc26359cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0ab31f4-2152-4d5a-b786-918bc26359cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cec051fb-4fcc-41b8-b64e-8ee37f89ed16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cec051fb-4fcc-41b8-b64e-8ee37f89ed16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5b5958e-4ab6-4d54-9762-61a2d783c64d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5b5958e-4ab6-4d54-9762-61a2d783c64d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93ee13d3-7710-4871-a70c-3525e61e7d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93ee13d3-7710-4871-a70c-3525e61e7d5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3967784b-b6c2-4a54-a13a-c17938219351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3967784b-b6c2-4a54-a13a-c17938219351" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbae3991-2a42-4b6e-9358-5222a330586d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbae3991-2a42-4b6e-9358-5222a330586d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2562a897-06f1-4f1e-b399-a8f5f935fb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2562a897-06f1-4f1e-b399-a8f5f935fb4f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_715dbbed-f4d9-4fae-a83c-ab0515c964ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_715dbbed-f4d9-4fae-a83c-ab0515c964ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f64fe312-2d5c-46fc-89bb-903d37b1eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f64fe312-2d5c-46fc-89bb-903d37b1eedc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fbe2f7e-9314-40db-aa9b-a2ec82f09d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fbe2f7e-9314-40db-aa9b-a2ec82f09d96" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_643d1295-f20f-4d83-bdc5-b745eff7c127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_643d1295-f20f-4d83-bdc5-b745eff7c127" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3124a0e7-db9f-4737-af64-c095dfdcb05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3124a0e7-db9f-4737-af64-c095dfdcb05c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4133a229-7fac-45ec-a5fd-db4834236307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4133a229-7fac-45ec-a5fd-db4834236307" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3f31388-4152-4977-85d7-7b810ebe98d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3f31388-4152-4977-85d7-7b810ebe98d8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90a1924b-4aa2-433e-b328-efbf3cd191b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90a1924b-4aa2-433e-b328-efbf3cd191b7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:to="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381fd436-389a-49fc-a072-e4e68b726c22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381fd436-389a-49fc-a072-e4e68b726c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_514d12e8-7100-496a-b105-31a9e8f46a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_514d12e8-7100-496a-b105-31a9e8f46a1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended" id="id796c1cab47a4139954d8b240495a8db_EquityIncentiveAwardsDetails3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_6caaf78f-1d43-45cc-b93c-e8d9f970b12a" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_6caaf78f-1d43-45cc-b93c-e8d9f970b12a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_f13b7d5c-9624-4029-9b0d-05236abae06e" xlink:href="lxrx-20211231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_f13b7d5c-9624-4029-9b0d-05236abae06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59c950dc-fa97-43e5-8c64-9add9f873470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59c950dc-fa97-43e5-8c64-9add9f873470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e05a6ed-9ead-4433-8501-05efe2eb1c99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:to="loc_us-gaap_PlanNameDomain_6e05a6ed-9ead-4433-8501-05efe2eb1c99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_deb408a7-2e27-40d5-a6e0-f3fc04607b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:to="loc_us-gaap_PlanNameDomain_deb408a7-2e27-40d5-a6e0-f3fc04607b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d22ac74-cf3d-4c31-9de9-c11289b110da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d22ac74-cf3d-4c31-9de9-c11289b110da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf692c70-6028-437a-8c48-5b16c66b56f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf692c70-6028-437a-8c48-5b16c66b56f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29c1fb75-8502-4ec4-9880-3f7f56e0ac87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:to="loc_us-gaap_ClassOfStockDomain_29c1fb75-8502-4ec4-9880-3f7f56e0ac87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97ea2c12-a6c3-453b-b6fb-96f9d1868948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:to="loc_us-gaap_ClassOfStockDomain_97ea2c12-a6c3-453b-b6fb-96f9d1868948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:to="loc_srt_RangeMember_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea26b8e0-42e1-4d2b-871a-05b15f4f867c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:to="loc_srt_RangeMember_ea26b8e0-42e1-4d2b-871a-05b15f4f867c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended" id="i44e1a61351434fef967e57fbcad6b58d_EquityIncentiveAwardsDetails4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17660da1-f986-4ce1-9626-bfb054261ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17660da1-f986-4ce1-9626-bfb054261ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa4f6b5d-e8c7-4b2e-a107-d4fcd717d6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa4f6b5d-e8c7-4b2e-a107-d4fcd717d6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de560fd5-4e6c-4cb8-960d-0cdbb3830ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de560fd5-4e6c-4cb8-960d-0cdbb3830ce5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0629d715-0225-4a55-8c7d-faeb72f7876a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0629d715-0225-4a55-8c7d-faeb72f7876a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8502a3f-be77-495b-baef-05b4f0f115ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8502a3f-be77-495b-baef-05b4f0f115ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b270e1e-eb6c-4a56-9136-0203b422a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b270e1e-eb6c-4a56-9136-0203b422a0d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f3bbc18c-1a7d-4286-be67-9c0a452fe604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f3bbc18c-1a7d-4286-be67-9c0a452fe604" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_4d63b6c8-3a9a-4e60-8a8f-581cb1811dfa" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_4d63b6c8-3a9a-4e60-8a8f-581cb1811dfa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:to="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0530df-1b87-4f3f-91a4-f6382ddb2361_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0530df-1b87-4f3f-91a4-f6382ddb2361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f5b4418-2308-452d-9453-22a69e83cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f5b4418-2308-452d-9453-22a69e83cf46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i592ff6a247d24d7d9a1352a190a5e6f4_CollaborationandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_a5f82a39-14a8-4fd8-9935-8f759658f9f4" xlink:href="lxrx-20211231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:to="loc_lxrx_SettlementPaymentFromTermination_a5f82a39-14a8-4fd8-9935-8f759658f9f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_d860c123-6c22-4e60-948f-9b5a92b78429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:to="loc_us-gaap_LegalFees_d860c123-6c22-4e60-948f-9b5a92b78429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:to="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9f3a3263-b475-4cf6-a287-a2c7ba777d64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9f3a3263-b475-4cf6-a287-a2c7ba777d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_20bd6e76-8540-46ed-a0fc-87711a45856b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:to="loc_us-gaap_SubsequentEventMember_20bd6e76-8540-46ed-a0fc-87711a45856b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended" id="i5710ed4851b8470783b782807391611d_SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_96afac51-254d-4fc4-a556-be9a3fe8b9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_Revenues_96afac51-254d-4fc4-a556-be9a3fe8b9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_717c3619-697d-4e9d-8a74-14ebe9f934f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_OperatingIncomeLoss_717c3619-697d-4e9d-8a74-14ebe9f934f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dede70b-c90a-4737-b8a1-0b83e86a7046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_NetIncomeLoss_0dede70b-c90a-4737-b8a1-0b83e86a7046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3dc82af5-aa69-435f-8553-2e034a8d3e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3dc82af5-aa69-435f-8553-2e034a8d3e99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5aa58991-b18b-45c9-90ec-6df893d4dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5aa58991-b18b-45c9-90ec-6df893d4dc19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_98e59d51-0527-4d58-8c58-b0325b543344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_EarningsPerShareDiluted_98e59d51-0527-4d58-8c58-b0325b543344" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f0ef889d-4cd5-409c-b42f-a48a27e8dd28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_EarningsPerShareBasic_f0ef889d-4cd5-409c-b42f-a48a27e8dd28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2282bd7-450c-426b-9082-21041c8ddd7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2282bd7-450c-426b-9082-21041c8ddd7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d4ce33f-1247-46c1-b46a-1d6e32fe99b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d4ce33f-1247-46c1-b46a-1d6e32fe99b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#AssetSaleDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended" id="i64240f32505a4f7c9573cdbd28301f95_AssetSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_326b334c-1340-4beb-a3c1-3fcde07c7a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_us-gaap_SeveranceCosts1_326b334c-1340-4beb-a3c1-3fcde07c7a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_cdca81ed-ce99-41e0-8c20-fa072554014f" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_cdca81ed-ce99-41e0-8c20-fa072554014f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_b384ef35-e1ef-4e37-a8c4-33bb3e125886" xlink:href="lxrx-20211231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_b384ef35-e1ef-4e37-a8c4-33bb3e125886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_fd86eed8-dfd3-4c42-98d1-cbf5a0122d5c" xlink:href="lxrx-20211231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_fd86eed8-dfd3-4c42-98d1-cbf5a0122d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713_9aacbb79-fe3a-4040-b506-5a198887beca" xlink:href="https://xbrl.sec.gov/naics/2021/naics-2021.xsd#naics_ZZ541713"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:to="loc_naics_ZZ541713_9aacbb79-fe3a-4040-b506-5a198887beca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f50f4a6-ab37-41f0-9ac0-81b9eb130d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f50f4a6-ab37-41f0-9ac0-81b9eb130d6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#OtherCapitalAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended" id="ia28df0ac97f240ecb90f6248c231aa17_OtherCapitalAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_cfbbcad8-e396-4212-b916-54b0fba75f27" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_cfbbcad8-e396-4212-b916-54b0fba75f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_3881f2a0-bfb1-493d-8aa2-0d76e24fddd2" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_3881f2a0-bfb1-493d-8aa2-0d76e24fddd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_b2d4e5b4-4e53-4156-97fe-cc7b2a9c4e99" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_b2d4e5b4-4e53-4156-97fe-cc7b2a9c4e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_4500af0b-1f36-4b29-97f2-3b44ac8f800f" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ATMOfferingTotal_4500af0b-1f36-4b29-97f2-3b44ac8f800f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOffering_2153da96-921d-4c63-aa03-967ebb7289f0" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInSeptember2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOffering_2153da96-921d-4c63-aa03-967ebb7289f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOffering_4d15369f-8090-4ae3-a735-e35e59a0c81d" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInSeptember2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOffering_4d15369f-8090-4ae3-a735-e35e59a0c81d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a8036439-a503-4585-84eb-7fdd385a8267" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a8036439-a503-4585-84eb-7fdd385a8267" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19643062-91a0-4ae9-bfff-38ae64325fe7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19643062-91a0-4ae9-bfff-38ae64325fe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b797b9b2-65eb-4c7c-b1d3-fbd1b9baf0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:to="loc_us-gaap_SubsequentEventMember_b797b9b2-65eb-4c7c-b1d3-fbd1b9baf0d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>lxrx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ca00c5d2-38ca-4b3b-880d-9b2f12c1bdea_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_8f163fde-8f89-421f-9166-3f705deb1fa4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1f131ea6-a5dd-48cc-9b5e-2218a1af522d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6fcd6e49-0023-40fe-a1a4-ff2ddd71078a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_030159f2-e2fa-48d5-bd94-09f2998152e4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_789657ca-115c-496f-97ea-df914cf299f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_586fcf96-0303-44db-9ffa-24700f60c4a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7c6a17a7-4429-4c09-94d5-125075edaf18_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f3e87af5-385a-4f6d-8348-23a7bd292f07_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cb150de2-7067-4d41-bb54-7d1cfd29d0d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9d7c77a6-b40c-4cc7-a098-64027a6152b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_95e1ca64-30de-46c3-8bf8-650fbee9b999_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_b34d6057-c148-446d-83e7-3af70609f386_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c9a7f5f4-3a7d-409e-8199-8e0cc57870d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d1016540-0f10-426b-b5d7-cc00ce8ab7ce_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7dfc2d74-3ec8-4828-aa04-aab5648091de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f0a21dcb-cb90-40f0-a9fe-8f0c154df299_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cb61da6e-205e-422e-9c0c-ea5d3b0c3c48_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_25491b89-9e8c-4d17-806e-3d29f0badb7c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6551ad3e-dacb-4115-b65a-8eae20902596_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_33aad596-e8a0-4004-aa2e-c65f80dd78ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5575c3ed-af93-49e4-883a-58e3b8418a03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_436430aa-2cb3-4e8d-9bfb-379b917a0ac0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ef02ba3d-d838-458d-88b0-f9e43f818f55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_a92dbdb6-483b-4f63-b697-b7bb98e69d0f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ff8d48f5-9827-4a1f-a90e-3a2b7b74ef77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e64dc134-945d-4cef-af6d-4ba9f2906627_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4d379037-061f-4e7e-8906-3e9b22dcf620_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:to="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9c767ca6-47ea-4e3e-a38a-401abf084e27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_2a69a5f2-400b-40e0-8f59-949eb1273a62_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_d38dd0be-210e-4752-9d86-c3847135ad98_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1d37bd53-cf80-4ea9-ad25-1336297d112d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b54d2bc1-4338-4406-b598-f57615125263_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_65056234-41fb-4c3a-b916-eae99f8920bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_faf6e1ae-69e1-496c-b4a2-a41d5c6e0eda_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20211231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_4f2aaeaa-4559-4442-82bb-9d597ae751a5_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercial milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_edb91d3c-47c0-403f-baa3-5e58c396166a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_ada9add2-ed42-4c05-9b35-b0ea310be034_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_3f38f708-7d9a-4751-9adb-4bd15c0ecc66_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9d01dc75-826a-4346-bd44-99c32d7c2272_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_naics_ZZ541713_a12cb769-af01-4655-92b4-d963b435c8ff_terseLabel_en-US" xlink:label="lab_naics_ZZ541713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">541713 Research and Development in Nanotechnology</link:label>
    <link:label id="lab_naics_ZZ541713_label_en-US" xlink:label="lab_naics_ZZ541713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">541713 Research and Development in Nanotechnology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713" xlink:href="https://xbrl.sec.gov/naics/2021/naics-2021.xsd#naics_ZZ541713"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_naics_ZZ541713" xlink:to="lab_naics_ZZ541713" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_6cafd267-d648-4aee-8200-93a1618d1d3e_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a7a20059-caf4-4408-af0f-585d530b41a8_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_9a757106-44ea-43f6-a3a0-5a2ad6ad44c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3ec5b746-abbe-458a-a08b-5fd9f3d83968_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4c965026-063f-4887-b662-eacdd107072c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_892524e3-0463-474d-be3a-6239b8c102d0_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8e276d04-beac-44c9-b19d-06baf8981413_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_7c2b8123-9994-44fa-bf1d-d84209ba71a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa0db7de-84de-4296-9a9c-4e2823399788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_40ec0858-b058-4ece-a693-d9b3c6ae74fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9c803805-81d7-41d8-8e5c-0a9be7b4c4cd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_dcc5f90e-1298-40d0-b66b-f4e3a16e172f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e578d34-5095-454f-bf9d-73ca832a4566_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_56391db6-0d64-4bd3-85c2-63b2874561a6_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f72735ee-359a-4d9c-92e2-47564abe4612_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_920d7b49-3c46-498c-b1b7-3ffc9ce6d853_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06251b10-141c-4c94-962d-5fba1901943d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c699f8b8-dad6-4a8d-b9aa-23a818131e6b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_734d330f-d012-4b46-a0a5-d947681fd12b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_546227ca-cf0c-4b57-8126-e2f366338314_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_90d516f1-6fba-4143-893e-2dc790bd78bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ca937333-e9f0-4caf-a157-a40ebdf771fa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fb657391-fa39-4251-9da1-0a28b7768f21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_273df408-3332-472f-9b89-84ed314ae118_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_88f3b5bb-f1fe-4610-aa5c-8b5497347154_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5a71681c-26e9-456b-a713-22029f6afcef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_628d96cd-a089-419a-96db-bfec312448b3_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f46cb4c3-de78-4e05-8ad5-82f94773be05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a7551b6-a3e0-4979-9e1f-fce4a84fa851_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_e8f4429f-0742-4dbb-b23d-9b1b0e0d686b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2bb754a-5a4a-4882-892d-3ab29610d3ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_29e9069f-4991-4350-bb62-183f6f405a32_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a1daab5a-d428-42d7-96f6-dd5a37728ebc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_2b4f2047-6601-4120-be5f-aa7df0fa6832_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstate" xlink:to="lab_us-gaap_MortgageLoansOnRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_b240dfdf-040c-4231-a7a1-b07ff99684b8_terseLabel_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:href="lxrx-20211231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:to="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_5bc1b032-cea7-4ee1-9347-bdc5b0afd7ca_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:href="lxrx-20211231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:to="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_480d5423-eabe-4db5-b1de-d2b10a0eec2f_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:href="lxrx-20211231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_36817d36-4bc4-4207-b541-31c15815064e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a9170771-91f2-433d-8577-23d5ce86b641_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_0518fcd7-70cb-4c11-ad29-022bf0a8f4a4_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_554bc9f2-f1d5-4511-8edd-ea14a36ba9a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ea673916-459f-4ac4-88f9-6f6070b3a608_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_8dcfbe08-c6ae-4685-888d-cf5f6ce5e254_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d02a8ff6-970d-48d0-82b8-f62e318d8255_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_11410d26-bfd8-401e-ae9e-3a6e66e8a712_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8a96c3c4-ef65-4cd7-8ddf-ae90093ac7c4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_00c5b377-36b5-4c57-af3e-08e0dbf50d93_terseLabel_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_label_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_documentation_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:href="lxrx-20211231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:to="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_96509b70-32c9-4fb1-a129-304c7cea058f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_ec887c79-bad9-46a5-a282-9b8805810571_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ab4c3c03-12f0-409a-bf7c-5a9229459bee_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fba9fd6c-2aa6-4e9f-903c-b511afdc2bff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_ef1a60c6-1b5d-428a-b4ca-08cc3d2a1a4a_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_916db697-71eb-415d-867a-17bcdebe2f1d_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_efa59a98-3b71-4434-a84f-a44c27256064_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_34e2d654-128e-4a7d-9b71-64f6e83f3680_verboseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b5e7357-d421-42fa-83e0-8bfe55f85904_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_b4970135-4d05-441a-82d2-0d28635f5b5c_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_face1f85-7589-4f02-bed0-449a95fd0260_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_db16b807-adfa-4e54-b17e-f3d98f3dbdb5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0aa72992-7dd0-4be2-8baf-09e9c37227ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_f92f523e-9141-4748-94a7-aa3c3eb140e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_688173d1-5c53-457c-9974-7aa9bcb6fc40_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_37fc0072-1425-49a1-bdf2-84ed96f913a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f087ed32-e687-4f78-bd8d-ab6249658721_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconBorrowingRate_92fcf9ab-50e6-4353-8195-121c68e1ee57_terseLabel_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate" xlink:href="lxrx-20211231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconBorrowingRate" xlink:to="lab_lxrx_LexiconBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0bbccc47-98af-4083-ab63-18c51d0b95da_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Ipsenproductsales_2b19a83d-6ca6-4901-a479-ed432c2cde54_terseLabel_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_label_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_documentation_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales" xlink:href="lxrx-20211231.xsd#lxrx_Ipsenproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Ipsenproductsales" xlink:to="lab_lxrx_Ipsenproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_24bad0aa-27aa-479c-8a67-1f6c369c0bf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dd09f7e-a91a-49c8-9d64-5b6afc20496f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_c01f1928-f27b-43bf-89b2-fb6c7af2d9cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35b8b285-b8b6-411b-9b48-d65eb7854083_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_80cab8d2-0b24-4639-9c03-60a93cb28068_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_265db8a3-3150-4745-864a-0cef0e188196_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e69b2791-19ad-431f-9740-a3a62574265b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_21d0a6a5-1ff7-4711-9e05-a4866364fdc4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_4c506c50-fb2b-4097-b059-f5ebfdc0fd98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8f66c9c4-d925-4a21-99b9-c4f32dd0a0bf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_7e39cb90-cc97-4ef5-88aa-b3ca3c5f8155_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_04a9a860-54d4-456e-87cf-378f586a564b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f8380a6a-3aed-42cc-8922-92129c553270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2c698863-6147-4ed4-8041-d9bebb8bdb3b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2a263f6e-2e90-4d71-b3db-1a437b67114c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bed7cb1c-b91c-4900-aea0-143accdd3f86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_67ccb84f-c87f-4b7a-babb-2250ba2a2d93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_25015e49-fd06-44bf-ab2e-938f83104d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_feeefb91-efa0-4e50-8caa-3c13a5f4b552_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_label_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate" xlink:href="lxrx-20211231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPaymentsToDate" xlink:to="lab_lxrx_IpsenTotalPaymentsToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthGoodwill_22176c64-2ff7-48b2-b689-8c3795fb85c8_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_label_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_documentation_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill" xlink:href="lxrx-20211231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthGoodwill" xlink:to="lab_lxrx_CoelacanthGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5be013da-684b-4a56-ae0d-2642aa8d23d8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ee25fc76-85e4-40dd-b8ec-ecd38cac48b6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e649c336-238e-4c21-b589-1c04811b25e3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_392d11f1-564f-450e-83ed-50766761afff_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:to="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_e2a3daf5-bad8-45b4-a1d6-c8e80826334e_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_c976cff5-05ee-4e21-9f34-5ec6725f23aa_terseLabel_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_label_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_documentation_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments" xlink:href="lxrx-20211231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiSalesMilestonePayments" xlink:to="lab_lxrx_SanofiSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9e586de7-0e1e-4a26-aa36-9de58b77b5a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec78b275-f877-4cb5-bc4c-fe3b2f5772a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4cecb88d-be2b-4ebd-9e42-1fcc29a9abc6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_973ced5e-5dfa-418a-9020-29e8401502f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0d877fe9-dc0a-4887-9f36-deb3de3f1702_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_f3448ae8-1d9b-414e-9972-c6c7a1c90018_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e8846bab-7c17-45c8-ad7d-38ffa1a2dabf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cca87b9a-3d83-4ff9-81c4-b1063a3ef65f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_ae8469ba-4c1a-4eaf-9a40-ecdaac910af5_terseLabel_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_label_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_documentation_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:href="lxrx-20211231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:to="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_52924c35-a164-4272-a865-3728de727daf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_c2d32b68-d697-4a1e-ba7b-1c0cfc20c333_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c887ba59-7293-4856-8810-d5e2a4f6f746_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_ff6b3815-dc09-4d87-96e4-33b1b04ae049_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_783e97ae-c47a-41ac-997b-d43792109f3f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $6,293, $6,898 and $7,122, respectively</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_04e3ba23-fdd2-4e84-acc0-fc25438b2434_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_18ff6c5e-b6f8-452f-9a62-0ed99bff4e4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_2adb43e1-cc37-411f-bdb4-b4117f3a8844_terseLabel_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:href="lxrx-20211231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:to="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b07223b7-f58a-4f91-a43b-ca45c558eb55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_9e5808d2-fb33-47e8-9902-755906616ac1_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments" xlink:href="lxrx-20211231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8d40b4fa-33a3-4927-8b86-e45d961fb85c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryBuildingsAndImprovements_03d3188b-c529-4601-a9bd-7b9c1a56399b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Buildings and Improvements</link:label>
    <link:label id="lab_us-gaap_InventoryBuildingsAndImprovements_label_en-US" xlink:label="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Buildings and Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryBuildingsAndImprovements" xlink:to="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b6c5042a-8176-4947-a7c8-8bffccbcda37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f44a5280-bdc3-418c-a14e-22f7ba8a0a8e_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_e2089021-cb3a-4e3e-80ba-3632c7da1216_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_aebe573c-259e-4b01-bdde-b5adf87833e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_6e664695-4220-41c9-8bac-1b85bf60a6ba_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3c75f66-fccd-40a4-8fcf-57d596741789_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e28a5ba2-d385-4f6d-971b-53f0a824a4d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_e6876f30-6fef-4d32-9206-9774e18ff694_terseLabel_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_label_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Commercialization Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_documentation_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:href="lxrx-20211231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:to="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_80876460-7296-4a6f-9b65-25d2283ce637_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_279afdb7-5e44-401c-8987-cc819ea821fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_c08348ce-e7b4-439a-b017-931530daf99b_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:to="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a3e2fc18-1501-489a-92a9-025ee1728657_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35a1ebab-cb15-4fb9-aa0b-f3c22324d63d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c51dadcf-a084-42d2-89c7-9b49986026d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_95fe328c-f067-429b-b7c8-51081ed591ef_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e728cbbf-ef7f-4d7a-b890-abfa09be1de5_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_d0c72475-857b-41c3-9982-503ca8c9d657_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e39ffb8-aa5b-4e25-aba0-69a1b23d620a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_7b6c7670-8bfc-4ff6-a145-7010c430bd9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d31c99db-06c1-4551-8c54-a9f3eaf2475b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DecreaseInNOLs_fdbe9f5c-7bf5-4437-8b5f-3fae2fea14a1_terseLabel_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:label id="lab_lxrx_DecreaseInNOLs_label_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:label id="lab_lxrx_DecreaseInNOLs_documentation_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs" xlink:href="lxrx-20211231.xsd#lxrx_DecreaseInNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DecreaseInNOLs" xlink:to="lab_lxrx_DecreaseInNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_7a2e5726-e576-453e-a49a-b55603b49769_terseLabel_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_label_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_documentation_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_WriteOffOfTaxCredits" xlink:href="lxrx-20211231.xsd#lxrx_WriteOffOfTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WriteOffOfTaxCredits" xlink:to="lab_lxrx_WriteOffOfTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_addaa41b-ad22-4c73-b510-8aa55bf0f7eb_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_cd13332e-da66-4055-8ec7-0ea97308b8f4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_a11ab92f-99ae-4914-882d-48afb8675a62_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_92a8b06a-9d38-495f-942e-f025e62380ff_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_83c141bb-8d8f-4de4-985e-1a0c546b70a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_e7b653dd-88ee-41cc-a76b-157009444705_terseLabel_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_label_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_documentation_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease" xlink:href="lxrx-20211231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020FederalNOLIncrease" xlink:to="lab_lxrx_A2020FederalNOLIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_775cc375-6e27-4c1e-89ff-a7c0525eccbd_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20211231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_4f4c0a85-6476-47e2-8426-41d43b7ca30f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfRealEstate" xlink:to="lab_us-gaap_ImpairmentOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_36862206-31c0-4dc4-9b7f-8a3bda14efe8_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_77f06900-27ab-43d7-ace1-a6b24bbdb903_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4c72649d-5dae-4a26-ae1d-11ec821e04e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7a4d4312-fb1e-4341-9843-362fc28fc900_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_13ddb6b3-a312-44ad-9e88-ecc7eb361c0b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_38f943c3-cea6-4c26-be93-648887615995_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_fdaf4d0b-d8dd-4820-bb0d-7cd4ec460c41_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:to="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_022884db-0f44-43ba-99b8-717cebe72b4b_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_8e6acdc1-b37d-40eb-b766-9fa92c2d68d5_terseLabel_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_label_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_documentation_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:href="lxrx-20211231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:to="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_17052778-ceb2-41d2-a50b-d7cc87cbe8fb_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5d728c29-a63a-4cf9-ab29-74802c0a1aaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5a8b29d-1c79-4690-9f2d-b571e5995aae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_09a95c08-e7e6-4f4e-b7bb-19e7d6fc621e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:to="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a6c5c5c0-27cb-4ac7-9c43-41b151814229_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c1d2fefe-7d1f-4cfc-b8b3-8c16c3f8865c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_d462ee0e-c5e4-463c-9b82-d34d3ab0e53a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_623d201d-b7d5-4b6f-98f7-af480492fb28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_8d328a49-c9ae-42ea-bbbe-ca87a390197f_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_4cbe3c1c-a891-4b4e-8036-2ad00222dddc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5c7ec7d9-610f-4bf8-a616-7284a8e36528_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_d838c1a8-47e7-4adf-a4f5-37566cfd87fc_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_label_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_documentation_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice" xlink:href="lxrx-20211231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthPurchasePrice" xlink:to="lab_lxrx_CoelacanthPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_6d8b857d-e76f-4697-9232-0b886bf78ac8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_fcc77e46-81a3-44aa-ac44-43bc6073c9af_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f52776a0-68a2-4085-9e22-9e915ff39caf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_94316f08-beff-4161-92ca-c705ea53917a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_b082ba32-f149-439b-a97a-db035bd05ada_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRegulatoryMilestones" xlink:to="lab_lxrx_SanofiRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_7da8319d-7c71-4b6f-8bb2-527995ee3763_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f3faa467-5e6d-42ad-8f3d-1b879e3a5a32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cfd79b60-55d8-438e-b109-041148ec8002_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_61a269df-3ab4-49ed-a11d-d661686b30de_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6273368c-6903-4f8d-a29e-b8ca247a8400_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cd4a9138-3713-4bbb-8762-8b6e65cffb25_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7268491e-2a64-43f1-b4d3-50779dac0915_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c75e744f-6afd-482b-bbf4-ba52edb289fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8b8b6778-7ae7-483c-8eae-a303c488f506_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_11193fd8-1087-49e4-84a1-e14bc918c344_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a159ffd-9303-4f58-9b28-f2023ac56a75_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a653662-4f64-47cd-9f1a-039ec0e48423_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_363089e0-01f6-4bf7-8f7c-ccb9bf62ae92_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_bffac9a3-ea2a-4899-8fb6-cdf43870339c_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a4c4197d-9372-439e-b3e6-09d132919b99_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_05a4d4ed-ac60-42a3-941c-6a821d62d307_terseLabel_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_label_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_documentation_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease" xlink:href="lxrx-20211231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RDTaxCreditDecrease" xlink:to="lab_lxrx_RDTaxCreditDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_47cb4b07-c8d9-4b20-8a88-b39a0fec0bc4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_1727b6d5-c63d-42c6-b8cb-c13deaf6a265_terseLabel_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_label_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_documentation_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:href="lxrx-20211231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:to="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_e4e8982a-69d9-4b20-b7da-b0b00ad36827_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f59c606c-058a-4851-ad6c-d3fc3dfca5fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_0a8e3aca-4369-4dea-9eae-28ffc079d48a_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_17f59008-3f1d-4050-93b0-2ad3a2ce6798_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09e48de9-fda1-4855-a975-70a59fe5897e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_19e8dba9-5382-4ad3-a5c9-8c9045caa1a3_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_eaf2d9ae-bbde-46e2-a12d-7117e60ae382_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_8b6cc279-674c-4ce7-9921-e451f67be4ae_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4cacb36a-882b-412d-b1cf-ccea2f630fcb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_251e95f5-3047-46ca-b3e5-aacaba19e7c0_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d223dc0e-b48c-4d26-906d-a15fb693b483_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_daf8957d-82c3-4611-83a0-e7365e221149_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d72631a-f128-4ba9-b988-54511f6edb24_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_42e9eecc-e7cc-4411-9bf0-7ea1cf97feb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae55477a-61ef-420c-a73f-ca4acab50699_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_22c78850-719a-49b8-aca8-1af4a59cab67_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_930e0be2-5114-4d28-8662-43204ac712de_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4b02aab0-629b-4dac-8b7a-96f81516056d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ac67256c-4ba6-42cc-9388-c05f59524155_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Federal</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_80811dd8-3d83-4eff-9275-1047336277bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_419cf211-d686-47cd-94bd-8e25eace20be_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4a196c38-dc4a-4335-bd6e-ecd9e49deeeb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_df2fe585-20c0-42c2-9ef6-17d007e0df8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_4ff1d382-9009-4d0b-90a3-a6d078d691f7_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_72a5a1af-6448-4b27-99a6-0c435201e945_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_02fc6c24-88a7-491f-b48b-156a596add55_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_7185d82b-d4f7-4ff5-8dc4-8237fe0c2c89_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:href="lxrx-20211231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_daaef803-851a-4e24-934f-0702dc8e99f1_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c265532c-278e-4555-80d7-9c04801de8e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_492a9f4a-927f-4e0d-b299-de26fab6ddbe_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_db8684cd-3a93-4cc8-affd-5e821e6e1c83_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of gain or loss on extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_592321fe-e6af-4f88-943c-225655faf8e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of gain or loss on extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_93c3ef22-98b8-42e1-8339-0f5b3188c9f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7ff45b77-7bbc-42f3-8204-467f3a47b4f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_d7382f07-c801-4bc5-ac05-feeaec723323_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6a6d41ec-3c91-4076-ba17-27d08592cee9_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_81e1a3f2-c255-4276-90b5-b0baa957a3a8_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:to="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_3935b10a-a4e3-4f0a-b7d3-69b0feb81eca_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_4aa1c7fc-83eb-4443-b508-d488dafa392e_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_081b0db1-b75f-4c32-839f-c5730eab0178_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4dd049cc-5a09-4d18-a3b2-fc079faf01f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2fca61fd-1641-43c6-a5c8-ccac85e99163_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_575e2a48-b414-4e28-9ee6-380f008b0ad5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_29920a0c-ce2e-4e37-bf1d-753e12a5b75a_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_1aa4dbe2-2d05-4705-b374-bc70ebc3f0fb_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_e83ecf62-17ab-4036-9279-331fbb63e744_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0b426b9e-85fa-45ab-aa73-804c8b489486_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d02873cb-cf82-4a5d-8925-ad6a227abffc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_07a5a1b6-2262-40d8-84c5-a4b64bcf57db_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_b79fb382-9889-4811-ae49-ae70a7c63fbb_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d843e397-9b34-4957-accf-56808d853467_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_26e8ef27-1534-421c-98fc-eb41253ffcdf_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_ac37fe04-5408-442d-9bc8-a4f3a3a869e2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_804db92e-c1c5-4fd1-981b-bce57fa03638_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0426c63d-05cb-47ab-a2ed-29bc64411820_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_82cda013-a34c-4981-b49d-4e8f97277678_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_a7e3b0d2-cc26-4e50-986d-11817a9df4a8_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f8d13887-3944-4c14-9f82-4ff90d0912c4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_0ee853e2-7e1a-425d-9fc4-6525416e9407_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_3f515b32-fdc3-48cd-9286-713f8cbc1879_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_79b9db39-eab3-48b7-8c1a-5e2852124dfe_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e5eb84da-5ee7-4c28-8ccf-1593fbba8a56_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aba4a87f-7506-405f-88cc-4c6c770f70e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_6f121fa5-40d4-4cab-94cd-4ab46493d4e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ac0a93f-5a2d-41a2-a280-86e153b58ec5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_dc83e538-e917-4e7d-9fa1-408d84468570_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $4</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7acb887c-d371-407a-a039-ac7e2ad1c706_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_29fbda4c-2fdb-4c6e-9e5b-9f41663e24a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ef0c15ce-32ee-4814-88d7-e78976f25dd6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_66d7d35e-0544-4106-a32b-218e47ab7fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c9a06b89-3a51-4ff2-8ceb-0ca63d845fed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_a52b4f76-3258-4331-af6e-8232a6046437_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94e7a632-191d-40eb-8871-2cd8a2393a90_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bee9b990-ca11-4626-9f26-546ee59cf791_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_7136757d-b52d-4d3b-8a8b-4b6aa26ef65e_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_5a168d51-e8b7-4f54-bfff-24d242a1d5f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_ae8f8d2d-9987-4589-8028-17aa46be405e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_99fa09a8-2d7f-4fe4-8a58-7285138888e9_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cac7a9c3-9d57-4fac-97eb-71bd960163ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_c13447d3-3911-436a-b276-4515714d1ae7_terseLabel_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase price</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_label_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_documentation_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:href="lxrx-20211231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:to="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5fa951e8-682d-4629-9c74-c72f4d01e259_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_8a407b9b-543a-4812-866d-5e4e1eb72525_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:href="lxrx-20211231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_29d92b0b-fe43-44a4-8171-bd2ccc6f4ef9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_13887f19-a517-4d3a-a0ce-59d241137024_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_02c58786-e073-49ff-8219-35d0a3b7025f_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_5d7c3f0a-f2c7-4237-9713-15082b21b978_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4ee3a5c4-612b-4112-8c1e-79996c4e0ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3291994b-617e-4718-af84-3fad34deb373_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_b7e00a2b-304a-4e6c-9be2-beca65d6df81_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3e21cfc5-5c02-4ab1-abbf-a780431e6ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_a82672e9-8a76-418f-aa3d-ca7bcd6f4110_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_63f59bdd-a247-4666-8cc7-fb0f85d80b7c_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ccd6ca6c-2da1-485b-b43d-9f654c8348b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_eba17818-c263-46d9-98f6-3f221416010e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_4e48854c-b377-474c-8740-32822dd88652_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_c7bb4677-8317-48fe-a003-f2bcc2e61725_terseLabel_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_label_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:href="lxrx-20211231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:to="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a0ad5a5c-cc6c-4ea1-85f1-354d0aac67ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_c769fcdd-7d52-4b00-a7a9-1375459b23c6_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of regulatory milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_74e5f249-3802-4524-9405-aec6682079b1_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_9cf1badf-cb99-425b-af48-1d0be58aa049_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_624e2d0f-0842-4697-8f4d-966161a60564_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_332159a7-e429-47fe-9002-b7af79615208_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b6a1570d-efe5-4df7-83b6-423d7143288f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_8327834f-a660-444e-a7ee-7c52168bd145_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_60992930-61de-4caa-9126-ccb21e774aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_28a72fe0-b1be-42a7-9ef4-6528fc8cb57c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_15cd87ba-96b7-409b-ba7b-8ad1585d2fc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_dd2b9711-13ac-45f8-8a14-1684ccdc07a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_6f45d4b9-6d6e-4e90-8fca-9d61e4390c9d_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_e8d76d7b-c517-4762-81a7-8bebfdb73e1a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_2f07e57f-c897-4e07-abe7-cbb588aa82c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a90efbc6-9316-475d-aeb3-1a439c3afa7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c7fa8fe7-d92e-4b65-9f3b-2ea6c8e81791_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_48a742c0-af6b-46d4-ac2b-1fccd1084929_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_44b9fccb-beba-4fa5-9c70-e10d545590ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17597879-0f1f-4dab-8734-cca9fd1a91e0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6acc29cd-2bbe-403d-84d6-c348f2a6b4a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_15656676-6b5e-4cab-9523-7923051dc767_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5bfdf9a-042d-47b0-85ae-a440b15f9be0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28b7260a-5264-48ec-b0a8-9d58429cf5c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_1b3a7ada-7905-4b59-9440-c7b66c4e65ab_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f9b670db-a27a-4a97-bc1c-d0f29dbd2b3f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f830b09d-cc9b-4a95-963e-33e3beb765f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e7f1f279-3054-4e0e-8461-dd82982f0182_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_bd3fb1f4-b5cb-414a-9f1b-a55e4fdeeb2f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_69c82520-b5c9-417d-8134-f75d2e8be633_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_021cf8b8-728b-4b03-8e45-1e78bc22a003_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2bdc7def-0cd3-4599-8815-005377020499_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35b42cb4-ba76-46bc-adff-05eb6ade9617_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d9b549d2-dd58-40a4-a380-5e490ba1a148_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_0c6c13bd-1879-48b4-a112-c8211318a99d_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ecaed12b-52ef-426e-ba59-9fe1347ac366_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_422aff2b-ce38-4375-bf1b-0965fc528948_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a3b8a9df-8937-43e4-a0e0-60ee9bc701b5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_1c56db34-0190-405f-87f9-bb307fa5a719_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c7a06cee-b68d-447b-8dc8-c772b673165a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_1fde11fd-4633-43be-9e46-07d0b96c2866_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5a41e9fa-e44a-4e30-8256-a29fd49cfd4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_8db74fbd-2f1b-4bcf-a2b4-28c7466c9a4f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e3ab5b4a-f49f-4226-b383-7bce4d71dd87_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_b1f88aeb-c12d-4cf1-b4c5-6c5b38dbd6b8_terseLabel_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_label_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_documentation_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:href="lxrx-20211231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:to="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5a323e52-3d2a-4b5d-8e85-594c34dc1200_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_11c6ac2e-edf5-4f0e-8c87-e5b590fc2568_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cac949a1-fffd-47ff-8e67-2305e8e0fc22_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $4,284, $6,376 and $7,096 respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_2459ac22-03a6-4bf1-a380-22e1f0ec797d_terseLabel_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:href="lxrx-20211231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_dcae1a2a-7947-40bd-9593-3c754031b1d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_22f63f07-aa9e-4940-b2c6-3bae6d6afa73_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_1b66e5f5-092e-42f4-9954-3dba6a63618d_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_931e40db-0aec-4473-8850-3930f69e2fd4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79fcfe48-92ce-40cc-b84d-8bd4d9751e00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dd59023-66c1-445e-ae8e-264d828e7368_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_eb34c54e-7d75-48a6-be89-ebebc57643c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_03d91817-a32d-44a7-a467-f3cf37038ade_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9bbae646-0145-4116-b832-c78751facd9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GoodwillAbstract_3547ff1c-6956-4586-9614-97d9996ed2e7_terseLabel_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_label_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_documentation_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract" xlink:href="lxrx-20211231.xsd#lxrx_GoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GoodwillAbstract" xlink:to="lab_lxrx_GoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_83cee5f8-2e96-4586-ab4a-bbd8c374e6a7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7f7aebca-26ad-40fa-9ad0-88b6b76667db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6412fe87-02b8-4986-b672-140bd97452e3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ea9b34d3-6e1f-460e-b2fb-9a48540d79f0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_3ee91875-5594-4fb9-8448-a288615454ea_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20211231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3c972bbb-15bf-4ca3-ba4f-cfd9deaf9cc8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_73643125-72b9-4af4-91be-384e158dbb58_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_97a2cd63-7ac4-4339-b685-2e6451804b78_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_dc020ded-6ec9-47e2-bb46-94744399ff01_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_14955075-38a2-457e-a1e6-f82c2cbf7940_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_f03dc971-536f-4f0b-8b74-18ddf00b5e9b_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_aa3dabb9-7dcb-4161-ac2f-c85a2eb5aa11_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_163a4761-4fde-4f7f-88ae-f2bae1445f83_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_label_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_documentation_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:href="lxrx-20211231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:to="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca5d110b-02e9-4686-accc-d3f3a36c514d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_492e553e-b275-49db-8f1e-4f2afdbf3b2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_a10a310b-ee60-402c-9b45-d037a407d569_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 407 and 236 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_53799dd7-7929-4f06-ae91-c778dff33fd9_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_49675f0d-e9a6-4ab2-a021-3c02cda3306e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_7798eefe-8e56-41da-b1b4-9128f91b54ee_terseLabel_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_label_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets [Text Block]</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:href="lxrx-20211231.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:to="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_63944f90-6149-4e0b-b2e8-3f17abee5c06_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInSeptember2021ATMOffering" xlink:to="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_0c3d2a5d-ec1c-4bc6-9637-e445032e36fa_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b54e6463-2391-42cd-a37a-99068766e633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f209ecb9-3f79-482b-a8e7-d12fa3217a0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f798238c-ca39-4a38-9625-cf45ced9e6b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9e134278-5c09-4f20-abc5-b25a76480aeb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_bd2acb8e-3f8d-4abd-8a75-043ed47e8635_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3df47f7a-86a5-4237-ae07-fc59924d0eac_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_7ed2e4f4-1cf5-4c7d-9312-adb0b15b3f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_56552d30-c9d1-4588-94f3-c7575aa6da3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_5dc64df6-303a-4f81-a9b6-0976a6c9445b_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_33b8b313-bd61-4ac8-a727-d00b0ef6b2ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_dbb289e6-5cf0-41e2-bc6b-75de238d43e5_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_label_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_documentation_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:to="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a3317a7d-0e12-4891-a1ba-03d256243c01_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e42403fc-7991-4e8f-884c-fc23ba6469a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_d8c3872b-5be5-4e2f-b8b1-678a2607f4fb_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_858a30a1-fa2c-4c9b-af36-c75db4a2b402_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2f2ad948-d5bf-4a03-848e-29524fe27a92_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9eb76841-50fe-4d01-a623-163d4935a5df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2dc375fa-e44c-4d3b-84c2-175c55cded60_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_313ae2a2-792e-45ee-bd54-1d9cfe0c5229_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_39d88b7e-ee99-4b8c-b360-f30d130447a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ac3436e-ddc9-4fac-bc20-e514fb826aa4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_aa50788e-35a9-4826-a9ae-d257fb04b7f2_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_9e33a3a0-b5c9-4ba7-a540-d3806dd52a92_terseLabel_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_label_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_documentation_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment" xlink:href="lxrx-20211231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiUpfrontPayment" xlink:to="lab_lxrx_SanofiUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2de69d61-3258-453f-b4da-00179af7d30a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b685033b-414e-41fa-85f3-7c1c3eec42d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4295c94e-664d-459a-9d91-e7ab50a1d3a2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_e1fa9d35-4901-4478-aa3c-38abcab294ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8bf10d6b-17ac-4b31-bdd1-94eae550bb7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_64b13208-202c-476e-830c-aab039bf4f7b_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_6c27c8d9-cf3d-4add-8789-0645bad3ceae_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20211231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_20bd7afa-2db6-4825-b370-6cec76370575_terseLabel_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_label_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_documentation_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:to="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_5a053e57-13fe-4950-88e3-fd3b68f454ad_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_41bc77dc-a8bb-4b43-95a2-37fda18ef052_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a7673d4f-3447-495a-82ff-bfd588dd69f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_47146b79-7de8-49e7-b904-7fb5c0150808_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b5f0d5c9-2b76-4fc3-b22f-fba7dc8fdc53_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3d9e2973-6e8e-4102-b002-1b1aed31e189_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1cf8cfa1-261c-4810-a027-32861bdf250c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_ecdfb54a-69a4-41bd-91b9-735497f0e5e6_terseLabel_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years of service</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_label_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_documentation_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:href="lxrx-20211231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:to="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_80613a2e-c500-4944-8e79-e2d1f7af8862_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_a8603ed5-93de-4d8e-a81d-8a9e570cf816_terseLabel_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_label_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_documentation_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:href="lxrx-20211231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:to="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ea73da37-c6a3-4a9b-91e5-17a55baaad90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_485c64db-f599-48d4-9ec8-961090d30965_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c0b8d2aa-224f-4201-b87a-77328cd5afa9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6be4dc49-70b2-4ea2-9d8c-afbacf0354fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_6799471e-96f1-4590-8725-b86723a89759_terseLabel_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:to="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_51137913-b747-4b07-b795-73159581dc1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9ebf39c7-1757-4ae4-b497-ed44fd00b9ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3d724d06-2dba-4d72-b65e-2ef43a79860a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_fca0b7b8-dec9-4fdc-b4a7-8679acab0f28_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_1935f2de-01ce-4fea-b2f4-2b043a91d6ce_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_aa7dd35b-b565-4b8e-bc7d-d0ef0478b7c8_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_548b5d94-71f1-4c7b-97c8-cbfa014f29e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_8d465151-76c1-435a-89ab-6ebe1e67b083_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_be7f769e-85c5-4199-9515-b92bca80a324_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_82a9783b-3351-404d-aa04-19e69edc117a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9a4ae202-e9cf-4f2e-a3dd-b3afa82d73e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_cdb28fd1-da8f-40b1-9a13-596fd3694884_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded commercialization costs</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_72f1f0d0-c253-40d2-a601-3e840186e639_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6a6e8989-a892-46f0-a50b-bda37e847832_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_52e13011-b533-4e4c-8fec-d7bd8f95f07f_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20211231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_f45ceb11-3cbf-4d8a-ad05-8ca9b0af1325_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_564b8a12-f783-4c92-bfca-0949f3fbd75e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c7978a43-0769-41cb-ab2e-d4ca18b3bb8d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_876b822c-c4f3-4cf6-a961-2758b270aae0_terseLabel_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_label_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_documentation_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement" xlink:href="lxrx-20211231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiTerminationAgreement" xlink:to="lab_lxrx_SanofiTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_a3ebb139-d38c-4515-ad2c-35483c84d292_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_42c17e3c-c6ad-4ced-aabe-957f73f75d32_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BenefitPlanAbstract_a47449fb-2f09-4024-b570-6aa80999001a_terseLabel_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_label_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_documentation_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract" xlink:href="lxrx-20211231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BenefitPlanAbstract" xlink:to="lab_lxrx_BenefitPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_96802e19-3baa-44c7-9d01-0aafdbda72e0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ce113965-11b8-4090-817e-e472c37249e9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_fff5fc41-0a7a-418b-a65f-cd31b21c49f4_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20211231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_97714e7c-8e20-4ff0-a7b7-fe7fb0d5a3fa_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_68d994a0-ecad-43d3-b554-4c9306da54c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_01fdd3c7-eca3-40de-b885-99df73a1f708_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_3bf270b2-e147-49ab-bdd8-8714a53ae6d5_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_45c5a0c2-28d6-4b1f-af95-0c96c8ef2d32_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1b810e61-9a7d-47a1-a4d8-e36e2e441dc6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_57665336-55e7-464d-a1f9-bab9e434d96b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_f0f965ab-248e-4fe0-a4c3-ccd7ba2deef8_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_bc699535-2af3-4eac-99b1-28e9c81ca022_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_95e78119-88c6-4522-b7bb-ab8b56d6a1f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_23b90a67-76da-4877-a1b5-8152c5225852_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e6a90079-cbb9-4e81-8cfb-0ba569ffb06e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_5e8ae6bb-bbd9-475b-a6dd-788d7a02eaa4_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_b008b8c4-2b8d-471d-800e-842506630f82_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_55f23ef4-2e79-4499-8235-40ca52da2078_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36d2127b-6260-4500-8efb-4b865860a0ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_4a854934-ff30-43e2-b3ad-e7ed75a910be_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_e5ea0836-34f0-42c6-8fbd-20652253df8f_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e7d3ef2-0364-43e7-81a7-819a7572096f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InterestOnLeasePayments_1150c922-52bc-42b0-b37f-043734879184_terseLabel_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_label_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_documentation_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments" xlink:href="lxrx-20211231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InterestOnLeasePayments" xlink:to="lab_lxrx_InterestOnLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4667779b-6b47-46cf-9565-07ec2555bc52_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_daa92d42-4ed4-4ab8-9075-afa23b44c5ea_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_label_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_documentation_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill" xlink:href="lxrx-20211231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyIconGoodwill" xlink:to="lab_lxrx_SymphonyIconGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_350d359c-8940-4565-9e8f-2766f75b8047_terseLabel_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_label_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs [Member]</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_documentation_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember" xlink:href="lxrx-20211231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RDSeveranceCostsMember" xlink:to="lab_lxrx_RDSeveranceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b8633e5f-dc81-48ba-a6ed-0fd474c1cc38_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bd98fdd1-7d63-48cd-a01f-7a6e9023160e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_f5c18c43-b242-4d79-96dd-d69fcdf66d62_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_163915ac-07e8-4166-9808-5c88bcc8a276_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_0dad7087-76b5-4a2d-a475-dd916c2f9c8f_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_191c4da1-d386-41db-a2f5-074466410eb7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_13daed66-9dd0-44c0-aa81-98859964a952_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3edec4af-5f66-46af-abad-1ea3d44e617f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_18c24e5a-af56-4fae-abd1-fb3b6577225e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93fc36eb-88bb-44b6-b947-e07d50d540a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fbc4ebb7-6105-49a2-8751-912f70a61e94_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3dca8c01-2854-4aef-8c35-0d063cd918ba_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a2d1f53-1f1c-4796-b284-9fe1d317a5c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_767b68a9-648e-4f9a-b9b0-b9483110c68b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_907b031b-247c-4714-8df6-af398501ca8b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84e91f8a-bf5c-4807-826c-efd5aa384365_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_daef5816-b5e7-4663-99ac-71c337f2b8be_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c1fd62fd-9ad2-4039-b48b-c133f1839a06_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fe58b767-63e5-45d5-ba69-d1bd1c965b6e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ca610261-c1b0-4b34-818d-017acf708c7c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_fd5ac838-0cc2-41bd-8e85-2ece56539d44_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_30cc8263-719e-4f57-91b0-345d8e114372_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ab582d80-846a-4ead-960f-fac75068ad30_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_26c41bdd-67cc-418b-8017-b4f57fe4dffd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_9ae2af89-3cb6-4c1f-b551-b79a4815cd2e_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_cd14bced-29d2-4d83-9922-1949f950f754_terseLabel_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_label_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract" xlink:href="lxrx-20211231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract" xlink:to="lab_lxrx_OrganizationAndOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c58179ee-8a37-439d-af4c-f66cc7c7092d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_37c833ae-ef40-45c3-9533-d7d2ea216af6_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d2c55e2f-91f3-4978-9074-12211c23305a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_531940be-4986-4a82-a62a-54fa5c85766a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_cc4d50dc-53d1-48e9-b44a-2edd0ced01ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b597a395-0925-4fcc-a1f0-0655901cc601_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_a8778c57-024a-4d6d-b3aa-026366e811b2_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ed19c2e3-8301-45b5-a50c-9b942e62727b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1850576d-b59a-4b0b-9328-509c270edf83_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Other Accounts Receivable, Policy</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4fd06fff-1657-49d1-8ad8-7fb12cd00287_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_782d444b-2579-4597-b5ec-ece7a028bcef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5255a538-d7d9-41d5-90d2-e9c786459cc0_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9866b81c-7e0e-4caa-ae4a-d8cd13287252_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_e99f5614-b15f-43ea-94fa-173d0443c209_terseLabel_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_label_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:href="lxrx-20211231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:to="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_4f52efa3-8e47-44cf-922f-59f34ffc72a7_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones" xlink:href="lxrx-20211231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDevelopmentMilestones" xlink:to="lab_lxrx_SanofiDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_9d7b4f64-9765-4bf5-9daa-055988b53c5e_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_10a6ad8d-a856-4868-9aaf-1bea4576cab5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6b008435-232d-4777-bdac-c25e70c96356_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, State</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01f1d4c2-571b-4451-bcbf-bc815aadc7ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_cc145796-5316-447d-9920-3f2b78c416b1_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_889b4869-040a-4695-ab50-65942d0be910_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_7259d61e-5b4f-4d99-9f56-02e9de8a3296_terseLabel_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_label_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_documentation_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract" xlink:href="lxrx-20211231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract" xlink:to="lab_lxrx_PropertyAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0712cf3f-3116-4547-a7f1-d510b10f78a7_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_120ad8e4-d7d1-4d3a-ad35-be9ed089dd8c_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_fb037db6-3377-4c7c-a542-31e733f6b541_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3cad4b3f-d0c2-4492-aaa1-3fc9004147d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8acb83e9-fafc-49be-a5cc-6da7a343a6b8_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_066565b8-be3a-45bf-a716-0720d421e1dc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77c902a6-0f02-49d6-bdab-a274845b204f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>lxrx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a6716a7d-4a06-4363-b566-b3a2b4452f5e,g:6a7fb8fa-8e13-4f21-8b0c-f2ff13cd1a22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dded4c69-ef8f-4772-b066-4978658656e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentType_dded4c69-ef8f-4772-b066-4978658656e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_22017f4e-c92f-401e-a1de-9bd236145c52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentAnnualReport_22017f4e-c92f-401e-a1de-9bd236145c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4bd65daa-c85e-470b-93eb-681a7ff9a93b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentPeriodEndDate_4bd65daa-c85e-470b-93eb-681a7ff9a93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cb6f905b-e65c-4dae-9a9a-7ee59a672d67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentTransitionReport_cb6f905b-e65c-4dae-9a9a-7ee59a672d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c445b763-8275-440c-8188-11b0aa7af249" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityFileNumber_c445b763-8275-440c-8188-11b0aa7af249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d2723e65-99ee-49f2-a418-c04566356f4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d2723e65-99ee-49f2-a418-c04566356f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7ee60007-42e9-4346-8a63-59d17bf42b81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityTaxIdentificationNumber_7ee60007-42e9-4346-8a63-59d17bf42b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7b2dbbee-56ac-4c67-b328-68c1a8bb73b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityAddressAddressLine1_7b2dbbee-56ac-4c67-b328-68c1a8bb73b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8f20dfff-07a8-4fee-b2b5-8b6659c99bb5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_CityAreaCode_8f20dfff-07a8-4fee-b2b5-8b6659c99bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_45f9b2ea-0a66-4bab-8e75-4533b0f0bf4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_LocalPhoneNumber_45f9b2ea-0a66-4bab-8e75-4533b0f0bf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_43fa1170-7f75-462b-8663-907f31657a06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityAddressCityOrTown_43fa1170-7f75-462b-8663-907f31657a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5d72cd96-bb97-409f-90c6-28fe07ac861d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityAddressStateOrProvince_5d72cd96-bb97-409f-90c6-28fe07ac861d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1dfbb585-cb70-4d6d-9073-f7c02c5ebded" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityAddressPostalZipCode_1dfbb585-cb70-4d6d-9073-f7c02c5ebded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9b353758-cfe6-46cc-a475-203a2a0d62f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_Security12bTitle_9b353758-cfe6-46cc-a475-203a2a0d62f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d09bf7d8-9ea8-41e3-b393-3977740e4991" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_SecurityExchangeName_d09bf7d8-9ea8-41e3-b393-3977740e4991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ad14f4ee-79c3-4e26-a892-c7ed27a8f717" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_ad14f4ee-79c3-4e26-a892-c7ed27a8f717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d5054aba-672c-4ed9-adf4-734b90cea06f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityVoluntaryFilers_d5054aba-672c-4ed9-adf4-734b90cea06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_97e81d6c-7a0f-4443-8fb5-725cb471eb52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityCurrentReportingStatus_97e81d6c-7a0f-4443-8fb5-725cb471eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a3b3b956-4cb9-4fc6-82c5-7b856e97c009" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityInteractiveDataCurrent_a3b3b956-4cb9-4fc6-82c5-7b856e97c009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bdf5322d-2a5a-459f-9eef-a6fa54833ba8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityFilerCategory_bdf5322d-2a5a-459f-9eef-a6fa54833ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_09dfdd96-0a42-4ace-bc02-3862e1607e58" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntitySmallBusiness_09dfdd96-0a42-4ace-bc02-3862e1607e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c0a79da5-a2b1-4ab9-be08-24aafbea7f78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityEmergingGrowthCompany_c0a79da5-a2b1-4ab9-be08-24aafbea7f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_23142cfc-9a55-4a01-894d-2af44ec9ccc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityShellCompany_23142cfc-9a55-4a01-894d-2af44ec9ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7cf26013-0c8f-46aa-b8ef-2ce32540287d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityPublicFloat_7cf26013-0c8f-46aa-b8ef-2ce32540287d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1cafc3b1-e391-4ccd-bce4-66cb9d5a413d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1cafc3b1-e391-4ccd-bce4-66cb9d5a413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9703ad7a-1e75-4d1b-9c4d-504728f506ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityRegistrantName_9703ad7a-1e75-4d1b-9c4d-504728f506ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_869c7145-ab9a-4c11-b18b-99ed2f06b0a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityCentralIndexKey_869c7145-ab9a-4c11-b18b-99ed2f06b0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0f3cca8d-e048-46eb-80bf-d494ac25df37" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_CurrentFiscalYearEndDate_0f3cca8d-e048-46eb-80bf-d494ac25df37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d8eefaa7-8be2-4ec8-9c29-32f74e53e60c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentFiscalYearFocus_d8eefaa7-8be2-4ec8-9c29-32f74e53e60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_66287545-1749-43c6-8c8c-69043a9390cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_66287545-1749-43c6-8c8c-69043a9390cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b675dd8b-38a4-4d16-a436-ed741029e587" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_AmendmentFlag_b675dd8b-38a4-4d16-a436-ed741029e587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_32804c98-db1d-4e80-b2cf-4b6af7af8c00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_TradingSymbol_32804c98-db1d-4e80-b2cf-4b6af7af8c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c378cbc4-92ca-41f1-9da6-7e021d65f908" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c378cbc4-92ca-41f1-9da6-7e021d65f908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_52eee407-70c6-4407-ad14-7bf99c7f95f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_52eee407-70c6-4407-ad14-7bf99c7f95f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5290685-549a-4738-80c8-eb39d05fc1e3" xlink:to="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:to="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f0c39131-9a66-4035-9140-b916db9ab22b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_68567d41-d1cc-43ae-9e7b-6a4770346d4a" xlink:to="loc_srt_RestatementDomain_f0c39131-9a66-4035-9140-b916db9ab22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4e661ca7-c350-4e11-b54d-1f786d28989b" xlink:to="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_caa49b23-aff5-4384-bc78-c43680ecc938" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_caa49b23-aff5-4384-bc78-c43680ecc938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b2219fdf-8d57-4256-9213-e7a25189d012" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_CurrentFiscalYearEndDate_b2219fdf-8d57-4256-9213-e7a25189d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a4aa30fe-e06e-4574-a99c-573c9fc15cdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorName_a4aa30fe-e06e-4574-a99c-573c9fc15cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e79e7153-6993-4598-9ec7-1b1e22b36f16" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorLocation_e79e7153-6993-4598-9ec7-1b1e22b36f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a98d759d-fd52-4c23-b5eb-7fb97e7bff6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_da90e539-221d-480d-adba-ac644866907a" xlink:to="loc_dei_AuditorFirmId_a98d759d-fd52-4c23-b5eb-7fb97e7bff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7910d962-ad80-4cf3-b911-e8c57fc80758" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7910d962-ad80-4cf3-b911-e8c57fc80758" xlink:to="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:to="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_338c07a9-9bd2-4887-a1d6-0406462f7be8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b87b1950-eaea-4ffc-a532-3ff7420e9994" xlink:to="loc_srt_ScenarioUnspecifiedDomain_338c07a9-9bd2-4887-a1d6-0406462f7be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d6f90a7-4dcc-4455-8a01-9b47b05d7aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f04ff962-9976-46c4-9ef9-08528cf0ead2" xlink:to="loc_us-gaap_ClassOfStockDomain_9d6f90a7-4dcc-4455-8a01-9b47b05d7aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2aa66fff-21ae-4b90-b3a4-f4c99d5f94c3" xlink:to="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30ad54ef-b2ba-4c6c-baf3-d113022803c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30ad54ef-b2ba-4c6c-baf3-d113022803c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3bcd5dd8-7897-45f5-be5a-d9b8a2f53150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_ShortTermInvestments_3bcd5dd8-7897-45f5-be5a-d9b8a2f53150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_550b9be9-ac22-4a16-aef9-d57565266494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_550b9be9-ac22-4a16-aef9-d57565266494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b587f12b-4e73-446b-8f2a-cb1c83335da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_InventoryNet_b587f12b-4e73-446b-8f2a-cb1c83335da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cd8d642-6050-43e3-8c24-b9a12b6ea473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cd8d642-6050-43e3-8c24-b9a12b6ea473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f11e4df2-d9c4-4412-a36f-b30f76eafa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d71123f-9d2d-438e-a975-4fd14d99777b" xlink:to="loc_us-gaap_AssetsCurrent_f11e4df2-d9c4-4412-a36f-b30f76eafa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4b776f48-355e-4172-bab2-881429669cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4b776f48-355e-4172-bab2-881429669cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_450a0a5b-d182-4d60-892a-00a3f5d21419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Goodwill_450a0a5b-d182-4d60-892a-00a3f5d21419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_9bfa4852-15f1-45f8-9297-0d256497c522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_9bfa4852-15f1-45f8-9297-0d256497c522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa8b8862-b0c0-45fa-bb55-88de470adfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fa8b8862-b0c0-45fa-bb55-88de470adfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3ed91df5-2653-4520-a5d9-c0388d3afd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Assets_3ed91df5-2653-4520-a5d9-c0388d3afd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c12c6e33-747e-4d54-9256-592d0f47e62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_AccountsPayableCurrent_c12c6e33-747e-4d54-9256-592d0f47e62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cdf77113-649b-41f0-b4bb-395a0372c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cdf77113-649b-41f0-b4bb-395a0372c2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8335d969-2db5-44c4-a24a-d0e8d6050c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_LongTermDebtCurrent_8335d969-2db5-44c4-a24a-d0e8d6050c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4dfe61a-85f4-4c77-adab-5294dc2330a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01128e59-0659-4901-b4c8-6b20498185fa" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4dfe61a-85f4-4c77-adab-5294dc2330a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3a6faddc-395a-4cc7-a064-d5f355acd323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3a6faddc-395a-4cc7-a064-d5f355acd323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_599111ae-8c66-4a57-8704-cabe05b9e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_599111ae-8c66-4a57-8704-cabe05b9e4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f9ef11b-4729-4ad0-babc-6bcc1dbeab39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_Liabilities_5f9ef11b-4729-4ad0-babc-6bcc1dbeab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ec94245b-0e85-42f2-a731-6ee53e377027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ec94245b-0e85-42f2-a731-6ee53e377027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7d84276d-cfcc-4f0f-8ed8-5416db2885a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_PreferredStockValue_7d84276d-cfcc-4f0f-8ed8-5416db2885a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5315be5c-9653-43b1-82cd-093aec55369f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_CommonStockValue_5315be5c-9653-43b1-82cd-093aec55369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1db442e-1779-4448-8a8e-f55c68e27491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1db442e-1779-4448-8a8e-f55c68e27491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dc03911-e1ad-443c-bfe8-a5dea596afb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dc03911-e1ad-443c-bfe8-a5dea596afb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cfd0e05-3c23-4d31-9355-da38110f5599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cfd0e05-3c23-4d31-9355-da38110f5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1c1ff4ba-6e1c-4b3d-8d32-8818a864c4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_TreasuryStockValue_1c1ff4ba-6e1c-4b3d-8d32-8818a864c4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05ebaad7-cf37-4b68-96b5-360b3fb6c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66739914-413a-414a-942b-172c8dc0e4b9" xlink:to="loc_us-gaap_StockholdersEquity_05ebaad7-cf37-4b68-96b5-360b3fb6c347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5515044-88f6-4139-9f93-b72b68e4f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5515044-88f6-4139-9f93-b72b68e4f3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b4e1f90-c42a-4032-af71-df6512d2282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b4e1f90-c42a-4032-af71-df6512d2282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e455cf4b-1c44-40e7-b4ad-cf4a453c8397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e455cf4b-1c44-40e7-b4ad-cf4a453c8397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c55801bb-3796-4f92-83f4-c43ff02fa76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c55801bb-3796-4f92-83f4-c43ff02fa76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8fe0ede0-e461-4215-ac39-6895b495cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8fe0ede0-e461-4215-ac39-6895b495cfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8860fd0e-2f05-4a2a-bf56-c2eb36a97866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8860fd0e-2f05-4a2a-bf56-c2eb36a97866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5cae64c4-9700-4265-b516-3ce5ab36ad2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab276c56-534b-47bd-aad7-ed351cf0e2b2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5cae64c4-9700-4265-b516-3ce5ab36ad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20211231.xsd#BalanceSheetParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_05ac257a-8927-49e8-8156-e7000f18b8c4" xlink:href="lxrx-20211231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_05ac257a-8927-49e8-8156-e7000f18b8c4" xlink:to="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dffaf25f-8977-4dc9-9902-e4d5ca9425c1" xlink:to="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_229f50a4-e769-41dd-b858-e8040618d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07b04332-40ea-470b-a240-d6a1c57f152b" xlink:to="loc_us-gaap_CommonStockMember_229f50a4-e769-41dd-b858-e8040618d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03c7b25e-3560-4898-a8d6-29684d0155d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_41504111-f221-4b57-bd79-4edbc0744480" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03c7b25e-3560-4898-a8d6-29684d0155d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a640b596-0fd0-4d18-8c41-2f0964585cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68803d4b-a51e-46f7-afc5-e771fe301984" xlink:to="loc_us-gaap_ClassOfStockDomain_a640b596-0fd0-4d18-8c41-2f0964585cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc987a2b-decb-4b7f-8c3c-3928e574d5a1" xlink:to="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5f5bf32-842d-4aee-b1dc-17ef3529bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5f5bf32-842d-4aee-b1dc-17ef3529bd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c82bff4b-81d0-4864-b6c8-37c2122ff5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c82bff4b-81d0-4864-b6c8-37c2122ff5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_766f0b64-ae85-4f65-ad4e-e60da7e69e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_766f0b64-ae85-4f65-ad4e-e60da7e69e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_db12858d-bb1e-4abb-96b6-b77cbcd623ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesIssued_db12858d-bb1e-4abb-96b6-b77cbcd623ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9fa908a0-a350-4c1d-93ca-e55d26ac2dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9fa908a0-a350-4c1d-93ca-e55d26ac2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_da2ae359-b0ba-49b0-aa7b-a06cfe002ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_da2ae359-b0ba-49b0-aa7b-a06cfe002ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_364d2242-64f5-472d-9e0d-89536361fba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_364d2242-64f5-472d-9e0d-89536361fba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_191b30ce-eb68-4b73-9d45-132a1d96c789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_CommonStockSharesIssued_191b30ce-eb68-4b73-9d45-132a1d96c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_aa90863c-4481-40de-8481-3a80f0fb332a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3353081-5012-4063-a94b-12ec99d37ecf" xlink:to="loc_us-gaap_TreasuryStockShares_aa90863c-4481-40de-8481-3a80f0fb332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_adad6c58-cf5b-4a42-8515-fe1579bf8a73" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_adad6c58-cf5b-4a42-8515-fe1579bf8a73" xlink:to="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:to="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_50067e02-3ec6-4017-9a83-587719010b2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_329624b7-1b9e-48ca-ba69-4536eb35ce1b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_50067e02-3ec6-4017-9a83-587719010b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_283ab52b-5f27-489b-8e4f-84b5b3fc72d5" xlink:to="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_765f3816-e70c-46ba-af52-d5ff29b976aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_765f3816-e70c-46ba-af52-d5ff29b976aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a588acc5-4dd5-443b-87f3-345bb0afdf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a588acc5-4dd5-443b-87f3-345bb0afdf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_3a961e9c-680b-4779-99ff-2432e7147d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_3a961e9c-680b-4779-99ff-2432e7147d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_71d92225-3aef-4b4e-8ee8-597330ba385b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9abebe83-6e61-443d-9bdb-8168c615b8d5" xlink:to="loc_us-gaap_Revenues_71d92225-3aef-4b4e-8ee8-597330ba385b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_175f36f8-85de-484d-855d-cff17ef8a860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_175f36f8-85de-484d-855d-cff17ef8a860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0995f3c2-5b00-4d37-bfb5-e546ec550be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0995f3c2-5b00-4d37-bfb5-e546ec550be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c69c1242-4879-495b-b302-058f32cd8b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c69c1242-4879-495b-b302-058f32cd8b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e37def-f541-4f5c-a8ef-5b6a5de51b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e37def-f541-4f5c-a8ef-5b6a5de51b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e59f6ac5-8897-4fb2-9cda-319493a0a988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e59f6ac5-8897-4fb2-9cda-319493a0a988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f487fb8d-1276-49b7-95aa-612e37e38523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_us-gaap_OperatingExpenses_f487fb8d-1276-49b7-95aa-612e37e38523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_ade44b47-8574-4c8f-abe0-f768cbe5a6ea" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3aa3da6c-53ed-423d-b400-ac54c753ada9" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_ade44b47-8574-4c8f-abe0-f768cbe5a6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e757a76e-8067-4129-b84c-63d316c6f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_e757a76e-8067-4129-b84c-63d316c6f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9ffdab65-3191-4c3e-9c54-77c112996d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9ffdab65-3191-4c3e-9c54-77c112996d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_37d908bc-fd18-48ac-901f-4a6d8c8add0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_InterestExpense_37d908bc-fd18-48ac-901f-4a6d8c8add0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5404c4da-f842-4a57-955d-35bfad65d138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5404c4da-f842-4a57-955d-35bfad65d138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52f521d6-9d54-4770-8fe7-ae45bb99a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52f521d6-9d54-4770-8fe7-ae45bb99a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7d1d1131-3601-4061-9d39-0b92e1cff725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7d1d1131-3601-4061-9d39-0b92e1cff725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47f7e4c2-6972-4c44-bb7e-ff72455eeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_NetIncomeLoss_47f7e4c2-6972-4c44-bb7e-ff72455eeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2bf6864b-c7b7-4870-adeb-f749ad5847ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2bf6864b-c7b7-4870-adeb-f749ad5847ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_52ff9513-6ed7-4122-ac54-47e6f24b932d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5834cdd1-3d01-4c01-b592-225cd350d3ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_52ff9513-6ed7-4122-ac54-47e6f24b932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3bfb991-21d5-4277-ab92-cd1a84311f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3bfb991-21d5-4277-ab92-cd1a84311f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_339253ee-f8f4-4de1-8bef-bbb18e046e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_339253ee-f8f4-4de1-8bef-bbb18e046e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8d257cd-5b78-4a0c-aad4-f9b5e659fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8d257cd-5b78-4a0c-aad4-f9b5e659fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_ce677c3e-4c00-49dd-a23e-8f74086e532e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4111688c-54cd-4bf4-ac95-6329832471bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_ce677c3e-4c00-49dd-a23e-8f74086e532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20211231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_ff9de4ea-0501-4ff8-b96f-9a41e34e9ed2" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_ff9de4ea-0501-4ff8-b96f-9a41e34e9ed2" xlink:to="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:to="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6d7d65aa-dfc9-4a0c-8744-b52d9208c2e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_02c26d22-002f-4205-868e-831583869d3d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6d7d65aa-dfc9-4a0c-8744-b52d9208c2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7d4415e0-aaaf-4291-9522-81e6b10cc331" xlink:to="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_3a830d04-0dd5-441a-862a-4491b3e472e4" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_3a830d04-0dd5-441a-862a-4491b3e472e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_4502b0ce-0e30-4408-a024-574d266cbc49" xlink:href="lxrx-20211231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7695c9dc-6456-4dec-8578-f40d7f75c83e" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_4502b0ce-0e30-4408-a024-574d266cbc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_8a041593-bca7-4484-90e5-0ec712fbade4" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_8a041593-bca7-4484-90e5-0ec712fbade4" xlink:to="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8edf17ed-5038-41c7-825a-e44d0a313042" xlink:to="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed6df58f-ade0-484f-9a8a-842aad53108f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_CommonStockMember_ed6df58f-ade0-484f-9a8a-842aad53108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e20afdcc-58c8-4bbe-8029-33ea01dd6614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e20afdcc-58c8-4bbe-8029-33ea01dd6614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c0d15218-3fd7-4a45-a315-8f61f1a7e03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_RetainedEarningsMember_c0d15218-3fd7-4a45-a315-8f61f1a7e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d943b09-418e-49a3-afff-bc783746f69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d943b09-418e-49a3-afff-bc783746f69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_31b37f4e-981a-4f96-a041-8379b4970490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d38f2d-998f-4db0-935e-e234fc66c4c0" xlink:to="loc_us-gaap_TreasuryStockMember_31b37f4e-981a-4f96-a041-8379b4970490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1929d56-5d64-4e9b-9e9e-9befd1cafeb9" xlink:to="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_035d255f-a589-4dd7-86df-1ac6ed051e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_035d255f-a589-4dd7-86df-1ac6ed051e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8aa941c7-8502-4b27-8883-3e3bf5165f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockholdersEquity_8aa941c7-8502-4b27-8883-3e3bf5165f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07c604e6-879a-49f4-9f35-d32b060621f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07c604e6-879a-49f4-9f35-d32b060621f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20a878a0-58a5-496b-8942-d450b39f954d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20a878a0-58a5-496b-8942-d450b39f954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca9883ab-f530-41e5-b8ca-7f7d54b5cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca9883ab-f530-41e5-b8ca-7f7d54b5cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a7e72fff-6a31-44d9-a602-86273ea944d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a7e72fff-6a31-44d9-a602-86273ea944d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_88cddc43-bc1d-4f6b-8420-6c9228d7711f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_88cddc43-bc1d-4f6b-8420-6c9228d7711f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e438a44-0843-4d3a-baaf-2d561529d81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e438a44-0843-4d3a-baaf-2d561529d81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_39a74a00-1d59-4159-aa1e-194da8390076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_39a74a00-1d59-4159-aa1e-194da8390076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_54740bfa-f561-42ed-8533-b74b5240a566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_54740bfa-f561-42ed-8533-b74b5240a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b2d8aa8-da93-48d9-857d-77cbea204ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_NetIncomeLoss_2b2d8aa8-da93-48d9-857d-77cbea204ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4f2dfdbe-79af-4932-9af1-38d5711a7510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4f2dfdbe-79af-4932-9af1-38d5711a7510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fa9d66f2-7684-4f5d-a39f-db75db5e960b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fa9d66f2-7684-4f5d-a39f-db75db5e960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_136ce4c5-b71e-4ee9-b0a7-f9c068989ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_StockholdersEquity_136ce4c5-b71e-4ee9-b0a7-f9c068989ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_d4468030-889c-4dce-91b2-b41c182c5897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_d4468030-889c-4dce-91b2-b41c182c5897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_fbea0609-90dc-4318-b53e-5785655586cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_fbea0609-90dc-4318-b53e-5785655586cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b7f95c4-bbf2-483d-803d-edbccb59f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b7f95c4-bbf2-483d-803d-edbccb59f9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_bf4f216e-0fa1-4c8b-92aa-432639067bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_bf4f216e-0fa1-4c8b-92aa-432639067bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8e8bd27e-c58c-4ec2-8ae9-8649328941d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8e8bd27e-c58c-4ec2-8ae9-8649328941d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_2e3e3fe8-9232-439c-8721-4c371a94a628" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_2e3e3fe8-9232-439c-8721-4c371a94a628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a744a4e7-fefc-49f0-88b7-11fe2df54fae" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a744a4e7-fefc-49f0-88b7-11fe2df54fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_692fc6ed-e9e2-440a-a5a3-9f3fad4388ac" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_692fc6ed-e9e2-440a-a5a3-9f3fad4388ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_ec217246-5a1e-467f-afe4-c289043a9471" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_ec217246-5a1e-467f-afe4-c289043a9471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_50cd0297-fa72-4c32-a6dc-96f1e202fdfb" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_50cd0297-fa72-4c32-a6dc-96f1e202fdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_c9932404-0c94-4da1-951e-bbe71297ba9b" xlink:href="lxrx-20211231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_c9932404-0c94-4da1-951e-bbe71297ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_6ae7553a-fc50-4f8f-aa2a-7b7014c3a79a" xlink:href="lxrx-20211231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_6ae7553a-fc50-4f8f-aa2a-7b7014c3a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_e1db2322-fb4c-4404-a401-b984e2ca52c9" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_ATMOfferingTotal_e1db2322-fb4c-4404-a401-b984e2ca52c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_410b3d40-5b4f-49a0-8b13-7b0ef0de6a02" xlink:href="lxrx-20211231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_410b3d40-5b4f-49a0-8b13-7b0ef0de6a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_065df43b-6b7e-4095-81dc-086a3f109780" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83cd2bea-e4ee-4e75-9643-f45cecc10e09" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_065df43b-6b7e-4095-81dc-086a3f109780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_b067ee85-5f2a-49f8-be7c-a4be6f60b4bf" xlink:href="lxrx-20211231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_b067ee85-5f2a-49f8-be7c-a4be6f60b4bf" xlink:to="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:to="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d684994e-2b3e-4cb8-8672-3b9e83961c58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f056931d-1ea9-4276-89d4-3dafabf7191c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d684994e-2b3e-4cb8-8672-3b9e83961c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1e0038c0-44a7-4341-ab1a-8a3ae284a7bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_a7eaed69-3590-46e4-b54d-55269e75725a" xlink:href="lxrx-20211231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f734a20d-ae93-4c2b-b66f-2cbc3091c4a0" xlink:to="loc_lxrx_RDSeveranceCostsMember_a7eaed69-3590-46e4-b54d-55269e75725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dae24096-dac6-4b9b-aeac-fbdfc45e057f" xlink:to="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ef872db-109b-44a7-9e21-6d5b0259403a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_ProfitLoss_2ef872db-109b-44a7-9e21-6d5b0259403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98e91e06-8d64-4b95-88ed-bff3601def87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98e91e06-8d64-4b95-88ed-bff3601def87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a30c2317-cf73-4f3e-9f84-8d388fbfdb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_ShareBasedCompensation_a30c2317-cf73-4f3e-9f84-8d388fbfdb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_6043bb29-723d-48e7-abfd-ce042143d365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_6043bb29-723d-48e7-abfd-ce042143d365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a56694e4-5c55-4ce9-ae49-1e8b36bd2b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a56694e4-5c55-4ce9-ae49-1e8b36bd2b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e78fb8c-970e-4a94-9386-fda5f9cfc6aa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0d82279c-e5e0-4e97-8d8f-45dd4c84dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0d82279c-e5e0-4e97-8d8f-45dd4c84dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3024b6eb-a712-466b-99fb-a0d5e270d410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3024b6eb-a712-466b-99fb-a0d5e270d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56aba8a6-280f-4005-ab40-712ab6339f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56aba8a6-280f-4005-ab40-712ab6339f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82d7c452-9cfd-4923-92ac-90bca8e17b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82d7c452-9cfd-4923-92ac-90bca8e17b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_132e3190-b7f5-4bce-aac6-80f516ed4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_132e3190-b7f5-4bce-aac6-80f516ed4a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e4d85684-02ce-49db-810d-74b85e541590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72ad03d5-b604-407b-afe4-85b453bec93e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e4d85684-02ce-49db-810d-74b85e541590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82cf8169-2f56-4003-9962-709405aeb5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cfa1c7cb-02de-4fb2-bb8b-7d5c4b70a80c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82cf8169-2f56-4003-9962-709405aeb5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad926764-b572-43d1-9b05-364a214e9192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad926764-b572-43d1-9b05-364a214e9192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8e459f70-c993-4471-bf26-26dd4e8752ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8e459f70-c993-4471-bf26-26dd4e8752ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bba7c471-3c96-4027-8d6e-33b8932edab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bba7c471-3c96-4027-8d6e-33b8932edab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_017a49c5-7155-418c-98d4-37406632d7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_017a49c5-7155-418c-98d4-37406632d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c64ae282-bd4e-47d0-96b7-4821d5e97e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c64ae282-bd4e-47d0-96b7-4821d5e97e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b08e85-e37a-4382-aaed-31e3e656decf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e9b73a0-9b8f-404e-8a47-2727bb3b5c06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b08e85-e37a-4382-aaed-31e3e656decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a51f3ced-5379-49ee-bf66-953397a080ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a51f3ced-5379-49ee-bf66-953397a080ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_147be746-ff37-4b02-9a5e-cd6b2d489839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_147be746-ff37-4b02-9a5e-cd6b2d489839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f4ce75b8-8814-4970-99ba-a676c7fa55e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f4ce75b8-8814-4970-99ba-a676c7fa55e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1a6f721d-a35c-46ad-90e3-0b944793344e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1a6f721d-a35c-46ad-90e3-0b944793344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63f713b8-3bcb-40a6-8386-f6128734d2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7581515d-5fa7-4a64-9bf9-49803439808b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63f713b8-3bcb-40a6-8386-f6128734d2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76a333a0-b4d5-4dd9-ad82-b266466d7617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76a333a0-b4d5-4dd9-ad82-b266466d7617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6827f682-4409-49cf-890a-847e277d9250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6827f682-4409-49cf-890a-847e277d9250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_931e27cb-c516-4095-905d-dea6fe229fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_931e27cb-c516-4095-905d-dea6fe229fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b34a902e-84f8-4f05-b28e-758ba951fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9675c9a3-959f-431e-9baa-90b5cd03e50d" xlink:to="loc_us-gaap_InterestPaidNet_b34a902e-84f8-4f05-b28e-758ba951fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bc0c9afe-0cf5-4e0b-b924-f421e2b78ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bc0c9afe-0cf5-4e0b-b924-f421e2b78ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ef8350ad-e247-435b-a4f6-a02f453ecd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ef8350ad-e247-435b-a4f6-a02f453ecd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_51039df2-577d-4ed7-b18a-a991cb957995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_51039df2-577d-4ed7-b18a-a991cb957995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_316ff804-69d1-40c2-aa44-4d26b8d67f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_316ff804-69d1-40c2-aa44-4d26b8d67f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_36bccf9d-d8f9-4ebf-9011-6d5b2ca4d4f9" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_36bccf9d-d8f9-4ebf-9011-6d5b2ca4d4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_fd5319ee-9b40-447b-8314-ed5a9e986f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_fd5319ee-9b40-447b-8314-ed5a9e986f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de4f68c7-2fa8-491c-a5f2-9fd9430b1949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de4f68c7-2fa8-491c-a5f2-9fd9430b1949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7e6d3d8f-2df1-4c00-a08b-0d771facd107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_AssetImpairmentCharges_7e6d3d8f-2df1-4c00-a08b-0d771facd107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3ea060af-179b-44d4-8eb2-c95dd10b46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3ea060af-179b-44d4-8eb2-c95dd10b46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_61b8cdcf-a575-4261-bfd4-0c02dff512ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_61b8cdcf-a575-4261-bfd4-0c02dff512ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3d848b51-5029-483d-a726-3984261c9676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_SeveranceCosts1_3d848b51-5029-483d-a726-3984261c9676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bab3b95c-3509-4769-bb47-c36dec43fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bab3b95c-3509-4769-bb47-c36dec43fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3310cc92-b502-4b14-8cdd-6bc1758fe5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafcba9f-91cb-45be-8744-4fb9a973834d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3310cc92-b502-4b14-8cdd-6bc1758fe5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="lxrx-20211231.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_47c15b2a-b23c-4080-ba89-4265c5bb147a" xlink:href="lxrx-20211231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_31128ffb-7936-4447-824f-aa3ba75a136f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_47c15b2a-b23c-4080-ba89-4265c5bb147a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_31128ffb-7936-4447-824f-aa3ba75a136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bb97ed68-733c-4fa4-9216-e542ea36fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_28c92b54-c52f-42ec-8690-9ed73eaeb747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb97ed68-733c-4fa4-9216-e542ea36fcc1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_28c92b54-c52f-42ec-8690-9ed73eaeb747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e566f6bd-31a9-43cb-b6f2-2e3374f54033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e566f6bd-31a9-43cb-b6f2-2e3374f54033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e8ca0a39-ad10-4aee-847f-d1f83bac00aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_UseOfEstimates_e8ca0a39-ad10-4aee-847f-d1f83bac00aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4b735fcf-3030-4151-84f5-045d97fe8b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4b735fcf-3030-4151-84f5-045d97fe8b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f3cfbc1e-2373-461f-8cb3-9ea6763f5b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f3cfbc1e-2373-461f-8cb3-9ea6763f5b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_effcbb99-3a95-4782-852a-05eee7cefd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_effcbb99-3a95-4782-852a-05eee7cefd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_042be58e-e4fc-4691-86e9-32b8db30fef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_042be58e-e4fc-4691-86e9-32b8db30fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bbd9ce95-f726-4980-9daa-d00da2a02a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bbd9ce95-f726-4980-9daa-d00da2a02a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_227982c4-5a3a-47f8-b8ce-e914b4a49180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_227982c4-5a3a-47f8-b8ce-e914b4a49180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_27d06d3a-669e-4dac-a221-31300a1aa73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_27d06d3a-669e-4dac-a221-31300a1aa73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b79f2a79-b721-4890-b144-7bd990e92b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b79f2a79-b721-4890-b144-7bd990e92b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b05bc3e2-a352-4e49-ab77-c99aaafdc5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b05bc3e2-a352-4e49-ab77-c99aaafdc5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9641ef04-7edf-4436-9f50-7dc48d2770a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9641ef04-7edf-4436-9f50-7dc48d2770a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_73fdd600-6a0a-4109-aed8-92b502a72a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_73fdd600-6a0a-4109-aed8-92b502a72a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_93ca8458-313f-42df-be57-08d9fdab50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_93ca8458-313f-42df-be57-08d9fdab50d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ef21a7a-d790-4353-90ba-9d0c33737382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ef21a7a-d790-4353-90ba-9d0c33737382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4d2cb156-435a-470b-b29c-1400b33a9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4d2cb156-435a-470b-b29c-1400b33a9a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_edff3589-ca78-4b66-87fd-30e120f5153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_edff3589-ca78-4b66-87fd-30e120f5153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_dcb21ba8-ede5-4e46-8fcc-2ff588e8e252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49a91903-f169-4661-8cd4-cd13918e58ad" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_dcb21ba8-ede5-4e46-8fcc-2ff588e8e252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_119ba7f9-b2ac-4391-808d-185889959b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_835ae3b9-e8e5-4cda-b2a3-1ffe0151e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_119ba7f9-b2ac-4391-808d-185889959b43" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_835ae3b9-e8e5-4cda-b2a3-1ffe0151e7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43542af8-e170-4ab4-b8fa-d0b71f1941f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_f968b9a7-a801-4462-86ec-91a5193ed560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43542af8-e170-4ab4-b8fa-d0b71f1941f9" xlink:to="loc_us-gaap_InventoryWorkInProcess_f968b9a7-a801-4462-86ec-91a5193ed560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_7bd636ea-db89-496a-81ce-7d50e07c9462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43542af8-e170-4ab4-b8fa-d0b71f1941f9" xlink:to="loc_us-gaap_InventoryFinishedGoods_7bd636ea-db89-496a-81ce-7d50e07c9462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5d13c4f5-5578-409a-a255-832d01ce4b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43542af8-e170-4ab4-b8fa-d0b71f1941f9" xlink:to="loc_us-gaap_InventoryRawMaterials_5d13c4f5-5578-409a-a255-832d01ce4b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_269b1887-2621-4479-ae58-6d418fdee945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_e6046b5b-7c50-4a10-959b-399a9d00be6c" xlink:href="lxrx-20211231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_269b1887-2621-4479-ae58-6d418fdee945" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_e6046b5b-7c50-4a10-959b-399a9d00be6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_d13ed6bf-69d6-4dd4-9a0e-f44b5be2daf6" xlink:href="lxrx-20211231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_269b1887-2621-4479-ae58-6d418fdee945" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_d13ed6bf-69d6-4dd4-9a0e-f44b5be2daf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d7dd4e8-2894-49a6-925c-103f051dceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0a6abecb-30aa-4ae4-924a-bc17cb35f820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7dd4e8-2894-49a6-925c-103f051dceea" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0a6abecb-30aa-4ae4-924a-bc17cb35f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage_9acb21b3-c5ab-4008-9dc4-0a009703079c" xlink:href="lxrx-20211231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7dd4e8-2894-49a6-925c-103f051dceea" xlink:to="loc_lxrx_EntityWideRevenueSanofiPercentage_9acb21b3-c5ab-4008-9dc4-0a009703079c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration_be8710b0-a16f-423f-be74-ddbddd9083c2" xlink:href="lxrx-20211231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7dd4e8-2894-49a6-925c-103f051dceea" xlink:to="loc_lxrx_LXRXDiplomatcustomerconcentration_be8710b0-a16f-423f-be74-ddbddd9083c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration_44634ea1-b215-4301-bc60-5931f6506fd7" xlink:href="lxrx-20211231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7dd4e8-2894-49a6-925c-103f051dceea" xlink:to="loc_lxrx_LXRXBiologicscustomerconcentration_44634ea1-b215-4301-bc60-5931f6506fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9978fb5c-8610-4fcc-9eb2-36cb4156f53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9978fb5c-8610-4fcc-9eb2-36cb4156f53b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e692aef-4775-4a29-8c50-de6e1540d424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69926265-042f-4e19-bdcf-802cddac3e80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e692aef-4775-4a29-8c50-de6e1540d424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f997978c-0d31-44e5-930d-c6498b7e56d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_bb68482b-2569-4991-a2dd-142e712c831d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_bb68482b-2569-4991-a2dd-142e712c831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_b81e1e91-3a0d-4a76-9073-d9e55b01362a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_b81e1e91-3a0d-4a76-9073-d9e55b01362a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_933e5957-40bc-41af-990f-669e9b573044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cb42d83e-74b5-406d-87eb-ac30aac661a0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_933e5957-40bc-41af-990f-669e9b573044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_754c1635-6ce7-4d61-907f-ca7c64891f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754c1635-6ce7-4d61-907f-ca7c64891f2c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:to="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39823091-54ee-4e4d-ad9a-13860b9925a9" xlink:to="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ce3f2bbf-5a5d-43b5-9fbc-e90be8838c02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:to="loc_srt_MinimumMember_ce3f2bbf-5a5d-43b5-9fbc-e90be8838c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_233f4f8d-4c9e-440f-b67b-c3195af474e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_020869f7-5234-4161-87b5-b2514d6d30dc" xlink:to="loc_srt_MaximumMember_233f4f8d-4c9e-440f-b67b-c3195af474e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a36ae235-2584-4dbc-9911-f207a17af4eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1449bfe-786a-4932-9eda-8817b7438b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1449bfe-786a-4932-9eda-8817b7438b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_c1757008-d0b9-4273-85d1-b67692af8479" xlink:href="lxrx-20211231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_c1757008-d0b9-4273-85d1-b67692af8479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_c9919840-6d26-4a0f-8063-d76eba29ed02" xlink:href="lxrx-20211231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_c9919840-6d26-4a0f-8063-d76eba29ed02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_557ed2dd-1097-4fdd-8e0e-d6be2a044d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_557ed2dd-1097-4fdd-8e0e-d6be2a044d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a35f5111-d6bf-4ed0-bca0-0992e08206f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a35f5111-d6bf-4ed0-bca0-0992e08206f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_322bfc2f-88b5-4a81-8e4a-35eb319152bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3a4d73-aa65-479f-acbf-8de9c3d5b7c6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_322bfc2f-88b5-4a81-8e4a-35eb319152bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d71a06c-fdb5-444c-9d54-f6fb7f950450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a3d4651b-5b0b-4dbe-9e9e-c40cc840413a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d71a06c-fdb5-444c-9d54-f6fb7f950450" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a3d4651b-5b0b-4dbe-9e9e-c40cc840413a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_102d25cf-099a-4b06-ba64-9632b2b9f3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d71a06c-fdb5-444c-9d54-f6fb7f950450" xlink:to="loc_us-gaap_AssetImpairmentCharges_102d25cf-099a-4b06-ba64-9632b2b9f3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7bf30f49-989c-409c-a360-5cdbaf2caf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d71a06c-fdb5-444c-9d54-f6fb7f950450" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7bf30f49-989c-409c-a360-5cdbaf2caf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_33ed45c4-1f51-4271-a688-1f245cebf73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d20df173-9a10-41ff-b3ed-ede3eb2eb1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_eeda94e2-4b79-491d-8863-8f34505e21cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d20df173-9a10-41ff-b3ed-ede3eb2eb1b5" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_eeda94e2-4b79-491d-8863-8f34505e21cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d11013f8-9033-4960-bdd3-a9b2ee8ba92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d11013f8-9033-4960-bdd3-a9b2ee8ba92c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6256d2d-0893-47c2-8a75-5d1a20b92f0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d80a60f2-4711-43d2-9587-b62c41791f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4870ce60-6d14-40d4-ad3c-94901fe89671" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d80a60f2-4711-43d2-9587-b62c41791f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf830ec7-9ff0-454e-83eb-f60192efa4a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_041c7f14-a108-477b-bccf-13968bec427f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c131031-8c36-438e-b913-6e01b449e386" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_041c7f14-a108-477b-bccf-13968bec427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b644fe58-3236-46cc-8ad5-500acf2bf36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b644fe58-3236-46cc-8ad5-500acf2bf36f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:to="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_88ddf5bd-90fe-4100-87ca-544c6e07be5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6724c576-0d9b-4ff1-8da7-9ad39ac8f604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a813d0eb-cec8-4287-ad3f-356e8e3b34a3" xlink:to="loc_us-gaap_StockOptionMember_6724c576-0d9b-4ff1-8da7-9ad39ac8f604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6354f0a5-7132-47bf-a2bd-b92c95b6d2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b61e513-ebc7-4a2b-8677-98e805cc6b71" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6354f0a5-7132-47bf-a2bd-b92c95b6d2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81c4e9eb-7c82-4760-9ff5-1c758c701888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_50478ec2-c9d7-42f3-9b32-6183848f93ae" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_50478ec2-c9d7-42f3-9b32-6183848f93ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_a9bb3d50-9ccd-45e7-986f-e56bb2432c02" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_a9bb3d50-9ccd-45e7-986f-e56bb2432c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_c474bf55-6272-43e6-9384-57b4714fbd63" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_c474bf55-6272-43e6-9384-57b4714fbd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_0acbf815-1962-4a01-aae0-5e36073613d2" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_0acbf815-1962-4a01-aae0-5e36073613d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_89802a53-6063-4ff1-ad82-9e5e926e3f04" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_89802a53-6063-4ff1-ad82-9e5e926e3f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_5994130f-fc98-4d75-9692-3ce466248a5b" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_5994130f-fc98-4d75-9692-3ce466248a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_0135fa43-b724-4316-afdf-371f338d381d" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_0135fa43-b724-4316-afdf-371f338d381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d738522a-da1d-459f-963f-3a2e013a968b" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d738522a-da1d-459f-963f-3a2e013a968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa444d24-c170-4269-b44d-1aced012210f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_baab0f43-668a-4c47-9399-43aa0b9a74ac" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa444d24-c170-4269-b44d-1aced012210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d7dadcc-d7a7-4487-90ba-c71fe987a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6989c096-7c49-4e57-9ed6-19f4cf5097d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d7dadcc-d7a7-4487-90ba-c71fe987a14e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6989c096-7c49-4e57-9ed6-19f4cf5097d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ce576d3d-5e4d-452a-9b0c-7462f94e68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d7dadcc-d7a7-4487-90ba-c71fe987a14e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ce576d3d-5e4d-452a-9b0c-7462f94e68b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lxrx-20211231.xsd#RecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_34b115bd-cd99-4dba-bb43-182d3da3db1e" xlink:href="lxrx-20211231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a164d2a2-d311-4d8c-85e0-cd7175f55aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_34b115bd-cd99-4dba-bb43-182d3da3db1e" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a164d2a2-d311-4d8c-85e0-cd7175f55aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#RecentAccountingPronouncementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_de31e296-2259-4f33-b5e0-f8d99b144288" xlink:href="lxrx-20211231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_de31e296-2259-4f33-b5e0-f8d99b144288" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3c1c6c6d-0a8a-41ac-972c-c00499fed8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d18e99e9-b0df-4eb1-9480-c5e9e5cc9b55" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3c1c6c6d-0a8a-41ac-972c-c00499fed8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a1837efa-8e2a-4b8f-92e5-188eaf448722" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e28b7db0-fb18-44a9-9ed6-c4774eb4f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_791d1164-19c9-4f54-af2c-95a30a42d2dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e28b7db0-fb18-44a9-9ed6-c4774eb4f09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_e02117f0-c6e9-4639-95f0-f2dc37c70985" xlink:href="lxrx-20211231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_82b8548e-8737-4b50-a2d6-a45680bda570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_e02117f0-c6e9-4639-95f0-f2dc37c70985" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_82b8548e-8737-4b50-a2d6-a45680bda570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c46058fa-28f7-4960-aa7d-823d636fedc9" xlink:href="lxrx-20211231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6c89c129-3b94-4a58-b79e-9b6d5a26e627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c46058fa-28f7-4960-aa7d-823d636fedc9" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6c89c129-3b94-4a58-b79e-9b6d5a26e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_813fd138-0a5f-4056-b62d-98f556c288f9" xlink:href="lxrx-20211231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_813fd138-0a5f-4056-b62d-98f556c288f9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:to="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f9de2f20-beeb-4124-a4b0-d44eb508017c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_21426f79-8cff-40ee-9d96-c5c4e02fa8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_CashMember_21426f79-8cff-40ee-9d96-c5c4e02fa8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_caa55123-131d-4cd0-b4b8-56157e7a4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_caa55123-131d-4cd0-b4b8-56157e7a4cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d15fee10-9cd7-4a50-b9a7-b21288ce1e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d15fee10-9cd7-4a50-b9a7-b21288ce1e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_80d8a23e-3644-45d2-9333-cc3b8900eebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4ad23cc9-7442-466f-999a-f424c4a22a38" xlink:to="loc_us-gaap_InvestmentsMember_80d8a23e-3644-45d2-9333-cc3b8900eebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_767d91ef-62a3-4568-930b-8c8efed24635" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_0f63d2ba-0a76-4f0f-aa0a-6c9b54dbd262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_0f63d2ba-0a76-4f0f-aa0a-6c9b54dbd262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2ce59521-d398-4ef9-9704-c60035f907d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2ce59521-d398-4ef9-9704-c60035f907d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dc1a4b91-5c20-4228-9b66-307660872ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dc1a4b91-5c20-4228-9b66-307660872ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_645399b1-cdce-49ce-a234-58c0f3347e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_645399b1-cdce-49ce-a234-58c0f3347e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_b8fd90ac-5b91-4678-8a31-26ee5b1d6253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b927c9b5-9290-4061-95ba-8035f00d2f91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_b8fd90ac-5b91-4678-8a31-26ee5b1d6253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_9c569291-d9c7-4eac-bc84-c063d798cadd" xlink:href="lxrx-20211231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7c5b8b8e-aa26-4676-983b-a068c2b65f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_9c569291-d9c7-4eac-bc84-c063d798cadd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7c5b8b8e-aa26-4676-983b-a068c2b65f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_d12ee35a-00fd-416a-8392-c0e32f45aa86" xlink:href="lxrx-20211231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_249cde1d-bf3a-4bc2-b26f-6e6c719b975d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_d12ee35a-00fd-416a-8392-c0e32f45aa86" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_249cde1d-bf3a-4bc2-b26f-6e6c719b975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_e1597e52-1fe6-419d-9676-470c75f622f6" xlink:href="lxrx-20211231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_e1597e52-1fe6-419d-9676-470c75f622f6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d209b0da-5aca-4e1a-96ba-a7858d91cd44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d0a7f1ca-ffd9-4f9e-864c-6c4f0a2dbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d0a7f1ca-ffd9-4f9e-864c-6c4f0a2dbb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_914a7370-21b0-4673-968f-491ea259dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_914a7370-21b0-4673-968f-491ea259dba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7167daae-48b3-4a72-bb89-7ef3ac8404ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a247b9a-c728-4bfd-8adf-ab4b66d3f8fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7167daae-48b3-4a72-bb89-7ef3ac8404ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a4816669-00ac-40f7-bf2f-f2a5777ca43d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb8b9930-fa99-4dde-9a10-8c0e96e7d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb8b9930-fa99-4dde-9a10-8c0e96e7d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_5d744b63-429e-4b1d-b75c-5dc776f20316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_AvailableForSaleSecurities_5d744b63-429e-4b1d-b75c-5dc776f20316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_d893c9ae-3879-42a7-8994-0e5067309363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_915ac691-008d-41e8-ba50-de2e65b524a9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_d893c9ae-3879-42a7-8994-0e5067309363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_430784b6-191f-4421-834d-2ab5caa43791" xlink:href="lxrx-20211231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_430784b6-191f-4421-834d-2ab5caa43791" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d1e25c2b-96ed-456e-b285-c4ffd425ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_692d914b-26f6-4509-84aa-f11bf91a829f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d1e25c2b-96ed-456e-b285-c4ffd425ea49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_48c861a8-bb98-4973-aedf-fabffdb68638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0122e2e7-32e5-44f3-aee4-41f98df3e684" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_48c861a8-bb98-4973-aedf-fabffdb68638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lxrx-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_ab571414-d33c-434e-a877-ed49a773acf6" xlink:href="lxrx-20211231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cb76410b-7dbe-4f41-8a11-9ac49394db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_ab571414-d33c-434e-a877-ed49a773acf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cb76410b-7dbe-4f41-8a11-9ac49394db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_0b9a9242-dfd4-4e42-a759-27ad715957a3" xlink:href="lxrx-20211231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f9602322-3de8-4620-baaf-7edd55033664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_0b9a9242-dfd4-4e42-a759-27ad715957a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f9602322-3de8-4620-baaf-7edd55033664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_b76c9417-b44d-4bd6-94b1-342ba08f423f" xlink:href="lxrx-20211231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_b76c9417-b44d-4bd6-94b1-342ba08f423f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d5537058-d838-41da-8763-d7b3f3ea436b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b70d7b03-7786-4f25-b7ae-3723f80d974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_ComputerEquipmentMember_b70d7b03-7786-4f25-b7ae-3723f80d974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9235079b-0950-41a5-8a95-26038f8d153c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9235079b-0950-41a5-8a95-26038f8d153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c101fe42-3734-41a8-99a4-1de439f600bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_EquipmentMember_c101fe42-3734-41a8-99a4-1de439f600bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8e55f27e-f49c-40f9-b277-9de884c95ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8e55f27e-f49c-40f9-b277-9de884c95ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c74e457c-4384-4d4a-8259-d5cb097557d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c74e457c-4384-4d4a-8259-d5cb097557d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_744c6a58-29b3-4126-8ab4-4918efaa8af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d368e15e-53f6-4acc-b2ea-0321279fd9b9" xlink:to="loc_us-gaap_LandMember_744c6a58-29b3-4126-8ab4-4918efaa8af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:to="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f2f19845-c31b-4a11-b4d8-c36b8b62cc86" xlink:to="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_339d5dec-ed95-4625-8a92-95047966beea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:to="loc_srt_MinimumMember_339d5dec-ed95-4625-8a92-95047966beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_502fc1df-c820-4e27-afb3-c73c112f8f10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b65c752-9b51-487d-9d44-489104cd68c7" xlink:to="loc_srt_MaximumMember_502fc1df-c820-4e27-afb3-c73c112f8f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_278adb81-e3b5-42a2-b48f-1154a4846357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1986dde4-b0e0-4bbf-82ef-77aac380d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1986dde4-b0e0-4bbf-82ef-77aac380d13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_22fecd9a-e777-4ba2-a1d3-6ab84f3dfcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_22fecd9a-e777-4ba2-a1d3-6ab84f3dfcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5999a5c-3392-4284-bf47-fd1b3b8672da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5999a5c-3392-4284-bf47-fd1b3b8672da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a283ed6-5995-4160-b1e1-3054c9b35e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a283ed6-5995-4160-b1e1-3054c9b35e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_96ddb2e0-0159-4eae-b279-069316b39ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_96ddb2e0-0159-4eae-b279-069316b39ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_8d034c38-9c2b-4f95-be7d-54a79e79ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_Land_8d034c38-9c2b-4f95-be7d-54a79e79ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements_b97aaf08-4ec1-4406-b982-cb641cc21198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_InventoryBuildingsAndImprovements_b97aaf08-4ec1-4406-b982-cb641cc21198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1a947a0a-1b69-42b8-9cb7-c3a41609c92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_AssetImpairmentCharges_1a947a0a-1b69-42b8-9cb7-c3a41609c92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_70177cbc-f411-45e3-94fd-e22638fb7e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_70177cbc-f411-45e3-94fd-e22638fb7e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_3359a48d-3d03-42b0-aacb-4d9727a4119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba656c22-770f-48b6-9283-083dddb21a1e" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_3359a48d-3d03-42b0-aacb-4d9727a4119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d778c8e9-25a4-4fac-9c00-caa44be8e670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a577394d-0acd-49d7-8c27-8e40ad858620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d778c8e9-25a4-4fac-9c00-caa44be8e670" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a577394d-0acd-49d7-8c27-8e40ad858620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6808d6e-7c37-4573-a388-d3bf9955bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_17c2be1f-514a-45f5-a232-cd7d59024a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6808d6e-7c37-4573-a388-d3bf9955bb43" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_17c2be1f-514a-45f5-a232-cd7d59024a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3bba8763-b8d8-4ade-9d07-08762f229a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6808d6e-7c37-4573-a388-d3bf9955bb43" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3bba8763-b8d8-4ade-9d07-08762f229a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_419d0231-6198-4f2a-8b73-5292cb4b51bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_419d0231-6198-4f2a-8b73-5292cb4b51bf" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3a647b71-6395-46a4-aa98-4156365bad48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ee7bb9e-155a-4151-808f-5f0503717efd" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3a647b71-6395-46a4-aa98-4156365bad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0d0df5a8-fe58-4318-a422-428d7f266ee2" xlink:to="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6daeeebb-be20-46fb-a6a4-407e4f6711df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6daeeebb-be20-46fb-a6a4-407e4f6711df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d40c1117-fb45-482d-abd7-15a1566d69e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d40c1117-fb45-482d-abd7-15a1566d69e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_59f2747e-5842-4834-b102-0fe2392756bd" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_59f2747e-5842-4834-b102-0fe2392756bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa6373f2-636b-4381-b6a8-99d8769751d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa6373f2-636b-4381-b6a8-99d8769751d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1649fe1c-98e8-4464-9ac3-c667b8d71a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1649fe1c-98e8-4464-9ac3-c667b8d71a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1002da13-c991-4b7f-989b-db95573214ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1002da13-c991-4b7f-989b-db95573214ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2e659190-26e3-45b1-8d53-3d32c2196a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2e659190-26e3-45b1-8d53-3d32c2196a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_b0a915a5-109b-4f77-93e7-09544c9a6465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_b0a915a5-109b-4f77-93e7-09544c9a6465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b7f8f8fe-221e-452f-a534-7330d98a54cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b7f8f8fe-221e-452f-a534-7330d98a54cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32cc57d2-98aa-4da9-8f86-d239512b702f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32cc57d2-98aa-4da9-8f86-d239512b702f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ade17fc5-6f43-42a8-8718-cd44026c8248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_ade17fc5-6f43-42a8-8718-cd44026c8248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4fb8210c-a2ef-4829-b0aa-c37075e575b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4fb8210c-a2ef-4829-b0aa-c37075e575b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease_9da5fe5d-1a53-49f3-9e8c-cb997dc32c37" xlink:href="lxrx-20211231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_A2020FederalNOLIncrease_9da5fe5d-1a53-49f3-9e8c-cb997dc32c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs_45fa925a-b811-46fb-b259-891d93ff4f44" xlink:href="lxrx-20211231.xsd#lxrx_DecreaseInNOLs"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DecreaseInNOLs_45fa925a-b811-46fb-b259-891d93ff4f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease_18e529e0-2a17-418d-86e3-e4c20263205c" xlink:href="lxrx-20211231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_RDTaxCreditDecrease_18e529e0-2a17-418d-86e3-e4c20263205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_8662fedd-0c2a-41c8-88d1-77ef23314490" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_8662fedd-0c2a-41c8-88d1-77ef23314490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_61e6c4b8-d7d6-477e-a9f1-b75de139031f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_61e6c4b8-d7d6-477e-a9f1-b75de139031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cab11ba3-7f44-4a0f-885b-a1b0cf23a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6255f8ee-7212-44bf-a052-c4a209bfaea6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cab11ba3-7f44-4a0f-885b-a1b0cf23a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6368a57-73b5-4771-95af-cce9cc61fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6368a57-73b5-4771-95af-cce9cc61fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b3014163-040f-45e5-98d8-7cb38230a414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b3014163-040f-45e5-98d8-7cb38230a414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7b5a4b13-1378-43d5-ac34-11123244d813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7b5a4b13-1378-43d5-ac34-11123244d813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d55c71e9-a0e3-4b58-b6fb-28c758b464a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d55c71e9-a0e3-4b58-b6fb-28c758b464a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a7ab78a9-0efc-4914-9165-3f838f8a0dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a7ab78a9-0efc-4914-9165-3f838f8a0dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9d582d-7f91-4d8b-bd56-0f386f6718ca" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c44f15f8-103e-49ea-a974-c402c067173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_330e279c-feb2-45e0-82ff-948516f6b269" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c44f15f8-103e-49ea-a974-c402c067173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_d4d76d3e-54fc-47aa-9d10-3ec42eae5c9e" xlink:to="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_c6f93116-d0cb-42ad-a867-b72f49a96532" xlink:href="lxrx-20211231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_c6f93116-d0cb-42ad-a867-b72f49a96532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ff9091e-2644-46cd-8dff-02fc404c4396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4b6667aa-cf03-42f1-b67b-10a48b07afb8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ff9091e-2644-46cd-8dff-02fc404c4396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="simple" xlink:href="lxrx-20211231.xsd#IncomeTaxesDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_54d33ca9-7f65-4278-9afa-6b47ee590e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_54d33ca9-7f65-4278-9afa-6b47ee590e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_467dd097-fb6f-40cd-ac32-ad02354ae96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_467dd097-fb6f-40cd-ac32-ad02354ae96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_583e196a-1ef7-4fd2-b1b7-da8f0a6d16e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_583e196a-1ef7-4fd2-b1b7-da8f0a6d16e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b3ae378b-33f0-4fd8-8849-4b5df411367d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b3ae378b-33f0-4fd8-8849-4b5df411367d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ac2b3b75-0d87-4203-8133-10d8db9c167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ac2b3b75-0d87-4203-8133-10d8db9c167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_WriteOffOfTaxCredits_ca095dbb-f48b-45e9-8f75-2058a57b50fe" xlink:href="lxrx-20211231.xsd#lxrx_WriteOffOfTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_lxrx_WriteOffOfTaxCredits_ca095dbb-f48b-45e9-8f75-2058a57b50fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b3990d8c-1445-4c23-a867-ba9b5076a0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b3990d8c-1445-4c23-a867-ba9b5076a0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1f681276-ab2a-40cc-8afa-b82079a5cebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1f681276-ab2a-40cc-8afa-b82079a5cebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_25c40e10-6edb-47ba-8823-95bff7089506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedda1ed-3aca-4e5f-98f3-1acd6f712541" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_25c40e10-6edb-47ba-8823-95bff7089506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:type="simple" xlink:href="lxrx-20211231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_71919e73-6e19-4ff8-a483-1c554e33fcc8" xlink:href="lxrx-20211231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_480b436b-40a2-4235-8f54-64e72f5c9cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_71919e73-6e19-4ff8-a483-1c554e33fcc8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_480b436b-40a2-4235-8f54-64e72f5c9cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_e001e05c-ab6a-44a1-b57d-ec8207441774" xlink:href="lxrx-20211231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill_250a22fe-ae2f-444d-ae60-a37429c451f9" xlink:href="lxrx-20211231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_e001e05c-ab6a-44a1-b57d-ec8207441774" xlink:to="loc_lxrx_CoelacanthGoodwill_250a22fe-ae2f-444d-ae60-a37429c451f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice_c308368f-0728-4fa1-804f-0921f51522a3" xlink:href="lxrx-20211231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_e001e05c-ab6a-44a1-b57d-ec8207441774" xlink:to="loc_lxrx_CoelacanthPurchasePrice_c308368f-0728-4fa1-804f-0921f51522a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill_36cf096f-de0d-4319-a3e0-c746fb5c6bb4" xlink:href="lxrx-20211231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_e001e05c-ab6a-44a1-b57d-ec8207441774" xlink:to="loc_lxrx_SymphonyIconGoodwill_36cf096f-de0d-4319-a3e0-c746fb5c6bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20211231.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_3d4ade47-93e0-42dc-b6d8-120c35240137" xlink:href="lxrx-20211231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3fbf96a3-9a75-4bb8-9dd0-baf1a16d3676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_3d4ade47-93e0-42dc-b6d8-120c35240137" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3fbf96a3-9a75-4bb8-9dd0-baf1a16d3676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#DebtObligationsDebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_72d9135d-8c1f-4317-a96d-8849a93027ff" xlink:href="lxrx-20211231.xsd#lxrx_DebtObligationsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#DebtObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_a6091a35-8f96-4371-9248-da0647a07af9" xlink:href="lxrx-20211231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_a6091a35-8f96-4371-9248-da0647a07af9" xlink:to="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91663526-9e21-44a9-bfaf-dc126d6c5f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ba2a8e9-8a46-4bc3-b8b2-1eb0bf94edca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91663526-9e21-44a9-bfaf-dc126d6c5f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:to="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09f5e285-8557-44fd-a8c1-490347e2c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_056b5f90-4766-4c38-bb40-8e42c6a9b705" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09f5e285-8557-44fd-a8c1-490347e2c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_587ae0c7-c4a0-4c0f-8b69-86a773c57cc0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_d3b01e61-8dfc-46a2-aa45-fc0941c4e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_d3b01e61-8dfc-46a2-aa45-fc0941c4e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_aedaceba-1fa7-4831-831f-b475fd315b30" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_aedaceba-1fa7-4831-831f-b475fd315b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bebd66d5-f474-4a5b-be09-e244c1b0079b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bebd66d5-f474-4a5b-be09-e244c1b0079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_28d0fd0d-2ca0-4348-9973-e32bcc739347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_28d0fd0d-2ca0-4348-9973-e32bcc739347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_91a7ec99-702c-4ad3-9c6d-c41c89313f42" xlink:href="lxrx-20211231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_91a7ec99-702c-4ad3-9c6d-c41c89313f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_658a1508-2444-49e4-9d2e-80af67e283d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_658a1508-2444-49e4-9d2e-80af67e283d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_29a41e71-f6dd-49b9-b0f3-801344a670b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentTerm_29a41e71-f6dd-49b9-b0f3-801344a670b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a2bf6bcf-e032-4ea4-8826-c4842bda12d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a2bf6bcf-e032-4ea4-8826-c4842bda12d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_24672da6-635a-4103-887b-31a2fd705ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentFairValue_24672da6-635a-4103-887b-31a2fd705ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d396cd66-a382-41f8-a133-0fca83ca47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d396cd66-a382-41f8-a133-0fca83ca47b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b826646-dcb3-4e40-9214-a9fdb0b09580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b826646-dcb3-4e40-9214-a9fdb0b09580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99c558c3-83b5-42a2-97b9-be3072cad92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99c558c3-83b5-42a2-97b9-be3072cad92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_e3ea6386-c5d7-474a-b151-00c19d50dbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_e3ea6386-c5d7-474a-b151-00c19d50dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5c2ecd5f-87bd-4cc2-a360-cb997c9c192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5c2ecd5f-87bd-4cc2-a360-cb997c9c192c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_57009c7c-df38-4486-a197-40bebe15f478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_57009c7c-df38-4486-a197-40bebe15f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_57a7b80b-cda6-4dab-8323-b1c2dc044380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_us-gaap_ConvertibleDebt_57a7b80b-cda6-4dab-8323-b1c2dc044380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_2328ed2f-9197-4da0-b074-884d7687c306" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_2328ed2f-9197-4da0-b074-884d7687c306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_66583cca-896d-4745-8642-2bf983d2d05f" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_66583cca-896d-4745-8642-2bf983d2d05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_fbf86389-8562-4586-802d-e4af4e4c8f0e" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_fbf86389-8562-4586-802d-e4af4e4c8f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f2da0430-f793-4a36-8e50-c786db2f1257" xlink:href="lxrx-20211231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f2da0430-f793-4a36-8e50-c786db2f1257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_d975ebab-0519-4416-9e67-cb9fd2bcbec3" xlink:href="lxrx-20211231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_d975ebab-0519-4416-9e67-cb9fd2bcbec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_15478960-47af-4f75-8a38-5f6b0db83cb1" xlink:href="lxrx-20211231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_ConvertibleDebtExchange_15478960-47af-4f75-8a38-5f6b0db83cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_263afc15-a500-4a8a-8e66-80051af82a21" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_263afc15-a500-4a8a-8e66-80051af82a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_d0858472-cc5d-4449-bce6-fd5b14546f0d" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_d0858472-cc5d-4449-bce6-fd5b14546f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_6734650a-f910-456e-9fa2-fafc1df991e6" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_6734650a-f910-456e-9fa2-fafc1df991e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_2a6b63f1-22a2-4277-bd62-7c4d287f65c1" xlink:href="lxrx-20211231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6a973a-b7f9-4d60-a8b3-5c49953fb488" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_2a6b63f1-22a2-4277-bd62-7c4d287f65c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="simple" xlink:href="lxrx-20211231.xsd#DebtObligationsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_6bb16ad4-2c93-4932-87f3-ce4ed14f5489" xlink:href="lxrx-20211231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e43fafe2-e6ad-45be-9bcd-bc24141be8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_6bb16ad4-2c93-4932-87f3-ce4ed14f5489" xlink:to="loc_us-gaap_LongTermDebtCurrent_e43fafe2-e6ad-45be-9bcd-bc24141be8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9236487e-2d62-4677-8b52-747e79925ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_6bb16ad4-2c93-4932-87f3-ce4ed14f5489" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9236487e-2d62-4677-8b52-747e79925ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_bf6417ce-7ffe-4535-85d1-c0349dbf83f1" xlink:href="lxrx-20211231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d9237ed3-a652-4389-9afe-e6ad92543ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_bf6417ce-7ffe-4535-85d1-c0349dbf83f1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d9237ed3-a652-4389-9afe-e6ad92543ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_dee8b50a-8aec-4c33-8c9b-6ee8a25daa45" xlink:href="lxrx-20211231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_39628cbd-aae6-418c-b45c-bb1531c40068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_dee8b50a-8aec-4c33-8c9b-6ee8a25daa45" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_39628cbd-aae6-418c-b45c-bb1531c40068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_5a65d948-1e35-4647-9c72-af376c1d5eb6" xlink:href="lxrx-20211231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_5a65d948-1e35-4647-9c72-af376c1d5eb6" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:to="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0097bd68-f66a-41d4-beb0-ef35571844dd" xlink:to="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4f92678-a173-45db-9087-45d56d7f73fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:to="loc_srt_MinimumMember_d4f92678-a173-45db-9087-45d56d7f73fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_57c3deed-ffbb-4b73-9d97-33bc8dd1b889" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c506748-4dc5-441b-9227-ac345f20ab21" xlink:to="loc_srt_MaximumMember_57c3deed-ffbb-4b73-9d97-33bc8dd1b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_badee1a2-30f9-40e7-a51f-2af4f65b2fb5" xlink:to="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e2099935-d22f-491e-96df-7e2ccca42f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_1a3b256d-d110-40d9-b5a7-69f284f698a6" xlink:to="loc_us-gaap_AccountsReceivableMember_e2099935-d22f-491e-96df-7e2ccca42f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_2a6d0411-dee7-4c6a-8956-52643ceaea3f" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_c27320b4-2412-4dce-93c4-195faa33c790" xlink:href="lxrx-20211231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_c27320b4-2412-4dce-93c4-195faa33c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate_2f1a54af-6b45-4d91-9ddd-b95d1557ca6f" xlink:href="lxrx-20211231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_LexiconBorrowingRate_2f1a54af-6b45-4d91-9ddd-b95d1557ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_a0ad7267-e132-4429-883e-c0056473faef" xlink:href="lxrx-20211231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_f9085412-5819-4101-a5fc-1dc5edd3e74b" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_a0ad7267-e132-4429-883e-c0056473faef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:href="lxrx-20211231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f5c74c44-cedf-45ff-b957-48ceda46a9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f5c74c44-cedf-45ff-b957-48ceda46a9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f8eaf97e-dcee-43f2-a5fc-fbd5f973365b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f8eaf97e-dcee-43f2-a5fc-fbd5f973365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4e315190-c912-41cf-abb4-f28051afde21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4e315190-c912-41cf-abb4-f28051afde21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_24f1eef5-16cf-4331-bb0b-741ff5939fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_24f1eef5-16cf-4331-bb0b-741ff5939fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_28eaadda-1bf9-4bc7-b5dd-9b2670c87941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_28eaadda-1bf9-4bc7-b5dd-9b2670c87941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_c332357e-1b32-489a-bf60-2108b2cdf7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_c332357e-1b32-489a-bf60-2108b2cdf7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_d8c86ec9-1121-4033-8444-7f4c0dfc8944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_d8c86ec9-1121-4033-8444-7f4c0dfc8944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments_ae92e264-bdc9-452f-b3bf-6f3ef0f1e0b5" xlink:href="lxrx-20211231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_lxrx_InterestOnLeasePayments_ae92e264-bdc9-452f-b3bf-6f3ef0f1e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments_d1a95769-c55b-4886-a665-e1a7277cf7e7" xlink:href="lxrx-20211231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_lxrx_PresentValueOfFutureLeasePayments_d1a95769-c55b-4886-a665-e1a7277cf7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_92f0ea32-3a8e-46e4-988f-ef37a70b8863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_92f0ea32-3a8e-46e4-988f-ef37a70b8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_36fbb048-cb37-4553-9213-7b8ad762742c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_36fbb048-cb37-4553-9213-7b8ad762742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4eef859f-9caa-4ecc-8efa-07c616c3a1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_b3b318d1-28d2-4180-a582-b842a0f31e4e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4eef859f-9caa-4ecc-8efa-07c616c3a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_36272dca-a410-4991-bc02-7db7976a582b" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e04a6e6f-414b-40a4-bdb2-fa5cb4b6a146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_36272dca-a410-4991-bc02-7db7976a582b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e04a6e6f-414b-40a4-bdb2-fa5cb4b6a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_d65c37cd-6ba8-4d4d-be35-31bd01fceb4c" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f532505-f146-40a1-8a46-3ac113a415e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_d65c37cd-6ba8-4d4d-be35-31bd01fceb4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f532505-f146-40a1-8a46-3ac113a415e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_faa7d5fa-a19b-49a3-a842-6dbffb58b126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_d65c37cd-6ba8-4d4d-be35-31bd01fceb4c" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_faa7d5fa-a19b-49a3-a842-6dbffb58b126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_2b20cc09-01e9-4ce6-bffe-fbeb9acd56f7" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_2b20cc09-01e9-4ce6-bffe-fbeb9acd56f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:to="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2cc08e04-166c-4056-829f-9334a35391a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_968959cd-b8ff-4851-85cb-1040e6b35363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_968959cd-b8ff-4851-85cb-1040e6b35363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_73ff6a72-5ea5-4c7d-b60f-68e1a4f15b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb33451-3c66-4b72-9024-92901db337c8" xlink:to="loc_us-gaap_RestrictedStockMember_73ff6a72-5ea5-4c7d-b60f-68e1a4f15b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:to="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b6e15b1-2ad3-4306-81cb-c521c6d54f28" xlink:to="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a25d51d-82f6-4d31-9027-7ba9d7befb69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:to="loc_srt_MinimumMember_6a25d51d-82f6-4d31-9027-7ba9d7befb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2037dd0-4e4e-4aec-8e1a-c1e88c8a583a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cf0193c-c444-4440-a327-291f9be549eb" xlink:to="loc_srt_MaximumMember_e2037dd0-4e4e-4aec-8e1a-c1e88c8a583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90f6b7a6-7d10-4b64-b63d-b6d8f8ab172a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_681ad277-56ed-4272-940c-9d17c2416a73" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_681ad277-56ed-4272-940c-9d17c2416a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8060796a-5cc2-4377-a4a0-870e00f4fdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8060796a-5cc2-4377-a4a0-870e00f4fdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcb96322-d08a-4561-903b-f2ead412b28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcb96322-d08a-4561-903b-f2ead412b28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_bd07d084-1aa3-4f91-a853-1b34dd6cf0dd" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_bd07d084-1aa3-4f91-a853-1b34dd6cf0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_82aa20d7-8c1c-49bd-b60f-afc03ed472d7" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_82aa20d7-8c1c-49bd-b60f-afc03ed472d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_c5f65eb3-1cda-446a-9179-0aac9929cbc2" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_c5f65eb3-1cda-446a-9179-0aac9929cbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_345b3d95-5464-4bd1-9f13-0faa3bcac850" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_345b3d95-5464-4bd1-9f13-0faa3bcac850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_d3e972d1-e663-4008-82e0-07a4add69582" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_d3e972d1-e663-4008-82e0-07a4add69582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6e2f9581-ffae-44a9-9fa2-cc83927e8625" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6e2f9581-ffae-44a9-9fa2-cc83927e8625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_8d1484e5-20fc-4174-87fb-5bdf5a6c0271" xlink:href="lxrx-20211231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_8d1484e5-20fc-4174-87fb-5bdf5a6c0271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_5be1aa1a-9e1d-453b-b6ee-d8f32638e9aa" xlink:href="lxrx-20211231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_5be1aa1a-9e1d-453b-b6ee-d8f32638e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_25688c61-6833-49f3-9bb5-ef56731c9e73" xlink:href="lxrx-20211231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_25688c61-6833-49f3-9bb5-ef56731c9e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_2527e0d2-6e94-446a-9204-6882cf0d5d50" xlink:href="lxrx-20211231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_2527e0d2-6e94-446a-9204-6882cf0d5d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_78762a81-b956-4bc1-803c-b4a9fe7d55bf" xlink:href="lxrx-20211231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_78762a81-b956-4bc1-803c-b4a9fe7d55bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7c7391b-1e85-4cd9-b75d-95bbc20655ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7c7391b-1e85-4cd9-b75d-95bbc20655ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_021f24b6-323b-4e0e-8b94-d8ae8bf0491f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_021f24b6-323b-4e0e-8b94-d8ae8bf0491f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8b91c33f-4bd0-43f4-91e5-b437c2d7a015" xlink:href="lxrx-20211231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84f02d2-4068-4921-83bc-506a60d6cc90" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8b91c33f-4bd0-43f4-91e5-b437c2d7a015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_d19474d0-1967-4a5a-ac65-d436d69055b0" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_d19474d0-1967-4a5a-ac65-d436d69055b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:to="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_381fd436-389a-49fc-a072-e4e68b726c22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_514d12e8-7100-496a-b105-31a9e8f46a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66edfb98-413b-4254-995f-c956ddc31d61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_514d12e8-7100-496a-b105-31a9e8f46a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b85eccb5-7164-4f2c-ac59-a199f1587c71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a842b6b-f4bb-43b0-b25d-df2fad0ca555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a842b6b-f4bb-43b0-b25d-df2fad0ca555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a689b73-2105-4326-8041-9cbca2f71dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a689b73-2105-4326-8041-9cbca2f71dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6545ac94-7d31-4274-8af1-f89706019aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6545ac94-7d31-4274-8af1-f89706019aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0ab31f4-2152-4d5a-b786-918bc26359cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0ab31f4-2152-4d5a-b786-918bc26359cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cec051fb-4fcc-41b8-b64e-8ee37f89ed16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cec051fb-4fcc-41b8-b64e-8ee37f89ed16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5b5958e-4ab6-4d54-9762-61a2d783c64d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5b5958e-4ab6-4d54-9762-61a2d783c64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93ee13d3-7710-4871-a70c-3525e61e7d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93ee13d3-7710-4871-a70c-3525e61e7d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3967784b-b6c2-4a54-a13a-c17938219351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3967784b-b6c2-4a54-a13a-c17938219351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbae3991-2a42-4b6e-9358-5222a330586d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbae3991-2a42-4b6e-9358-5222a330586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2562a897-06f1-4f1e-b399-a8f5f935fb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2562a897-06f1-4f1e-b399-a8f5f935fb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_715dbbed-f4d9-4fae-a83c-ab0515c964ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_715dbbed-f4d9-4fae-a83c-ab0515c964ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f64fe312-2d5c-46fc-89bb-903d37b1eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f64fe312-2d5c-46fc-89bb-903d37b1eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fbe2f7e-9314-40db-aa9b-a2ec82f09d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fbe2f7e-9314-40db-aa9b-a2ec82f09d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_643d1295-f20f-4d83-bdc5-b745eff7c127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_643d1295-f20f-4d83-bdc5-b745eff7c127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3124a0e7-db9f-4737-af64-c095dfdcb05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3124a0e7-db9f-4737-af64-c095dfdcb05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4133a229-7fac-45ec-a5fd-db4834236307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4133a229-7fac-45ec-a5fd-db4834236307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3f31388-4152-4977-85d7-7b810ebe98d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3f31388-4152-4977-85d7-7b810ebe98d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90a1924b-4aa2-433e-b328-efbf3cd191b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4da6ffb7-f980-4755-b9d1-8799667bf6a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90a1924b-4aa2-433e-b328-efbf3cd191b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_02513b17-0bc6-4854-b1e7-413272d30341" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_02513b17-0bc6-4854-b1e7-413272d30341" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_deb408a7-2e27-40d5-a6e0-f3fc04607b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6e05a6ed-9ead-4433-8501-05efe2eb1c99" xlink:to="loc_us-gaap_PlanNameDomain_deb408a7-2e27-40d5-a6e0-f3fc04607b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf692c70-6028-437a-8c48-5b16c66b56f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4d22ac74-cf3d-4c31-9de9-c11289b110da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf692c70-6028-437a-8c48-5b16c66b56f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97ea2c12-a6c3-453b-b6fb-96f9d1868948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29c1fb75-8502-4ec4-9880-3f7f56e0ac87" xlink:to="loc_us-gaap_ClassOfStockDomain_97ea2c12-a6c3-453b-b6fb-96f9d1868948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea26b8e0-42e1-4d2b-871a-05b15f4f867c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46eb0dc9-2852-4b5a-8dac-fdfa6f2a95c3" xlink:to="loc_srt_RangeMember_ea26b8e0-42e1-4d2b-871a-05b15f4f867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f412a1d-409a-4982-8ad6-2cda64d34371" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_6caaf78f-1d43-45cc-b93c-e8d9f970b12a" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_6caaf78f-1d43-45cc-b93c-e8d9f970b12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_f13b7d5c-9624-4029-9b0d-05236abae06e" xlink:href="lxrx-20211231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_f13b7d5c-9624-4029-9b0d-05236abae06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59c950dc-fa97-43e5-8c64-9add9f873470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01e60150-4187-4224-a684-cf269b4038ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59c950dc-fa97-43e5-8c64-9add9f873470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_2c4efb93-1497-4288-8c89-07ca63f13b6b" xlink:href="lxrx-20211231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_2c4efb93-1497-4288-8c89-07ca63f13b6b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:to="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1e0530df-1b87-4f3f-91a4-f6382ddb2361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f5b4418-2308-452d-9453-22a69e83cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2b5af41-2c50-4689-bb68-d0f72cebf282" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f5b4418-2308-452d-9453-22a69e83cf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98b7d9bf-a42c-45ef-835b-6665c9668ba8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17660da1-f986-4ce1-9626-bfb054261ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17660da1-f986-4ce1-9626-bfb054261ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa4f6b5d-e8c7-4b2e-a107-d4fcd717d6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa4f6b5d-e8c7-4b2e-a107-d4fcd717d6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de560fd5-4e6c-4cb8-960d-0cdbb3830ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de560fd5-4e6c-4cb8-960d-0cdbb3830ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0629d715-0225-4a55-8c7d-faeb72f7876a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0629d715-0225-4a55-8c7d-faeb72f7876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8502a3f-be77-495b-baef-05b4f0f115ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8502a3f-be77-495b-baef-05b4f0f115ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b270e1e-eb6c-4a56-9136-0203b422a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b270e1e-eb6c-4a56-9136-0203b422a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f3bbc18c-1a7d-4286-be67-9c0a452fe604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f3bbc18c-1a7d-4286-be67-9c0a452fe604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_4d63b6c8-3a9a-4e60-8a8f-581cb1811dfa" xlink:href="lxrx-20211231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2710c3d3-02be-4099-965b-756e76b174cc" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_4d63b6c8-3a9a-4e60-8a8f-581cb1811dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:type="simple" xlink:href="lxrx-20211231.xsd#BenefitPlan"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_f1f5ca28-29b3-4988-951e-984df025b5db" xlink:href="lxrx-20211231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7bd8c1ab-f4f8-481e-b685-4e8fd5a73865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_f1f5ca28-29b3-4988-951e-984df025b5db" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7bd8c1ab-f4f8-481e-b685-4e8fd5a73865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#BenefitPlanTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#BenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_36da3ff1-8c10-4f2f-9e2d-36a796312650" xlink:href="lxrx-20211231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_845ba7f2-f431-4e70-9296-7076797840b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_36da3ff1-8c10-4f2f-9e2d-36a796312650" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_845ba7f2-f431-4e70-9296-7076797840b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_454fa058-d017-4cc8-ae8d-00c4259949ff" xlink:href="lxrx-20211231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_36da3ff1-8c10-4f2f-9e2d-36a796312650" xlink:to="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_454fa058-d017-4cc8-ae8d-00c4259949ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_2315fbea-405d-4f5d-a26f-5bb6821d705a" xlink:href="lxrx-20211231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dc77391a-163b-40fa-af9c-f023938f86f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_2315fbea-405d-4f5d-a26f-5bb6821d705a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dc77391a-163b-40fa-af9c-f023938f86f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:href="lxrx-20211231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment_ffd1bb84-bc99-4a2c-937a-d8d9a8f53346" xlink:href="lxrx-20211231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiUpfrontPayment_ffd1bb84-bc99-4a2c-937a-d8d9a8f53346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones_03f5e263-e18a-4ac7-abdd-016ab95ed761" xlink:href="lxrx-20211231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiDevelopmentMilestones_03f5e263-e18a-4ac7-abdd-016ab95ed761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_fd1c87de-c687-4480-84bd-becf992ada42" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_fd1c87de-c687-4480-84bd-becf992ada42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones_dbd2c1e5-9f1e-453e-9239-3763c520cfd3" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiRegulatoryMilestones_dbd2c1e5-9f1e-453e-9239-3763c520cfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_2bb442df-71e7-4a9b-8201-92b520f304a9" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_2bb442df-71e7-4a9b-8201-92b520f304a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone_fdcb6ce3-4496-4245-ac98-a751a90ac112" xlink:href="lxrx-20211231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiOutcomesStudyMilestone_fdcb6ce3-4496-4245-ac98-a751a90ac112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments_6e9415ce-c259-49cb-b44c-f50c8bc40d97" xlink:href="lxrx-20211231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiSalesMilestonePayments_6e9415ce-c259-49cb-b44c-f50c8bc40d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_4be7e31c-8599-48e0-8e43-8b9a81ab10aa" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_4be7e31c-8599-48e0-8e43-8b9a81ab10aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_ac93bd07-5912-438a-994e-2bc3166397d5" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_ac93bd07-5912-438a-994e-2bc3166397d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_7ff8efe7-f0fc-40e4-9889-abfae3fe434a" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_7ff8efe7-f0fc-40e4-9889-abfae3fe434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_772a2a32-e45d-48b5-a972-6563322687be" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_772a2a32-e45d-48b5-a972-6563322687be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_54f00e3e-aa83-4e61-bcb2-7784f35c1b16" xlink:href="lxrx-20211231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_54f00e3e-aa83-4e61-bcb2-7784f35c1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_6688c2f8-ee64-4fbc-98dc-b08d17c56fed" xlink:href="lxrx-20211231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_6688c2f8-ee64-4fbc-98dc-b08d17c56fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_96cb9ad2-99f9-48a6-9002-317302bac414" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_96cb9ad2-99f9-48a6-9002-317302bac414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_4e07ff20-ab34-4345-8112-db6e599b6e1a" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_4e07ff20-ab34-4345-8112-db6e599b6e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_1e7a6a96-86ae-47b9-9358-7dd43d5ef5a6" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiRevenueRecognized_1e7a6a96-86ae-47b9-9358-7dd43d5ef5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_d4f51b2f-b8fc-472f-ac96-6572026f08a9" xlink:href="lxrx-20211231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_d4f51b2f-b8fc-472f-ac96-6572026f08a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate_30c7fe3f-1c73-4589-ba79-66e0d20e6fee" xlink:href="lxrx-20211231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenTotalPaymentsToDate_30c7fe3f-1c73-4589-ba79-66e0d20e6fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_95f1a7e4-f659-4ff8-8583-86386509005f" xlink:href="lxrx-20211231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_95f1a7e4-f659-4ff8-8583-86386509005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_ef038d0f-ca88-4b13-9b20-9d73f49c7c19" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_ef038d0f-ca88-4b13-9b20-9d73f49c7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_62e2de16-097d-47de-a542-c6b6d5facd89" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_62e2de16-097d-47de-a542-c6b6d5facd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_2c13b656-1395-4f35-9e0c-7a984233575b" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_2c13b656-1395-4f35-9e0c-7a984233575b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_e0e449c4-cbfd-4047-8cb9-e22d1cd08b85" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_e0e449c4-cbfd-4047-8cb9-e22d1cd08b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_52cb5324-8ee0-4b4a-bffc-1b7c41fe94d8" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_52cb5324-8ee0-4b4a-bffc-1b7c41fe94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_8e150f28-0008-410c-ab84-ba3b1a53497e" xlink:href="lxrx-20211231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenRevenueRecognized_8e150f28-0008-410c-ab84-ba3b1a53497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales_8c5f1184-5451-4387-bacc-867579d9e4be" xlink:href="lxrx-20211231.xsd#lxrx_Ipsenproductsales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_Ipsenproductsales_8c5f1184-5451-4387-bacc-867579d9e4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_60b7e158-03f7-43ea-9b7e-8a3e673bce8e" xlink:href="lxrx-20211231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_60b7e158-03f7-43ea-9b7e-8a3e673bce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_823d4e37-3cf9-49a2-85fb-e1eb5473b49f" xlink:href="lxrx-20211231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SettlementPaymentFromTermination_823d4e37-3cf9-49a2-85fb-e1eb5473b49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement_96c6135f-f903-4184-85fc-f806e3ec53e9" xlink:href="lxrx-20211231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiTerminationAgreement_96c6135f-f903-4184-85fc-f806e3ec53e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination_4d939760-cf43-4a5b-8482-863a82d240a7" xlink:href="lxrx-20211231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_lxrx_SanofiDeferredRevenueFromTermination_4d939760-cf43-4a5b-8482-863a82d240a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_bb476702-2343-40d0-90df-cd78b4731be8" xlink:to="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9f3a3263-b475-4cf6-a287-a2c7ba777d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_20bd6e76-8540-46ed-a0fc-87711a45856b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_963dd27f-c16e-443f-a1e0-090a32942484" xlink:to="loc_us-gaap_SubsequentEventMember_20bd6e76-8540-46ed-a0fc-87711a45856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_69cc1134-7386-4b0b-b42b-47d729cc391a" xlink:to="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_a5f82a39-14a8-4fd8-9935-8f759658f9f4" xlink:href="lxrx-20211231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:to="loc_lxrx_SettlementPaymentFromTermination_a5f82a39-14a8-4fd8-9935-8f759658f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_d860c123-6c22-4e60-948f-9b5a92b78429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_afddd785-cda8-4ccf-926c-11bb27073dac" xlink:to="loc_us-gaap_LegalFees_d860c123-6c22-4e60-948f-9b5a92b78429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_de64f765-6dd3-4dd5-8b4f-52f6e6d4d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_04da464c-0916-4ae4-8d51-03c81143e187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de64f765-6dd3-4dd5-8b4f-52f6e6d4d2d7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_04da464c-0916-4ae4-8d51-03c81143e187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b364e417-0e7f-4fdc-a895-f80c19e1aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_61e54a2d-bace-4f59-95dd-48b47304ceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b364e417-0e7f-4fdc-a895-f80c19e1aca2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_61e54a2d-bace-4f59-95dd-48b47304ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_569d99ec-ee83-4608-a9fa-c392dba520dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_NetIncomeLoss_569d99ec-ee83-4608-a9fa-c392dba520dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_25c75420-d766-431f-8c58-baa4892cb4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_25c75420-d766-431f-8c58-baa4892cb4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abc946d1-5854-472b-99fc-4ebfa19e40e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abc946d1-5854-472b-99fc-4ebfa19e40e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1190ce9d-24b1-4daa-83b7-d741dac52272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1190ce9d-24b1-4daa-83b7-d741dac52272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_abfb1701-c5e9-4a7f-85b0-9cc15ae8790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_abfb1701-c5e9-4a7f-85b0-9cc15ae8790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e81611e-c86e-4e5c-b8cd-044d8c0414de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e81611e-c86e-4e5c-b8cd-044d8c0414de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_940acef7-fcda-4e44-8814-f3494ef5b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_940acef7-fcda-4e44-8814-f3494ef5b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eda2c783-c91b-4cc4-b419-0564cdda923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eda2c783-c91b-4cc4-b419-0564cdda923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_86dbbe2f-76ad-4111-a215-9722459b742a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_86dbbe2f-76ad-4111-a215-9722459b742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_10a0f086-0fbd-4cfc-a756-1c155add3474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35c704ae-3c1b-4dc8-b202-0a3472a444f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_10a0f086-0fbd-4cfc-a756-1c155add3474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_01e018d5-a4a7-4e39-8ae4-3e787f24983c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ac0457fa-8538-4a40-a253-bc61325276bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_137584a6-8901-41a0-81ca-c9dfa3f90fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_137584a6-8901-41a0-81ca-c9dfa3f90fe0" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d4ce33f-1247-46c1-b46a-1d6e32fe99b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2282bd7-450c-426b-9082-21041c8ddd7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d4ce33f-1247-46c1-b46a-1d6e32fe99b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b63dec53-7304-41f1-823a-8834984f471c" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_96afac51-254d-4fc4-a556-be9a3fe8b9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_Revenues_96afac51-254d-4fc4-a556-be9a3fe8b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_717c3619-697d-4e9d-8a74-14ebe9f934f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_OperatingIncomeLoss_717c3619-697d-4e9d-8a74-14ebe9f934f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dede70b-c90a-4737-b8a1-0b83e86a7046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_NetIncomeLoss_0dede70b-c90a-4737-b8a1-0b83e86a7046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3dc82af5-aa69-435f-8553-2e034a8d3e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3dc82af5-aa69-435f-8553-2e034a8d3e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5aa58991-b18b-45c9-90ec-6df893d4dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5aa58991-b18b-45c9-90ec-6df893d4dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_98e59d51-0527-4d58-8c58-b0325b543344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_EarningsPerShareDiluted_98e59d51-0527-4d58-8c58-b0325b543344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f0ef889d-4cd5-409c-b42f-a48a27e8dd28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ccbb39df-21b2-44bf-9484-a4d744cfc347" xlink:to="loc_us-gaap_EarningsPerShareBasic_f0ef889d-4cd5-409c-b42f-a48a27e8dd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSale" xlink:type="simple" xlink:href="lxrx-20211231.xsd#AssetSale"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_580049b2-6d06-4cba-bbc9-d08fb86317a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_7f4c6f25-07c1-42f1-a4db-4fb7bafb9983" xlink:href="lxrx-20211231.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_580049b2-6d06-4cba-bbc9-d08fb86317a4" xlink:to="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_7f4c6f25-07c1-42f1-a4db-4fb7bafb9983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleTables" xlink:type="simple" xlink:href="lxrx-20211231.xsd#AssetSaleTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_56ab7b30-98af-4303-9874-6f87c33b3e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#AssetSaleDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_982d478e-55b9-4c22-9d79-8e590c261d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_827b2d03-3fa2-413c-ad91-3d2d473d2c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_982d478e-55b9-4c22-9d79-8e590c261d00" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_827b2d03-3fa2-413c-ad91-3d2d473d2c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e37cccd-22a8-4611-b93e-e746b5215e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_982d478e-55b9-4c22-9d79-8e590c261d00" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e37cccd-22a8-4611-b93e-e746b5215e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4392ae15-1789-4c08-8d11-181a3d81a063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_982d478e-55b9-4c22-9d79-8e590c261d00" xlink:to="loc_us-gaap_SeveranceCosts1_4392ae15-1789-4c08-8d11-181a3d81a063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_982d478e-55b9-4c22-9d79-8e590c261d00" xlink:to="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_344ec6be-0cea-4c2e-ad07-6373cbbb2ab6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713_9aacbb79-fe3a-4040-b506-5a198887beca" xlink:href="https://xbrl.sec.gov/naics/2021/naics-2021.xsd#naics_ZZ541713"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:to="loc_naics_ZZ541713_9aacbb79-fe3a-4040-b506-5a198887beca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f50f4a6-ab37-41f0-9ac0-81b9eb130d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_07ec7425-dd4a-4a40-b849-ab020e9aa5cd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f50f4a6-ab37-41f0-9ac0-81b9eb130d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4ca3582-ef98-4193-ae33-cb13992b90f6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_326b334c-1340-4beb-a3c1-3fcde07c7a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_us-gaap_SeveranceCosts1_326b334c-1340-4beb-a3c1-3fcde07c7a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_cdca81ed-ce99-41e0-8c20-fa072554014f" xlink:href="lxrx-20211231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_cdca81ed-ce99-41e0-8c20-fa072554014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_b384ef35-e1ef-4e37-a8c4-33bb3e125886" xlink:href="lxrx-20211231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_b384ef35-e1ef-4e37-a8c4-33bb3e125886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_fd86eed8-dfd3-4c42-98d1-cbf5a0122d5c" xlink:href="lxrx-20211231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f9d33cc-3113-4e83-bc9d-1ec37b1f056e" xlink:to="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_fd86eed8-dfd3-4c42-98d1-cbf5a0122d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20211231.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_21e526df-ed1c-42c0-aef7-7ba5e44ea904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_cd285f34-863b-4504-8d88-4226a2279b88" xlink:href="lxrx-20211231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21e526df-ed1c-42c0-aef7-7ba5e44ea904" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_cd285f34-863b-4504-8d88-4226a2279b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20211231.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_72c9d33a-78c5-45c4-abf1-44ee1f848c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_72c9d33a-78c5-45c4-abf1-44ee1f848c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_e8306249-3d2f-43d7-95b3-3b8f0a0e6fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_e8306249-3d2f-43d7-95b3-3b8f0a0e6fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_57e67191-df6d-4807-93c1-d0268100186c" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_57e67191-df6d-4807-93c1-d0268100186c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_470717d4-6a67-43df-8e39-87e00f58ea5a" xlink:href="lxrx-20211231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_470717d4-6a67-43df-8e39-87e00f58ea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_254f0679-171d-4c0e-b174-8b4cc7313e2e" xlink:href="lxrx-20211231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_254f0679-171d-4c0e-b174-8b4cc7313e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_e5368972-18ab-4d5a-b6f8-db56b137c223" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_ATMOfferingTotal_e5368972-18ab-4d5a-b6f8-db56b137c223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_c80e0064-d0e2-4de4-b76a-bf3e7cd09f12" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_c80e0064-d0e2-4de4-b76a-bf3e7cd09f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_ff7ed6a0-cf70-485f-96f3-992796817ec2" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_ff7ed6a0-cf70-485f-96f3-992796817ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_482befca-b6ce-4b96-9ebc-63aa29e35b22" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_482befca-b6ce-4b96-9ebc-63aa29e35b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_0adf91c3-509e-4af1-b641-5570fc732f7c" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_0adf91c3-509e-4af1-b641-5570fc732f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_baa710ed-594f-45aa-abc5-a2edca35fc0b" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_baa710ed-594f-45aa-abc5-a2edca35fc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_815a2ab6-2c79-4ee6-9a9c-b61dd483cecc" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_815a2ab6-2c79-4ee6-9a9c-b61dd483cecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a88d425-4671-46ca-9de1-fc2a3253b44d" xlink:to="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19643062-91a0-4ae9-bfff-38ae64325fe7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b797b9b2-65eb-4c7c-b1d3-fbd1b9baf0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8212432f-9f0c-48e2-8d90-a1f99c1ea32d" xlink:to="loc_us-gaap_SubsequentEventMember_b797b9b2-65eb-4c7c-b1d3-fbd1b9baf0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0427fd30-b125-4599-a804-da4cb1e06bdf" xlink:to="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_cfbbcad8-e396-4212-b916-54b0fba75f27" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_cfbbcad8-e396-4212-b916-54b0fba75f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_3881f2a0-bfb1-493d-8aa2-0d76e24fddd2" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_3881f2a0-bfb1-493d-8aa2-0d76e24fddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_b2d4e5b4-4e53-4156-97fe-cc7b2a9c4e99" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_b2d4e5b4-4e53-4156-97fe-cc7b2a9c4e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_4500af0b-1f36-4b29-97f2-3b44ac8f800f" xlink:href="lxrx-20211231.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ATMOfferingTotal_4500af0b-1f36-4b29-97f2-3b44ac8f800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOffering_2153da96-921d-4c63-aa03-967ebb7289f0" xlink:href="lxrx-20211231.xsd#lxrx_SharesSoldInSeptember2021ATMOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOffering_2153da96-921d-4c63-aa03-967ebb7289f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOffering_4d15369f-8090-4ae3-a735-e35e59a0c81d" xlink:href="lxrx-20211231.xsd#lxrx_SharePriceInSeptember2021ATMOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOffering_4d15369f-8090-4ae3-a735-e35e59a0c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a8036439-a503-4585-84eb-7fdd385a8267" xlink:href="lxrx-20211231.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_260681fd-a5ed-4bf7-8247-cd88f7c007f9" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a8036439-a503-4585-84eb-7fdd385a8267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lxrx-20211231_g1.jpg
<TEXT>
begin 644 lxrx-20211231_g1.jpg
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6+1EA3<RK;')_6N@K-\8_P#(L7O_ %P- %:"W\:SPI.NM68#J& -L>X^M/\
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M5L5C^!_^01+_ -?LW_H5 &Q1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCZUP/[/_ ,2?%OB_]N+QSXBUWX1:QH-W-X+L$DTG4)(S-$$D 5B5.,-G(^E
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
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M'[,7[5?_  2S\7^%(?C9H7CSPYIW@YOAE?P.-5\'*RQ7T5]#;'BPMK(-NED
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M)XE_XENG8_OIO^>9?9=K5TWPZ_9)^ WPTO?[;TSP1%J6K,V^76]>D-[=N_\
M?WRY"-[H%KTFE]4XMS/_ 'BO#"P?V:2]I4^=6I'E7FE1NNDNHOJ/'&<?[WB8
M8.F_LT%[6K\ZU6*@O-1H772>S/#_ /AG?X]_%/\ ??M _M"W=M9R?ZSPUX"C
M-C;8[JUPP,LJGH0P_&N\^&/[._P5^#J*?AY\.]/L;@##7[1>;=-ZYFD+.<^F
M<>U=I179@>%LDP.(6)]G[2LO^7E1NI4^4IMN*\HV79'?EO!?#N6XI8M4O:UU
M_P O:LI5:ORG4<G%?W8<L>R04445]"?5!1110!C^)?\ D+Z/_P!?I_\ 036Q
M6/XE_P"0OH__ %^G_P!!-;% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
M?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H
M-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8
M_P"@U!_WU6?XH\4>'[SP_=VMKJL3R/$0B*>2:W/[.T__ )\8?^_0K.\76-E'
MX:O'CLXE80G!6, B@ L?%WAJ.RAC?680RQ*"">AQ4O\ PF/AC_H-0?\ ?53:
M?I]@UA 390DF%<DQCT%3?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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MZ445\"_\&^G[2?B_]IKX _%OQ3IMYK%_\)]*^/'B#3O@-JFO"7SY/"RM&]O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_\@B7_ *_9O_0JV*Q_ _\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )\8?^_0J:B@"'^SM/\ ^?&'_OT*SO%UC91^&KQX[.)6$)P5C (K7K-\8_\
M(L7O_7 T 3:?I]@UA 390DF%<DQCT%3?V=I__/C#_P!^A1IW_(/@_P"N*_R%
M34 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 87B.RLTU7
M252TB :\(8",<C::U_[.T_\ Y\8?^_0K-\2_\A?1_P#K]/\ Z":V* (?[.T_
M_GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ
M* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#G
MQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H
M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0K(\%V5G+I4C2VD3'[9*
M,M&#QNK=K'\#_P#((E_Z_9O_ $*@#2_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*F
MHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FKRGXB?M=_#CPIKC>!? EG>^-O%
M)R$T#PO'Y[1L./WTHRD2@_>))*]UKSLSS?+,GH*KC:J@F[*^\GVC%:REVC%-
MOHCR<XSW*,@PRKYA6C3BW97>LG_+"*O*<GTC%.3Z(]0_L[3_ /GQA_[]"O+O
MB7^U)\(? FM'P1X;T^;Q=XI8E8O#?A>T%S.&'_/5E^6(#C.X[@.=IK!_X5'^
MTE\??](^/'CW_A#M EY_X0WP=<?Z1*G]RYO.<^C*F58'^$UZC\-/A!\-/@]H
MHT#X;>#K+2K<@>:;>/,DQ'0R2-EY#[L37@_7N),ZTP5+ZK2?_+RJKU&O[E&_
MN^3JM-=:3/FO[2XNXATRZC]3H/\ Y>UXWJM=X4+KE\I5I*2>]%H\I'PE_:1^
M/S?:/C%XGA\ >'93D>%?",JO?3)_=N+S&%]"(QM(/(!KT[X9_ SX3?!_2/[&
M^'G@:QT]& $TXBWSS^\DKY=_Q)QVQ7645WY=PUEN7XCZU*]7$;>UJ/FGYJ+T
M4$_Y:<81\CT\IX0RC*\5]=GS5\3:SK57SU-=U%V4:<7UA2C"']TA_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHKZ ^H(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ
M* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#G
MQA_[]"IJ* (?[.T__GQA_P"_0K.\76-E'X:O'CLXE80G!6, BM>LWQC_ ,BQ
M>_\ 7 T 3:?I]@UA 390DF%<DQCT%3?V=I__ #XP_P#?H4:=_P @^#_KBO\
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M 4444 %%%% !1110!\EV/_!3#7?A]\=?BGX"_:+_ &:/'^D> O!OC)=,\/\
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M['Y_J]6I2YOK'+S>SFX<UO8.U[7M=VVN]S]I"0!DG '4UY+X\_:_\ :+KK^
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MZ;'2I?\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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MW,]7NS^=<[^B;1S;.L3CJ6;NG&K4G-0=!S<5*3DHN;KWDXIVYGK*UWJS@?\
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M_P"I\0?&/Q3'8[,]-^GV^;@>IPQ]*/\ AE'_ (*:?&3]Y\?/^"A-CX-LI?\
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M8O?^N!K2K-\8_P#(L7O_ %P- %S3O^0?!_UQ7^0J:H=._P"0?!_UQ7^0J:@
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MX[G7/$&N6L2P!H'^QF/=<-&)&:>2,1%W,I5%$C 'W%^U?_P58O/V2_C[\'O
MOC'X!V]Y\-?C9K]GI/A7XRP^,PFDVEQ<*KQQWD9M"T$DBMNB&YHY!SYBA9/+
M]5_9P_:I^('[0^O?$'4M-^!"V_@KPCX@OM'\,>+;+Q0EP?&$]J^R5[.&2&%5
MB619(&EDE">?$ZH9(QYU?/\ ^WII_P #/V^M)TS_ ((GW&M^"].\4Z_X5M=:
M^(5CI5U;SOX&TNS,#Q_8(3M)O'F\N.W7:HBMQ+.ZA1'%-R/_  0__P""B'A.
M7PEX@_X);_M,?$KP=9?%_P#9QN9/"[S:9J5O#9>*-#LD*VVI685@I*6\86>,
M?-$4#N$+LJ 'L_["O_!2?X8?M(>%_P!H/X@^)_@<_P '],^"7Q+U?0_',VO:
MC:22RS:?:QRWM_=&T#1(4 925EG!6$,)"" .3^+_ /P5^\>?!3X!>"_VWO%O
M[%FK2? SQIK.GV]MKMCXF>;Q18:=?G%GJMQHB61C6WDRC;%O6G59H@T0=FC7
MXV_8[T72/VV?V9?^"HW[,O[/'Q'T/5_&'CCXW>-[OPIIVGZS"SZE!+"B6\L>
M&^:WGE3R1,/W?S]<5[;_ ,$W_P#@N_\ LT^*_P!D'P#^S3=:-XB_X:4\,>'+
M3P?=_ QO"]]'J=SKEE MKRWD&*VM6:+SI)I'5;:,OYF"F" ?8WQ>_;0GT+]I
MJQ_8K^ 'PZM?&WQ.F\)/XIUBRU3Q =)TG0='$XMXY[V\2WN9$DFF)2&&*WE=
MMCNWEH-YY/\ 9N_X*60?&KXH?%']EOQO^S]K7AOXW_"2"*[USX9V>MVEX-:L
M)U5K>_TJ^N&M8;JVD#H"THMVC9U614) /S%>^++K_@G[_P '#?C/XW_M5:S;
M:%\-/VD/A3I.E>$?'VHR>1I%AK^F1P1MI,UQ(0ELTJQ3S()&&\RQJNYBVWI_
MA'H7@[XQ_P#!=OXB?\%)?!'C72D^$?P^_9YM/ FK>/(]0C72=5UV34FO)TBN
M]WDSI:VZQ),ZL5CE*(2&5@ "#P/_ ,%Y?C)\9_V'-=_;H^ W_!,3Q=X@\/\
M@Z[UF3QK;ZAX\L=.73=/TZ1Q-)%)+$6O;E88VF>&"-HT V>>TF4'W7^SI\=?
M _[3_P  _!G[1GPTDN&\/^.?#%EKFCB\C"3)!<PK,B2*"0LBAMK $X8$9/6O
MR1_X)7_M _ JS_X-N?CY;WWQB\,6\MO:?$J.>WN-<@CD1[M+U[1"C.&#3*RF
M-<9DR-H-?='_  0=\;^#?&__  2'^ 3>#O%6G:I_97PXTW3M3_L^\28VEY#"
MJRV\NTGRY%/5&P1D<<T ?.O_  <;ZSX>\+?&_P#8/\7>*=6LM.T_2_VN_#UQ
M?ZGJ$Z0PVENES;O+))(Y"QQJJ;F8D !<GI7F_P#P54\2?#_]I?\ X+3?L:7/
M_!./Q1I?B;XN>&/%CWOQ3\2^ +N.ZCTSPE]HLRZ:K<VY*"-H!?*L4C;BLS+C
M]]&&Z?\ X./?CS\$O"/[37[#^@^*/BOX=LKWPU^U1X?UOQ)97.KPK+I>FPW%
MJ\EW<(6S#"%=6WN N#G.*_4OP*OP]NM"C\0?#1=&DTS4@)X;W0A$8+H=!('B
M^5_J": /S)\#?%3XC_"?_@X%_:^G^"G[/FJ_$?Q7J7PP\#?V;X?L-1@TVV)2
MR&Z6[O[C]U;1@;5'$DKD@)&X5RGT7^SK_P %A_AI\4_V'OBW^V%\9O@WK_@#
M4/@-KVN:%\6/ 0NHM4N],U/2U5YK>WFC$:70821A9,1IN+ D*I>O"/V//V@/
M@5/_ ,'&7[7*1?&7PLWVKX:>$(+5AK]OMGEL[,&[1#OP[0@CS ,F/G=C!KPO
M]E']O"X_9W_9O_X*;?'C]E:?P]X\\;:!^T3XD\1^'- MKM+U;C3YIK:V.J^3
M$VZ>SB5I9F=?D=8"-PSF@#[CTW_@JE\1_!_Q/^ 'A?\ :._92L_"GAS]I$BW
M\":_H/C]M6N--OI+1+N"TU2TDT^V%N\D;A=T$MRJNK G:-YS?C)_P5^^)7@7
M]N/QE^P%\+_^">WC?QCXY\/_  OE\8>'+=/%.F6J^(T6[C@0(X>6.TMF'G-Y
M]Q(DH:)(A;L\R+7P;^U#^T[^QSXN\?\ ["/[5?A']H[Q+\3YH/CAI<_Q'^*N
MM17]S;VUS-9EC8A5C%II\GF;F.G6<:&,(&>/)#O]'^ /VD/@1J?_  =)ZXD?
MQ8T*&;4_V1;30;2UO-2CAF_MC_A(8ISIC1N0R7HB.XVS 2@ Y48- 'K,?_!9
M'XG:7^TG\*?V4/'G_!-SXCZ#XT^)_P -KKQ1!H]SK^F2RV]Q#$2UC'Y<A7B0
M;'FNVLUC'S,O\-+\*/\ @KW\</'7QW^)'[&'BS_@G-XFTGXY>![*RU+2O!.F
M^.+*^TS6-*N@3'J#ZNT<,%G$GRAU=&?=(J1K*X9%\S_:T^./P9T+_@Y5_9KT
M76OBMX=M+K3_ (/>*;+4(+G68$:UN;@,UO!)N8>7)($8HC89L< Y%,^!GQY^
M"%U_P<X_&>QM_B_X8>6;]G71=+A1==MSYE]#?H\MJOS_ #3(C*S1CYE!R0,&
M@#WW]D__ (*R^&/C9\%/CE\0?C_\#=8^%WBC]G"^U&#XL^"SJD>LM91VEH]Y
MY]K<P(BW<<D,<A3"J2R$8P59N7L_^"O_ (X\-Z/^SO\ %OXT_LE0^'OAI^TS
MXFTC0? GB'3/'WV_5=,O-6A,VEKJ>GM80QP":, L8;JX\K#!LX&[Y2_9:_;7
MTCX1?'?_ (*C?&G]F[4/#OC[Q?HVL66O^#O#=EJ270UC[)I-PDDJ1POON88I
M$;S!$<_(5RI8&O'?VNOVL_V5OC9^S#^Q7^UPG[1NO_$KQ=I_[4/P\UWXP>-[
M^*]?3_"V([F:]T_R(T%CI(27 6TA199([=9&,Q E8 _7WXH?MB:O;_M&2_L?
M_LV_#2P\<?$33?"\?B+Q-#K/B5M(T?P_82R-%:_;+R*UNY5N+ATD\J".WD8I
M$[N8UV%_//@)_P %<?AA\0OV:_BM\>/CC\)O$GPYU+X)^,[OPI\0/"UU&;YV
MU:*6.&*'3IPD8OQ<RS0QPG;&S/*H*J&5F^2O%'[:O@C_ ():_P#!;WXG_M%_
MM>QZUX<^"7[5OP]\*W?@WXB7WA^\^S:9J6DV MAI]U&(O-MG97GD9&0.AEB+
MJH+LGH7_  5-\<^/O^"I'_!)SXF^//V)_AI?^*?#^@:UH.N^!/[2T.>(^/H]
M+U"&]OS;VDZ+)/9[$V190&YDMY@BLC1.X![+\7O^"HGQ(_9-^.'PJ\ ?MJ_L
MJ6G@KPC\9?$<?AWPKXTT#XA+K)TO69@#;V.JVQLK=;5I,X\RWFNHE96R^T%Z
MZ_\ 9]_X* >(?C7^V=\:OV&]8^!L&A^*_@YH^CZA+J4?BK[7IVKKJ5NT]L$?
M[+'+" H4.6C8J2V P +?*/[(7_!0C_@B3^V0W@[PW^R)^Q=X&U#XRZS=VIF^
M'B_!:*WO/"DJRI]JN[V]%D+>""T&Z0S++F0HB1@RNJ5'X9_:7^!_[#O_  <*
M_M*:A^U9X_M_!=K\5_AGX+NOA[=:M!*$UXV=N;2:"UV*QGG\[*+"F7<J0JD\
M4 >T^'?^"K/Q;^,O[)O[37Q5^#7[-&FV/CO]G;Q?X@\+:AH?B#QAYFG75YI5
ML)I[Q9XK=7>$ DK%L1Y-H4M%NW+RO[#7[=/[1'A7_@BGI7[9/[1G[.E]XYAT
MOX4GQ-J%QHGBRSN;WQ%!Y-S=7UU<0W:VZ6R*J9,:/.[!RJ(VW:?!O^"9GCBS
M^*WP=_X*:_"KPMX?UP>*/$'QF^(^I:?X>NM$G2Y\NZL###&XVE4G,H*>26\P
M,"-O!K8_9"_; _9P\2_\&P7B'PCIWQ3T]+SP;^S'K'A[Q+]LW6\5EK#Z5>PI
MIIDE"H]VSKQ A:0AXSMQ+&6 /L7PA_P4I^$^C?\ !/3X1_M@ZI\+;K26^*VG
MZ!8_#_X8^'YXI[J\U;4T466D6SLL$1(&<R,(XXXXG<[50T>&/^"A'Q.\,?MU
M^%?V#OVGOV7E\*:S\0?"MYK?@7Q7X/\ %<VOZ1=_9%=[JSNI9=/LVM+A$0L/
MEDC8.@$FYPM?G'\2/$WC"P_X(C?L%_MW?L^:2WQ"TO\ 9F\1>%]=^)?AWPQ.
MEU<0V-O8&"^RB$[)H-P5@PS$)C(P"(QK]&/V7/\ @KM^RA^WOXY\/^#/V%_$
M]Y\0(YXC?>-M6BT"^M+3PK8"%V074MQ#&GVN6<1PQVRL7(,LN-D1) /.?B#_
M ,%GO%>E_L__ !7_ &S/A/\ LC?\)-\(?@YXXO\ PYXHU6^\<G3=>OOL$\4%
M]>6&FM820RPQO(=HFNX)'$3G8IPIX?\ X.&_&OAKXJ?\$U_A/\3O"DK3Z5K_
M ,;_  %JNDS2Q[6:"XN/,C8@_=)209';)%?(?QY_;M\#?M]?\$O_ -J75/VG
M_&OB*7XYZ(WB6RL?@'IUK?QVO@2QM)L17$UC;J(YML:F674KW?LE9HXVB^6-
MO0O^"I/[47P$\5?\$(_V8-5TWXE6$,,GC/X<BV.HEK1KI+&&(WDT*S!&FAA*
MNKRH#&K(PW9!H _2[XS?M@ZOX5_:CT+]B_X+> ]#\2?$+5_!%WXON+7Q1XN?
M1;&UTB"ZBM-XFBL[N6:9YI"%C2$J%BD9W3Y _3?LI_'3QO\ M ?#>_\ %7Q(
M^#5QX"US2O%6J:'J/ARXU=+XQO97+P><DR1H'CE"B5"%&4D0]\#XU_X*8?#;
M_@FW^WC^TQX0^"_Q7_:'E^%?Q7TCX?1>+/@C\</!WC>/3KMXI[N[@GMK:?<(
MKA8VMHI?*W[W2:0Q&/9*YH?L+?\ !3WQO^RI_P $T_&_[0__  51^+[^*=#^
M&_Q?U'P7X4^+6@^'WE/CW289H;>TU2*. %95DF:>,3J=CK;Y+NV7< _26OS%
M_P""WUK;3_\ !4S_ ()R//;HY7XR:SM+*#CY=+;^:@_4"OT:^%'Q2\!?'#X8
M>'OC+\+/$<.L>&O%>BVNK:!JL"LJ7=G<1++#*%<!EW(RG:P##." 017Y<?\
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M?X0B?K'X8\/O?2!?3==$ 'W'X5P_ZV4:_P#N6$KUO2DZ:^4J[I1:\TVCSO\
M7C#XG_D78'$XC_#1E2B_2>(=&#7FI->9[77XK7MY:Z=9RZA?3K%!!$TDTKG
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MG[4_@KPQ\.X_!OQ,UJ:UETR0I97'V268/;GE0?+5B"IR.>VW'2OUSTK_ (*
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M_9M'A,G@ZT_9R\.ZA!H3N-[V$,Y(#0PLQBC"*L2(BK&J1JJ@ ^MO^";VN?\
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MAIER/O6VJ^'-8@9?J6M=OJ.O:NPT'_@HC_P39\1D#3_VR?"D>[I]O\1&U_\
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M.,-IEV%PN&7_ $[PU)R7I5JQJ55\JA\GZ'_P17_8)M]077?'?@?Q!XWU-?\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:LSPKX5T[4-.DFFGN01<R*
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M\R2XO(T5)&,EP_SB!E\N-I4*>[^ _P!I[XN_MV_MN_&_]FGX)_&K4?AMX*^
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M2O>[\ ^$O_!'O_@EEJ&FP>,/#?PTM/'4;_ZO6]0\97>I1S?]\3^2W_?->[>
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MH]FT?'6N?\$1/^"8%GJ.FP6W[,>U+BY*3#_A--:.X;<XYO>/PKW?]F/]C?\
M9S_8WT+5/#'[.'@&;P[I^LW:76HV;:]?7L<DRKL$@%U/+Y;;< E,;@JYSM&.
MV\2_\A?1_P#K]/\ Z":V*Y:&597A:JJ4:$(2751BG]Z5SZ#-N/\ CS/L#+!9
MGFN)KT96;A4KU9P;3NKQE-IV>JTT>H4445WGR(4444 %%%% !1110 4444 %
M%%% !1110 4444 %8_@?_D$2_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5 &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_
M "+%[_UP- %S3O\ D'P?]<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'
M_P"OT_\ H)K8H **** "BBB@ HHHH **** "BO)O^&S/@W_PV1_PQ%_:O_%7
M?\(E_;GWQY?W_P#CU]?.\K]_M_YY\UZS65*O1K\WLY)\K:=NC6Z]3T,PRK,L
MJ]E]<I2I^UA&I#F5N:G*_+-=XNSL_(****U//"BBB@ HK$^(>C^-]>\)7>F?
M#GQK;^'M9D3_ $+5KO2!?10MZO 9(_,7U =3Z$=:_/+_ ()7?\%H_B9\8?VO
M?B!_P3>_X*#6?A[1OBCH/BW6[/X=>*?#^DSZ=I'CBRTR_N;"Z%M'<22,)XYK
M.X8 .0ZI(,!H&W 'Z445\U_MA?$3]J7P+^TM\"O 'P:^+>@:1X>^*'CJ^T#Q
M!;:MX0^W7%K%;:!J6K>;;2BXC =CIK1$.K@><& ^3:WTC;1S16T<5Q/YLBH!
M)+M"[VQR<#IGTH ?1110 45YO^V#XC^*_@S]E[Q[XV^"'BK2=%\3Z'X3U#4M
M*U#6M%;4+=)(+:24!H5FAR24 !+$#.2K?=/FO_!(#]H/XL_M6?\ !-+X0?M$
M?'3Q,NL^+O%GA?[;KNII8PVRSS&>5<B*!$C0!54851T]<F@#Z2HHHH ***^$
MO^"]W[;7[6O_  3L_9<TC]IO]F'Q?X75Y?&NF:!J.A>*O"[7L3QW7G@SQR1W
M$3*ZLL?RG*D ]#S0!]VUX9XH_P""=_[-M_\ M!2_M9_#71M0^'7Q/O(#;ZQX
MV\ 7*64^LP,06BU"W=)+34 2%.^Y@D=2BE64J"/(?VV?BC_P5!_87_9J\1_M
M8^'/B?\ "CXLZ7X TB76?&7@W4OA]>>'[N\TVW7S+J2ROHM3N$AE2)6<)+!*
M&"D;LX!]0\*_'#QW_P %"?\ @G+I_P >OV'_ (F+\._$GQ)\#Q:AX*\0Z_HD
M6H?V#=R ;EFMW!CE:-UDB)(9,C<%<  @'O&D65UINEP6%[J]QJ$T,022]NDC
M66<@??<1(B!CU.U5'H!TJS6/\/=+\8Z)X T/1?B)XIAUSQ!9Z/;0:[K=O8BU
MCU"\2)5FN%A4D0K)(&<1@D*&QDXK8H **\W\)_M3_";QQ^U!XM_9+\*:W'?>
M*? WAG3-9\4QVTJNFGK?R7"VUO)@Y68I;M*4."$DB;HXKTB@ HHJCXFMO$=Y
MX?O+7PAJ]GI^J26[+87NH:>UU!!*1\KO"DL32*#_  B1,^HH O5\V_\ !2C_
M ()]W_\ P46^'GA?X6W_ ,<I_!>D^&?&FG^*HI=,\/1W=U<:A9,[6X9Y90BP
M@OED$>YBH^<#*G@_^"%G[6'[1W[8O['OB'XF_M2^.;/Q!XHTSXM>(M!^W:?H
MT%A MM9W"Q11QQ0@84?-@N7?GYG;&:^SJ *FAPZW;:/;0>)-1M;R_2$"[NK*
MS:WBED[LD322% ?[I=L>IJW110 45D^.[#QMJG@_4=.^''B73]'UV:V9=,U3
M5=)>^M[:4]'>W2:$R@<_*)%YQU P?E#_ ((+?M;?'K]N3_@F+X(_:7_:7\5P
M:UXQU[5]>34;VUTR"TBV0:O=P0QI% BH%2*-$!P6(7+%F)8@'V+1110 4444
M %%%?!G_  7A_;8_;$_X)\_!#P3\<OV6_&OA)3XD^)FE>$+[1/%OA1[V-!>1
MW+"Z26*YB8,K0J"A!#!C@J1R ?>=%9?@O2_%&C>&;33?&GBJ/6]3B0_:]3BT
M];19V))R(E9@@ ( &X].236I0 455UR'6KC1KN#PWJ%K::@]LZV-U>V;7$,,
MQ4['>)9(VD4'!*AT) P&7.1\<?\ !$3]JS]I;]K+X*_%_7?VI_B!8^(]?\%_
MM$>)O!]A>Z9H4.G6\=A8):)'''%%D[=[ROF1Y)/WF"[ # !]HT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 > ?\%0OVV'_P"">?[$
M'C/]JRU\-VNJWFA?8;33+7497CLTNKV^@LH9KET^9;>-[A9)-N&*(54AF!KS
MGX_?M&?M-?L0Z]\#?%?CCXSZ/\5-"^+/Q7T7P'KNE6OA2+3I()]527R=1TN2
M"5SY,+Q;Y()S<,T!9A,I3+>@_P#!5+XF?LS_  K_ &"?B'K7[7'P\?QCX)U'
M2X](N_!UN!]HUZZO)H[>TLH#D>7,]Q)%ME!!B(\W(\O(_,_X%_"G]IW_ ((<
M?M7_  /TK]O*(_%[X%:Y=0>%?A5XSN=5N+V;X+ZUJ)*_80)-L<T3!OLPO3&C
MF")C$+==]K( ?H)\;_VR_B9X]_X*&:-_P3+_ &7M=TW1-;L_ ,OC?XH^.=0T
MP7S:%I?GI;6EE:0,ZQM>W$LBL6EW)% "WER%QLT/V*/VT_&OQ"_:7^,/[ W[
M0\NF2?$KX.W5A=Q:YI%F;6V\4>']0@6:SU!(&=S#,F[R+B-6*"4!DPL@1/FS
M]C'3]0TK_@YV_;%;Q*K+-J?PH\'W?AWS!C?8+8V$,I3/\(N$(..-P-.^"5OJ
MFK?\'6_QEU?158Z;I'[*FF6.N.GW%NYM1TZ:!6_VS$KD9[*: /TQHHHH *\%
M^'W_ "D/^(/_ &(FE_\ H=7=4_8(^#6KZG<ZM<^*O&ZR74[S2+%XON54,S%B
M  >!D\#M7 _L_P#P1\)?#C]N+QSX+T+4]8FM+;P782QR:AJLD\Q,D@+9=CDC
MC@=J /JNBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
M@#%^*W[.O[/WQWLSI_QN^!O@_P 8P%-GE>*/#5K?J!Z 3QMBOF7QU_P0'_X)
M>>*=8/BOP7\"+[X?:Z,^3KGPW\5W^CS09_N1PS>2O_?NOK3_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:OI,GXQXLX?CRY9CZU&/:%2<8OR<4TFO)IHQJ8>A5
M^.*?JCXQ_P"'5'[:/PD/F?LF?\%F_C)I,<7,&G?%;3;'QE!M_P">6ZY6)D3L
M",E1TS1_:?\ P<)?!(?Z;X8_9V^-^FQ#Y?[/O;_PWK%QC^]YN;1,]L=\YXK[
M._X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:O=_XB/FV*TS/"X7%+_IYAZ<9OUJ
MT52K/YU/0S^J4X_!*4?1O\G=?@?&/_#W7]I7X4'ROVN_^"//QW\*B/BYU'X>
MQ6GC&Q@]7>:T>/:GO@]N#72_#7_@O1_P2M^(FI_\(Y?_ +45IX/UA&"W6D?$
M#1KS1);9CV=[N)(0?I(0*^J?^$'TC_GYO?\ P+:N;^(O[,WP-^,&F?V)\6_A
MMI'BFSVE?LGB/3H;Z+!ZC9,K#'X4?VWX>X__ 'O**E!]\-B)**_[<Q$*\FO+
MVL?47L\7'X:B?JOU37Y&M\-?C1\'?C-I?]M_!_XL^&?%=EM#?;/#6O6]_%@]
M#O@=AC\:Z:OC7XA?\$!O^"5GCW4?^$@L/V:H_">K(Q:VU;P)KEWHTMNWJB6L
MB1 _5#7,7/\ P1L^/WPS7?\ LE?\%>_CQX4$?-MI_CVXM?%UC!Z(D-RL6U/;
M<>_-']B>'N/_ -TS>I0?;$X>2BO^W\/.O)KS]E'T#VF+C\5-/T?Z.WYGWC17
MP%)\-?\ @OS\%#FP\7_ +XVZ9%]X:@NI>&]8GQTV^46M$SWSWZ4A_P""CW[7
MOPC^3]K/_@C=\;]*BBXGU+X4:]9^,H-O_/7;;-$R)CD@Y*CK1_Q#C-L3KEF*
MPN*7_3O$4XS?I2K.E6?RIA]<IQ^.,H^J?YJZ_$^_JS?&/_(L7O\ UP-?%O@;
M_@N!_P $I_%&L+X4\;?'[6_A[KO'G:'\2/#VI:/-#G^_)+%Y*^G^LK\X?^"J
M/_!RK\6+?XUZS\&/^"=6MZ9IWA70+M[.3X@W4$>I3ZW.AP\MJLP>W2UW A&*
M2-( '#*&"U]#PEX#>*'%^=_V91P$Z#4>9SKQG2IJ.U^9Q?-=O104F][63:RK
MYI@L/2YW-/R6K_KU/W\T[_D'P?\ 7%?Y"IJ_ 7_@D[_P<B?&OQ-\?_#WP!_X
M* 7UEKF@^*]2ATVQ\<:?:II]UI5W,X2%KB. +!);ERJL51&C#%R6"E:_>+_A
M!](_Y^;W_P "VKP?$CPNXL\*\XAEV>0C><>:$X/FIS2=GRMJ+NGHU*,9+1VL
MTWK@\;0QU/GI/;=/=&Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M7YV=9
ML45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_
M  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8_
M_"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I
M'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"
M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0 >)?^0OH_\ U^G_ -!-;%<IKGA73K74
M=-ACGN2)[DJY:X8D#;V]*T_^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/
M^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BL?P/_P @B7_K]F_]
M"H_X0?2/^?F]_P# MJS/"OA73M0TZ2::>Y!%S(H"7#*,!J .KHK'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8K-\8_\
M(L7O_7 U#_P@^D?\_-[_ .!;51\2^$M,L=!NKN&XNBT<1(#W+$?B* .@T[_D
M'P?]<5_D*FK"LO!>E2V<4K7-YEHE)Q=-CI4O_"#Z1_S\WO\ X%M0!L45C_\
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M4 'B7_D+Z/\ ]?I_]!-;%<U?Z%9Z-K.EM:RSMYEYAO.F+=%/3/2NEH ****
M"O,?VG/%7[5WA;0M+N/V4?A5X8\5:A+=NNK6_B?7'L8X(0N59&4'<Q;@CTKT
MZBLJU-U:3@I.-^JM=>ETU^!W9;C*>7XZ&(G1A64?L5.9PEHU[W+*,O/22U1\
MF_\ "W_^"QW_ $9[\)?_  X,W_Q%'_"W_P#@L=_T9[\)?_#@S?\ Q%?65%>?
M_9E;_H)J??#_ .0/L?\ 7C+O^A'@O_ <1_\ -)\F_P#"W_\ @L=_T9[\)?\
MPX,W_P 17,_&3]KW_@JC\ _A;KGQD^*'[*_PDT[0/#U@]WJ5V?'T[%4' 55"
M99V8JJJ.69@!UK[8KYY_X*0?L0>,OV^_@W8?!'1/C[_P@ND)JRWVM[/#1U!M
M3\L?N8C_ *3!L17)<CYMS+&>-G/)CL!F%+"3EAJ]2=1+W5>FKOI=N*5N^NQ[
M_"W%G"./XBPM#.LKP>'PDIKVM10Q4G&&\K1A7G)R:5HVBUS--Z7/P0_X;*^-
M?_#8/_#;?]M)_P )G_PE7]N;_F\G=N_X]L9SY'E?N-F?]7\N:_9WX-_M>_\
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M#:Z??:I%;.KVEOJ6I&26XFMHF1"T 8^<$"._E9B;WWPM^R!X\U/XX_$_XO\
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M'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *S?&/\ R+%[_P!<#6E6;XQ_Y%B]_P"N
M!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M;XQ\):)X\\,7O@[Q)'<O8:C 8;N.TOYK61XSU42P.DB@]#M89!(/!(K2HH \
M[_9K_9/_ &>_V/O [_#+]FGX;P>$?#C3F=-!TZ\N&LX)&9F=XH9)&2$LS$L4
M"[S@MD@8]$HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&_VJ/\
M@GI^Q%^VZ;*?]J_]F'PAXXNM-B,.GZEK.E*;RVB)+&*.Y3;,D9))V!PN3G&:
M]DHH \O^!O[%/[(_[-'P^U;X5_ 7]G+P?X6\/Z^CIX@TW2=#B1=6#HR-]K8@
MM<Y1F7]Z6^5B.AQ4_P"S'^QY^RY^QCX,N?A]^RM\"?#?@72+V\-U?VOA_3EA
M-W-C'F2OR\K ?*"Y.U< 8 Q7I-% !1110 4444 %%%% !1110 4444 %%%%
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M KP7X??\I#_B#_V(FE_^AU[U7@OP^_Y2'_$'_L1-+_\ 0Z />J*** "BBB@
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M1UJ]MO']UX8\.06T\EM>+ +>YN7A16DBBE@,8+$[6NQC&XFOO?"_+/"/C7Q
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&JVK^&_$/B#2;K0
M=>GTJ^L;VW>"\LKS3Q+%/$ZE7C=&R&5E)!4@@@D&NAHIQE*,DT[- ?$6J?\
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MASHVH7NR/Q/!JZZQ!:L[?ZRYC6"&2.,=S&)2/[I'-?FW_P %Z_@M\:/V?O\
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MW_!>+2_^/[_@F;\*M4V?>_LSXS)!YF>FWSH^,=\]<'%>7_Q#O,9?P\=@I?\
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M ,/_ /\ 8MM#CQ'\*_CAHY7_ %HU/X/:DOE^F[:K=>,?44?\1$G_  2^M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_!3;_@DA^R__P %2/!6G:5\98;_ $7Q-H*2+X<\::"46\LT<Y:"17!2> L
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M9T\C_GILW?:PN.?^/?=_LU^[W_!)#_@F1X)_X);_ ++Z?!O2O$*:]XFUJ_\
M[4\:>(T@,:7EX45%CA4Y98(D4(@)R27<A3(5'T9XE_Y"^C_]?I_]!-;%?K/B
M1](/Q"\4,FAE6:2ITZ$6I2C2@X^TE'9S<I3;L]5%.,;V?+=*W!@\IPF"J.I"
M[?GT] HHHK\//3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \5_:$_;2\-?!SXS^$OV7? G@:_\<_%+QM876I:/
MX/TJ[AMUL]+MB!/J=]<S$+:6JNRQ*V'>65@D<;D.5O?LK_M@^!OVH;CQCX.M
M?#^H>&?''PWU\:+\0O VMO$UYHUTT0F@?=$S)-;7$++-!.AVR(>BNKHOQ7^R
M!JVJ^./^#GS]K;4?$TKR/X*^#?A/0/#@E.3#87-O87\J)Z*;AW<@=V]:?\"]
M>U'PY_P=4?&WP1H+NFF>)OV7=(UCQ!#&<+)?VE]86UM*_8LL$\BC/.'..,T
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MX4O_ ,%K?^CR/A9_X2/_ -S4 ?8U%?'/_"E_^"UO_1Y'PL_\)'_[FH_X4O\
M\%K?^CR/A9_X2/\ ]S4 ?8U%?'/_  I?_@M;_P!'D?"S_P )'_[FH_X4O_P6
MM_Z/(^%G_A(__<U 'V-17QS_ ,*7_P""UO\ T>1\+/\ PD?_ +FH_P"%+_\
M!:W_ */(^%G_ (2/_P!S4 ?8U%?'/_"E_P#@M;_T>1\+/_"1_P#N:C_A2_\
MP6M_Z/(^%G_A(_\ W-0!]C45\<_\*7_X+6_]'D?"S_PD?_N:C_A2_P#P6M_Z
M/(^%G_A(_P#W-0!]C45\<_\ "E_^"UO_ $>1\+/_  D?_N:C_A2__!:W_H\C
MX6?^$C_]S4 ?8U%?'/\ PI?_ (+6_P#1Y'PL_P#"1_\ N:C_ (4O_P %K?\
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M45\<_P#"E_\ @M;_ -'D?"S_ ,)'_P"YJ/\ A2__  6M_P"CR/A9_P"$C_\
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M;_T>1\+/_"1_^YJ/^%+_ /!:W_H\CX6?^$C_ /<U 'V-17QS_P *7_X+6_\
M1Y'PL_\ "1_^YJ/^%+_\%K?^CR/A9_X2/_W-0!]C45\<_P#"E_\ @M;_ -'D
M?"S_ ,)'_P"YJ/\ A2__  6M_P"CR/A9_P"$C_\ <U 'V-17QS_PI?\ X+6_
M]'D?"S_PD?\ [FH_X4O_ ,%K?^CR/A9_X2/_ -S4 ?8U%?'/_"E_^"UO_1Y'
MPL_\)'_[FH_X4O\ \%K?^CR/A9_X2/\ ]S4 ?8U%?'/_  I?_@M;_P!'D?"S
M_P )'_[FH_X4O_P6M_Z/(^%G_A(__<U 'V-17QS_ ,*7_P""UO\ T>1\+/\
MPD?_ +FH_P"%+_\ !:W_ */(^%G_ (2/_P!S4 ?8U%?'/_"E_P#@M;_T>1\+
M/_"1_P#N:C_A2_\ P6M_Z/(^%G_A(_\ W-0!]C5F^,?^18O?^N!KY+_X4O\
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M%K?^CR/A9_X2/_W-1_PI?_@M;_T>1\+/_"1_^YJ /L:BOCG_ (4O_P %K?\
MH\CX6?\ A(__ '-1_P *7_X+6_\ 1Y'PL_\ "1_^YJ /L:BOCG_A2_\ P6M_
MZ/(^%G_A(_\ W-1_PI?_ (+6_P#1Y'PL_P#"1_\ N:@#[&HKXY_X4O\ \%K?
M^CR/A9_X2/\ ]S4?\*7_ ."UO_1Y'PL_\)'_ .YJ /J[Q+_R%]'_ .OT_P#H
M)K8KX[\*W?\ P40^#OQK\!Z/^U%\<_!?BK2?$_B(6-M;^'] ^SR0%8G=V+>6
MG4;0.O>OL2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI]I7PVN;C4/'6C:=#X.\ RW@62]\0WLGV>/3O.VC,:SK*6E"@F&%W"YPM/\
MC!^UG^U%_P $]O'OP5U?]LGXD^&/&7@OXO>,K;P3XHO]#\,'2QX0\17D+R6,
MEL3-(9M->2*6!_M!,L?[N7S2-T=?-W_!>7]GKP;^S+^QQ^Q=\%/AII<EM\.O
MAO\ M.>!]+N896W>7:0P7,,<T[8 8G#[W(Y>7)Y:NS_X.K+?5-5_X)Z>!/"G
MAE6;7=;_ &@_"MCX=2/_ %CWK_:FC"8YW?*V,<T ?1'_  65_:S_ &G/V'?V
M!O'/[47[,/ACP;J&I^$M-2ZO9/&$]RRP1O<0P;H;>!0)W F9_GEC4>6!A]Q
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M>.,KNE+/*9GECN) #]6J*** "BBB@ HHHH **** "BBB@ HHHH ^/OVH[O\
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MM\;:I\1/#7C#5/B#'HDG@[SXP][;:DDEO,[P1I"A$MNDA B9RA,I2, ^DO\
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M*_#W_IMMZ /5**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@#Y_P#^"FO[&?CS_@H'^R#XK_9%\)?&K2O ECXTLDM-;UJ_\'2:Q,L*SPS
M0(M]:K&Q,14EBXP_ !'/I?[.WP[\=_"3X*^&_A?\1?'.E>)-2\/:-:Z<=9T?
MP_)I<5S'!"D2N;>2ZN2C'9D_O".> ,5VM% 'C=M^R]JVH?M[77[9?BWQ9;W=
MIIGPOB\(>"M CMFW::9[YKS4[MW8D%Y_)T^,!0-J6IR3OKV2BB@ HHHH ***
M* "BBB@ HHHH **** "OG[_@HU^RI^TM^V1\$$^"/[//[7]K\'8-0N\^*]4;
MX?KKT^JV8P?L*A[VW2&&0Y$P(D,J'R_E0N'^@:* /AGX;_\ !.C_ (*I:?XR
M\*VWQL_X+6OXF^'NAZK9SZUX!\-?L[Z/X;_MBRMW1UL/MMI=-+;0-Y:QN(Q\
MT99,8;CU[XN_L1^(G_:^L_V\/V9/B!I'A3X@S>#F\*>,+/Q!H4E_I7B;2A,)
M[?SHX;B"2*ZMY1F.X5F)C9XF5E*E/HBB@#Q']B[]BKP_^R7%XX\9ZKXN;Q7\
M0OBGXLD\2?$CQG)IXM!J-X5$<,$$ >0VUG;Q 10P&20HNXL[LS,?./$__!._
MX\>(/^"IFC_\%*[;]J/PM;)HGPZG\$6W@=OA=<2"32I+V2\+O>?VP";G>X'F
M"$)A/]5R:^M:* /"/VT_V)K?]J;7/AO\6_!?Q"/@[XD_"#Q4^N_#_P 4R:5]
MOMHGFA-O=V5W:^9$9[6Y@8QR*DL4@VHRR*5(,5K^R)XS^)G[3W@3]JO]IOQK
MH&JZK\+=.U2'X?Z#X5T*:TM;"[U*!+>\OIY9YY9+B0P(8HT C2-992PE9D:/
MWRB@ HHHH **** "BBB@ HHHH **** "BBB@#X7^/7_!.#_@IW\3?VM=9_:B
M^%'_  5\TCP+'+9OIGA+PW_PSE8:Q'X=TQG#M!#->ZBQ,TI6,SW"K&TYCC!5
M4CBCC]:_9#_8V_:.^&N@>.K3]O']MFX_:(U#QM;1Z:6O_ %GX>T[3])6.57L
MDL+662%C*9Y?-F.'D41*V1&IKZ.HH ^(8_\ @D=XYN/V4[?_ ()M:Q^TQ#<?
ML[VVI*HT@>&Y5\3SZ"EX+N/0'U/[7Y7D!@(3<+;B9K91%A6S,?KKQ3X1\2VG
MPT?P3\$]6T/PQ=VVGI::)/J'A][ZRL(T4(B_98;BV+*J@ *)4 P.W%=)10!\
MR?\ !)G]@+QW_P $R?V0-#_8YU_X]:5X_P!%\+SWKZ%JEKX)DT>Y5;J]GO)5
MGW7]TLN)+API41X4 '<>:U/VE?V.OB3^VO;2_"C]HSXL6>G_  CGO0^M> /!
M=G/!=^)X$DW):ZAJ;R[EM'PIEM[>&)WQM,YC+(WT/10!2\.>'/#_ (/\/6'A
M+PGHEIIFE:79Q6FFZ;86ZPP6MO&@2.*-% 5$55"A0    *NT44 %%%% !111
M0 4444 %%%% !1110!Q/[1G@KXT?$?X+:_X&_9\^-%G\._%VJ61M])\:7OA<
M:RNDEB \R6AN(%DD";MA9]JN59E< HWPYX _X)1_\%B?A3\-(/A/\-?^"]UM
MHND0)+AK7]E;1'NI9)7:2:XDN);YY9;B61WDDN'9I7D=G9RY+5^C-% 'SI^T
M=_P3XT+XS>%?A%JW@OXD7FA?$?X$:E;W_P -O'^JVS:G*'6V6UNK>_1I(WN[
M>\@!2X42QR,=KB167F;X._L2:[IG[5NM?MV_M#^/]*\4_$^\\'Q^$_#']C:%
M)9:3X7T59FN'@MX9)Y999YIV\R:X>0%@J1HL2 AOH6B@#\];;_@EW_P5YT;X
ML>,?C)X0_P""XVD:3J_C6^2;4GC_ &6=*NOL]O$&%O8P/=ZE+)%:PAG\N'>5
M#22R'=)+*[^W^%O^"=-_\0OV&/&7[''[?W[0^J_'*^^(KWC^-?&MWH<&C-,T
MAC%L;.RA:2&P^S+!;-&L>4\Z(RE<R,*^FZ* /DB?_@G/\6_C1)\)O"'[:?[1
M.D>/?!WP8URRUW0])TGP?)IUSXGUBRB:*QOM8EDNYTD\E7,A@A2..6?]XV$
MA'UO110 4444 %%%% !1110 4444 %%%% !7R/\ \%!?V$?VX/VN_BEX0\6_
M ;_@HMI?PF\.>#9TU"Q\+3_!:V\1K>:LI/EWUR]W?I%*8?E:!##B&0>:"9%C
M>/ZXHH ^4/V4OV*_^"A/PW^.]K\5_P!LS_@JO>_&C0M)TNYCT/P5I_P@T[PI
M:P:A,%C^VSR65Q(UWLA,Z+#("H:8.,,@R^P_X)^?&#X%>/OBQJ_[$?[06B>
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M.!'>WDNKDB0B,LQ$FTEN%&.?0J* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?%'PO>^%XKZ;Q3:/ JVT,-P_S69CE#,60@MO&20FQP#U&BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ>_P"#>?X7?MJ?%O\
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M8;N/)(V7"E25() /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KZKI6EZ]I=SH>N
M:;;WME>V[P7EG=PK)%/$ZE7C=&!#*RD@J0002#5BB@#Y>T#_ ((I?\$F_#'Q
M _X6=H7_  3^^&4&K?:EN4'_  C<;6B2J25=;1LVZ%221MC&#TQ@5]01QI$@
MBB0*J@!548 'I2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192414625048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2022 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this annual report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192410683400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 64,065<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">22,678<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $4</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">5,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">88,921<span></span>
</td>
<td class="nump">157,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">136,909<span></span>
</td>
<td class="nump">203,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,152<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,972<span></span>
</td>
<td class="nump">29,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,124<span></span>
</td>
<td class="nump">46,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,314<span></span>
</td>
<td class="nump">47,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,608,749<span></span>
</td>
<td class="nump">1,561,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,487,776)<span></span>
</td>
<td class="num">(1,400,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 407 and 236 shares, respectively</a></td>
<td class="num">(7,518)<span></span>
</td>
<td class="num">(4,843)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">113,595<span></span>
</td>
<td class="nump">156,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 136,909<span></span>
</td>
<td class="nump">$ 203,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192414612264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 4,853<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192410701448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,404,000<span></span>
</td>
<td class="nump">$ 32,331,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">289,231,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
<td class="nump">511,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">23,995,000<span></span>
</td>
<td class="nump">322,073,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,929,000<span></span>
</td>
<td class="nump">3,231,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $4,284, $6,376 and $7,096 respectively</a></td>
<td class="nump">55,046,000<span></span>
</td>
<td class="nump">153,621,000<span></span>
</td>
<td class="nump">91,924,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative, including stock-based compensation of $6,293, $6,898 and $7,122, respectively</a></td>
<td class="nump">32,342,000<span></span>
</td>
<td class="nump">47,230,000<span></span>
</td>
<td class="nump">56,835,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and Intangible Asset Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,638,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,388,000<span></span>
</td>
<td class="nump">204,380,000<span></span>
</td>
<td class="nump">180,628,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,585,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(87,090,000)<span></span>
</td>
<td class="num">(47,800,000)<span></span>
</td>
<td class="nump">141,445,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(802,000)<span></span>
</td>
<td class="num">(14,544,000)<span></span>
</td>
<td class="num">(20,676,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">2,767,000<span></span>
</td>
<td class="nump">3,350,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before taxes</a></td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">124,119,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,014,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">130,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (87,762,000)<span></span>
</td>
<td class="num">$ (58,664,000)<span></span>
</td>
<td class="nump">$ 130,229,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
<td class="nump">116,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
<td class="nump">106,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192415619464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss Parentheticals (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 4,284<span></span>
</td>
<td class="nump">$ 6,376<span></span>
</td>
<td class="nump">$ 7,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense', window );">Stock-based compensation expense associated with general and administrative expense</a></td>
<td class="nump">$ 6,293<span></span>
</td>
<td class="nump">$ 6,898<span></span>
</td>
<td class="nump">$ 7,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192409524744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2018</a></td>
<td class="num">$ (26,405,000)<span></span>
</td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 1,447,954,000<span></span>
</td>
<td class="num">$ (1,471,577,000)<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="num">$ (2,876,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,218,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">14,218,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(941,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(941,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">130,133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">117,101,000<span></span>
</td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">1,462,172,000<span></span>
</td>
<td class="num">(1,341,444,000)<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="num">(3,817,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,274,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,274,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">6,963,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">6,959,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="nump">63,007,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">62,987,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,026,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,026,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 156,371,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">1,561,096,000<span></span>
</td>
<td class="num">(1,400,018,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(4,843,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">20,312,500<span></span>
</td>
<td class="nump">20,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Stock, Amount Issued</a></td>
<td class="nump">$ 15,714,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">15,704,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromNov2020ATMOffering', window );">Proceeds from Nov 2020 ATM Offering</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommissionsFromDecember2020CommonStockOffering', window );">Commissions from December 2020 Common Stock Offering</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering', window );">Offering expenses from December 20 common stock offering</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ATMOfferingTotal', window );">ATM Offering Total</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromDecember2020CommonStockOffering', window );">Proceeds from December 2020 common stock offering</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">35,491,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">35,485,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">1,593,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">1,591,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,675,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">113,595,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 1,608,749,000<span></span>
</td>
<td class="num">$ (1,487,776,000)<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="num">$ (7,518,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInNovember20ATMOffering', window );">Share price in November 20 ATM Offering</a></td>
<td class="nump">$ 1.992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalAgreementsTextBlock', window );">Other Capital Agreements</a></td>
<td class="text">Other Capital Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In December 2020, Lexicon sold 20,312,500 shares of its common stock at a price of $3.200 per share in a registered direct offering pursuant to an existing shelf registration statement.  Sale of the shares resulted in net proceeds of $63.0&#160;million, after deducting underwriting discounts and commissions of $1.8&#160;million and offering expenses of $0.2&#160;million.  The investors in the offering were Artal International S.C.A., an affiliate of of Invus, L.P., the Company&#8217;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P.  All of the net proceeds of the registered direct offering are reflected as issuance of common stock in the accompanying financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $50,000,000 from time to time through Jefferies acting as its sales agent.  In November 2020, Lexicon sold 3,709,233 shares of its common stock at a price of $1.992 per share pursuant to the sales agreement, resulting in net proceeds of $7.0&#160;million.  In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the sales agreement, resulting in net proceeds of $16.4&#160;million. In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the sales agreement, resulting in net proceeds of $19.1&#160;million. The net proceeds from each of these sales are reflected as issuances of common stock in the accompanying financial statements.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ATMOfferingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ATM Offering Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ATMOfferingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommissionsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commissions from December 2020 Common Stock Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommissionsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering expenses from December 20 common stock offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OfferingExpensesFromDecember20CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from December 2020 common stock offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInNovember20ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in November 20 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInNovember20ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413369912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (87,758,000)<span></span>
</td>
<td class="num">$ (58,574,000)<span></span>
</td>
<td class="nump">$ 130,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">292,000<span></span>
</td>
<td class="nump">2,934,000<span></span>
</td>
<td class="nump">3,654,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">13,274,000<span></span>
</td>
<td class="nump">14,218,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="num">(707,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,014,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">53,227,000<span></span>
</td>
<td class="num">(50,608,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="nump">2,885,000<span></span>
</td>
<td class="num">(1,948,000)<span></span>
</td>
<td class="num">(2,652,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) decrease in other assets</a></td>
<td class="nump">661,000<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and other liabilities</a></td>
<td class="num">(14,158,000)<span></span>
</td>
<td class="num">(20,969,000)<span></span>
</td>
<td class="nump">20,097,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,990,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(87,017,000)<span></span>
</td>
<td class="num">(142,969,000)<span></span>
</td>
<td class="nump">113,807,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,221,000)<span></span>
</td>
<td class="num">(87,000)<span></span>
</td>
<td class="num">(70,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">160,385,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(34,261,000)<span></span>
</td>
<td class="num">(58,555,000)<span></span>
</td>
<td class="num">(322,385,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">37,592,000<span></span>
</td>
<td class="nump">268,000,000<span></span>
</td>
<td class="nump">166,600,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">2,110,000<span></span>
</td>
<td class="nump">380,756,000<span></span>
</td>
<td class="num">(155,855,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of fees</a></td>
<td class="nump">37,084,000<span></span>
</td>
<td class="nump">69,970,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(2,675,000)<span></span>
</td>
<td class="num">(1,026,000)<span></span>
</td>
<td class="num">(941,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings</a></td>
<td class="num">(11,700,000)<span></span>
</td>
<td class="num">(216,580,000)<span></span>
</td>
<td class="num">(1,285,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">22,709,000<span></span>
</td>
<td class="num">(147,636,000)<span></span>
</td>
<td class="num">(2,226,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(62,198,000)<span></span>
</td>
<td class="nump">90,151,000<span></span>
</td>
<td class="num">(44,274,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">126,263,000<span></span>
</td>
<td class="nump">36,112,000<span></span>
</td>
<td class="nump">80,386,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">64,065,000<span></span>
</td>
<td class="nump">126,263,000<span></span>
</td>
<td class="nump">36,112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">799,000<span></span>
</td>
<td class="nump">17,353,000<span></span>
</td>
<td class="nump">19,211,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,714,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,437,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">1,013,000<span></span>
</td>
<td class="nump">1,465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(132,585,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment of Real Estate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">28,638,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,003,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 1,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411597000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OrganizationAndOperationsAbstract', window );"><strong>Organization and Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, the success of its ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411781304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2021, short-term investments consist of U.S. treasury bills and corporate debt securities. As of December&#160;31, 2020, short-term investments consist of corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160; In 2021, customers in Switzerland and the United States represented 76% and 24% of revenue, respectively.&#160;In 2020, customers in the United States represented 98% of revenue.  In 2019, customers in Germany and the United States represented 89% and 10% of revenues, respectively. &#160;&#160;At December&#160;31, 2021, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2021, AC Bioscience Ltd. represented 76% of revenues and Taconic Farms, Inc. represented 24% of revenues, respectively.  In 2020, two specialty pharmacies, Biologics, Inc. and Diplomat Pharmacy, represented 65% and 22% of revenues, respectively.  In 2019, Sanofi represented 89% of revenues and no individual XERMELO customer represented more than 10% of revenues.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, including finite-lived intangible assets, in 2021 or 2019. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than the Company&#8217;s carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  In 2019, Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 14) and Lexicon&#8217;s resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;D in 2019.  The impairment reduced the remaining book value to zero. There was no impairment of indefinite lived intangible assets in 2020 or 2021. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2021, 2020 or 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2021, stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $15.9 million, which is expected to be recognized over a weighted-average period of 1.2&#160;years.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2021, 2020 and 2019, respectively:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2021, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2021 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2021 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $326.6&#160;million at December&#160;31, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412050072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text">Recent Accounting Pronouncements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and adoption of this ASU did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU during the first quarter of 2020 did not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411695432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">Cash, Cash Equivalents and Investments<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at December&#160;31, 2021 and 2020 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>There were no realized gains or losses for the years ended December&#160;31, 2021, 2020, and 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411690344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; significant unobservable inputs </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2021 or 2020. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411644872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at December&#160;31, 2021 and 2020 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411680776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted on March 27, 2020 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws. For the year ended December 31, 2020, the impact of the CARES Act was immaterial to the Company&#8217;s tax provision. Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2021 and 2020 are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2021, 2020 and 2019 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:51.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at 21%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,014)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019 and nondeductible expenses for the years ended December&#160;31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#8220;ownership change.&#8221; An &#8220;ownership change&#8221; is generally defined as any change in ownership of more than 50% of a corporation&#8217;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2021, Lexicon had both federal and state NOL carryforwards of approximately $1.1 billion and $86.9 million, respectively.&#160;&#160;In 2021, federal NOLs increased by $132.7 million related to a current year NOL. The Company had $342.0 million of U.S. federal NOL carryforwards as of December 31, 2021, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2021, the valuation allowance increased $17.2 million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021 and 2020, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2021 and 2020, the Company had no accruals for interest or penalties related to income tax matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411618488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412062792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text">Debt Obligations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of 5.25%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes.  In 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $9.6 million was recorded and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.  As of December&#160;31, 2020, the carrying value of the remaining Convertible Notes was $11.6 million. In December 2021, the remaining balance of $11.6&#160;million was repaid in cash.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs were amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMzNjA_fd6c9083-ac60-4aa0-af6d-eabe40774af9">seven</span>-year term of the Convertible Notes.  There are no debt issuance costs as of December 31, 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provided for a $12.9&#160;million mortgage on the Property and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzMzI_73bd8c0d-44ee-40f0-9385-b10f02c7cfec">two</span>-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3&#160;million, which was paid in full in August 2020.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LP under which $150 million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO Sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. </span></div>In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5MTU_7b0c5791-d8c3-4747-83ec-263e9d8b54d5">five</span>-year term of the BioPharma Term Loan.  There are no debt issuance costs as of December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412673160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include leases of office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.  As of December&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $2.3 million, which is included in other assets in the consolidated balance sheet. Current and non-current liabilities relating to the leases were $1.1 million and $1.2 million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2021:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Arrangements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NDQ_e22aa56a-ed2a-4ea4-b4d9-85a943d8c4ac">six</span> or 12 months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411778968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 30,000,000 shares at December&#160;31, 2021.&#160;&#160;As of December&#160;31, 2021, options to purchase </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,958,179 shares and 1,822,043 restricted stock units were outstanding, 2,285,702 shares had been issued upon the exercise of stock options, 4,314,948 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate 1,200,000 shares.&#160;&#160;As of December&#160;31, 2021, stock options to purchase 408,864 shares were outstanding, none had been issued upon the exercise of stock options, 32,192 restricted stock units were outstanding and 216,040 shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#8217; Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 were $4.85, $2.35 and&#160;$3.18, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2021 was $0.6 million.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 6.7 and 5.3 years, respectively, as of December&#160;31, 2021.&#160;&#160;At December&#160;31, 2021, the aggregate intrinsic value of the outstanding stock options was $1.8 million.  At December&#160;31, 2021, the intrinsic value of exercisable stock options was $0.7 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQzMjM_2603f12e-430e-4fbf-beee-195251baa8fe">three</span> annual installments.  The total fair value of shares vested in 2021, 2020 and 2019 was $8.7&#160;million, $3.2&#160;million and $2.9&#160;million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its non-employee directors 32,192, 85,104 and 27,728 restricted stock units, respectively. The restricted stock granted in 2021, 2020 and 2019 had weighted average grant date fair values of $5.04, $1.86, and $5.67 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, an aggregate of 10,221,278 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 14,048,092 additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412670344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
<td class="text">Benefit Plan<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $0.4 million, $0.9 million and $1.2 million in the years ended December&#160;31, 2021, 2020 and 2019, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years  of service.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411689784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September 30, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized under the Agreement was $0.3 million and $4.9 million for the years ended December&#160;31, 2020 and 2019, respectively.  Revenue for each of the years ended December&#160;31, 2020 and 2019 included $0.3 million of royalties from Ipsen. Revenue for the year ended December&#160;31, 2019 included $1.3 million from sales of bulk tablets of XERMELO to Ipsen. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development and commercialization of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#8220;Termination Agreement&#8221;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $208&#160;million in September 2019, $12.1&#160;million in March 2020 and $2.7&#160;million in September 2020.  An arbitration panel issued a judgment in Sanofi&#8217;s favor in November 2021 with respect to a dispute regarding amounts withheld by Sanofi from its March and September 2020 payments offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable under the terms of the Termination Agreement.  Such judgment obligates Lexicon to reimburse Sanofi for its attorneys&#8217; fees and costs relating to the arbitration proceedings, which could require a payment up to $2.1&#160;million. Neither party will owe any additional payments pursuant to the Sanofi Agreement or Termination Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes and heart failure.</span></div>Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $300 million in December 2015. The Company recognized $126.8 million of the $300 million upfront payment for the license in 2015.  The Company was recognizing the $113.8 million allocated to the development services performance obligation and the $59.4 million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $23.5&#160;million allocated to its performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $260&#160;million, representing the full expected cash consideration from the Termination Agreement.  Subsequent to the Termination Agreement, the Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $286 million for the year ended December&#160;31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411690344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings (Loss) Per ShareThe following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of the numerators and the denominators of the basic and diluted per share calculations.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:40.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 10,221,278, 11,113,054 and 8,206,390, respectively, for the years ended December&#160;31, 2021, 2020 and 2019.  Prior to the extinguishment of the Convertible Notes, for periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411610024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SaleOfNonFinancialAssetsTextBlock', window );">Sale of Non-Financial Assets</a></td>
<td class="text">Asset Sale<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO product and related assets (the &#8220;XERMELO sale&#8221;) to TerSera pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The final consideration paid by TerSera was $160.0 million and the net gain recognized in connection with the XERMELO sale was $132.6&#160;million.  The gain is reflected on the consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65.0 million for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made. Such adjustment would be included in Gain on sale of XERMELO in the consolidated statement of comprehensive income (loss).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#8217;s operations.  For the years ended December&#160;31, 2020 and 2019, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#8217;s XERMELO operations is $12.2 million, and $15.4 million, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company incurred and recognized severance charges of approximate $5.5 million. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SaleOfNonFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Non-Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SaleOfNonFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411667608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalAgreementsTextBlock', window );">Other Capital Agreements</a></td>
<td class="text">Other Capital Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In December 2020, Lexicon sold 20,312,500 shares of its common stock at a price of $3.200 per share in a registered direct offering pursuant to an existing shelf registration statement.  Sale of the shares resulted in net proceeds of $63.0&#160;million, after deducting underwriting discounts and commissions of $1.8&#160;million and offering expenses of $0.2&#160;million.  The investors in the offering were Artal International S.C.A., an affiliate of of Invus, L.P., the Company&#8217;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P.  All of the net proceeds of the registered direct offering are reflected as issuance of common stock in the accompanying financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $50,000,000 from time to time through Jefferies acting as its sales agent.  In November 2020, Lexicon sold 3,709,233 shares of its common stock at a price of $1.992 per share pursuant to the sales agreement, resulting in net proceeds of $7.0&#160;million.  In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the sales agreement, resulting in net proceeds of $16.4&#160;million. In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the sales agreement, resulting in net proceeds of $19.1&#160;million. The net proceeds from each of these sales are reflected as issuances of common stock in the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192407732008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy</a></td>
<td class="text">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2021, short-term investments consist of U.S. treasury bills and corporate debt securities. As of December&#160;31, 2020, short-term investments consist of corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy</a></td>
<td class="text">Accounts Receivable:&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure</a></td>
<td class="text">Concentration of Credit Risk: Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations </span>for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy</a></td>
<td class="text">Impairment of Long-Lived Assets:&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, including finite-lived intangible assets, in 2021 or 2019.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy</a></td>
<td class="text">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2021, stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $15.9 million, which is expected to be recognized over a weighted-average period of 1.2&#160;years.</span>&#160;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy</a></td>
<td class="text">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than the Company&#8217;s carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  In 2019, Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 14) and Lexicon&#8217;s resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;D in 2019.  The impairment reduced the remaining book value to zero. There was no impairment of indefinite lived intangible assets in 2020 or 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2021, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2021 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2021 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $326.6&#160;million at December&#160;31, 2021. </span></div>Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411663688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412070632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411673720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411681336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411737432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2021, 2020 and 2019 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:51.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at 21%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,014)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412050072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192415534440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411593352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of the numerators and the denominators of the basic and diluted per share calculations.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:40.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413277512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent', window );">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413231080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details) - segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueSanofiPercentage', window );">Entity Wide Revenue Sanofi Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LXRXDiplomatcustomerconcentration', window );">LXRX Diplomat customer concentration</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LXRXBiologicscustomerconcentration', window );">Biologics customer concentration</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueSanofiPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EntityWideRevenueSanofiPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXBiologicscustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXBiologicscustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXDiplomatcustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXDiplomatcustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192495026360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Intangible asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and Intangible Asset Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411836008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,669<span></span>
</td>
<td class="nump">$ 21,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,972<span></span>
</td>
<td class="nump">$ 29,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413301720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">28,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411693144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 28,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192409437032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cost of Sales (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411855928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</a></td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192410884360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192416406872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192405585512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">15,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">15,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">64,066<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">64,065<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">7,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">7,561<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">22,687<span></span>
</td>
<td class="nump">26,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">22,678<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">86,753<span></span>
</td>
<td class="nump">152,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">$ 86,743<span></span>
</td>
<td class="nump">$ 152,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413141704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 64,065<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">22,678<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">86,743<span></span>
</td>
<td class="nump">152,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">64,065<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">7,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">71,626<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">15,117<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">15,117<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192405549016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,029,000<span></span>
</td>
<td class="nump">$ 6,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,853,000)<span></span>
</td>
<td class="num">(5,815,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176,000<span></span>
</td>
<td class="nump">295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryBuildingsAndImprovements', window );">Inventory, Buildings and Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 28,638,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Noncash or Part Noncash Divestiture, Amount of Consideration Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Payments to Acquire Other Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,027,000<span></span>
</td>
<td class="nump">3,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,692,000<span></span>
</td>
<td class="nump">1,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="nump">$ 417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryBuildingsAndImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of building structures held as inventory including any additions, improvements, or renovations to those structures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryBuildingsAndImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412006296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Deferred Tax Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 229,427<span></span>
</td>
<td class="nump">$ 201,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">29,290<span></span>
</td>
<td class="nump">29,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug', window );">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</a></td>
<td class="nump">24,524<span></span>
</td>
<td class="nump">24,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, In Process Research and Development</a></td>
<td class="nump">36,770<span></span>
</td>
<td class="nump">47,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">5,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">326,630<span></span>
</td>
<td class="nump">309,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="num">(412)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="num">(412)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="num">(326,218)<span></span>
</td>
<td class="num">(309,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (6,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2020FederalNOLIncrease', window );">2020 Federal NOL increase</a></td>
<td class="nump">132,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsSection163j_LXRX', window );">Deferred Tax Assets, Section 163j_LXRX</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</a></td>
<td class="nump">$ 342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020FederalNOLIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2020 Federal NOL increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020FederalNOLIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsSection163j_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsSection163j_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413839192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change in Amount</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating Loss Carryforwards, State</a></td>
<td class="nump">86,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 29,290<span></span>
</td>
<td class="nump">$ 29,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413817192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State and Local Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (269)<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">17,210<span></span>
</td>
<td class="num">(20,418)<span></span>
</td>
<td class="num">(35,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</a></td>
<td class="num">(18,429)<span></span>
</td>
<td class="num">(12,300)<span></span>
</td>
<td class="nump">26,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WriteOffOfTaxCredits', window );">Write-off of tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WriteOffOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of tax credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_WriteOffOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192415560856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 30, 2010</div></th>
<th class="th"><div>Jul. 12, 2001</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthGoodwill', window );">Coelacanth Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthPurchasePrice', window );">Coelacanth Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyIconGoodwill', window );">Symphony Icon Goodwill</a></td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyIconGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyIconGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413739448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage', window );">Convertible Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalCashConsideration', window );">Convertible Debt Exchange - Total cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal', window );">2020 Convertible debt exchange - share payment total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,368,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal', window );">2020 convertible debt exchange - percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangeAccruedInterest', window );">2020 convertible debt exchange - accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchange', window );">Convertible debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX', window );">Mortgage Debt Interest Rate_Base_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX', window );">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInstrument_Revere_LXRX', window );">Mortgage Debt Instrument_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtBalloonPayment_LXRX', window );">Mortgage Debt Balloon Payment_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangeAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2020 convertible debt exchange - accrued interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangeAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2020 convertible debt exchange - percentage of principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2020 Convertible debt exchange - share payment total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Exchange - Total cash consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtBalloonPayment_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtBalloonPayment_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInstrument_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInstrument_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRate_Base_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411682616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (11,646)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192412027288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192410706216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 1,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Operating Leases, Future Minimum Payments, Due in Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Operating Leases, Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">2,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InterestOnLeasePayments', window );">Interest on Lease Payments</a></td>
<td class="num">(330,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PresentValueOfFutureLeasePayments', window );">Present Value of Future Lease Payments</a></td>
<td class="nump">2,279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="num">(1,089,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">1,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InterestOnLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest on Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InterestOnLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PresentValueOfFutureLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present Value of Future Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PresentValueOfFutureLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411877848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock', window );">Stock Option Exercise Price as Percent of Value of Common Stock</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan', window );">Total Shares That May be Issued, Equity Incentive Plan</a></td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingEquityIncentivePlan', window );">Options Outstanding, Equity Incentive Plan</a></td>
<td class="nump">7,958,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Equity Incentive Plan</a></td>
<td class="nump">1,822,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedEquityIncentivePlan', window );">Stock Options Exercised, Equity Incentive Plan</a></td>
<td class="nump">2,285,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</a></td>
<td class="nump">4,314,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan', window );">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</a></td>
<td class="nump">113,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Totalvalueofsharesbynonemployeeinayear', window );">Total value of shares by nonemployee in a year | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan', window );">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Options Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">408,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan', window );">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">216,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">10,221,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">14,048,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">32,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Totalvalueofsharesbynonemployeeinayear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Totalvalueofsharesbynonemployeeinayear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413148232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 2) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">8,367<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
<td class="nump">6,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="nump">$ 9.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="num">(1,271)<span></span>
</td>
<td class="num">(2,557)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.17<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,032<span></span>
</td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.99<span></span>
</td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192415520472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</a></td>
<td class="nump">32,192<span></span>
</td>
<td class="nump">85,104<span></span>
</td>
<td class="nump">27,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411985688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 4) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(1,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</a></td>
<td class="nump">$ 5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192411610824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DefinedContributionPlanRequisiteServicePeriod', window );">Years of service</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DefinedContributionPlanRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DefinedContributionPlanRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192405504824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiUpfrontPayment', window );">Sanofi Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable', window );">Sanofi Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable', window );">Sanofi Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueRecognized', window );">Sanofi Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable', window );">Sanofi Revenue Allocated to Funding Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalPaymentsToDate', window );">Ipsen Total Payments To Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Ipsenproductsales', window );">Ipsen product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiTerminationAgreement', window );">Sanofi Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiDeferredRevenueFromTermination', window );">Sanofi Deferred Revenue from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalPaymentsToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalPaymentsToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Ipsenproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Ipsenproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiDeferredRevenueFromTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sanofi Deferred Revenue from Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiDeferredRevenueFromTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoFundingDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sanofi Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SettlementPaymentFromTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment from Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SettlementPaymentFromTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192405412232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (87,758)<span></span>
</td>
<td class="num">$ (58,574)<span></span>
</td>
<td class="nump">$ 130,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Debt Instrument, Convertible, If-converted Value in Excess of Principal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,365,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">145,652,000<span></span>
</td>
<td class="nump">110,841,000<span></span>
</td>
<td class="nump">116,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">10,221,278<span></span>
</td>
<td class="nump">11,113,054<span></span>
</td>
<td class="nump">8,206,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</a></td>
<td class="num">$ (87,758)<span></span>
</td>
<td class="num">$ (58,574)<span></span>
</td>
<td class="nump">$ 135,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">145,652,000<span></span>
</td>
<td class="nump">110,841,000<span></span>
</td>
<td class="nump">106,218,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192410709800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 23,995<span></span>
</td>
<td class="nump">$ 322,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) From Operations</a></td>
<td class="num">(87,090)<span></span>
</td>
<td class="num">(47,800)<span></span>
</td>
<td class="nump">141,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,758)<span></span>
</td>
<td class="num">$ (58,574)<span></span>
</td>
<td class="nump">$ 130,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
<td class="nump">106,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
<td class="nump">116,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413762312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160,385<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,200)<span></span>
</td>
<td class="num">(15,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">132,585<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones', window );">TerSera Maximum Development, Regulatory and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle', window );">Final Consideration including amounts released to settle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713', window );">541713 Research and Development in Nanotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Consideration including amounts released to settle</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalConsiderationIncludingAmountsReleasedToSettle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>TerSera Maximum Development, Regulatory and Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140192413335512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,312,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromDecember2020CommonStockOffering', window );">Proceeds from December 2020 common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommissionsFromDecember2020CommonStockOffering', window );">Commissions from December 2020 Common Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering', window );">Offering expenses from December 20 common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ATMOfferingTotal', window );">ATM Offering Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInNov2020ATMOffering', window );">Shares sold in Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInNovember20ATMOffering', window );">Share price in November 20 ATM Offering</a></td>
<td class="nump">$ 1.992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromNov2020ATMOffering', window );">Proceeds from Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ATMOfferingTotal', window );">ATM Offering Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="nump">8.463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="nump">8.463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInSeptember2021ATMOffering', window );">Shares sold in September 2021 ATM offering</a></td>
<td class="nump">4,176,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInSeptember2021ATMOffering', window );">Share Price in September 2021 ATM Offering</a></td>
<td class="nump">4.732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromSeptember2021ATMOffering', window );">Proceeds from September 2021 ATM Offering</a></td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ATMOfferingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ATM Offering Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ATMOfferingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommissionsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commissions from December 2020 Common Stock Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommissionsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering expenses from December 20 common stock offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OfferingExpensesFromDecember20CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from December 2020 common stock offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInNovember20ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in November 20 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInNovember20ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price in September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in September 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>lxrx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20211231"
  xmlns:naics="http://xbrl.sec.gov/naics/2021"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20211231.xsd" xlink:type="simple"/>
    <context id="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b830e55112e413294d94a95da2c31d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaea6bf5e65b144809174989bbe6607b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75536cf4a4174691b204bb1a118bb561_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2de7ae68674e4d58a012b15b9e1f640d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a484df8d34a48168ddc67636fee53d7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idbc0d4d9dd1147749e2496817aad0133_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieaf0e7cc645e4f69a6ece2184dc576cb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ica5229e5ba37471fb75d1796184d22b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66d73276a9f54188a234d30a5c7db573_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib61ea8ca87054ca299e35899d20f0821_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f0c660c256a4099bc5d00a590fa3ae2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51590a994bf24c4ca00c39f49378fafb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i479d65c47ea34ef3a9d80c56a9fa552a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib658c65a014d4e83b3f212fa1f301a87_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id62e4b39721d47a18227ec951181b233_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6a8eb0c931e47bb8781df60680b3b5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66152bef9ef94ee28758450b0c7d3bf1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f855dd7993f49eeb1b627eb46715eef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d0ad57c0c334f0386685e094334b434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdb78b879b1247648386171510533efd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic759629006f74192a60c2905a8f645ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if92be0a5177c4f85879df29eafff809c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i729d06e13a06473b9ca5a295173d860e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80201290325143af97f2fb030d3e10d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a188a482da64a818cb53605d5b01571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8522830166f449a58c9cec1c88e894b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">naics:ZZ541713</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib18d8e20549d44f094d78c20f57067a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb7da2f3e97c46d389e37d815311f301_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37cf340c919946f4bfab989e262c817c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c48b80d6d71414d86074d2c8dec0efa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dc58a9208454195ae83b844c05fd101_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a1b6c22beee4da5b9a413b0fd5a000c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i091b4225a0724082a4b25d2b383f9518_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53afd739da224f3588c2279414d4f677_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2adb638834b14d05ad8e434cc4531023_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id30138e6503c4ffda82b615c312c176c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib964838f757842dc89d306cdb12966ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ede039b32984c72893e8e8c75c2b9fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id380ecc83b6e49a789334d406e5727f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4dd544ad16c4850b2b176d752df0a1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic29f411a667c4474b294d320f9ebcb4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i251665a0c7944e8d9bb8853d049ed549_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i535698f3d692460b81cba7884c86e4e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1397c77d1b6f4185845e1699cd219089_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c9e7435336a44558427742a97851cad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30aff4dded0c44ae865d00df32ebe612_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0eced0a8b11146888768ff4b14b2f375_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4455ddb6c214da7961fd95cd24842c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic47c902d195d41518cadfff77db8830a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib99f027008024261ace720d15f140e6b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i815538a41da140838b0cb583686e2574_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0b5aed98e3345b39cf920b0e50e105d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1e10dc122274204badbada626c6296e_I20010712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2001-07-12</instant>
        </period>
    </context>
    <context id="i5170da333de84c9ab9e1c854f5a3f263_I20100730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2010-07-30</instant>
        </period>
    </context>
    <context id="i33b1d627868546fca39177189a903e94_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="if9cb62af37d048978f015209a192adc4_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i74800149cb834920a98e1fed9979820d_I20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-08-30</instant>
        </period>
    </context>
    <context id="ia89421ae837f48509b4bf1206d468d61_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="iddcd02aeb6f54c27b62d323917d83e97_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1154d94c6995462ba768d2bd7b39e722_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie941169ab2164798abaed9016c336c29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7478be4ff58a46a4936f451a7f97265d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bdba477612f406591bdc6aaf6c502bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89e3823a40a049809c8d559277e562bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00be06ddbff74be8bbf65ceefcef5599_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i721b502840b14174be6cc3a22bfa99fd_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i13c3e38005194277b23efa2e68887d55_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>lxrx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV80LTEtMS0xLTE2MTE4_ebf5169f-3693-4e77-bf00-03e2d07165dc">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV81LTEtMS0xLTE2MTE4_c4d7bb25-3863-4fb0-913f-a73320c246f6">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV82LTEtMS0xLTE2MTE4_0779aa08-be54-4d8c-aa71-73cb45699458">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF80L2ZyYWc6YmZhNGI4MjIzMzk0NDIwNWJiOGUzYmNmNDMxNTFiZjUvdGFibGU6NzA3YWMzYmE3ZmM4NDdiMDhhOWYwMjVkNTA5ZDJlOGEvdGFibGVyYW5nZTo3MDdhYzNiYTdmYzg0N2IwOGE5ZjAyNWQ1MDlkMmU4YV83LTEtMS0xLTE2MTE4_43589f59-91e1-4a89-8045-e32dad083422">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtInstrumentTerm
      contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMzNjA_fd6c9083-ac60-4aa0-af6d-eabe40774af9">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzMzI_73bd8c0d-44ee-40f0-9385-b10f02c7cfec">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="iddcd02aeb6f54c27b62d323917d83e97_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5MTU_7b0c5791-d8c3-4747-83ec-263e9d8b54d5">P5Y</us-gaap:DebtInstrumentTerm>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="ifa9cb31eba5a42ada8c477bca789b70b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NDQ_e22aa56a-ed2a-4ea4-b4d9-85a943d8c4ac">P6M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0bdba477612f406591bdc6aaf6c502bf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQzMjM_2603f12e-430e-4fbf-beee-195251baa8fe">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV84NQ_94372846-055c-461d-aa03-b4d6b65bfcf6">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8xLTAtMS0xLTE2MTE4_3c48b631-a678-4d5c-82a9-40c9e29ed2b3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8zLTItMS0xLTE2MTE4_93a6d69b-b8e3-4601-81d8-d4ec418e2ddd">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZDc3MjU5ZDczNTI2NGYwNjgzNTczZGE5Njk1ZWNjZjgvdGFibGVyYW5nZTpkNzcyNTlkNzM1MjY0ZjA2ODM1NzNkYTk2OTVlY2NmOF8zLTItMS0xLTE2MTE4_5cb4ca1f-f3b9-4479-a6cc-877ff91c4523">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZWQxNzRjYmVkM2ZlNGJlOTg2YmUzMzQyNDUxOTA0M2UvdGFibGVyYW5nZTplZDE3NGNiZWQzZmU0YmU5ODZiZTMzNDI0NTE5MDQzZV8wLTAtMS0xLTE2MTE4_ed9e51bf-a961-4ad4-97dd-6f12a9d3e5df">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xMjE_f282deed-09f3-43d7-858e-c02c280e5506">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDMz_c75c0cba-4485-4c14-8d24-396ce803bf00">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6YmI0MmQ5OGY2ZGNjNDIzOWFlMjJiNjQ3NTljMTM1OWIvdGFibGVyYW5nZTpiYjQyZDk4ZjZkY2M0MjM5YWUyMmI2NDc1OWMxMzU5Yl8wLTEtMS0xLTE2MTE4_e5dfa78a-9c80-4414-8884-c54b5c888a7a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6YmI0MmQ5OGY2ZGNjNDIzOWFlMjJiNjQ3NTljMTM1OWIvdGFibGVyYW5nZTpiYjQyZDk4ZjZkY2M0MjM5YWUyMmI2NDc1OWMxMzU5Yl8wLTMtMS0xLTE2MTE4_2a60d4c7-18a0-4bde-9caf-5328a74127ab">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTEtMS0xLTE2MTE4_b9d5143b-10ba-4d1f-9de4-fe71d47238e5">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:CityAreaCode
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTUtMS0xLTE2MTE4_ed127fac-6bc3-4fd6-85dd-cbb704ae3042">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8wLTYtMS0xLTE2MTE4_4a140651-2d73-4ab1-89b4-e305f20ba505">863-3000</dei:LocalPhoneNumber>
    <dei:EntityAddressCityOrTown
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTEtMS0xLTE2MTE4_72674c32-62e1-498f-89fb-22c306fd6dd6">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTItMS0xLTE2MTE4_2d39b862-8220-420b-971c-fd26dd836976">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6ZmJjYjFhMzZhMGYzNDg2ODlhY2I5Y2QwOWQzMDFiNWEvdGFibGVyYW5nZTpmYmNiMWEzNmEwZjM0ODY4OWFjYjljZDA5ZDMwMWI1YV8xLTMtMS0xLTE2MTE4_31353da9-c7ad-4d58-bb18-69c77ac2610c">77381</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTEtMS0xLTE2MTE4_4990094b-a2b3-4a5f-aa2b-0973be16dfd3">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTItMS0xLTE2MTE4_ed1b6b43-1730-4fcb-89a4-c65907bd10f8">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGFibGU6OGQyMDg5ZThkNmRmNGU3MTljNzRhNGQxN2JjNTE0OWMvdGFibGVyYW5nZTo4ZDIwODllOGQ2ZGY0ZTcxOWM3NGE0ZDE3YmM1MTQ5Y18xLTMtMS0xLTE2MTE4_41d73fec-3c42-4229-bdd7-5b0c4241d00a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV80Nzg_70487d40-5895-480b-a8cd-0f715e25a8b1">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV82NDU_fa0780a8-d46c-433b-b069-3f7c946c1c58">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV85OTY_7de9a5f6-0360-4970-9fc3-a3a06bc092da">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xMjk5_ee4b1e0e-f892-4611-8d93-d9c094e4cdf1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzE0_ce8b2443-5b2e-4f2c-b57c-84e6b0dba20d">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzcy_772405b4-6ba2-4516-8f65-72d02cd3abeb">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8xNzk5_857cd120-d4c2-41d3-b4df-276ff7e0a8a6">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDM0_c2bebc9d-2dce-49c8-a3d1-ca059f6c9f68">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8yNTUw_2ab21ea1-e09f-4f2b-9399-c54dcc514fc2">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7b830e55112e413294d94a95da2c31d6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8yNzM4_10b0d66d-5b0d-415e-b76e-6ad04f00d1d5"
      unitRef="usd">309400000</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xL2ZyYWc6NzhkOWU0MTY4OTNmNDg0Mzg2NjgyMWU3MjAwNDZmNDkvdGV4dHJlZ2lvbjo3OGQ5ZTQxNjg5M2Y0ODQzODY2ODIxZTcyMDA0NmY0OV8zNDM1_f4efd8c8-51bd-417f-b7f1-f3459892180d">Certain sections of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s 2022 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this annual report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzMw_7a3b32dc-264c-440e-be2a-caf470510ce2">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzNA_5e4f2ee9-275f-44af-a6fe-4df49c9aa62d">Houston, Texas</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF84NS9mcmFnOmMzYmY5MWYzODcxNTQwNzI4NzM0NDM2ZTUwYjg1MDhmL3RleHRyZWdpb246YzNiZjkxZjM4NzE1NDA3Mjg3MzQ0MzZlNTBiODUwOGZfMjE5OTAyMzI1ODEzNQ_82331d81-8983-4f87-a6ed-8107ccf0ac72">42</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzQtMS0xLTEtMTYxMTg_a32cf862-1615-4d86-bc43-83487e8a1ed4"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzQtMy0xLTEtMTYxMTg_8090d0c7-09e4-460c-989a-01279ea19ad6"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzUtMS0xLTEtMTYxMTg_6c8b49cf-f5e9-48be-9dae-d3524f8037e6"
      unitRef="usd">22678000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzUtMy0xLTEtMTYxMTg_9e39871b-e967-4346-a7f0-672612796944"
      unitRef="usd">26012000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzYtMS0xLTEtMTYxMTg_066521cf-d617-4e25-a1a9-0e2cda547a2f"
      unitRef="usd">14000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzYtMy0xLTEtMTYxMTg_5c7d3921-c6ed-4083-b3a0-b5d574a45642"
      unitRef="usd">395000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzktMS0xLTEtMTYxMTg_6cb5ef48-312c-4c3b-9872-bc827c7f5e3d"
      unitRef="usd">2164000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzktMy0xLTEtMTYxMTg_65346aa8-a732-431c-b130-d06c4c19329c"
      unitRef="usd">5049000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEwLTEtMS0xLTE2MTE4_724c77df-a1d5-4b90-8d7b-31a019825eeb"
      unitRef="usd">88921000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEwLTMtMS0xLTE2MTE4_ac517166-29b7-4a1c-af13-3b4cd7400b20"
      unitRef="usd">157719000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MWQyN2Q5ZmYzYzI0NGJiODllYjc2Yzg0NDU3OGE2OTJfODA_c7326471-0286-4951-8a05-cd85dc204bd9"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MWQyN2Q5ZmYzYzI0NGJiODllYjc2Yzg0NDU3OGE2OTJfODc_63edb102-8f62-46a6-afef-5677b2ee9103"
      unitRef="usd">5815000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTEtMS0xLTE2MTE4_08ae1e6a-bc9a-491e-8d04-bbc8c030c04f"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzExLTMtMS0xLTE2MTE4_62c26a8c-ff5b-4b67-b6f4-19f2bcd8ca4d"
      unitRef="usd">295000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEyLTEtMS0xLTE2MTE4_d79de4ad-f08a-4d32-bdcc-434e2e20e030"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzEyLTMtMS0xLTE2MTE4_1fb884f9-df89-4b34-b99e-32f35a0939d3"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE0LTEtMS0xLTE2MTE4_f67bf9c2-5401-45e3-a7ea-fe7972ab0847"
      unitRef="usd">2269000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE0LTMtMS0xLTE2MTE4_f1713956-84b0-489f-be25-b53f9e735198"
      unitRef="usd">1231000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE1LTEtMS0xLTE2MTE4_cac6dafe-ab04-48fb-b66a-c7b635439372"
      unitRef="usd">136909000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE1LTMtMS0xLTE2MTE4_788cb786-8545-48fc-9d28-df7511477e52"
      unitRef="usd">203788000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE4LTEtMS0xLTE2MTE4_3dcb98f3-4c59-489e-95c2-bedeb6bd64f7"
      unitRef="usd">9152000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE4LTMtMS0xLTE2MTE4_05f4a957-d766-4748-b240-906be1b28fa6"
      unitRef="usd">5469000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE5LTEtMS0xLTE2MTE4_a00e4a2b-3d73-4151-81b0-8d0cb90020e6"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzE5LTMtMS0xLTE2MTE4_1067377d-fdf1-4ef2-bd30-6490c17f5059"
      unitRef="usd">29691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIxLTEtMS0xLTE2MTE4_b146774f-87af-4a60-8805-e35da58605db"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIxLTMtMS0xLTE2MTE4_cb4aec7e-5b87-47ef-b367-aa808cb35140"
      unitRef="usd">11646000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIyLTEtMS0xLTE2MTE4_653a76c4-ab09-4729-8f70-ff4b39282afc"
      unitRef="usd">22124000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzIyLTMtMS0xLTE2MTE4_08376849-e527-4b3f-85b2-9e6f8e050222"
      unitRef="usd">46806000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI2LTEtMS0xLTE2MTE4_53299aff-22e7-4cbc-92fa-2d18598282ce"
      unitRef="usd">1190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI2LTMtMS0xLTE2MTE4_98ac44ed-69d2-4e7c-a7af-223211df55f8"
      unitRef="usd">611000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI3LTEtMS0xLTE2MTE4_8097eea7-ad10-472c-b3ae-886fded5b1ea"
      unitRef="usd">23314000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI3LTMtMS0xLTE2MTE4_fb8d55af-f85c-4b6e-a08c-c6c73e630ed6"
      unitRef="usd">47417000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI4LTEtMS0xLTE2MTE4_c777da7b-56b9-40cb-a728-cc3f853df04d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzI4LTMtMS0xLTE2MTE4_539447e0-d957-44cd-b052-0ee0570a6915"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMjE_27a3df4e-46ea-4765-82d5-556cedad6649"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMjE_d09f2a5e-2ea4-4e33-9aff-2d7a52215d56"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMzU_19f59020-6791-4216-ba96-02092301636a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfMzU_e9ba9393-452c-4c4a-a25a-10e21f1005b8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_175b4f5d-3735-4d2a-ad8a-4524bdc8f213"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_1bbea409-08c8-416e-84aa-b896ded19a28"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_33642187-31b3-4187-a81a-94ffeab07adb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTAtMS0xLTE2MTE4L3RleHRyZWdpb246YWEyNDhmNWEzMzMyNGNiZTkwNWI1ZjVhZjYwNjgyMTJfNTc_f27446c2-620f-48c3-816e-69dfc693e638"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTEtMS0xLTE2MTE4_a2636386-4414-4085-812c-b0507e72498e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMwLTMtMS0xLTE2MTE4_7f8d52b3-849f-4df7-a768-3b0f3c155437"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMTg_843019bf-35bb-4315-b9e3-0ad7be3e8819"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMTg_fdb92310-fcb9-452a-9cd2-faad951542cf"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMzI_0eee4f56-cfea-484a-ba1d-209453cf3417"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfMzI_5390eb96-6f9c-4f3d-a57b-3cdd489cf775"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfNTQ_60ec1097-15bc-44d0-8633-85e2bbb97363"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTAtMS0xLTE2MTE4L3RleHRyZWdpb246ZDlmZTY0MDA3MzU1NGY5ZWJlOWRiNzRlZGYwMjIyZDZfNjE_2235ea24-7a2b-4951-8f27-8f6789cae5a9"
      unitRef="shares">142289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTEtMS0xLTE2MTE4_7be58699-8f1c-47d8-a325-f70f9abca8dc"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMxLTMtMS0xLTE2MTE4_21d76471-9386-4b60-9f83-e6f2359972af"
      unitRef="usd">142000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMyLTEtMS0xLTE2MTE4_b1ce75e5-ba06-43f7-a96d-e6090d3471cd"
      unitRef="usd">1608749000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMyLTMtMS0xLTE2MTE4_c625f818-da94-4767-b049-cc9f910a7fad"
      unitRef="usd">1561096000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMzLTEtMS0xLTE2MTE4_8ee9b042-fc4d-48a5-a06c-239c198c9f14"
      unitRef="usd">-1487776000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzMzLTMtMS0xLTE2MTE4_2589975f-3f1d-4948-8a4f-ae6d7e339a4c"
      unitRef="usd">-1400018000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM0LTEtMS0xLTE2MTE4_e79a91a6-0781-453b-bc48-5562e8ea493f"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM0LTMtMS0xLTE2MTE4_8b58f7f4-fc33-47a0-9e34-6771541c852b"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTAtMS0xLTE2MTE4L3RleHRyZWdpb246OWE3NzI5ZmU4ZmI5NGY0OTliZDBkNTg2Zjk0YjQ5NGRfMjk_6255b217-ddd1-454e-b65d-ca000646710c"
      unitRef="shares">1165000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTAtMS0xLTE2MTE4L3RleHRyZWdpb246OWE3NzI5ZmU4ZmI5NGY0OTliZDBkNTg2Zjk0YjQ5NGRfMzY_22edb5c6-a508-4d0e-84fb-8d3704ac720a"
      unitRef="shares">793000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTEtMS0xLTE2MTE4_0a8a748b-bd66-432b-9861-14cd3ab7bb61"
      unitRef="usd">7518000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM1LTMtMS0xLTE2MTE4_290b0518-950f-4b34-a8f7-1814b5c03b10"
      unitRef="usd">4843000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM2LTEtMS0xLTE2MTE4_ae8fcc70-8acb-4ea5-9b5e-cb940c95f5ff"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM2LTMtMS0xLTE2MTE4_0f0b90ce-85cc-45bc-94a7-68c78916d6e8"
      unitRef="usd">156371000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM3LTEtMS0xLTE2MTE4_19c985d8-cd9e-4fa0-8f78-64bf8137aa35"
      unitRef="usd">136909000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzAvZnJhZzpkMmYyMzdlOTFkMmE0Y2QxYmUyMTc4NWU5M2I4ZDU0OC90YWJsZTo1Mzk5ZmViYjVhOGQ0NTI4ODQ1NzVhMGNkNjNkNjczZS90YWJsZXJhbmdlOjUzOTlmZWJiNWE4ZDQ1Mjg4NDU3NWEwY2Q2M2Q2NzNlXzM3LTMtMS0xLTE2MTE4_93b15685-f960-40b9-8503-4d42920bb242"
      unitRef="usd">203788000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtMS0xLTEtMTYxMTg_d64c42ae-3380-4570-b481-2f185a6640ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtMy0xLTEtMTYxMTg_a1d36636-d434-418a-acd1-8a48e752218a"
      unitRef="usd">23404000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMtNS0xLTEtMTYxMTg_83e40488-685e-4434-8021-d6d3b19578a5"
      unitRef="usd">32331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtMS0xLTEtMTYxMTg_d1ee7816-ba6c-4c39-9d96-9e8e3986d972"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtMy0xLTEtMTYxMTg_26c1d913-bc09-498e-b77e-3927696d1d9a"
      unitRef="usd">33000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzQtNS0xLTEtMTYxMTg_5cae452e-6982-48c8-9b2f-621d362b6f26"
      unitRef="usd">289231000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtMS0xLTEtMTYxMTg_2fd0a09e-4cf4-4c0e-878d-d189d287346f"
      unitRef="usd">298000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtMy0xLTEtMTYxMTg_dab32b21-1e7a-4a6a-ab0c-4b43a1b460d5"
      unitRef="usd">558000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzUtNS0xLTEtMTYxMTg_a30ee23f-19ef-40f7-8985-85d77cbed276"
      unitRef="usd">511000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtMS0xLTEtMTYxMTg_b2e0cacf-db41-4818-981f-be9b98e84c22"
      unitRef="usd">298000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtMy0xLTEtMTYxMTg_aba6bad9-c601-4cab-a166-5d84f2d8f1ee"
      unitRef="usd">23995000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzYtNS0xLTEtMTYxMTg_e117dd25-4900-4677-b894-94664d874e27"
      unitRef="usd">322073000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtMS0xLTEtMTYxMTg_6dc5cada-a7c9-4139-abf8-0d7805ab9013"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtMy0xLTEtMTYxMTg_417c2b9c-649b-4a80-b3b2-9e15412aeb93"
      unitRef="usd">1929000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzgtNS0xLTEtMTYxMTg_a1529872-cfd0-4251-8185-b94b93145d24"
      unitRef="usd">3231000</us-gaap:CostOfGoodsAndServicesSold>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF82OA_3f908dfe-7fb1-4a53-a2c0-a00c21b7dbdc"
      unitRef="usd">4284000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF83Mg_2cd3d22f-e018-496f-ad04-2c9277c3bc2a"
      unitRef="usd">6376000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjplZWJiZmY0OWI5YTc0ZThjODUyYjVkNmI0NzkwZjZhZF83OQ_cebaf36d-a065-46e8-aec1-1dfc0ae7b11a"
      unitRef="usd">7096000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMS0xLTEtMTYxMTg_e923ac4e-e2bb-487e-ac1b-060c5173f548"
      unitRef="usd">55046000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktMy0xLTEtMTYxMTg_a9eed46d-5352-4ef7-9cf4-f139146ede51"
      unitRef="usd">153621000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzktNS0xLTEtMTYxMTg_ded5fcfa-b112-41b7-ad9e-f7918f1dbdc7"
      unitRef="usd">91924000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfNzk_6d4f6485-6afd-4397-9a21-659f7e22b98c"
      unitRef="usd">6293000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfODM_aba6d462-0735-46ae-984c-bc9865c87270"
      unitRef="usd">6898000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTAtMS0xLTE2MTE4L3RleHRyZWdpb246MDViZDZkYmVjMDQyNDcyODgxNjk2ZTMyZWFjNzM4MWNfOTA_17ba4546-c5c4-48d4-af18-1e4d9477156e"
      unitRef="usd">7122000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTEtMS0xLTE2MTE4_24d36ce6-ee0b-42f1-b27c-44cf4705bfc5"
      unitRef="usd">32342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTMtMS0xLTE2MTE4_aeb6cc77-63ac-4311-8d72-54446b2bb7a3"
      unitRef="usd">47230000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzExLTUtMS0xLTE2MTE4_171ef795-16d2-4a77-acf5-455ef7d7cebf"
      unitRef="usd">56835000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTEtMS0xLTE2MTE4_a989633b-8232-422b-8a31-e87cd19caa81"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTMtMS0xLTE2MTE4_4089f9be-10ee-43ee-9d05-0e304e7882e8"
      unitRef="usd">1600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEyLTUtMS0xLTE2MTE4_4c826ca8-04a5-4495-a16b-8460344ac807"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTEtMS0xLTE2MTE4_2011393e-e2ff-43cb-a68c-9ff3c8342512"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTMtMS0xLTE2MTE4_9488abe7-cad7-4489-9a43-6d6475b47670"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzEzLTUtMS0xLTE2MTE4_b6f78d13-fad2-4ad5-a738-c17196f2c075"
      unitRef="usd">28638000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:OperatingExpenses
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTEtMS0xLTE2MTE4_2da6a766-8637-4545-8dbe-bc57602fce7d"
      unitRef="usd">87388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTMtMS0xLTE2MTE4_54a3a7a3-71e0-4fb2-9f01-b2e2201e1839"
      unitRef="usd">204380000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE0LTUtMS0xLTE2MTE4_63441f79-df49-4259-b2f9-8080acd4c9e0"
      unitRef="usd">180628000</us-gaap:OperatingExpenses>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTEtMS0xLTE2MTE4_271430eb-cb86-4f31-a9ac-cc981da8cfe1"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTMtMS0xLTE2MTE4_7d4513fc-a900-4fd8-941a-d151ea82bf0d"
      unitRef="usd">132585000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE2LTUtMS0xLTE2MTE4_c52826fa-fa11-4e18-9bee-936e9ab9eeb1"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTEtMS0xLTE2MTE4_38c2af13-155b-4cc5-ab43-c555baf7fac8"
      unitRef="usd">-87090000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTMtMS0xLTE2MTE4_511873c1-b668-46c1-9912-d6d1bf98f576"
      unitRef="usd">-47800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzE3LTUtMS0xLTE2MTE4_fbfffa43-f218-4520-aaf7-8bba18e6f790"
      unitRef="usd">141445000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTEtMS0xLTE2MTE4_13c59c50-c9fb-43ed-93f7-cdd3807b2e63"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTMtMS0xLTE2MTE4_4e7dca1f-d925-4070-97cb-e8ccfaa0c383"
      unitRef="usd">1003000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIwLTUtMS0xLTE2MTE4_5987cb2b-3413-444d-a24b-a32e7a4fe1ef"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTEtMS0xLTE2MTE4_dc54a5ed-553b-471d-8e72-5978b45c0e64"
      unitRef="usd">802000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTMtMS0xLTE2MTE4_bc20d21d-f65f-41c1-82fd-a37becf7db2c"
      unitRef="usd">14544000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIxLTUtMS0xLTE2MTE4_b3982542-6e3a-449d-8b00-ab47b66e61d0"
      unitRef="usd">20676000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTEtMS0xLTE2MTE4_cad78e47-0de3-43d2-91a7-55d4c685ff29"
      unitRef="usd">134000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTMtMS0xLTE2MTE4_d1e5d5d6-4e25-4287-ac27-ebf79813714d"
      unitRef="usd">2767000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIyLTUtMS0xLTE2MTE4_ab18fa68-f8ff-4520-a9c9-f6875ab53052"
      unitRef="usd">3350000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTEtMS0xLTE2MTE4_e3870f03-c798-4b0f-a51f-92dafb672e82"
      unitRef="usd">-87758000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTMtMS0xLTE2MTE4_8a33e541-a898-43b1-bc99-7316dda26f3d"
      unitRef="usd">-58574000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzIzLTUtMS0xLTE2MTE4_d024420f-3d65-4f07-b624-6261af632333"
      unitRef="usd">124119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTEtMS0xLTE2MTE4_c48293d5-7b17-4634-b19f-33babb5f4ade"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTMtMS0xLTE2MTE4_b7e74afc-2955-4aa5-8423-6ef53d857b20"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI0LTUtMS0xLTE2MTE4_8f5135e7-2983-475b-907b-6925f17becbc"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTEtMS0xLTE2MTE4_7a4efce4-0e68-45cf-882f-2e3741e650e3"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTMtMS0xLTE2MTE4_80440268-86e1-4297-bedc-87db9176b12a"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI1LTUtMS0xLTE2MTE4_9dfa7baa-259b-46de-9a4f-1625686afc70"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTEtMS0xLTE2MTE4_7f4c84b3-49f8-4111-9c14-d33a4eb4146f"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTMtMS0xLTE2MTE4_ac5fcade-4eb5-414c-8e1b-28fbe90aeb30"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI2LTUtMS0xLTE2MTE4_192fb07d-6d13-4706-9f62-48d734b40d61"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTEtMS0xLTE2MTE4_6e3385a4-c74d-443c-994d-848ae298e23e"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTMtMS0xLTE2MTE4_39366a6f-072e-4c17-8cef-5ffda06cd629"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI3LTUtMS0xLTE2MTE4_b7adfa0e-5cae-49bd-9eef-df10401bdd41"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTEtMS0xLTE2MTE4_b18a26e4-e3fb-4456-9b54-2cfde3c0cd56"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTMtMS0xLTE2MTE4_518dc7f1-a659-4321-8bc1-f9c678768c47"
      unitRef="shares">110841000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI4LTUtMS0xLTE2MTE4_f8946366-cfc0-48f9-a59e-e019dc646107"
      unitRef="shares">106218000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTEtMS0xLTE2MTE4_74e8602d-d11b-464e-9043-97973b05d1e0"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTMtMS0xLTE2MTE4_7c394243-cb59-403a-9fe3-c616daa10f48"
      unitRef="shares">110841000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzI5LTUtMS0xLTE2MTE4_684c5752-d6c9-471e-b399-f33f4502d5a6"
      unitRef="shares">116747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTEtMS0xLTE2MTE4_60294a62-0f74-4b9e-8b58-86a55215b320"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTMtMS0xLTE2MTE4_9b5d071f-a4a9-42f7-8fac-8edbc7646693"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMyLTUtMS0xLTE2MTE4_0975b854-f66b-489b-be7b-f4462ede542d"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTEtMS0xLTE2MTE4_42f13e7c-96b6-40bd-810d-43cc8eb0128f"
      unitRef="usd">-87762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTMtMS0xLTE2MTE4_50eda140-0601-430c-b743-0332a7481107"
      unitRef="usd">-58664000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzMvZnJhZzpiOWI1YzdhYTU1MmQ0ZGNhOTMzZDBmZGRjM2E5NjJmNi90YWJsZTo4ZDdjN2Y2YWU0YzI0OTFiOTJmNzhmMmRmOGM2NDA1OS90YWJsZXJhbmdlOjhkN2M3ZjZhZTRjMjQ5MWI5MmY3OGYyZGY4YzY0MDU5XzMzLTUtMS0xLTE2MTE4_395748fd-d1ef-41f1-9a0e-d9ff7a51c5cb"
      unitRef="usd">130229000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2de7ae68674e4d58a012b15b9e1f640d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTEtMS0xLTE2MTE4_5190f21e-cfc2-47e1-970a-7213db643b7b"
      unitRef="shares">106162000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2de7ae68674e4d58a012b15b9e1f640d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTMtMS0xLTE2MTE4_294f5c2a-66c1-4963-b36d-e1e9cd0d3959"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a484df8d34a48168ddc67636fee53d7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTUtMS0xLTE2MTE4_ca1b499a-ce78-4885-955c-5e34b859c41b"
      unitRef="usd">1447954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbc0d4d9dd1147749e2496817aad0133_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTctMS0xLTE2MTE4_4e8155d2-06e8-4446-bc16-55294c90146a"
      unitRef="usd">-1471577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieaf0e7cc645e4f69a6ece2184dc576cb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTktMS0xLTE2MTE4_3bf637c2-79e4-4938-9ca2-47d9fb407416"
      unitRef="usd">-12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica5229e5ba37471fb75d1796184d22b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTExLTEtMS0xNjExOA_9a85ce6d-36dd-417e-9eff-51fca414b727"
      unitRef="usd">-2876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE1LTEzLTEtMS0xNjExOA_b8167093-2f08-42e3-b179-cbfc38317a0c"
      unitRef="usd">-26405000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTMtMS0xLTE2MTE4_b6e6c682-a693-4cf8-b046-55b637c9059a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTUtMS0xLTE2MTE4_1fa5456c-2498-4d9c-b048-5e7d8746bd2e"
      unitRef="usd">14218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTctMS0xLTE2MTE4_dbbecec6-7f1c-43e9-b3c2-0dc3db0b93cb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTktMS0xLTE2MTE4_bfb9a268-fbdb-4e00-b4ab-5ddb87aeb0a2"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTExLTEtMS0xNjExOA_3bd1ffae-5c1b-409c-baf8-d69d80aa7013"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE3LTEzLTEtMS0xNjExOA_20ef6301-d888-42e7-9398-d9afee710ef3"
      unitRef="usd">14218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTEtMS0xLTE2MTE4_f31a8cb5-a892-4c68-8cdb-d9a019a513cd"
      unitRef="shares">517000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTMtMS0xLTE2MTE4_9437973f-7e90-4a14-bb1e-97fa33b94599"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTUtMS0xLTE2MTE4_954c449d-8e98-4c30-9c14-2c81029ef9ff"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTctMS0xLTE2MTE4_9b91fa2b-dc21-453b-957e-7e1c9884702a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTktMS0xLTE2MTE4_7457d3fe-b197-4c08-9041-00459560180c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTExLTEtMS0xNjExOA_92cd55b6-3325-4b77-bda5-a14e13247a8e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzE4LTEzLTEtMS0xNjExOA_eb9c1b23-71d8-4f70-a99c-b5cc0d3b63c6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTMtMS0xLTE2MTE4_830b32ec-19fd-42f2-80be-c73031e525c6"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTUtMS0xLTE2MTE4_3d59314b-53c8-4d72-9680-83ca391434d2"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTctMS0xLTE2MTE4_a643407e-341e-4ab5-aba0-8a9f1ed33a8b"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTktMS0xLTE2MTE4_4320c036-7083-4f80-9c2a-541916042177"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTExLTEtMS0xNjExOA_e2f6a7c0-f6d9-4faf-b9e3-50d887044cc0"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIxLTEzLTEtMS0xNjExOA_54d6714c-5e23-46af-8491-591a0669565d"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTMtMS0xLTE2MTE4_67f182f3-6b44-4bf3-aa08-483daa929584"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTUtMS0xLTE2MTE4_dabd8478-47d4-4024-883d-048f28ea09c3"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTctMS0xLTE2MTE4_ae6b98ec-c16d-4442-a97f-03da76e51716"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTktMS0xLTE2MTE4_1006c872-1cae-4a2b-bd9f-b0d32816e0b3"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTExLTEtMS0xNjExOA_d23b779c-4291-4412-8c38-b9c924d25213"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIyLTEzLTEtMS0xNjExOA_a55de9d9-0eef-4781-80e0-840eb44b5a45"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4cfff0250cda440eb58a3be729b0487e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTMtMS0xLTE2MTE4_2faf0068-8030-49c4-bd81-e479fcd20de4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibaddcab6e05e40779d737e9c248dbafd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTUtMS0xLTE2MTE4_d6802c14-6c35-42a3-8963-49cd5f1a1662"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id23ad27e304a4df3b48e42abf2d802d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTctMS0xLTE2MTE4_ff85284e-0f5f-4196-a81a-3fe95f5e290c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i57e136dfba7c416fb7caee4327047bd7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTktMS0xLTE2MTE4_ce4da4d9-3e0f-46e9-b673-3d42c39e3116"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib67a0154dda142aebb4cdafaa27e9016_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTExLTEtMS0xNjExOA_d9e2c30d-a35d-4b26-bacf-66be966de339"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzIzLTEzLTEtMS0xNjExOA_a4cf3aa2-64d2-41aa-913c-05b8ed7b5c5a"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i66d73276a9f54188a234d30a5c7db573_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTEtMS0xLTE2MTE4_446b390e-8ecf-4564-ba17-2e1e850520b0"
      unitRef="shares">106679000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66d73276a9f54188a234d30a5c7db573_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTMtMS0xLTE2MTE4_0a5a012a-f1ea-40a1-b3f1-db42a67bc7b8"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib61ea8ca87054ca299e35899d20f0821_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTUtMS0xLTE2MTE4_f0c510a8-7512-44e5-ac3f-1bca34d2620c"
      unitRef="usd">1462172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f0c660c256a4099bc5d00a590fa3ae2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTctMS0xLTE2MTE4_4f6db1a9-b245-420c-a35b-c94e430f9203"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51590a994bf24c4ca00c39f49378fafb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTktMS0xLTE2MTE4_a00a423e-9956-4fe3-a61c-19e88b3215d0"
      unitRef="usd">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i479d65c47ea34ef3a9d80c56a9fa552a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTExLTEtMS0xNjExOA_b453a294-c6ac-413a-8b30-f7f7bd15a952"
      unitRef="usd">-3817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI1LTEzLTEtMS0xNjExOA_1646448d-3747-4780-9fab-f7c82acfd706"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTMtMS0xLTE2MTE4_4d4c5a7d-d7cd-4f03-84cf-aae21c2a4dbc"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTUtMS0xLTE2MTE4_d432e8e1-4a12-4431-88b4-89691d267873"
      unitRef="usd">13274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTctMS0xLTE2MTE4_5cafdeaf-025b-4c83-bba9-07065dd15fd1"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTktMS0xLTE2MTE4_9cf66b21-68b0-4fbc-9029-d2ee90d1d522"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTExLTEtMS0xNjExOA_9a7bda48-0acb-4b69-abf5-d0be01405738"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI3LTEzLTEtMS0xNjExOA_ebc876ee-cae6-4a1b-9dab-f1ddfebd2fae"
      unitRef="usd">13274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTEtMS0xLTE2MTE4_6ea4ba8d-6d32-4c06-99a9-10b737f5c4ac"
      unitRef="shares">3709000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTMtMS0xLTE2MTE4_6bf10d08-7afe-4d9f-92a9-7da71ffbdcd2"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTUtMS0xLTE2MTE4_b83c9dd3-425f-4a81-ac3a-2facf797c95d"
      unitRef="usd">6959000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTctMS0xLTE2MTE4_66685a54-2bb1-4518-9791-1b396f912f38"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTktMS0xLTE2MTE4_c6276273-8deb-40af-86a1-9f4cdb50bfdb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTExLTEtMS0xNjExOA_33436e2d-731b-4d05-8d67-45129d4b0d44"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzI5LTEzLTEtMS0xNjExOA_f6f3a1e2-dcca-4d5f-8f29-3d90efbea6ae"
      unitRef="usd">6963000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTEtMS0xLTE2MTE4_b1874e78-099c-4cc6-a5f6-bae6ea29f93e"
      unitRef="shares">20313000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTMtMS0xLTE2MTE4_9f121973-2e19-47bb-8dd2-1261ef8fb446"
      unitRef="usd">20000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTUtMS0xLTE2MTE4_ecbf3ff2-a298-47f2-9e05-27bf4b45f702"
      unitRef="usd">62987000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTctMS0xLTE2MTE4_e78ad863-d120-4309-a463-9034328813b6"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTktMS0xLTE2MTE4_3efaa7fe-129f-4e18-85db-24b098e3977c"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTExLTEtMS0xNjExOA_5aaf5ea5-1143-47cb-b5a5-46c9237d82be"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMwLTEzLTEtMS0xNjExOA_fa19190a-eda0-4e98-a09a-0f032ab2c8a7"
      unitRef="usd">63007000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTEtMS0xLTE2MTE4_0505c133-4893-4736-958c-4e4d6a11f05a"
      unitRef="shares">10369000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTMtMS0xLTE2MTE4_70921dd0-c013-4943-93a4-d1daf720454e"
      unitRef="usd">10000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTUtMS0xLTE2MTE4_dfef7f71-d9a0-465d-adeb-673905c57f40"
      unitRef="usd">15704000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTctMS0xLTE2MTE4_31bcd661-5582-4c46-b278-76b48cd33a59"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTktMS0xLTE2MTE4_8d221337-9948-4aff-b460-a25301caf2ce"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTExLTEtMS0xNjExOA_c5c1faa8-3524-4e1e-8eea-16cf50cc09e0"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMxLTEzLTEtMS0xNjExOA_58ad855f-1aa4-4a50-a888-5565a7b14307"
      unitRef="usd">15714000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTEtMS0xLTE2MTE4_16300af9-f86a-4884-ac7f-5f8f3a3df8ae"
      unitRef="shares">1219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTMtMS0xLTE2MTE4_6fc5fe99-a6cb-456e-bd13-cc603d31e326"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTUtMS0xLTE2MTE4_da45919d-1483-4c61-b551-e9a3bd45b49e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTctMS0xLTE2MTE4_030e92cf-1089-46cf-8850-9f34d6a6ad74"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTktMS0xLTE2MTE4_b354a6dd-3e2f-4902-8dc8-673925474d12"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTExLTEtMS0xNjExOA_95df793a-6b34-441c-8a8f-e105b6b60780"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzMyLTEzLTEtMS0xNjExOA_d8202520-e662-47d2-b10f-302cc6219ca9"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTMtMS0xLTE2MTE4_cd26d683-deac-4fe0-b326-a6459a149e8c"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTUtMS0xLTE2MTE4_a1b8a2e3-0ac0-447b-bec5-877e9f002f47"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTctMS0xLTE2MTE4_b36334d8-fc8c-40e4-9242-d1e0c2cedbc0"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTktMS0xLTE2MTE4_0ea023d2-4ce0-48bb-a4cf-b5364056a840"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTExLTEtMS0xNjExOA_25a21c0f-8291-46f9-984c-b4fc1abbd753"
      unitRef="usd">1026000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM1LTEzLTEtMS0xNjExOA_e0e08fcd-d43c-46a3-b4c3-38b083f7dd8a"
      unitRef="usd">1026000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTMtMS0xLTE2MTE4_208fba54-e4bd-43af-8de3-a55f32f78dc4"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTUtMS0xLTE2MTE4_115c5018-80be-4c7f-9554-f6b93f154bf6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTctMS0xLTE2MTE4_5cecafac-16c8-4ae4-9e43-d123bf758572"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTktMS0xLTE2MTE4_88790731-80b2-4829-9846-c3b76857aa93"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTExLTEtMS0xNjExOA_2e8fadf1-3cc7-4b27-877c-daf0ce037dd6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM2LTEzLTEtMS0xNjExOA_e8f0f911-4d97-4841-87e1-228789b8ff6a"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibf9c7b10493a400fb424f79354ab6d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTMtMS0xLTE2MTE4_742fbdf2-1d2f-4eb8-b7e3-4abfc62586ab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id62e4b39721d47a18227ec951181b233_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTUtMS0xLTE2MTE4_af2af1a7-f0fe-4aa0-a49f-6ff32120f4f3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1ed3799f237461bbd23f465e8e3cbff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTctMS0xLTE2MTE4_ecdc65c0-1cbf-4a21-9e47-96cb262dd7e3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if9b2c8dec0a54f4b85bdcd965ce66cba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTktMS0xLTE2MTE4_92c9e6f1-6348-49c3-9707-67127e77a189"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia08505a35eae444e85dce6b20fd10ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTExLTEtMS0xNjExOA_edad7746-727c-4310-a01f-14420f8b5165"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM3LTEzLTEtMS0xNjExOA_829643ba-a686-4e3a-8b61-bf4964ba35e9"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTEtMS0xLTE2MTE4_256bcf24-6774-4d7e-917e-7f02a18490d4"
      unitRef="shares">142289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iba61095c2ba147c9b7bf78d9d5f7f77c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTMtMS0xLTE2MTE4_6a83616d-3b05-4e9f-aafb-c46a371ca80a"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6a8eb0c931e47bb8781df60680b3b5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTUtMS0xLTE2MTE4_a25b9aef-e66d-489f-95a5-350e8a14a702"
      unitRef="usd">1561096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66152bef9ef94ee28758450b0c7d3bf1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTctMS0xLTE2MTE4_536b34ce-9321-49cf-b889-4f24e1d61d36"
      unitRef="usd">-1400018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f855dd7993f49eeb1b627eb46715eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTktMS0xLTE2MTE4_2f096e11-720e-4f7d-b5cd-6a4662145699"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d0ad57c0c334f0386685e094334b434_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTExLTEtMS0xNjExOA_78801ac4-bf0e-4b8b-8ebb-a324e59e0818"
      unitRef="usd">-4843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzM5LTEzLTEtMS0xNjExOA_dfaa84ce-81fa-402d-9fd4-b3762a087669"
      unitRef="usd">156371000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTMtMS0xLTE5MDUw_8d7b1c55-bbde-46bd-a29e-b68842833c23"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTUtMS0xLTE5MDUw_c74830fb-c28a-48d2-8244-bb9efaf01bab"
      unitRef="usd">10577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTctMS0xLTE5MDUw_a86abbb3-9c18-4572-9a62-6cde1de61d9e"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTktMS0xLTE5MDUw_d0cd42f0-be17-45d3-9d59-425a1e4b93b2"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTExLTEtMS0xOTA1MA_4c670775-5b34-4db1-9cd6-6e6a26965e1c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQwLTEzLTEtMS0xOTA1MA_6ddc4a60-126f-4c49-a667-a24845278271"
      unitRef="usd">10577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTEtMS0xLTE5MDU3_d606e76c-0b35-483c-8cc5-6d460ae30e04"
      unitRef="shares">6177000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTMtMS0xLTE5MDU3_40e2addb-3fad-46f8-9b3a-b42cddc4e8ad"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTUtMS0xLTE5MDU3_57eb6c7d-f989-47c0-ae0c-2c7bc9331548"
      unitRef="usd">35485000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTctMS0xLTE5MDU3_dd6bc366-0129-4726-9e85-d9b4f6bcf72e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTktMS0xLTE5MDU3_88b548aa-1901-47bf-bc82-72c808ffb587"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTExLTEtMS0xOTA1Nw_59b4659f-7917-49f5-8399-c0379449d93c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQxLTEzLTEtMS0xOTA1Nw_06d0bbc7-f979-4c52-acc6-467aa9c9313d"
      unitRef="usd">35491000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTEtMS0xLTE5MDY0_2e08d2db-ff89-4c48-a366-1cfa0f1d3207"
      unitRef="shares">1616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTMtMS0xLTE5MDY0_e094670f-27e2-41b9-8a8f-73f781efcd19"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTUtMS0xLTE5MDY0_b78d3935-3896-4f62-8a78-f865252f327f"
      unitRef="usd">1591000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTctMS0xLTE5MDY0_e4aaa1f7-86c0-45d3-ba4d-853a6f683962"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTktMS0xLTE5MDY0_9b5d918c-0c9a-438f-b6ea-077f4af357e1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTExLTEtMS0xOTA2NA_c1d8d95b-5a30-4e50-baf0-4499fd929b81"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQzLTEzLTEtMS0xOTA2NA_14e09df1-0486-4d25-a862-42a1eb4453d1"
      unitRef="usd">1593000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTMtMS0xLTE5MDcz_47cede46-2746-4e8c-bdfd-eff191a10cb9"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTUtMS0xLTE5MDcz_3b346a25-4f2f-4de6-99f7-2f5784a80fbf"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTctMS0xLTE5MDcz_e3cffe5a-4db6-44ba-a7b5-1c7f06394028"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTktMS0xLTE5MDcz_60328f4f-9f45-4fc7-bac4-7124777920e4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTExLTEtMS0xOTA3Mw_949ef857-1ac6-463f-911a-6d54446e8b06"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ0LTEzLTEtMS0xOTA3Mw_3009ae82-5547-477c-abbc-1b7275db9bf7"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTMtMS0xLTE5MDgw_95d77d86-ae77-4320-8b58-090fb0860051"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTUtMS0xLTE5MDgw_02289914-c881-47ec-b847-1587e20701dd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTctMS0xLTE5MDgw_636e50ec-86d5-4a65-901f-88d3ce74c8ff"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTktMS0xLTE5MDgw_28c1357f-efca-4972-b5e4-60adf08df158"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTExLTEtMS0xOTA4MA_e0c7af6d-d681-4bf2-a35c-560822ca9b6a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ1LTEzLTEtMS0xOTA4MA_4cdc0687-ac1a-4866-ab29-69b72372d0a5"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifdb78b879b1247648386171510533efd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTMtMS0xLTE5MDg4_006f932b-9041-4cd7-bf4d-7879bd23872b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaaf17d1d6a9845fead5f8dc3bfa0b2b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTUtMS0xLTE5MDg4_ac8aacf2-4c3b-4e8b-8b27-c007acafa1fb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i15da4c00733e4662ae695e4c07bded8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTctMS0xLTE5MDg4_e4caf7c0-d1a5-47bf-a568-138bc7030b68"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic759629006f74192a60c2905a8f645ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTktMS0xLTE5MDg4_18894acf-fe39-422e-8283-03f778b1fa3c"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9fdc50edeb4a4764b9bc650aa881919c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTExLTEtMS0xOTA4OA_7c08799b-8409-49c6-99b2-7257a3316d97"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ2LTEzLTEtMS0xOTA4OA_e521094a-ef3f-430d-a56f-f765bbab9d1d"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTEtMS0xLTE5MDk1_b01c043d-aa01-477b-b5f9-ab9d1dbeff2e"
      unitRef="shares">150082000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i75536cf4a4174691b204bb1a118bb561_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTMtMS0xLTE5MDk1_45a46b44-933d-4ac5-8df6-086c05fcd782"
      unitRef="usd">150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if92be0a5177c4f85879df29eafff809c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTUtMS0xLTE5MDk1_d47c53f5-2325-4028-b0f1-ae242d7857ca"
      unitRef="usd">1608749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i729d06e13a06473b9ca5a295173d860e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTctMS0xLTE5MDk1_e2be38eb-37a3-46a0-89f1-65033a8d4508"
      unitRef="usd">-1487776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80201290325143af97f2fb030d3e10d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTktMS0xLTE5MDk1_0890c248-8044-4363-9d2f-c95f9e6485a3"
      unitRef="usd">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a188a482da64a818cb53605d5b01571_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTExLTEtMS0xOTA5NQ_d64b870c-a161-48f8-9c49-88bc929e0ab0"
      unitRef="usd">-7518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzYvZnJhZzplOTQ3OGE5OTg0ZjU0NWQyOGRlODg4OWNmOTVkNzdjOC90YWJsZTpiMzIwYzVlYWJkNGM0Nzc0OWVhOGQ0NDFhNjQzMGM5OS90YWJsZXJhbmdlOmIzMjBjNWVhYmQ0YzQ3NzQ5ZWE4ZDQ0MWE2NDMwYzk5XzQ3LTEzLTEtMS0xOTA5NQ_72ff0faa-f258-4e33-aa49-183da6b50be7"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMS0xLTEtMTkxMzQ_90752ca5-21c5-4b1a-a9bc-b76973e9e9d6"
      unitRef="usd">-87758000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMS0xLTEtMTYxMTg_4bb9fa18-ffcf-4213-8c95-4175d9a7cc93"
      unitRef="usd">-58574000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMtMy0xLTEtMTYxMTg_30985afe-805a-467c-8a6d-11a1135e5eb8"
      unitRef="usd">130133000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMS0xLTEtMTkxMzQ_0a52d1ab-8505-4da5-b5ec-7e6207f82aac"
      unitRef="usd">292000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMS0xLTEtMTYxMTg_7b82165c-8a1a-4b34-b955-fdaafb766d3f"
      unitRef="usd">2934000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzUtMy0xLTEtMTYxMTg_3aeb11cc-c078-40b5-a378-e42d89b5163e"
      unitRef="usd">3654000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMS0xLTEtMTkxMzQ_a69d4516-8c46-4a52-bec7-be9f70a6b6c3"
      unitRef="usd">10577000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMS0xLTEtMTYxMTg_686ccac9-82cc-4a41-ab1a-d1c227270e24"
      unitRef="usd">13274000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzYtMy0xLTEtMTYxMTg_88489802-1829-4609-9251-35fbb3eaacc4"
      unitRef="usd">14218000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMS0xLTEtMTkxMzQ_ab22dc64-6321-4802-840b-7e5abb2a2c32"
      unitRef="usd">54000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMS0xLTEtMTYxMTg_019f1ea1-c825-4a56-a5e8-9f5a97395fa4"
      unitRef="usd">1013000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzctMy0xLTEtMTYxMTg_6d7801be-38aa-404d-a6a6-0b731c59cd14"
      unitRef="usd">1465000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMS0xLTEtMTkxNDc_beffba23-098c-4b0d-b278-ace863a7e034"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMS0xLTEtMTYxMTg_87f00bd1-0ec4-472d-b740-bdeacaa3335a"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzgtMy0xLTEtMTYxMTg_989ba7bf-be68-4232-b9e9-e588ae2c590f"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMS0xLTEtMTkxNDc_172d1586-8827-45ea-a623-1bd2f5b148fa"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMS0xLTEtMTYxMTg_0b6f46e4-7ebc-4200-83b1-eb3d159d07e8"
      unitRef="usd">132585000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzktMy0xLTEtMTYxMTg_d1148e41-c509-451f-b53c-5dee01624a7f"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTEtMS0xLTE5MTQ3_2f81fa75-7582-4c6b-893a-f06e6168d901"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTEtMS0xLTE2MTE4_55434dcc-7b8d-4d91-8b3b-1fe3c33b96f1"
      unitRef="usd">1600000</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEwLTMtMS0xLTE2MTE4_30bd1e42-b0f7-42c3-b3f3-3d39bb614198"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTEtMS0xLTE5MTQ3_1d86e222-7be1-447b-9be9-43616f5918ef"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTEtMS0xLTE2MTE4_03f8f882-d86e-4419-9aad-d43dde8ef661"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzExLTMtMS0xLTE2MTE4_b416e082-ac00-4c68-b0da-41d09280bd6f"
      unitRef="usd">28638000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTEtMS0xLTE5MTQ3_64b3b158-f734-4ac4-aa73-208f0faaff4d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTEtMS0xLTE2MTE4_1acd4ff7-fbae-4ac5-901d-6b0162d1e93a"
      unitRef="usd">1003000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzEzLTMtMS0xLTE2MTE4_d1401819-8bb8-489b-b9c7-68479aa577a8"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTEtMS0xLTE5MTQ3_b16e2958-b2e6-490d-98a5-e48820fe155c"
      unitRef="usd">-49000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTEtMS0xLTE2MTE4_4127c397-fe67-4455-9758-2f8b6998ff24"
      unitRef="usd">707000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE0LTMtMS0xLTE2MTE4_7f09026b-1238-4f24-9da5-b303fa3a61c8"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTEtMS0xLTE5MTQ3_9a1c8bf0-f64b-4549-b8d3-df90df91e9db"
      unitRef="usd">-381000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTEtMS0xLTE2MTE4_204b6abb-a8cf-4153-bfcf-ecffe80ed2f7"
      unitRef="usd">-53227000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE2LTMtMS0xLTE2MTE4_2b26518d-94a2-4ffa-bd16-04083908c9ad"
      unitRef="usd">50608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTEtMS0xLTE5MTQ3_bc933a7b-1b8e-422a-af7e-296e517c5089"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTEtMS0xLTE2MTE4_415db859-40df-47ee-bd00-e9b0eb7e88fb"
      unitRef="usd">-345000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE3LTMtMS0xLTE2MTE4_5a7612cc-3232-40fe-92ee-14f02a0370c8"
      unitRef="usd">-437000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTEtMS0xLTE5MTQ3_c3665552-1eae-4865-97dc-9ef843c2f037"
      unitRef="usd">-2885000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTEtMS0xLTE2MTE4_116e251b-d3ed-40d7-bcee-c863c88c9dec"
      unitRef="usd">1948000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE4LTMtMS0xLTE2MTE4_6329c70a-a9a9-4374-88ab-6161857180ac"
      unitRef="usd">2652000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTEtMS0xLTE5MTQ3_1b78e278-d1b8-490e-a432-b0c88853ccf8"
      unitRef="usd">-661000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTEtMS0xLTE2MTE4_04c8d130-8453-4a3d-aeeb-fb109f52fcb0"
      unitRef="usd">-424000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzE5LTMtMS0xLTE2MTE4_eeadcc07-1df4-416a-811f-e6ba8cbee766"
      unitRef="usd">-429000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTEtMS0xLTE5MTQ3_3c862721-ab78-4e91-b3fc-0613c228ff80"
      unitRef="usd">-14158000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTEtMS0xLTE2MTE4_ef6d472d-0f02-4edc-bd38-c344ff5f0a96"
      unitRef="usd">-20969000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIwLTMtMS0xLTE2MTE4_9a31f6cb-37ec-4669-8bf2-c5c6020459bf"
      unitRef="usd">20097000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTEtMS0xLTE5MTQ3_a1aa4f16-b55e-456b-99b2-67a3c947ad92"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTEtMS0xLTE2MTE4_d0e12c13-dee1-44b3-8897-ed8f31724d73"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIxLTMtMS0xLTE2MTE4_30165b23-e163-43ef-980a-05ae4e3b45a6"
      unitRef="usd">-25990000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTEtMS0xLTE5MTU0_bfd7c646-dc81-4590-941d-83db9e0a5fb6"
      unitRef="usd">-87017000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTEtMS0xLTE2MTE4_91c2028d-ede5-40bd-be5b-172b49db2a3b"
      unitRef="usd">-142969000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzIyLTMtMS0xLTE2MTE4_e7a163d8-dd59-4eda-86e0-adc99604fb02"
      unitRef="usd">113807000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTEtMS0xLTE5MTU0_57b9bf6e-32f7-4719-ab16-91035d82b9fd"
      unitRef="usd">1221000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTEtMS0xLTE2MTE4_4ff9beb9-bdbc-47a2-8dca-a0404f5a66d9"
      unitRef="usd">87000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI0LTMtMS0xLTE2MTE4_a05d13e4-416c-4405-bef7-b3e85a05f5fa"
      unitRef="usd">70000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTEtMS0xLTE5MTU0_5e5759bc-e30c-4594-986b-667c5ac5bebe"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTEtMS0xLTE2MTE4_c03cb9df-7410-4542-85df-e15d22de7e4f"
      unitRef="usd">160385000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI1LTMtMS0xLTE2MTE4_42f9062d-5596-4309-b64b-1d1674b6f43d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTEtMS0xLTE5MTU0_699a57cd-d139-465c-bd59-a5537ff84ead"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTEtMS0xLTE2MTE4_1e77fde9-833e-4aea-949f-cbbdf0366890"
      unitRef="usd">11013000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI2LTMtMS0xLTE2MTE4_8d18992a-1721-4d97-bb17-02552bd19e59"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTEtMS0xLTE5MTU0_34bb79cd-7dd5-459c-90db-514a614e0ea7"
      unitRef="usd">34261000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTEtMS0xLTE2MTE4_6c121c07-d091-4ab5-9437-9314ac088e86"
      unitRef="usd">58555000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI3LTMtMS0xLTE2MTE4_a12a8234-7962-496d-b0af-47e8e3b48aa5"
      unitRef="usd">322385000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTEtMS0xLTE5MTU0_2e5c2564-a133-4313-86bf-47d864f579dd"
      unitRef="usd">37592000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTEtMS0xLTE2MTE4_e71aa107-b861-4fb2-bc05-d4933cd1ebcc"
      unitRef="usd">268000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI4LTMtMS0xLTE2MTE4_9746bc48-e3a4-4c33-99ee-32559248a3c3"
      unitRef="usd">166600000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTEtMS0xLTE5MTU0_e300aa4b-d29b-4bbc-8a83-2cde2465f85b"
      unitRef="usd">2110000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTEtMS0xLTE2MTE4_8d96bf37-cf50-4284-b98e-51faffc99eec"
      unitRef="usd">380756000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzI5LTMtMS0xLTE2MTE4_f95f266d-2a19-4fd0-b943-b7347c8aab82"
      unitRef="usd">-155855000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTEtMS0xLTE5MTYx_27aea6de-3e9a-41a2-bae0-042cd9881ff2"
      unitRef="usd">37084000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTEtMS0xLTE2MTE4_bb022cd4-1942-4a1e-a499-d1bb3682b54f"
      unitRef="usd">69970000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMxLTMtMS0xLTE2MTE4_e26991b8-6a1d-4c5e-9fa4-bd87d9971afe"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTEtMS0xLTE5MTYx_072aa611-564a-4174-bcca-1e44cb046cf9"
      unitRef="usd">2675000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTEtMS0xLTE2MTE4_669ad34f-00e7-4cc6-9ebf-2c34df74a445"
      unitRef="usd">1026000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzMyLTMtMS0xLTE2MTE4_403988f1-4a02-4918-97e2-e2aca9678d38"
      unitRef="usd">941000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTEtMS0xLTE5MTYx_8a6134be-a5e7-42e9-bfa5-b4b079b6c4e4"
      unitRef="usd">11700000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTEtMS0xLTE2MTE4_41ddae49-2487-4f8a-b3f3-864db885c2a8"
      unitRef="usd">216580000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM0LTMtMS0xLTE2MTE4_7856f7a3-878b-4390-9f82-20307502aa47"
      unitRef="usd">1285000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTEtMS0xLTE5MTYx_d4a684c4-9ff8-42ef-a18d-ea64f3e37fd4"
      unitRef="usd">22709000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTEtMS0xLTE2MTE4_79d18aa6-6ce8-4361-a15d-83a3e34e18bd"
      unitRef="usd">-147636000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM2LTMtMS0xLTE2MTE4_2c5e82d1-0c98-47c1-87e0-d49a13fe830d"
      unitRef="usd">-2226000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTEtMS0xLTE5MTYx_e6219749-e23f-4f99-a8b4-c93c42518b0c"
      unitRef="usd">-62198000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTEtMS0xLTE2MTE4_c74f558f-7980-4fc7-a010-4b7eb1642980"
      unitRef="usd">90151000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM3LTMtMS0xLTE2MTE4_74292659-2abb-4130-bebb-6fb4af8c54ac"
      unitRef="usd">-44274000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTEtMS0xLTE5MTYx_5e60b9db-53c4-4bab-9379-1cb529efc9ee"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTEtMS0xLTE2MTE4_af6305e4-0020-477e-b762-ea3c02e64467"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic2c996fcb03a4ebd82c203bbc643ca20_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM4LTMtMS0xLTE2MTE4_3ae823a0-0a8c-428c-8200-962f6c7e5178"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTEtMS0xLTE5MTYx_4d0e2653-a429-4eea-a64f-8380f9c5a095"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTEtMS0xLTE2MTE4_c2442a0d-9e41-4a16-85b6-f86ae978285e"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzM5LTMtMS0xLTE2MTE4_0705c732-f94e-410a-97a8-43ae3c7dcc74"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTEtMS0xLTE5MTY4_d16b8446-97e0-4a63-9959-11091a519e3c"
      unitRef="usd">799000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTEtMS0xLTE2MTE4_3de75c50-be02-49d1-8a0e-0891bd2d93b2"
      unitRef="usd">17353000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQyLTMtMS0xLTE2MTE4_f65b3577-c0ee-41d2-a175-a6e804f1b3f1"
      unitRef="usd">19211000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE5MTg1_a688761e-8fae-49b6-bf32-0a6c2770d0e5"
      unitRef="usd">1704000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTMtMS0xLTE5MTky_d3d685a1-d31c-46b9-b7d5-59c68958be1b"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTUtMS0xLTE5MTk1_95e41980-4831-43b0-9c54-5dd99d658e5a"
      unitRef="usd">1799000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE5MTc1_0f47a5b2-b052-43e8-aac2-6eeb7f3d7674"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTEtMS0xLTE2MTE4_fecb7d0e-33d2-4364-916a-47901875f0d7"
      unitRef="usd">3437000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib658c65a014d4e83b3f212fa1f301a87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ4LTMtMS0xLTE2MTE4_5f1ec211-d24c-4216-8583-ba07b5bfa00c"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTEtMS0xLTE5MTc1_f91adc96-6cf1-45e6-8b53-049870553aaf"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTEtMS0xLTE2MTE4_d0eecfc4-1d07-4f52-917a-ef71a18cbafd"
      unitRef="usd">15714000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xMzkvZnJhZzo1ZGI2YTUzNjZkODI0YjY0OTljYzQwMmQ1NGRlODNmMC90YWJsZTo1MDhiY2E4MTI5Nzg0YzhjYjgxNGY0MWI2M2FkMjNhMy90YWJsZXJhbmdlOjUwOGJjYTgxMjk3ODRjOGNiODE0ZjQxYjYzYWQyM2EzXzQ5LTMtMS0xLTE2MTE4_f8bc977d-f480-4692-86d9-a0348b4c09eb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDUvZnJhZzowYWJjNDc0YmE3MTA0Zjg1YTRlM2ZkZjU1NjgyMzVhMy90ZXh0cmVnaW9uOjBhYmM0NzRiYTcxMDRmODVhNGUzZmRmNTU2ODIzNWEzXzE4ODA_faa8c833-2376-419c-afb8-b3a06bf6d94b">Organization and Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#x2019;s future success is dependent upon many factors, including, but not limited to, the success of its ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk3_924b7e55-3f47-433b-b670-32ec509333c8">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2021, short-term investments consist of U.S. treasury bills and corporate debt securities. As of December&#160;31, 2020, short-term investments consist of corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160; In 2021, customers in Switzerland and the United States represented 76% and 24% of revenue, respectively.&#160;In 2020, customers in the United States represented 98% of revenue.  In 2019, customers in Germany and the United States represented 89% and 10% of revenues, respectively. &#160;&#160;At December&#160;31, 2021, management believes that the Company has no significant concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information and Significant Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2021, AC Bioscience Ltd. represented 76% of revenues and Taconic Farms, Inc. represented 24% of revenues, respectively.  In 2020, two specialty pharmacies, Biologics, Inc. and Diplomat Pharmacy, represented 65% and 22% of revenues, respectively.  In 2019, Sanofi represented 89% of revenues and no individual XERMELO customer represented more than 10% of revenues.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, including finite-lived intangible assets, in 2021 or 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than the Company&#x2019;s carrying amount, the Company calculates the asset&#x2019;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  In 2019, Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 14) and Lexicon&#x2019;s resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;amp;D in 2019.  The impairment reduced the remaining book value to zero. There was no impairment of indefinite lived intangible assets in 2020 or 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill Impairment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2021, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#x201c;TerSera&#x201d;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#x2019;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer Credits:  The Company&#x2019;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2021, stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $15.9 million, which is expected to be recognized over a weighted-average period of 1.2&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2021, 2020 and 2019, respectively:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2021, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2021 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2021 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $326.6&#160;million at December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Income (Loss) per Common Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDg1_90b61e70-aeb4-46d2-9a70-2cecbdb53611">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDc0_e41766cc-d8c1-46e8-af85-0a6ee3a6ae00">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDMy_2250c08e-0828-469d-9f21-a5cd29d48777">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2021, short-term investments consist of U.S. treasury bills and corporate debt securities. As of December&#160;31, 2020, short-term investments consist of corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTE5_b7769331-aea7-453d-835f-60e23c3f6a18">Accounts Receivable:&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTEy_2ec7a70a-abd1-4afe-aeea-81b6026d5a88">Concentration of Credit Risk: Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE0MjQ_12d9b9fe-4f39-42d0-bbb0-5d8c766f44a4"
      unitRef="number">0.76</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODEwOTE_c95e7792-c9fb-41c2-b603-7e856c16bdae"
      unitRef="number">0.24</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5MDg_8b37f8e7-6804-4479-aa04-90b52f9c6bbd"
      unitRef="number">0.98</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5ODY_f8d0ddc0-96f1-467f-9931-ddfcf2cf334c"
      unitRef="number">0.89</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI5OTM_0fd17b2a-dd4a-47fd-9ab9-4394466e1f92"
      unitRef="number">0.10</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDY2_4853eee4-95ca-497a-a46c-885988d06808">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information and Significant Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations &lt;/span&gt;for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzMyNzQ_c30d1b5e-7be7-473a-945c-b71a2779c842"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <lxrx:LXRXBiologicscustomerconcentration
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODEyOTE_f541d0a7-4bd0-462e-8088-2a60d7ac49ea"
      unitRef="number">0.76</lxrx:LXRXBiologicscustomerconcentration>
    <lxrx:LXRXDiplomatcustomerconcentration
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1MTk_821d5e16-8282-4a62-9e0c-c237e1afb839"
      unitRef="number">0.24</lxrx:LXRXDiplomatcustomerconcentration>
    <lxrx:LXRXBiologicscustomerconcentration
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM4ODY_68464451-9ac5-4d86-8b76-ce529cb8682d"
      unitRef="number">0.65</lxrx:LXRXBiologicscustomerconcentration>
    <lxrx:LXRXDiplomatcustomerconcentration
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM4OTM_1823dd47-0dbb-4aa5-b168-ed885ad5c38c"
      unitRef="number">0.22</lxrx:LXRXDiplomatcustomerconcentration>
    <lxrx:EntityWideRevenueSanofiPercentage
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzM5NDY_2b1810f5-7734-4157-9aa5-272fdae115e3"
      unitRef="number">0.89</lxrx:EntityWideRevenueSanofiPercentage>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDIw_9cc71fd0-86e5-4957-9412-cdfc9f5e29e4">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwNzU_78c30209-91dd-4d59-b89c-77875cfa96d0"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzUwODE_7bfb2d09-6fc7-497e-a508-738598501276">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzMtMi0xLTEtMTYxMTg_1f7f51be-53d5-4907-9984-ba346b8d0c54"
      unitRef="usd">3669000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzMtNC0xLTEtMTYxMTg_fbd404ac-3837-4c0d-9613-78931dd9793f"
      unitRef="usd">21962000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzQtMi0xLTEtMTYxMTg_7007bcb6-4e87-4e2a-bb5a-08d7362155e8"
      unitRef="usd">5711000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzQtNC0xLTEtMTYxMTg_1864a2ed-4930-42e0-a1a8-7fe9cc5a9626"
      unitRef="usd">6200000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzUtMi0xLTEtMTYxMTg_df27b334-2838-4e46-9f10-37148c99e981"
      unitRef="usd">1089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzUtNC0xLTEtMTYxMTg_3c3e2e83-eb26-4397-89ac-ce3f14b438e6"
      unitRef="usd">553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzYtMi0xLTEtMTYxMTg_2ff1551a-1006-4ef4-bd60-8366ad0a6ffc"
      unitRef="usd">2503000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzYtNC0xLTEtMTYxMTg_8aca2fab-4bd8-4208-9b14-288eae81af3f"
      unitRef="usd">976000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzctMi0xLTEtMTYxMTg_832bdd4c-2755-4cad-9afa-182e67de2705"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0MDg1NjgzMGRiNzM0N2U3OTY1MGM1NTg5OTdhMzQ2ZC90YWJsZXJhbmdlOjQwODU2ODMwZGI3MzQ3ZTc5NjUwYzU1ODk5N2EzNDZkXzctNC0xLTEtMTYxMTg_f1badf60-8d37-4141-9e45-76939b41e33a"
      unitRef="usd">29691000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk1_21d2d1f6-ad11-47c0-99a8-185871489639">Impairment of Long-Lived Assets:&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, including finite-lived intangible assets, in 2021 or 2019.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1MzY_4089f9be-10ee-43ee-9d05-0e304e7882e8"
      unitRef="usd">1600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzYzNzE_1c9d9718-56fa-41f5-8e24-a41d0d96cecc"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzYzNzE_ce299a56-b4b3-4975-ab71-d7d529bd0ccb"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDg5_3690ee93-3e83-4549-ad98-96ec95476d2e">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than the Company&#x2019;s carrying amount, the Company calculates the asset&#x2019;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  In 2019, Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 14) and Lexicon&#x2019;s resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;amp;D in 2019.  The impairment reduced the remaining book value to zero. There was no impairment of indefinite lived intangible assets in 2020 or 2021.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIxOTkwMjMyODE1NjI_5d1b9d49-c110-4de4-83da-2b6086de00bb"
      unitRef="usd">28600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDQ2_9f486704-8c59-4a18-8dcb-8faabfb76178">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDk4_0bfc5a5b-9dc9-4c1d-a65c-1ac79ecf147c">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#x201c;TerSera&#x201d;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#x2019;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer Credits:  The Company&#x2019;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTI1_5b787ebf-9a56-43c7-8cef-eb1df71ae521">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzE3MjYz_8c4368b8-12dc-401a-a655-3eccc9248955">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDUx_016cd7f7-f636-4e73-8141-b46571e176c6">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that conducted and managed the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDQw_8747d048-2214-46aa-a7b0-18f9868a1b8a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2021, stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $15.9 million, which is expected to be recognized over a weighted-average period of 1.2&#160;years.&lt;/span&gt;&#160;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzE5OTYx_6fbb9411-ff75-4a86-bd55-d7beef6fd55f"
      unitRef="usd">15900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIwMDM0_ca46a72a-f429-45bc-adb2-9f9dc5e0a2f1">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTIy_ae22c612-be83-4da2-92a7-8514cec97e13">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItMS0xLTEtMTYxMTg_d002498f-312d-4805-bea0-2d02d033a988"
      unitRef="number">1.04</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItMy0xLTEtMTYxMTg_622ed979-e5a1-487a-9d18-bc556a5f7ca3"
      unitRef="number">0.007</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItNS0xLTEtMTYxMTg_366b7f95-77af-4ef4-a8ae-6ef66f349144">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzItNy0xLTEtMTYxMTg_13a896a5-a5cd-4786-9ac2-59cefbcb0a84"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtMS0xLTEtMTYxMTg_b498d6b2-c852-48ea-a34d-d58080642803"
      unitRef="number">0.90</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtMy0xLTEtMTYxMTg_73e564a3-bda7-44ed-930c-b9cb90230574"
      unitRef="number">0.010</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtNS0xLTEtMTYxMTg_85c7c283-474e-4f7b-aa74-7d23238e0c8b">P6Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzMtNy0xLTEtMTYxMTg_5add94f9-f1ce-4d70-a648-062a51bdfa42"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtMS0xLTEtMTYxMTg_55e4bc64-7e49-478c-863f-5cfbcb8c8df8"
      unitRef="number">0.98</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtMy0xLTEtMTYxMTg_5bf079cf-f495-4c5e-a655-382e7b996145"
      unitRef="number">0.013</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtNS0xLTEtMTYxMTg_da74c889-2997-4488-8818-381e2f0b99bd">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzUtNy0xLTEtMTYxMTg_b225308c-a860-4373-a6e2-719e667e08d9"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtMS0xLTEtMTYxMTg_c7eaf0ba-24ef-43e1-9d69-54783d50faf1"
      unitRef="number">0.85</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtMy0xLTEtMTYxMTg_27999356-7462-4a8e-985b-a31d1ce5c490"
      unitRef="number">0.014</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtNS0xLTEtMTYxMTg_17dd5837-e6b9-43cb-9d4c-dfff3aa1d9e1">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i25da1acedebb4b8b93db0a99f0e0ddf2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzYtNy0xLTEtMTYxMTg_3e7a30db-52b4-41b0-b21e-7843c58c5395"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtMS0xLTEtMTYxMTg_e4b458a9-3599-43d9-8b45-8ba37505f6e6"
      unitRef="number">0.88</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtMy0xLTEtMTYxMTg_e4820464-c0cc-4583-bce6-69059f92b132"
      unitRef="number">0.022</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtNS0xLTEtMTYxMTg_72fff5ca-6b3a-4f63-9fe4-0ee60cd1e0b4">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzgtNy0xLTEtMTYxMTg_6dfd4d7c-0785-411c-835f-df336a91369c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktMS0xLTEtMTYxMTg_910d4cbc-fa7a-4642-96d4-74b56298f710"
      unitRef="number">0.77</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktMy0xLTEtMTYxMTg_8d63f383-a324-47f2-8f45-dee859ffd31c"
      unitRef="number">0.026</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktNS0xLTEtMTYxMTg_0d6b35aa-bb1c-4185-9460-0cb62ddba6d0">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i760651d6d6e4423e8f91cc179f8414f6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90YWJsZTo0NTc2ZjUyMWNkZjc0ZmNjOTc1ZjRkMmFkYWI2NTFjNC90YWJsZXJhbmdlOjQ1NzZmNTIxY2RmNzRmY2M5NzVmNGQyYWRhYjY1MWM0XzktNy0xLTEtMTYxMTg_887cbf2f-b2b5-4a60-aac5-5428a4d58300"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MTAw_991c3d6e-1357-4635-870c-1eb7084bae93">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2021, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2021 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2021 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $326.6&#160;million at December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzIzMzU4_2b45bd4c-b776-4015-9cc0-bd0c483ce5f1"
      unitRef="usd">326600000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNDgvZnJhZzpiYWY2ZTQ5M2FhMmI0MmY4YmMyMjFiZjkyMThiNjkzMC90ZXh0cmVnaW9uOmJhZjZlNDkzYWEyYjQyZjhiYzIyMWJmOTIxOGI2OTMwXzI0MDMw_8ac7faee-7f74-4f64-9513-5709e5ec2bd7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Income (Loss) per Common Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTEvZnJhZzo5ODJjZDAyYTc3MjU0NGI5YjE2Mjg5NDY1OTM1YTJkOS90ZXh0cmVnaW9uOjk4MmNkMDJhNzcyNTQ0YjliMTYyODk0NjU5MzVhMmQ5XzE2OTk_6ba4deb4-b156-48c8-a3e4-87261666d5a4">Recent Accounting Pronouncements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and adoption of this ASU did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU during the first quarter of 2020 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <lxrx:SaleOfNonFinancialAssetsTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzIxMTA_d15d7962-e6bd-45cd-9fc3-0f77ad54e853">Asset Sale&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company completed the sale of its XERMELO product and related assets (the &#x201c;XERMELO sale&#x201d;) to TerSera pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The final consideration paid by TerSera was $160.0 million and the net gain recognized in connection with the XERMELO sale was $132.6&#160;million.  The gain is reflected on the consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65.0 million for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made. Such adjustment would be included in Gain on sale of XERMELO in the consolidated statement of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#x2019;s operations.  For the years ended December&#160;31, 2020 and 2019, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#x2019;s XERMELO operations is $12.2 million, and $15.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company incurred and recognized severance charges of approximate $5.5 million. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</lxrx:SaleOfNonFinancialAssetsTextBlock>
    <lxrx:FinalConsiderationIncludingAmountsReleasedToSettle
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzMxNQ_b11d5a39-3230-450a-a164-fbc29c15da8a"
      unitRef="usd">160000000</lxrx:FinalConsiderationIncludingAmountsReleasedToSettle>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzM4Ng_b3e203a0-2c80-4d51-b33d-060265510b4a"
      unitRef="usd">132600000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzYxNw_f6ed83e4-7efe-47e8-ae19-7840207ccb5a"
      unitRef="usd">65000000</lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE2MzQ_0aac2823-1795-4a1a-81a2-9c7d6dee7ddd"
      unitRef="usd">-12200000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE2Mzg_9a852a2b-b929-4168-950d-955f85661231"
      unitRef="usd">-15400000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:SeveranceCosts1
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE4NzQ_eeba343b-470d-4733-9b72-514c22c658a0"
      unitRef="usd">5500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i8522830166f449a58c9cec1c88e894b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE4OTQ_410d8267-19b3-48b6-aa34-9d34f57b1d24"
      unitRef="usd">2500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ib18d8e20549d44f094d78c20f57067a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTQvZnJhZzozODY3MzA0YzJmZjM0NTRkYTZmZjE0MmZmNDYxMTBkZC90ZXh0cmVnaW9uOjM4NjczMDRjMmZmMzQ1NGRhNmZmMTQyZmY0NjExMGRkXzE5NTA_8ee2b335-75bd-434c-9295-9a1c7714a4ab"
      unitRef="usd">3000000</us-gaap:SeveranceCosts1>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzI0Mg_de44f83d-838c-408a-8ecc-27d609a35714">Cash, Cash Equivalents and Investments&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There were no realized gains or losses for the years ended December&#160;31, 2021, 2020, and 2019.</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzIzMQ_714ebad6-2eb0-4df4-8204-d9a55e35454b">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtMS0xLTEtMTYxMTg_6c28b53c-ddba-4bf8-ab79-e8d418b44874"
      unitRef="usd">64066000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtMy0xLTEtMTYxMTg_eebfe6b1-a3d6-4383-84c3-d33948b33fd6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtNS0xLTEtMTYxMTg_0bd72ed4-d508-4126-84b0-e2590312b146"
      unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ieb7da2f3e97c46d389e37d815311f301_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzMtNy0xLTEtMTYxMTg_8a01d532-2036-4117-964f-cf24724bdcf5"
      unitRef="usd">64065000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i37cf340c919946f4bfab989e262c817c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtMS0xLTEtMTYxMTg_0770650a-a800-4885-9b11-c7254f7bae5b"
      unitRef="usd">7562000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37cf340c919946f4bfab989e262c817c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtMy0xLTEtMTYxMTg_3f14b805-8602-4bc6-8980-a765993722d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37cf340c919946f4bfab989e262c817c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtNS0xLTEtMTYxMTg_5d2766c7-495d-4fcc-afa1-a03bbe2dfce0"
      unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i37cf340c919946f4bfab989e262c817c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzUtNy0xLTEtMTYxMTg_e45273d2-308a-4231-b7a1-6d50dc88a297"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtMS0xLTEtMTYxMTg_b5627f62-c3ca-4cde-bf96-b8bdee11d329"
      unitRef="usd">15125000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtMy0xLTEtMTYxMTg_5dc8227f-6958-4bd1-9bb0-5370b1897431"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtNS0xLTEtMTYxMTg_672301de-4b51-4834-8838-b02a7fda6772"
      unitRef="usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzYtNy0xLTEtMTYxMTg_3a019901-2757-4f0b-ba2b-cd585fb7a663"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctMS0xLTEtMTYxMTg_ca538e5a-d1c6-4c6a-ae89-ab79300c35e1"
      unitRef="usd">22687000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctMy0xLTEtMTYxMTg_61d0b736-16d3-4f7e-b742-ce3408985cff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctNS0xLTEtMTYxMTg_c67b5bde-e485-48bf-9999-e965cfc7e3f3"
      unitRef="usd">9000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5aa43b6a0cac429cbaaa292eb38627c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzctNy0xLTEtMTYxMTg_3d695fa4-c87a-434b-a11c-a3c0b870c349"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtMS0xLTEtMTYxMTg_3bac7243-ca7a-403e-90e0-f3d6982d7d26"
      unitRef="usd">86753000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtMy0xLTEtMTYxMTg_4a85a3e1-2112-499d-a034-11f4320cb81c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtNS0xLTEtMTYxMTg_502cfed8-2b02-4d20-beee-2f021da2eef0"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i8c48b80d6d71414d86074d2c8dec0efa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0MWJjOWU3NmFmNjI0YTFiODhhYzkyODQ2NGMzODNjNi90YWJsZXJhbmdlOjQxYmM5ZTc2YWY2MjRhMWI4OGFjOTI4NDY0YzM4M2M2XzgtNy0xLTEtMTYxMTg_08a4b6a3-d4ed-4b1e-a73c-db53b9787df4"
      unitRef="usd">86743000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtMS0xLTEtMTYxMTg_0355752b-8fca-41d3-b6cb-bc951620f222"
      unitRef="usd">126263000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtMy0xLTEtMTYxMTg_2cfeb944-ae80-4837-bdc2-6b2f4410d5bd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtNS0xLTEtMTYxMTg_be7c5471-5fef-42b0-9a3b-7888c3341ad7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i8dc58a9208454195ae83b844c05fd101_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzMtNy0xLTEtMTYxMTg_b591e072-fcd8-46c3-86a4-ff5d36b7722c"
      unitRef="usd">126263000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i3a1b6c22beee4da5b9a413b0fd5a000c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzUtNy0xLTEtMTYxMTg_8d2d38af-56e9-4614-937e-b4919667fcb2"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctMS0xLTEtMTYxMTg_3f11a997-d76c-4b0c-ab97-402421cf7a2d"
      unitRef="usd">26018000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctMy0xLTEtMTYxMTg_f1b0d1b4-6356-45a8-a234-27605b2ce5ce"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctNS0xLTEtMTYxMTg_52560623-710a-4aea-8c03-abe9322dbb7c"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i091b4225a0724082a4b25d2b383f9518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzctNy0xLTEtMTYxMTg_c73904b6-4af6-4179-b338-7a74ac6eb22d"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i53afd739da224f3588c2279414d4f677_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtMS0xLTEtMTYxMTg_a8dd3168-7129-4cb0-932e-aa5193c6e473"
      unitRef="usd">152281000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53afd739da224f3588c2279414d4f677_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtMy0xLTEtMTYxMTg_2ef15eb1-c49c-42f9-880a-e7f108939e81"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53afd739da224f3588c2279414d4f677_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtNS0xLTEtMTYxMTg_f3d7360e-6854-4bc7-b2c9-3a1b6bf2a542"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i53afd739da224f3588c2279414d4f677_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90YWJsZTo0OGJmMTBmODNkMGE0ODk0ODQ2NWU1M2M2YzVmMjlmZS90YWJsZXJhbmdlOjQ4YmYxMGY4M2QwYTQ4OTQ4NDY1ZTUzYzZjNWYyOWZlXzgtNy0xLTEtMTYxMTg_c35271d1-674f-4752-8e11-b780f284e6f4"
      unitRef="usd">152275000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNTcvZnJhZzowOTUwMzBhNjM5ZjI0MzI5Yjc0YmMxZjI5NjU3Y2FlOC90ZXh0cmVnaW9uOjA5NTAzMGE2MzlmMjQzMjliNzRiYzFmMjk2NTdjYWU4XzE2Mw_0d5b4802-548c-417b-a948-3a40dd17e956"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90ZXh0cmVnaW9uOmVmZWNjYTA4ZTE4YzQwMmQ5NmRjMDEwNTNmYzJmYjk3XzE1NzE_04f28c46-3fc5-42c2-a761-9797df7b354e">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; quoted prices in active markets for identical assets, which include U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities at December&#160;31, 2021 or 2020. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90ZXh0cmVnaW9uOmVmZWNjYTA4ZTE4YzQwMmQ5NmRjMDEwNTNmYzJmYjk3XzE1NzA_bde55dfa-12cf-4f92-a73b-b98e44789367">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtMS0xLTEtMTYxMTg_5533248c-ad43-4e15-b5c3-d697d88d9ba9"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id30138e6503c4ffda82b615c312c176c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtMy0xLTEtMTYxMTg_1152e110-64d4-4476-84e0-985b7f64f116"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib964838f757842dc89d306cdb12966ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtNS0xLTEtMTYxMTg_f34aa5ca-2462-4090-a049-6ec5d3465081"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzUtNy0xLTEtMTYxMTg_7781a67e-3b92-45e0-aad7-43067d65839f"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtMS0xLTEtMTYxMTg_e8ffd4c8-2edb-4178-b1da-03e0b9324181"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="id30138e6503c4ffda82b615c312c176c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtMy0xLTEtMTYxMTg_89d0884c-e3d6-467f-be16-e87e2140c96b"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ib964838f757842dc89d306cdb12966ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtNS0xLTEtMTYxMTg_bbbb5524-b56a-437a-a138-c1848dff37e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzYtNy0xLTEtMTYxMTg_fb3ea934-f934-4e2f-8182-7364683eb049"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2adb638834b14d05ad8e434cc4531023_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctMS0xLTEtMTYxMTg_8dbe360e-2120-4bf5-89e6-4f86b2892619"
      unitRef="usd">71626000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id30138e6503c4ffda82b615c312c176c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctMy0xLTEtMTYxMTg_f1ab9e78-78c8-42b9-9c56-5a90c4d3d69b"
      unitRef="usd">15117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib964838f757842dc89d306cdb12966ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctNS0xLTEtMTYxMTg_d803f396-24f1-42e3-b1a4-924b17d6fed5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTo2ZjRhM2Y5YzdjNTc0OGU3YTRiYjBmYjA1MDgwMjQ2Ny90YWJsZXJhbmdlOjZmNGEzZjljN2M1NzQ4ZTdhNGJiMGZiMDUwODAyNDY3XzctNy0xLTEtMTYxMTg_ab7a2c56-bc8a-41c7-8ac1-adbee8b08c69"
      unitRef="usd">86743000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtMS0xLTEtMTYxMTg_1f307942-2f90-45a8-b0f3-18e9f5343076"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtMy0xLTEtMTYxMTg_9101a038-8b95-40b5-8183-84c0137cf744"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtNS0xLTEtMTYxMTg_5613f448-4a4f-4972-9c8e-0720e4b19f6c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzUtNy0xLTEtMTYxMTg_08a9ce7f-08cb-444f-b1f0-0d21a8841fa1"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtMS0xLTEtMTYxMTg_8e8df265-6fa1-4f3e-8a0c-9f7e53ad276b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtMy0xLTEtMTYxMTg_120c080d-36ce-4cdf-afd3-b155faf4d161"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtNS0xLTEtMTYxMTg_9e4f73ce-aaf2-4f31-9d56-f9e9082f021a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzYtNy0xLTEtMTYxMTg_1f53db77-2761-4397-83cf-ac68f67263b2"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8ede039b32984c72893e8e8c75c2b9fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctMS0xLTEtMTYxMTg_f1657d8b-571a-47e7-a1bb-3c56aa49d851"
      unitRef="usd">126263000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id380ecc83b6e49a789334d406e5727f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctMy0xLTEtMTYxMTg_b789d0ef-5d17-43ac-b82a-ef7eb86d1b22"
      unitRef="usd">26012000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if4dd544ad16c4850b2b176d752df0a1e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctNS0xLTEtMTYxMTg_09530ec6-34fa-4773-b265-14b13a66d86c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjAvZnJhZzplZmVjY2EwOGUxOGM0MDJkOTZkYzAxMDUzZmMyZmI5Ny90YWJsZTphNDJkMWY4NjFmNjY0ODdkYmVmMDQ2MTcxZDY2ZDhmYS90YWJsZXJhbmdlOmE0MmQxZjg2MWY2NjQ4N2RiZWYwNDYxNzFkNjZkOGZhXzctNy0xLTEtMTYxMTg_d27ac6f2-026c-452c-be73-0a84748c034a"
      unitRef="usd">152275000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzUwNg_ae81d0cc-8f46-4cb1-a5e6-130aaa7b8c98">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment at December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzQ5NQ_8628f96b-f7df-4c22-aeb4-5ac6ea0c84f6">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic29f411a667c4474b294d320f9ebcb4f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjpiYjRmY2MwZDg0MDg0ZTRkYmRhM2QyYWVjZjJiMzE3OF80_38158472-4933-4169-8634-70878d7b9f06">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i251665a0c7944e8d9bb8853d049ed549_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjpiYjRmY2MwZDg0MDg0ZTRkYmRhM2QyYWVjZjJiMzE3OF83_5759aaa8-e5ec-4f1f-95ee-2471efa8c0a1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i535698f3d692460b81cba7884c86e4e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtNS0xLTEtMTYxMTg_c9c18cfb-964c-4e87-97d8-4649ae6415d9"
      unitRef="usd">3027000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1397c77d1b6f4185845e1699cd219089_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzMtNy0xLTEtMTYxMTg_a6cccb54-4885-4949-9d4a-297bc989b4af"
      unitRef="usd">3826000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2c9e7435336a44558427742a97851cad_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo2YzM3M2I5ZGU1M2M0N2YzYjI4MTkxNjFkNDg3MTM3Ml80_9285a313-7717-42e6-b918-4e7af3f60562">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i30aff4dded0c44ae865d00df32ebe612_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo2YzM3M2I5ZGU1M2M0N2YzYjI4MTkxNjFkNDg3MTM3Ml83_8143f694-2a39-4cd0-b2ef-c680f93dccd2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0eced0a8b11146888768ff4b14b2f375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtNS0xLTEtMTYxMTg_a22ee8d5-3242-495e-b9d2-b38042f0fbb8"
      unitRef="usd">1692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4455ddb6c214da7961fd95cd24842c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzQtNy0xLTEtMTYxMTg_ddf5019a-f29a-42f4-b0f5-9e9c0bdbe931"
      unitRef="usd">1867000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic47c902d195d41518cadfff77db8830a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo1ZjAxZmZmZjc4MTY0OTk1YmY1Y2QzN2I3Y2Y1MTk5NF80_3c74bc33-20f0-4dc6-bb68-25f919f4e341">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib99f027008024261ace720d15f140e6b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtMS0xLTEtMTYxMTgvdGV4dHJlZ2lvbjo1ZjAxZmZmZjc4MTY0OTk1YmY1Y2QzN2I3Y2Y1MTk5NF83_766ad0a2-9add-40a7-aa3e-af40a93f97ee">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i815538a41da140838b0cb583686e2574_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtNS0xLTEtMTYxMTg_aba35a33-de5e-434d-935b-5bb0016b7ba5"
      unitRef="usd">1310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie0b5aed98e3345b39cf920b0e50e105d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzYtNy0xLTEtMTYxMTg_84c03a81-e4d7-4490-8521-de7f64132123"
      unitRef="usd">417000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzktNS0xLTEtMTYxMTg_ebb86b0b-7439-4be1-89f9-405915f2d3c6"
      unitRef="usd">6029000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzktNy0xLTEtMTYxMTg_8298c6fc-076e-4aaf-8479-943c30f64847"
      unitRef="usd">6110000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzEwLTUtMS0xLTE2MTE4_b3c4ef20-6454-42fc-8c89-8438b427060b"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzEwLTctMS0xLTE2MTE4_dd3be792-e5e2-44e6-a6fb-1f7f95be88e8"
      unitRef="usd">5815000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzExLTUtMS0xLTE2MTE4_4127cf54-3c9a-444b-afd8-c4fd32b58c97"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90YWJsZTo1MWViN2Y1YTUyZjU0MmI5ODQ0ZDAyZjEwMTYxOTA5NS90YWJsZXJhbmdlOjUxZWI3ZjVhNTJmNTQyYjk4NDRkMDJmMTAxNjE5MDk1XzExLTctMS0xLTE2MTE4_6d1aa359-753d-4bbf-9a5b-783d79602ec5"
      unitRef="usd">295000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIwNg_b0e93510-4a4d-4baa-9ad5-098f8508b41e"
      unitRef="usd">11900000</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:Land
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzI0Mw_b8d12613-0dc8-4ea3-adea-1c692e137b37"
      unitRef="usd">2700000</us-gaap:Land>
    <us-gaap:InventoryBuildingsAndImprovements
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzMxMg_8ed30196-d4c8-41df-a8b8-71864d0920e4"
      unitRef="usd">7900000</us-gaap:InventoryBuildingsAndImprovements>
    <us-gaap:AssetImpairmentCharges
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTYyODE_66ab80c1-0172-49f8-9300-dd716284e644"
      unitRef="usd">1600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTY3NzM_d5c597b9-d79e-403c-9bd8-3d5dff6958db"
      unitRef="usd">1300000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjMvZnJhZzo4MjRlOGI5ZGM2ZDA0NTZlYjAyYWFmOWZmZmQxYzQ2YS90ZXh0cmVnaW9uOjgyNGU4YjlkYzZkMDQ1NmViMDJhYWY5ZmZmZDFjNDZhXzIxOTkwMjMyNTY4NDQ_45dd8502-121b-453c-a096-2d162d7b7a14"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwODg_037d2a69-7100-4b80-bc9e-3414d1bc72cd">Income Taxes &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted on March 27, 2020 &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws. For the year ended December 31, 2020, the impact of the CARES Act was immaterial to the Company&#x2019;s tax provision. Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Lexicon&#x2019;s deferred tax assets (liabilities) at December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2021, 2020 and 2019 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense (benefit) at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write off of credit carryover due to 382 study&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019 and nondeductible expenses for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#x201c;ownership change&#x201d; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#x201c;ownership change.&#x201d; An &#x201c;ownership change&#x201d; is generally defined as any change in ownership of more than 50% of a corporation&#x2019;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December&#160;31, 2021, Lexicon had both federal and state NOL carryforwards of approximately $1.1 billion and $86.9 million, respectively.&#160;&#160;In 2021, federal NOLs increased by $132.7 million related to a current year NOL. The Company had $342.0 million of U.S. federal NOL carryforwards as of December 31, 2021, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#x2019;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2021, the valuation allowance increased $17.2 million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2021 and 2020, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2021 and 2020, the Company had no accruals for interest or penalties related to income tax matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwNzg_91643caa-29f4-446d-a589-983d815455c4">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzQtMS0xLTEtMTYxMTg_039eded5-9d10-4da5-b5e3-face5790eaea"
      unitRef="usd">229427000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzQtMy0xLTEtMTYxMTg_d8d784d9-3fe9-4f8f-8325-c249d6f9d583"
      unitRef="usd">201610000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzUtMS0xLTEtMTYxMTg_79f7f048-e04e-496c-a0d6-60ee9f4a0664"
      unitRef="usd">29290000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzUtMy0xLTEtMTYxMTg_52379834-8090-4cc8-977e-78460c82e633"
      unitRef="usd">29304000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzYtMS0xLTEtMTYxMTg_ba37f443-c5e7-4052-add1-f7558060aec1"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzYtMy0xLTEtMTYxMTg_e2e8649b-81c6-4fd8-ba29-55924e4abb09"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzctMS0xLTEtMTYxMTg_151ddf7c-efcf-4d01-b62a-78178eeb8f10"
      unitRef="usd">36770000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzctMy0xLTEtMTYxMTg_b3983c9a-9f61-4fec-9bda-c3be06cfa157"
      unitRef="usd">47075000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzgtMS0xLTEtMTYxMTg_adac7299-5b53-4ed1-bc5d-9947fbf13782"
      unitRef="usd">5163000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzgtMy0xLTEtMTYxMTg_43e072b6-db5c-4f6b-8464-f4664467b5bc"
      unitRef="usd">5651000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <lxrx:DeferredTaxAssetsSection163j_LXRX
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEwLTEtMS0xLTE2MTE4_2fae5dd4-0664-49ff-a143-e712258aa983"
      unitRef="usd">148000</lxrx:DeferredTaxAssetsSection163j_LXRX>
    <lxrx:DeferredTaxAssetsSection163j_LXRX
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEwLTMtMS0xLTE2MTE4_f2710c4c-127f-44f6-a447-f8b7d74c75f9"
      unitRef="usd">0</lxrx:DeferredTaxAssetsSection163j_LXRX>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzExLTEtMS0xLTE2MTE4_ea3892b7-53e1-4acd-8494-56c292b07621"
      unitRef="usd">1308000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzExLTMtMS0xLTE2MTE4_84f810c9-ce02-48c5-bf0a-48694eca9b0a"
      unitRef="usd">844000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEyLTEtMS0xLTE2MTE4_14aac96c-d19c-456c-b870-b455e3af6b6e"
      unitRef="usd">326630000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzEyLTMtMS0xLTE2MTE4_89dd4c9f-4448-4444-8518-ce7c83e5f307"
      unitRef="usd">309008000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE1LTEtMS0xLTE2MTE4_af00acb8-ab5f-4e73-9d78-cb0f011b5351"
      unitRef="usd">412000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE1LTMtMS0xLTE2MTE4_a1a041a4-a17f-4b81-bd92-6385e8a64b7b"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE2LTEtMS0xLTE2MTE4_19c10c53-0015-4a14-9aeb-3e4e28436c56"
      unitRef="usd">412000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE2LTMtMS0xLTE2MTE4_980972f9-4dff-495a-9eed-8bfbebfcde09"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE3LTEtMS0xLTE2MTE4_d658a1c7-20c5-43e8-8953-2dbb91f7676d"
      unitRef="usd">326218000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE3LTMtMS0xLTE2MTE4_615d176c-4a58-4824-91c6-2bafd89cb345"
      unitRef="usd">309008000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE4LTEtMS0xLTE2MTE4_28cfd9f6-6205-416d-b089-2850b279c76b"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZToxYzMwYWIzNjlhNWY0Yjc4OTgwOTAxZGRhOTUyMDc1OS90YWJsZXJhbmdlOjFjMzBhYjM2OWE1ZjRiNzg5ODA5MDFkZGE5NTIwNzU5XzE4LTMtMS0xLTE2MTE4_1b9bbc37-1812-485d-9699-41d9d3aadec4"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwNzk_8f7aa163-c26b-4cb4-855d-b41774a31f46">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2021, 2020 and 2019 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense (benefit) at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write off of credit carryover due to 382 study&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMC0xLTEtMTYxMTgvdGV4dHJlZ2lvbjoyN2JhZjdlNjE3ODI0NGJjODg1MWQxYzhmN2VhNWMyNF80NQ_b7ca6868-328d-4999-a614-5d844dc3a983"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMS0xLTEtMTYxMTg_d183d9f5-ae42-4982-a93b-75dc1566f1f2"
      unitRef="usd">-18429000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtMy0xLTEtMTYxMTg_f7801f1d-cb8e-4f27-9583-ff021566c374"
      unitRef="usd">-12300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzMtNS0xLTEtMTYxMTg_6c43c228-346b-434a-80e9-522f1e850239"
      unitRef="usd">26065000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtMS0xLTEtMTYxMTg_42daeed8-e20c-4b99-a652-c193af26c656"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtMy0xLTEtMTYxMTg_55297f35-5a38-4abc-b07d-c3f741281074"
      unitRef="usd">-269000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzQtNS0xLTEtMTYxMTg_3b9ac82b-887b-41fa-801e-fc887aea76d0"
      unitRef="usd">445000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtMS0xLTEtMTYxMTg_0fda4f4d-4bda-42e5-871d-6bd33d2a625e"
      unitRef="usd">851000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtMy0xLTEtMTYxMTg_8f96af07-db43-4efa-94b3-f40f6c49e51d"
      unitRef="usd">1777000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzUtNS0xLTEtMTYxMTg_b3987044-0792-4e85-92b6-ea892a8a0eee"
      unitRef="usd">1688000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <lxrx:WriteOffOfTaxCredits
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzExLTEtMS0xLTE2MTE4_e8f38f32-f8fa-462b-a7a8-de74805ef48d"
      unitRef="usd">0</lxrx:WriteOffOfTaxCredits>
    <lxrx:WriteOffOfTaxCredits
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzExLTMtMS0xLTE2MTE4_e49e3e89-9298-4aa2-a45c-4cc6b0170771"
      unitRef="usd">31053000</lxrx:WriteOffOfTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTEtMS0xLTE2MTE4_dbffe84c-41f0-45c0-a873-4ea4e83e007a"
      unitRef="usd">17210000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTMtMS0xLTE2MTE4_1136546f-ec31-4734-af9d-1fbd60993da9"
      unitRef="usd">-20418000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEyLTUtMS0xLTE2MTE4_562c340b-6cd0-49bc-b9a6-8e08ea2cf27f"
      unitRef="usd">-35276000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTEtMS0xLTE2MTE4_2de37996-828d-4b29-89c7-580ed57ec199"
      unitRef="usd">368000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTMtMS0xLTE2MTE4_c985a38e-5986-4251-b6b6-583c6f737662"
      unitRef="usd">157000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzEzLTUtMS0xLTE2MTE4_9ca0eb9a-faae-40d5-805a-02647ea130ed"
      unitRef="usd">1064000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTEtMS0xLTE2MTE4_cc66284b-21a1-46ee-b48e-edac6207d738"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTMtMS0xLTE2MTE4_2829dabb-4e80-4a33-9a22-05cc6904ea9e"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90YWJsZTplOWJhYjQ0MmQyZWI0YmEwOWM2OWQ5M2FhZTk0OWJjZi90YWJsZXJhbmdlOmU5YmFiNDQyZDJlYjRiYTA5YzY5ZDkzYWFlOTQ5YmNmXzE0LTUtMS0xLTE2MTE4_f30eb1c6-eb68-4e17-8895-3f75b91e6b84"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI4ODY_e0c34323-aa58-4f94-a0c3-a0417e7f204a"
      unitRef="usd">1100000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI4OTM_73fd6457-a759-4b25-9b1b-3bdeb7731ef2"
      unitRef="usd">86900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lxrx:A2020FederalNOLIncrease
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzI5NDc_1b0f3aee-59e5-471d-9acd-01b32527ffbe"
      unitRef="usd">132700000</lxrx:A2020FederalNOLIncrease>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzIxOTkwMjMyNjIyMjk_74bd011e-3d0f-40db-8d04-040fc08611d6"
      unitRef="usd">342000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzM3Nzc_3be33780-386e-4ba8-9c00-6902a37417bf"
      unitRef="usd">17200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwMDc_1daed868-f5f3-4b9b-88cd-f98771d95c92"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjYvZnJhZzphOWYzZGVhZGI0OGU0MDk3OGM4NWExYzgwNDdjNTgyOS90ZXh0cmVnaW9uOmE5ZjNkZWFkYjQ4ZTQwOTc4Yzg1YTFjODA0N2M1ODI5XzUwMDc_dfd5edc2-b014-435a-a4e3-9c1d04229bf7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzEzMTI_0348dffd-f304-4edd-86ea-153251e3c192">Goodwill&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#x2019;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#x2019;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#x2019;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <lxrx:CoelacanthGoodwill
      contextRef="ic1e10dc122274204badbada626c6296e_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzQ2NQ_e02ee4d4-2ca3-4e91-8fe6-804da54b449a"
      unitRef="usd">25800000</lxrx:CoelacanthGoodwill>
    <lxrx:CoelacanthPurchasePrice
      contextRef="ic1e10dc122274204badbada626c6296e_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzUwNA_4743ac1a-300e-4250-9518-bf89228be944"
      unitRef="usd">36000000</lxrx:CoelacanthPurchasePrice>
    <lxrx:SymphonyIconGoodwill
      contextRef="i5170da333de84c9ab9e1c854f5a3f263_I20100730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNjkvZnJhZzpmOGZmNjlmM2Q2MjU0YjYyOWVhNzNkOWVmNjk4MWFmZC90ZXh0cmVnaW9uOmY4ZmY2OWYzZDYyNTRiNjI5ZWE3M2Q5ZWY2OTgxYWZkXzc5Mg_c1bc86a9-0fad-4364-9d8f-e1612ae470c9"
      unitRef="usd">18700000</lxrx:SymphonyIconGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzcwODE_df049125-f995-46a8-8927-2a0671770e56">Debt Obligations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of 5.25%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes.  In 2020, the Company issued 10,368,956 shares of the Company&#x2019;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $9.6 million was recorded and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020.  As of December&#160;31, 2020, the carrying value of the remaining Convertible Notes was $11.6 million. In December 2021, the remaining balance of $11.6&#160;million was repaid in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs were amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMzNjA_fd6c9083-ac60-4aa0-af6d-eabe40774af9"&gt;seven&lt;/span&gt;-year term of the Convertible Notes.  There are no debt issuance costs as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage Loan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#x201c;Property&#x201d;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provided for a $12.9&#160;million mortgage on the Property and had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzMzI_73bd8c0d-44ee-40f0-9385-b10f02c7cfec"&gt;two&lt;/span&gt;-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3&#160;million, which was paid in full in August 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BioPharma Term Loan.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LP under which $150 million was funded in December 2017 (the &#x201c;BioPharma Term Loan&#x201d;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO Sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive income (loss) for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5MTU_7b0c5791-d8c3-4747-83ec-263e9d8b54d5"&gt;five&lt;/span&gt;-year term of the BioPharma Term Loan.  There are no debt issuance costs as of December 31, 2021.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzk4_927c27ba-b2f4-4d8e-8b69-8af8df3b1c93"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzEzOA_8ef23d71-0249-49e7-952e-53d0f3e0442d"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzIxOTkwMjMyNjU3MTM_8ef23d71-0249-49e7-952e-53d0f3e0442d"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzUzMQ_d0ec37cb-301c-4f55-88af-85b3d3ac5988"
      unitRef="usd">75800000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzYxNA_36ff23bb-827f-4f36-a111-c45c6239aa21"
      unitRef="number">0.85</lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal>
    <lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY5NA_60357527-55b0-49c7-a236-375bd3991b39"
      unitRef="shares">10368956</lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal>
    <lxrx:ConvertibleDebtExchangeTotalCashConsideration
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzc0Mw_16b52776-69d8-49cd-9e39-3bb8987ec105"
      unitRef="usd">50000000</lxrx:ConvertibleDebtExchangeTotalCashConsideration>
    <lxrx:A2020ConvertibleDebtExchangeAccruedInterest
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzc3MA_9a325423-9252-4abf-941a-b1b8b38bf2c0"
      unitRef="usd">1300000</lxrx:A2020ConvertibleDebtExchangeAccruedInterest>
    <lxrx:ConvertibleDebtExchange
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzk5Ng_69459633-8caf-4683-b302-e5a20ea42697"
      unitRef="usd">9600000</lxrx:ConvertibleDebtExchange>
    <us-gaap:ConvertibleDebt
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzExOTQ_fefc9540-3397-46f4-8a14-9c26b623d883"
      unitRef="usd">11600000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzIxOTkwMjMyNjI4MjM_fefc9540-3397-46f4-8a14-9c26b623d883"
      unitRef="usd">11600000</us-gaap:ConvertibleDebt>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i33b1d627868546fca39177189a903e94_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzMxMTg_f2bc040f-d727-4c15-9cf4-22663be5c58b"
      unitRef="usd">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQyMDg_19001bca-aee0-4a90-8f18-980afb58d03a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQyOTQ_176f013c-52be-4253-b473-97844501c745"
      unitRef="usd">12900000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if9cb62af37d048978f015209a192adc4_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQzNTI_476ec688-ef00-4bb2-a978-bcade737d69f">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0ODE_10b6e18d-a501-45bd-a6ef-b19b10de4223"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0ODE_eb7473d0-c9c3-4db5-96a4-b93304fb528f"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0OTE_0c2e1c95-e1ea-4ed5-99d6-cbea90421ec2"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ0OTE_48684574-62c3-492d-8670-663c1a5521ba"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ1MzI_395476ac-626e-42c2-af9c-9979cedfc870"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i74800149cb834920a98e1fed9979820d_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ1MzI_8cd61fce-ef7b-4ce3-bcb7-765692968589"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia89421ae837f48509b4bf1206d468d61_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzQ4ODI_c65566de-a213-401e-95fb-39786aca5c53"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzUwMjY_72f5b0b0-47f8-4ecb-bb31-dfff68760e57"
      unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia89421ae837f48509b4bf1206d468d61_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzIvZnJhZzpmOTRhOGVmZDgwZDg0NGE0OTExODExNGUxNDFjMjU0Mi90ZXh0cmVnaW9uOmY5NGE4ZWZkODBkODQ0YTQ5MTE4MTE0ZTE0MWMyNTQyXzY2NjQ_372bafff-21b7-4c32-8717-338202a7044a"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzQ4NzM_cd61fe52-c476-4b6e-a113-96774abb6854">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;Lexicon&#x2019;s operating leases include leases of office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.  As of December&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $2.3 million, which is included in other assets in the consolidated balance sheet. Current and non-current liabilities relating to the leases were $1.1 million and $1.2 million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employment Arrangements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NDQ_e22aa56a-ed2a-4ea4-b4d9-85a943d8c4ac"&gt;six&lt;/span&gt; or 12 months and, in some cases, payment of a specified portion of the officer&#x2019;s bonus target for such year, in the event of a specified termination of the officer&#x2019;s employment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5MzI_3bf1b265-bddb-4ac7-a7b8-f563cfa3c39d"
      unitRef="usd">2300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5NTE_702c3b3f-4e92-4638-839a-b6c8fa72bc86"
      unitRef="usd">1100000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzIxOTkwMjMyNjE5NjY_76bc52b7-e4ef-48bd-a6c4-601851509707"
      unitRef="usd">1200000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzQ4NTc_8ecf463d-03e5-4eca-8ade-5ae054203d5e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzItMS0xLTEtMTYxMTg_7f2cf2be-9c66-4bb3-9085-ef9a4454e631"
      unitRef="usd">1163000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzMtMS0xLTEtMTYxMTg_7470dc06-0873-425d-8abf-dc54bbc80416"
      unitRef="usd">531000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzQtMS0xLTEtMTYxMTg_3860d2e6-b730-4e33-8f5c-b980548b451e"
      unitRef="usd">544</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzUtMS0xLTEtMTYxMTg_961ed188-7a8b-49bc-8940-ad1e3d1281b0"
      unitRef="usd">371</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzYtMS0xLTEtMTYxMTg_ea60de7f-a451-4464-9f59-f3a14144c443"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzctMS0xLTEtMTYxMTg_cd1b01f5-4c54-4631-9c4b-3927560eddd6"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzgtMS0xLTEtMTYxMTg_7e5627cc-a1a6-460c-9c63-073f78829104"
      unitRef="usd">2609000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <lxrx:InterestOnLeasePayments
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzktMS0xLTEtMTYxMTg_be572f06-eaa6-45f4-952c-d00a2e92648f"
      unitRef="usd">-330000</lxrx:InterestOnLeasePayments>
    <lxrx:PresentValueOfFutureLeasePayments
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzEwLTEtMS0xLTE2MTE4_8243d757-2221-46aa-b34d-d7ee3d90cb28"
      unitRef="usd">2279000</lxrx:PresentValueOfFutureLeasePayments>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzExLTEtMS0xLTE2MTE4_a8955f3e-31c6-4ec7-8f16-edb1aa901b1f"
      unitRef="usd">1089000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90YWJsZTpmNzQwMzVlOWNlZDI0NzFjYTMyNGM3YmJjNmRlODNjMy90YWJsZXJhbmdlOmY3NDAzNWU5Y2VkMjQ3MWNhMzI0YzdiYmM2ZGU4M2MzXzEyLTEtMS0xLTE2MTE4_0359bc86-a644-4278-8a29-e9f085b5c8bb"
      unitRef="usd">1190000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzUvZnJhZzpmMzcyZjMxZTI2YmI0OTc5OTBiMzE5OTg4YzQ2ZmM5NC90ZXh0cmVnaW9uOmYzNzJmMzFlMjZiYjQ5Nzk5MGIzMTk5ODhjNDZmYzk0XzE0NTA_4b3707de-d7ee-41f1-8fb5-014b35718f19">P12M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUxMTE_37efda2c-af91-4a22-b7ed-0b3bef50392b">Equity Incentive Awards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Equity Incentive Plan:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#x2019;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 30,000,000 shares at December&#160;31, 2021.&#160;&#160;As of December&#160;31, 2021, options to purchase &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,958,179 shares and 1,822,043 restricted stock units were outstanding, 2,285,702 shares had been issued upon the exercise of stock options, 4,314,948 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Non-Employee Directors&#x2019; Equity Incentive Plan:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#x2019; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#x2019; Equity Incentive Plan (the &#x201c;Directors&#x2019; Plan&#x201d;).&#160;&#160;Under the Directors&#x2019; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#x2019;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#x2019; Plan have an exercise price equal to the fair market value of the Company&#x2019;s common stock on the date of grant and a term of ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#x2019; Plan shall not exceed in the aggregate 1,200,000 shares.&#160;&#160;As of December&#160;31, 2021, stock options to purchase 408,864 shares were outstanding, none had been issued upon the exercise of stock options, 32,192 restricted stock units were outstanding and 216,040 shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#x2019; Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s equity incentive plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 were $4.85, $2.35 and&#160;$3.18, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2021 was $0.6 million.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 6.7 and 5.3 years, respectively, as of December&#160;31, 2021.&#160;&#160;At December&#160;31, 2021, the aggregate intrinsic value of the outstanding stock options was $1.8 million.  At December&#160;31, 2021, the intrinsic value of exercisable stock options was $0.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Bonus and Restricted Stock Unit Activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQzMjM_2603f12e-430e-4fbf-beee-195251baa8fe"&gt;three&lt;/span&gt; annual installments.  The total fair value of shares vested in 2021, 2020 and 2019 was $8.7&#160;million, $3.2&#160;million and $2.9&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020 and 2019, Lexicon granted its non-employee directors 32,192, 85,104 and 27,728 restricted stock units, respectively. The restricted stock granted in 2021, 2020 and 2019 had weighted average grant date fair values of $5.04, $1.86, and $5.67 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aggregate Shares Reserved for Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, an aggregate of 10,221,278 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 14,048,092 additional shares were available for future grants under Lexicon&#x2019;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzY2OA_7179aae1-3c71-4c92-807a-2ccedd3121d7"
      unitRef="number">1</lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzg2Mw_dc9564a6-56c3-4cc0-821c-aa1a889f2b73">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwMDI_7a151c3a-62a7-4270-b4a9-de4b7161a1de">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzExODY_11b09fae-7ab3-43e3-951d-4800670d5958"
      unitRef="shares">30000000</lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan>
    <lxrx:OptionsOutstandingEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0MDc_8779f269-e2e3-404b-970a-2ad315ae042d"
      unitRef="shares">7958179</lxrx:OptionsOutstandingEquityIncentivePlan>
    <lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0MjE_65b04ac4-eb5b-4ccf-a33a-03a01a34e287"
      unitRef="shares">1822043</lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan>
    <lxrx:StockOptionsExercisedEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE0NjU_56817524-0120-4391-8a9e-93a81982be49"
      unitRef="shares">2285702</lxrx:StockOptionsExercisedEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE1Mjc_361594c8-ee57-4e3c-a01a-03c2f0a5c643"
      unitRef="shares">4314948</lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzE1OTI_45aae404-5f14-43ba-8919-b6caad4e37cf"
      unitRef="shares">113940</lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan>
    <lxrx:Totalvalueofsharesbynonemployeeinayear
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzIxMjQ_40acda60-791d-411e-bb3a-fe79977c0da0"
      unitRef="usd">500000</lxrx:Totalvalueofsharesbynonemployeeinayear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI0NzY_d08804a7-c71b-403f-90e5-36abf48e80b7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI2NTI_e7f752af-ae22-4277-9660-83d04f78b16a"
      unitRef="shares">1200000</lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3MDA_5b08c130-8b98-4986-9b50-5878d6e76769"
      unitRef="shares">408864</lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3Mjg_b0f2ca8f-af37-471d-bee0-3c9a62cd8d34"
      unitRef="shares">0</lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI3ODM_0f095ee3-8265-4d2b-b62b-c18a9d9fa233"
      unitRef="shares">32192</lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzI4MzA_db3f7285-18ce-49fd-9e06-05bf94971bdb"
      unitRef="shares">216040</lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUxMDE_560589b3-05bf-4401-a4cd-d972123c66b2">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMi0xLTEtMTYxMTg_b483e976-6db9-47a3-b283-69fbd4008c5b"
      unitRef="shares">8397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItNC0xLTEtMTYxMTg_76d7cb3e-9507-46be-b482-89c0aed50f4a"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItNi0xLTEtMTYxMTg_32f367c5-1730-47f0-9941-6e02d18ed6f6"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItOC0xLTEtMTYxMTg_f34cb41d-a8e1-4b30-ae3f-422d05614b18"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMTAtMS0xLTE2MTE4_dfe54926-d3d5-4587-ab71-54a8b76375f2"
      unitRef="shares">6152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5057b343c90a43809bf3fd8b0c66c0dc_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzItMTItMS0xLTE2MTE4_d137d19b-15cd-4acc-a150-180b11d5ae0e"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMi0xLTEtMTYxMTg_6a27f2dc-736f-4aae-a6ea-76f68edf87ae"
      unitRef="shares">1808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtNC0xLTEtMTYxMTg_39a976db-3c2f-497a-af13-d6fe701dab7d"
      unitRef="usdPerShare">6.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtNi0xLTEtMTYxMTg_114afb42-b4c6-4cad-bcc2-4329891eb21a"
      unitRef="shares">3495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtOC0xLTEtMTYxMTg_3085831c-aa5a-4202-bdec-4583bdaf2c23"
      unitRef="usdPerShare">3.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMTAtMS0xLTE2MTE4_22d31dc7-2b1d-4bd9-bf20-06d445599439"
      unitRef="shares">2435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzMtMTItMS0xLTE2MTE4_73247290-b7d1-4a9c-9157-92a3204e40c1"
      unitRef="usdPerShare">5.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMi0xLTEtMTYxMTg_7f1a2281-62e3-4629-ac48-b1d8b664ef0f"
      unitRef="shares">376000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtNC0xLTEtMTYxMTg_3ae6aa90-82f4-4add-987f-66e0c8424370"
      unitRef="usdPerShare">4.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtNi0xLTEtMTYxMTg_003f8ee7-ddd7-4592-bb28-cf030941b48b"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtOC0xLTEtMTYxMTg_9b499bad-1910-4e5d-a027-99a6bc75cb84"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMTAtMS0xLTE2MTE4_27c6360d-f9cb-4aaa-a9af-0212c2cd509f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzQtMTItMS0xLTE2MTE4_c1a3800f-c278-48d3-8313-e6d0594ca33f"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMi0xLTEtMTYxMTg_6b0ef146-22aa-4ea4-b6a5-8ae344445ae0"
      unitRef="shares">191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtNC0xLTEtMTYxMTg_033f8fbb-ceb7-4193-a424-a698a8e859ae"
      unitRef="usdPerShare">12.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtNi0xLTEtMTYxMTg_45024855-0d83-41dc-98c1-738a22438960"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtOC0xLTEtMTYxMTg_961c432e-929a-46e7-9f27-e92d01ec8468"
      unitRef="usdPerShare">12.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMTAtMS0xLTE2MTE4_f7b3ae8e-ea1a-4514-b43c-9bf823b7c397"
      unitRef="shares">212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzUtMTItMS0xLTE2MTE4_a97d89ce-311f-421d-bbb5-da8790334dbb"
      unitRef="usdPerShare">9.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMi0xLTEtMTYxMTg_741fee69-44ef-4ea7-b0d5-2f9d76263afb"
      unitRef="shares">1271000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i671625944c6c4a89969d7d0d7f394222_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtNC0xLTEtMTYxMTg_c40d5c55-eb0d-4211-8d12-34e7938571b1"
      unitRef="usdPerShare">8.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtNi0xLTEtMTYxMTg_07a45c33-249c-4907-a8ba-7855575b9733"
      unitRef="shares">2557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i145c45c78532462ebdd3b820baa9a7f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtOC0xLTEtMTYxMTg_f4e3cd92-5949-43c6-b307-9dc5f6f96d37"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMTAtMS0xLTE2MTE4_25b34d28-8972-42fd-ad36-d3f583103fe3"
      unitRef="shares">680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iec9e9d79b8164e3299da05fb6470fb8e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzYtMTItMS0xLTE2MTE4_5e1d7369-0d56-4f06-97dd-11f1798b7b66"
      unitRef="usdPerShare">10.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMi0xLTEtMTYxMTg_cb396750-9a43-4363-bde5-d8532143996c"
      unitRef="shares">8367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctNC0xLTEtMTYxMTg_8887fa06-29f2-435f-a607-d6ae3888ec71"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctNi0xLTEtMTYxMTg_853368e2-fc4a-42cc-9926-2c61ed234401"
      unitRef="shares">8397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctOC0xLTEtMTYxMTg_9e9a8119-615b-417e-9dc5-817f17fc492d"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMTAtMS0xLTE2MTE4_85a8f282-9372-418b-bc25-0483b369e571"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzctMTItMS0xLTE2MTE4_0b373670-7416-42de-a9d4-56e9c2759d7c"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMi0xLTEtMTYxMTg_c3af105c-a33a-49c3-97f8-c8c057cd9636"
      unitRef="shares">5032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7478be4ff58a46a4936f451a7f97265d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtNC0xLTEtMTYxMTg_fcaf30ff-5b27-4f4f-8045-2ce56a036735"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtNi0xLTEtMTYxMTg_8ce33c6e-8557-4cb6-8e39-1cd0687c32f3"
      unitRef="shares">4684000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1154d94c6995462ba768d2bd7b39e722_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtOC0xLTEtMTYxMTg_6410e952-47fa-4540-9c87-79987baa4d62"
      unitRef="usdPerShare">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMTAtMS0xLTE2MTE4_244049ac-33ec-49c4-8779-f47cba626693"
      unitRef="shares">4275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie941169ab2164798abaed9016c336c29_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZToyYWY5ZjA5ZTBmZWQ0MjNiYjUzNGY1ZTg5N2MwYmNhMy90YWJsZXJhbmdlOjJhZjlmMDllMGZlZDQyM2JiNTM0ZjVlODk3YzBiY2EzXzgtMTItMS0xLTE2MTE4_abcf5734-b19f-4e30-9d65-312554f25ba2"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMxOTQ_204054eb-e6a0-4f03-8e29-a22787e9d7ef"
      unitRef="usdPerShare">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMxOTg_35c94a9e-981a-4e5e-89b3-c81c2667842a"
      unitRef="usdPerShare">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMyMDU_cb5c1395-08b8-4130-94fc-48d213c9dd8a"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzMzMDY_9f129f4b-d716-4908-b9ef-df72a4db0e42"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM0MDg_5fd8d6f3-66fc-4f60-b2a8-0edd8a1f97c4">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM0MTU_88344008-9931-4279-a5c3-750947642f54">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM1MjQ_9afca810-d273-4601-8f2b-5b4bf6cabc36"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzM1ODk_8292c509-ac39-47cb-b87b-96ead311615f"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MDc_6c75ab25-d68e-41e3-bab8-4cb2c2b274a3"
      unitRef="usd">8700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MTE_da7918b2-19d2-405c-904a-5c1d7f83ff3e"
      unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ0MTg_0d8f7b37-d218-4ff6-946a-7ad248908e75"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3NzU_cbbd1912-b8bd-412c-8345-8224231f2b7f"
      unitRef="shares">32192</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3ODA_aee04487-0bb3-40a6-9d5b-6dbf3f96a402"
      unitRef="shares">85104</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM3ODg_4541fd5d-1cd1-4906-8b65-f0d875be3dc6"
      unitRef="shares">27728</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5MjY_516e5070-79c4-49b9-94d7-349ebea86fb9"
      unitRef="usdPerShare">5.04</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5MzE_38c90c90-fc10-4f8a-aae0-6900c9faf804"
      unitRef="usdPerShare">1.86</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzEwOTk1MTE2MzM5NDA_f4706135-365b-43e8-af5b-5f15ba3bc75f"
      unitRef="usdPerShare">5.67</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzUwOTc_b9679a9a-a2d6-492b-96d6-9460bd2e3e27">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i89e3823a40a049809c8d559277e562bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzItMi0xLTEtMTYxMTg_ede633bb-9b19-45ee-843f-4fda1315f45e"
      unitRef="shares">2769000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i89e3823a40a049809c8d559277e562bd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzItNC0xLTEtMTYxMTg_78166cd0-78e6-49dd-939d-65be8e4d64fa"
      unitRef="usdPerShare">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzMtMi0xLTEtMTYxMTg_89458ba2-2fcc-4c6b-86e3-62b185b21a69"
      unitRef="shares">663000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzMtNC0xLTEtMTYxMTg_3a4890c1-d044-474b-80f3-306ff09ad226"
      unitRef="usdPerShare">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzQtMi0xLTEtMTYxMTg_7048eca2-1c4d-4ecd-bbe2-c091c306490a"
      unitRef="shares">1239000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzQtNC0xLTEtMTYxMTg_bc4fb6ac-1fd9-4091-a6b4-e01d512d3724"
      unitRef="usdPerShare">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzUtMi0xLTEtMTYxMTg_534484e6-7fa1-4817-b4c8-0e04fc018c92"
      unitRef="shares">339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue
      contextRef="i9d127ea6f2c94296af6546f678ba870f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzUtNC0xLTEtMTYxMTg_38cddeb4-1c65-4fe8-ab60-997a3f47624a"
      unitRef="usdPerShare">5.03</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i00be06ddbff74be8bbf65ceefcef5599_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzYtMi0xLTEtMTYxMTg_b8f04fcf-66e0-4231-b8b7-ede0ddd77b41"
      unitRef="shares">1854000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i00be06ddbff74be8bbf65ceefcef5599_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90YWJsZTpjYWJhMDZiOTFiY2E0MTEzYmM2NmE4MWI3MTVmZDAxZC90YWJsZXJhbmdlOmNhYmEwNmI5MWJjYTQxMTNiYzY2YTgxYjcxNWZkMDFkXzYtNC0xLTEtMTYxMTg_8a18fced-530e-4cd5-95f3-419dd81bdebc"
      unitRef="usdPerShare">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ2Mzk_f8360baf-74b0-43e9-b221-ab39fa6d1af9"
      unitRef="shares">10221278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xNzgvZnJhZzo5YWJmNGU1MzFlYzE0OTkxOWFkZmQ3NzIyZDhmNGYzMy90ZXh0cmVnaW9uOjlhYmY0ZTUzMWVjMTQ5OTE5YWRmZDc3MjJkOGY0ZjMzXzQ3ODk_ca08b55e-ab20-4143-85f1-e236fdb19b8c"
      unitRef="shares">14048092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzY0NA_3d2d2fc8-5af2-4677-98d3-b7b4e3654b6f">Benefit Plan&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $0.4 million, $0.9 million and $1.2 million in the years ended December&#160;31, 2021, 2020 and 2019, respectively.&#160;&#160;Company contributions are vested based on the employee&#x2019;s years of service, with full vesting after four years  of service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ2Ng_88cf4af6-3de5-4598-a1c3-fae83e943d7a"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ3MA_a5ab5bfa-a916-4121-9399-c784a1e31047"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzQ3Nw_b66ea91b-4ea3-4070-8f75-9fab1674e036"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <lxrx:DefinedContributionPlanRequisiteServicePeriod
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODEvZnJhZzplN2EyNzM0ZTA4YjI0ZTU4OTI2ODM4OTU4NTA0OGQ2NS90ZXh0cmVnaW9uOmU3YTI3MzRlMDhiMjRlNTg5MjY4Mzg5NTg1MDQ4ZDY1XzYyOA_20a48ff5-0cff-40d8-920b-1a7f1bd20a97">P4Y</lxrx:DefinedContributionPlanRequisiteServicePeriod>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NzE4_5fa9bf77-1061-4cc2-879e-463d8435e832">Collaboration and License Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ipsen.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized under the Agreement was $0.3 million and $4.9 million for the years ended December&#160;31, 2020 and 2019, respectively.  Revenue for each of the years ended December&#160;31, 2020 and 2019 included $0.3 million of royalties from Ipsen. Revenue for the year ended December&#160;31, 2019 included $1.3 million from sales of bulk tablets of XERMELO to Ipsen. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#x201c;Sanofi Agreement&#x201d;), with Sanofi for the worldwide development and commercialization of Lexicon&#x2019;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of September 9, 2019 (the &#x201c;Settlement Date&#x201d;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#x201c;Termination Agreement&#x201d;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $208&#160;million in September 2019, $12.1&#160;million in March 2020 and $2.7&#160;million in September 2020.  An arbitration panel issued a judgment in Sanofi&#x2019;s favor in November 2021 with respect to a dispute regarding amounts withheld by Sanofi from its March and September 2020 payments offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable under the terms of the Termination Agreement.  Such judgment obligates Lexicon to reimburse Sanofi for its attorneys&#x2019; fees and costs relating to the arbitration proceedings, which could require a payment up to $2.1&#160;million. Neither party will owe any additional payments pursuant to the Sanofi Agreement or Termination Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes and heart failure.&lt;/span&gt;&lt;/div&gt;Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $300 million in December 2015. The Company recognized $126.8 million of the $300 million upfront payment for the license in 2015.  The Company was recognizing the $113.8 million allocated to the development services performance obligation and the $59.4 million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $23.5&#160;million allocated to its performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $260&#160;million, representing the full expected cash consideration from the Termination Agreement.  Subsequent to the Termination Agreement, the Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $286 million for the year ended December&#160;31, 2019.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:IpsenTotalPaymentsToDate
      contextRef="iaea6bf5e65b144809174989bbe6607b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4MDA_4d4ad066-9099-49fa-9d8e-073dd9518131"
      unitRef="usd">47200000</lxrx:IpsenTotalPaymentsToDate>
    <lxrx:IpsenRevenueRecognized
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc3MzY_a14a6477-106c-4cb6-a198-b58541b13a5b"
      unitRef="usd">300000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc3NDA_1281ec1c-59e1-44bd-a761-8be4a0b71e03"
      unitRef="usd">4900000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc4NTg_a14a6477-106c-4cb6-a198-b58541b13a5b"
      unitRef="usd">300000</lxrx:IpsenRevenueRecognized>
    <lxrx:Ipsenproductsales
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzc5NDM_982ed8ef-bb86-4a11-b026-a67cb02ea142"
      unitRef="usd">1300000</lxrx:Ipsenproductsales>
    <lxrx:SettlementPaymentFromTermination
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzg5NDA_481efb46-1ebc-4afc-83ee-4840be377aa4"
      unitRef="usd">208000000</lxrx:SettlementPaymentFromTermination>
    <lxrx:SettlementPaymentFromTermination
      contextRef="i721b502840b14174be6cc3a22bfa99fd_D20200301-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0NDA_c1426be0-e544-4e84-8019-1136835ef446"
      unitRef="usd">12100000</lxrx:SettlementPaymentFromTermination>
    <lxrx:SettlementPaymentFromTermination
      contextRef="i13c3e38005194277b23efa2e68887d55_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0NjA_1e86ac40-100b-4f25-ab70-474c48df62de"
      unitRef="usd">2700000</lxrx:SettlementPaymentFromTermination>
    <us-gaap:LegalFees
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTQ0OTg_fea1dc6e-9f51-48e3-bffa-ad8c76de3024"
      unitRef="usd">2100000</us-gaap:LegalFees>
    <lxrx:SanofiUpfrontPayment
      contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzIxOTkwMjMyOTAyNzk_3158ab5c-038d-4309-b140-57d820fe92cf"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiRevenueAllocatedtoLicenseDeliverable
      contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4NzYx_18f8127f-e1a9-4515-b71d-4fa7d8e981d4"
      unitRef="usd">126800000</lxrx:SanofiRevenueAllocatedtoLicenseDeliverable>
    <lxrx:SanofiUpfrontPayment
      contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4Nzcx_3158ab5c-038d-4309-b140-57d820fe92cf"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable
      contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4ODQ4_700f3fdc-515f-4b5c-a8db-30191590d17b"
      unitRef="usd">113800000</lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable>
    <lxrx:SanofiRevenueAllocatedtoFundingDeliverable
      contextRef="ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE4OTIw_e944bb7d-f0de-4b82-a7f4-8b8c5d5e2f62"
      unitRef="usd">59400000</lxrx:SanofiRevenueAllocatedtoFundingDeliverable>
    <lxrx:SanofiDeferredRevenueFromTermination
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5MjMy_0465d7fb-2501-4c2b-98b9-a394549bdccc"
      unitRef="usd">23500000</lxrx:SanofiDeferredRevenueFromTermination>
    <lxrx:SanofiTerminationAgreement
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NDA1_b70a40a8-f381-48d5-9a36-b4b8e5bd2038"
      unitRef="usd">260000000</lxrx:SanofiTerminationAgreement>
    <lxrx:SanofiRevenueRecognized
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODQvZnJhZzpkYjhlNWEwM2I0OTg0NjkxYTMxNThmNGViZjk4MzUyZS90ZXh0cmVnaW9uOmRiOGU1YTAzYjQ5ODQ2OTFhMzE1OGY0ZWJmOTgzNTJlXzE5NjU5_dc42da68-9694-4a3a-8eda-8afcaf491cb1"
      unitRef="usd">286000000</lxrx:SanofiRevenueRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzgwMA_f5556f70-c4b9-499b-84e4-b6448e9c046c">Earnings (Loss) Per ShareThe following is a summary of Lexicon&#x2019;s earnings (loss) per share calculations and reconciliations of the numerators and the denominators of the basic and diluted per share calculations.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Add interest expense on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add effect of potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 10,221,278, 11,113,054 and 8,206,390, respectively, for the years ended December&#160;31, 2021, 2020 and 2019.  Prior to the extinguishment of the Convertible Notes, for periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzgwMQ_73a10321-67bb-4928-bbc7-98ee4ae342ea">The following is a summary of Lexicon&#x2019;s earnings (loss) per share calculations and reconciliations of the numerators and the denominators of the basic and diluted per share calculations.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Add interest expense on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add effect of potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtMS0xLTEtMTYxMTg_3b719981-679e-433e-91e3-fef46501489e"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtMy0xLTEtMTYxMTg_e419777a-52f1-4ad4-8210-c467c517f371"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzMtNS0xLTEtMTYxMTg_9f429e2a-d622-4783-b7a8-744369c8c484"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtMS0xLTEtMTYxMTg_a339cc07-ead1-4ed6-9255-7fa89ad81257"
      unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtMy0xLTEtMTYxMTg_ec1004f8-47eb-4565-ba1a-b476bbef98df"
      unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzQtNS0xLTEtMTYxMTg_00b5b8d2-fe32-4389-ac30-e5bac878f640"
      unitRef="usd">5067000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtMS0xLTEtMTYxMTg_e9f12f55-8006-4b60-82f7-a42a164a621f"
      unitRef="usd">-87758000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtMy0xLTEtMTYxMTg_768ae625-8337-4076-b460-52ca807ea93c"
      unitRef="usd">-58574000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzUtNS0xLTEtMTYxMTg_4445952b-c042-4c77-9ef1-d71fc2a82d81"
      unitRef="usd">135200000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtMS0xLTEtMTYxMTg_e1456cec-2bbd-40b4-b1fb-a223edae93a8"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtMy0xLTEtMTYxMTg_281dc9ef-fa50-46ff-9a2d-07656d61d12b"
      unitRef="shares">110841000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzgtNS0xLTEtMTYxMTg_1c5635b1-69e2-4896-9efb-9d3c96f84661"
      unitRef="shares">106218000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTEtMS0xLTE2MTE4_f0c15bef-08b5-4465-8650-8ca9e9a24d42"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTMtMS0xLTE2MTE4_0c5c9fb3-63b4-4d26-a65f-d88b02994462"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEwLTUtMS0xLTE2MTE4_38e17e8f-454e-49d3-b280-ff80e368989f"
      unitRef="shares">164000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTEtMS0xLTE2MTE4_f5630a80-9af1-44af-8902-d1b56b3f9f68"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTMtMS0xLTE2MTE4_cd1f3dbf-653f-4683-89a3-543d9b3c2704"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzExLTUtMS0xLTE2MTE4_1fac5bc8-e8c8-4595-8e1d-5fc79f750814"
      unitRef="shares">10365000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTEtMS0xLTE2MTE4_ecf1ce4c-46ae-4ce6-9138-3e12d80e9d20"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTMtMS0xLTE2MTE4_620bd16c-2971-4d6d-bfc0-f6fd3139c690"
      unitRef="shares">110841000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzEyLTUtMS0xLTE2MTE4_95834ab0-0697-4b37-9481-c55c70a11a11"
      unitRef="shares">116747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTEtMS0xLTE2MTE4_7dd88241-3123-4211-ac52-e6a8ab420494"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTMtMS0xLTE2MTE4_2a661bb3-f260-4014-8029-744f5232075a"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE0LTUtMS0xLTE2MTE4_abd78fcb-0898-4177-a653-f7efa72ac867"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTEtMS0xLTE2MTE4_96de08fa-bcd4-4a6b-bae4-93c614887464"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTMtMS0xLTE2MTE4_6c47956b-14a9-4c1d-b223-7bec6bc30ac2"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90YWJsZTpiNTRiYjRjZTQ2NmE0NzdkYWNlNzhhNzMzZDgyNzNjYS90YWJsZXJhbmdlOmI1NGJiNGNlNDY2YTQ3N2RhY2U3OGE3MzNkODI3M2NhXzE1LTUtMS0xLTE2MTE4_44e46027-cfb1-4991-8bcd-988012f80e7b"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU1MQ_5aaf644a-809f-4159-8af0-42fdedb36a7d"
      unitRef="shares">10221278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU1NQ_3e85bfb8-3764-4368-b6a7-8b79df505216"
      unitRef="shares">11113054</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xODcvZnJhZzo2ZDI3N2Y4ODUzZDg0MjNlYmZkM2UwNDg5MDA1ZWNiMS90ZXh0cmVnaW9uOjZkMjc3Zjg4NTNkODQyM2ViZmQzZTA0ODkwMDVlY2IxXzU2Mg_2d1739ee-5fe6-4fc6-9e05-49c2e1ed3117"
      unitRef="shares">8206390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <lxrx:OtherCapitalAgreementsTextBlock
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzE0NTU_d9de948d-830a-445c-88ed-8100b054c095">Other Capital Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  In December 2020, Lexicon sold 20,312,500 shares of its common stock at a price of $3.200 per share in a registered direct offering pursuant to an existing shelf registration statement.  Sale of the shares resulted in net proceeds of $63.0&#160;million, after deducting underwriting discounts and commissions of $1.8&#160;million and offering expenses of $0.2&#160;million.  The investors in the offering were Artal International S.C.A., an affiliate of of Invus, L.P., the Company&#x2019;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P.  All of the net proceeds of the registered direct offering are reflected as issuance of common stock in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Lexicon entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;sales agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $50,000,000 from time to time through Jefferies acting as its sales agent.  In November 2020, Lexicon sold 3,709,233 shares of its common stock at a price of $1.992 per share pursuant to the sales agreement, resulting in net proceeds of $7.0&#160;million.  In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the sales agreement, resulting in net proceeds of $16.4&#160;million. In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the sales agreement, resulting in net proceeds of $19.1&#160;million. The net proceeds from each of these sales are reflected as issuances of common stock in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</lxrx:OtherCapitalAgreementsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzgy_7dc778f5-c344-4adb-90c6-a825fb8ddc06"
      unitRef="shares">20312500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEyNg_58a09fe3-182b-4227-a0f0-403c8a431d96"
      unitRef="usdPerShare">3.200</us-gaap:SharesIssuedPricePerShare>
    <lxrx:ProceedsFromDecember2020CommonStockOffering
      contextRef="i587514ba7f3d429f8b6ea5cb4ad3770b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzI3Mw_98fa2cf0-d13b-4064-a090-def666d0da81"
      unitRef="usd">63000000</lxrx:ProceedsFromDecember2020CommonStockOffering>
    <lxrx:CommissionsFromDecember2020CommonStockOffering
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzMzNQ_4576d787-29c3-4e9d-be64-c8bfeb9a2102"
      unitRef="usd">1800000</lxrx:CommissionsFromDecember2020CommonStockOffering>
    <lxrx:OfferingExpensesFromDecember20CommonStockOffering
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzM2Mw_62413e5b-71c0-4673-860c-e359a0ff0e13"
      unitRef="usd">200000</lxrx:OfferingExpensesFromDecember20CommonStockOffering>
    <lxrx:ATMOfferingTotal
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzk2MQ_1ec7e2f8-b876-4e3a-b93d-af2802a43f35"
      unitRef="usd">50000000</lxrx:ATMOfferingTotal>
    <lxrx:SharesSoldInNov2020ATMOffering
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEwNTk_053a5457-af0a-4381-8c2e-65e97d29c848"
      unitRef="shares">3709233</lxrx:SharesSoldInNov2020ATMOffering>
    <lxrx:SharePriceInNovember20ATMOffering
      contextRef="i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzExMDM_46d05d7c-f5b3-4b7d-a0da-0ef1672e333d"
      unitRef="usd">1.992</lxrx:SharePriceInNovember20ATMOffering>
    <lxrx:ProceedsFromNov2020ATMOffering
      contextRef="i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzExNzg_dfcbe724-c14b-4394-b848-924aea2e3d1f"
      unitRef="usd">7000000</lxrx:ProceedsFromNov2020ATMOffering>
    <lxrx:SharesSoldInJanuary2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEzMzA_b1c1a426-2114-4312-b07e-664796c1b800"
      unitRef="shares">2000000</lxrx:SharesSoldInJanuary2021ATMOffering>
    <lxrx:SharePriceInJanuary2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzEzNzQ_7fc88788-3d3f-4d91-958a-f4ab91213631"
      unitRef="shares">8.463</lxrx:SharePriceInJanuary2021ATMOffering>
    <lxrx:ProceedsFromJanuary2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzE0NDk_0bd3be89-e233-4f30-9ad0-d214e0725a35"
      unitRef="usd">16400000</lxrx:ProceedsFromJanuary2021ATMOffering>
    <lxrx:SharesSoldInSeptember2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNDg_feb11e62-3335-4123-95c0-4ffa63e42959"
      unitRef="usd">4176953</lxrx:SharesSoldInSeptember2021ATMOffering>
    <lxrx:SharePriceInSeptember2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNTc_8269ed15-87e7-4dc9-994b-2a20112482e7"
      unitRef="usd">4.732</lxrx:SharePriceInSeptember2021ATMOffering>
    <lxrx:ProceedsFromSeptember2021ATMOffering
      contextRef="i09ba3109a243423eb3308bcb07d56ce6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4ZTFkMjk4NjhiMTQ5YzlhZmY1Njg1YWM5MzhhMWU4L3NlYzpjOGUxZDI5ODY4YjE0OWM5YWZmNTY4NWFjOTM4YTFlOF8xOTAvZnJhZzpmOTg1OTU2YzNlZDM0ZmM0YTA5YTliM2EyYjVlNzViMS90ZXh0cmVnaW9uOmY5ODU5NTZjM2VkMzRmYzRhMDlhOWIzYTJiNWU3NWIxXzIxOTkwMjMyNTczNzM_129fda45-18c3-480c-85c5-82d084d8e890"
      unitRef="usd">19100000</lxrx:ProceedsFromSeptember2021ATMOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MEK7]N1"\$*T!P/\S*?7VPCQ@]SKK^G]02P,$%     @ XXIJ5"Z8_GZ5 @
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MD'=)#HOY1:<MT<:-K#>B JT%*Z2LNX!">7,[\<[G-JL% IS2V+>WTR6&9&'
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M<FL>-R+)1*4!\/>UE/7^AQ[@\-GBU?\ 4$L#!!0    ( ..*:E1>-JWC  4
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MLE<1'C)E;$N>2A.UO^7!:=4[/5"72+H'M E_UJ0#^8IJ=CSLZ2/#TN-7YF:
M&=9@GW$9?)HZ9,.2;]%U.O20)(A_\]4%7_8Z1:K&="1TM31M;OI691>,,W\?
M6X/8*N.4TPC-P-C?2U$%WTJ*N,OTNF#0YPPRE)K@^[JAJ"RH ES[MAVE1"NM
M. 2@X:SK#TNLN5R%>;4UL$@>47?J(-2BY-,DZG' T%N32%$;#2MK5>$G*F+K
M$5- XT0$03?_2,A#BR4E%6I< K?*FC+/+0G_2EH>6G81=3#=7(")=>.\]?6!
MK-'HT4RJ#LR9XG)*[1#PDFJ1Q&6O=5 2A&!,@0ZC(:G&U6-H)1=#"JP(0"K
ML![P5_0CU#JJVNW3,V2_3WT0JEISC%+$)>/J*L5KWX$W]#Q0!8<^@!-TLGT)
M?TLJ^D3.)T32FI0K=IGK88*"8%EI5WOAYSQ,C<LUE..8!L?9Y0I5-88FQJH8
M"AOJ^2+ALB3' HZ+$!+5O56@A:KMD#I(D)WF@@Y]31HH(@J*9]\8T3+PR+#X
M'=>;; ;99O)ZEEW.F7"$&E*%-;')_'%5?J1<1AWO*0<0A.0"/I<A$A?\0=ED
M^+C(YN(<R[+/'.\5.\ML5>M[-XB:D&I0 ?14G\L'Z1OJHVTY:(."'%L?WXF@
M1G0>8\2'[P/"%&N?QG8S (D#P8E]AY:59"@FT[$_R]TDC"(:5^*R#8>O8L?:
M5#A1C/KT;3Y:XC/G:<A^JR!454GB_SO[3Q>&K+"#D%I.?>+IO(RI#AZ-A5,N
M''ER9($%Z:@=2A=I.W2>O4D-55S.<:(0$D\5-QS\W&?@.#N/?87@36X0JC,)
M9F"&ECNRE4>4$?57="77!&+!^V>J5@7667$@0XOQL V*-^+6YIL##9R#N$N9
MJ\3%4N14,$X7J1C[(!UV@GW\J*\^=EVOCYY$T*'.#[^(M* "A]?1/#N_+:^&
M)]7]]N%A^@:-T4!\RQ5,-ZNG3Q9#YJ=!\EU^8!4^X;F6/QN\CSG(!JQ7'I4Y
M#L3!_.*^_ M02P,$%     @ XXIJ5('>D"4_'P  ;V   !@   !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6S=75MS&S>6_BLH;SQE5U&T)-NRI5RJY$L25SD3
ME^5,IFIK'\!ND$3<;#! MR3ZU^^YX=+-IJSLS+SL2RR2W<#!P;E\YP+DNQOG
M/X>U,9VZW31M^/[!NNNV%T^>A&IM-CK,W=:T\,O2^8WNX*-?/0E;;W1-+VV:
M)Z?'QV=/-MJV#W[XCK[[X'_XSO5=8UOSP:O0;S;:[UZ9QMU\_^#D0?SBHUVM
M._SBR0_?;?7*7)GNM^T'#Y^>I%%JNS%ML*Y5WBR_?W!Y<O'J&3Y/#_S#FIM0
M_*UP)0OG/N.'=_7W#XZ1(-.8JL,1-/QS;5Z;IL&!@(P_9<P':4I\L?P[COXC
MK1W6LM#!O';-[[;NUM\_>/E U6:I^Z;[Z&Y^-K*>YSA>Y9I _U4W_.RSIP]4
MU8?.;>1EH&!C6_Y7WPH?BA=>'A]XX51>."6Z>2*B\HWN] _?>7>C/#X-H^$?
MM%1Z&XBS+6[*5>?A5POO=3]<\68HMU17=M7:I:UTVZG+JG)]V]EVI3ZXQE;6
MA.^>=# ?OO6DDK%?\=BG!\8^.56_N+9;!_6VK4T]'. )$)JH/8W4OCJ]<\0W
MIIJKIR<S=7I\>G+'>$_3ZI_2>$\/C#>Q3/7?EXO0>9"6_[EC@F=I@F<TP;/_
M"'O_76.K5SK8@ ]^\":8MM.H$1?JT]J 6E1NL]7M#E^H7!O@G5IWIE9+V^JV
MLKI1 5XPH(E=4+:MFKXVJI-7>_P2!GYO;FV%6M;6RL)7-VO7-+LC=]/"2*%?
M!%M;[8&6N7K7=L;+I HXW09-&AKHY85N8%:@67NC3&-!YHD:VQ;4P=-S]5LP
M.//;T%G03A-X/6":MMK3(_CK@47@6&C1;+<#A>O6ZK>YNIJKE6F-UT XKLUL
M<5Z=V;GUL'J[;8"X1W_[KY>GI\??_G1Y^8'^//GV,=BH/WL+# ;];,&@X5RJ
M<_#I,ZPD4DF+U &,X)87W:UUI_1R"6:*N KT.T\S;Q)WX7G3\:N-U0O;V,[*
M4+4-5>-"[XD9L"PD%6<^] [/@EN,+^#?DSS"]PZ1X\VU:7LAP-R"@PCPH>X]
M<@E?VAIO73T'6>QZ&!9X D8R '5]@Q3#8KU:>K>!AUTHF#-7KW58S^B_ZBUP
M\UHWB9JK-1!R],GX#8C0-;Q#A%XDT4/QL+7Q\'33J#688Q# QL(H*#WI!=YO
MY^T*EMW [G1 -[&&V.&-41NV6LXKV.N >[@PJD*:3*8)5D>O@$TRFP4L*-JE
MF0I$:8>4EA,3@:'#EWZ;@[1UX$5AXW8*-J?A-5;. [MQ;VJSZ%0PE1!W:+;C
M^\QVQZBH,J]9%U&.3UY\&PX-B I9-2!68&E0'N";:VT;O6C,$>C240"^%&.S
MH.,[VGMZH5-+;;T"_O5F1KZT5K!O?_8.Y0MLV6< (:!D5=P+<XA4=8W>F0S-
M5V@H'E#P@.I!W%#]>^]120#<L*T((*0K[6O:\#AYIYDPDI#=0&=DCAV8H1:V
ML;%?X,D5@"#1.!=0)6!UH:_6 XI\J5/P&7XD@P6,@L6YELA:PN2N^@Q&% 5:
M=H:D#Z?\._#IX*0S6!_L'6R;V(=K4(JVYIG%?),Y38_!EVYCF,&58Y$I* :;
M"\^'O&&T_JVIT.,H'+PCWT,F=V- I4GSQ3=\!($%E0'^9TWU!B02* +C7Q=N
MQ*='D3R<I47@U:#=\&SL%WT +QCPV88V!W23R,%]A]^WWM5]U9'N!N.O499F
MJC6T)MVB97 WZ%](&-!T53A*Y4UM.V$@&"$'3[1=]B*O^?>/-GQ.JTCJ,C8,
MLZ'6M/7D"D$&V!>K+8@_L)#66<Q+8BB$>9AXJ "Z T.][<@X@8L$-_G%W#D2
M#D&2/Z*6/79!\&*GMHVNT)277\.K:%*/_@2#CLJ0G0:(7^?[#=O$*7LRM7P4
MQKXE*4,]B*8BD<TBNEUK$(#*]!W(5\/XP,(BJW7K&K?:*881**6-J^);;WL/
M>IT\V&^MQ1^N.O8P)1?7H("MZT@0P$;!Y$C+3H4"3PUD ]F-9@!1C!A[!NGH
M=F#J*W N7XQO:$%3\^=]AZ]>G#VDITZ?/2S<Z@S])0HFA"O-+LYT/)KI[I'/
M7Y8CRA@GYZ,Q?@(33\+T54I?GC.E)\?EN&%,ZF4WY0X+.+0 1 ?O"NKI]K9B
MR/F[U>'*K&C,=RW'IE;@9PF&7\?E9N/#)M\0 \#:9I,2>+P98%<+-AL<$;@D
M"UAPZ8!K;,T).@'B<M?&[V;@3F'=;DMDL/O>P&2H%?9+,AXC(4XF"BT0CH<P
M@)0,'U[WP"V< J ![-L5(.=.DTXC* 5<(_YGK&,)DJWU-:S)&!@$1/H:<3P"
MK=KWJTPYCF0)9L]4I_T*[".8 T'6L(H&'*:+?(]TCA:+9@Y\PX:0$0X$N]SL
M),X@$+B&3ZBFM&Q#")=^1)2-( W=#RGLYQ9\G>L[L&05B'^AWQ"_$+B<40Q1
M>1M!LR/G#P3K!<\N;"5/ !]7N,Z6:%U!B-%%>-52:!<_@;_M"1\O/$92]&ZA
MVI>OU2OK0D660;WOP*^-U7>,AC]IF /<XH^PYT#&N[8:OC-4]3T%2KK>W3CV
ML<"F710ABR^\$I[&T7'6-Q"5.% !]8$?W,T&DYX]%SMS^O7)T4A<Z=8M[9X!
M&*\5U-6VA"\0Y/_S[<=?WK[_-5F8P>L;YS%F!-$>69 YA*2HD1U;(<3\)&$7
MP^]-_)X-!PC9VC1L8GM$)3:4,)- #($?) %XB"2@FJ\$UWF-R9HCC*@%L2B4
M%_HU!B,T\K)O0#J6"?9)4,46 N1J!:R00 8#!T ]OC>#@.MBZLL(SA%/20SF
M$)D A1>'P@H2#/6(3+_K RPO/$YC(Z.U!YIXU5E1(PA2WZBGL[.S<_@7)/O\
M[#2]BEH .I;MYP+4<XG:]7SVXN1$G<U.CX\Y^%(4$S1HFM)J=NID=OSR7#U_
M_E3]"BOQZG3V_/BI.G]Q-KGR;]3)Z>S\Q2D2<CX[.S]1[\"261\-X'O7KH[>
MD^&Z)&9?\%<-?<7\!\&E_7/+(\3SLBE+BM?0&M R *" -Y/W .O"9EE"'A(7
M$P['. )-)+QJ,QDW:S"?** ,)*LU;S2B)^NK?H,FN:(O:L2])GLS%$+*I'"T
M3$@: P"9=*-WA#<6AC PB!R"H3F"9/[ ',T1/X>>>[*^H< 1_EX(! */R,[F
M !$(?7%$''#9=Y@M0%!,8' )@A<R%N8I.1/2\11)\L%&#!<DH(WB[O0N<]*
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MW 3I=_B:*,\&0L=\! "W[1([D]0.-2UG1")4+*@B,V^T;^\8[#)'5L/@I4:
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M"E!6:,4,K"X'5^'Y]93DO< 7 5O;&S/R)-'ZD2:_9Y>#,1$"":DC!(Z?#=R
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M!1@2P/V5QHNEF9"![D_*\A]02P,$%     @ XXIJ5-1J9V'* @  %08  !D
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M EA2Y4RY!D^#'J_0Y0H1$78>+6Q-H6!I4%-03LN"U/-[B^5F0R%-)J\\:^0
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MHU'[LO6+8.LX**YLP-@9/PO,^>SD LYS:T._$ 7#_QPN_P102P,$%     @
MXXIJ5-OGS2?K"   11L  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
MS5G=<]NX$?]7,*K;L6<8BE^2*,?QC),XU\S<M9FXR3UT^@"1D,0)23  :$7]
MZV]W05*41-JY- ]]L$42B_W>WR[(FYU47_16",.^%7FI7TVVQE37TZE.MJ+@
MVI65*&%E+57!#=RJS5172O"4-A7Y-/"\^;3@63FYO:%G']3MC:Q-GI7B@V*Z
M+@JN]J]%+G>O)OZD?? QVVP-/IC>WE1\(QZ$^51]4' W[;BD62%*G<F2*;%^
M-;GSKU]'2$\$GS.QT[UKAI:LI/R"-^_35Q,/%1*Y2 QRX/#S*-Z(/$=&H,;7
MAN>D$XD;^]<M]W=D.]BRXEJ\D?GO66JVKR;QA*5BS>O<?)2[OXO&GAGR2V2N
MZ3_;6=IP-F%)K8TLFLV@09&5]I=_:_S0VQ![(QN"9D- >EM!I.5;;OCMC9([
MII :N.$%F4J[0;FLQ* \& 6K&>PSM_=?Z\SLV?LR$27ZA]WMN$KUS=0 <R29
M)@VCUY91,,+(#]AOLC1;S>[+5*3'#*:@5:=:T*KV.GB2XUN1N"ST'19X@?\$
MO[ S-21^X9\SE?W[;J6-@O3XSQ-"HDY(1$*B_]V?/\2(G3W_D/-2@X_\Q?#:
M-=RS!U$94:R$8OYR.7/8K^);EF!1I!(64F:V@E;8@Y')%_;/BDH&MSMLM\V2
M+=MQ#96[TN)K#<SS/>-0FA!HQLL4JK.$6\MF7!-VB>M_^TL<!-[+00I:\U]>
MN>Q?0#G,I%+R,4N%9H!()'"C>&F87+.L(]1DA20K-#.2B:+*Y5[ +E2WA*>&
MF]I(M7^"UF%II@ ]I++;P&$:BAVD:12'LM_(HN+EWNI;H7H\UY)50A494!VI
M9P6M9%D#.PJF XZ#U,L2#(%='EVHR\QTJPUM!3B<9)QBI1!^K)X@G= :W''$
MU>VY\ADW;#G1,/%-J"338!LH(] *W_/^RL#SA52B]<*:9_" JR_01!YY7HL3
M]V!8_<5+#1XL"M"UD5423<H-T9.?7  1;4Z4H15P1 WY9D,^G!DK ?P%>P37
M-7G9J,]7.8AXA,T<G9/)% 6N9:W87G"E7[*MW E<U\B C%\)47:2=YG90C*L
MUP(RW9"$K-PP;)%IG0OP[,,/:6S=S RD"[D,1))";*UD,>0=3#,C#<]965,Y
M8UYM.60+7AVYUVRY@:#LP1*6:5V#.E6M=(W9"%G>3XQG]001.8B4!CR:"."4
MV=CQS4:)#:H8>H[GT5^K#T@'!+>@TZ*XR^Y(T;,%IU^ H&:RA4[+%LYR%CO^
M8MGQA)CZ#F"$XT7A<(UHMA.8F;6!W"Y3"!-(<()XYBR\H.6SY:D-<..8NFJ2
ML<OWKEX;O1P6.:$?.<LH'F/2]^Z(:J2_'P(7[WNXG",&5MX(9GQOTKD6H?\A
MRQ?W#=*QMRW.-97Z1"=Y)U:JAO$-N$"\!QL)KCS#_R>UF1\PXJ@)G6TY;D*?
M.D\.$CJ(H"_:=M%K%DW5M0$Y*S)J%(0IV#"Z&K*=@BJ>$+6#TE):N(62+MG%
MK*FSM%8(0H"O+.$Y>(E;.'.8X5\@H8S<")"F6DE(IK=LC5VPXEE*&5:#SP>M
MP!('/('A7]L&@^U6"_5(?:!L ]]!^TJ"D:CLP0V-@B3C2,/GX7+0WV-="7(%
M !&L^;F]B%+N_PJ<A[WR/#C[3G"$S4_ \-DTU(%QY,5./(]:B\Y1%M)(_!"R
MAH'C+X/OA7,*2^#/H05\%XB>PR4AR?AX];WIZ!ZCV!V>+P%OKBD/UC*'\RZJ
MFP%VMV?>4^/MH11!RLHZ+2IA$>PPV")RZ&N*%?[S$ :7[)(B+FL-IH$_,0TJ
M<UHED*S\JE%6L]_IN I&WL'8 Z=O=M]2?R#JGT[7#Z"!8&VRLL0;\ A6%8N=
M<+E@%VSAPDERX<SA+'+!8A=^YHX_"^#&]]QYS'YI@@-C@!>SN1LN6>A$0!:Z
M002=/@IG;.9Z\TZ!E%V&B_D5B]QP0;CO!R]'?^^_51!JV.(O_2OF!^[,8Y=!
M.*?KI0_7?G#%EJC6.ZG6(C-$[ 0+((]=:$F7@3.;+:Y LT7,+N>Q=X6*1\&I
M!P -^[;/%[ C]AHW])Q +KCOS;$G>V>.%P;DM^429I1Y','-TH4Q)0*M9M9O
MLSDEY:X-$F^"A'-LP?'):.\9'L4;:,?:L)AHF_0 H%"64LEBIE(Q7T0NC&/L
M(G A5KAT$;I^3&>>2M!;FGS?1].LA%HM=9:,:26Z4)_H-:86C1D7D$^LR/(<
M>+C#_E$"WVLA1ZA*>D= G:;I",=*G$)4_^R!XB AZ/G,#:W/C@UV&!_&9 #K
M@4G:.8'X 1\A05^I8W7) [X;'SPP+F: >=^Z <8>&-LQMC#YVHZQX(&/!_"U
M2Y\0? _X^?;'DNLPC+99BNWC</(?Z2^ G7DF:C3*3CT\33,"9V@>O"PQXL>8
MW1RF(6.T&..*1T3;B!6.IC_3HI&ATW91AT%I^5YD>2R<11"/J#A4;V>4G=QR
ML)RQ[YX5S2"44&Y? #!'#J7=W+&5/W,!^2H\>6,G/]7I<W/0AKTC?I9) KV^
MG=_6F=(XMY6P7^FFX1Y>PJ!.[C/M>>SD]G2C)M(7^'HX/9Z:J6%WKZJ>PJ1K
M]F"'F;-62BV/O46'OD.'?J8B/&KZ5Z?MY90]3 K.8KZ$=A AZK9==#X/H<,$
M 7FZ:67A\@H[:-3O<&'S,'Q.CH^->88]:.;Z<W;7 51C'-0^G"& );KDO<8I
M#::#T7'TZ'Q$;Y\<.)M!8XO')FOJ,*HO)6NET"S:GT/'T1%S\_&0?'W"IX[V
M$0REL>/!,-N""()';V#FCSS+"311LW5M:M4DI_Y3(Z#-XN9( V6(25S)/$LH
MAVN-BD+H\/3':\@2E?VW.4.#MG9&;OT'F:D$US6^ Z1'#@K+:^N5YKU+ EK@
M7+3:'PX$S3$#OP^U!RX+H#!O/F*\H&%"&23-E(_'&J@)O=ZW-A&0=@'1[M#K
M]VGOTT8AU(8^X.#AK2Z-_<K1/>V^$=W93R,'<ON!Z3>N8.C4+!=KV H=:C:Q
M;TW;&R,K^E"RDL;(@BZW@D-0D #6UU*:]@8%=%_.;O\ 4$L#!!0    ( ..*
M:E2<2PNW*P,  .$&   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)U5
M;8_;-@S^*X0W%!N0^NW2]=HF 2[7%2NP L'=VGT8]D&QZ5@X67(E.KG\^Y%R
MXMYM[:'8!]L2Q>?10XJB%P?G[T*+2'#?&1N624O4O\ZR4+78J9"Z'BVO-,YW
MBGCJ=UGH/:HZ@CJ3E7G^2]8I;9/5(MHV?K5P QEM<>,A#%VG_'&-QAV629&<
M#3=ZUY(8LM6B5SN\1?K8;SS/LHFEUAW:H)T%C\TRN2I>K^?B'QT^:3R$!V.0
M2+;.W<GD?;U,<A&$!BL2!L6?/5ZC,4+$,CZ?.)-I2P$^')_9W\78.9:M"GCM
MS)^ZIG:97"908Z,&0S?N\!N>XGDA?)4S(;[A,/J6\P2J(9#K3F!6T&D[?M7]
M*0\/ )?Y-P#E"5!&W>-&4>5;16JU\.X 7KR9308QU(AF<=K*H=R2YU7-.%JM
MT6*C"39&V45&S"CVK#JAUR.Z_ :Z*.&#L]0&^-766#\FR%C*I*<\ZUF73S*^
MQ2J%BV(&95X63_!=3/%=1+Z+[X@/_KK:!O)<"'\_P3R?F.>1>?X_,_?]:/@=
M[W7%)2J7B/@)H*2R&%(_9SMYO1UB#0>UUW87H!?4P"GW<'LJ[WE>_'3W,[@&
MJ$5X;PF]509N<(]V0+AV-:;P!R]%;.7VZ -?14Z(LJ25,4?@%S2#,<^)KQU@
MUQMW1 PI;)0G7>E>$>_^98'U'D4GJU#0.Q]UC *T!^X1I.X!E;>B>09##^2^
MKNX6_5Y7",K:@<V/8C:ZTY3"&G?:"A-HR\61Y[-(=>VZ7MDC'%3@'O%YT!YK
MV8;O:]5.4A\Q<G:KROE:N-A30>BQTHUFH#2YP:@Q49%"G!Z#R9$R[/MCGL[Y
M1AK#UIG,7IUG' 8O%VDY&5BRB#UR,@*@7!7@0L=NRZD[%WM\YQ%;YL6K&8<C
MPJ1IF6,Z!?JO2#S"'@,QH?2F&MRXTSGP9S]<EL7+-^&T-1].&%,]XSY#;3SN
M2"!QJH:/A7,P^/^XIU^[,-F#MM.AW\7F&ECA8&GL0)-UZM]78]OZXCXV_P_*
M[Z3N#38,S=.7+Q+P8T,=)^3ZV,2VCK@EQF'+_R#TXL#KC7-TGL@&TU]M]0]0
M2P,$%     @ XXIJ5+I+>=0,"   /Q4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C N>&ULK5AK;]PV%OTKQ*RQZ +3>=FID\8V8+<IMD72!G&ZN\!B/W"D
M.Q)K2E1(RI/IK]]S+R6-QO9X@W:_V".*O(]S7X>ZV#I_%TJBJ#Y7M@Z7DS+&
MYMOY/&0E53K,7$,UWFR<KW3$HR_FH?&D<SE4V?EJL?AF7FE33ZXN9.V]O[IP
M;;2FIO=>A;:JM-_=D'7;R\ERTB]\,$49>6%^=='H@FXI_MJ\]WB:#U)R4U$=
MC*N5I\WEY'KY[<T9[Y<-_S"T#:/?BCU9.W?'#S_FEY,%&T26LL@2-/[=TW=D
M+0N"&9\ZF9-!)1\<_^ZE_R"^PY>U#O2=L_\T>2PO)R\G*J>-;FW\X+9_I\Z?
M%RPO<S;(7[5->\^P.6M#=%5W&!94ID[_]><.A]&!EXLC!U;=@978G12)E=_K
MJ*\NO-LJS[LAC7^(JW(:QIF:@W(;/=X:G(M7\,;JM?,Z853GZJW)@#FIZ\(3
M ?X8+N81FGC_/.NDWB2IJR-2EROUSM6Q#.I-G5-^*& .$P<[5[V=-ZMG)7Y/
MV4R=+J=JM5@MGY%W.OA]*O)._X3?ZM_7ZQ ]$N<_SV@\&S2>B<:S_S/2?UZJ
M>DN?38;7I0[(6(\RR%&%\$W7T6AK=PI_E-LH@\V>[JEN*:B-=Y7*?5NHW(3,
MW9/?B8(<&ZQK6#2?,[K.*$Q5U+Y $[G7UN3)FFQL&^0YKV))A^?K?*I,K8*K
M2&6H+@C2M;:[8 (;Q/N;$D_.NL)DVBK:;%#0\K*@&F9J&\G#(4BYJUUVA\Z#
M0LEHJAKO\C:+*FC+<@MVH1:UA=>,"WL#7"3$[ %E9<V*=LHF$+'(.&7>-,F'
MZ 0C.*BY%_0BJL:U^&'-VJ.S)84S]6,3J,:_6OV21;<FC^1=GDV'<,"2SG*(
MU4/@6.1A6(=03M6V-%FIM@@D&T:?6JQR_/ V3R"\TQX[H.F%^HHC0-+W[&XJ
M8/[U+R]7J\5K,6TO5U:7K_\&^2:6R?!C\6)W*_(9$L?\GNQ#+/[UYL.[-V]_
M44 _F)SZV/U:FPBS;J..'5@_Z4;7ZJN1+9W?N?I(WIOH_*XW9Z8^8ML#6\5Y
M'8(I:IP!<CAV2UZS[[?41*H2TJL%KP#GNAL XAKK[6WE,,U@(DI"UA\HV@=*
MT@7*T@:83Y\SVP; .E7>[9"!NZ_7I+VI"^5Y#(BG70ZI5A1PVC1  0[(EH0&
M,G;[=8E& C_&N.Z-A ]LVV.0NOP2.#R%!NEIUI8D;+"MYK*UIF"%J!GG8_@#
M2E33^M#">R4I6K6Q3?VB07%Q&WF<#(W52/K;=OT;<!>5Y"/8 8-&J8SVR#YE
M/-:Y;-F##.U.JCYZ:."MGUKC4]C=6J1Z*EJKQ=9D%':SE-XUD8B2,+4SZ'J[
M.O?<:SJ/W[0>_ 811:*ZFEL1 INSZE@ZQ(Z[ U5PB<._WCT) 4SD+GI0)PS"
M5")<ZEPT;8P/7>A3',1)53FL.FSPCYS=5]7L6;Q8>@8Q<H(;^4-!#YW@ \>,
M3B6W%Y?GAD.F'TO=HG>Q)VMBI2Y+TBENB1*VC?;1H.JY4>;*I<5:Q]9+>P@M
MVM0#H<]68UIH-,+8PX' Z0(["BAGF2=GY[,5NC^FDNCSKBW*45<X70B!6,S4
MAS3E &;FBAJUD'=URJH/>\W)8G8ZR.20GIS-7@T+?01VJ/^@4A<&6>GT)<*R
MD&-HR:^F$KV^)>_-8"FD 4C7-[],6I>NV'-@(V2DKF3Z*=Y-HK&V7LO32@YD
M+T>R19S,-U:S;NT=!C\R,8[SE=.B4WFK:[<Q,@1_1K5TO7GYXN@4_ )"\R53
M\*<6SU!T_LP03+8=G8+=ZQXLW"YLON79]D4#L7./92[/7X,R&(WB &S"J#*<
M8YI$8#Y1%]9LK/O=)+(PA +F?S/MS0!(H/]29,+2T@S9Y^Q#9Y(/7;9Q0&3P
MSM0;X4\  S.4[=P7QZLN\./9C$M9M$D>KA>T1^A(]#YV5O:Q&YW?6\8OWDD;
M149:$AXU5CH6\B@XX]A,#\932HJGL8"O(P#9 # (AY#Q(^AMTW)H^NZU;R]Y
M+TNZ71!O\G&78JD#4WW2\#U6W*<,DQ9NTET 8?=!!O2VM17V;5K>V+=[3/.X
M^Z/I>*B$]4"T01)FB9WWE7K87T]6BY=#Z3_@5]S,3I:KV7*\H2>?79,Z6<W.
MCYWG+GP-._S:Q*[:D: $J^ ]@Z1^:_-"O.*38MU031M]#QS,05-9+1_EO.YC
M*]A[&>RZ E<'\KRW)"L3L2]U;FY<7<F-E, 'C++1NW2E<IL-9X.0E([?Q-+X
M7*;>KAN@+,!P@<C\E"5TU=9[&FOM(@XI!\MIM$(AM]=1H?_OC&/V!?,'^-P:
M/% (>!]7R/9DJC6JA\9]CGW7$62JIEWHP%8;&NXY0>Z'(!+"D)R8<!! [S(B
MACGT33IS+3#NB!L"TB&HVH8%G(SR9Z9^)B-,*&&X-7PIW?*%:#<F(D,,QL7_
M9-G#HR, ?1SQDU+?,^,!#_2IO2:F I]0=7W]/%&%KB[< 4D-$=2QPRI1.OGF
M9%A+(H,RXI-WYC&18_3=EHER(Y?/<8^2S!;*M+=++J?'6?9,W5!AZIIM/"C-
M?4?*K!-NABLSJ(!-U/"1/Q+Q1+KY_?L2'5N='E)'[W!)JL2-1ZTF[AI2J_T$
M%%H,?1%E;"SHX.RISROST4<M]+-"/MTQF47UIN];P^KP=? Z?13;;T^?%N$Z
M@ C*T@9'%[/S%Y/4?_N'Z!KY1+9V2/Y*?L) 5!QOP/N-<[%_8 7#-].K_P)0
M2P,$%     @ Y(IJ5)K>DD=<!   H@H  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&ULI5;K;]LV$/]7"*\84D"S];!L-W4,)&F'%6B#H-D#P[ /M'2R
MN%"D2E)U\M_OCI04%TZR#/TB\7'WN_?QUGMM;FT-X-A=(Y4]F]3.M:>SF2UJ
M:+B=ZA84WE3:--SAUNQFMC7 2\_4R%D:QXM9PX6:;-;^[-ILUKIS4BBX-LQV
M3</-_05(O3^;))/AX+/8U8X.9IMURW=P ^ZW]MK@;C:BE*(!9856S$!U-CE/
M3B_F1.\)?A>PMP=K1I9LM;ZES8?R;!*30B"A<(3 \?<5+D%* D(UOO28DU$D
M,1ZN!_2?O>UHRY9;N-3R#U&Z^FRRFK 2*MY)]UGO?X'>GISP"BVM_[)]H,WB
M"2LZZW33,Z,&C5#AS^]Z/QPPK)YB2'N&U.L=!'DMWW''-VNC]\P0-:+1PIOJ
MN5$YH2@H-\[@K4 ^MWG/C1)J9]DU&'93<P/KF4-<NIT5/<9%P$B?P$A2]DDK
M5UOV7I50?@LP0X5&K=)!JXOT6<1W4$Q9ED0LC=/D&;QLM#+S>-F+K61_G6^M
M,Y@4?S^#/Q_QYQY__EU>?"'&R4=M[>L'J%]K8)666#YXS81E?"@AIBOV$>Y$
MH=6//ZS29/G6,AAAI(=I$<9ZBPLNBTYR*@;$4"76%#(60HK^#-$<RE)= X8[
M;0(5'96@-"9?..S)L!9$X2E*(3L'Y1.BINQ/U"FD!L/ 0K-%.@KNR0>%2+JS
M"&(C!G<%M.X A3>Z4PYMH"R@3XR?Y V[&A0\95?8MH0J= .#O:_8R6H9+?.5
M7^:K*%_.:9ED<91D&3LO2^1P8, Z%(G-S0+#]G"IU5<P3FPEL"OMP#+OTO3M
M^,^C>+%$_G^P*M$4]3]$YQ$V231^].)I"*UEG072AR%.VSD*\#$N>03W#6KI
M'1/UOD_F>;3(4Y8D<;2:)RR)%U&:K+R)4%78]RA6+1JCG. RQ E[(+-0=$8X
M@?)#,5!?*QG?<U,>VYTLYB_P#NJ0+?+O,VM(I"/#DD6TG"\?B?9#LOS4.P4]
M'T\7\>NPR#,?@&F:_0?S(/IQ]F3!\ T@!J'10_C\6?0IDN^%J[$>R3C"C'QE
M[/U30 Y%G^'+1A5%.8_!L,$]^#I:AUE/CB'YQ&5Y0W6.CXQ&S./J&F0<^6W*
MJ$,\*8M;JPLL\4%;?%**6Z;;PSZ G5 41!$N.R6<1:6X0UM0/:Q,V5'Y5D8W
MHT)CIWGP8V#1G2P?TD[>]QR/,0CE;:\ZU^%NSRWE49HF4;I<11CW*$FR*,[G
M7L\55M$BRM[$$:G<@G_0Y7WDO48P]R@!.^!QIZ$&$H4.0D#41:;L&H.)?-JS
MPAUE:2=LC1.'&WK<4=H'62_,@R<"\"BP3P.E?8H&7_>N"17D6REI]8SSMU!P
MK#OBNO=P'/T_U/STL5=N=C W8$O=^>G(HDALNV&$&$_' >P\S!T/Y&%Z^\3-
M3F ^2:B0-9XN\PDS82(*&Z=;/X5@=N-,XY<U#I%@B #O*XUNZ#<D8!Q+-_\"
M4$L#!!0    ( .2*:E2HMOT<B 4  -P,   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;+57;6_;-A#^*X07#"W@^$6)TZY- B1MLW58UR#I7H!A'VCI
M++&E2(VD[+B_?L^1DB,733!LV(?6$L5[[NZYYX[,Z<:Z3[XB"N*NUL:?C:H0
MFA?3J<\KJJ6?V(8,OJRLJV7 JRNGOG$DBVA4ZVDVFYU,:ZG,Z/PTKEV[\U/;
M!JT,73OAV[J6;GM)VF[.1O-1OW"CRBKPPO3\M)$EW5+XI;EV>)ON4 I5D_'*
M&N%H=3:ZF+^X/.;]<<.OBC9^\"PXDZ6UG_CE;7$VFG% I"D/C"#QLZ97I#4#
M(8R_.LS1SB4;#I][]*N8.W)92D^OK/Y-%:$Z&ST?B8)6LM7AQFY^H"Z?!>/E
M5OOXO]BDO8O92.2M#[;NC!%!K4SZE7<=#P.#YP\99)U!%N-.CF*4KV60YZ?.
M;H3CW4#CAYAJM$9PRG!1;H/#5P6[<'[A/2I_*S6=3@/P>'6:=[:7R39[P':>
MB7?6A,J+-Z:@8A]@BD!VT61]-)?9HXBO*9^(H_E89+-L_@C>T2Z[HXAW]&AV
M-Q24(R@IB/=+K4H9]?!:^5Q;WSH2?UPL?7 0R)^/^#S>^3R./H\?\,E<"KL2
M/UMS>*6,-+F26L1(_-<X?ASMOC[BK1&WU 2JE^28H-E8A(K$*ULWTFQ%CE]-
M@8JXZKLH5/#B]S<W[][\]%XTSA9M'H0T!?I)2]XK8USB"=M\^\WS+)N][+<S
M1%R:OWPJ@A4?R-V2DZ)IG6\ER,2:-"DS<=VZO$)W1/ 8[D7I*)&.?^3@2QE8
M*"-^;/4V)C 1'^!V!9(TPD>C%\"/Q6FD*L1RN_.YD5X<S$]FDQF:0.O8SR9E
M:N"]Q/1!2KDMC?H</3&>Z3I_HT(5MPXSZR"/LLE)#YG"B5C*\\3AT0$T0+ U
M1VBU*B)O/N G9@>2F7I'%8^J-<$YWDD\@;C\4X&Y&:VW)!V80)\(J#P5L5-Z
MQT-?2$@5(7A!D*I:(E*PAMR(L0M:8XXV['B,Q;)%%:W;1C(X*\^Y$*:&(7"X
MY7V>(VR;KEJR1%G0 5$<!R>+ :%]I ,?$1?9U.18Q>ISJ@Y,>RH5URJHZ"?R
MO%1:8;J+V$\BA_R1*,/4JC@,!(Z$LUNIPW80H(E53 GL@W\-;I\NJ XA0V&8
MCE'\,G :+,7:M@PO72H>,.(6+"H=4Y5YI9!MHE.M$.=VS 'XAG*U4KG 1R!,
MQ-N5 #L;E'@GA8@66"E#[U8L"86!4-94[#?H!CSCTR&MI6ZY OS1KB%OK"?5
M_0/9IN;ME!XK6GS$,9&DB#<<&C6K@M62RY!7AZ@]SBW$J5+P#3EE[XG:A9]J
MBWVU+&@B;MN\&H)O;*L+S@[ZUFV1NNQ[#AM6_;@95.Y?MTPJ[U[2!::!L4'4
M?$V)P$XA:"6C:!TUU@5E2NSS<(G'EMNVZ:8)%.#9RJ6F9R IN'Z!2M385VH5
M$AVLI2=<:"Y5)=?T%#MK^1%+M%JA+OTLZ&K*XW'^[*4?^)J(JT''^X=:/M8Q
MF\V_2QH!%T'>Q2Y@#@8CIP!%5/S'X?-EN#VY XH43\-LDO7C8!PC/)@O)L?W
M2Q!V0_$>I;<33'ZP@R5<@#B0+Z6ZKW[%IQ/'S(<.K/@DBGJ+@R=':2H%P<4/
MK"V>)[C/I6\X"62#X^M.X1X&WS@S5CQ ,): N#\/P$#K^+C9ZQ201MQJF!\"
M!Y4KTZ09H(J#Q61Q?Q2\YX1 2MH\%@?9_=<H(X9V71N !!2;^P4^A_.3[AJN
M7^+R:#!LOT3 /15'?SD6)1F>"-%"%FA+%97*M>W!NN:2>9Y29N7_CX?3U^Y$
MT\&-$X=#&>_5((L';KI\[E9W5_>+=&.]WY[N_>_ +Q]WFE8PG4V>+4;"I;MT
M>@FVB??7I0VX#<?'"G]^D.,-^+ZR-O0O[&#W!\WYWU!+ P04    " #DBFI4
M'C,1S6D$   Q"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RM5FUO
MVS80_BL'+Q@Z0)#U8L=Y<0PX;HNE2):@WKH/PSXPTDDB0I$J2<7)O]^1DE4[
M38*U"!!'(GGWW'.OXGRC])VI$"T\U$*:LU%E;7,R'INLPIJ94#4HZ:10NF:6
MEKH<FT8CR[U2+<9)%!V.:\;E:#'W>S=Z,5>M%5SBC0;3UC73C^<HU.9L%(^V
M&Y]Y65FW,5[,&U;B&NU?S8VFU7A R7F-TG E06-Q-EK&)^<3)^\%OG#<F)UW
M<)[<*G7G%A?YV2ARA%!@9AT"H\<]KE (!T0TOO:8H\&D4]Q]WZ)_]+Z3+[?,
MX$J)OWENJ[/1T0AR+%@K[&>U^1U[?Z8.+U/"^/^PZ623Z0BRUEA5]\K$H.:R
M>[*'/@X["D?1"PI)KY!XWITAS_(]LVPQUVH#VDD3FGOQKGIM(L>E2\K::CKE
MI&<7U[9"#2O6<,L$+$N-2"&W9CZVA.YDQEF/=-XA)2\@Q0E<*6DK Q]DCOD^
MP)AH#=R2+;?SY%7$]YB%D,8!)%$2OX*7#KZF'B]] >_#UY;;1_AG>6NLIG+X
M]Q7,R8 Y\9B3-XC?SR'!2M4UU>_:JNP.3N!" @4&ZUN2IL!$ 5SB \](PBB1
MTU:0QDDPC2(P%=-H0!7 "2;K8(R'8188-)IGZ(X/TI":&!I"]#K J5VHY4IN
M+&K,(>>:NHA$"]1<EM"TVK1,6K *F 2R;ZS;ISH41:^HF6\[8YGUCH2P9L*;
M(T>WW.A'[4,6R**D$=1HE2'FGO3!81I&5/-"$$X K" NU'!YFWE;+569WFCN
M%SDWF6I=M)C,O:O<N+G1 <7AT1;'GP]^X ,--]/%Z" *DZU4"']6+@KW2.'2
MQK%SI >]#44%EMHEZD(2+>E]I=4Z7(7+,'!!847!!2?G'3C]7<C[UE"RPALZ
M=VB4UX;)QU]_.4KBV:D!P71)]KH,591+U(&G>_[E(]PP;242%:??.8EDG^_8
M\5Y\+[L48AOTIQ%V>Z]DV54"S4@W0.F441B,RWI7,WOEU,>'95GGD],NN"19
M3D$92L"$KGJO,ZN^+UZ4'0DNNYJZILS %=-WQ-D7SM 1L+Z"=\Z<BUP2G1HZ
MI;QOC_UN?/H;#5);P2?TWI# Y>4*WO4JP^X@K%$P7TED?:<^G^F=<*!<L\<N
M6#X?]*41^U&IV+T/(^6H)':EJX6.[-!Y;>,,'DRC((K\#PJM:K#TW?-,_+/2
MJBUW76%=![B,$+FM_[['*+Y_J/L7IT,:S*+C($G3'Q@.<7A\G.P,A]WF]Z':
MCW_0-[5C^%Q7S[XUM:?[B<F6K@-^R#^=94-4_C_;HW!RF+X=V_@PG.S17;8E
M?95]QM?8V"'23[GO99V0)D$\.PR.IS\2^4DX2]\P\O%Q&.]/N#T17WG(LJH?
M#68P\-(<,#\_")[[](YWKC$UTC!TES47(1KLW8UFV!WN@\ON&O1-O+M,TN H
M.4U_@06I1N&,KE^ZNZ!U"ZL:?RFZ59:N6/ZUHCLM:B= YX52=KMP!H9;\N(_
M4$L#!!0    ( .2*:E39\S$0P!D  +)0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;-U<6W/;QI+^*U,ZJ51<1=&B',N68KM*OB11E7/BDNS-J=K:
MAR$P)!&# #, )-&__GS=/3>0(&2?[+[L0V*1Q,ST]/3EZ\O@Q5UM/S<K8UIU
MORZKYN71JFTW%X\?-]G*K'4SK3>FPB^+VJYUBX]V^;C96*-S'K0N'Y^>G)P]
M7NNB.GKU@K_[8%^]J+NV+"KSP:JF6Z^UW;XV97WW\FAVY+^X+I:KEKYX_.K%
M1B_-C6D_;3Y8?'H<9LF+M:F:HJZ4-8N71Y>SB]>S<QK 3_Q78>Z:Y&]%6YG7
M]6?Z<)6_/#HABDQILI:FT/CGUKPQ94DS@8Z_W*1'84T:F/[M9_^9-X_-S'5C
MWM3E'T7>KEX>/3]2N5GHKFROZ[M?C=O04YHOJ\N&_Z_NY-EG9T<JZYJV7KO!
MH&!=5/*OOG>,2 8\/SDPX-0-.&6Z92&F\JUN]:L7MKY3EI[&;/0';Y5'@[BB
MHE.Y:2U^+3"N?74CIZ'JA;HIEE6Q*#)=M>HRR^JN:HMJJ3[499$5IE$_^+\>
MO7C<8FF:X''FEGDMRYP>6&9VJGZKJW;5J'=5;O+^!(]!<R#\U!/^^G1TQK<F
MFZHGLXDZ/3F=C<SW)##B"<_WY,!\0SO^[\MYTUH(SO^,+/!C6.!'7N#' PN\
MJ:L&$^>:I'$BBVR'.#D^S6O=% T=UP=K&E.U/-V%^K@RD/"L7F]TM:5-9&$Y
MDZM%4>DJ*W2I&@PPT*JV4465E5UN5.N&=O0E)GYO[HN,%*;*58&O[E9U66Z/
MZ[L*,S7=O"GR0EOP9ZK45=4:ZU958%75:-:VAD?/=8EEP4AMC3)E ?EE<HHJ
M(0]/3T?8^S2P]^DH7SXUAHA_U[0%=-4T8QS^MIF$N;!Y&VV97/KU $=I7V0J
MBW8+16Y7ZM-4W4S5TE3&:G"1&&TVQ ,=Y6UC<13%IB0=^_X?ST]/3W[ZY?+R
M _\Y^^D1C-]?78'3AMY7L)2TEFIK?/H,KGHJF>&Z@77=R &T*]TJO5C _/$1
M@_[:\LKK<-1XWK0RM"STO"B+MG!3Y463E773668&MD6DTLJ'QL@J)&\T@/X>
MY!&-.T2.-;>FZAP!YAZ>I\&'O+/$)1JT,;:H\RG,4]MA6O $QK<!=5U)%&.S
M5BULO<;#=9,P9TS SH* G8WKKVY63!C_\0Y'<JM+VM*8I#T\Y61O/E[D9@7N
M''\T=@T=N\5&F'L703E)?XK<6#Q=EFH%WP,5+0O,0NH5!H@0UK98XBQ*B$P+
M9O)Y\1E98]1:[')M%02P(<&:&Y4132;2!);S$%A=LYZ#R][R3E3#E+9$:;HP
M$]BT-.C3%"K0 C- FK8*$E/*'K/:0@9(8'(S;U5C,D?<H=5.OF:UD5E)C]^(
ML2+EFCW[J3DT(5FLK(2LPR.2D.*;6UV4>EZ:8RCX<0.^)'.+]M$8;2T/:-5"
M%U:!?YV9,'#(%<[MKZXFH8?/_0S(!<W/_%F80Z2J6X(B;(H?H"%Y0.$!U4$'
MR"9UUI+F LJ) 6N@.4MM<SYPOWBKA3"6D&U/D=T:VZGZ5.$8R^(+GEP"\CDS
M4#>DI]A=TV6K'D4V571\QH]L1<$H;*ZNF*P%%J^SSW S)-#N9%CZ:,E_@D\'
M%YU@?S@[')LS6K=0BBJ7E9V#8W\3'L.7]=H(@[-:1":A&$X)SS?QP'C_&Y,1
M,E(T><L8B?W VL#.Y&/&Y5DP+L]&+<%'J^&):0N_8T'K\5>CKJ$"4$*<Z)B9
M&9]\8+*+[_\Q.SOY2?[O;8HUT!WPKA5B_"@;1A$CB1\5X>&2S*X57SGO&JS9
MT+,EBQ&L"#..)!2_;VR==UG+5J8Q]I:D?J(JP]S7%=FP^HZ@ HLM6?Z,9LFL
MR8O6'?48FY\'-C]_"(-E.$'GQJ^+YK-Z&_S<$&._93ILY8T03!,'4QTLS:Y-
MG?0-3I4/LASJ(T!/;6 Y('W,^&1=UF#'*8N%^[9#MW"\FY;M.N 7(-@7,SH3
M3<%&8X=:@8,)P?.MVI0Z(]><?HVAY(V._X*#)CL200 TM[7=6MS)D"D>VC[I
M<5>Q@I()\58VD"W:O5EI2&1FNA:J60KV++#);%759;W<*H&HI.!EG?E1[SH+
MDQ@0R:>JH!]N6D8,J8*D#%W!C%5URT(*2P\ZB*RM:I+HJ2>WQ'DRIF/R>Q[D
M]WQ4X&[,DM'?-=M48OVX^([.1@'_1;,!VUX>L8S96W,4EKBJ).0O7"201H=O
M."Z%K8YX1'R+X?.'68\6H9'Y)@@C"C@'>#SXO@)(>%$CO!6WP< 1&ZEOC=U.
MX+=O35EOF S!"6LL1C)4? FJMG/DP<*0 :'Y"&^P2-+#JP[0F98 !H'MOT$0
MTVK6 (+D %#.T>U*9 "D*WV+/1F#27#JMQ12$<S,;;>,E--,!0<\$]5JNX1Y
M@_*X& >[*.&9:Z]J(](P.XG!^\FH/'P@ ;;0,F(304AFVF!X/CK1L"@,SWZA
M>M\;_[T$''"=*U.*IG;D0HLFQ43L<=E3DUG#D9+&D:@L'0BQFM(HQT2?<Z^*
M>,N_>CC/,R^Z$O''(F 4%Y:(E"$07>+47"A *!<^T':F%[)<#'WID20Y?Q?%
MU.2<0.'%(0S,T%3]P,ZQ[AILKWD4YB9N:INMW*ZC9'L_J+Y33R9G9^?X%W#Z
M_.PT#"6CA1 HZN <8>2"<.#3R;/93)U-3D].)%)0#&!+$N^PFZV:34Z>GZNG
M3Y\X5'$Z>7KR1)T_.QO<^7=J=CHY?W9*A)Q/SLYGHS*:))AFHS)Z!94JK&BB
M)7NUJ0$+.-%05\OC]ZQ-EWQZ8Q#G&U89F+F/=^C7DG_5;EW+4E<OC@DR.U%:
M<$BD&X?NX<C@']PXP$F(6,$>RL7##'4)JI-QP- B4G2W@N$@4R((*%N)>)*7
M+6S6K<D89?Q%3M#2B"J1\)'J<#I'HF0&JX2QW:)KO65G-#<,WJ HY#2GBI">
M?!)!B*&^A'=[*KKFX Q_SYVO! P0.WN "@)M-"--N.A:2A,0G&/4L("^-!'%
MR9*2 FEEB:"P4W75WY'S[AS;AK'"2I-/>&#"6/F9M@[G]&5_*[R.T#S&TL1^
MF/O,&,+ I/DA@.L_-'5"Y9;/6:3%8/0#'ED0W(#N'6*E39?A@(QL),_=F+($
M@RH7^B8.*MTR3B+A"&$.6NN[V?0,@ \.B?QKC0%PCZ9/PL#6^/!Q]O0ST#V>
M76\ZEE3"0'_4=5Z2>9NHC^9>-]ZI8W_&14Y5-(^.ZIHHC*8[C8IYN_$GVJ^D
M+AMB,BV)>7GRJDXVR1LL]Y58XCV:85Q7Z4DQW#51.3L?@V:STVCH3D=-T"_@
MSATXSHIU%1?]"MOVE1-'(]>S9^'W0J I1 O@\ OIR[QCEPQ@Y@22#!IYX*IC
M[+-CJ'2:*B1&=A7A6/):HX X-^1_"DH0!SW;F:00G2+)HIA04A'XT>%#GV]T
MT3I)HLM:#&41IPDK_,RP&@#=+.Y$ G!IPWC 5(?4?NGYYI6>E@4WRJ(GIWL[
M7Q06/ 1'-SX@3E@(()J16!<"_#UC#AB4'2:Y4*1R-A@3MSZ4[FMM*NQ^&STZ
MKQ:[*Z:6;7>RBHRX98P@^7LBWZ6=Q5'T%%"L##_BS5!O\<M<3H*"OD2X*!IJ
M1(')<<TYGTM1AF1:M,O2%&O*OF#VH@?*%6(M.CG*>7Z%+V4AN./$<,^M3A2T
M@T#29U.2@\"JT)G) <L81(2DG/&_]T6C-B,6G69/1E7[6@(,]M=@Y$.EH6^?
MC=$Z14;JVL<R'VQ!,5(]&/'XC,V_WEW_]N[][WSV/JD3(<1'8V^@P&RA]89C
M,!BX]^_?A *&>R+4,' ^-U3X2#R#"]EBD-6#WC'H8YJ:E"BG=;V G2D-3\Z[
M\C-B,)C?MC<2M%]M&E-- UO"ZNQG$K\:+8>+=E4];S7;.*J&V/I@U.@VYKUC
MG4GRHMO4%#Z24T*LZ-7:3=[/VB1D[' I),TV,%.9RQ!QO": ]1;(C;_U(,J5
M&Z.Y"+DV&1!V)TD+'&-TR-;,I90&+4,X.]?99WS@>+?C!)8U0'Z5?-?: MZ&
M;(>+;-3"T%@ZER6!T8JM0)C3H3[UFR'M!.\_:,0Q;Y4 UR40H][@Z6(]IRQC
M2"[M'?R$)B&:NH:\QYP:#9B;:0%(3K>7U%U3*.K,@/,)+N DMD#FS2WE.A8P
MB#5,CB?7NR66 2UU*!8]$-/AR:VWFVN?X\O!8<L)=2V!!.P/<#(G.#WSYYWX
M)OR\T5MQ))2Z W.CJ#:K8K/QC\%PY1$MR?X2X*QAT,L%+)>87NI]X)JD.!<1
M7Z[7+LB>'C &GCRG7,2!9+4TO1XRZ:2 TY @<@E15T(]/#W/5U/Y#M.1"".,
M)CZM&U=\?$B4)SVA$SXB^-^T@9U!:ON:%J,4SEZT/:K8>R!ZKT8FNZ2JAA0B
M^Q ])\0M,QLZC+(7<%!Y,LSB$A5U&Q-9SI3Q>1TR45.8U&33_*LNFSHNS?/V
M9]2, +;R-.V-YKD6I;Q0EWWCX)0UM JLP5BV#)'TKLI=>D84N<C56\J*R90D
MNTNKUWZ)4.W501W9+/:T:6F-TW>.P)=<Z8TZ)37-33>' :32#91._6"FR^DD
MD/#(ITIH\[=<)PV;Y*5#T9FB=;UHW1867"6E@([ZCB@&$@OO64C!3)P:H1 D
M O M*S;:Y2K_E_<UL WN].C52\(I)66K:([\42D;W&00>MAKGU,=3LE' ]HK
MS"3CI&X_'S2RA<V905M?[PS)L& ,^0_)]WMY#14W76*DR_-2@BHY%^?/XZ'R
MTK'-HJANZR)SV'6CN2B.L[%8G6I\,4K1E C#0;A6E3X&20+7$":+#N\D-Z ?
MY!;RD'WV7N*O#MLW-BEQB"$&^BF[AK,H.P30#)^K^JZ"9C'AGKF!-QO&;VYF
M3J X 7-Y&#^ [*CGJ8EM,:F-TOF?'6]6YI3V"D]2".^EB83Q@& 0YX;=X\0H
MGH>D&+8_8H6+] .K1K0;? (,C1*GI+/4*P))=1 6S:82,M)2P$J[T?ORL26=
M"BBDMD1[38R1LC@A%5V4Q*\W POYG<;3CW4*:K42G?S58,55,+I7%9C:,N2A
M8F9='4-+25DS^&4&Q.SM#7FN,H5 5'OCC*O;'D<<A6:>_NP>O^D \+;J)EO!
MEE/Q-\JV9TH>03IL3V"M$)^Y$O=7,(I.$RC.HSQJV\H^DV#[VHZ49]@[DX3.
M37MG'#;FE43!7+KMP05#O6V78)G&5XX?G,:MUP?0?<,88:NZTXEQ%/T2?XCU
MAD1ONH=+WWA<^HO>")[9?8(J)YDMN/]*2D/>?#N_R1U<'2%*Z*G KD5'3D-Q
M%B F7'=G+JJFL\X^)>B8]KBWJ.MAP-P(-20#!2A9'"Z[]FT\%UJ\=1O%YGUK
M__<,N4=L?QK7/ACF7>'(:\LU/EIBJGX&QQ+7W"<)I_S_RPGTC'TS8.T7CAW_
M9]:^><#<U\<>%5.WE*1?+B P(G(":I)@/HHR&>@UU0R,I;C:B:L4+/JXR$C[
MJ @S)[-9S##MP-H[_0^NT*63LAB;AJ&A4>H<CS>"7B/*"Z6XJ#32WL*/X?"-
MM%^ZFB8KA<-NSD("$QT+)M(Y-610R9,"3.)D*!!C;Y<!+8XEFF+S\>RA[F,)
MT&[(Z VFEKYA_(52;]* ;[=H&O<8[5T(52>04>Z5=QTEXMJYRKLR.G<1)@ZE
M=N5AEJ#='-!4?7U8/!:H]K;!P5-XVFDZI=)U:IQWZPDL3]Z._>U:]NQ'M24#
M-9I?C$W1L_%>YNNT^OPVJ3Z_D^[:T63CWYL:4G)]J/8=>GM[?9N--*5'(^H:
MRX^;#76+6^DAO#,42C=I/\6M.5QF=\;6-U4V)B[$(:T3/\ESRAS'/N$99#+0
MZT,\]P43Y$GNUPEB[Q'X2\]*D,Z^P?]6^#PU=SEQ3"52>G@W+.*W7!"#5P6B
ME.T[9\#5ZY0\AM:!0)5VOGC,T1Q.8QI!LB[#%3X @NE2\'Q,X.\8-W<T-=T3
MF$#Z<QY)35L,MSWDBCNM[5)73M.$SS77(^"#<C:/ZF=!.X&,INWR8L_'L;UO
MXHDEP7C4.9!-I!!LP.;IWA#+6FE:AQ9<04EH7"-P  BI#!4\Z*835-S1LT],
M%!5K@O=)B.#^R8[3X.0YO)LTE84\)ZOGG>U9'5I@*T71$03G05%*UM:;U,H;
M5\+8E/LKXL4H"4@8/=SH"F%,0#&I^)&EK,$V&*NR_@)!Y8>V&Z-.H4@:D8'3
M$6B-Y0[H$F(Y2=66IKPK2*P)WH1<6"1BL@,L]S87&F="]5\P)[OE!2@*E7D^
M"S+E")F:3DO#@#]6!TW67=G2W0LO:/O'/RBBHK=4<Y1,&XV2ZQGY_@D4TN9&
MV<6Y6>ERT<<HZ[HJ.,?LI,$)@[3-N?03T( 4]O<F[E5HXE&Z.,K<M](["I##
MZ&EEZVZYDDI;Q1DH:2_'U ["N^Z%?D[8AULIER(I!;#Q;8%_F@<E-#=T)CX)
MCV]-*8V"K@$68I]M_5$/X*=(@O2P1W>KVXZW833W&0HDX]/TB57^AD*/7#0X
M/01!M[0=1 Z&"H!,;NJK=RJZ10J$1=\K0[5?OD]GJ41C:T!M"AR"-!=)6R4U
M[(KPCGO[>$-E-GZ?Y 8AECF6M=XDS6,3]?LF(-<K;ITEI_$!P48S!@ >6(V:
M]H]?[ZUV,5S*:OK];,Y.^FI_<D-(BG^P]"N*$6^-:]E7/U#5^1&;G";9J(/Q
MO?X/OD^@ZDUT)M3[CRB2VTSX1ZJW4\JTZ436 =S+>LL5J[1,5*3].;%9-0D&
M(53<WDK&1.S&P"Z3@EZ @"Z> @-<X%4%(GKE=Q#G5" 4.2A:NI?2=[#3LBU]
M!YV8*CD;V<@@032*GQ4S6'>M]^4^ I82_DZ9GV.C'6C+Q?IO7_(KU]OA5D@L
MY%+0-\/3T"QI4PJ[ W!QSK51G!QG'MV],K&(WAP)[H_EU=Z<:VI9.WP5ZA +
M..K@_5.O<=<2!LNEZ^-66G.^6F(IQ?'=[.GTW'=W^;B]V&NYVV6CAF>E8S/Y
ML79)DQC3SZ:G7Q%XQ/LLL_$[)^^T)9@$\X*%V2Z-AAKCD]$5H"MG!-ZS$=A0
M;;%>PW/*Y!=\3:AO*.B93)YA>\&MR#B5KM]S['FB/$\B.N-AWB#Q/')*\0"G
MLOQ^O JIP70M^URZAS;Y^A-VR()JC^&B1DEUG!*4<\F.&4O;<_NJ7(V18P#V
M0W7;BWJ]7>K:@"EENGQHOKG)-$427"=D& L:^'E8XU'QB/=P9N,W9Q[JE1O\
M*C>NKX\[>T?E:7SU9*JQ=EY.!_C6N4,=<Y4$6884S#4:$3@!A].G+%\@;CAC
MIOZ@H,R9+2^%@WU2_=!&VL[D5TB<7+!QX9]K4NCA$Y#%$90TWT5H(@DT769=
MZ6UHOS&-'>,N1^BR]R*]@3P'<,.NI?_"E\"]4TR)Z^^'J^QL2@?:L&)*=K]5
M;O^,,(E<6:71@_T+_9Z_/CL#!YK8_QI&)MU_O.\'^F9['81IAVOKFXCVDD8@
M_LX6;4M72B@2PJGT!_/M>FY/G81*S&Z?I:98?+DT[,BX*<XYMA#RWINL2\/(
MCSQ>K$!(,8K)<G'?#]S/N>!%8#K^"1.D9C\^8DG?O=(FA\Z93I,5C>LU;GK7
M:^CNIERZHL?KSF9I,7,GNO2Y8 ?6>Z#N_;]F)T]F0@?]^41T$5Z<&[W4O$:,
MJ9IME6-R,_$!S%C\*CS&CBKWDA#)-5*CRRYC#Q\"'=L^;7X'#Q!)62S#;R:A
M-J1J3TXF>YT]_99XYTCHXN9>+[B4O[@;_/3Y]$P24TE/^-6'Z^_U>O,3_?=6
M>J)GYRXL2J:1UG%_:]_E/Q2]:,5I J;Z8FP]]0W;?$,NG8%L2C"YZI#)E:;L
M$VG*/IV-.IIX86XV?F/.P8:/^G[47_P'%^7BS*8Y&/)@TX:UL=7W>Z]82.Z9
M]*INSI'3$#IWQ &F<M?$7>,KRUV\DY8 /5^G;;G^%9I:AE_#@ 5<!U\_(<'W
M\FAHK)FX_'51I2^N8-$6-K3$!KH?+MU  I4Q8O)5+.#6@*A6O3Z] Y7G@5WM
MVONXRSG?XJ%; \/K"QHTE12!F2^A6:;4=RR;1EZEX9C*4#G&;GU"FY"$]6B<
M:FF6KAZ^3;F1[-YG''SW8;SK&&M2[#*/Q64>D],[)I>9P;3 3FDBQO.0+^4N
M,$)FY= _5,:;%6-+"8@XL[*3CM*DFWS/?G \/G 3:FCA=_=<8\XVW]_DE*^T
M<[JFW/8=L;]1&^_-T+MDZ-1<]9RS6PR4ZATCM$^'R !X*(&FE)B\A/J+N?UG
M0@9^Y^4)28\393I%*25@PG9^IP/Q22.)@65;0RSCF-8A-ZF6>PXEQ/G+*1R0
M\'MA:LK0WLH-Y<HL!4X9?L5!QF97IG1,V;WQ)<YOX"3D1M%L]T91H._0+B2!
M'!S1'D6ILY;Z]YH %CWB7Q'AHWFYE"E*)"G:_5N57+7W+ B[[B^1M@S06WGD
MD/P['BZYL4_V)3[+Y6@"Z3[9N[?.#E:L8U%0 *Q3(GDOCOA KS<'^?<?*0ZA
MZ\%+ITN0ZUY/$:YF9P&62E3K/^T=U52]]F:%4I"]:S9I0H4[F)SD1U;O,H<X
M(1B$ P$R=7+#$WN?<"ITM\%E4+QV0FA^;<P01P:T\5? *BP[D:OXW*@LV;&"
M.K?G?QK7O.G*^CL[%.;WVHR=6:![*O']"TY&L*%];71Q"V>0DM!  A\QL)*'
M7EHR4_O["LT?";TCK'(S,]KB3/,]YZCA]K][<GJ67/X#87O",QV\VOLX>8W<
MV@ ZTLOR^.U*52MOE O?AA?R7<IKZ.+C\C:_WX \R8.49H&A)]-G3X_DCJW_
MT-8;?BD=5+*MU_PG55J-I0?P^Z)&W.$^T +A-86O_@U02P,$%     @ Y(IJ
M5#)4MB>\ @  % 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULE57;
M;AHQ$/V5T4I(K92P%P@0!$B0I&H>HB!(TX>J#V9W%BR\]M8V(?Q]QU[8T J0
M\L+Z,N><F?',,-@JO38K1 OOA9!F&*RL+?MA:-(5%LPT58F2;G*E"V9IJY>A
M*36RS(,*$291U D+QF4P&OBSJ1X-U,8*+G&JP6R*@NG=!(7:#H,X.!S,^')E
MW4$X&I1LB7.T/\JIIEU8LV2\0&FXDJ Q'P;CN#]I.WMO\,IQ:X[6X")9*+5V
MF\=L&$3.(1286L? Z/.&=RB$(R(W_NPY@UK2 8_7!_9O/G:*9<$,WBGQDV=V
M-0QZ 628LXVP,[7]COMX;AQ?JH3QO["M;+N= -*-L:K8@\F#@LOJR][W>3@"
M]*(S@&0/2+S?E9#W\IY9-AIHM07MK(G-+7RH'DW.<>D>96XUW7+"V=&\>@Q0
M.<SY4O*<ITQ:&*>IVDC+Y1*F2O"4HX$O+VPAT'P=A):$'3Q,]R*32B0Y(Q(G
M\*2D71EXD!EF_Q*$Y''M=G)P>Y)<9+S'M FM^ J2*(DO\+7J-+0\7^L,WZEX
M?XT7QFHJF]\7!-JU0-L+M,_EF;HIVPCTB5XQC=>NEC*8LAV5."5\RW1V!7.K
MTC4\EZYBS16\,K%AOGK'AMJF.CZ5_XOBKK'[IF0I#@/J7(/Z#8,1/+R7U!KD
MPZL2)"*XW<&,F_5UKA'A45HD6PLS9O'#]@5U ??\C6<H,Z!GP&*!NGZ*/CP4
MI5 [I/S%4;L!4;/;@#9$T(#GG(H+M0%&2*GD->Y-(>.:V!5=W48-B)OTT_&0
M__FC8_[;GK-M?8:^=^,@Y%;W%'U\>TS?(_JDF7R&OMMUD$X#>@YRJFK"HTXM
M4"_]/#+@BZ]JVOJT'GGCJM,_S*MY^<3TDDL# G."4IYO M#5#*HV5I6^[Q?*
MTA3QRQ6-;=3.@.YSI>QAXP3J/X+17U!+ P04    " #DBFI4^;,.N"X#   F
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6S%5MN.VS80_96!:A1K
M0+4DVI*5K6W N[D"#;"(L\E#T0=:&EM")-(AJ76V7]\A)<MVN]ZDZ$-?K.&0
MYYRY:$3/]E)]T06B@6]U)?3<*XS970>!S@JLN1[)'0K:V4A5<T-+M0WT3B'/
M':BN A:&25#S4GB+F?/=J<5,-J8J!=XIT$U=<_5X@Y7<S[W(.S@^E-O"6$>P
MF.WX%E=H[G=WBE9!SY*7-0I=2@$*-W-O&5W?3.QY=^!3B7M]8H/-9"WE%[MX
ME\^]T :$%6;&,G!Z/. M5I4EHC"^=IQ>+VF!I_:!_;7+G7)9<XVWLOI<YJ:8
M>ZD'.6YX4YD/<O\6NWQBRY?)2KM?V+=G$^9!UF@CZPY,$=2E:)_\6U>'$T :
M7@"P#L!<W*V0B_(E-WPQ4W(/RIXF-FNX5!V:@BN%;<K**-HM"6<6MUP7P$4.
MSGCUM2D?>(7":.=\)QY0F]JMKS[R=85Z. L,Z5ITD'4:-ZT&NZ 1,7@OA2DT
MO!(YYN<$ 07<1\T.4=^P9QE?8C:"<>0#"UGT#-^XK\+8\8W_<Q5^7ZZU4?0N
M_?&,[*27G3C9R079%8U8WE0(<N.4_:?U5X54YA>#JCX-Y:D^/"MGY_M:[WB&
M<X\&6*-Z0&\!2VWEJ:)8KU'U585E3:KEGTA%D=K &R6UAGM!DU\Y[QN:>/U/
M]V^T1NJT-B7-##E>\U+!)UXU"%>E %/(1E-6>@A]U3-KX$G6 T@F?I@D9/S\
M4\HB]BM95]'PL!'#"K-&E:8D*9(A4VQI<DQ!"E(@/")7UW _6HW 4&BZ48^@
MCY"I'R>LI[;$UA-1IFHG%85-@[TVIX@H]B,6'R'IT+FB*7R4AE>@CSTJ3UZ7
M 3#F)^GT/)$7PVYCFG;P[&(IK/.<,4W\:3S^6VG"8;<S&5_H:/@_=S1BB<^2
M\[B/UF'WA_IZN4W$$D8IQ%01:JI;L>]VJ,4,"#5H<8-SY+]I3A0SGZ71.9MS
M3F-XZI,1G'R[:U1;=T-IR&0C3/L9[[W]);ALO_W'X^T-^IZKK>U@A1N"AJ-I
M[(%J;Z5V8>3.W01K:>A><69!%SDJ>X#V-U*:P\(*]'\-%G\!4$L#!!0    (
M .2*:E3!ID"DQP(  /<&   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;*U546_:,!#^*Z>LFCHI:Q(# 76 !.VZ36JEJG3=P[0'$PYBU;%3VX'VW\]V
M0DJGPE1M+_C.OOONNR_X/-Q(=:]S1 ./!1=Z%.3&E*=1I+,<"ZI/9(G"GBRE
M*JBQKEI%NE1(%SZIX!&)XS0J*!/!>.CWKM5X*"O#F<!K!;HJ"JJ>ILCE9A0D
MP7;CAJURXS:B\;"D*YRA^5Y>*^M%+<J"%2@TDP(4+D?!)#F==EV\#[ACN-$[
M-KA.YE+>.^?;8A3$CA!RS(Q#H'99XQER[H LC8<&,VA+NL1=>XM^X7NWO<RI
MQC/)?["%R4?!(( %+FG%S8W<?,6FGY[#RR37_A<V=6S'!F>5-K)HDBV#@HEZ
MI8^-#CL)@WA/ FD2B.==%_(LSZFAXZ&2&U NVJ(YP[?JLRTY)MQ'F1EE3YG-
M,^,+RA3<45XA7"'5E4*KN-%P?$OG'/6'861L%1<;90WBM$8D>Q 3 E=2F%S#
M9[' Q4N R-)K.9(MQRDYB'B.V0ETDA!(3)(#>)VVYX['Z[RQYY^3N3;*_D]^
M'2C2;8MT?9'N7XN$,'^"*>549 @S?].^*%F53*Q>4_<@K+NCI[JD&8X">PDU
MJC4&8YAHC;8!*A9PR>B<<6886M_ 3J\3#7()5DPLYJA:0>$2U\AANY)F[<"M
M-)3#,1-@<EEI"ZX_;"N=49W[<IDS\*%B:\J]B$>0=L,X[5GC_;L!2<BG%U9S
M.,NE,A\-J@*86*,V]1?HA[TT@:07)DF_32(D3/N#ADZVM[#;W,4Z@GX2IB2U
M1@.XRV.0AOUNYU^$B_^[< E)0Y)V]BBW/=TC7:M6&L;V"O[AOEV\9S(-Q LN
M/1*2?@]>NR?1SC J4*W\R-60R4J8>BZUN^U4G]3#[#F\?A*NJ%HQH8'CTJ;&
M)_U> *H>L[5C9.E'VUP:.RB]F=N7"94+L.=+*<W6<07:MV[\&U!+ P04
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MIIB^!_!)72LQVDD\BPXB7F!R G'8@RB(P@-X<1MR[/#B_POYYV*EC:)?\NL
M1[_EZ#N._C\X>K 4C,#?47V4U(-PMC(GNF()SCPJ/8WJ!;TY7&K#Z5]B"H\:
MLUK #7UP#0L-,@/*&A8K5"YSUR7\0*:T2Z$= NCP$DPN:TW2=!?.95'5!LG$
M2M4R,QNF$.+C 1Q!W NBD9O'T1"N:E5R4].M-<WXJUUK&!R/(.P-3R,:Q\,1
MW" 52RY%"KRHE'Q!&[HF1&L6AP'TPQ$\2,,$5/LO@NV+#(GVE,:0C&]0ZPDL
MDJ0N:N%B3I%2D7#6%#<YLD(JPW\W!YU^;SR(N] 9],;AH M?J;]]0G-$>L+1
MD.;H=  ?/;Z_5U\%JK7K(AH269>F*;7VM&U4BZ8^_YHW7>Z6J34O-0C,R#4X
M&0T\4$WG:#9&5JY:5])0[;ME3LT6E36@^TQ*L]M8@K9]S_\ 4$L#!!0    (
M .2*:E2N#XNU0P0  (X)   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;(U6VV[C-A#]E8&[+6Q C27J8L6U#>16-,!N-TC2+HJB#[0TLHF51"])Q7&_
MOD/*EIW4=OLBD2+GS)G+(3592_55+Q$-O%9EK:>]I3&K\7"HLR567%_(%=:T
M4DA5<4-3M1CJE4*>.Z.J'#+?3X85%W5O-G'?'M1L(AM3BAH?%.BFJKC:7&,I
MU]->T-M]>!2+I;$?AK/)BB_P"<UOJP=%LV&'DHL*:RUD#0J+:>\J&%_'=K_;
M\+O M3X8@XUD+N57.[G/ISW?$L(2,V,1.+U>\ ;+T@(1C6];S%[GTAH>CG?H
M/[O8*98YUW@CRR\B-\MI+^U!C@5O2O,HU[_@-AY',).E=D]8MWOCL =9HXVL
MML;$H!)U^^:OVSP<&*3^"0.V-6".=^O(L;SEAL\F2JY!V=V$9@<N5&=-Y$1M
MB_)D%*T*LC.S^SJ3%<(S?T4-_6<^+U$/)D-#T';#,-O"7+<P[ 1,P."3K,U2
MPUV=8_X68$B<.F)L1^R:G46\Q>P"PL #YK/@#%[8!1HZO/ _ X5;H;-2ZD8A
M_'DUUT91:_QUQD74N8B<B^B$BR=23-Z4"+* 6RQ0*<R=PRNMT6C@=0X?!9^+
M4AB!^EB6SSJP AWK%<]PVB,%:E0OV)L1>NLPPVJ.JLN9??C0%S68I6PT.=>#
M/2U#M+BC-89?2?ND<L6-J!= F=&0<:4V)/DU5[F&#\#8I1>QD1WY@9<$/CR2
M?ZZRI8LJQQ>2]XK$:AQR1BX$14Q6[-*WK]"/X+-:+7D-N6H6^QV1%[-H][KA
M*V%X*?XFANJ4@S#Q1B,?HI'GCV)X,C+[^J,59@Y483JL-'=ZC[T@">F9Q '<
MUP8)ST 0I?##=RD+V$_PV2PI70%12R&-(GB6Y-HJ^GV&(&2)EX0^A/ZEY]/N
M-UDL]Q4=;S'[4< &G9\CN <V[S9_1$TP+[QLVBAX2<<FKS.$OF7!@G1 HY;'
MP%7N)/"'#G0_.M/E<=?E\?_N\KNB0'>LPH&\'KE!:H],UAE1<6$<:_7S7JZH
M_H<(UAOE%K3AIC%2;5RXRKHRTJU@QZ5;H09V2QMJ) UH3Z9_Z\1KA6*[C'K[
MDIJ(;AQM],YC(6T)2!EC^(-PV@/NE-P<PCO-W;VNB!C9B#9'EAZ^VD:EHLZQ
MQD*8 7 #+/B>2M4/4I+:Y< -&76G;X=4>S^QW6[CV@.A]J"V\BV@P)PD7,(6
ML2MYGR4$%D4QW'UKA-F\54E*Z@A(3R-Z)FD*7Y0PMK2%A6Q%VAX&\H6"S1N7
M[C!E5(@FWW1.* M^'';3&]+YPO(\VLG!B/J8CB;F>U';S[''1LE@IYY@0!I/
M(8@M*3^)=LUE$[>+[EAS4\(H2T$T.-;EPX,[LD*U<'\"=-#)IC;M==E][7XV
MKMH[=K^]_5/YQ-5"U!I*+,C4OQA1*ZOV]F\G1J[<C3N7ANYO-US2#Q,JNX'6
M"RG-;F(==+]@LW\ 4$L#!!0    ( .2*:E2;WT*8OP(  /@%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;)U4VV[;, S]%<(;AA3(ZEN27I8$:-H5
M&]!B0=MM#\,>%)N)A>KB27+3_OTH.7&SH<V O=@B19YS2)L<K[6YMQ6B@T<I
ME)U$E7/U:1S;HD+)[*&N4='-4AO)')EF%=O:("M#DA1QEB2C6#*NHNDX^.9F
M.M:-$USAW(!MI&3F:89"KR=1&FT=-WQ5.>^(I^.:K? 6W==Z;LB*.Y222U26
M:P4&EY/H+#V=#7Q\"/C&<6UWSN K66A][XW/Y21*O" 46#B/P.CU@.<HA <B
M&;\VF%%'Z1-WSUOTRU [U;)@%L^U^,Y+5TVBXPA*7+)&N!N]_H2;>H8>K]#"
MAB>LV]C1((*BL4[+33(ID%RU;_:XZ<-.PG'R2D*V2<B"[I8HJ+Q@CDW'1J_!
M^&A"\X=0:L@F<5SYCW+K#-URRG/3<RTE=]1E9X&I$LZU<ERM4!4<+?3NV$*@
M/1C'CKA\1EQL<&<M;O8*;IK!-4%5%CZJ$LL_ 6(2V2G-MDIGV5[$"RP.(4_[
MD"59N@<O[RK/ U[^7Y7_.%M89^B?^;F':M!1#0+5X!6J6QJELA$(>@F7C6L,
MPC577#82;HB?"9BSIU8)C1E\J=$PKP6ND'XX^U+W]Q+Z23ZU-2MP$M&H6C0/
M&$VAQQ6X2C>6RK4'OH\9O(6TGXYR;^0PS%-_&,!P,/"'(>1'P3."=V^.LS3[
M '<5TNPO'9IGE_85-*KDMM"-<EB"[BH0O@(0G"VXX.Z)^++^*#FARJP]!29]
M@F]+&U=OVV PZ Y?!#AADN6@E^?) <S;&WA@H@DM7;8M_0LBZV='6QY;:>/>
M$XK<(ZV7]I/CDP.XTFKUK]C0MI,$7OHYXIUIE&A68>=8"+UI![/S=FOMK)WF
MY_!V)UXSL^+*$OV24I/#HV$$IMTSK>%T'69[H1UMBG"L:#6C\0%TO]3:;0U/
MT"W[Z6]02P,$%     @ Y(IJ5,1AOI:: P  70@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&ULK5;;;N,V$/V5@5H4,:#J0MU3VX"SFVWW8=L@Z68?
MBC[0TM@6(I%>DHZ3O^^0LE5OD+@MT!>10\_ES/ ,Q].]5 ]Z@VC@J>^$GGD;
M8[:78:CK#?9<!W*+@GY92=5S0Z):AWJKD#?.J.]"%D5YV/-6>/.I.[M1\ZG<
MF:X5>*- [_J>J^<K[.1^YL7>\>"V76^,/0CGTRU?XQV:S]L;15(X>FG:'H5N
MI0"%JYFWB"^O,JOO%.Y;W.N3/=A,EE(^6.%C,_,B"P@[K(WUP&EYQ'?8==81
MP?AZ\.F-(:WAZ?[H_8/+G7)9<HWO9/>E;<QFYI4>-+CBN\[<ROTO>,C' :QE
MI]T7]H-NSCRH=]K(_F!,"/I6#"M_.M3AQ*",WC!@!P/F< ^!',KWW/#Y5,D]
M**M-WNS&I>JL"5PK[*7<&46_MF1GYM=?=ZUYAH^B1F'K XL]5XV&B]_YLD,]
MF8:&HEC=L#YXO!H\LC<\Q@P^26$V&JY%@\VW#D*"-V)D1XQ7[*S']U@'D,0^
ML(C%9_PE8\Z)\Y?\QYS_6"RU4<23/\\$2<<@J0N2OA'DCMJGV74(<@5W&Z[P
M1TN>!M[)GAI*<\M)'^Z,K!_@MZV5M \+RU'"]EK5SX:SO7NIM[S&F4?-J5$]
MHC=W!;.?B#YQ!1>M +.1.\U%0]'PJ<:MH055W6J$K6IKA(9H-#E"@B^.UH1[
M\8B*NA2NC]HW3OM_U]L9;0A>*]; #2QQW0IA!2KC,W(%I9]4!7P/14!$*_R\
MRD@H UIR/\X8"7$4Y"7\K+BP<6*_C$K(@Z2"Q$])+0E8"LQ/DPRR(,I'  U<
M)$4^@31("OCANY+%[*<WU^NG;:NL25S%$XA9D$5PP9+<[:N8]C&;0&5AT>.Q
MPM8X99\5I%X&<4$:?I85$T)6E'"1E]'$ D_9RPJ@:$YSSPNR**-#&4Z*X$IP
MR,6V[DO;S(\2YNI659#Z>9F24 5I20(KLJ%N60YGJ)^-U,_^-?5_E>(1M<W^
MEA:Z8KL=6/]9M$:?I?S9,&]0WO7:*SQS? !Z(Q$^\%;!/>]V^&U'3%[6GAX>
M[)>HCH\/M9%?Y!75BDB2C13+\X3*SQC<#YG:>TZJB:57>GK]R>$P^:<XL65M
M9B\H"^+7KR0\>?)[5&LWV#34<B?,\/J/I^/L7 PCXV_U8?!^XHJ:3$.'*S*-
M@H+*KH9A-@A&;MT 64I#X\AM-S3_45D%^GTEI3D*-L#XCV+^%U!+ P04
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M$>CPZH2#5:V?]!MEZ=WPVST]U*B= /W?*DI+?W &AJ=_]0502P,$%     @
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M8BD6$^_*(REDM.*XDKMOT,3C!":2:_=+=LW9P"-)I5&6#=@H*)FHO_2E\>$
M$%YT *(&$+T'C#H PP8P/!4P:@ CYTP=BO,AIDBG8R5W1-G3ALT.G)D.;<)G
MPJ9]C<KL,H/#Z;I.-Y$96;-<L(PE5""9)8FL!#*1DZ7D+&&@R4**! 0JZA)F
M  L%*4.R8OJ)?(D!*>/ZZ]A'(\N2^TDC85Y+B#HDA!%YE (+36Y%"NE; M_$
MTP85[8.:1[V,,20#,@S/2!1$X1%!B]/AP1%X?#(\O.Z)9MBF:.CXAAU\QW+Q
M>[;1)A,)_NFY8-1>,'(7C+H$,YUPJ2L%Q"3V'F2NZ+9@"9F91J+/R J>051
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M$@51>$;0[')X< 8^OQ@>7K>XZ=;%ZSJ^;@/?N2K]F*RU47B=?K8$Z-4!>BY
MKR' EUVQ!F4/![XSBKI(537UN7*6; /'9A^<?8Q)WI\1T*\%]%L%W*([\TSP
M"@!9PA[$#LB*"IDQL@"5H Y\F\X5HIWVZKH3!&]:$C2H]0U:B3X_+!_(G&VY
MQ M1W5=,6"*%U:;<)3F7J';6J/>OO/)XOH*+7K$UK&T-6XFF3'*9LT3_AZ5V
MQN&@R5([;M!OLN2?/'HH,'?- P7;&U$^"/5JW9\F[EE^L3[%OE6VF3\T9=.[
MIRIG0A,.&5(&G2&>*E4VDG)BY-8]K6MI,$MNN,'>"\INP.^9E.8XL0'J;A[_
M!E!+ P04    " #DBFI4HH*&'FX"  #C!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6R-5-]/VS 0_E=.$0\@#?*K,(;:2"T96R60*CJVAVD/;G))
M+!P[LUT"__UL)\TZH%U?$I]]WW?WW=DW;H5\5!6BAN>:<37Q*JV;*]]7684U
M46>B06Y."B%KHHTI2U\U$DGN0#7SHR"X\&M"N9>,W=Y")F.QUHQR7$A0Z[HF
M\F6&3+03+_0V&_>TK+3=\)-Q0TI<HGYH%M)8_L"2TQJYHH*#Q&+B3<.K=&3]
MG<-WBJW:6H-5LA+BT1KS?.(%-B%DF&G+0,SO":^1,4MDTOC=<WI#2 O<7F_8
M;YQVHV5%%%X+]H/FNIIXEQ[D6) UT_>B_8J]GG/+EPFFW!?:WC?P(%LK+>H>
M;#*H*>_^Y+FOPQ8@O-@!B'I ]!HPV@&(>T!\*&#4 URI_4Z*JT-*-$G&4K0@
MK;=ALPM73(<V\BFW;5]J:4ZIP>EDV;4;1 %+6G):T(QP#=,L$VNN*2]A(1C-
M*"J8<TUX25<,@2AE;N1QBII0ID[@%!Z6*1P?G< 14 [?*K%6A.=J[&N3HXWD
M9WT^LRZ?:$<^801W@NM*P6>>8_XO@6_$#0JCC<)9M)<QQ>P,XO #1$$4OI/0
M]>'PX!UX>C \_+1'33ST*W9\\0Z^&\JIQM-;\UCR[8Y,;4<4_+PU_C#76*M?
M>Z*-AF@C%VVT(]H7(?*6,@:FF6^BP;QN")5F!NCW^MPQGSMF.WR>$E.^I^W"
M_]<C?>L175[$EX-7)\K?NOXURM*-$07N!G?W9-@=)M74/=!7^S,SP;J!\Y>F
M&W]W1):4*V!8&,K@[*/)278CI3.T:-PC6PEMGJQ;5F8*H[0.YKP00F\,&V"8
MZ\D?4$L#!!0    ( .2*:E3&\D^BA0,   $,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;+V648_:.!#'OXH5]:&5]C9Q @$J0-J%/5VE71TJU^M#
M=0\FF1"KB4UM!W:__8T="!1"=G6ZNQ>(G?G/_#QVQC/>2?5=YP"&/)>%T!,O
M-V;ST?=UDD/)]*W<@, WF50E,SA4:U]O%+#4B<K"#X,@]DO&A3<=N[F%FHYE
M90HN8*&(KLJ2J9=[*.1NXE'O,/&9KW-C)_SI>,/6L 3S9;-0./(;+RDO06@N
M!5&03;P[^G%.^U;@+/[DL-,GS\0N927E=SOXE$Z\P!)! 8FQ+AC^;6$&16$]
M(<>/O5.OB6F%I\\'[[^ZQ>-B5DS#3!9?>6KRB3?T2 H9JPKS6>Y^@_V"'& B
M"^U^R6YO&W@DJ;21Y5Z,!"47]3][WB?B1(!^V@7A7A">"^(K@F@OB,X%O2N"
MWE[0<YFIE^+R,&>&3<=*[HBRUNC-/KAD.C4NGPN[[TNC\"U'G9DNZ_TF,B-+
MOA8\XPD3AMPEB:R$X6)-%K+@"0=-?B$+A>=-F1?"1$H>?E1\@R? D/=S,(P7
M^@.:?%G.R?MW'\@[P@7Y(Y>51EL]]@VRVHA^LN>ZK[G"*UR4/$EA<DT>1 II
MBW[VBC[L<.!CDII,A8=,W8>='N^J]2V)Z T) SIL ^J6SR$YR$/:(I^_71YT
MK"9J]CUR_J(K_@Y;>4,6A=WPGW?TVR.:DT\&2OU71[!>$ZSG@O6N!'O0AN,G
M"BFI-&1500J>@3UR3&LPK:>CVR$-R LPI3O8^@U;O],5GG15(9D"C1Z3W&4B
MA2U6Q#H7&M26)WC^DTHIG&C;^CI$WX6PE78[C>)X-/:WIQM\:13241PV5C_A
MQPU^_";\1)9X%6A6%U-<P@H$9-QT8M>NXQ.B_H#2,^Q+HQ@OE7;J04,]Z*3^
M'<\><]7E$;!HWY!'SE:\X/8\SJ[S#BY0:# \3_.E4;\?M>,.&]QA-Z[)09%#
MJ@^L6!,[:8<7(&$_B,YH+XU&@[B==M30CMYT)$XXV_!&%\>1AJ-!>,9W:16.
MXA%M)Z3!\=8).AF?N.!E579\O_3D!J/_?2FCX3%<^"\7L]DK'J-7BQD]EG4:
M=2>6/;^6V&/5IKW_(;''0DR[*_$_26RWQU['->&?]$PEJ+7K/;%:VK:G;I^:
MV::_O7-=G7\TKYOC)Z;67&A20(;2X': 5*KN-^N!D1O7@:VDP7[./>;8HX.R
M!O@^D](<!C9 T_5/_P902P,$%     @ Y(IJ5#SK:!^V @  IP<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&ULI55=;YLP%/TK%MI#*[7E(PGKJ@0I
M']U6J96B9MT>ICTX< &KQF:V*=V_GVT(2UM"(^T%;'//N??X8-]IS<6CS $4
M>BXHDS,G5ZJ\<ET9YU!@><%+8/I+RD6!E9Z*S)6E )Q84$'=P/-"M\"$.='4
MKJU%-.65HH3!6B!9%046?Q9 >3US?&>W<$^R7)D%-YJ6.(,-J(=R+?3,[5@2
M4@"3A#,D()TY<_]J%9IX&_"=0"WWQL@HV7+^:"8WR<SQ3$% (5:& >O7$RR!
M4D.DR_C=<CI=2@/<'^_8/UOM6LL62UAR^H,D*I\YEPY*(,455?>\_@JMGHGA
MBSF5]HGJ-M9S4%Q)Q8L6K"LH"&O>^+G=ASV 'QX !"T@> T8'P",6L#H6,"X
M!8SMSC12[#ZLL,+15/ :"1.MV<S ;J9%:_F$&=LW2NBO1.-4M&GL1CQ%&Y(Q
MDI(8,X7F<<PKI@C+T)I3$A.0Z*8H,1':<F6B;SG+SF^U9PF:2PE*HI,5*$RH
M/$7GZ&&S0B<?3M$'1!CZEO-*8I;(J:MTR2:Q&[?E+9KR@@/E^0&ZXTSE$EVS
M!)*7!*[6V@D.=H(7P2#C"N(+-/+/4. %?D]!R^/A7@]\=33<_S2@9M39-[)\
MHP-\?3[]G&^E$OI _1I(,.X2C&V"\8$$+TV_80JSC&PI=*9?/\>T2DP!7SA/
M:D+I:9_-39:)S6*NHJ=([][3_KZ_&[$:BG@A;M*)FPR*LQKV_^MECD4&O?]I
MPQ0."'@;X8?>:PUO@X++<'39KR/L=(3_8]*97M)7(6%$P3FU1_98V\)W;7L;
MT:-ZB*91[.Y=805H$TPKD,C^W<WA[E:[;C.WE^RK]87N0DW3^$?3M+ [[2UA
M$E%(-:5W\5'7(YJVT$P4+^U%N>5*7[MVF.M."L($Z.\IYVHW,0FZWAS]!5!+
M P04    " #DBFI4@9)D(24"  " !   &0   'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q]5.]OFS 0_5=.J!]:J0J$I$U7$:2DV8]*JQ0UZ_9AV@<'#K!J
M?,PVH?OO9YN$95*3+^"S[]Z[=SR3=*1>=85HX*T64L^#RICF/@QU5F'-](@:
ME/:D(%4S8T-5AKI1R')?5(LPCJ+;L&9<!FGB]]8J3:@U@DM<*]!M73/U9XF"
MNGDP#@X;S[RLC-L(TZ1A)6[0O#1K9:-P0,EYC5)SDJ"PF >+\?URZO)]PG>.
MG3Y:@U.R)7IUP6,^#R+7$ K,C$-@]K7#!Q3" =DV?N\Q@X'2%1ZO#^B?O':K
M9<LT/I#XP7-3S8.[ '(L6"O,,W5?<*_GQN%E)+1_0M?GSF8!9*TV5.^+;0<U
ME_V;O>WG<%00CT\4Q/N"V/?=$_DN5\RP-%'4@7+9%LTMO%1?;9OCTGV4C5'V
ME-LZDV[ZCP%4P(:7DA<\8]+ (LNHE8;+$M8D>,91PV>BO.-"P.4*#>-"7\$%
M< G?*FHUD[E.0F,[<KAAMF=?]NSQ"?9Q#$\D3:7AH\PQ_Q\@M%(&/?%!SS(^
MB[C"; 23\37$T?C#RV8%EQ=79V GPY@F'G9R O:]>?Q<;+51UE:_SA!,!X*I
M)YB>(#@,]QH>ZX9Q97UOX"OI=X?:0]UX*'?K=FE\=QM%2;@[[B \<D6-JO3>
MU^"%] 89=H?KM>A=]2^]OYM/3)5<:A!8V-)H-+/<JO=['QAJO,>V9*QC_;*R
MOPA4+L&>%T3F$#B"X:>3_@502P,$%     @ Y(IJ5!B"68M  @  ] 0  !D
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M    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,U8;6_B.!#^*Z-()^U)E+Q
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MWC10%F#FMU+B(;&W8'@ET[]02P,$%     @ Y(IJ5 6TS1)=!   318  !D
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M@C>$Y0;R^992<1KD$]0GR(M_ 5!+ P04    " #DBFI4\C_O@5<#  !'#P
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M]^K7>? JF"<BZ)1%?X6!7%_VO!X(Z)*DD;QGV]]H$5 _T_-9)/*_8%N,M7O
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M.X2Z-RM.Y;6GF5#MB>ZDBJ/1Y9S@H=+1$'-^UD-EAY"!*E;EDT9,^2K_EB2
MG[V]V+WO+Z^6WZLF^5>:@^M3>#'??772,KN/8'>$K\)$@(@NE:1]/E!)YKOO
M2KL3R3;YAY,G)B6+\\,U)0'EV0#U^Y(QN3_))BB_[HW_!U!+ P04    " #D
MBFI4,B\BW3L$   P$   &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RM
M6%USFS@4_2L:3Q_:F21( H/=<3R3V.UN9M(VD[3=ONTH<&W8 O)*<IS^^Y4
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M34OSCH&T"69_+83>![95AI<Q_0U02P,$%     @ Y(IJ5"\P/0#/!   K!,
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M\-JMEIP96"GQG9=8+X/W 2EAQUJ!3ZK["(.>N>,KE##^2[H^=CX+2-$:5,T
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MIM,':1>8]SLA]&E@'=3_'1;_ 5!+ P04    " #DBFI4Z7Z+/6<$   "$@
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M@-^U']4ZJQ9U#/TP\D<=*@1K?81N@7R)B+\YOYH:&B#8R5Y+*'Q&0_?WM>O
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M<[D;>Z'WO'##-YFQ"_YDM&4;7*&YW2X5S?Q&)>4%"LVE (7KL3<-+Q<#BW>
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M--2FW#"C+P]4%D#[:RG-\\0^H/F6F?P%4$L#!!0    ( .2*:E0DLM"S- ,
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M#"+,,%8F!-&/%8XQRTPDC>.Y"NK4:QK'W?8V^HTEK\G,B,0QSW[31*4#I^=
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M"S0 83;HYVO.U6%B')3_7DS_!E!+ P04    " #DBFI40_V^:3X$  "&#@
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MU(^>NJ/XWCX#UESI1X5M[O1#D0@#T-\WG*MCQTS0/CWG_P)02P,$%     @
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M!]I-P.\+A3I5O[@ S7UR\A]02P,$%     @ Y(IJ5"E4+_0Q!   W!   !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULM9A=C]HX%(;_BH7VHI5F2>Q
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M.Z!KX/H!=7_#F#R=Z ;R/S3&_P!02P,$%     @ Y(IJ5):#T\,B P  ;!(
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M;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R 1_<UM@/+51JW@3=
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M2P$"% ,4    " #CBFI4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ..*:E3HRU]G[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ..*:E297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ XXIJ5(1?:=@$!P  J1P  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ..*:E3M[")%6 8  "P:   8              " @4</  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #CBFI4B>(5G08#   8"@  &
M            @('5%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ XXIJ5./D+L>A!@  VAH  !@              ("!$1D  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ..*:E0NF/Y^E0(  *,&
M   8              " @>@?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #CBFI4=&8+_[X*   N-0  &               @(&S(@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ XXIJ5$Y"^2Q
M"0  PB@  !@              ("!IRT  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( ..*:E1>-JWC  4  'T+   8              "
M@1TW  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #CBFI4
M@=Z0)3\?  !O8   &               @(%3/   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ XXIJ5/4LUS36!0  1PX  !D
M     ("!R%L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ..*:E3>)Z<& 00  %X)   9              "
M@=9W  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ XXIJ
M5$2[\JHD!P  "Q(  !D              ("!#GP  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #CBFI4;'VC(G(%  !%#   &0
M        @(%I@P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( ..*:E3;Y\TGZP@  $4;   9              " @1*)  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ XXIJ5)Q+"[<K P  X08
M !D              ("!-)(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #CBFI4NDMYU P(   _%0  &0              @(&6E0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .2*:E2:WI)'
M7 0  *(*   9              " @=F=  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ Y(IJ5*BV_1R(!0  W P  !D
M ("!;*(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #D
MBFI4'C,1S6D$   Q"P  &0              @($KJ   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .2*:E39\S$0P!D  +)0   9
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M970R."YX;6Q02P$"% ,4    " #DBFI4K@^+M4,$  "."0  &0
M    @($4TP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M .2*:E2;WT*8OP(  /@%   9              " @8[7  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ Y(IJ5,1AOI:: P  70@  !D
M             ("!A-H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #DBFI4US.%MW@#   &"   &0              @(%5W@  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .2*:E2+%M$IJP(
M %D'   9              " @03B  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ Y(IJ5-^L^>2_ @  V0<  !D              ("!
MYN0  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #DBFI4
MHH*&'FX"  #C!0  &0              @('<YP  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( .2*:E3&\D^BA0,   $,   9
M      " @8'J  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ Y(IJ5#SK:!^V @  IP<  !D              ("!/>X  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #DBFI4@9)D(24"  " !
M&0              @($J\0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( .2*:E08@EF+0 (  /0$   9              " @8;S  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ Y(IJ5$NG00SM
M P  H!(  !D              ("!_?4  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #DBFI49S\S\Y("  #+!0  &0
M@($A^@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .2*
M:E2JY[/K+ (  #$%   9              " @>K\  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ Y(IJ5 6TS1)=!   318  !D
M         ("!3?\  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " #DBFI4\C_O@5<#  !'#P  &0              @('A P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .2*:E04,T#P;@4  .D;
M   9              " @6\' 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ Y(IJ5#(O(MT[!   ,!   !D              ("!% T!
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #DBFI4L=WR
M;T(#  !D"0  &0              @(&&$0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( .2*:E1\3&BQLP,  !8,   9
M  " @?\4 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MY(IJ5%UN87XC @  )04  !D              ("!Z1@! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #DBFI4+S ] ,\$  "L$P  &0
M            @(%#&P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( .2*:E0$<P[B 0(  &X$   9              " @4D@ 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ Y(IJ5%]JW!)L @
MH@8  !D              ("!@2(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #DBFI4]<Y#HG #  !'#   &0              @($D
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .2*:E3I
M?HL]9P0   (2   9              " @<LH 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ Y(IJ5+D*NJ@:!0  <1H  !D
M     ("!:2T! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .2*:E1#_;YI/@0  (8.   9              "
M@5E  0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ Y(IJ
M5-VI"X*% P  #PL  !D              ("!SD0! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " #DBFI46&:JSA$$  !;#@  &0
M        @(&*2 $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( .2*:E0I5"_T,00  -P0   9              " @=), 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ Y(IJ5):#T\,B P  ;!(
M  T              ( !.E$! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #D
MBFI4EXJ[',     3 @  "P              @ &'5 $ 7W)E;',O+G)E;'-0
M2P$"% ,4    " #DBFI4B!SL%>,$  "D*0  #P              @ %P50$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y(IJ5"=EU:4, @  A"4  !H
M             ( !@%H! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ Y(IJ5.[5[1CF 0  ]20  !,              ( !Q%P! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $< 1P!H$P  VUX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>443</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheet Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals</Role>
      <ShortName>Statements of Comprehensive Loss Parentheticals (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115103 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2161116 - Disclosure - Asset Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetSale</Role>
      <ShortName>Asset Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - Other Capital Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreements</Role>
      <ShortName>Other Capital Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345310 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwards</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2356312 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Intangible asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cost of Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails</Role>
      <ShortName>Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/Goodwill</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Debt Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsNarrativeDetails</Role>
      <ShortName>Debt Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Debt Obligations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails1</Role>
      <ShortName>Debt Obligations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails</Role>
      <ShortName>Equity Incentive Awards - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Equity Incentive Awards (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2</Role>
      <ShortName>Equity Incentive Awards (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Equity Incentive Awards (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3</Role>
      <ShortName>Equity Incentive Awards (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Equity Incentive Awards (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4</Role>
      <ShortName>Equity Incentive Awards (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlanDetails</Role>
      <ShortName>Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/BenefitPlan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2457430 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2463432 - Disclosure - Asset Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetSaleDetails</Role>
      <ShortName>Asset Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/AssetSale</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lxrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2465433 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalAgreements</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lxrx-20211231.htm">lxrx-20211231.htm</File>
    <File>exh1010formofrestrictedsto.htm</File>
    <File>exh103offerlettergranowitz.htm</File>
    <File>exh211subsidiaries.htm</File>
    <File>exh231ernstyoungconsent2021.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>exh48descriptionofcommonst.htm</File>
    <File>lxrx-20211231.xsd</File>
    <File>lxrx-20211231_cal.xml</File>
    <File>lxrx-20211231_def.xml</File>
    <File>lxrx-20211231_lab.xml</File>
    <File>lxrx-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lxrx-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="701">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 99,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 536,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://www.lexpharma.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 83,
   "keyStandard": 360,
   "memberCustom": 0,
   "memberStandard": 25,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lexpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115103 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Property and Equipment",
     "role": "http://www.lexpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Income Taxes",
     "role": "http://www.lexpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Goodwill",
     "role": "http://www.lexpharma.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Equity Incentive Awards",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - Benefit Plan",
     "role": "http://www.lexpharma.com/role/BenefitPlan",
     "shortName": "Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Earnings Per Share",
     "role": "http://www.lexpharma.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SaleOfNonFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161116 - Disclosure - Asset Sale",
     "role": "http://www.lexpharma.com/role/AssetSale",
     "shortName": "Asset Sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SaleOfNonFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - Other Capital Agreements",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreements",
     "shortName": "Other Capital Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheet Parentheticals",
     "role": "http://www.lexpharma.com/role/BalanceSheetParentheticals",
     "shortName": "Balance Sheet Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345310 - Disclosure - Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356312 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails",
     "shortName": "Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails",
     "shortName": "Summary of Significant Accounting Policies Intangible asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "if9cb62af37d048978f015209a192adc4_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "Summary of Significant Accounting Policies Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i9586ddfde7c44033ac94f6914e1c0a80_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
     "shortName": "Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ife64f0069a7f41919b9ecd84a38a72b3_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i1f70aba4e16249469f10a9d94389de4f_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Recent Accounting Pronouncements (Details)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails",
     "shortName": "Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash and Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "if9cb62af37d048978f015209a192adc4_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Income Taxes (Details 1)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Income Taxes (Details 2)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Income Taxes (Details 3)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails3",
     "shortName": "Income Taxes (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ic1e10dc122274204badbada626c6296e_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Goodwill (Details)",
     "role": "http://www.lexpharma.com/role/GoodwillDetails",
     "shortName": "Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ic1e10dc122274204badbada626c6296e_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "role": "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals",
     "shortName": "Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i33b1d627868546fca39177189a903e94_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Debt Obligations - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
     "shortName": "Debt Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i33b1d627868546fca39177189a903e94_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Debt Obligations (Details 1)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails1",
     "shortName": "Debt Obligations (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i7e060bfed2de437eb4c9ab572015fc44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "iaea6bf5e65b144809174989bbe6607b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
     "shortName": "Equity Incentive Awards - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Equity Incentive Awards (Details 2)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
     "shortName": "Equity Incentive Awards (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Equity Incentive Awards (Details 3)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
     "shortName": "Equity Incentive Awards (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i00be06ddbff74be8bbf65ceefcef5599_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Equity Incentive Awards (Details 4)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
     "shortName": "Equity Incentive Awards (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i00be06ddbff74be8bbf65ceefcef5599_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Benefit Plan (Details)",
     "role": "http://www.lexpharma.com/role/BenefitPlanDetails",
     "shortName": "Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SanofiUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Collaboration and License Agreements (Details)",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "ic2a6fd97adb24a8197c8779ad6404b17_D20151101-20151130",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SanofiUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i2de7ae68674e4d58a012b15b9e1f640d_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i2de7ae68674e4d58a012b15b9e1f640d_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457430 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "role": "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463432 - Disclosure - Asset Sale (Details)",
     "role": "http://www.lexpharma.com/role/AssetSaleDetails",
     "shortName": "Asset Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465433 - Disclosure - Other Capital Agreements (Details)",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i93ed1731ed474b05b4b91f4a93d4f013_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "lxrx:SharesSoldInNov2020ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.lexpharma.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211231.htm",
      "contextRef": "i3445f59e896a4f8b8b5b59c6ea1bb92c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information",
        "verboseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage",
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangeAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 convertible debt exchange - accrued interest",
        "label": "2020 convertible debt exchange - accrued interest",
        "terseLabel": "2020 convertible debt exchange - accrued interest"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangeAccruedInterest",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 convertible debt exchange - percentage of principal",
        "label": "2020 convertible debt exchange - percentage of principal",
        "terseLabel": "2020 convertible debt exchange - percentage of principal"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangePercentageOfPrincipal",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Convertible debt exchange - share payment total",
        "label": "2020 Convertible debt exchange - share payment total",
        "terseLabel": "2020 Convertible debt exchange - share payment total"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangeSharePaymentTotal",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_A2020FederalNOLIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Federal NOL increase",
        "label": "2020 Federal NOL increase",
        "terseLabel": "2020 Federal NOL increase"
       }
      }
     },
     "localname": "A2020FederalNOLIncrease",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_BalanceSheetParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Parentheticals [Abstract]",
        "label": "Balance Sheet Parentheticals [Abstract]",
        "terseLabel": "Balance Sheet Parentheticals [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_BenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit Plan [Abstract]",
        "label": "Benefit Plan [Abstract]",
        "terseLabel": "Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "BenefitPlanAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CoelacanthGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.",
        "label": "Coelacanth Goodwill",
        "terseLabel": "Coelacanth Goodwill"
       }
      }
     },
     "localname": "CoelacanthGoodwill",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CoelacanthPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.",
        "label": "Coelacanth Purchase Price",
        "terseLabel": "Coelacanth Purchase Price"
       }
      }
     },
     "localname": "CoelacanthPurchasePrice",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CommissionsFromDecember2020CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commissions from December 2020 Common Stock Offering",
        "label": "Commissions from December 2020 Common Stock Offering",
        "terseLabel": "Commissions from December 2020 Common Stock Offering"
       }
      }
     },
     "localname": "CommissionsFromDecember2020CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies",
        "label": "Commitments and Contingencies [Abstract]",
        "terseLabel": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "label": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "terseLabel": "Consolidated Statements of Operations Parentheticals [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalCashConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Exchange - Total cash consideration",
        "label": "Convertible Debt Exchange - Total cash consideration",
        "terseLabel": "Convertible Debt Exchange - Total cash consideration"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalCashConsideration",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.",
        "label": "Convertible Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Convertible Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtInstrumentRepurchasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Percentage",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Repurchase price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePercentage",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_DecreaseInNOLs": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in NOLs",
        "label": "Decrease in NOLs",
        "terseLabel": "Decrease in NOLs"
       }
      }
     },
     "localname": "DecreaseInNOLs",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Arrangement With Individual, Payment Period",
        "label": "Deferred Compensation Arrangement With Individual, Payment Period",
        "terseLabel": "Payment period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPaymentPeriod",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DeferredTaxAssetsSection163j_LXRX": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017",
        "label": "Deferred Tax Assets, Section 163j_LXRX",
        "terseLabel": "Deferred Tax Assets, Section 163j_LXRX"
       }
      }
     },
     "localname": "DeferredTaxAssetsSection163j_LXRX",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.",
        "label": "Deferred Tax Liability Related to Acquisition of Symphony Icon",
        "terseLabel": "Deferred Tax Liability Related to Acquisition of Symphony Icon"
       }
      }
     },
     "localname": "DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DefinedContributionPlanRequisiteServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Requisite Service Period",
        "label": "Defined Contribution Plan, Requisite Service Period",
        "terseLabel": "Years of service"
       }
      }
     },
     "localname": "DefinedContributionPlanRequisiteServicePeriod",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.",
        "label": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent",
        "terseLabel": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "label": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "terseLabel": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EntityWideRevenueSanofiPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.",
        "label": "Entity Wide Revenue Sanofi Percentage",
        "terseLabel": "Entity Wide Revenue Sanofi Percentage"
       }
      }
     },
     "localname": "EntityWideRevenueSanofiPercentage",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EquityIncentiveAwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Awards [Abstract]",
        "label": "Equity Incentive Awards [Abstract]",
        "terseLabel": "Equity Incentive Awards [Abstract]"
       }
      }
     },
     "localname": "EquityIncentiveAwardsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FinalConsiderationIncludingAmountsReleasedToSettle": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Consideration including amounts released to settle",
        "label": "Final Consideration including amounts released to settle",
        "terseLabel": "Final Consideration including amounts released to settle"
       }
      }
     },
     "localname": "FinalConsiderationIncludingAmountsReleasedToSettle",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_GoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill [Abstract]",
        "label": "Goodwill [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "localname": "GoodwillAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_InterestOnLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest on Lease Payments",
        "label": "Interest on Lease Payments",
        "terseLabel": "Interest on Lease Payments"
       }
      }
     },
     "localname": "InterestOnLeasePayments",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.",
        "label": "Ipsen Maximum Regulatory And Commercial Milestones",
        "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "IpsenMaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.",
        "label": "Ipsen Revenue Allocated to Committee Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Ipsen Revenue Allocated to License Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPaymentsToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.",
        "label": "Ipsen Total Payments To Date",
        "terseLabel": "Ipsen Total Payments To Date"
       }
      }
     },
     "localname": "IpsenTotalPaymentsToDate",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.",
        "label": "Ipsen Total Upfront Payments",
        "terseLabel": "Ipsen Total Upfront Payments"
       }
      }
     },
     "localname": "IpsenTotalUpfrontPayments",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Ipsenproductsales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.",
        "label": "Ipsen product sales",
        "terseLabel": "Ipsen product sales"
       }
      }
     },
     "localname": "Ipsenproductsales",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LXRXBiologicscustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues",
        "label": "LXRX Biologics customer concentration",
        "terseLabel": "Biologics customer concentration"
       }
      }
     },
     "localname": "LXRXBiologicscustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LXRXDiplomatcustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues",
        "label": "LXRX Diplomat customer concentration",
        "terseLabel": "LXRX Diplomat customer concentration"
       }
      }
     },
     "localname": "LXRXDiplomatcustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LexiconBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon borrowing rate",
        "label": "Lexicon borrowing rate",
        "terseLabel": "Lexicon borrowing rate"
       }
      }
     },
     "localname": "LexiconBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "lxrx_Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_OfferingExpensesFromDecember20CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering expenses from December 20 common stock offering",
        "label": "Offering expenses from December 20 common stock offering",
        "terseLabel": "Offering expenses from December 20 common stock offering"
       }
      }
     },
     "localname": "OfferingExpensesFromDecember20CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OptionsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Equity Incentive Plan.",
        "label": "Options Outstanding, Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Options Outstanding, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OrganizationAndOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Operations [Abstract]",
        "label": "Organization and Operations [Abstract]",
        "terseLabel": "Organization and Operations [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_PresentValueOfFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present Value of Future Lease Payments",
        "label": "Present Value of Future Lease Payments",
        "terseLabel": "Present Value of Future Lease Payments"
       }
      }
     },
     "localname": "PresentValueOfFutureLeasePayments",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount of convertible notes",
        "label": "Principal amount of convertible notes",
        "terseLabel": "Principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromDecember2020CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from December 2020 common stock offering",
        "label": "Proceeds from December 2020 common stock offering",
        "terseLabel": "Proceeds from December 2020 common stock offering"
       }
      }
     },
     "localname": "ProceedsFromDecember2020CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from September 2021 ATM Offering",
        "label": "Proceeds from September 2021 ATM Offering",
        "terseLabel": "Proceeds from September 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and Equipment [Abstract]",
        "label": "Property and Equipment [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyAndEquipmentAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_RDSeveranceCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D severance costs",
        "label": "R&amp;D severance costs [Member]",
        "terseLabel": "R&amp;D severance costs"
       }
      }
     },
     "localname": "RDSeveranceCostsMember",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_RDTaxCreditDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D Tax Credit Decrease",
        "label": "R&amp;D Tax Credit Decrease",
        "terseLabel": "R&amp;D Tax Credit Decrease"
       }
      }
     },
     "localname": "RDTaxCreditDecrease",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "terseLabel": "Funded commercialization costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "terseLabel": "Development costs period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "terseLabel": "Number of commercial milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "terseLabel": "Number of development milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "terseLabel": "Number of regulatory milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "terseLabel": "Royalties percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units outstanding under the Equity Incentive Plan.",
        "label": "Restricted Stock Units Outstanding, Equity Incentive Plan",
        "terseLabel": "Restricted Stock Units Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan",
        "label": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SaleOfNonFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Non-Financial Assets",
        "label": "Sale of Non-Financial Assets [Text Block]",
        "terseLabel": "Sale of Non-Financial Assets"
       }
      }
     },
     "localname": "SaleOfNonFinancialAssetsTextBlock",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.",
        "label": "Sanofi Commercialization Costs Funded by Lexicon Maximum Amount",
        "terseLabel": "Sanofi Development Costs Funded by Lexicon Maximum Amount"
       }
      }
     },
     "localname": "SanofiCommercializationCostsFundedbyLexiconMaximumAmount",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDeferredRevenueFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Deferred Revenue from Termination",
        "label": "Sanofi Deferred Revenue from Termination",
        "terseLabel": "Sanofi Deferred Revenue from Termination"
       }
      }
     },
     "localname": "SanofiDeferredRevenueFromTermination",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.",
        "label": "Sanofi Development Milestones",
        "terseLabel": "Sanofi Development Milestones"
       }
      }
     },
     "localname": "SanofiDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiOutcomesStudyMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.",
        "label": "Sanofi Outcomes Study Milestone",
        "terseLabel": "Sanofi Outcomes Study Milestone"
       }
      }
     },
     "localname": "SanofiOutcomesStudyMilestone",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.",
        "label": "Sanofi Regulatory Milestones",
        "terseLabel": "Sanofi Regulatory Milestones"
       }
      }
     },
     "localname": "SanofiRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Sanofi Revenue Allocated to Development Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoFundingDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.",
        "label": "Sanofi Revenue Allocated to Funding Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Funding Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoFundingDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Sanofi Revenue Allocated to License Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.",
        "label": "Sanofi Sales Milestone Payments",
        "terseLabel": "Sanofi Sales Milestone Payments"
       }
      }
     },
     "localname": "SanofiSalesMilestonePayments",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiTerminationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Termination Agreement",
        "label": "Sanofi Termination Agreement",
        "terseLabel": "Sanofi Termination Agreement"
       }
      }
     },
     "localname": "SanofiTerminationAgreement",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.",
        "label": "Sanofi Upfront Payment",
        "terseLabel": "Sanofi Upfront Payment"
       }
      }
     },
     "localname": "SanofiUpfrontPayment",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in September 2021 ATM Offering",
        "label": "Share Price in September 2021 ATM Offering",
        "terseLabel": "Share Price in September 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock units under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in September 2021 ATM offering",
        "label": "Shares sold in September 2021 ATM offering",
        "terseLabel": "Shares sold in September 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with general and administrative expense.",
        "label": "Stock-based compensation expense associated with general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with general and administrative expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.",
        "label": "Stock Option Exercise Price as Percent of Value of Common Stock",
        "terseLabel": "Stock Option Exercise Price as Percent of Value of Common Stock"
       }
      }
     },
     "localname": "StockOptionExercisePriceAsPercentOfValueOfCommonStock",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_StockOptionsExercisedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Equity Incentive Plan.",
        "label": "Stock Options Exercised, Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SymphonyIconGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.",
        "label": "Symphony Icon Goodwill",
        "terseLabel": "Symphony Icon Goodwill"
       }
      }
     },
     "localname": "SymphonyIconGoodwill",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "label": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "terseLabel": "TerSera Maximum Development, Regulatory and Commercial Milestones"
       }
      }
     },
     "localname": "TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.",
        "label": "Total Shares That May be Issued, Equity Incentive Plan",
        "terseLabel": "Total Shares That May be Issued, Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_Totalvalueofsharesbynonemployeeinayear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year",
        "label": "Total value of shares by nonemployee in a year",
        "terseLabel": "Total value of shares by nonemployee in a year"
       }
      }
     },
     "localname": "Totalvalueofsharesbynonemployeeinayear",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_WriteOffOfTaxCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of tax credits",
        "label": "Write-off of tax credits",
        "terseLabel": "Write-off of tax credits"
       }
      }
     },
     "localname": "WriteOffOfTaxCredits",
     "nsuri": "http://www.lexpharma.com/20211231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "naics_ZZ541713": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "541713 Research and Development in Nanotechnology [Member]",
        "terseLabel": "541713 Research and Development in Nanotechnology"
       }
      }
     },
     "localname": "ZZ541713",
     "nsuri": "http://xbrl.sec.gov/naics/2021",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r298",
      "r334",
      "r375",
      "r377",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r598",
      "r599",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r298",
      "r334",
      "r375",
      "r377",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r598",
      "r599",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r298",
      "r334",
      "r356",
      "r375",
      "r377",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r598",
      "r599",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r298",
      "r334",
      "r356",
      "r375",
      "r377",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r598",
      "r599",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r133",
      "r134",
      "r135",
      "r139",
      "r140",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r176",
      "r240",
      "r241",
      "r418",
      "r447",
      "r481",
      "r486",
      "r487",
      "r488",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r133",
      "r134",
      "r135",
      "r139",
      "r140",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r176",
      "r240",
      "r241",
      "r418",
      "r447",
      "r481",
      "r486",
      "r487",
      "r488",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r149",
      "r155",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r131",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Schedule of Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r149",
      "r155",
      "r280",
      "r376",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r36",
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $4"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r570",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r39",
      "r70",
      "r71",
      "r72",
      "r586",
      "r607",
      "r611"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r79",
      "r80",
      "r81",
      "r133",
      "r134",
      "r135",
      "r471",
      "r602",
      "r603",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r418",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r414",
      "r415",
      "r416",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r139",
      "r140",
      "r141",
      "r143",
      "r155",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r283",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r444",
      "r445",
      "r446",
      "r447",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r508",
      "r530",
      "r554",
      "r555",
      "r556",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r379",
      "r381",
      "r419",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r110",
      "r318",
      "r327",
      "r328",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r110",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r127",
      "r200",
      "r204",
      "r210",
      "r233",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r466",
      "r472",
      "r497",
      "r532",
      "r534",
      "r563",
      "r584"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r67",
      "r127",
      "r233",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r466",
      "r472",
      "r497",
      "r532",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Assets, Current [Abstract]"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities, Fair Value Disclosure"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Available-for-sale Securities, Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Available-for-sale Securities, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r383",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r43",
      "r112"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r125",
      "r127",
      "r161",
      "r165",
      "r168",
      "r170",
      "r172",
      "r181",
      "r182",
      "r183",
      "r233",
      "r284",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r332",
      "r333",
      "r335",
      "r336",
      "r497",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r57",
      "r279",
      "r571",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r87",
      "r574",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration Risk Disclosure"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Stock, Amount Issued"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r30",
      "r566",
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r552"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r441",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current State and Local Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r312",
      "r319",
      "r320",
      "r322",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r29",
      "r30",
      "r126",
      "r131",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r325",
      "r326",
      "r327",
      "r328",
      "r520",
      "r564",
      "r566",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r297",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r54",
      "r297",
      "r338",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "Debt Instrument, Convertible, If-converted Value in Excess of Principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r295",
      "r325",
      "r326",
      "r518",
      "r520",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r53",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r55",
      "r126",
      "r131",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r325",
      "r326",
      "r327",
      "r328",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r55",
      "r126",
      "r131",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r325",
      "r326",
      "r327",
      "r328",
      "r338",
      "r340",
      "r341",
      "r342",
      "r517",
      "r518",
      "r520",
      "r521",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r128",
      "r442",
      "r452",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income Tax Benefit",
        "verboseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2",
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r31",
      "r32",
      "r432",
      "r565",
      "r581"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred Tax Liabilities, Gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Deferred Tax Assets, In Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Operating Loss Carryforwards, State"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred Tax Assets, Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r426",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r110",
      "r199"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r85",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r88",
      "r145",
      "r146",
      "r148",
      "r149",
      "r150",
      "r158",
      "r161",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r487",
      "r488",
      "r575",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r88",
      "r145",
      "r146",
      "r148",
      "r149",
      "r150",
      "r161",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r487",
      "r488",
      "r575",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r421",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r79",
      "r80",
      "r81",
      "r133",
      "r134",
      "r135",
      "r140",
      "r151",
      "r154",
      "r180",
      "r237",
      "r337",
      "r343",
      "r414",
      "r415",
      "r416",
      "r446",
      "r447",
      "r486",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r602",
      "r603",
      "r604",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r489",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r489",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r371",
      "r490",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r310",
      "r357",
      "r359",
      "r364",
      "r371",
      "r490",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r357",
      "r359",
      "r364",
      "r371",
      "r490",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r371",
      "r490",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r491",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r371",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxNoteTable": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments.",
        "label": "Federal Income Tax Note [Table]",
        "terseLabel": "Federal Income Tax Note [Table]"
       }
      }
     },
     "localname": "FederalIncomeTaxNoteTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r255",
      "r257",
      "r553",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r110",
      "r262",
      "r267"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Recognition of gain or loss on extinguishment",
        "terseLabel": "Recognition of gain or loss on extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $6,293, $6,898 and $7,122, respectively"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r245",
      "r247",
      "r534",
      "r562"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and Intangible Asset Impairment"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r249",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r110",
      "r246",
      "r248",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r258"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfRealEstate": {
     "auth_ref": [
      "r110",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.",
        "label": "Impairment of Real Estate",
        "terseLabel": "Impairment of Real Estate"
       }
      }
     },
     "localname": "ImpairmentOfRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r260",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r200",
      "r203",
      "r206",
      "r209",
      "r212",
      "r561",
      "r572",
      "r577",
      "r596"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income (loss) before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r268",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Information by Financial Statement Line Item [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r428",
      "r430",
      "r437",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r424",
      "r425",
      "r430",
      "r431",
      "r436",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Increase (decrease) in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "(Increase) decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r166",
      "r167",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r120",
      "r254",
      "r549",
      "r550",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r82",
      "r198",
      "r516",
      "r519",
      "r576"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r104",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryBuildingsAndImprovements": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of building structures held as inventory including any additions, improvements, or renovations to those structures.",
        "label": "Inventory, Buildings and Improvements",
        "terseLabel": "Inventory, Buildings and Improvements"
       }
      }
     },
     "localname": "InventoryBuildingsAndImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r15",
      "r64",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r65",
      "r121",
      "r179",
      "r242",
      "r243",
      "r244",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory, Raw Materials, Gross"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investments, Owned, Federal Income Tax Note [Line Items]",
        "terseLabel": "Investments, Owned, Federal Income Tax Note [Line Items]"
       }
      }
     },
     "localname": "InvestmentsOwnedFederalIncomeTaxNoteLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r19",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r50",
      "r127",
      "r205",
      "r233",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r467",
      "r472",
      "r473",
      "r497",
      "r532",
      "r533"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r42",
      "r127",
      "r233",
      "r497",
      "r534",
      "r567",
      "r588"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r127",
      "r233",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r467",
      "r472",
      "r473",
      "r497",
      "r532",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of deferred financing costs",
        "verboseLabel": "Long-term Debt, Excluding Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r55",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageLoansOnRealEstate": {
     "auth_ref": [
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate",
        "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r73",
      "r75",
      "r81",
      "r86",
      "r111",
      "r127",
      "r139",
      "r145",
      "r146",
      "r148",
      "r149",
      "r153",
      "r154",
      "r169",
      "r200",
      "r203",
      "r206",
      "r209",
      "r212",
      "r233",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r488",
      "r497",
      "r573",
      "r593"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.",
        "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31)",
        "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r137",
      "r138",
      "r141",
      "r142",
      "r155",
      "r156",
      "r157",
      "r230",
      "r231",
      "r238",
      "r239",
      "r349",
      "r350",
      "r351",
      "r352",
      "r417",
      "r448",
      "r449",
      "r450",
      "r484",
      "r504",
      "r505",
      "r506",
      "r531",
      "r557",
      "r558",
      "r559",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r136",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r148",
      "r155",
      "r176",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r283",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r444",
      "r445",
      "r446",
      "r447",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r508",
      "r530",
      "r554",
      "r555",
      "r556",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Noncash or Part Noncash Divestiture, Amount of Consideration Received"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r200",
      "r203",
      "r206",
      "r209",
      "r212"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (Loss) From Operations",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Operating Leases, Future Minimum Payments Due"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards, Federal"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r66",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "terseLabel": "Payments to Acquire Other Property, Plant, and Equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r356",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r383",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Adjustments for New Accounting Pronouncement"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfBuildings": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of buildings.",
        "label": "Proceeds from Sale of Buildings",
        "terseLabel": "Proceeds from Sale of Buildings"
       }
      }
     },
     "localname": "ProceedsFromSaleOfBuildings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r73",
      "r75",
      "r81",
      "r105",
      "r127",
      "r139",
      "r153",
      "r154",
      "r200",
      "r203",
      "r206",
      "r209",
      "r212",
      "r233",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r465",
      "r469",
      "r470",
      "r474",
      "r475",
      "r488",
      "r497",
      "r577"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r46",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r45",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r25",
      "r26",
      "r265",
      "r534",
      "r579",
      "r589"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively",
        "verboseLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r265",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r25",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r25",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of assets",
        "verboseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of debt borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r423",
      "r548",
      "r636"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $4,284, $6,376 and $7,096 respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r343",
      "r418",
      "r534",
      "r587",
      "r606",
      "r611"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r133",
      "r134",
      "r135",
      "r140",
      "r151",
      "r154",
      "r237",
      "r414",
      "r415",
      "r416",
      "r446",
      "r447",
      "r486",
      "r602",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r196",
      "r197",
      "r202",
      "r207",
      "r208",
      "r214",
      "r215",
      "r217",
      "r346",
      "r347",
      "r552"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r196",
      "r197",
      "r202",
      "r207",
      "r208",
      "r214",
      "r215",
      "r217",
      "r346",
      "r347",
      "r552"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition, Policy"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r83",
      "r127",
      "r196",
      "r197",
      "r202",
      "r207",
      "r208",
      "r214",
      "r215",
      "r217",
      "r233",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r497",
      "r577"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r527",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of Stock, Consideration Received Per Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r251",
      "r254",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r46",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r383",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r389",
      "r401",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r194",
      "r195",
      "r200",
      "r201",
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting Disclosure"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r391",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r380",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r383",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans Policy"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r28",
      "r568",
      "r569",
      "r583"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-term Lease Commitment, Amount",
        "negatedTerseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r125",
      "r127",
      "r161",
      "r165",
      "r168",
      "r170",
      "r172",
      "r181",
      "r182",
      "r183",
      "r233",
      "r284",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r497",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r59",
      "r79",
      "r80",
      "r81",
      "r133",
      "r134",
      "r135",
      "r140",
      "r151",
      "r154",
      "r180",
      "r237",
      "r337",
      "r343",
      "r414",
      "r415",
      "r416",
      "r446",
      "r447",
      "r486",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r602",
      "r603",
      "r604",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r180",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r337",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r337",
      "r343",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r59",
      "r337",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r337",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r343",
      "r382",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r40",
      "r41",
      "r127",
      "r226",
      "r233",
      "r497",
      "r534"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r515",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r515",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r515",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r515",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade and Other Accounts Receivable, Policy"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r58",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r58",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r58",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost, 407 and 236 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r337",
      "r343",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r139",
      "r140",
      "r141",
      "r143",
      "r155",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r283",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r444",
      "r445",
      "r446",
      "r447",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r508",
      "r530",
      "r554",
      "r555",
      "r556",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r130",
      "r357",
      "r371",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Change in Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r160",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted Average Number of Shares Issued, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918705-209980"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=123726495&loc=d3e600178-122990"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Column G))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r637": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r638": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r639": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r641": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r642": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r643": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r644": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r645": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r646": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r647": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001062822-22-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-22-000005-xbrl.zip
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MT@%3@06$R-K:1JB[#(+?%QI #WCS>CKGLN*TG:FM/$&>OP)^6TY:R1G^M\@
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M<EP6JRT=++V6P7)^!(,E<0<G1_+SCN&18;O,HM8#&CEHJB?-'H?]X]#^Z>>
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M46JSFC3!S6N38R.3AG/M$\Z69>(*\IK0SIP)+F3R+'2_L;7X"U(PODZVYJP
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MVS)_?GB>/0W=2^]B[\?IU7^+BQ_:06B .! 0>'G%10ZW5@O&7-H0!($5>O7
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MG-5[WC_4:X#V>"[0 "]\V-U+/RD^U(#;!"YM==7E@V]9X\4]8@PE:SI)*D/
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MG;%.N_%/IF+V4=S*$ ^_)%QG/!2EFXFIL\L\;(+R1\<K"_0$(=)]5!#YD1L
M R\\F[*;7$U2$8W@Z!U2M(=(I#!<KI!001N7.>/YE)6YU25Y?*18+ML"=CC+
M<*<ET!7S$(\T4QD2 JN\W(9 +D)A#-=3$LGXC<"X2SH-GE'4P9"I2]4P!@F$
M4B,U@UB.[K $P89-$ADFS)3TL^@_$5I42F@"F30I<CA*!R?2)IB@*43H#"2]
M!4Q3]#KQ=K HP71Y&9ZQ#[3TG@;V!8ME#G014!=HJ@/X$$>S7FJ7>0S_R:ET
MP768EA%T K%+T*D#[5*G4U8 <,05XE":+LA0X="L#0V^1:XFJI-$F4( #%"
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M:'1M[5QI<QNW&?[>7X'(K6/-\))D^9 4SSB2T[AU;(^MU--/'7 72R):+C8
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MI7].K,%S'%\^%/VS3=:B6ZA@>)[,:#"UX'R7>B*R=.J@_G"(7+7,Y?Q %ZP
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MI%DW3F<]MM(G.*KBMN>./>+M^.AG<'XS:_7D*4%:]+6S]9)MFTX86<P"$7(
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M@CX9Y%H]<3DU&:>N, V T3PR \L3%F5!1+EG4&Z^/.(^/E!;/55M5Q#3X5'
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M861:1@A^!@#/R HB%OA #>K0T"/N&D3!;R/$UZ,F!"1"D,,R%NL25[49L\S
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MK1UJ<U]1V[IRKFLB:IOJ"(-.=K\HXJJ-S$[*DD$12PBVW_1[>9^E7#4$PFM
MU_634EYRV!-J2*\>^@MG'=/]:;&9^\#BMU=P]@Q8U]G8_HS-QN)2[N22"@R^
M2.K/(T%&;2?(^DVC!BR9>\V3O&S.L'[>/(GWBN36EG/]C>TA-CNJ.S"H6-I1
MO]=+Y&>6#V2G_U=D]K)987E*;.V0F?\*S-:5<SVZL?U>=H/!=J-2=0$48V>Y
MJ)29[#*[HUJ ,OP"O,^=84=0O&&H!(<H[A6RO6R>^8DAF_^Z"6M]6=?&L\-E
MRSV%TV0U'G^M;7GY9/^9\=GK?JRU95V?;&P?RE[5!ZGJ,@M/>D57+YO@UM+V
MCCZY67I<1?9^:V&V?]5:JVS3X!%C8WOH#F)U&LMEF^3]+(>78?OE/"YX7'52
ME8=*?,K%)?8P/4B+7M5B]5Z:[E6A/5]>N)]*6^.>23]:0KQVZ)(8K^AR7673
M=U%+-TWJ]YHF]8>C3>K?UVV;M0]X A%&^UX#?"^<*YX2@CXWA?; /G"O ;[5
MLRX\:&-[J,;P_".1%LMPFE\#?,^=[,M36>N'P1[8ON05@ST'WC4WMJL-5@/M
M\"H%V-6)>[+K='7@R!\B%8#',,6J?I>P;%A&7-4#S]W>]0K67CC[_,QH[8%=
M45[1VG/@76=XJI+47QCS ^57C&FT8SP)61T*!TZJJE%1/JMV &_MX=%#/^Z2
MO@*\Y\XI/S/ >V!#E5> ]QQXU\<&=7$:QCU <%7UG&3EM9T.6_<):/M"5*7:
M(K^,PQ\N 'H%R<^=Y ]-03T$*CS/W-1?/UMJZH'M;5ZMYC,066)C)+<3!_$:
MFQJ<Q$21?+-32#L*.X+WDU?3\^+YV/)_WOC, WOJO,9GG@/O>AO;S:G+VE&_
MVV7YX#7.\L(I;M_KA"7G\2U3=;^.%\OC35^)O11B4[*Q?00KSLHE[(!Y12'/
MG=0VO4VNYQ[E/'Y@K0E#KK[!PZ+-FL0Q!N'54<9/CS348;T=H=7'#:>LJYJ,
M)-E9IK%<:+GLCRERP;4R9US '"YD\Z2'G5 \O2A3WO^*EN'[0_YWWWFNGMH'
MJ59V8@SAI7WPJG+1R_(2=R<W>&53P_9:U/AU'H7ES^37B<LFORX[JHZ(I8/)
MGZ[$Y#?]HOX"F:_Z,NOG];<@KR+7RNQVKI,WQV6A%?V@B'G,\E@4K[PX/D]_
M9L3MR;ES]L'AU2%_VDX4X4X&M>_ABN5<_YAE%_AYV#!D_63O^';! [R08DJW
MP,;$<M))->FBF?26.CY9_1LT=R%&?H2'8N87Y23J(S;1Y,804->Y!L)4?QDU
M,96>R.7FN#048P_^)K0.PW93)3RYA[ED>&2,RQ='@UM&IP4##;BI&Z>PHF<#
M+4[#I"^WKU0BC:VL,)U33FF 0"0QC';RZY!-*19<I3CM3U^:]1,^^:4HRK@[
MXW7B&K?*3'X;XVGU4\_HLBD-UDNFQ]7+\*A[6-:I'\!XQM,O*SHXX/I+(%&M
M'>,D&?D6]6@JSE2_+["[I20ZKK*BJ]SD&**BS1&(C*[_EC;%(6C2LS09:-6@
MY"XBJ3;32SRZ3KM(LRO5T**?JK_SN+@ !=L')I$5!]C.6EZ@7AVQJ@I^2&P<
MLKP+N*Y$,<"'85U5-4,\I%TC.V,L-WK&9[-2<GL3++\6LC[, WFX8F40YGY1
MYH.F$R3<J<1*=G?<U!)@ID0"%:R N)2=O$?8'9_#P@ZRG%H88/! :,@J.9 0
M%HC'H(-RC#=&>=:%"0]J^7GP.X#IX-X"E@-^B;L]X'@N1492Z1:A_W%5M_U;
MD+_=7C^5N9.4("9G'>U*:)6*4%R!/*:$6%6_($1(X)- 5I:_WJ*F%+!E19:B
MR&SBPT'1I%FIG?49]H(7XD>)O:6!$L7WX%,5]R,+\7XY0%[K]SAJ:OQ*R?2M
MPXU*H12!O$G><+LE@3> FL2Q5<PU\C3X;5)8^FD"? F?_^['N>+)A%W-9[N*
M1!;=<FT@8R\K9'_5=]+^@)X"'<;+3A7)'+VQ8C!C> L+BBSIE].WS.?;T7_C
MLV/^^\8BN<R-^J9./HR0G D] %:XT.4BOV/)%1L4&V_'I0-$8V+*]QWM;$_]
MB4#F;*RE<IMS:3PRS'-0M6#X5Z0"E'V8'N>"9#<W1FY:S4HK>[>E:?4D'FD0
M\HGOXA*H%BXPK#_Z!7Q7S ?2+X4%G-6SP.$EELN(J_5=Z]%QKAX7S(D#:&@6
MM2#.>F/?*WP,ME:V96-:-U8]P\&2]N"_ L8 %K>+B!@EHD(86#XK32CX*S&:
MS@IL:@F8N&+284);S\5E)KW6;E:4^'2$JG@H=#\/A;2\$AJ#069YV-G$ZT62
M]9J]"  /$<;+7N5X.$V(!TCGZ*K%-^K;ZIGR^8Q?(O+@&L_[9PA@>(SXH'@W
M1;R%,.!8M@!).X8!=>(] K')7<0FMF1)< ><7Q]9>]XRA%_',RG6%K%Q,894
M1RI*T):5["R)HR2[B5.LN098B-Z$S@4R#6*KH@M?  $!K/;!71NG'=R"#%P"
M(BDE5R 7=(!;X"\6)PA(D4_*04]H!%P4%@@@.%B6VF-78!!>HP#690-@E1=3
M7F4H,@ (32V$64KA*-'C >_DDB5]5M8.G) A&&2XL4DASDPR6 KT,]&_ QX5
M=>1!Q@E"[%B17;("YL=R6!V&,@>C'I\'MDWL]?+L6OKGX' 18],V#'DEV:3P
M5RUVFS@'V=D"UGF@)JN0]54E,;*EHIQI,"+:*"CP"C"&0XG*Q1F,"IS,@7K[
M)<X_T[JJ:_;X3"L_XFL:J_U!*%NS""+1.7C/V.HQ!]:36H;G[ J'I9S5&.,"
M8X.1"#W'<GRDMP@[BA8Q'B:EU!2^N[YS.+%I4/XPX7YZO2U%>5$^[>3@@OTX
MITX(RC33>8:QB?^JV,ZZC>TP4?)UZV@+_*R,J_T4*+P['/P#>888$G83'<']
MW9U-14JX3AJ?!%XOGP>NJ@!?$O>7(3-6W5U^E%7Q^AESG6)?F,5.65FEO_NB
M*#?E-3!>($LQ''*O'\!8M#98LU"HHS*07OT4]]KAR_XME-3!6*\Z0@:"\%]*
M,%6"4\D*&(^!%,]Z"C,$4ZHT&$:G>F@/NPL6TIB#ILG@*QCWT=B$<;2!$!4Y
M+X=>_UX?CS0'QH9Y5PN)H2-4JW Q/^^GP"H8S4R!W=0].>L-ZMN'FA>][/$5
MW=2"?BG?C#[] (@@1S TT@FZS?""CN#+$M,GL,&+PL)5VF 8PI0-GF."/_[7
MIX0LR_:F OD)+!A(0X_%Z2Q3.\?"DBF]A5E3.3K)\;4) QC+^RK9P:I;Z<2M
M(W<"GRI^Q '!.O:0?Y.I<:HW:(7 IR_T5%#$):QWWI./QN>QY"QF,.'J&F1\
ML%<B1FG;9P! CW,67L#:%[(60HJ;4MY*HRCQ'R+<!8?^*CI/*CHC[ =@JN&0
MVDF1C#3;3Y'V-ZL?,&2NT:N!Q=#\5?9 !M*UM-\-P%Y@))6K@YGP)I1%4.5G
M.9.)C?@L3I6)EW<I&%5B%YWJ6AX7(;;5&:#]!T&<$26_E6]6PPO:J-<X^N]:
MRNJ9@XPU$X?!)2R0=2R70LE+$<:X=W/.4B@ ^4<.J"1+]-8 M[X?_=V/@T#M
M QT'#_C-CQ!I=*B8,+J+3HBDLD(,!XNX@><PMQ0CSZ"U!D4IL&5G"/"$Y6=H
M:6.9T=*KRZ359\"=,>*/.)3Y@3YF5LY$*I-8X06>AB.!-=Y9YZR8&MY9+H?=
M WPE/7PYS<J;EF$ U)&C]P*?#T<E+7U1]KE,W6B]SJ"0PY.WX5L" 18B1O.C
M10@X9(("WY%(Q]W>!":3(Y4HK8L82PZN*%1Z")_:+^,$T5:5'H#YE@)SPT#V
MC#=Y(^5$(*R4.++3!PZMG@SJNDE)*E*HM1QU%ZN<+N:A< " SZ0IE&@*C*9J
M50]8&2LL,&>5:I?Q9;8))C27>9@4O#:C?J[B.A@HN"H5C(OBI/*9QGEAO66U
MTIQ762XS-4%6(B/6.ZI+8 Z%:'.9N1J1WCK9*IT% ?P"')'$R'9%[?/%.; E
MN)<5TX6L)^.Y-YBVE1(V0LEF/6ONGA"X2=5=2ZYB@$*("WQ%+N0^<G$=)OU"
M)IE1X^C#S[*>L(E>!;*IACI K\H(+_I>Y-D1I%;IG2;"A=]-A+)J0('JHGE*
MK5\2S,#A4LE 0S*8[[ #<2I?HU#X3LD/>G?X9A!)*</P(9U8G"'Q*J]<);TG
MPHM2YN.LT1B#*N 8UW2M/$E\XL1:51G^20L[,_)7+W?E0DVLU<1B3+YW^HFX
M7"+/8W Q<:"@+PO0!S.6<&8D\KZ+W<MCK(+'\) 866ZI5\"%3"MM-B(K,O,O
MU_LJ5O2_Q/'UJS5EH70286J8!X:9%TJ+CL1;,8P+AH%GTF,#A%M(M[+A'YFT
ME1BH.W+L$#RQ,F4/A*+//$9^A9X^6)&J.Z%4]KLB85=,A>7^[&,TSO?M345V
M:16SYJQ,O.1(], 6(D# Z^2RXU-1E/#:5,9*VJS@[&_M0Y(%N']+8'J^/I\.
MGK$#')%H%-8 1.Y0PIRZ7V)',/YW'[A9]NR!4259*$<*]*2696O'0TG#QK@@
MP'\DEWQK4R,$.&,_R;)\4X[A6Y;Q!(8'?'8LKF&(KFMZ1*$@)'()H^IU,L ,
M%>")"^T-]<@OFN>8NJD&]["4R'HP"2[\;;6@%1F (]3/Q>COGX%#^KDLDIG\
MU<.;):@!!N)-Y8%2Y?7%" ]D,4S4S].XZ" DZ^<%GGB(%Q^I;L8:,=^P7_ R
M8K_AO]2(J.K]A*IK[SJ4A_%H.RH.2'S3DGS39: PV"6+$UD;%6%4$15I!^UG
M;5&'?'<E@@+4V2B[K2IE.YM:5U=76PFH.RG16R"=JW,J<8-F 9X$QN^*834-
M*GHLD GE@@\K5X#4,EX8:2NM*EE=$<;L-23S2UM64Z6RFF485PM-^F-$Q%&5
M-&+^'LR22H=LU@#J:._]6$9VY-@'0"7]E-?27LNX*K^4P""041 $/Q@D1!2U
M0(T5AM(3"214@F!3&V1]"5EJ8"(+KT;T8C7,IF2Q'LFSU#*%"+?.LLM5ZI?Y
M]6?WM+@+EHGXJR\3D0FEW1%?X%/E]+S6C2QGE,^K4$.;+!AH8ED328V'5 4H
M^%6G0^[QY%MR'N ^9,/IS(D2#F.)X&EEVB7+XPR<M@)F*E38H(X45TLY*W)\
MA_#/XOA[ .['S0;<LPYO++/Y*NC+&>5XNEA:\COS@37C-H&#"5F)*JPQEB1>
MH#H'?2P9L"_!/RY&@Z[R:57T=+)^81,^\KC?U<^2?HCP*,QD29K,.JITOR(%
MD2#HZ,/'8U*']Q>ZCS;W4=R]H?SA\<#B,*,0L$)Y]C#D.!^Y0.W1P!!VPD*U
M14N-1#X8WR#CHT*UI)$5'Z52HV6L#_.!'0%(#(:&.SGR#.!3MY^4<0^HT@77
M0AYP#PLTG)(\C%#.MBM*%F1)7'1E&G-$G70S(#6L_Z>1[S!L'XOIU08Z=P$#
MEBHB(B<UJL?DX)M@;TVR#D,E&+'+3.V]&7UY%?W6:N^EBL%53RQD- 2_CFH:
M+ WN/"]!/,#@4JB"1=0@MMQM<28W67#MB*6P2OK.I90-N+!?%F$' S;:AV[P
M;Q3:)@Z]B0'WA%]A#/"-_%:F//YD,*E?-K4\&["D'.A!540BH]8RX*H$>!.P
M>=K'W4JUG(X:;3'.#6#R#D:C7#!P7PY<=KZ3@];D:;^RXDUMN9);,\:S=>B?
MC 8T&B.,E3]R7Y2LB\O #QF&V^\.!0\#\N.#7C(#S=DW^B0L=4^/Y=]2">\K
M)7SO=7C*WC[N2!%<71C&[U.76;!(E%6&"0P7*)XF3SB=UL4\C2J/*Q8HW$3M
M)#W2.E8O4M[+XE09IQ*>GLRL[MP$%BZJ/%45(YZ-4/N@-H&K+^,"!S9U#4C=
M'ZA>)U= )HA5*6253*A%,.6J3%M"3S6+O@Q0@X%(J^AA$TVHQ70$GD_(:@0?
M,UFVJ20UF#L:/* -[6&_U(1,MP0"9"7%6^'M+5DY00UJ/+%2G]LVZ*GJ.Q'J
M'+T__+*W.X>?@:? <&/8%^M]/:LIMZSHA-B)CO@P82?/X';M(N:IP%V9X)(5
M52X.K4.UOY<#- !^SB53@MVMJC&U7!9V :.)#_M?-I'LU$8N<0RM*_<_ W1)
M^\CR(E]=??G&MD:V7%-[G'"N@_4^"]2X3\5;L5&);LJ[)]K/(!I4;5WH2E<-
MZ!ED?* !0 3++@$[4TE N?U8NN83"JMB(%20P!TIS[KP0@XN?M8'"*<'\!;X
MU ,P*X),KX F\JLJ^)A6LYPKQ0/^;<KA9=+#E?NL+W'3IZPG@:49.@U8^Y;)
MRX@#&#4M.YAT_M3(P;BVP_CZK#5>N:ACZJZ+%<!8AL2P[ITC-)]V8RK4H[*.
MF"A0F169]@8W(A>U1E85[Y<HTV=8^(RK:LF7Q)'63S&NVI/==C29J*X-&X]5
M&#<+PWY>U6DW%@P/9&/AT)15>W%KHSI,9"ORXBBEK9#&;AC>J!HIH(D$UA*2
M>M+V524*$UPF]ZL7B]C%S44,HW1L:OZH<^I2!8[SHFH#4/]6\3"LR"XKV; V
M4\VTZ&17M:<SY,T9#UVE@*O26I6B9AK6F<9(3UEC Y9:]H09)]0L?(*$&%O.
M*;),TX 5P]4$-JS6$IP((890#!>R">?/93G,%%3CA 'ZIC&%KYH^':%,I_(Q
MGMQ41,&M"=5E]:^C9-)KMD"=T),3LLW).ZI9J&N4I& =$_[+WG+F#@O-)!GN
MC- 'L)B+C6)\$=TM>Z%'C@U3>_/O+[\;6Z[UJ^;;_]3>'\ 'Q\3'&5N>]ZO6
M^U=2_FIL&0;Y97Q&=(LVZSJ;+Y8V,;IE/7ABOC$R,5=.C&P1"A.#SZ9=30IW
M_K-:9G$G ]@6=H:.I"S>56JL([H9P*  BRM(*&'/#GDO48^Q93O_?,#,V,@;
MY&.H_<_9LQE544J+B$N)E&<". RI1\H#QC!*56DH41J^)U$)-/C&G '4UA<L
MK529SD9+;\8%Z&"2C!A$D\41#R+DF62N7-$28?C??;6-Z871=:6$G477S;I?
MR)U: U2$$FW'6(J&(.X<#3'!:4="Y848AU$53:\J"4@2]6P999;=GAJO78$7
M3*3)_3I<**]>A05&P2-6%HZ84[I%_JF]27\GA#851 VC+VA0X3*RY<G'^-;<
MITP:V3_JR/D8M&UV#ZEI*W+);"'&^Q#TCR\+3EV5JZKZ1:QY4QV7L+M2'J>R
M<A%+;^#KJ#H&7GM#R!8H;'C<.*;#1\/2PZ]$_EJ-^9=-]+SSO(-ZP:ONG'VK
MLV5,W(D[8+L8OL28%E+KC;UESG^W-?6  ,OPHEQ%:+$,KQK<S-O!ND_<CA0"
M!(>X3NL.0MRZ.+848*3G/P[L\-CC$+,!%<ZJ>M]I8M1$V!SN:;H09<;"&+P@
M+"($>9KU.G#UC&I9ZG=)IT-6U%>D7Y =*P/;&?3 Z@]"T8V!:J1:UNG7DHD%
MEZ\M8M!'@(=@!E>XF7'H"<CWW-)ZZF'QJY^QQHL^MQJOYQ,.E^8+X6T5,YR(
M%2*'5KN,9$LVN=.P=F_#3)^*4V\.]]"@$,$H]3+3I=2"R+!D(+WRNN-6G!=E
M;212M<^9:5UVG@T%?MQMD)"ZM?-^;U-I@C'PHUR*VZ(!:9;""BK]E,EKI#:/
M6%Z9SWSDDJ+,LXLJ/#!OM'>]$I\XX>NJJR=#$-.&M-G-(C=-UQ7]E3,R:^F5
MTP5H466VY\3@5;!<1L]E\+PB1;69*JM-6NV,C[OMM6LNB_QEM[=;8C5WPP-,
M>>=<]945:4=V<5.#89BH5UE<&62H1JE@3UPTZR M<E1O8V]V:DUXT</4N1QH
M94-D/*S>=E#Q-*X(MJF1I?C8FFE\?9JD3997W]2(#.6BZA67#A\5C]9 JB:&
MRF[%W4H:XD)!?C935F)<Q%XO&=0!CUH69S- L#C0:;9,U^4!\^41Q4W=6SG,
MWF@DP*4J$N#[RF$VP&->OLA,Q>.JF(0W&I-PJI&0:B2 <JM<$=:6%F437E/%
MKA5E&X&97,^?,G-T^/'PX.CX[M31)J7T]LR1=M7)9'T&;EF7\4+9K&%(VMJ,
M7($N$#)Q-]V?9BD)@F$H7\023 8B0K"'^Y[@"PGV<%\"!W,O"XJJ(4KOI]JH
M<&<F 28@%LLEO.BP_2J]\!>4,JA"SNC)R(3VCS)P15VECV>R&SZL=IR1F*QJ
MJJ,J\H'+)5?-$ VXU?+0*<=>;O5\5?.+2ER00Z\R-;IA@G_L"3:1WF0TTONG
M02RC^UW'AQP(?-"(=F^<J&J_JJCP@=Q4(!^,C9PJQVIVR&CE:O@U5?1\4D6.
M\;!4$;7L>Z:*3'ORCMM2161K_KB6EBMRMLP'YU0<=P28V15$].Q;DD4$;GJJ
M;!&A/Y '&T._MJ?21;1.%SDXK;UAP==,?V02E#(9Z&J49]''QN=-YY5Q<:AV
ME?,^UO^+\\J]DT&[>C?6O_?SO?W-&1W_JO80 @3\\I:[>WO[3QX=-C$VAM%A
M[T>"P[0*#A-WX>#P\0]$?3'P!P24[0[?.+/C?G6LU9D(ELZ/&%O2F,YYD#T5
M+V8A)F^JG%"<GO?AH?",6R*W5A6''8_<#N/.SFTWFQ,WWR-.>UMLV)@]:1FL
MI1-14P6I(]E #T- <\*P,\/N2XS^S@T[SXRYRQ>[JX__/J>08^5LWB?FR*:U
MZ2W!Q%6%YV9K_-?0W/J%YG9F1M_F3^-^D;<GB9&14;SB5E"LCM89YCK%R)YJ
M?\"7T8:237BT2I'('2@S55<5[I&]6V4OC<J2X*CVTC.YJ^;/K"];L\'*MJIV
MYWA9.[NL-[I00X6$1S;M4"+WOL@FQ&59E1(\>F-E-8Q]$>1]I#D,@\IA3'=:
MAOGA\Q9OKSS6^*P:S72KY;$NG;<UFIYX^7/>?Z(*@>;WX'BV.WR.U:;*W2J\
M^R+Z$CPOKCBNVK;>W;=Z9(<+\5?0Q5KYEM*K3L%^=>O85%T:(#O-5GVG,?0'
M+Q95_]T:*\R;UX@BA*GA>T;V\DB%-*8J-]5F/ME*6^G%;*)1MNPZ/6P0?CGL
M<KV,UMEJ2,T\<!="/^Q,-_>^?V/OT5U,9)$.W:^%(C^L6,S70I%;-=3!L&D<
M;L<=5QXR:["D9O#X55<^2JM<^K#9<BZW_$AX-DP[CN@KE7J0Y9A=)IL-<G&]
MPL#X;4=R_^NL7.&A*KB#R-4NSMZN9<'O*M=M4R:WPZ9_577N(/ EEE>7,YB6
M"_360.'W<+MD,LGP(QU>\'DS3S289:OO.#!ACAAFZBA$%;'#\\4? )F?/:2J
MNPU-;O2^S\$F/[+5NV$![%/4%:J39E%D83S,!$\V*GF91,#"DEY\*0,\<7H,
M:R6ZY,X2$]<W9Q68+(),W[.4<?8C!22J1 .?9<TJUIB1BZXJ1*@%:X&=BR=*
M1.JM[2K8!M=YZCJ@D$H@2" Y;@1E(!3UA:R5&2TGJ%[FJ&=412A-DEY5#3RX
MH&,8A57AJI&]!;A3H<H#U'D4_&%DC-4,FMG+?K$:#K-.Z:L3,<8+UX8G%\-<
M$ 'B'HFQ>@*I8/$"',+P)-CA-B7WGTUH3W8CQN[\]5:8RTH[SDH4(,R?%<B7
MN;#=_^S@!GC9\A#[Q(,3HV.=WJ;JJI/T9:14S;F/6W$D[%#" !1GA3K5(6%%
MES6M<V3/K2K;V$0(5=5L=7#MG=M%%ZDK:59!\G43M<7&^</4_)"\1;T31<6\
M*D.K-I18YC\;<Z,D0Y:0C&XGD;."*[WAE=;L*S?OW+]BC*5)JA:F-1=)*U>S
MUX-2_,B3,J8GAZ9XJ1(6G']5;E+;])EK*Q,W_:)4+634!;<LL0HF2J&5$=]^
MDF@V5<++^_E8A%P1>ZPL<U(920V$^UKJPAA4=/#($<F:G',5F<R"*O6+Q3.W
M/1Y<X>Z<HHH[9EO!]FZ=<[US8*-CFF ;&$2=V97)@R7H!L0]<]0 "'N=?Y")
M BG%6H*ML";'2*?'^&0K@KVZ9W+2M,E14=400ZVA&)<<'<:CTD@3&=OQ-/GF
M+=PA.<K#73:;FD<PMXE7N?Z6]\_QD]M^G3&08G9U@7RFNV7#$XA,I,I3X7"3
MU.0CZX#(^&,G*Q)X7\9D9KW%D@^U<-L1/LN1+YTX<.Y3<WQ'R&JK/X-YY$ET
MP#WRN;G 8V9K.R^Q!NKWD20AL&XJDKJ^<R0-5T>C9 A)O1& (T:^=5%@ :?*
M*H"].DLSY#4MS&-,6;%*?PWS?./(J3[C#P_&J <B9NU?"NLEXOV\5JNW,IE4
MA=31WOC  *#;B8OU _8_E4$8?EJ8K68>^G?/>8U(\KWF03![;^$T?.T-%CI4
MLR!84$%_8!8O$]=KLX ]O1O8>S,KQ\>!O?)8Y=(>%#D3R2N:WZE6JW&A-L=3
MZC\KP+_3GH]"> G:?P;,;OJ+8G;3709FIZ^8?1',?K0\F+@D1/^\\*2#&P$V
M-<?#JC^)R[P?QI..A*B )PWU2 _^6#J<-"5^-+&,4<')R5&_PLF%89B)G0L,
M"2?K/]6B8@\!<UW0I(%H4LZB&3>.L(&6KV!R5J1^V,:^.?$(Z\ZR#!%=)8PH
MZ+5E[F:I/#\M/9-!N?<?6INJZ4ICBH<A9Q5+J''J1.R_CI>.X1,,]HU2O:Y1
MF@<,L>I1'K3;'.16]?/.)0")U B;P;]Q#9UXAM8]>\L__C*RS4\.WI8M-D#?
MV"ZJE;G[R:K]A+-R$NHYLO 8>V[*LO"YS[%F/J="=2F>4PB&%TU5!:=&;4_S
M1'5 <06A*OMR+'<LXJ8&I5GEJ)K-9JJ;JZ+%A$V\TZ161=( 5K"8$?Q0"=0:
MX#(N.74GKWJ9ZPX%#=$J*H&FE2^=:$\^\CJ9ZJY @ERPL<U.]>X,^>S7^HH1
M(;>>6WW%:I9!\1L+L+RA$7]IP)-*:0RY,A#@9VIN=9'D/,P0-ZI"\70QK"N6
M[9BQI;0F#_^0=1;-R2!DRR(:^%"YBG&:(#/51^FCL&:;Y)7,;>,0^'"/J=!&
M]=6X:I/N.:A%?-J(EYS?*;H_@6T[E&=G*[MC+K"WWC+LAZ8^J[C)#P1+V.P@
MR;UC)'-"('+#^<PP" X?'-BSN$JRUV!TN-\*@_?#_;DS:BB6D? $+PQ!1^7>
MW2] ,1(,63Q8$4X$*Q8(HL@B2F6$QUU_%0^8B&G@N=D9%AT&228C2S#DNB'\
M5#SD]DC&?(^YZ$NRYS/+(]Y0#WRP7V:YG]H;8H_%5G]@^1^XY!.AC@7"$\/-
MPI\6B.K(,YL6"^W<.P@PVZ$__F%'?;Z'#JC45CZN;<_(R]S/-3?K'(^SY2_?
M)Z?#IYNOWOA,;WRN(R,=<5<U[5..*R7HN1I3GNO3^MVW#MA27?^6,-ZQ'4"C
M7J19FXN'[O09.]/&?4S$\US.6),ED^H8O)>)[]3<EG3&V6+G 2YRHAER7GWZ
M(.,,V"[71RH0+^(4@:@ZO&QGYS]DJ6>0X0-'SAP;AC9 T&(\J2$4JO!;^<J3
M4Y3(<,9)8M6$5)5WJBI81\]K:LYV5 ):CU!I[)$%N\IR.<S*M\%9R[,AAU,"
MHL5RE%)'_9''"*+TU@#K.(_^[L=!H)1#<Z34 T^10DLT^WBT:JICYZ*A^Y[C
MCEZ17\HS'0';B2[HP%34)ZZH+< C_87E>@8">T-G<H^-6DS9M6IRV9LZ&5G(
M*G?)])!=4&5WT T?DJ##ZF@/C&N?%:5VG /QJPW;(SMKZSTP:DO-<%4PJ-(<
M/P>2UT,<GTQS^\M4&K>=0446*TS>'*]*EK$O>3!YF %SX[J.\-%8"ZA)EY,H
M4QAF'756LCQ5,2D[@VJSIQ"J*<K]G$I,&P+#2I<%D]B@_>1K&E]S(@<_-E %
M>R='&DG1>N2Q-B<?+C#:R5* +L-=Y*G4'/)VY'IBR>Y7:K.8"FA*LF[.E'%V
M#_+6AQQ6!J#9JMYEUW&WWZV>@$_E=1X;/#7I85U*GQ[=?+V9F0RCJSA4I;ME
MJR[53:MVS' #_,0X[FZD(M4Q$(J#)R>J_ADWX!V!_]:T6*U[ :695,9Z?33:
M; _BY>D%"92J Y*1^?M* [-**TRF+#:U+WL?#_;V]=U/;9ULWF/SPH@1G=BU
ML(A"5J71G]H5T96$ OA!%S>LCK)3 JOV@UW+ \* P<QAGZ5BW$F'ISTX9C4V
M;=S<,=E"920GP>IND(F69(PWS UK0E34*Q^F4ZI5&C;&&Y?U655$I'G&W$?,
M<(R:]6]NN(IA\0(Q;*:L@FTI:.JJTF@8Q6K";?>-?DW6_\B<47-$@9J9! 4
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M_#[/EV1PU%93GX(8KMY^/)ZV)VR85()M:*9MN@>RDWBT\-F(N50!XB95C=+
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MXLKL#43!Y,!,K1=ZS 7[/H)Q/E*5^3VK+80V0UON2)L1<LAF!\[EW<TN'H?
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M(J<W:A',BI476X3'WBV,"L]J@S")K,;'A89" <Z)^M_:5%@-XLL([;;)^3=
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M_?FGJK(EFBBX0>WL1U.9BO]?.5D\P5&\%>[_\0CH_&$Q D=K_^?SZ7-YGYM
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MX^&(MDU--GH+F"WM]9.?_\>S[^XAP1<SC&QQ.(83(-0#7D&M]+%U'JNM@G9
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M0K'<_&$/K2H,CKE">LO.8$%MQ*'M-<_LXEM5;L[E)#\>#'GGZ-_2+->)F8=
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M&5]2'KR0U)+"DD7+%:-1A=SSBP X'VX51HPM>D?ILEM+Y^^8F@N\IXD2@N_
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MHS0G%&<KC*FE>.@:Y-I%C.*?' 5N)".6#-GE/@X8'(FX%QVL&7+M2 N%DYN
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M-D1ZTG$!6*QQV_F<LR@MD#=!)/&1"A,I1LN,V"L6,ZVZ0=SA_(@R&GQ"5X5
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M4H>] N#UGH$%!)_G:1S@SAE(9BNV^<%S*84G0160-&F\P/-28A*/HLM#%[D
ME9_Q!L_V0O%Z$A.F^CT0)R[U]>>F&J=JL83>EFH*[UQ/-_DC3@LP]Q=<&NLT
MEF*,+TR ;O8I!3G.[;U0S*+'5UMOA0KSU9>R(3>U582<T!X):[WD^5W2UB1'
M;X6Y>E:L]7;H^=QG>A>F+J\ 6H!JQ5$&2 #2O!$#43JV:\;+-B5$Z<!=GE>J
MR97&%>T#<2X- V<M+IS])XO/#,@P&0Q1%@K2)=?0.62HA3@STR2V&4ER$56
ML0\K=TV&;FN6K[W,A-M*-O>[]_+24#\Y<Y$6=86ZCW^%P1J,(6$6R^;P!=89
M,$L5K39_2XFE&D3SG73Y7<B]4)@;\#',L;E:AF5O"8]SP%/*S<T9=!50G;3E
MN)N8:3DD?*F ^Z_UZOKY;UF&@'"7ZQ)MD$O*U&AUEA7*AM 5+@33XL:N<7HW
MR=4WU;:?*>+;U//OG$MGR3*[4^"<Q!H)>K-1DZFS;4!Q9O&"Z$HIG:;?$5P"
M[B]5W@G*?A6DL!2S*3=A(?93>_^@*VIC^?;+>NNP3) #&A8+3V(0_-)W']ND
M>A[3N"T_6U4.5Z'KB,:$[;EP-=7#IFO9C>:;?!'HV9_CH=@<N]7^"OR7K"](
MK,=E<3F?]!H9P X(12_JS#-KZH[R9HX=\[::?6V(1?![B]"9UTV=1T=#W64S
M,)1L"(O6:)W.V88/F$63\699C&Y)D*\V:&]7FF1UNK[GAE&V2+MMUL/IV0RE
M3\*G=0)6R?9<OI9NH<0&\82?/ S<:?4E]=ZDZF!/F/"5B@9/HY4W9Z^HY*G#
M[OMA4LQN:?+X+5)T0BEP";[UJK>_\ETHD(@/A1VE7"J8*)+C;IP-0E;*?A*
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M(9:T$-WJ9&H*P?BZ*D7K3SO,8DO%<J%E#I@[)M^O$H)GS@</%@Z?/2]ZTOZ
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MHDRM?<VS\A;-3<OY.H@^-]11([<*@[6'IRF(:D0^#-[!3M7&@U>_T:H7PA%
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M6U(Y9*^$ ?"B^%@G8Y4LW"Q\36^-!Y3S#+!N4^F6:=\HS1&G1=JPSL6#HEZ
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M-C$K$A:QGZ_@LE1F/-9K&P'#%".1F#5)BB81.G)N3UU*IX%XY7+K)8-R&;-
M.7$>,7M1/!"#U-SV!IB1):+:\VJ\+6D.#6N?16!H-PM<2W0.8-IS@FC,.<#M
MG1)[>H(SM424<(+(V"@29]T2+_FS1,X"X5DECY7(54H!]]]M8:N/_>&)*/1(
M(2T$/ ].#%Z9R5Z<%;E14*^\"<6>:.663,.5M3=.R/9>@BM5_7(A%Q(L8R7.
MQU:ZPA^E M',G3W"F%<W#-",T64/;!-?[*R5[4%UNJ20[9:5B5JVH[MT2=P
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M4VZF<>TC0-+(K:!JA+ %MKQ?TI!)+36\/'7VO?BGS 3IC&D+)V=$@RO%17N
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M($?O3 7>^O!.B5>^:#$WYZ#TD1?D=Q--X@L3C=(<\T,,I,)H-$6>*S9_X#(
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MN_T3!F*[13VDI-,WCSC7KDW'I%HQQ5=IMP#AH3IB=W-P2V/X#-5W[3&,#F4
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MJ>L1;;9A\*6:.247\+UUIM@-'?EWA_&K\2B4W>"2.1R] $LOE].D=:.(L3[
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MAB32!I$P;K H?B@@70,*CZ4SW=:R?_8<7)62X3GXT3EX2J?@FO X0@G0G$6
M$LJ V44(6(2952L8I\;J,2J%V;T:<?!S\S1M#0J<%%F7-C[?"-IZ\8&'ZR#I
MMB;=2D-254K%8.6/A@M_H'NED]RCSYW0YW1&?X",A1@9_4$Q9-!'XQ ()#B
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MK;%A#J;[J2G:/7-M=S!CCQX5HH=!C:T)]/A(CIKZKZ/+;U_518(IV__Z^?(
M?S9C.;TZO=J#!Q_^S@YWFLW3'Q*?7IU!^]S##[OX\.3O]'!GZ[LTYA"C$0(0
MQPQ0'B(0"Q@"J>)020QIHOC&6]J(P]F$.D>J=R'-"B,=GC37G#3E=T:T2A#$
M($Z9,=F98$8NZA2$+(H2K#5'D%B3/4:S09?&H.>;:V,ZIU2D=VH]@LA8R&@'
MVO-:Q;PV93K"6&BDF0")Y,+@.-+&=(04)(F,)2100FH3"1HH8C7R;WGW=$WM
MO^LYV3/K'9EURN)C6&(F8@G2-$P 35@$$I92@'B*$Z-Y24%M+.GAR03U<T77
MVOW\H=-1O[-FTR<5/K:F,%AIKQ54"#27,UJ!BKC2!OM!:O0#0!7!(%%2VC1G
MC36&&MKZ=Y0V0EJG\U(^Q;"F:H%GV\=AVRG] *5)'-.4 Y7&W.@'Q.CQG&M
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M!UP7IUJMU=GB6/[(=_90A?99&-F5GM(?DU[^G.^C"# \H[N&!',NTA1@K(T
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MI,&L,&18QUI03JQ#=C9<<GN<\NZ.&G-PY0J(Y^#'YN IA2-.PCB-4FHL"4(
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MG9S_.-SY<GGZXY^?!ZT]>'#U\[=[U_L8'VY])RF'L4HUB-($&54A)$!@"8&
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MA,BYD[;6$FP_H%N/^55 ;PC0*S$^$QE#0UF#M<* <#F#%XJ 8Y(3&EQFH;T
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M 5C0/EC.J11F9Y?+OC"R8GMKL=UZ@/,[L%W]C[> =5C1M:/R@2L%A+(":Z;
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MUDO/[R69O&*ZZU95%=2;0_.*;16I(-10"\9[ \)8#]X&#<H(;9V36KL:L>D
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M\F_CT=&K-#EYBMM1-:L6&9JLF4L&;24N? (GBV;%D@6?G034F8FV7@611-,
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M5([ZJ/E6M-:;&5ME\-;R0:<K;2X6C]:$P,L?AN5@H\$_*;'PA?7>*UZ!2Y1
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M-S1'92)^+4M^;OS?O=63D5_I;)YJ[O/K"[YNO#:/U^&'F'YH1_64Z>[9M!3
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M1#7_LO359#'IZJDD6<U?XNB%9''?[01K-88RK,=M<_Z;[PY.HO]@Z \P'7@
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M&%Q06'/J$B/2G-#<I:"P"D^,X(Q8G_)$*IG9HKCME),&!QL<7(-5W\3-]I!
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M!TN\W)I6_SW 76X-AJUNV&G<Z-;X,%ZN'K4\D+6;5E2/"%"652^+JV^$& 6
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MOITVCYIGL)ZSW:W7^T5AK,*.($QR&^.HD&88(^\E*:CBH># Y61CD3]E)""
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M'UZ,?OECU%*GU<D$D;_TQ['I';0ZHZ2MY/.8RK#*)%N^7;E#M-Z06"8SN"I
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MI2D=U_617%,3K 9A,=@%WQVF@8PWGH3U3-OF+W&#5AON5R9:59N:R\%V/EO
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M#2.1%VN- -+C)/%#;QCF<,@L#S\T@[QL]";.-HTF'QP&6(89# ?=WEFVFGM
M XU!-[\31A1R^0Z(SOS663"]?B/ 0_F+^>8E@#.RWDC$EW_BW.H79+5.A-QO
M]0?]T6UC-_FN$O@N"?Q 7"1JO82RC/NPNVUST@\O1K_\,4H[;77R'N4O_7%L
M>@? \A7^)7:?POR\EO+M"@ETL2$52V!0>5FJ&U<XL9%Q8DJ,E>\)LJ$I6?@V
MWEC\WE67)61#,KWTR[(-H>A]+)8S^7062ZZYLW=UNRUTIQ-QAW#_TYK._07
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M?56? AEP@6V$J_G F0R6.VVLD!03$1WG5_0IR+Z?42_?5V,4-L;^G^$(MSL
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M[%DWH!&,G:GL*&W(P'P#.35( K(2II]"J:I)RG[Y^J]Q1;9=/*:/DOG/\"T
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M#4%)0_7GK-_S(S=L#$#5A7&/\!6ZZ;%5& /?)BE;H-SA&P1WW,4'730Z)0_
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MVMR32'T 8M*<F#Q*HJUVF<\"CXJ_V<J*:XIA+-)2+'=A%?G@ :SR[/I@"+N
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MD/&2-W[YO3<8_*OQ!Q:JQ+6_OB+(CTCTIX@$_'BM9M>V*#*ALQR8.2\DBZ;
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M:8I(U1X,DA/UEL2SMI/QB8K>74VD)J0[$U+SLO7Q4&:Y\KG."2^<(#(4GM@
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MM[Q_5;UMV7(F&!H:!0JUG3GOEVU_W3YR^\S,/LH&MBX(Z+WV7&W>M-!1OHF
MQO@1/1NLDR*,6E.]<<N;K"FT(\';26A#M52&5&LC"/Y+YJ%(]#;JH (-C1W<
M*EBESH&HPVW@0"M]V3(A]3W8*E@U$US/5>J>ECJK94+V=V!"OX$)/<\M55Q4
M,Z'?)B;DU4/:E%\"*.UMO^^6"UQRT!:2U]#0;H IK6P?M'Q)O:R*PMIG8;>M
M[3.JVNN?>6ZI7*?5I7A7>,2'HY!,#$]%;\*I]<JY6ZZ2$AB< HKV$GWC3T.M
MHX5,K8M>]\MJ?Y,]Y2]:J*0VB/L5,7&R[ F;*JTF/&HE]L;KE:K*2MSI.$NL
M+XHM,H_:ZN#5K'GK]4I5*^6%T\KH[9+.9B3=4A:[VE06\.#(Z)8 %0ZE!?+$
M=1RE+? 5MG0GO(COA3-;G/=OQJ0T1)[;+_L)2BZUT0@IB+RU03+!J=2 7L_K
ME6M-E"QLNZ52T-XXS:6#2\V_OM<KEWZIEV K\V#IM6<W\GH!D-S!3\0"_?56
M#:TV89Y;KHA-\3A+1$Z*J>U\,#1;*AQJ@W76+[L5-3QIHZFJ).S61DH/FUJ]
MG8.!TF58VPU3);V-39(:BYI;K[U>:?.]=GF]F*$-ZNIOS*BQJ'GTQNN5-BL;
M>=2JW1H5=;V]\,AKX-%;KU?:;&CDD=<F'EW@"-#QNQ!%^C><%V"4KMM9URT7
MX&?0C@!O)Z$-O;0RI-(W.W/[97^Y2/0V.F0%&IIZ7Q6@2J5SUO-ZI5V%=?JW
MT*>ZI&&(1I3EUYK=$E"_,1Y,&#8\9-*,2:V38'54!/H%G#+4S[ Z*[0OS%K1
MPCS-IHE0O;(\KU>1)FUF72M7W"?$(A)-XCO,'H =^J_XE #5Z^G,+9]SR%$X
M@,.12%I,>-.D3#6XVN:?]\N.5ID);;3\F^0T3K[4P*LUU6NO7\Z/5?"CA7KI
M 8?8YSCX5X(8QRQ<7!,P"3Y!X17BZ%N$DH!P\>"I)H-T\:FUV!NW?-PAQ^PL
M43M+W(Y [OR^1/_"P1+%3>],-\*J5H=O^V4?SXB;;=24F@PH_URX(MCXPKH]
M]JG4R.==KU^^8=U()#J5S8KW([=1G<O+.\6]?MH\7T$H5?*YZY9/@TA8>8U@
M&TELJ%$WX90Z\[S7+_OQ*W*W42$NZ6>JU4J :M74]_HEY[U(^19JE2&?8G:)
MYH2C<(L<40VX6M]X;OG@DT3D9)C:F0RJIJ7IDE!C4:^/,Z]?\N;J&/-W7RWO
M3]=?;$__7GO57;SI#HZ-/)HM&"B>D_YQ#_-#S)\.HN */^&0RJ/; \90-)%-
M16T30SY_I!">"I?FFC))Y/C3\YRDZ37XA5"(S- HEFT_G(Q1*%ZO%B_9B\OT
M]MA'1$1>3[QUS5DB'L@>L9"\F\M?!3D^G 1)"G'BQ D,B/!$_/69T63^X21M
M#H[;[,3ALGGZ30YT [\(-.D+V)4D&X['T%LT@;&)?&)\S>CL"OMX-L*LUQ6U
M8322-Y7F#6L)LP4FD^FGOXW2MX+A!SPBW(@HT#TL&K;0(,K-'-;)%_1,9LGL
M'D^$Z%.V&(B:N]D,,^$2?R'@)W! &=<2Q!#+#L3PY;LWAZ+& XKHF*P&G3UQ
M**Z[CJ^3*,#!:'&+GXE/\]D.9N(*QUK";(_05H&1B:[2+=,%I7"Q6#6Y0PNI
M,L2.?'H]-8V2&.0"5 MGQ)?OA<+7GP&:QS=-"NF7]'T@116+@<4Z:JKPMN:@
M^$[G("-*D3SI$#.MU QXJ+EQH>0TYC;H=7O=:QS R,*OP]N;")8S$ORM87AM
M>UM71_5+N,.Q/A=-,!R;G5?"Z<&R/)N1D40M-L3O\5\)B0'O V9/Q,<-J]H0
MR_$="5E&'L>"%^N6W\R+,$5CJ\R+<V$W$4PQ$=_?XWD"/B.L4F"8*,E"D_KU
MK0.Z=WX'G'7$IU@@$=UHS%%]$W33FM:%/O9ZKM,]Y7?8M]5B*DS'GOT.X4ZA
MO73M#A=8U?5T?*V8Q@"YEY]Y7T+RQ9M0#9%#+92]D<*VKNCR"LI!'">SN;3H
M(HX4_N@C9K-/LWE(%U@1;/V*KH\O3AM>^K>(@/Y(>,Q1%(C0>[V*.*UWK5]N
MQJB:"4 B@<!,P+2#@+WR6#P2>\TPOHDXAN[Y/>AC<"O IV(B'OI*HYSS5X2!
M-%#VBX1OJX%9X0^D<?T]*.,HP:"NZ 0B+X6:JVUOK8*3BOF1<A1^FX_!7^$9
M,QN20-40ULY2;,@,QR!HRPW@]/'"1_S,+T)0%@J.-D(>4%)YWHO&'._27+A<
M?,/Q=<(3AF]%&-W(40U( SWY:QF[F,VG-%K<^(!U><M8'2\K&V\_-3L3<+F=
MR\.M6'J4CU,4#5-U#$[F&(O:B#P9]AV3R13^'CQA!K'84H7OWSKL<VR'-1!R
M_$;Z,U\LC_0*[)N&^MP$^+L)HLH/O2)/),!1(%R!([G"-4.PP^\XQ(3_3<6&
M9P@+T!K/<,NA6<&C*SS&C(G*QN?,)4#/E]+872+&%A#.RP.*0S8']7;%DOH,
MX1:8;-45,I69\U;LA8$05/'0)*[;#:D-$5Y\ R(/JR%A<0(]/=+"1I5DK1$Y
MML=X9%J4Y/P!^ ;XW?/^__RX_>/^#_T54H:T=$6(P5T0&M()\6,_B3D56\14
M\B574363U@&U1!.NW3W7E#2N;7[LS'!!RFX)&J7V"(<BN?U(!WZZ3P7]#<?%
M2$)':(W0V1IK7=((G'!.1J) <L0_/?M38?,5&U\U[2U=JJEB?: A!!\/>,[S
M;3IW\/BE<9=/#]C6O3T9E&1IJT$84E\(*:>%78@K'!(1@HW"AM!&'XNUV:+*
MYZ.:M%H#T+%UVPY[45\3(<O#<0%.HU;L<!T>B)0DXGB"F08M'S%[ "'.*KD*
MH]R^LFX7E-:NHX-O(N01P/&V,58CL,(32Z. S?EF]:LP%0JR SKY.^'3ZO69
M-57'8GOIP%93N+:%4[!BV?4$.G;0!(6UB[=P?TJ3Z:ML>FR#)]?U2+'T1XM5
MD^HB4E0J(N545+PDH7!.X[2BE%0GJN6/(J^KF4VW:Z1VY-8_(Q(-H[H=N%IZ
M-H%9N^3$T]:#T@O:@[47M!LKLHQP''N1KLX&#://F$X8FD^)/Q#5OYGZ%"63
MGY[!X$8HO,QR(/& IR6D(I#^C-D,18OZ*'R/75AAX^7>41IN/DX1_X(6%SC-
M!NZ::-T#YB-G&&]7%ASX.8.5+[#[L!CFJ=ZL3[8U0UJK-^X8]3$.9'GQ5_HD
M*HMU4A9-8+9Z:'M8T9] 9/DBOA2%NFP!D2:=$1]"JJP@^9#*I+%K*Y3,1<K)
MARG&_ X67P2!.2<^T*+1&=2 /+;9&:3%]Y7IR8'OPYB"/,A3GUG1Q6'K4I+*
M_@[<1@AJ005D24OM?*<:TMI)UX1GAME.4S36FH^Z(G[A0UZ'].?69YDJ$!Q[
MY3?4"._J0>T+_9'=J-1&?2<!SL0[E76-DSX:D%;8MR^4\0D,)SV9M,KGB=36
M79C$/\3P&5;O2ILAV3=/MZ]G?EPYN,L;&!K47#6(M2KM_NI!D%YT)8_/?)'V
MJ?;<5DWK TIJ0&>(Z)R/.-@I$*OJO[0&=/S#*@7W1L;*]<YAJ:&MSE#E-?U-
M!K\!Z-A&/E599MN52AAK]5S1\RH&7D8N6PW@L;G8?$+>+##='M^Q*5&LJ] X
MA%37W&8IKHJBI>84,83@' EP0[F<(19;%7)U>>=&8)&]);5K8>T!NCIRY))E
M7M9<DRC(-BCCRX0QE:^K"6UO@5[A3OU!Q77]S2I2&\&Q=6*A*#RO"9?9J$&<
MQ9K#<7:>K7#)ADZ)N0DV*T+9/11:&94J':R_H]=U%3=$MKWMQ0B'I86P>^#P
MJFSMUTA4=7]'EZ@'S'GZ718)"[$HY%+J%5(CH+7>7$T5</HH+\=:%51&.*RE
MQ YR?4\7*.0$Y_9'E7/==S=66+6B'C4NQM<#MC4"V AD5J>EBSEF&<$&&M*Q
M)39[LM5E-2!NU 0.[K))5X7"6CU2>,]\L/%*>K-'KP%Z;%^^;A_EA\@A[[03
M4X'!!L'.+Y]HXEZYG4VLND"PGFB4.2CZ#*J$LS6FS@_QU6QVB$+W&U E3R1(
MEC<Z-%^$N37*X^^!% L_MCLEUPALJV'.SJ!O>3V9)O21$VBB6CI<2Y7"^,)$
M##>]LCJ^!QBQM_=(TR"E=L+;H+(T(C[X!216[<8:#<RZ:.&_490 5[>)%>I
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M01N$YLYGQD5GA6]Z^@FHNQ?!WE4V[Z+L2_K]%LYQ$%0(DA4$9 9!::L@>)]
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MIJTFH[(LY')O!DTO!MP-G--0?B<A-[#;EW@&$K/GN6@01M?<$,$@Z.PA,4E
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M7E^2? 47#Z98,O8A2)U F9#!,Y3 HE?*>BF5:A,(V(3HY,G2BRH:! "V%\/
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M]:>!!F[DL\_T;E73CS;RVCKU'::+Z6*TQ;/SR71><=?TNX%(=;XXJ3++6N"
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M++IH=0*=D[6&W$C)V]C2FS%]9RSJ23E-XS%K29V=E\D'.O =>8E*D*7GO%?
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M5L>V9-@ [,18T8?XU]"C6Y3V&:F&_8*U_GOTV]EKPCBM6:(#GX,NJ#-P.M>
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M+/7QZN.U($D53P%I9=NP$I1.) ASMOZ3-LD6BDF'V^CO?'J\'.(DXR^'L-R
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M/*-\)Y. MKZ829VU1Q8=3[W#L&?O]B&M.F")_KUSY*" Z)@T2E)>JPF-E1L
MG,H!+ 4-TFETPG2+OKM\[3FX?7"K#EB(_R O$5."/B\I2.1U@)GV))UC"A*J
M&'AF)J2=8_HY\WL=X__!S#N5-\5#O#3<$WB9$974=[-K><HL2@'I,-._$;KD
M3@P+0]#V3([?JY>C._)[]3'XJ 1.701[Y??JZ<#.3$['6']4>#C!!<E1@*+7
M",IE 2Y1H(.\>!]Y1BG:/!H^#7ZO-JCH8_31^+V"]3;X(,!HBG-4M)'VQR2A
MA,3I[RGC38WF6T^=WZN7NSKQ>_6Q=5]^K^N_KG\$7.7_^H__!U!+ P04
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MPI)AY%#;;5LF+(%L#,'1DYL-Y"F UBM6W_\8"ORV_"I^3F;N48@%BP\4H.A
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M3QO76PL=DW>0>'Q^^8E]947PN;@YX[==BZT%XZ8Q)P[R:'(2;<&;N,X&,PK
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MO*-,\^47:'?3$HXTU3\9ZR<._WCAU0G[AOE"_=_H-TV)-K7I7Y4<\JMM."O
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MEQ*TOSXD:Y+>D6E!5B.J;/C*<T'#5!)OE=SQYZY4VU&$[BA .@I7/[/X15(
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M?U?QGJ7&$F!_=>+P2U.9;>.\Y2G(%\]'^9&3DA=*RY-Q.Y-=KG?#^BLE'R0
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MH)-A%R'&F$M_%IAA?,QI/B 6]UZS79S+_AW5:;?^/]/!_Z["A1O&4/W0?@I
MM=]^?FK47T\_<^Q.JWM0.M^'7E&L0VD1O*F5OSO>;:\B(\^'HT>N6':J012F
MW/SI_;']IZZ=Y91F?2?O?G=K_%2YD,Z:S*-'\&2];^EGP_FE.I449@ :L72
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MFC<JC :>=?C;O@J4^5Q/3[P!VL^OCU>V^<MBO:-6MUE4YQO4_3QLK:NE5N.
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ML7L0WT P>',$K<0Z@G;Z^@?$:\(VN7V'PR^-'VE_>:DF6M<W;M3MA/FW ?&
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MI=Q#C.J+HPP89)%$+_SX/H-PN74IN''Q?GSI2QG#/YV?\D[/%'<2R!FY9^J
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M0'Y-A!O]E7_=DH&@F>Y0E)/?S[E?B,'K!@\%UZIKCQ=R$AXCH-KKI3:8ZY=
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M35,O@K=)!P7+[W0[,W=-JR^P+*)0\@*J->6M,FP:JX']!@G1'B7.^Z@HS:U
M7.;#I#@V4/I69#MF.?2&2Z!S,Y=5@;S<O EC;57"ED*M1^DF5_47TMG72 OY
M_IYD\7@?,ZX>&$%/G)<#!4R9>06TH+D=/UQZYH@ANC8.Q],-,2EMI7KUG2?&
ME'T3#I&WYY%T$1?FU]_61> NXV-&U3@2X1U\V >UV'I/S.[ ;#B G!-6:PL*
MBMJB*;UWRGW<:S@FJ."+V";[;1$.G6_?=<;=[%J[3O/:!P$:GDS?305'9,U
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M7.)$.SV")^YY8O1R1OW5]#UCQ>4MUW(3S1?S#/77&/7AD-S,P!D&$E0EM)!
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M?,R-7@>F!=,\Z5%@5PGJJ7U-C7>.?O"7@V4[OYOY\27)U+N5F;[E'DYGI;5
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M67QE+Q\GFH?0XD_N+CZ,S?Z5)N4XU<E_3XTW<*HQ]^[+0+EBS'5.]'8"ZX\
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M%?\ \H+Q0L[8CYC[[&6YR;Y("7GQI*;?-]F'(J>\+)>Q<$-?, YC$2<0>:Z
MB2OGWKZ(G(!QX@J,;)CJN)BY$=-&RX5>C4@. HVF"_!3D9>E'1&=P-:,=RY'
M;&2:Z0^6-;5T8S$HDYP0-2EQ=)M[R!-GKNY'"V]PD<EU?BDGL)_N<<$_Y*N4
M/GV6<Z)74M._+EVYM'8Y#B$.F%R@QY3*24P@%YJ>&V,7B\#SF T_G)$W-Z)H
MU0527Z 57H!:93N&. >S&54,"-[(G'$:-_!;\[]2&VB]!YR;&"(T*).<DSDI
MI1@"<,@MIK?U(QG=Y"M<<G:=/SSRK*PG-D4A'QD]\7GUM+WD WY27UU]Q05[
M\[=U6CW=9'(&I'<<R]OJGA>?[W%V^ZB:*/_,2[DZE&2HU]_+4% 6<I1 Q_%\
MB!S!H20I!(7P&&.1ZT0Q7C[;:3B_-)A(?Z,7V&Q;9M!UAK(-JOU%!G8! #L(
M /($=J]K4  :A@6H@0 [2  -!:@D%J !8P%J./0,0P-BN1Z<ZC$S7%#.Z:F9
M:$4ZOR?%?GD[<;<-NSZ>2OEI%]@3=\FS%?K4\OL-L]?KHI!"/E5R8+C*F#I>
M6GW&W]Y\4RKS5SSC(JV6CN^X02(\R#V!Y8R>!9"P!$%'?B??;S?PN-6*WTCJ
MW.;UC=) :PUPQH#6&TC%0:,Y^*[1_7N[4<BL%\R&D,&Q'9G_AX'5FK*M8!J4
M;\TD3TJ65F <,IW=S?UHZBU.BS_CU9K_S+$Z#M#$N/GR?Z:\D$W>/[W.'W":
M+:,X"8.(8NBZ 84H"05,(HXA$XF+J*(LX=G0E97TN=&6TA-H11=@5_\%V/X%
M;&P O]56G%Y?#] _9D0V&NHC$]I16!6OO;_Z\WEXK8FL%TR#$IJ=!I,26R]P
M#@FN7R/]B.X]KVXRFC_P=WE9+H,X%%0D(903,!\BQ A,A)R!>2AR'!$Z%&%)
M9)MS[K.OU%[K5D1UXLA^R/=&*B?79DH[\-U*ZF<YA]I'+J(A=B,<2="\!"+J
M)#!!<MKJ>H$3!9QAX<;++[P@N>D@T!N[72GCHK>R/H7:!TWX/(ZP"* ?!W*:
M+T(&8Q_%T/-Q1)B7>,*);,;-_H_;!..B NRF>=R4?M^#JZHJ4K*N,%EQ4.7@
M U;SFDL -1OH>L,T\D!V,4+68]E1) 8=J_8E3#H6'37N<*PY?E&_L>3V48Y,
M59K=O9/C%O^HO&EOQ2\EORI+7BTI<0.'<0]&3BAIDB$7$A(@&#&7"OFR,X<Y
M-B][I[2YO?Q:/9@+N):K2ZPTM"3.;FS-WOO!$!N9!S9Z JWH FS0D\H"K>UP
M%& $RJ"4T"UQ4HHP,OZ0,LQNZD<AK[G@<G7/Y'I>-U=NA4E^NL9%\23R0FU;
MELN$132*< @)<N2JF]((8B>)88@<3W[M!AZQ6G5;R)X;O;2JZTVL6OD%V'F-
MI/Y@SP [\K'I%3,J&@GKD8EI.)BM::H'8(.2EHW\22FL!S"'A-:GB7[T]J%H
M1'VJ<OI7?1Y3WJXK%7:C(IF62<!=BD,$?3E3@BBD/HR)D)06.()PGI D26PH
M[8R\N='81EU0*GT7H-0:@WRKLAUQG</;C*P&1'%D@MH"^*D&L%86W!H :$U)
MAK ,2D/G9$Y*/88 '-*-Z6UV%+/Z5GR33$:J6[)*[_3A;[F)+B ^8J$31)"Z
M*(8(Z8T6'D$?"[D:<Q+AQZ$)KW0)F1N9*#7!CIXF<0;FB'8SQU XC3Z?&1,B
MUH3@ZJ]'AVI/VKP@,V96$RQJ.E57:HYTO88A.^^=A!9-M&^YT.C:OD$D:CM+
MGPZKYZ$-8+[ZEI9+FN!(!$+.KW0HMY-P&,LNAS%W* VB.')8;!=)<E+6W.BP
MV5C=Z I:9>43+-6U/'_M IFYCAL&R(&.<!V(O)! $C Y]E#'H3S&)*+<[BAD
M()BG.1C9#6TC3^!MFN&,IGBU"WV:<7 C?QD<>[,)[4!XCCPZ]7YB>X3TG,5C
MX+B>T_(F#NXY:_CS")_SM_0C[BM*\W56E>_SBI?O<BQ'A(PUKT]V]Y%3GGY1
M!T&OGK:?/TM1^L&/F* >BR2S<RIGN+$70XP=)'^0($2QD[B,VS#[)<K,C?JW
M&@*E8B_2N:ASS%AI*LA'IBU+M*W):@B8!F6SBQ2:E.Z&@.Z0#P=ITXXPRZ):
M?E1NW3_S!\*+I7"PYS)*("6)HR**'(@3H<*E'>H&B"D'1!/N.VAW=C2F5+/T
M%SR$JIN)+@!@9%)1XVU:5JER5-[Q"AO0O>^$[5U,(6_980GYVR%#'+8YR<M^
MPI#VO3WU9[M7D/%T^8G3=9%63V^^T7O5X'O9?TM*0I?A4&6Y"KA<_'@<)M2A
MD.. ^<2A/D5&*\Q3 N;V4K8Z@E9)H+0T>SE/@MC]E@X!S=BOJQTJQB_I.=./
MO*TEIS_<Y5]^E+?JE_5O2'V$]4?]EIYL=)+7]9Q)[7M[]CK[%_A-5NG()YH7
MCWFAES%Z77.M!O3BZ3J72P8O0(E+X@0F/*80,3>"L2-?;Y]YB7 (9B2BIN^S
M@;RYO=ZURF!/YT43.I,7H-$<*-7-WWD3W,]3P,!HCLP(0P!I11,6\/1F#1,9
MDY&(A<&[G&)S6[]]C?^UQH5\5U=/FZW G2W"UYN,8YMSDS (7,Q\#AF6<WKD
MN@$D8:!2BF+N.8GC!8G185U/^7.CH(WZ.UNINWNL6PNLCZ_Z]I#9?L:(N(],
M5L-";KW#T1.X03<U;'68=!^C)T"'6Q=]F^GKVDFJ;93Y=9Y]X465DA6O/ZK$
MSA^*E')WZ?L8,TERD,=8[6?H;5RYD*)A(&*'L2C&5OF<C"7/C?KT8?-6\P78
MT;W]16D/M/JV/IVFW6'&=J. /#+/#81O#V=.2ZP&=N4TE3ZQ(Z<E*,_=.&T;
MZ.O$F5/.6?E6FO )K_BMD-\\2EE/'^3355UE.J7&HU)B&0110'W.(!:)#U'"
M$8QC'\,@YCZ)D2L)SK=SZ#26/3<R:U6OT^\KY56.W5;]!= &+'3@\L8&6V]/
M\XXQ([61X!Z9U@9%NH=;J#5F [N(FLN?V%W4&ICGKJ/V3?3THGIXQ&FA&KH5
M-UDE'R_%I+5[_)MO=+56KJH_Y3G[FJY62^2'R'<PAAXEDN9XK-*("P+]*"&)
M&V$'4ZO8/BOI<R.ZK?+JM=NJWT2,@.\V%H#6!,O0<[O.,:.ZT2 ?F>P&1=O>
M<Z@/:L/Z$EEI,*UW41]PGOD;]6IDXAR@3::TMWDA>%K)-7.YR</(A>,1[#/(
M8C^&*)#4&,?$@4+.!7T1N[$(@BG3?9Y6U>BE_EUF]MQD9-RQ>O($GAW/B!E#
MOU27_V[2<O;LYNFR;Y[OB'DDVNS0\_>14_,\T(.ESS00U6\P^LC55@:53<H!
M[CHOU>Q>?L>++[53)4X\1A@)(8I]HI+G^)"$201)1$@2\S!ACK"9<Y^1-[=9
M]IZZ_?U:SZ%L1LT#8C<RS=K#9DV/AF ,2G7G9$Y*6X8 '%*0Z6T]D_.HK+[U
MM/F]-*/.H;D4(F9(3D%A$GL11-@5$"<.AZJJ940BQ$5DE8'KJ)2Y44>=J[M7
M%IZC()IQQ,70C,P,-2IM5HNMB@.FVNE"8-@4.T<E39M:I\O89REU.B_NN9BE
M]YRMU1[AV;E->6IR\UEYJR]YB!AU?003%#"(*)<DH7+U(8)5/FXG##TKDAA,
ML[D12VN8VHDR6<^4G0L:\)LVTG)",URW&ZY*7Z(SQUZ+3MN/]@O0H3$?=MDY
MF';3+C:'!O79$G-P ;TRA&QR';U+,4E7:?7TD:_J^K57]&_KM$R5,E+)IX?'
M^SQ[NI'X+1'SH\3Q(^B$<HJ(>,1A+(D?^CPAGL>H"#VC YX+=)@;V>\E ]O8
M 1I#5+;2'5,TDS3& &6-57Z-7EW63=\3=<3H#CSS[@.K%"AC]\5$&5)N,_ ?
MZ]43\)T%\!Q7_GS'OZ525R!E\T(71)(=@^4(^J!K6FM'!+7XU7WV0>IQ+VFO
MV<T%5W<%KS=_OZ;5_7X'ZCO_9[YBNHR?^J5,']:K"F<\7Y=2!_Z-%S15([*<
M8!\VO5!?%EP.W07'"F"]):(O+/*[ C^4/ZA;RC66PJ7&ZB^X45D:\E"J!^IH
MNZW!CSC=T>^/K@,>TM4J;11/RW(MFW+]A>='B\!--NG.!*#YPX.\3*=!4[(9
M+].[C-=_W+28[T/MJ<UN-9:4 M/VB9<X8\;THX-7X(]^L-%!356DBO5,)=_D
M8?EAHSY>E;*?%/[Z57K ?^5@_:@^_A%MFTGW!#3MR17DU_N4W@-U*B>MR<JT
MU >T@?/?:ZV>ZF\9KWWN-T(+'24K#7W<@5Y=ODJI'"EU%\EQLFPL7,ON*!I9
M;1.R[]2<#,O.2>7TZQ$7DA,*E:>T5(TI;-5C@5?IWSEX]ZOK^-ZB_M]7L1BY
M7@@_RKYXD$_XN@ZZE#<]YO4;6(*'7([C=<Y'U?^E?"I A8L[7@$L1=SG$EA6
MK.\ 52F]F'RNY:/T^3XMI76/LH?UE%'=R5K^JB1_K3;\5?"V]?JI4W]-'^3[
MIB$4:[7-+!_%O*C2O]?H2;6E>J4^^$XW)Z:EVN3(I:7JQ=*O3[H]'Z_W/T#]
MY+=_WWN]VCZ4#R7(\DIJR]94>]0!(04JK60G2;G2O,&2'UW"@F=R(_5J>LK4
M29?8?I!9Z:*F)CX]?[]6D;C-M+B\^H+3E9KFOLV+G]2;O$QH%$84AQ"IHCJ(
M^QQB/Y:?'!<3X<2(6^X_C*3HW&:H QRIUA9OUL$EV!BM*4";/='Y^;FG9.1#
M] '[?OXGZ1=U^W3GZ89],H]#]7/*_CY.U@TA'^QXW51>CZT0=;:F"BE=9>PU
M_\)7N?:;W='I.L]TX-/G_ ,O5&"4E*IWZLM6JYW[?DY7<@F39[Q<>CA,<" \
M%;I$Y _NP%@$JB!0PHGK13X.C1+3CZKEW :K+>6PK;IJD='H:[%8'ZUC#;94
MYM!=X[L0:!.!M!'L*+L[ONCH*6TG^)R#QE+EEU472BXW0\RMV&OBYUGUM\7V
MS1SZ?:(-GA?N?[L%Y=C]TKGD'$WX=(O2L?';6[:.+JQO1F$==U.6Q_5K4HLQ
M/V;,(1QZKL/E4C7P8,+B$%(_1I'K!Y@EEKF%#:3.;12_R6"C-=C0!-ZG"=MD
MMR;8FZW]!D=TY('V1@4>=X,)?JNU'C09K@5* Z?%-9$\<8)<"S">I\JUN;EO
M_JJWDN9J]ENZS(\("WQ(1>Q Q'$",?,"Z/I^Z"41D\.34>*$8XW/C6EJ_8!2
ML)E+V":@V@&NFS\NA6-DFK! HD<&J><F7Y@N:J?!B7-#/3?E>2*H(]?TS&;-
M_O]U6>E3F,_YU>: [ -.V4UVC1_3"J_TI@8YW!7YR.O]>?Z)%U]2RNMH@H^<
MYG>9;D67@5Z2 #&/4!<B7P66(2>$)$AB*((H= /7"[S0*K7 V K/C4!T]9UF
M^Y/N6&.9%WOL;C:;VLRI\T:FNZL/-]>+XYO7N^O/FXP6JCZEWK!6WO1@QZ8!
MLW%/!/RP&;O'5GK:K-X3=<&SS-]3R7V98.8WC>_,)I[M<UZI#&%5D69E2FMV
M"@,G"#T?0>0* A'U,22)&T*.>9*(./$<8I6J:PJE9S<0#1CYNK%_&_>Z !H#
ML $!:!2FC7HV>IA&/L$=Z1&9_VEN]]-A^EQ,'B9MTU'S..*U4?SW<=S;HRN&
MCJRVDMWC&/B*TF)]H%S&7O&,B[0JK]M 22Q"[F(.PX3+)5<24D@0]B!&+@MH
MR!W.L/&9KI'(N0U3C=)[:R6]'4D:O<&Y@,&^V!L<NPZ.Z-B+F!<#T^),<W!0
M)SJ@- 870,#67'N^R@'1!4\<#[!W9H]=YR&B64O3G0A:6;9WO&=WY\MX]%QO
MG,-W_ "0\##F&$,4! E$"'DP]@B!"0N2"/,H<'$PI4//,27G-EQL_7FV_O8O
MYLYSM%>G\>:YM*]^9\X\6W-?S)?G:&=/Z\IS::?_3CUY[#I_<D>>KEX9VX_G
MJ.S?E1M/%WI#>_%TRNJY';HF)?_;6HI_\T7^4)F/ZMIY2\Y(XC*?0A1156[
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MU*#G/HC'+^NY#DK5P>"[](O:=:ED]RD?YCK-\+M-9F O#!B)L2^9,'!4K&H
MXQ!AZ% N'.[&L9N$5DL9 Z%S>\%KG:%6&FRU;E,R&Z47[M\#AJN*@7$=>V$P
M *3VJP,+C(:=X)L(GG:.;@'%LVFVS;W]J&EG G^5L4]53O]ZGZ_D_66=%W/)
MPX1X4>)"-\$,(M\5,(F0 [&/0R^(D*0MLJSR"J_,:.F<0"M*VH@=[_WYK&2
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M\>H?=N2^ ;7DCAW.K)"W,R.#XSFV2;D$)?C6_.\H:9=.< W;%\UJY&D[I+F
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M']V ]^)GIDP6$.8\29^S*MQUT>)2:5S4>;DFP/0^8VIOK2;HOA1U./5'MGH
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M*RD,0U]2&H<B0<B>:,5RU+DM=C7+;B,XV$A^T_*2;80WZ<4N1""VTV!AB<<
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M:T.4/MA=:(KB],@I&Z/TT?6@.4JO1_3=6S=G&N:AGTCYL31Y$=RL5)]$:=+
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M ),DD,*#U*?*,@0D@:F0",91@"7#C$:)4V7%\1!S,PD;"<$W+2,P0CKN"4\
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MJXPWF3.?!1-ZW$^B_%J2O"*FZ&1!>2BI+Q&D$5.NF8\(3*6O]GE1))#D0M#
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M+(0\38E0*HZ5L"K5;D=N:N;4+L.@X1C4+/<KX'<9<(L+0:\P#NZ)&!U!AXM
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MCX_1U<5N"<L%__JE4<9TKEM*=.!9MWVK;_A[TTK\;-QP$F<(J2R 28@RB&3
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M&PC/W;[/$!NYZW>WR,?=OR\\[]XX^&%)C2WR[?69%?,9#Q@1$:4PBI""*-+
M,9)2F*9Q1+C 5%&K?J)'(T_-+&B8 S5W]NV!]^'J7N%7@3#PDK:4WZD)\$E9
M>S?_W1]MM*:_)X78;?9[^H%^>_1'NER8#>>+7%8-4QP+EYU[?4+?6<NB<9V
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MSC**J-13 67&%40JDI#&0D 64T5))-+8S3$P$M]34UL>3JSW[1%U!X(;T((
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M&TUOP VLB4;#S.%VSQMV(]W(W2W /5\5=<7H$-V S_)'KK4.D-4MAKE^6Q6
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MLC>"H.,HADE%UM"4 [JD;4F.V9LO+6X+;+>E#K4 IROX%,*7R8?SR'H;?(E
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M&R=7\7\/.\:+4M]_ 'H4M0=6@*"#K*7,)60EG0MI;PMS#$YZ3]ZW$.S8.-G
M?G.BOI[_MOAZ9B>O<D,G*K="&=#U3E\96R 45)#H<&5*DGVT?'=S\M!2NZ&D
M]]1Z [&.#9*KF"=NZCEZE17-4F;"DUT,FY&,=(@&DQ.)JG"D#Y=<XMZ&Y/8Z
MN\&C]^SYT (=&QO5H9JN:H2WDZ^5/'GEJO8%3;Y.N0FU_RUM@!C1<F(Y!K\;
M5O9;=S?L])XA;RWPL;%T3O19E\X;_-W%G0DD."T#E*09J%*;$041P$;+.&V<
M8'W8"4Y[+[T;HGI/5C^!V,<&U17#^K&.]9T@SY$"/0$EJE3=,P5!U<F!WBD4
M*6B1=NO1>_.;=X-$[ZGAXX4VML:WQ37;=YXO/BUQV\WS(WY;_T2?^?M$<19E
M5@QT5+5&)E <%[DD]#(L+*,);+?Q+X\LM!L>>D_E#B[2L>'QZV*Y_A0^X2N,
MZ]?SU7IYNKE0?H]?<8F3-__Q_C\FS.A<E(Q@ZFAQQ;P&Q\D!8\X$63CSUK&=
M$/+X6KN!I/<\;0O!/KN^VR_#ZO,OL\7O!\WU>OQ+VW;9OH?XELVU+Y:\:*H<
MF;&(3H,N8O.PW@&YJ8F.FHBF&!95+#OMNYV7'+B5=@Y(SK8WD$,RH**/$# D
M.C5S24HCT[9-04;WK;2/4_8C';3W$?O8PY7N'"%4F#9>\@P<@Z^3@PTXGQ7(
M'$J(Q7+/=VKR]P<9O;67/A\=O;6/<,=&Q[TCH;)QRGN%(.)F7&9TX(P5(*-'
M)[WA2;OA$/)<1F_MI=J=1F_M(^<.2A+>8_6STGKS%J"^EWHQSW4RS_(K;@3$
MD19UJ<XXJ6,*I.(08AW&$R3M,4<_C&VZASY"6"?]LPXW-RT4T &>/M+GWI9K
M3)UMC&*E"H)E$DU]6Y5$A&A, 9%BDHSVF0J-&H7>1]*X1]:@BK_Y)'(0+8P=
M:+]_]:&&?F&>L,KGO%-SL!@P&P]2>Y*.P3K74&706AA/T:85>K><[=W?/RXJ
M!M+<8E@Q=F!8[D@TQ%!2#+X ,1]!Z=KNO4ZY5"7ZX*UTLEG'L8,:R;:_>3[^
M.#I2S!T Y3=<UUCQW7+Q=9HQ__3]KZM:B'PVR7G^Z45:3[]NWT&>1Y*I!)XL
M,<=$QLJ7@!A=!)MU4M&RX%@;)V=_6CL)LPY$Q^W'URU5U0$8B;4R76_?EF-Q
M5N0(G-&&W!SJ'@D5)NO(A/:*R= $9)<TC N>UMJ^]0SL(-%W )IK_4=K\]!Y
MFL[P6J>"CXM]16G1NA)= F\9B3)X!5XZ R4'77PJR80V\&O!S;C1WQ,#>70X
M=+ E7B&M7,>SDHKI]S/<Z'J>7YPLENOI/[9OV[Q#3U&3 ;=IH!_KY9###+$4
M:1C/U0HT@?@NU(UK>\?'T**Q0CL Z3WMK8)DB>)."XE".-K[$L$7IX@IZ4A^
M)4?#VX0IAW<;:V8[NP/B $KK 'J7;5Y>35=?%JM-L_&WY<5JA>O5Q# E8Q0>
MK) 9E$,+@5B A$P)KF26IDT+VP?)&C=F[@Z(PZFPG_YEK\Y6W\KT8_AV5B+X
M$\Z1G/-)[;KF%2K026M0"3T$5!XXNBA-S")J;'1B/TC8N-WBNX/FD&KLHFT:
M,5*;!N(KW/YZ173G16H7<A,A,YDU1-J"H)B-VW<63D>E9<3D91N([D[CN#WG
MNT-K(^5V<,K?YNRL <AJVQA]D_UEV0EA?0+4=:HN>DM.2QT]IW-6R:D<8QMW
M<Q?JQHV"6B'C40 >J:9^#O3;K+V>?R7)+Y:T>R>2"14-DJ@L%Z",B>!]H3^R
MK%%8EE6CII$/DC5NP#,:Y@Y53,]@>[?$+V&:S_V1,S?DQ7P[9_7,5=8FQ.""
M >$8[2?&-+G*B@&Q'J*1TA?1YEKP,'K'#8-&@^?@JNP9MQN>+OV=+7-.9)N4
M%D#^#(5T7LC:O(9<'A93<,AM9$]E+>^B;]P8:#1<'JVJGG%X[H>\"]^K$U+S
MK2DM3XG :8C3V<8'GW I4'+/(-I"T5Q,"*$6$M 6U-Q@)F_\J7"Y"[WC1C^C
MNY2#J;++^.;\>*AO@.:G.$&5G:[=A)E(=6!ZCN XRV!5=!IUG1WQ5-B\0=JX
M\[=&@^$Q"NH <;M?Y=(9D(KCQH,HVE1?A,X ;P18YA73 :/.;<:6[T[CN*[D
M$U^+-U+=X:"L[YQ;@K(&=*M[!%FGQ5L9&/A8<PA,(;B@+ @K;(PRZL3:C)O9
MG]9.*O??M*Q@&TI5'5C(LUEB=1+R=JH.\4I;;/W]W2S,:\UZ;=W^9?-0-V0O
MC#6UCKBVG9&9$X\4LDFC@N#$-_=M.J+N3F.7%7"#H>5F!5P;U?43X%QM@[3M
M1$P_R:=5BG@>N:'2OE@&M8\-*&4YQ"(,").S0F>UP#;7-X_3UF416S,L#JNJ
M'@SC71S=L[UB##95AF3RU0$1-=EO$*2,SE.,ED-43X?"(TSC4SN/3PK' 937
M RYO6OVM##<_FS!N@_))@^7UII[7&U97W[M:Q8R1(MM6YO !JL;--(Y]*!^J
MGGZ/X5]#?;BV_DZ[Z.5B-L--]__5VW*5TT2.!0I'\1[9=E VDS!-M*"<X%FC
MM]@HD7, L>-F&$>VC$,KLP,+N;M$)UQ&YFJ/$92VCA4@'D/ 3*!"B4:;C,T&
MY.Q*X[B)QR=&9R/5]9OT^64Z#_-T3Y&4=EQSG4&7^D(\4/CF8_&@O&-22?JO
M:S/?<']:.WD?VS3I,Y2J.K"05P^!.C2COAU_6ZYT\IP$S8M,M)VTM)4-1 K6
MC &OI?0V,,=N-G]O<'[?25J7*9[!L/' :7V\HGI WIE[_,MB^1Z_G"[3Y["Z
MP1%7-J)5!DJ1)*_(ZHA:C9"RB2(KYYUL<Q'S.&U=IG2:86]85?49SUQNJC>+
M^2=:XZ1VIYP4E=#JVMO)<3HTO"5OQL< P5B3; F:O-XG-']7:>LRC_.T]N]@
M575@ &DKG>VK&WSP8(JE> J"U F4"1D\0PDL>J6LEU*I-JF;^RCJ,FW3"FB#
MJ*4?$[>[]"9&%DNQE ,9JZ?,@@&W>8IAN'"6W&01V[RJWIW&+A,TK9#82'4=
MA,"5K9IFHE]J]OUKF-7]MIWD?+/R:&)-D+)F$:+*&E3.'D*N*2AAC#(F6\/;
MP'(?*L<UD0.'O<W4TRWT7M!.6RZ_TZ;Z]S [Q8EQPA;Z3YU?4#=K*N \"^"4
M16%M]D*W25KO1-ZX5O!)P':,0@Y&V9<-PHF_Y?H)L>8E)Q9(;DESL^UT[QF=
M&!G)X4 A?(EM^O4,A[6G'%[3'FO[*.1(K/T\S\,T)#G]\F6V$528G?=/?STO
MB^7)5E7G[H@W5B=?)PQJDJ B1LD=":$^;] I,XF:-6JDN!N!.Z'M*>?B'(.V
M%DKI(&Y]/:?OPM7Z79AF<E$G4=;'!8($HXHCP3!-9[]#(->7)*=Y":)-1>H-
M0D9NF-A"V;>*\@^7? ? .1?+;XMYHM]>7N7-\QTQS:OI*LT6J],E7LZ!2(Q$
M5Q!8JH]<D$6(7B@H2I#%CM9A:1<)'$/Y3M!\RO%.QQZB3Z;&#F"[27!O!\J_
MVK1IW@9"&U_AY8*X7ZXV_7NVOU]/XPP_8*JE%#4RQ^*D9B$#"E6;>^L(014#
M@8FBM,2419O\\5%D[P38IQPU==0Y_&0*[ "M/YVN2&BKU<O%2:3=6%566[5\
MFD__@?EU)J%.RW3SCG!3BWM6FI9I\UYY3DA_=WIR_8&AYDSZ7 1HBK9HTV8+
MD;L P5>->&V];]-9K!%#NWD+[)E O >M=P#^JSTEWY:+TVC3#)]XK6?1YBGM
M1')3BF,*C,^<0KQ42X:JK+,PT65CBVE3IKTKA;O!\[FT_VZBE[&'5M0V?F_G
MVYIR\H7.N JSLT<.TL24BL^07<WW8R3),;YM12U24%F5W8;'/KS.;D#I_97=
MT +MY_[M]<F7,%U6"=5A'V'V\ZI*;%*REKR6Z/C:Y40I&\%)K@"S#AZ],Z71
M1(N[Z=D-1<^E;&\ F7=PF%WE@B+_,/\TO3C ?_Z69J>93.A?%HO\^W0VFV0D
MI]0E"Z($!XJD!D'3P>U+]DJRR+UJ$V?L1>9N.'LN]V3M--0!_#9L7'+X\G-8
M?B*/T*+)LK:O$[G0"9T8HTC(16#96EY"RIRUR<'<3<]N@'HN=V$#R+P#Y-1S
M?%6[@>+J[?SG;S4W=#I=?=[NDTTIC<3 # L%N-V,Z<@*'$8!R>M,S$1EL$W*
M^%'2=L/3<[GO&E83_3A5MQ]U_G1*<B7V5A/#HTLY%3*N5H,2ICXN)K988K1]
MBN8BM/&L'B!J-U0]EWNMH:3?@:FZ/B^/3\C**A<U!\T$Q1A.9@A6&)#>55Z2
M-[:-8;I!R&Z >2XW!L=(N0.07#0:>E,+GMY//WTFZ_G7U=;1(\%$&;U.('6M
M3+'&0XS*0I+UX9F2!74;>_,@6;L!Z+ED\(?30 =PND'^V[BF4[H6=E+(\)EB
M"/QEL;S.\'E&]OM$2LY2\@(B;1U0D:)7,K<93$S<:E<Y;1/E'4'T;D]EGDNF
M_:FT-QA0_^7'6W(G2?Q]\U>;OZG_ZCV6'^JO?WW_^MKWS_#;%PI"3L*?T^)D
M^_UOEY_"_"R7&^;YC-?%?'6=\M7TY,OLQC.%VPG.^[_LQTL";Y)^]IVW4'(X
ML?AMC?.,^4]'I(.O+O7BZE*7SZ%MXCJ* %'(!(HY!C&X.HS>Z*0CP<'N-L[X
MT:6./O&N+/"2OG<QF^;SU=Y=T<9%+C_,+K;9E1O_CR37GV;U>9@D#EPI$:R7
MAL(,LLY.*/(2@XS!ZL"E:?.Z?FA.QBDR:@"P6T?LF"KOUMA].#TY"<OOB_)A
M^FD^+=-46P9M^_'6.@(24JIWR0=8OAV_>1@S> @;1]K$BY36K64NZX"BMYB-
M RLK7$M0X 4W@%H)# 2/E-K,+[F?IJ/CR8?D>[DWA",O(&H%28M"VQ,3..,9
M>,Q68L!H59LDZF[TC3S!<AC$W I"AU?-,S=;[<W7*&9L+'.F*';@GDDHM0&Q
M,H97[YZ E+GTW*%VC1*/[<S9-4=@\^7?+W<*:F.*B;7/3B!^)852T10! J6T
MJFC%I&S"[T-4=6NZ]D''K8K;H=300?;CK[5SQ,^K]?2$G,?5!%T*+,CZ9I S
M4 %K,;LMD'EQY"<FQAH-*[].Q\BC<MO Y@A1=P"4>QZAWD"_BE;JD@I()HDI
MKGE]#*&!*9V]+>BB;Y,0VXF\D0??-K)&@RNF [1]7(9\.9/JUA"_+7>3(E.)
MB2,(:26)C1<26Y3D'-8>([)0\-VF;'0G\D:>9=L&;<,KI@.TG4_L^W[K,"\E
M49#C00:O05DGP&D1@&E$M E+UFT =A]%(T^<;8.I0<3? 8S(+TS$R#8-^'ZZ
M^OM=>3BF1"1I(* JM6V-)T$9)!9%=#E*5K"TF=6P"W7COBYOYZX/JY8.H/8!
M/]5,[WO\4BOYYY_N8BG&[!/2QBGU,K]VN &?0X#,6 XB,!$:S7C?@;AQ'Y8W
M MK02ND 9S?+:'^9SJ=K?#/]BOGLJ*^SE)U("G20@6QT<1!=HGWDN8HJ*!):
MJ\%PCY V[BO?9F?ED KI &'WCG^XZ0P(FYG)Q)(Q'D'ED" (46$A*53F(5C9
M)C6Q*X7C/M)MA+<FZND =E?>"BS)3G]9K,)LVV!PLY>VF^LFC]'Z(H+U$"UQ
MIER=[\F5 DM&W3/T(K9JK7$ M2._J&UE_UKKK0-LGC]1H>UVT]S?XHSIF"2*
MV@13@$+E(41KZR2G$$+)28<VA1R[TSCRT]E&.&RDHP[0=S90]NR]^EU7'-XH
MCH71_L%<0"EIP!?-P.:D7!;6LM#&Y7N4M)%?WS;"VK :Z0!BM>[\;:EO%6YM
M%BM+SH8Q,(&1]\H9;1;,#FH1  5'5@37IJ_%_32-_!BW659D$!UT@*;WI! B
MH%Z"O**=,EML_-.?OWW!^>H\(>UE"DYI5]W16D9"NR2BML!<]B4'XBN[1B;K
M4>)&?H3;S&@-JY4.@/;A,PGTI[#"_')Q4OG85F!^.2O+?+U),Y(76F.ELTTU
M,5@$#S9 MN1U*JEE;2T7P&>6I+3T/]<FW7L L2,_WFV5E6NLM0Z ^7-8SNMS
MOW>XW'![Z_(WBQ1YG< N=4T)U0YOPB?@BK$H9?"A48[N$<)&?MW;"'!#:J,#
M<#T0Z=S^<\9R*R%)+FF1VGE(P3I0T1APMF20#+E@17,MVQ3B'4OYR,^$GSYR
M'5Z?'>"7#/SB!#^&;S?W84Y1\!@<8,;:]U(1'R4E$*5HY]"AT&V.YOLH&OF5
M<;,;BP'D_\Q+NS_6VIB&A=UGW_^49=UWL=2^J)MS'X,MGD[,D.@ K=?T%"T
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MN9]PCF6ZON2(;+QWBH')=1!-8/5NW4C(UF ,@K;,37?Z830]O-RX*>DG@-&
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MZ*PV-SL6#"OD^EI.4;[, KQV%DBP27'KZ[B#-E'^+N1U"\3C 7)K;,30VNH
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M@*ROO3)WZ#UZB"S7D5R1@U>.SCZ-'G5*/NI&#;GW(7/<!,@3PN=FOX5FNNP
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MN^./-Y>O@+VPM4 %O/",CFS#P>L8P#&I"V-9%-_FQ=XCA/4R)Z!5_#:D7CJ
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M\^!4"% XC\7SX(1O?%BSCZR1I!F#(.;I>[D3U3<F+)XNV5UQ; _/,D>ADXA
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M& &4.K] EY*AL#Y!P2AJ),O B5+ *Z<YB2L*TZ9_UZ7WAC@($,?VACA$.R-
MW1,M"9)2A>OB@#.2E_(8('BK("DF$J,=:64Z2]QW4;TA#M)]M]X0ARAB!'"J
M3?67JW4GW_?_G&'>MQGOSK]5-,;4;9C*NHEOO2$Q-A*O0;G(;"B-*J4.(G.L
M725.,6?M]#2B6_2;4L.?'_%J4[>\[BV]G%;=O2^??G[[_G4^^_DVS6F?F>(E
MYP8RJUVD1<@0G+$0K2C*!V^TW#D\?OEJ_8#UASXC;H:&)^[@6ZEF!";PT.X%
MNA3//$<0IE[*F93!97(:=:JO8BHIZ=O,F[J(1A/G@^@Y]'=!EZH[QT+'7JK*
M9I>J.P2>X5(5,>? ,8,,*8!"71^2%@D\I&R*Y4(KWBA<:7:I^OIZ4;??@U/#
MQY=Y6F4I4_"4H)LZ3MHZ\*$$,%%91.T9^C8I9R?RAG:>_2!FUP[UKYD1.,<N
MS8/W=P+X_:_:&N/N.'%[K:>,S9GYVOO'%%",K&](4D"HS4:U"NA-FS*DOCD9
MVKVV ?&@^AX!WN_8?L#RG_/JJJY),I3(;7?T$UU?M)-8'YD#QV)!E2P@\F@A
M!U=8,)D;;&-Z3R9]O)?"IR#ZO!H=SZNW)_B^J;+H\FHTRH#2N@A2%E89KQ76
MRM=KR5QGBTG:V^>$\@&TC_=:N0&66^ETO/;XB2*V5ZMMFEF#L.LZ*_2!&YN$
M)**,5@/+CG:RH%S3<4FRI]_GZ!.GG/.<@#Z.C?%>0C? ]ADT/?0)Z+\OIBM\
M7\K[<GMRL9RDP+S.,4)1M%F5QOIBG_@13-<JS:A9>3&[?_+KX[U9/@9!_0AQ
MO,9NW8CF5?[?U]OS-++AWA..$W!5^Z<F(;<'K,$32]8$5MJ<0'8D<-@QU&<V
M4"=I9P2@>ZDNG!?CN+ &0JS/[%A*X.J!172"61]TPMC&9_91I=]L+G4KD/6I
MC1& J\MQPDWT^ON,A+<.7M<>7.BD&'(&!C/9;AL#!:JTE[R.I5CFO&9MC-SQ
M- \[DWK((Z$>=#C:JY:_S>?YG].KJV/N5V[_;3^7*OM).?$F91T^W7SY%C&6
M>^[12E(=I^RPE#H"PQ%BDM8**7E,R76*/W>_?*I)N?W>NA:58%</<#;I[KYA
ML<JQJ-;]EUFH SRDIA!0*S *K2@Z^13;#.T]C,YAKD1.5_VNL6BHG=$;B./G
M^.Y\H5]C\>P$WW\[F>OM[>XI;-]\HE^^]Q+6Q%8B8QR93A24&?*N*G"(VF;
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M$!""TE 2\XHGA<*V:17U#%%CLD!'*GW>1@-#7\KLT'XGIIM6:K54:OUJ-'_
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MU7^T%$<0H;[H)9]RDN]NNXQDIPH3M6B)&0?*DZZ=C DT,\&P;%+:[5UUKA.
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MV6[ NMCC[W8J& 6X.A];(4-%YE9!BH6V#5,67*)D$H7(/&7FHNM6O''0LMW
M=;'GUNU4,%)PU4TS7:WP@476(D4MA0*'R,C%JP"Q4&+)HTV*%_1JM]/H8=#:
MMV@W8%WLF70K\8\)5O>;=R#7K @'C-6Q8YPL;EB_1PPR\J"E\O: 7/ZXHT-Q
ML0?-/0AU%+CXOICGZ[1:UI+BB4N497(B5RO-:Z&:)<)3HB33:NNS1]6QC.71
MI[NAX6(/DD\3Y2B L W7'M:6+R>&14N8)D#+LIZC'BB5M @N2#16QH3N $CL
M7Z0;."[VD+@O\0X-DT^X6EVMA;(];_B#1/D9%]^FL[7T)D[(K%!:D*G>TOH@
MP.D2 3E&31**RG<[_GMII6Z N=A3XEX%/3AJUE<D]ZB_E52]U3=<Z@+%,Q)0
MM9;$1H+BF$&)24L\Y#YJWQK=D'*QY\4]"7<<&'FS77D;5>V"7F4OO34,4JE"
M"CJ"4T[4$_#@1!:*A4.>CSV_6K<7_1=[?-R[P,<P0^ Z+O$_KTE OQ,[J\V8
M6^-3XEPJJ'U;*4]C]4V<B/4(TPKZ;[63TT/0]-7L?P\UW4!UB<?)O>E@A#BZ
MF6/OBPRRMF(A(6A0J1@(@L+Z()*-P5J;3:.Y$?L)&GB*[LF:?@$ZQXA]G.C9
M#I#W1N8L+&TD;A"4D@4"1P;,,V+0*Z'<V?"S(6E<"#I*X2^#Z CICP]&?\?U
M1&?!8JXS&2B24PR4P0RA/K=RUG(>E';:Q'- :$/.Z.!SC*J?!] 1<A\?>-[=
M3OH()6?RXII\>7"UTVX!+TP"SF.=%V5E#ND<^+FE:.")TXU]V'&"'SP9>^GT
M(>CB1) >N*K,E.S >ZG!%:N]T:[XTO%%1!_'/.<R,$<J\Z!SG4,D.P([\PZ_
MA*L_L+;I<H8E4BZ8),1F"H]7CN02=? B6J=$FR[&MR2,RI*<AI73Q#O:GL._
MA\5L.OM2W]FNIT(])+A;;^%'W^BGA_#SI)W8*_A&G;N+W";<&8TJUF@P.5/"
MG3-M^*@*:%$,FJRRR+;)YGF*HE/MPNYW[YIG,Y6#,BI1+,;)N094X+(FVF1R
MG"N)W)V'U8%[F_>*B5V[T8_X+\:.'#_@Z(DOM;$ISXXZ:F19HC0*%;? D-(A
MBB<2!.=UO0-(W",/*8B+LBR?TE?,UU?XONRN\%M83E-]RCR]NJZS,JNT[X!O
M.&H51*YW\%B' WCP.J_;.R@KF4H82A-!'$GP2*W2(7AZE!N=07478[-.&*_P
MU*?:6*T6PQ->A)G4R3+R3B 3I\0[)P>19  L2&5%4(I<XT69K3]Q]796>WN^
MFR^7$VU\]AX3(-8>'X8Y"+X$2-*+'(,6++<YA7E QDA-S"&ZWS4QQXMY!,GT
M&XRKNXFXK^>S'[A83<D4OBW;WV!>C[Q]._O]KX3+Y?OR83&=I>GW<#41)#6M
M!(-L#05VDA=P29/H0E#.BQ159$T@=0K5PZ;L31!X-B6. +"TU3;35&M+N&_?
MYK.U&)>O5IN9;VLO/G\\__FNO\QR$F+RRF0.VFE5WT3'VN C@<)8 @44BJ%L
M MO3:1]FY$-3\)Y9H9<"X<W&K<.$ZQR+N/J$Z7HQK2T^)YQ[EM!G$"IRDG8(
MX&2TM($5SR%I(6R;_.I$PH<9)S$\>'M2Y0B0^^\X_?*5G,FK^B#E"][.6=FD
M4!O>WU^OEJNP;D1!&[-$;@E(26.=-D7IF].10;WLT@&=]:Q- GP@H</,DFB*
MS):J&@$2]V;S$X^.&\X1DJMW\*@31)<R,*6R2TQQE?$L*=R:G&&F1S1%U>EB
M'R%VMGMBXA4+"8N%DG(@-I0"Y[B"(I576'14NYVB&Z%G2] P0R7.BI]C1#\"
M!+V:K::YDC[]@7?>G'*KJ^N,N=ZO4S3P_7JCK,='C]NNJYAK<9F3D'P59$H*
MHN(>F#8JY1R\D&WJJGHA?YB9$DW1>7ZUC@#+;QXS7 JFU?O9VKCO,KENQ3IQ
M)L>(HH U(8/BG$,07(.W0BCMHU6BC:D\AMIAID:T/?%IK;01 /.)"'83NKY=
M+J\Q;\(/S@(KS!E@)>9:NIOJE"H#G")7'7(F<;8I<>Y*X4#S'8;(+T[3SFAO
MTC[A%>TNS/_C.BQHK:N??TQG858[RKP)J_"/6;C.T]5NL^EN-VM=/]W/3=M1
MC/1T\_9XS;>SVN![S<?=T/M;>#*.C+NL(5 Z2D&A].!J\8A$ZVP1RCO9YL;J
M0$('A=SQ=2B'+7!6^#6L6CD4A('R5VU+ *>E Q44(Z>I)<3ZSE5H84W\OR!\
MGM;CJP[Z7/ZL #Y<( /!FTNKG0H&G"<(*AX8.)X"Y2ZY!%D\*]CF"O<H>!\N
ME^5B=:\&Z/6<1#Q;4BYWL^@G0L'F%FGS#B,:F>LK=:A%/B2/PL$)2;O?2?(W
MJBC+.VUW6O>>+.AWNW(XD+!AZR9:HNHFL&RIJ1%D,YL2D5LFWM5_4+57WQX&
M(9R(F6(<S1(H82)XY@0(SA1/KM;RMSFV?H:H80#7% 2/[^YZT<C1X*+,*<[;
MPFO[-I%GE5#6/M]"$4\F<8C*!.#9H!0%O8_ZG  ;PT/@WM3?#59':&)08-6=
M^-S^>QV^5[:6[VX?':44HR0#3U** I2*I3X74I2]9:MJWD^9?F^N\R#2ABGY
M.H<M:ZNE$;C-;9.8Y<2;4$+2'(16&51)1++6!B)ZBBC015_:F+ ;"H9SB T5
M/.]!VB- R?OO6%O,S+[<*\2UW"9IN >S;AY>BVQ<L JX0N*B>*EVWPOW!)@]
MQ QG@,Z'G5-U, (8/:SD9I2-HV61LA860%EI(;I &H].HC/!,F6: .CP@OG>
M*S[/"YWCY3Z*V+OS58C,R8E0-(1@/*C:)L]I<O@"F53!94GAW_@OJGJOT#PO
MV)IH:P3&Z]""/QV"=MY3_L%=I$0G><IQ,(')Q7F957XT$.=?J39S%)CL17<C
M@.:355\.M5^_!->"DN&LW?;I"9-"1ZVD5&U"M%,*[GHOV#POU/K0Q0@AM3'9
MA6%QSM<R@ZQ!,9]J%Z5"@G%!6'0Y"W<60'7WIKW7;PX+I\/U,-J:CU?+):YJ
MY_1C;B[O_G$_]XY/$-/3K>'ZZQ]Q-=T\9GD?KZ9?GKK;T8XQY0DH)C-#"HX!
M8B0'E)DKT1G);6ACM \@\L2VT/6\[L_Y[';SK%=>WC4'L$4E4X0&9A,' C:O
M>R76"?0VAA*]=_(E@'1;:M@C\E:PV&D*W:>XQV]-CB_8V?U$SY:E8='-04 R
M@=0J&7@7"J5=3-)/5H$ISB8IHT3;I@W#P?:E&41.J)AY](V>0=*R=N40E'@G
MLK(.0>M(R7EM4.>S]5"C6):$X9FUJ5LY@Q>Z6>K#8IX0\[(^/-A8R0^;63_3
M'[BQD1,G;!29MH@L@4(W+A.$3'FAS%4\]&NR;:K37J;M<ES7(5C:C7][UM$(
M,JLJH/EL-9U=8]Z>Z<]G=\>SE=&]?^4W+/,%;O[BY_#7Q*.T*:4,0M0>E(9S
MB%XBH%4F:L$U2;?1$Y%>&!BV3\BY\#N$MD< \D]83]IF"5_/EZLEGRCI14"N
M@5M71<@<N$P\<,>#S/0+,VU:@NP0,FQ_CW.![A3ICP \#]OM;(HW*$4)4CL!
M6'R=P.@E!)024N32>Q$]*VTN"_<0,VR?C;-9KA.U, (@?<1*?EI=+Z:S+W4O
MO)IE^C-<_-C,I)!*83(1@24,53Q(D0.S8*25*<8H0FP#JA<(&S:T.UGQCXI>
M^M/""$!51U*\+P^8VM8>,HO)*J$A9Q4V3UFB4QY"9(*A#T&GW 1.3Y(T+)!Z
M5?R\A18&A-,L3--R\K_^EU;<<CDANHAE,LT%9:@#S8EJS0SHP+USSD9,SSWX
M7F+Z;U_F/_YM_=4-<-8_KA&SQLK#]88%1D_*FY\LR1&8D[_AC&*U*]H:K_*W
MZ6Q:/7=-;G__ZWN]8=J.JK%%LU(??(0H;:U=9>!#JJ\^HD>RP2R;-OT .I$W
M;"K7+YK:Z64$8'OHVN]N*&WQ6<J42/M<@JJ=56/R&3@F:2-QI4V;!S)/$#0L
MH/H.@/J0^@C LYM52F&BE"H!EW5\5L0(0292<4D9F4TVZ$9#.(_(Z<\4+1^I
MW!?R]T,D/?2<J;^1X7T_>^K2<9)R"HYCAH2>,M(ZP,TEP: $9H76BG'5;9CX
M\^N,R8"<AHF^A3HT/C[CXA.!^^_AK^FWZV]O".E7\^]53!_QR_55_9<_R>?6
M9I^XJ"S^?7I%GGT^P^4D2J>P2%T'HA=83TH/+BF0,D:)7&CG3"?L'$_#L.>'
MO>/J3,H8&G-UOUR]GL^6TWQW G]U74L]-SW%EA_Q"FOWX\_SS32W2<G.(&8'
MN=1)/4D)\"YS\O=%!\:%R#IUPMKA:P][O-@[QAH+?[0%*>N>8*_#]^F*[/3M
M/.YC:@Z>^%(_E0==R.QK,LA_7D]7/V\/IP5'+4PN@)G71\"4-H7:HM+&H%$I
M#)XUJDY^0,=)EF6_].Y*JU(63A>IP!E9"\E9'<WE*($0P@0AK(_.=3(C+RPT
M\-B/XQ7[P%3T*<T+LPLGE"0]_\&65J+I&*&'F%+!N5R/<I2QO+[K#^ S<BA)
M!"FTC$JU.5OOQUC<9G;K$/[3BM"\[V'4V]EGRON6M%"=&VM%JCXW@'5)UU<H
M"D(LQ+U"Y,4IETR;:OM#J!R5Y3D$)8^2[E:J&</1S3U&/BRF"6^>$TPHCF-&
M*%^KI6HU:+;@=90@HRLL,#0E-9H=_A1) \\/ZA%0O0A]Z-SI?@'>&TSK8V]2
M*=N.XZC;Y7TALM;/YBR2F#RGN-W447Z,^*KG5)D)XSACW)EN2=,!BPX\L>=T
MN#25\M#HJ?1/EW4T2R?6E&66VZS !&/KQBC@UFU)+3)6M,-'1\I/ .BP=0<>
MG-,3AAK*>F@8W1"]O7S;X6\?=T*KPHSUP"VOS^080N16U7'+*5G))8H7 ^OC
MEAYXUDU/8&HK\:'Q].KSWV_H_CRGE&:"6AKGK0#N0NW4K0-$4QSDJ$WDTB8A
MNKTXV_WRP#-J>D+#2?(:6MF;..S3_(IB^#_G/ZH]O,?/)#E&!L\H\I\HB!54
M$*TA?HI$FS+SA8M.JG]^G8&'S?0$A!YE.0I8K./R-2M;RW:?FU(L9A,8I&(9
M!5JZ@#=%@O?">@JU+*8#D/'<4@//>ND3'+U)=&A\W _)]T!=.1&QI&KWZ@#S
MZ UXC F,#$%XE#J*;N!X?IV!9ZLT2&].E.70L+AO ?][F%V'Q<^JT_OLL)"+
MYTF"9I[8"8438XJ#UI85"H5$V7TTV,&C[%]KZ,DG#=Q*#T(=!4:VAO )=F((
MEC/,H+TJH'0($&+2$ 3F6FE6$HL'^Y93,#+F(]H60AT:(_=-XA/L.*Y#K8$'
MD2BM4HAD%D-M]6)XSLK)A+MGLQU<S"D8&?.I:PNACN'D_CHN\3^O28:__[@M
M1F5*V)(EHP2["DE[#\$QBKJ#2I$C,S&W&?N[CYINT!GS"6QOLAXA7NB?K=_:
M<&]4O70 7X=%J(">DK)20+J ]%^$+MBFZ\<3! U[;7BZIE^ SC%B'R=ZMD\I
MG.""Z*5\K=2._8[2>Y<]@\"+]XDC;:XV]^]/DC0N!!VE\)=!=(3TQP>C[5N9
M:+V-ZPY6&NO<5DM.EV<))69.?QX*RVTZS.\E9W3P.4;5SP/H"+F/#SSO;BM0
MA6'&\9(A: KQ52P67!WRD;)SE/PQ9DN;AB=/431LI4)K'W:<X(=.JSIDB:G$
MF$)V@-(;4+3?('IN0*O(2@Q6%[$3"C5.O<^$D",5>F .?HAT1P&6YX^=I"-!
M"7+EL43*)[RL$Q:" ):M0:%*SOGPVZ$3P'(N<](76/J3[M!@Z7"V$$56J*,"
M^E6"XMJ MP4A)1M%\$D]FC_0]L"F6=+=/UAZEN[08'ET8:XT8Q1I1>!%DEF,
MPE?B!=0#B9!<<8QU>_=X5(%!L]JE_H%PDN2&5OM]D_<)OZ]N"K >X%AP+7.H
M=UQB72AC)(10N[ :BS%:X2CR/]BE/+7:L-5(;9U*+Q(>!62V(=63#*E,'!E?
MP#&_/E4@AFQ]>REKW[_ DN/YX)#U),@T*UEJ&[3V(N&A(?.@)^I3#%':)XV2
ME/]I0K[23H-3E/]3>IBET\$)TRW+Z;+:L,5-;:.17B3<_C7:]C_47V)8XO_[
M__S_4$L! A0#%     @ Y(IJ5'.<8C?:$0  IEP  !X              ( !
M     &5X:#$P,3!F;W)M;V9R97-T<FEC=&5D<W1O+FAT;5!+ 0(4 Q0    (
M .2*:E0NW_+GB!(  "M0   >              "  182  !E>&@Q,#-O9F9E
M<FQE='1E<F=R86YO=VET>BYH=&U02P$"% ,4    " #DBFI4 ]MBXQ\#  #G
M"P  %@              @ ':)   97AH,C$Q<W5B<VED:6%R:65S+FAT;5!+
M 0(4 Q0    ( .2*:E3EYF((SP,  ($-   ?              "  2TH  !E
M>&@R,S%E<FYS='EO=6YG8V]N<V5N=#(P,C$N:'1M4$L! A0#%     @ Y(IJ
M5,G0G\?D!P  PBT  !X              ( !.2P  &5X:#,Q,6-E<G1I9FEC
M871I;VYO9G!R:6YC+FAT;5!+ 0(4 Q0    ( .2*:E3K]#+;[@<  +8M   >
M              "  5DT  !E>&@S,3)C97)T:69I8V%T:6]N;V9P<FEN8RYH
M=&U02P$"% ,4    " #DBFI4SD57WR %  !.'0  '@              @ &#
M/   97AH,S(Q8V5R=&EF:6-A=&EO;F]F<')I;F,N:'1M4$L! A0#%     @
MY(IJ5/\#-X()#P  ($L  !X              ( !WT$  &5X:#0X9&5S8W)I
M<'1I;VYO9F-O;6UO;G-T+FAT;5!+ 0(4 Q0    ( .2*:E1I^2:%WLD" ,XJ
M&@ 1              "  211  !L>')X+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0
M   ( .2*:E0-_OL3@14  ,P& 0 1              "  3$; P!L>')X+3(P
M,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( .2*:E3R*1FO0Q(  #*D   5
M      "  >$P P!L>')X+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #D
MBFI41"A0-25K  !!G 0 %0              @ %70P, ;'AR>"TR,#(Q,3(S
M,5]D968N>&UL4$L! A0#%     @ Y(IJ5(<(#K3+" $ \5@! !0
M     ( !KZX# &QX<G@M,C R,3$R,S%?9S$N:G!G4$L! A0#%     @ Y(IJ
M5,_P\?^H"0$ .?@* !4              ( !K+<$ &QX<G@M,C R,3$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( .2*:E3;'[\ ?ID  ,SI!@ 5
M  "  8?!!0!L>')X+3(P,C$Q,C,Q7W!R92YX;6Q02P4&      \ #P E!
&.%L&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
